Class_ID1,Entrez_Gene_ID1,Species1,TF_GO_codes_molecular_function1,TF_GO_codes_biological_process1,Class_ID2,Entrez_Gene_ID2,Species2,TF_GO_codes_molecular_function2,TF_GO_codes_biological_process2,PMID,Gene_mention1,Gene_mention2,Sentence,prediction,pair_id,num_entities,num_unique_entities,all_mentions,unique_mentions,feedback_PD
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,7677767,DAX-1,SF-1,This suggests that SF-1 may directly regulate the expression of DAX-1 and that these two transcription factors may be components of a cascade required for development of steroidogenic tissues.,1.61,PMID.dPMID7677767.s0.p0,2,2,SF-1|DAX-1,DAX-1|SF-1,<--
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,10965053,DAX-1,Ad4BP,"Even though the Ad4BP-dependent transcriptional regulation of the DAX-1 gene has been reported, DAX-1 did not affect the transcriptional activity of the hFTZ-F1 gene in our study.",1.23,PMID.dPMID10965053.s1.p0,4,3,Ad4BP|DAX-1|DAX-1|FTZ-F1,Ad4BP|DAX-1|FTZ-F1,<--
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,10446902,DAX-1,SF-1,"With respect to implication of Ad4BP/SF-1 in the transcriptional regulation of the DAX-1 gene, inconsistent findings have been previously reported.",0.70,PMID.dPMID10446902.s5.p2,3,3,Ad4BP|SF-1|DAX-1,Ad4BP|DAX-1|SF-1,<--
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,9232190,DAX1,SF1,"When cotransfected with 1550 bp of the DAX1 promoter, an SF1-containing expression vector increased the transcriptional activity of the DAX1 promoter by 4-fold.",0.33,PMID.dPMID9232190.s2.p2,3,2,DAX1|SF1|DAX1,DAX1|SF1,<--
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,11297612,DAX-1,SF-1,"DAX-1 is a repressor of StAR gene expression, and steroidogenic factor-1 (SF-1) is a regulator of CYP11A, DAX-1, and StAR gene.",0.10,PMID.dPMID11297612.s13.p13,7,4,DAX-1|StAR|steroidogenic factor-1|SF-1|CYP11A|DAX-1|StAR,CYP11A|DAX-1|SF-1|StAR|steroidogenic factor-1,<--
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,15879363,DAX-1,SF-1,"Mutation of the SF-1-binding sites within the hACTH-R promoter resulted in reduced or abolished DAX-1 inhibition, arguing for a mechanism that involves SF-1 for DAX-1 inhibition.",0.08,PMID.dPMID15879363.s1.p1,5,4,SF-1|ACTH-R|DAX-1|SF-1|DAX-1,ACTH-R|DAX-1|SF-1,<--
2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,3.1.3.4.1,5087,9606,,GO:0043433,18984668,DAX1,PBX1,"Both genes are activated by SF-1 in a dose-dependent manner in NCI-H295R cells, and, surprisingly, PBX1 is synergistically activated by SF-1 and DAX1.",0.88,PMID.dPMID18984668.s3.p4,4,3,SF-1|PBX1|SF-1|DAX1,DAX1|PBX1|SF-1,e
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,17560011,AhR,AML1,"Additionally, AML1-ETO protein also increased AhR expression, a ligand-activated transcription factor that mediates PAHs-induced CYP1A1 gene expression.",2.15,PMID.dPMID17560011.s1.p0,3,3,AML1|AhR|CYP1A1,AhR|AML1|CYP1A1,e
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15897893,AhR,c-jun,Induction of c-jun depends on activation of p38-mitogen-activated protein kinase (MAPK) by an AhR-dependent mechanism.,0.20,PMID.dPMID15897893.s4.p1,3,3,c-jun|p38|AhR,AhR|c-jun|p38,i
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,17963696,AhR,PPARalpha,"PPARalpha transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects.",1.51,PMID.dPMID17963696.s7.p0,3,2,PPARalpha|AhR|AhR,AhR|PPARalpha,e
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18483242,AHR,RELA,"Silencing of RELA expression alleviated IL-1beta-mediated repression of AHR transcriptional activity, whereas PMA-mediated repression was maintained.",1.64,PMID.dPMID18483242.s3.p1,3,3,RELA|IL-1beta|AHR,AHR|IL-1beta|RELA,c
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10620335,AHR,COUP-TF,The specific interaction of COUP-TF with XREs and AHR together with the inhibition of TCDD-induced gene expression by COUP-TF suggests that COUP-TF may regulate AHR action both by direct DNA binding competition and through protein-protein interactions,1.27,PMID.dPMID10620335.s0.p9,5,2,COUP-TF|AHR|COUP-TF|COUP-TF|AHR,AHR|COUP-TF,c
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10620335,AHR,COUP-TF,The specific interaction of COUP-TF with XREs and AHR together with the inhibition of TCDD-induced gene expression by COUP-TF suggests that COUP-TF may regulate AHR action both by direct DNA binding competition and through protein-protein interactions,0.14,PMID.dPMID10620335.s0.p6,5,2,COUP-TF|AHR|COUP-TF|COUP-TF|AHR,AHR|COUP-TF,c
1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15111621,AHR,p53,"Here, we show that repression of p16(INK4a) and p53 transcriptional activity by dioxin absolutely requires the AHR and is accompanied by promoter methylation.",0.43,PMID.dPMID15111621.s3.p2,3,3,INK4a|p53|AHR,AHR|INK4a|p53,c
3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11026560,PGA1,AP-1,"Interestingly, so far as PGA, is present in the medium, AP-1-mediated transcription enhanced by PGA1 cannot be detected by the standard luciferase reporter gene assay.",0.29,PMID.dPMID11026560.s2.p0,2,2,AP-1|PGA1,AP-1|PGA1,n
3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,8.2.1.0.2,8091,9606,,,8049495,PGA1,lipo,The combined administration of cisplatin and lipo-methyl-delta 7-PGA1 prolonged the survival of nude mice bearing HRA cells compared with each single agent alone,0.07,PMID.dPMID8049495.s0.p0,2,2,lipo|PGA1,lipo|PGA1,x
2.1.1.1.4,367,9606,GO:0016563,GO:0010552|GO:0034339,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17023856,AIS,ESR1,The effect of ESR1 SNPs on severity of scoliosis was analyzed in a subgroup of AIS patients (n = 364) followed up until skeletal maturity with the maximum Cobb angle recorded.,0.31,PMID.dPMID17023856.s8.p0,2,2,ESR1|AIS,AIS|ESR1,x
2.1.1.1.4,367,9606,GO:0016563,GO:0010552|GO:0034339,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17023856,AIS,ESR1,OBJECTIVES: To investigate whether: 1) PvuII and XbaI polymorphisms in ESR1 are predisposition factor for AIS and 2) these polymorphisms correlate with the severity of curvature in AIS.,0.18,PMID.dPMID17023856.s12.p0,3,2,ESR1|AIS|AIS,AIS|ESR1,x
2.1.1.1.4,367,9606,GO:0016563,GO:0010552|GO:0034339,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,18551363,A-R,ER-beta,"In adhesion cells, ER-alpha were higher at 10(-8) estradiol; ER-beta were higher at 10(-6) M estradiol; P-R remained constant; A-R showed a higher expression at 10(-10) and 10(-8) M estradiol; and PRL-R showed an exponential increase at 10(-10) M estradiol.",0.13,PMID.dPMID18551363.s1.p4,5,5,ER-alpha|ER-beta|P-R|A-R|PRL-R,A-R|ER-alpha|ER-beta|P-R|PRL-R,x
3.1.10.18.1,401,9606,,,1.2.3.2.4,9464,9606,GO:0016563,GO:0006355|GO:0045944,16280598,Phox2a,dHAND,"Phox2a and Phox2b transactivate the promoter of the gene encoding the noradrenergic biosynthetic enzyme, dopamine beta-hydroxylase (DBH), and dHAND potentiates the activity of Phox2a.",0.55,PMID.dPMID16280598.s7.p9,5,4,Phox2a|Phox2b|DBH|dHAND|Phox2a,DBH|dHAND|Phox2a|Phox2b,c
3.1.10.18.1,401,9606,,,1.2.3.2.4,9464,9606,GO:0016563,GO:0006355|GO:0045944,14512028,Phox2a,HAND2,Our data suggest that HAND2 regulates cell type-specific expression of norepinephrine in concert with Phox2a by a novel mechanism,0.53,PMID.dPMID14512028.s0.p0,2,2,HAND2|Phox2a,HAND2|Phox2a,c
3.1.10.18.1,401,9606,,,1.2.3.2.4,9464,9606,GO:0016563,GO:0006355|GO:0045944,14512028,Phox2a,HAND2,"Using transient transfection of P19 or NT-2 cells, HAND2 is shown to synergistically enhance Phox2a-driven transcriptional activity at the DBH promoter, an effect that is enhanced by cAMP.",0.45,PMID.dPMID14512028.s5.p0,3,3,HAND2|Phox2a|DBH,DBH|HAND2|Phox2a,c
1.2.5.2.1,405,9606,,GO:0043193|GO:0043619,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20508969,ARNT,Sp1,EGF-induced promoter activity and the mRNA level of 12(S)-lipoxygenase as well as the association between c-Jun and Sp1 were reduced by ARNT knockdown.,0.17,PMID.dPMID20508969.s3.p9,5,5,EGF|12(S)-lipoxygenase|c-Jun|Sp1|ARNT,12(S)-lipoxygenase|ARNT|c-Jun|EGF|Sp1,x
1.2.2.2.1,429,9606,,GO:0032582|GO:0045944,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,10774739,Mash1,Hes1,"Hes1 encodes a basic helix-loop-helix (bHLH) transcriptional repressor and functionally antagonizes positive bHLH genes such as the neuronal determination gene, Mash1.",0.56,PMID.dPMID10774739.s8.p0,2,2,Hes1|Mash1,Hes1|Mash1,<--
1.2.2.2.1,429,9606,,GO:0032582|GO:0045944,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,18491256,ASCL1,HES1,"There was a significant positive correlation between NOTCH1 and HES1 mRNA levels, but no indication that HES1 was inhibiting ASCL1 transcription was found.",0.44,PMID.dPMID18491256.s2.p5,4,3,NOTCH1|HES1|HES1|ASCL1,ASCL1|HES1|NOTCH1,<--
1.2.2.2.1,429,9606,,GO:0032582|GO:0045944,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,9570134,Mash1,HES1,"Conversely, null mutation of HES1 up-regulates Mash1 expression, accelerates neuronal differentiation, and causes severe defects of the brain and eyes.",0.19,PMID.dPMID9570134.s4.p0,2,2,HES1|Mash1,HES1|Mash1,<--
1.2.2.2.1,429,9606,,GO:0032582|GO:0045944,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,9570134,Mash1,HES1,"In contrast, another bHLH factor, HES1, which is expressed by neural precursor cells but not by neurons, represses Mash1 expression and antagonizes Mash1 activity in a dominant negative manner.",0.07,PMID.dPMID9570134.s6.p0,3,2,HES1|Mash1|Mash1,HES1|Mash1,<--
1.1.2.0.2,466,9606,,,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,16766266,EWS-ATF1,MITF,Knockdown/rescue studies revealed that MITF mediates the requirement of EWS-ATF1 for CCS survival in vitro and in vivo as well as for melanocytic differentiation.,0.20,PMID.dPMID16766266.s2.p0,2,2,MITF|EWS-ATF1,EWS-ATF1|MITF,x
1.1.2.0.2,466,9606,,,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,12966428,ATF1,Mitf,"Surprisingly, however, the Mitf-M promoter is not activated by EWS/ATF1 in transient assays employing CCS cells, melanocytes or nonmelanocytic cells.",0.05,PMID.dPMID12966428.s1.p1,3,3,Mitf|EWS|ATF1,ATF1|EWS|Mitf,n
1.1.1.2.6,467,9606,,,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,20828393,ATF3,ATF4,"The mechanism of ATF3 induction by M344 was found to be independent of MAPKinase pathways and dependent on ATF4, a known regulator of ATF3 expression.",1.87,PMID.dPMID20828393.s3.p2,3,2,ATF3|ATF4|ATF3,ATF3|ATF4,c
1.1.1.2.6,467,9606,,,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,20581861,ATF3,ATF2,Knock down of ATF2 abolished TA-induced ATF3 expression.,0.60,PMID.dPMID20581861.s4.p0,2,2,ATF2|ATF3,ATF2|ATF3,<--
1.1.1.2.6,467,9606,,,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,20581861,ATF3,ATF2,Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways.,0.40,PMID.dPMID20581861.s14.p0,2,2,ATF2|ATF3,ATF2|ATF3,<--
1.1.1.2.6,467,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17108111,ATF3,p53,"Moreover, we show that mutant p53 attenuates ATF3 expression by two complementary mechanisms.",0.76,PMID.dPMID17108111.s2.p0,2,2,p53|ATF3,ATF3|p53,<->
1.1.1.2.6,467,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18836721,ATF3,p53,"Furthermore, following the drug treatment, the protein expression of p53, phospho-p53 (Ser20) as well as the p53 transcriptional activated genes ATF3, puma and Apaf-1 were increased dramatically; MDM2 and Aurora A, the two p53 negative regulators were decreased; the p53 protein stability was enhanced, whereas the p53 mRNA expression level slightly decreased and ATF3 mRNA expression apparently increased.",0.33,PMID.dPMID18836721.s3.p5,8,2,p53|p53|p53|ATF3|p53|p53|p53|ATF3,ATF3|p53,<->
1.1.1.2.6,467,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19060337,ATF3,p53,We show that activation of tumor suppressor p53 by DNA damage results in inhibition of Cdc25A transcription as a result of activation of transcriptional repressor ATF3 that directly binds to the Cdc25A promoter.,0.29,PMID.dPMID19060337.s3.p1,4,3,p53|Cdc25A|ATF3|Cdc25A,ATF3|Cdc25A|p53,<->
1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,1.1.1.2.6,467,9606,,,20828393,ATF4,ATF3,"The mechanism of ATF3 induction by M344 was found to be independent of MAPKinase pathways and dependent on ATF4, a known regulator of ATF3 expression.",0.58,PMID.dPMID20828393.s3.p0,3,2,ATF3|ATF4|ATF3,ATF3|ATF4,c
1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,1.1.1.2.6,467,9606,,,15385533,ATF4,ATF3,The data suggest that ATF3-FL and C/EBPbeta act as transcriptional suppressors for the ASNS gene to counterbalance the transcription rate activated by ATF4 following amino acid deprivation,0.17,PMID.dPMID15385533.s0.p3,4,4,ATF3|C/EBPbeta|ASNS|ATF4,ASNS|ATF3|ATF4|C/EBPbeta,c
1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,14630918,ATF4,CHOP,Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation.,0.83,PMID.dPMID14630918.s11.p0,3,3,CHOP|ATF4|ATF2,ATF2|ATF4|CHOP,c
1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,17276738,ATF4,CHOP,"These results suggest that the presence of mtDNA mutations elicits upregulation of CHOP and ASNS genes through the elevation of ATF4 expression and its binding to the AARE and NSRE-1, respectively",0.32,PMID.dPMID17276738.s0.p1,4,4,CHOP|ASNS|ATF4|AARE,AARE|ASNS|ATF4|CHOP,e
1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,3.1.2.11.2,4488,9606,GO:0016564,,15970589,CREB2,MSX2,This MSX2 repression function can be counteracted by overexpression of transcription factors CREB2 and RAP74.,0.03,PMID.dPMID15970589.s3.p0,3,3,MSX2|CREB2|RAP74,CREB2|MSX2|RAP74,c
1.2.3.4.8,474,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,18668008,Math1,Basic helix-loop-helix transcription factor,Basic helix-loop-helix transcription factor Math1 was found to be necessary and sufficient for the production of auditory hair cells.,0.62,PMID.dPMID18668008.s4.p0,2,2,Basic helix-loop-helix transcription factor|Math1,Basic helix-loop-helix transcription factor|Math1,w
1.1.1.1.5,571,9606,,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,11069897,BACH1,Transcription factor,Transcription factor BACH1 is recruited to the nucleus by its novel alternative spliced isoform.,0.24,PMID.dPMID11069897.s7.p0,2,2,Transcription factor|BACH1,BACH1|Transcription factor,w
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2682663,BCL3,MYC,Cloning and sequence analysis of the rearranged MYC gene revealed that MYC was truncated at the Pvu II site at the end of the first exon of MYC and had joined into the regulatory elements of a gene that we called BCL3 (B-cell leukemia/lymphoma 3).,0.17,PMID.dPMID2682663.s3.p4,5,2,MYC|MYC|MYC|BCL3|B-cell leukemia/lymphoma 3,B-cell leukemia/lymphoma 3|BCL3|MYC,x
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2682663,B-cell leukemia/lymphoma 3,MYC,Cloning and sequence analysis of the rearranged MYC gene revealed that MYC was truncated at the Pvu II site at the end of the first exon of MYC and had joined into the regulatory elements of a gene that we called BCL3 (B-cell leukemia/lymphoma 3).,0.07,PMID.dPMID2682663.s3.p7,5,2,MYC|MYC|MYC|BCL3|B-cell leukemia/lymphoma 3,B-cell leukemia/lymphoma 3|BCL3|MYC,x
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11387332,BCL-3,NF-kappa B,NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence.,0.79,PMID.dPMID11387332.s11.p0,3,2,NF-kappa B|BCL-3|NF-kappa B,BCL-3|NF-kappa B,e
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10469655,Bcl-3,NF-kappaB,"We propose a model that p105 is inducibly degraded, and that its degradation liberates sequestered NF-kappaB subunits, including its processing product p50. p50 homodimers are specifically bound by the transcription activator Bcl-3.",0.07,PMID.dPMID10469655.s6.p0,2,2,NF-kappaB|Bcl-3,Bcl-3|NF-kappaB,c
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,6.1.1.2.3,5966,9606,,,11387332,BCL-3,Rel,Two observations are interpreted to indicate that bcl-3 is transactivated by NF-kappa B/Rel A: 1) expression of a dominant negative NF-kappa B inhibitor blocks tumor necrosis factor-alpha-induced BCL-3 expression and 2) expression of constitutively active Rel A is sufficient to induce BCL-3 expression.,0.51,PMID.dPMID11387332.s3.p20,7,3,bcl-3|NF-kappa B|Rel|NF-kappa B|BCL-3|Rel|BCL-3,bcl-3|BCL-3|NF-kappa B|Rel,e
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,16732314,BCL3,Stat3,Silencing Stat3 expression by small interfering RNA (siRNA) abrogated BCL3 expression by IL-6.,1.50,PMID.dPMID16732314.s5.p0,3,3,Stat3|BCL3|IL-6,BCL3|IL-6|Stat3,e
6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12808109,Bcl-3,p53,p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.,0.72,PMID.dPMID12808109.s9.p0,2,2,p53|Bcl-3,Bcl-3|p53,e
2.3.5.0.48,639,9606,,GO:0000122,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12165517,Blimp-1,AP-1,Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.,0.99,PMID.dPMID12165517.s8.p0,2,2,AP-1|Blimp-1,AP-1|Blimp-1,e
2.3.5.0.48,639,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17877160,Blimp-1,c-myc,Regulation of c-myc expression by Blimp-1 during the differentiation of myeloma cells   OBJECTIVE: To investigate the repression of c-myc induced by Blimp-1 in 2-methoxyestradiol(2ME2)-mediated differentiation of multiple myeloma cells.,1.52,PMID.dPMID17877160.s7.p0,4,2,c-myc|Blimp-1|c-myc|Blimp-1,Blimp-1|c-myc,e
2.3.5.0.48,639,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10713181,Blimp-1,c-myc,Transcription of the c-myc gene is repressed by Blimp-1 during B-cell differentiation.,1.27,PMID.dPMID10713181.s6.p0,2,2,c-myc|Blimp-1,Blimp-1|c-myc,e
2.3.5.0.48,639,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17877160,Blimp-1,c-myc,Regulation of c-myc expression by Blimp-1 during the differentiation of myeloma cells   OBJECTIVE: To investigate the repression of c-myc induced by Blimp-1 in 2-methoxyestradiol(2ME2)-mediated differentiation of multiple myeloma cells.,0.43,PMID.dPMID17877160.s7.p5,4,2,c-myc|Blimp-1|c-myc|Blimp-1,Blimp-1|c-myc,e
2.3.5.0.48,639,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17877160,Blimp-1,c-myc,Regulation of c-myc expression by Blimp-1 during the differentiation of myeloma cells   OBJECTIVE: To investigate the repression of c-myc induced by Blimp-1 in 2-methoxyestradiol(2ME2)-mediated differentiation of multiple myeloma cells.,0.41,PMID.dPMID17877160.s7.p3,4,2,c-myc|Blimp-1|c-myc|Blimp-1,Blimp-1|c-myc,e
2.3.5.0.48,639,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17877160,Blimp-1,c-myc,"In contrast, c-myc expression was decreased with Blimp-1 expression down-regulated by ASODN and the cell lines differentiation was arrested.",0.39,PMID.dPMID17877160.s1.p0,2,2,c-myc|Blimp-1,Blimp-1|c-myc,e
2.3.5.0.48,639,9606,,GO:0000122,3.5.2.5.2,6689,9606,GO:0003702,GO:0006357,11841448,Blimp-1,Spi-B,"Our results showed that plasma cells expressed a restricted set of TFs compared with CD19+ B lymphocytes, with continued expression of Spi-B and oct-2, increased Blimp-1 expression, and downregulation of BSAP and PU.1.",1.67,PMID.dPMID11841448.s2.p1,5,5,Spi-B|oct-2|Blimp-1|BSAP|PU.1,Blimp-1|BSAP|oct-2|PU.1|Spi-B,-->
2.3.5.0.48,639,9606,,GO:0000122,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18354204,BLIMP1,STAT3,"Lastly, through coexpression of BCL6 and STAT3-ER, we verified that STAT3 activation functionally mimicked IL-21 treatment and that STAT3-mediated BLIMP1 up-regulation occurred despite high BCL6 expression levels indicating that BCL6 is not the dominant repressor of BLIMP1.",0.22,PMID.dPMID18354204.s1.p32,9,4,BCL6|STAT3|STAT3|IL-21|STAT3|BLIMP1|BCL6|BCL6|BLIMP1,BCL6|BLIMP1|IL-21|STAT3,n
2.3.5.0.48,639,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17264218,BLIMP1,p53,"p53 binds to and positively regulates BLIMP1, which encodes for a known B cell transcriptional repressor.",1.24,PMID.dPMID17264218.s5.p0,2,2,p53|BLIMP1,BLIMP1|p53,c
3.3.1.12.2,668,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0016481|GO:0045893|GO:0045944|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,19797124,Foxl2,ERalpha,"In addition, ERalpha stimulation of the COX2 promoter was repressed by Foxl2.",1.06,PMID.dPMID19797124.s2.p0,2,2,ERalpha|Foxl2,ERalpha|Foxl2,c
2.3.2.2.20,688,9606,GO:0003702,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15087132,KLF5,Sp1,These findings suggest that Sp1 is a key transcription factor in KLF5's dynamic transcriptional regulation,0.46,PMID.dPMID15087132.s0.p0,2,2,Sp1|KLF5,KLF5|Sp1,<--
2.3.2.2.20,688,9606,GO:0003702,,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,12087155,Klf5,Klf4,"However, while Klf4 activates the promoter of its own gene, Klf5 suppresses the Klf4 promoter.",0.37,PMID.dPMID12087155.s3.p0,3,2,Klf4|Klf5|Klf4,Klf4|Klf5,p
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,12788047,Runx2,Runx1,"There are three Runx genes in mammals; Runx1 is required for definitive hematopoiesis and is a frequently mutated gene in human leukemia, Runx2 is required for osteogenesis and is associated with cleidocranial dysplasia, and Runx3 controls neurogenesis in the dorsal root ganglia and cell proliferation in the gastric epithelium, and is frequently deleted or silenced in human gastric cancer.",0.24,PMID.dPMID12788047.s3.p0,3,3,Runx1|Runx2|Runx3,Runx1|Runx2|Runx3,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19020999,RUNX2,RUNX1,These results demonstrate a novel binding target for RUNX1 and RUNX2 proteins and suggest that Galectin-3 is regulated by RUNX1 and RUNX2 in human pituitary tumor cells by direct binding to the promoter region of LGALS3 and thus may contribute to pituitary tumor progression.,0.14,PMID.dPMID19020999.s0.p6,6,3,RUNX1|RUNX2|Galectin-3|RUNX1|RUNX2|LGALS3,Galectin-3|LGALS3|RUNX1|RUNX2,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.1.4.1.2,1051,9606,,,17579210,Runx2,C/EBPbeta,"In the present study, we show that CCAAT/enhancer binding protein beta (C/EBPbeta) is a negative regulator of Runx2 expression and acts by directly binding a C/EBP element located at -591/-576 within the osteoblast-specific Runx2 P1 promoter.",1.16,PMID.dPMID17579210.s4.p0,3,2,C/EBPbeta|Runx2|Runx2,C/EBPbeta|Runx2,p
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.1.4.1.2,1051,9606,,,17579210,Runx2,C/EBPbeta,"ATRA, the effects of which are mediated by retinoic acid receptor alpha and gamma in C3H10T1/2 cells, stimulates the dissociation of C/EBPbeta from this element and promotes Runx2 expression.",0.31,PMID.dPMID17579210.s1.p0,2,2,C/EBPbeta|Runx2,C/EBPbeta|Runx2,p
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,3.1.2.5.5,1749,9606,GO:0016563,,16901655,Runx2,Dlx5,"In vitro and in vivo studies have reported that multiple integrated complex path ways (such as Wnt/LRP5/beta-catenin, BMP/Smads, 1, 25-(OH)2-vitaminD3/VDR/VDRE pathway, etc.) and several regulatory proteins (such as Msx2, Dlx5, Twists, etc.) play critical roles in modulating Runx2 gene expression, activity, and the subsequent bone formation.",0.15,PMID.dPMID16901655.s4.p5,4,3,VDR|VDR|Dlx5|Runx2,Dlx5|Runx2|VDR,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,3.1.2.5.5,1749,9606,GO:0016563,,17518720,Runx2,Dlx5,"Osx induced Dlx5 but did not affect Runx2 and Msx2, whereas stealth ribonucleic acid interference of Osx inhibited Dlx5 without affecting expression of Runx2 and Msx2.",0.02,PMID.dPMID17518720.s1.p20,8,4,Osx|Dlx5|Runx2|Msx2|Osx|Dlx5|Runx2|Msx2,Dlx5|Msx2|Osx|Runx2,n
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,16753023,RUNX2,HES1,HES1 cooperates with pRb to activate RUNX2-dependent transcription.,0.79,PMID.dPMID16753023.s15.p0,2,2,HES1|RUNX2,HES1|RUNX2,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,16753023,RUNX2,HES1,"Furthermore, both pRb and HES1 increase the amount of RUNX2 bound to promoter sites in vivo, pRb and HES1 synergistically activate a RUNX2-dependent reporter gene, and depletion of HES1 reduces RUNX2/pRb activity.",0.70,PMID.dPMID16753023.s1.p5,6,2,HES1|RUNX2|HES1|RUNX2|HES1|RUNX2,HES1|RUNX2,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,16753023,RUNX2,HES1,"Furthermore, both pRb and HES1 increase the amount of RUNX2 bound to promoter sites in vivo, pRb and HES1 synergistically activate a RUNX2-dependent reporter gene, and depletion of HES1 reduces RUNX2/pRb activity.",0.57,PMID.dPMID16753023.s1.p14,6,2,HES1|RUNX2|HES1|RUNX2|HES1|RUNX2,HES1|RUNX2,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,3.1.2.11.2,4488,9606,GO:0016564,,11683913,Runx2,Msx2,We have then found that the homeobox protein Msx2 is able to repress the transcription activity of Runx2 by interacting with it.,1.63,PMID.dPMID11683913.s4.p0,2,2,Msx2|Runx2,Msx2|Runx2,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,16960140,Runx-2,NFATc1,"In another study, NFATc1 cooperatively enhanced Osterix activation of the collagen 1a1 promoter, but did not enhance Runx-2 activity; evidence was provided for the formation of a novel NFATc1-Osterix complex.",0.38,PMID.dPMID16960140.s3.p0,3,2,NFATc1|Runx-2|NFATc1,NFATc1|Runx-2,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.1.4.2.4,4783,9606,,,18829486,Runx2,E4BP4,"Thus, the effect of E4BP4 was assessed in PTHrP-stimulated osteoblasts by measuring the RNA levels of both Runx2 and Osterix as major osteoblast transcriptional activators.",0.57,PMID.dPMID18829486.s6.p1,4,4,E4BP4|PTHrP|Runx2|Osterix,E4BP4|Osterix|PTHrP|Runx2,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.1.4.2.4,4783,9606,,,18829486,Runx2,E4BP4,"Because E4BP4 is a negative regulator of the cyclooxygenase-2 (COX-2) pathway that drives the expression of both Runx2 and Osterix, these factors were investigated after prostaglandin E(2) treatment to overcome the COX-2 defect as well as in E4BP4-silenced osteoblasts.",0.14,PMID.dPMID18829486.s5.p1,5,4,E4BP4|cyclooxygenase-2|Runx2|Osterix|E4BP4,cyclooxygenase-2|E4BP4|Osterix|Runx2,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.1.4.2.4,4783,9606,,,18829486,Runx2,E4BP4,"RESULTS: E4BP4 was specifically induced by PTHrP and inhibited both Runx2 and Osterix, whereas E4BP4-silenced osteoblasts expressed functional levels of both factors.",0.03,PMID.dPMID18829486.s3.p1,5,4,E4BP4|PTHrP|Runx2|Osterix|E4BP4,E4BP4|Osterix|PTHrP|Runx2,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,19414075,RUNX2,NF-kappaB,"The IKK2/NF-kappaB-induced BMP-2 up-regulation results in the enhancement of RUNX2 and Osterix expression, two critical regulators of the osteogenic differentiation program.",0.24,PMID.dPMID19414075.s3.p4,5,5,IKK2|NF-kappaB|BMP-2|RUNX2|Osterix,BMP-2|IKK2|NF-kappaB|Osterix|RUNX2,i
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,2.3.5.0.2,6591,9606,,GO:0000122,20128911,RUNX2,SLUG,"We found that SLUG is positively correlated with RUNX2 expression and deposition of mineralized matrix, and is regulated by Lef-1 and beta-catenin.",0.67,PMID.dPMID20128911.s3.p0,3,3,SLUG|RUNX2|Lef-1,Lef-1|RUNX2|SLUG,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Runx2,Slug,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.38,PMID.dPMID19756381.s1.p6,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Runx2,Slug,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.38,PMID.dPMID19756381.s1.p9,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Runx2,Slug,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.30,PMID.dPMID19756381.s1.p0,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,20196777,RUNX-2,SOX-9,"RUNX-2 down-regulation resulted in reduced MMP-13 expression in osteoarthritic chondrocytes and inhibition of SOX-9 in increased RUNX-2 and MMP-13 mRNA expression in normal chondrocytes, whereas inhibition of FGF-23 resulted in reduced RUNX-2 mRNA expression in osteoarthritic chondrocytes (all P < 0.0001).",0.98,PMID.dPMID20196777.s4.p5,7,4,RUNX-2|MMP-13|SOX-9|RUNX-2|MMP-13|FGF-23|RUNX-2,FGF-23|MMP-13|RUNX-2|SOX-9,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,19756381,Runx2,Sox-9,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.09,PMID.dPMID19756381.s1.p8,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,c
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19746444,Runx2,p53,"Absence of p53 correlates with increased Runx2 expression, while the slow proliferation of OS1 cells is perhaps attenuated by pRB retention.",0.92,PMID.dPMID19746444.s5.p0,2,2,p53|Runx2,p53|Runx2,x
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.3.2.1,7291,9606,,,12270142,CBFA1,TWIST,TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts.,0.90,PMID.dPMID12270142.s7.p0,4,3,TWIST|CBFA1|RUNX2|osteocalcin,CBFA1|osteocalcin|RUNX2|TWIST,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.3.2.1,7291,9606,,,12270142,RUNX2,TWIST,TWIST inactivation reduces CBFA1/RUNX2 expression and DNA binding to the osteocalcin promoter in osteoblasts.,0.90,PMID.dPMID12270142.s7.p1,4,3,TWIST|CBFA1|RUNX2|osteocalcin,CBFA1|osteocalcin|RUNX2|TWIST,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.3.2.1,7291,9606,,,12270142,RUNX2,TWIST,"This provides the first evidence that TWIST inactivation alters CBFA1/RUNX2 expression and Cbfa1 binding ability to the osteocalcin promoter, indicating that CBFA1/RUNX2 is a target gene for TWIST in human osteoblasts",0.43,PMID.dPMID12270142.s0.p1,8,3,TWIST|CBFA1|RUNX2|Cbfa1|osteocalcin|CBFA1|RUNX2|TWIST,Cbfa1|CBFA1|osteocalcin|RUNX2|TWIST,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.3.2.1,7291,9606,,,12270142,CBFA1,TWIST,"This provides the first evidence that TWIST inactivation alters CBFA1/RUNX2 expression and Cbfa1 binding ability to the osteocalcin promoter, indicating that CBFA1/RUNX2 is a target gene for TWIST in human osteoblasts",0.43,PMID.dPMID12270142.s0.p0,8,3,TWIST|CBFA1|RUNX2|Cbfa1|osteocalcin|CBFA1|RUNX2|TWIST,Cbfa1|CBFA1|osteocalcin|RUNX2|TWIST,e
6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,1.2.3.2.1,7291,9606,,,18453541,RUNX2,TWIST,We observed increased TWIST and RUNX2 expressions upon osteogenic induction and downregulation of TWIST through short hairpin RNA reduced the induction level of RUNX2.,0.05,PMID.dPMID18453541.s1.p5,4,2,TWIST|RUNX2|TWIST|RUNX2,RUNX2|TWIST,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,15688019,RUNX1,RUNX3,"We show that RUNX3 regulates RUNX1 expression, contributing to the mutually exclusive expression of RUNX3 and RUNX1 in human B lymphoid cell lines.",3.34,PMID.dPMID15688019.s4.p0,4,2,RUNX3|RUNX1|RUNX3|RUNX1,RUNX1|RUNX3,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,19403666,RUNX1,RUNX3,The TLE binding VWRPY sequence from the C terminus of RUNX3 was found to be required for repression of the RUNX1 P1 promoter in a B-lymphoma cell line.,1.68,PMID.dPMID19403666.s2.p0,2,2,RUNX3|RUNX1,RUNX1|RUNX3,p
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,15688019,RUNX1,RUNX3,"siRNA inhibition of RUNX3 in lymphoblastoid cells resulted in increased RUNX1 expression, indicating that continuous expression of physiological levels of RUNX3 is required to maintain repression.",1.05,PMID.dPMID15688019.s2.p0,3,2,RUNX3|RUNX1|RUNX3,RUNX1|RUNX3,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,19603429,RUNX1,RUNX3,RUNX3-mediated repression of RUNX1 in B cells.,0.79,PMID.dPMID19603429.s4.p0,2,2,RUNX3|RUNX1,RUNX1|RUNX3,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,19403666,RUNX1,RUNX3,The results demonstrate the importance of RUNX3-mediated repression of RUNX1 for EBV-driven B-cell proliferation and identify functional differences between human RUNX family proteins.,0.48,PMID.dPMID19403666.s0.p0,2,2,RUNX3|RUNX1,RUNX1|RUNX3,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,16584381,RUNX1,RUNX3,"Knockdown of RUNX3 in these cells induces RUNX1 expression and inhibits cell proliferation, directly showing that RUNX proteins can regulate B-cell growth",0.39,PMID.dPMID16584381.s0.p0,2,2,RUNX3|RUNX1,RUNX1|RUNX3,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,15688019,RUNX1,RUNX3,"We show that RUNX3 regulates RUNX1 expression, contributing to the mutually exclusive expression of RUNX3 and RUNX1 in human B lymphoid cell lines.",0.21,PMID.dPMID15688019.s4.p3,4,2,RUNX3|RUNX1|RUNX3|RUNX1,RUNX1|RUNX3,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,15688019,RUNX1,RUNX3,RUNX3 repressed the RUNX1 P1 promoter by binding specifically to conserved RUNX sites near the transcription start of the promoter.,0.14,PMID.dPMID15688019.s3.p0,2,2,RUNX3|RUNX1,RUNX1|RUNX3,p
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.3.2,1998,9606,GO:0016563|GO:0016564,GO:0006357,14970218,AML1,NERF-1a,"The interaction between AML1 and NERF-2 led to cooperative transactivation of the blk promoter, whereas the interaction between AML1 and NERF-1a led to repression of AML1-mediated transactivation.",0.12,PMID.dPMID14970218.s3.p14,6,3,AML1|NERF-2|blk|AML1|NERF-1a|AML1,AML1|blk|NERF-1a|NERF-2,c
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.3.3,2000,9606,GO:0016563,GO:0006355|GO:0045944,16581786,AML1,MEF,"The MEF (also known as ELF4) gene is repressed by several leukemia-associated fusion transcription factor proteins (PML-retinoic acid receptor alpha and AML1-ETO), but it is also activated by retroviral insertion in several cancer models.",0.00,PMID.dPMID16581786.s4.p3,4,3,MEF|ELF4|PML|AML1,AML1|ELF4|MEF|PML,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11078523,AML1,TEL,"We also show that the leukemia-associated fusion protein TEL/AML1 is modified by SUMO-1 and found in the TEL bodies, in a pattern quite different from what we observe and report for AML1.",0.88,PMID.dPMID11078523.s2.p0,5,3,TEL|AML1|SUMO-1|TEL|AML1,AML1|SUMO-1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,9652733,AML1,TEL,Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1.,0.66,PMID.dPMID9652733.s10.p3,4,2,TEL|AML1|TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8639909,AML1,TEL,"In the present study, we have sought allelic deletions of TEL and the presence of the t(12;21) in 50 children with B-lineage ALL, using a combination of microsatellite typing, fluorescent in situ hybridization (FISH), and analysis of the fusion transcripts resulting from the TEL-AML1 gene fusion.",0.66,PMID.dPMID8639909.s6.p5,4,3,TEL|ALL|TEL|AML1,ALL|AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19837270,AML1,ETV6,"The prognostic significance of the profiles of these genes and the association between alterations in these genes and known cytogenetic prognostic factors (BCR/ABL; ETV6/RUNX1, formerly TEL/AML1; MLL rearrangement; and ploidy changes of chromosomes) were also assessed.",0.60,PMID.dPMID19837270.s5.p4,5,4,ABL|ETV6|RUNX1|AML1|MLL,ABL|AML1|ETV6|MLL|RUNX1,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8609706,AML1,TEL,"Moreover, TEL/AML1 expression defined a distinct subgroup of patients characterized by an age between 1 and 10 years, B lineage immunophenotype, non-hyperdiploid DNA content and an excellent prognosis.",0.52,PMID.dPMID8609706.s1.p0,2,2,TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11801462,AML1,TEL,TEL-AML1 expression was normalized relative to the levels of AML1 transcripts.,0.45,PMID.dPMID11801462.s6.p0,3,2,TEL|AML1|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,15749681,AML1,TEL,We conclude that the incidence of TEL/AML1 is lower in the Indian population.,0.42,PMID.dPMID15749681.s0.p0,2,2,TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,10490596,AML-1,TEL,This translocation fuses a putative repressor domain from the TEL DNA-binding protein to nearly all of the AML-1B transcription factor.,0.41,PMID.dPMID10490596.s6.p0,2,2,TEL|AML-1,AML-1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,15704129,RUNX1,ETV6,ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications.,0.40,PMID.dPMID15704129.s11.p0,2,2,ETV6|RUNX1,ETV6|RUNX1,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,9359509,AML1,TEL,"In 14 of these cases (63%), TEL-AML1 expression was detected, whereas t(4;11), t(11;19) and t(9;22) translocations were found by molecular methods in only three cases (14%).",0.39,PMID.dPMID9359509.s2.p0,2,2,TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19813247,AML1,TEL,"We monitored the responses of patients with pediatric acute lymphoblastic leukemia (pALL) using DNA markers, TEL/AML1 expression, and scanning fluorescence microscopy (SFM).",0.34,PMID.dPMID19813247.s2.p0,2,2,TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19813247,AML1,TEL,"CD10+ ancestor cells with germline antigen receptors, but silent TEL/AML1 expression, may reside in the lymphoid stem cell compartment of treated t(12;21)-positive patients and might act as a potential source of cells for late relapses",0.26,PMID.dPMID19813247.s0.p2,3,3,CD10|TEL|AML1,AML1|CD10|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8913730,CBFA2,ETV6,Nine of the 34 patient samples expressed the ETV6/CBFA2 transcript.,0.23,PMID.dPMID8913730.s6.p0,2,2,ETV6|CBFA2,CBFA2|ETV6,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19890372,RUNX1,ETV6,Manipulation of ETV6/RUNX1 expression and chromatin immunoprecipitation studies showed that the high expression of the miRNA cluster is an event independent of the ETV6/RUNX1 fusion protein.,0.22,PMID.dPMID19890372.s4.p0,5,3,ETV6|RUNX1|chr|ETV6|RUNX1,chr|ETV6|RUNX1,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8751464,AML1,TEL,"In addition, our method could be a powerful tool for quantification of the TEL/AML1 transcript and for the detection of MRD",0.22,PMID.dPMID8751464.s0.p0,2,2,TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8657108,AML1,TEL,The t(12;21) translocation is present in up to 30% of childhood B-cell acute lymphoblastic and fuses a potential dimerization motif from the ets-related factor TEL to the N terminus of AML1.,0.21,PMID.dPMID8657108.s6.p0,2,2,TEL|AML1,AML1|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19403666,RUNX1,TEL,The TEL-RUNX1 fusion gene from acute B-lymphocytic leukemia retains almost all of the RUNX1 sequence but does not prevent B-cell proliferation in the same assay.,0.18,PMID.dPMID19403666.s5.p1,3,2,TEL|RUNX1|RUNX1,RUNX1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,9031076,AML1,TEL,"The crucial chimeric gene, TEL-AML1, is transcribed from the der(21) and encodes the 336 NH2 aminoacics of TEL fused to the majority of the AML1 protein.",0.18,PMID.dPMID9031076.s2.p3,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,9359509,AML1,TEL,Percentages of CD13 or CD33 expressing leukaemic cells were found to be higher in TEL-AML1 positive cases (n = 22) than in TEL-AML1 negative (n = 74) cases (P<0.001).,0.17,PMID.dPMID9359509.s4.p0,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,15837750,AML1,TEL,"The TEL-AML1 fusion product was expressed in all t(12;21)+ cases, whereas the reciprocal fusion product AML1-TEL was expressed in only 76%.",0.15,PMID.dPMID15837750.s4.p0,4,2,TEL|AML1|AML1|TEL,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11559948,AML1,TEL,"Deletion of 12p resulting in the loss of the normal allele of TEL and nonspecific del(6q) were noted in 8% (1/12) and 25% (3/12) of the TEL/AML1+ children, respectively.",0.14,PMID.dPMID11559948.s6.p2,3,2,TEL|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8751464,AML1,TEL,The reciprocal AML1/TEL transcripts were detected in 12 (86%) of the 14 cases expressing a TEL/AML1 transcript.,0.13,PMID.dPMID8751464.s10.p5,4,2,AML1|TEL|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,14527352,AML1,TEL,All fourteen patients positive for TEL/AML1 gene fusion were mosaic.,0.08,PMID.dPMID14527352.s13.p0,2,2,TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11001911,AML1,TEL,"This rearrangement results in the in frame fusion of the 5'-region of the ETS-related gene, TEL (ETV6), to almost the entire acute myeloid leukemia 1 (AML1) (also called CBFA2 or PEBP2AB1) locus and expression of the TEL-AML1 chimeric protein.",0.07,PMID.dPMID11001911.s4.p20,7,2,TEL|ETV6|acute myeloid leukemia 1|AML1|CBFA2|TEL|AML1,acute myeloid leukemia 1|AML1|CBFA2|ETV6|TEL,w
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,16965388,RUNX1,ETV6,ETV6/RUNX1 was found in 45% of cases and in the majority (10/18; 56%) of ALLs with sole +21.,0.07,PMID.dPMID16965388.s2.p0,3,3,ETV6|RUNX1|ALL,ALL|ETV6|RUNX1,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11001911,AML1,TEL,"Although AML1 stimulates transcription, TEL-AML1 functions as a repressor of some AML1 target genes.",0.06,PMID.dPMID11001911.s3.p4,4,2,AML1|TEL|AML1|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,9359534,AML1,TEL,TEL/AML1 transcript and p16 gene deletion in a patient with childhood acute lymphoblastic leukaemia.,0.06,PMID.dPMID9359534.s0.p0,3,3,TEL|AML1|p16,AML1|p16|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8751464,AML1,TEL,The reciprocal AML1/TEL transcripts were detected in 12 (86%) of the 14 cases expressing a TEL/AML1 transcript.,0.06,PMID.dPMID8751464.s10.p4,4,2,AML1|TEL|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11801462,AML1,TEL,The within-assay coefficient of variation (CV) for TEL-AML1 was 7.0% and the between-assay CV was 13%.,0.05,PMID.dPMID11801462.s3.p0,2,2,TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,9359509,AML1,TEL,These data show that TEL-AML1 expression is significantly associated with myeloid antigen expression by leukaemic cells and suggests that the prognostic significance of myeloid antigen expression in paediatric ALLs should be re-evaluated in the light of molecular cytogenetic markers.,0.04,PMID.dPMID9359509.s0.p0,2,2,TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,10910927,AML1,TEL,"After matching for unevenly distributed patient characteristics-that is, excluding patients younger than 12 months, patients with CD10-negative immature B-lineage ALL, patients with Philadelphia chromosome, and patients who were hyperdiploid (more than 50 chromosomes) from the TEL/AML1 negative group-the only remaining difference was a relative sensitivity for ASP in the TEL/AML1-positive samples (10.8-fold; P =. 012).",0.04,PMID.dPMID10910927.s1.p2,5,3,ALL|TEL|AML1|TEL|AML1,ALL|AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,20197715,AML1,TEL,RESULTS: The frequency of TEL/AML1 was 17.1% (21/123) in patients with precursor B-ALL.,0.04,PMID.dPMID20197715.s7.p0,2,2,TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,18635414,AML1,TEL,Reduced levels of TEL/AML1 expression were found in four of the six patients whose bone marrow or peripheral blood samples were obtained after treatment.,0.04,PMID.dPMID18635414.s1.p0,2,2,TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,12220513,AML1,TEL,"Here, we show that TEL/AML1 is localized in the cytoplasm and the transcriptional activities of CR1 promoter are affected by the subcellular localization of TEL/AML1 fusion protein",0.03,PMID.dPMID12220513.s0.p0,5,3,TEL|AML1|CR1|TEL|AML1,AML1|CR1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19010836,RUNX1,ETV6,Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.,0.03,PMID.dPMID19010836.s12.p0,2,2,ETV6|RUNX1,ETV6|RUNX1,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,8834231,AML-1,TEL,"The t(8;21) creates a fusion protein between AML-1 and a gene of unknown function, mtg8 (ETO), whereas the t(12;21) fuses the TEL (translocation-ets-leukemia) transcription factor to the N-terminus of AML-1.",0.03,PMID.dPMID8834231.s2.p5,4,3,AML-1|ETO|TEL|AML-1,AML-1|ETO|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,11801462,AML1,TEL,DESIGN AND METHODS: The quantitative estimation of TEL-AML1 transcripts was performed in 10 P-ALL TEL-AML1-positive patients.,0.02,PMID.dPMID11801462.s9.p3,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,10488742,AML1,TEL,"The 12;21 chromosomal translocation occurs in leukemic cells from 20(30% of patients with B-lineage childhood acute lymphoblastic leukemia, the result being the TEL/AML1 fusion gene carrying a sequence different from TEL or AML1.",0.02,PMID.dPMID10488742.s6.p3,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,15356655,AML1,TEL,"TEL deletions, trisomy 21 and an additional der(21)t(12;21) were detected in 52 (55%), 13 (14%) and 14 (15%) TEL/AML1+ patients, respectively.",0.01,PMID.dPMID15356655.s5.p2,3,2,TEL|TEL|AML1,AML1|TEL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.6.1,2120,9606,,,19837270,RUNX1,ETV6,"The prognostic significance of the profiles of these genes and the association between alterations in these genes and known cytogenetic prognostic factors (BCR/ABL; ETV6/RUNX1, formerly TEL/AML1; MLL rearrangement; and ploidy changes of chromosomes) were also assessed.",0.00,PMID.dPMID19837270.s5.p2,5,4,ABL|ETV6|RUNX1|AML1|MLL,ABL|AML1|ETV6|MLL|RUNX1,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.3.5.0.21,2122,9606,,GO:0016481|GO:0045892|GO:0045893,17693194,EVI1,MDS1-EVI1,A hematologic complete remission was accompanied by a reduction of MDS1-EVI1/ EVI1 expression levels of at least 2 log while persistent leukemia was reflected by an MDS1-EVI1/ EVI1 expression in the range of the primary diagnostic sample.,0.30,PMID.dPMID17693194.s3.p5,4,2,MDS1-EVI1|EVI1|MDS1-EVI1|EVI1,EVI1|MDS1-EVI1,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.3.5.0.21,2122,9606,,GO:0016481|GO:0045892|GO:0045893,17693194,EVI1,MDS1-EVI1,A hematologic complete remission was accompanied by a reduction of MDS1-EVI1/ EVI1 expression levels of at least 2 log while persistent leukemia was reflected by an MDS1-EVI1/ EVI1 expression in the range of the primary diagnostic sample.,0.24,PMID.dPMID17693194.s3.p0,4,2,MDS1-EVI1|EVI1|MDS1-EVI1|EVI1,EVI1|MDS1-EVI1,e
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,16628190,RUNX1,GATA1,"Thus, our data indicate that physical interaction and synergy between GATA1 and RUNX1 are retained in DS-AMKL, although it is still possible that increased RUNX1 activity plays a role in the development of leukemia in DS",0.21,PMID.dPMID16628190.s0.p1,3,2,GATA1|RUNX1|RUNX1,GATA1|RUNX1,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.3.5.0.37,2672,9606,,GO:0000083|GO:0010553,20075157,AML1,GFI1,We observed that both GFI1 variants maintain the same activity as transcriptional repressors but differ in their regulation by the AML1/ETO (RUNX1/RUNX1T1) fusion protein produced in AML patients with a t(8;21) translocation.,0.31,PMID.dPMID20075157.s4.p0,3,3,GFI1|AML1|ETO,AML1|ETO|GFI1,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17684492,Runx1,HIF-1alpha,"Vice versa, HIF-1alpha increased DNA-binding ability and transcriptional activity of Runx1 protein.",0.28,PMID.dPMID17684492.s1.p0,2,2,HIF-1alpha|Runx1,HIF-1alpha|Runx1,c
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17684492,Runx1,HIF-1,"More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1.",0.13,PMID.dPMID17684492.s2.p11,7,2,Runx1|HIF-1|HIF-1|Runx1|HIF-1|Runx1|HIF-1,HIF-1|Runx1,c
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17684492,Runx1,HIF-1,"More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1.",0.08,PMID.dPMID17684492.s2.p4,7,2,Runx1|HIF-1|HIF-1|Runx1|HIF-1|Runx1|HIF-1,HIF-1|Runx1,c
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,19235904,Runx1,TCF,"Both Cdk and ERK phosphorylate Runx1 to influence its interaction with co-repressors, and the Wnt effector LEF-1/TCF also modulates Runx1 activities.",0.96,PMID.dPMID19235904.s4.p9,5,4,ERK|Runx1|LEF-1|TCF|Runx1,ERK|LEF-1|Runx1|TCF,c
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,15024077,AML1,TCF,"The induction of plakoglobin by AML fusion proteins led to downstream signaling and transactivation of TCF- and LEF-dependent promoters, including the c-myc promoter, which was found to be bound by plakoglobin in vivo after AML1-ETO expression.",0.76,PMID.dPMID15024077.s5.p7,5,4,plakoglobin|TCF|c-myc|plakoglobin|AML1,AML1|c-myc|plakoglobin|TCF,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,9118910,AML1,MLL,The MLL gene at 11q23 or the AML1 gene at 21q22 are almost uniformly rearranged.,0.03,PMID.dPMID9118910.s3.p0,2,2,MLL|AML1,AML1|MLL,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15024077,AML1,c-myc,"The induction of plakoglobin by AML fusion proteins led to downstream signaling and transactivation of TCF- and LEF-dependent promoters, including the c-myc promoter, which was found to be bound by plakoglobin in vivo after AML1-ETO expression.",1.40,PMID.dPMID15024077.s5.p8,5,4,plakoglobin|TCF|c-myc|plakoglobin|AML1,AML1|c-myc|plakoglobin|TCF,x
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,16832676,AML1,RAR,"In primary AML samples, RARbeta2 expression was uniformly low; however, no specific correlation was observed between the methylation of the RARbeta2 gene and expression of the fusion proteins, PML-RARalpha, and AML1-ETO.",0.32,PMID.dPMID16832676.s1.p7,5,3,RAR|RAR|PML|RAR|AML1,AML1|PML|RAR,n
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,20696839,Runx1,PU.1,"Until now, only the promoter plus a distal upstream regulatory element (URE) could be invoked to explain nearly all Sfpi1 (PU.1) activation and repression, including bifunctional effects of Runx1.",0.05,PMID.dPMID20696839.s5.p2,3,2,Sfpi1|PU.1|Runx1,PU.1|Runx1|Sfpi1,c
6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,19235904,Runx1,LEF-1,"Both Cdk and ERK phosphorylate Runx1 to influence its interaction with co-repressors, and the Wnt effector LEF-1/TCF also modulates Runx1 activities.",0.96,PMID.dPMID19235904.s4.p8,5,4,ERK|Runx1|LEF-1|TCF|Runx1,ERK|LEF-1|Runx1|TCF,c
6.4.1.0.3,864,9606,,GO:0006355,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19403666,RUNX3,RUNX1,Cross-regulation of RUNX1 expression by RUNX3 plays a critical role in regulating proliferation of human B cells infected with Epstein-Barr virus (EBV).,0.72,PMID.dPMID19403666.s7.p0,2,2,RUNX1|RUNX3,RUNX1|RUNX3,x
6.4.1.0.3,864,9606,,GO:0006355,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19403666,RUNX3,RUNX1,Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation.,0.49,PMID.dPMID19403666.s8.p0,3,2,RUNX1|RUNX3|RUNX3,RUNX1|RUNX3,p
6.4.1.0.3,864,9606,,GO:0006355,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19603429,RUNX3,RUNX1,Repression of RUNX1 by RUNX3 is required to allow the cell proliferation and this provides an experimental system to investigate the mechanism of the different activities of RUNX1 and RUNX3 in these cells.,0.43,PMID.dPMID19603429.s0.p0,4,2,RUNX1|RUNX3|RUNX1|RUNX3,RUNX1|RUNX3,c
6.4.1.0.3,864,9606,,GO:0006355,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19403666,RUNX3,RUNX1,Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation.,0.37,PMID.dPMID19403666.s8.p1,3,2,RUNX1|RUNX3|RUNX3,RUNX1|RUNX3,p
6.4.1.0.3,864,9606,,GO:0006355,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16584381,RUNX3,RUNX1,"Epstein Barr virus immortalized human B lymphoblastoid cell lines express RUNX3, and cross-regulation of RUNX1 by RUNX3 occurs in these cells.",0.31,PMID.dPMID16584381.s1.p2,3,2,RUNX3|RUNX1|RUNX3,RUNX1|RUNX3,x
6.4.1.0.3,864,9606,,GO:0006355,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19446338,RUNX3,RUNX1,"Chromatin immunoprecipitation assays revealed that RUNX1 constitutively occupies the CD6 promoter in vivo, and knockdown experiments demonstrated that the steady-state level of CD6 mRNA is dependent on the expression of RUNX1, RUNX3 and Ets-1 transcription factors.",0.26,PMID.dPMID19446338.s1.p6,6,4,RUNX1|CD6|CD6|RUNX1|RUNX3|Ets-1,CD6|Ets-1|RUNX1|RUNX3,x
6.4.1.0.3,864,9606,,GO:0006355,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,16627973,RUNX3,FKHRL1,The cooperation between RUNX3 and the PI3K/Akt signaling pathway component FoxO3a/FKHRL1 suggests the putative role of RUNX3 in the homoeostasis of gastric cells and in stomach cancer control.,0.30,PMID.dPMID16627973.s1.p9,5,3,RUNX3|Akt|FoxO3a|FKHRL1|RUNX3,Akt|FKHRL1|FoxO3a|RUNX3,c
6.4.1.0.3,864,9606,,GO:0006355,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,16627973,RUNX3,FoxO3a,The cooperation between RUNX3 and the PI3K/Akt signaling pathway component FoxO3a/FKHRL1 suggests the putative role of RUNX3 in the homoeostasis of gastric cells and in stomach cancer control.,0.30,PMID.dPMID16627973.s1.p8,5,3,RUNX3|Akt|FoxO3a|FKHRL1|RUNX3,Akt|FKHRL1|FoxO3a|RUNX3,c
6.4.1.0.3,864,9606,,GO:0006355,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20442291,RUNX3,c-Myc,c-Myc oncogene was found to be downregulated by BMP and/or RUNX3.,0.00,PMID.dPMID20442291.s2.p0,2,2,c-Myc|RUNX3,c-Myc|RUNX3,e
3.1.1.8.2,1045,9606,,,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,15389642,CDX2,GATA-4,"Like in the colonic epithelium, GATA-4 was found to be also lacking in Caco-2 cells while CDX2 and HNF-1alpha were present at significant levels.",0.00,PMID.dPMID15389642.s3.p0,2,2,GATA-4|CDX2,CDX2|GATA-4,x
3.1.1.8.2,1045,9606,,,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,20637099,Cdx-2,Oct-1,Hydrogen peroxide stimulates nuclear import of the POU homeodomain protein Oct-1 and its repressive effect on the expression of Cdx-2.,1.08,PMID.dPMID20637099.s10.p0,2,2,Oct-1|Cdx-2,Cdx-2|Oct-1,e
3.1.1.8.2,1045,9606,,,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,16278805,CDX2,OCT-1,The aim of this study was to access the putative involvement of OCT-1 in the induction of CDX2 expression de novo in gastric mucosa leading to the onset of IM.,0.46,PMID.dPMID16278805.s6.p0,2,2,OCT-1|CDX2,CDX2|OCT-1,e
3.1.1.8.2,1045,9606,,,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,20637099,Cdx-2,Oct-1,"cAMP elevation leads to increased nuclear exclusion of Oct-1, associated with reduced recruitment of nuclear co-repressors to the Cdx-2 promoter and increased Cdx-2 expression.",0.22,PMID.dPMID20637099.s5.p1,3,2,Oct-1|Cdx-2|Cdx-2,Cdx-2|Oct-1,p
3.1.1.8.2,1045,9606,,,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,17922593,CDX2,TTF-1,"RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.",0.51,PMID.dPMID17922593.s2.p324,31,5,TTF-1|CDX2|CK7|TTF-1|CDX2|CK7|CK7|MUC5AC|TTF-1|CDX2|GCDFP-15|GCDFP-15|TTF-1|CDX2|CK7|TTF-1|CDX2|MUC5AC|TTF-1|TTF-1|CDX2|CK7|GCDFP-15|MUC5AC|TTF-1|CDX2|CK7|MUC5AC|TTF-1|CDX2|CK7,CDX2|CK7|GCDFP-15|MUC5AC|TTF-1,x
3.1.1.8.2,1045,9606,,,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,17922593,CDX2,TTF-1,"RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.",0.26,PMID.dPMID17922593.s2.p318,31,5,TTF-1|CDX2|CK7|TTF-1|CDX2|CK7|CK7|MUC5AC|TTF-1|CDX2|GCDFP-15|GCDFP-15|TTF-1|CDX2|CK7|TTF-1|CDX2|MUC5AC|TTF-1|TTF-1|CDX2|CK7|GCDFP-15|MUC5AC|TTF-1|CDX2|CK7|MUC5AC|TTF-1|CDX2|CK7,CDX2|CK7|GCDFP-15|MUC5AC|TTF-1,x
3.1.1.8.2,1045,9606,,,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,17922593,CDX2,TTF-1,"RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.",0.15,PMID.dPMID17922593.s2.p434,31,5,TTF-1|CDX2|CK7|TTF-1|CDX2|CK7|CK7|MUC5AC|TTF-1|CDX2|GCDFP-15|GCDFP-15|TTF-1|CDX2|CK7|TTF-1|CDX2|MUC5AC|TTF-1|TTF-1|CDX2|CK7|GCDFP-15|MUC5AC|TTF-1|CDX2|CK7|MUC5AC|TTF-1|CDX2|CK7,CDX2|CK7|GCDFP-15|MUC5AC|TTF-1,x
3.1.1.8.2,1045,9606,,,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,17922593,CDX2,TTF-1,"RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.",0.03,PMID.dPMID17922593.s2.p319,31,5,TTF-1|CDX2|CK7|TTF-1|CDX2|CK7|CK7|MUC5AC|TTF-1|CDX2|GCDFP-15|GCDFP-15|TTF-1|CDX2|CK7|TTF-1|CDX2|MUC5AC|TTF-1|TTF-1|CDX2|CK7|GCDFP-15|MUC5AC|TTF-1|CDX2|CK7|MUC5AC|TTF-1|CDX2|CK7,CDX2|CK7|GCDFP-15|MUC5AC|TTF-1,x
1.1.4.1.1,1050,9606,,GO:0045945,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,17347301,C/EBPalpha,ATF4,ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBPepsilon and C/EBPalpha.,1.16,PMID.dPMID17347301.s9.p1,3,3,ATF4|C/EBPepsilon|C/EBPalpha,ATF4|C/EBPalpha|C/EBPepsilon,c
1.1.4.1.1,1050,9606,,GO:0045945,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,17347301,C/EBPalpha,ATF4,We propose that ATF4 may regulate myeloid gene expression differentially by potentiating C/EBPepsilon but inhibiting C/EBPalpha-mediated transcriptional activation,0.84,PMID.dPMID17347301.s0.p1,3,3,ATF4|C/EBPepsilon|C/EBPalpha,ATF4|C/EBPalpha|C/EBPepsilon,c
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16247445,C/EBPalpha,AML1,"Although AML1-ETO downregulates the expression of C/EBPalpha, changes in C/EBPalpha expression do not correlate with changes in the expression of ELA2.",1.24,PMID.dPMID16247445.s3.p3,5,4,AML1|ETO|C/EBPalpha|C/EBPalpha|ELA2,AML1|C/EBPalpha|ELA2|ETO,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16247445,C/EBPalpha,AML1,"Although AML1-ETO downregulates the expression of C/EBPalpha, changes in C/EBPalpha expression do not correlate with changes in the expression of ELA2.",0.74,PMID.dPMID16247445.s3.p1,5,4,AML1|ETO|C/EBPalpha|C/EBPalpha|ELA2,AML1|C/EBPalpha|ELA2|ETO,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11283671,C/EBPalpha,AML1,AML1-ETO appears to suppress C/EBPalpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter.,0.68,PMID.dPMID11283671.s2.p0,3,2,AML1|C/EBPalpha|CEBPA,AML1|CEBPA|C/EBPalpha,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,17894555,C/EBPalpha,RUNX1,"Therefore, recruitment of histone deacetylase via CtBP and disruption of DNA binding could be likely scenarios for the RUNX1/EVI1-induced dominant repression on C/EBPalpha.",0.52,PMID.dPMID17894555.s2.p1,3,2,RUNX1|EVI1|C/EBPalpha,C/EBPalpha|EVI1|RUNX1,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,17894555,C/EBPalpha,EVI1,"Therefore, recruitment of histone deacetylase via CtBP and disruption of DNA binding could be likely scenarios for the RUNX1/EVI1-induced dominant repression on C/EBPalpha.",0.52,PMID.dPMID17894555.s2.p2,3,2,RUNX1|EVI1|C/EBPalpha,C/EBPalpha|EVI1|RUNX1,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,12472578,CEBPA,AML1,"In one of them, the fusion gene AML1/ETO, reported to cause transcription repression of CEBPA, was also present, suggesting that more than one mechanism might collaborate to suppress CEBPA gene expression.",0.36,PMID.dPMID12472578.s1.p1,4,3,AML1|ETO|CEBPA|CEBPA,AML1|CEBPA|ETO,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11283671,CEBPA,AML1,AML1-ETO appears to suppress C/EBPalpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter.,0.25,PMID.dPMID11283671.s2.p1,3,2,AML1|C/EBPalpha|CEBPA,AML1|CEBPA|C/EBPalpha,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16247445,C/EBPalpha,AML1,"Our observations indicate that AML1-ETO may not be a constitutive repressor of gene expression in every case in which it can associate with DNA, either on its own or in conjunction with C/EBPalpha.",0.22,PMID.dPMID16247445.s2.p1,3,3,AML1|ETO|C/EBPalpha,AML1|C/EBPalpha|ETO,w
1.1.4.1.1,1050,9606,,GO:0045945,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,15326310,CEBPA,AML1,The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.,0.18,PMID.dPMID15326310.s9.p0,2,2,AML1|CEBPA,AML1|CEBPA,w
1.1.4.1.1,1050,9606,,GO:0045945,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,19620289,Cebpa,GATA-2,"Surprisingly, GATA-2 also negatively regulates the expression of crucial myeloid transcription factors, such as Sfpi1 and Cebpa.",0.21,PMID.dPMID19620289.s3.p1,3,3,GATA-2|Sfpi1|Cebpa,Cebpa|GATA-2|Sfpi1,e
1.1.4.1.1,1050,9606,,GO:0045945,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,18550858,C/EBPalpha,GATA-2,"Ectopic GATA-2 expression suppressed the proliferation inhibitory effect of C/EBPalpha but blocked in part the effect on differentiation; GATA-2 siRNA treatment had no effects on C/EBPalpha induction of differentiation but inhibited proliferation of K562 cells, alone or upon C/EBPalpha activation.",0.03,PMID.dPMID18550858.s2.p9,7,3,GATA-2|C/EBPalpha|dif|GATA-2|C/EBPalpha|dif|C/EBPalpha,C/EBPalpha|dif|GATA-2,n
1.1.4.1.1,1050,9606,,GO:0045945,3.3.1.1.3,3171,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,19074951,CEBPA,HNF3G,"In exploring the DNA regions and TRFs involved in combinatorial transcriptional regulation, we noted that individual knockdown of a set of human liver-enriched TRFs such as HNF1A, HNF3A, HNF3B, HNF3G and HNF4A resulted in perturbation of the expression of several single TRF genes, such as HNF1A, HNF3G and CEBPA genes.",0.10,PMID.dPMID19074951.s5.p7,5,3,HNF1A|HNF3G|HNF1A|HNF3G|CEBPA,CEBPA|HNF1A|HNF3G,e
1.1.4.1.1,1050,9606,,GO:0045945,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12879022,C/EBPalpha,c-Jun,"We, therefore, hypothesized that c-Jun expression might be elevated in AML and subsequently inactivate C/EBPalpha.",0.37,PMID.dPMID12879022.s6.p0,2,2,c-Jun|C/EBPalpha,C/EBPalpha|c-Jun,e
1.1.4.1.1,1050,9606,,GO:0045945,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,15604894,CEBPA,MLL,"RECENT FINDINGS: Four prognostic biomarkers-the internal tandem duplication and point mutations in the FLT3 gene, partial tandem duplication of the MLL gene, mutations of the CEBPA gene, and overexpression of the BAALC gene-have been found to predict outcome in patients with AML and normal cytogenetics.",0.64,PMID.dPMID15604894.s4.p2,4,4,FLT3|MLL|CEBPA|BAALC,BAALC|CEBPA|FLT3|MLL,x
1.1.4.1.1,1050,9606,,GO:0045945,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17488484,CEBPA,MLL,"They include internal tandem duplication of the FLT3 gene, partial tandem duplication of the MLL gene, mutations of the CEBPA and NPM1 genes and aberrant expression of the BAALC, ERG and MN1 genes.",0.54,PMID.dPMID17488484.s3.p2,4,4,FLT3|MLL|CEBPA|ERG,CEBPA|ERG|FLT3|MLL,x
1.1.4.1.1,1050,9606,,GO:0045945,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPalpha,Myc,"A number of tumor suppressor genes are targets of Myc transcriptional repression including C/EBPalpha, p15INK4, p21CIP1, p27KIP1 and p57KIP2.",0.53,PMID.dPMID20426839.s12.p0,4,4,Myc|C/EBPalpha|p21CIP1|p57KIP2,C/EBPalpha|Myc|p21CIP1|p57KIP2,e
1.1.4.1.1,1050,9606,,GO:0045945,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19259613,CEBPA,MYC,"Furthermore, IL-6 up-regulated the expression of MYC via STAT3 phosphorylation and MYC bound to the promoter region of the CEBPA gene followed by the down-regulation of CEBPA expression.",0.25,PMID.dPMID19259613.s2.p11,6,4,IL-6|MYC|STAT3|MYC|CEBPA|CEBPA,CEBPA|IL-6|MYC|STAT3,p
1.1.4.1.1,1050,9606,,GO:0045945,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19259613,CEBPA,MYC,"Furthermore, IL-6 up-regulated the expression of MYC via STAT3 phosphorylation and MYC bound to the promoter region of the CEBPA gene followed by the down-regulation of CEBPA expression.",0.04,PMID.dPMID19259613.s2.p7,6,4,IL-6|MYC|STAT3|MYC|CEBPA|CEBPA,CEBPA|IL-6|MYC|STAT3,p
1.1.4.1.1,1050,9606,,GO:0045945,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,19059241,C/EBPalpha,PPARgamma,"CDX1 enhanced the expression of PPARgamma gene, a master transcriptional regulator of intestinal differentiation, at the transcriptional level, via functional interaction with CCAAT/enhancer-binding protein alpha (C/EBPalpha).",0.27,PMID.dPMID19059241.s2.p2,3,3,CDX1|PPARgamma|C/EBPalpha,CDX1|C/EBPalpha|PPARgamma,-->
1.1.4.1.1,1050,9606,,GO:0045945,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15160934,C/EBPalpha,RARalpha,PML-RARalpha appears to cause leukemia by acting as a transcriptional repressor of RARalpha target genes and by inhibiting activity of transcription factor C/EBPalpha.,0.03,PMID.dPMID15160934.s2.p4,4,3,PML|RARalpha|RARalpha|C/EBPalpha,C/EBPalpha|PML|RARalpha,c
1.1.4.1.1,1050,9606,,GO:0045945,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,18524846,C/EBPalpha,Sp1,Chromatin immunoprecipitation assays confirmed that Sp1 and C/EBPalpha compete for binding at the overlapping C/EBPalpha and Sp1 sites and reciprocally regulate CRMP-1 expression.,0.25,PMID.dPMID18524846.s5.p1,5,3,Sp1|C/EBPalpha|C/EBPalpha|Sp1|CRMP-1,C/EBPalpha|CRMP-1|Sp1,c
1.1.4.1.1,1050,9606,,GO:0045945,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,12424252,C/EBPalpha,SREBP-1,"Despite decreased levels of CNTFRalpha expression in fully differentiated 3T3-L1 adipocytes, CNTF treatment of these cells resulted in a time-dependent activation of STAT 3. Chronic treatment of adipocytes resulted in a substantial decrease in fatty-acid synthase and a notable decline in SREBP-1 levels but had no effect on the expression of peroxisome proliferator-activated receptor gamma, acrp30, adipocyte-expressed STAT proteins, or C/EBPalpha.",0.12,PMID.dPMID12424252.s4.p5,4,4,CNTFRalpha|CNTF|SREBP-1|C/EBPalpha,C/EBPalpha|CNTF|CNTFRalpha|SREBP-1,x
1.1.4.1.1,1050,9606,,GO:0045945,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,19620402,C/EBPalpha,LEF-1,"We have identified LEF-1 as a decisive transcription factor in granulopoiesis controlling proliferation and granulocytic differentiation by direct activation of its target gene, C/EBPalpha.",0.36,PMID.dPMID19620402.s5.p0,2,2,LEF-1|C/EBPalpha,C/EBPalpha|LEF-1,p
1.1.4.1.2,1051,9606,,,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8264594,NF-IL6,Fos,Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region.,0.75,PMID.dPMID8264594.s9.p1,3,3,Fos|Jun|NF-IL6,Fos|Jun|NF-IL6,c
1.1.4.1.2,1051,9606,,,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12574125,C/EBPbeta,Id-1,"The interleukin-3 (IL-3)-dependent expression of the Id-1 gene, encoding a helix-loop-helix (HLH) transcriptional inhibitor, is activated by both C/EBPbeta and STAT5 transcription factors bound to its pro-B-cell enhancer (PBE), but is inhibited by HDAC inhibitors in Ba/F3 cells.",0.82,PMID.dPMID12574125.s3.p5,7,6,interleukin-3|IL-3|Id-1|C/EBPbeta|STAT5|PBE|HDAC,C/EBPbeta|HDAC|Id-1|IL-3|interleukin-3|PBE|STAT5,p
1.1.4.1.2,1051,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15044620,C/EBPbeta,AP-1,"Deletions within the putative AP-1 box (-123 to -111) increased MDR1 promoter activity when stimulated by C/EBPbeta, suggesting that the AP-1 site negatively regulates MDR1 activation by C/EBPbeta.",1.38,PMID.dPMID15044620.s5.p5,4,2,AP-1|C/EBPbeta|AP-1|C/EBPbeta,AP-1|C/EBPbeta,c
1.1.4.1.2,1051,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8264594,NF-IL6,AP-1,"Thus, association with AP-1 results in repression of transcription activation by NF-IL6.",1.35,PMID.dPMID8264594.s1.p0,2,2,AP-1|NF-IL6,AP-1|NF-IL6,c
1.1.4.1.2,1051,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8264594,NF-IL6,Jun,Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region.,0.80,PMID.dPMID8264594.s9.p2,3,3,Fos|Jun|NF-IL6,Fos|Jun|NF-IL6,c
1.1.4.1.2,1051,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15044620,C/EBPbeta,AP-1,"Deletions within the putative AP-1 box (-123 to -111) increased MDR1 promoter activity when stimulated by C/EBPbeta, suggesting that the AP-1 site negatively regulates MDR1 activation by C/EBPbeta.",0.22,PMID.dPMID15044620.s5.p3,4,2,AP-1|C/EBPbeta|AP-1|C/EBPbeta,AP-1|C/EBPbeta,c
1.1.4.1.2,1051,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15044620,C/EBPbeta,AP-1,"Deletions within the putative AP-1 box (-123 to -111) increased MDR1 promoter activity when stimulated by C/EBPbeta, suggesting that the AP-1 site negatively regulates MDR1 activation by C/EBPbeta.",0.03,PMID.dPMID15044620.s5.p0,4,2,AP-1|C/EBPbeta|AP-1|C/EBPbeta,AP-1|C/EBPbeta,c
1.1.4.1.2,1051,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,15048722,NF-IL6,NF-kappa B,"In this study, we show that the IL-4 promoter is synergistically activated by NF-kappa B, NF-AT and NF-IL6 at the NF-kappa B/NF-AT/NF-IL6 composite sites.",0.20,PMID.dPMID15048722.s4.p9,5,3,IL-4|NF-kappa B|NF-IL6|NF-kappa B|NF-IL6,IL-4|NF-IL6|NF-kappa B,c
1.1.4.1.2,1051,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1427600,NF-IL6,NF-kappa B,Synergism between transcription factors NF-IL6 and NF-kappa B in IL-6 gene regulation   NF-IL6 and NF-kappa B are nuclear proteins supposed to play an important role in the regulation of acute-phase protein synthesis and inflammatory response against infection and tissue injury as a host defence mechanism.,0.04,PMID.dPMID1427600.s9.p4,5,3,NF-IL6|NF-kappa B|IL-6|NF-IL6|NF-kappa B,IL-6|NF-IL6|NF-kappa B,c
1.1.4.1.2,1051,9606,,,2.1.4.0.2,4929,9606,GO:0030528,GO:0034339,17224121,C/EBPbeta,NR4A2,Study of the involvement of C/EBPbeta in the 1alpha-hydroxylase regulation revealed that the transcriptional enhancement by NR4A2 on the 1alpha-hydroxylase promoter is inhibited by C/EBPbeta.,0.02,PMID.dPMID17224121.s1.p2,3,2,C/EBPbeta|NR4A2|C/EBPbeta,C/EBPbeta|NR4A2,c
1.1.4.1.2,1051,9606,,,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,17303761,C/EBPbeta,PPARdelta,"Intriguingly, activation or knock down of endogenous PPARdelta regulated C/EBPbeta protein expression.",2.01,PMID.dPMID17303761.s2.p0,2,2,PPARdelta|C/EBPbeta,C/EBPbeta|PPARdelta,e
1.1.4.1.2,1051,9606,,,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,8207232,NF-IL-6,RelA,"In addition, overexpression of the NF-kappa B inhibitor molecule, I kappa B, abolished the RelA- and RelA/NF-IL-6-dependent synergistic activation.",0.15,PMID.dPMID8207232.s1.p5,4,3,NF-kappa B|RelA|RelA|NF-IL-6,NF-IL-6|NF-kappa B|RelA,c
1.1.4.1.2,1051,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9359698,C/EBPbeta,p53,Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta.,0.51,PMID.dPMID9359698.s6.p1,3,3,p53|CIP1|C/EBPbeta,C/EBPbeta|CIP1|p53,c
1.1.4.1.2,1051,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20446924,C/EBPbeta,p53,"Our reports, here and previously published, show that repression of p53 by RBP-Jkappa and activation of p53 by C/EBPbeta through differential binding of these two factors indicates a type of co-operative regulation in p53 expression.",0.16,PMID.dPMID20446924.s1.p5,5,3,p53|RBP-Jkappa|p53|C/EBPbeta|p53,C/EBPbeta|p53|RBP-Jkappa,c
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,CONCLUSION: Myc represses C/EBPdelta expression by associating with the C/EBPdelta proximal promoter as a transient component of a repressive complex that includes Max and Miz1.,2.02,PMID.dPMID20426839.s2.p0,4,3,Myc|C/EBPdelta|C/EBPdelta|Max,C/EBPdelta|Max|Myc,p
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,This study investigated the mechanisms underlying Myc repression of C/EBPdelta expression.,1.35,PMID.dPMID20426839.s11.p0,2,2,Myc|C/EBPdelta,C/EBPdelta|Myc,e
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,Miz1 and Max siRNA treatments attenuate Myc repression of endogenous C/EBPdelta expression.,0.95,PMID.dPMID20426839.s4.p2,3,3,Max|Myc|C/EBPdelta,C/EBPdelta|Max|Myc,e
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,"These results identify protein interactions that mediate Myc repression of C/EBPdelta, and possibly other tumor suppressor genes, and suggest new therapeutic targets to block Myc transcriptional repression and oncogenic function",0.85,PMID.dPMID20426839.s0.p0,3,2,Myc|C/EBPdelta|Myc,C/EBPdelta|Myc,e
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,"Max siRNA expression, or expression of a Myc construct lacking the HLH/LZ (Max interacting) region, also reduces Myc repression of C/EBPdelta promoter activity.",0.32,PMID.dPMID20426839.s5.p9,5,3,Max|Myc|Max|Myc|C/EBPdelta,C/EBPdelta|Max|Myc,p
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,"RESULTS: Myc represses C/EBPdelta promoter activity in nontransformed mammary epithelial cells in a dose-dependent manner that requires Myc Box II, Basic Region and HLH/LZ domains.",0.20,PMID.dPMID20426839.s10.p0,3,2,Myc|C/EBPdelta|Myc,C/EBPdelta|Myc,p
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,RuvBl1 and RuvBl2 enhance Myc repression of C/EBPdelta promoter activity.,0.14,PMID.dPMID20426839.s1.p5,4,4,RuvBl1|RuvBl2|Myc|C/EBPdelta,C/EBPdelta|Myc|RuvBl1|RuvBl2,p
1.1.4.1.4,1052,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20426839,C/EBPdelta,Myc,Miz1 siRNA expression or expression of a Miz1 binding deficient Myc (MycV394D) construct reduces Myc repression of C/EBPdelta promoter activity.,0.07,PMID.dPMID20426839.s6.p5,4,2,Myc|Myc|Myc|C/EBPdelta,C/EBPdelta|Myc,p
1.1.4.1.4,1052,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,19800021,C/EBPdelta,NF-kappaB,"Taken together, these results suggest a potentially crucial role for NF-kappaB in the IL-1-induced expression of C/EBPdelta, and thereby downstream APP genes regulated by this transcription factor",0.45,PMID.dPMID19800021.s0.p0,3,3,NF-kappaB|C/EBPdelta|APP,APP|C/EBPdelta|NF-kappaB,e
1.1.4.1.5,1053,9606,,,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,17347301,C/EBPepsilon,ATF4,ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBPepsilon and C/EBPalpha.,1.22,PMID.dPMID17347301.s9.p0,3,3,ATF4|C/EBPepsilon|C/EBPalpha,ATF4|C/EBPalpha|C/EBPepsilon,c
1.1.4.1.5,1053,9606,,,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,17347301,C/EBPepsilon,ATF4,We propose that ATF4 may regulate myeloid gene expression differentially by potentiating C/EBPepsilon but inhibiting C/EBPalpha-mediated transcriptional activation,0.54,PMID.dPMID17347301.s0.p0,3,3,ATF4|C/EBPepsilon|C/EBPalpha,ATF4|C/EBPalpha|C/EBPepsilon,c
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15378003,KLF6,c-Jun,"We also show that all KLF6 effects on c-Jun were largely dependent on phorbol ester (TPA/ionomycin) extracellular stimulation, which enhanced KLF6 nuclear translocation and transcriptional activity and modified its phosphorylation status.",0.11,PMID.dPMID15378003.s1.p2,3,2,KLF6|c-Jun|KLF6,c-Jun|KLF6,c
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,2.3.5.0.42,5325,9606,,GO:0045944,10366751,PAC1,Zac,We report here that p53 and Zac induce expression of the PAC1-R gene.,0.96,PMID.dPMID10366751.s1.p2,3,3,p53|Zac|PAC1,p53|PAC1|Zac,e
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16054710,KLF6,Sp1,"Furthermore, ectopic expression of Sp1 increased the transcriptional activity of the KLF6 promoter.",0.45,PMID.dPMID16054710.s1.p0,2,2,Sp1|KLF6,KLF6|Sp1,c
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,2.3.1.0.3,6668,9606,GO:0003702,GO:0006357,17071613,KLF6,SP2,"However, upon activation of FXR, SHP interacts with SP2 and KLF6, disrupting the SP2/KLF6 repressor complex.",0.34,PMID.dPMID17071613.s1.p9,5,3,FXR|SP2|KLF6|SP2|KLF6,FXR|KLF6|SP2,c
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18174288,KLF6,p53,Small interfering RNA against p53 and KLF6 was used to assess the role of p53 in regulation of KLF6 expression by IGF-I and to evaluate KLF6 involvement in cell cycle control.,1.26,PMID.dPMID18174288.s2.p5,6,3,p53|KLF6|p53|KLF6|IGF-I|KLF6,IGF-I|KLF6|p53,e
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10366751,PAC1,p53,We report here that p53 and Zac induce expression of the PAC1-R gene.,0.89,PMID.dPMID10366751.s1.p1,3,3,p53|Zac|PAC1,p53|PAC1|Zac,c
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18174288,KLF6,p53,Small interfering RNA against p53 and KLF6 was used to assess the role of p53 in regulation of KLF6 expression by IGF-I and to evaluate KLF6 involvement in cell cycle control.,0.76,PMID.dPMID18174288.s2.p3,6,3,p53|KLF6|p53|KLF6|IGF-I|KLF6,IGF-I|KLF6|p53,e
2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,2.3.2.2.17,10365,9606,GO:0016563,,16988269,KLF6,KLF2,"ExoS was required for the enhanced expression of KLF2, whereas both ExoS and ExoY were required for the enhanced expression of KLF6.",0.09,PMID.dPMID16988269.s3.p0,2,2,KLF2|KLF6,KLF2|KLF6,x
1.1.2.0.1,1385,9606,,GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,18583320,CREB,DAX-1,"Herein we report that PGE(2)-induced StAR expression is independent of the transcriptional suppressor DAX-1 but is regulated by the transcriptional activator cyclic adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB).",0.38,PMID.dPMID18583320.s5.p2,3,3,StAR|DAX-1|CREB,CREB|DAX-1|StAR,n
1.1.2.0.1,1385,9606,,GO:0045944,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,18641343,CREB,ATF-2,"Additionally, ATF-2 controls expression of CREB and c-Jun during T cell activation",0.81,PMID.dPMID18641343.s0.p0,3,3,ATF-2|CREB|c-Jun,ATF-2|c-Jun|CREB,e
1.1.2.0.1,1385,9606,,GO:0045944,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,18039926,CREB,MITF,Up-regulated expression of MITF was found to be mediated via both the mitogen-activated protein kinase-p90 ribosomal S6 kinase-cAMP response element-binding protein (CREB) and cAMP-protein kinase A-CREB pathways.,0.20,PMID.dPMID18039926.s3.p0,3,2,MITF|CREB|CREB,CREB|MITF,-->
1.1.2.0.1,1385,9606,,GO:0045944,2.1.4.0.2,4929,9606,GO:0030528,GO:0034339,19570744,CREB,Nurr1,"5'-Deletion analysis, site-directed mutagenesis and luciferase reporter assay demonstrated that Nurr1 expression was induced by I-BOP in a PKA/CREB-dependent manner.",0.38,PMID.dPMID19570744.s2.p0,2,2,Nurr1|CREB,CREB|Nurr1,-->
1.1.2.0.1,1385,9606,,GO:0045944,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,12391146,CREB,Oct-1,"Accordingly, Oct-1 also potently enhances transcriptional activation mediated by a Ser133Ala CREB mutant.",0.45,PMID.dPMID12391146.s3.p0,2,2,Oct-1|CREB,CREB|Oct-1,c
1.1.2.0.1,1385,9606,,GO:0045944,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,12391146,CREB,Oct-1,Our observation that Oct-1 potentiates CREB-dependent cyclin D1 transcriptional activity independently of Ser 133 phosphorylation and E1A-sensitive coactivator function offers a new paradigm for the regulation of cyclin D1 induction by proliferative signals,0.06,PMID.dPMID12391146.s0.p0,2,2,Oct-1|CREB,CREB|Oct-1,c
1.1.2.0.1,1385,9606,,GO:0045944,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,12391146,CREB,Oct-1,Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism.,0.01,PMID.dPMID12391146.s10.p1,4,2,Oct-1|CREB|CREB|CREB,CREB|Oct-1,c
1.1.2.0.1,1385,9606,,GO:0045944,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,19113914,CREB,SOX9,The action of SOX9 was enhanced by overexpressing CREB.,0.55,PMID.dPMID19113914.s1.p0,2,2,SOX9|CREB,CREB|SOX9,-->
1.1.2.0.1,1385,9606,,GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17937658,cAMP-response-element-binding protein,Sp1,Sp1 up-regulates cAMP-response-element-binding protein expression during retinoic acid-induced mucous differentiation of normal human bronchial epithelial cells.,0.10,PMID.dPMID17937658.s10.p0,2,2,Sp1|cAMP-response-element-binding protein,cAMP-response-element-binding protein|Sp1,e
1.1.2.0.1,1385,9606,,GO:0045944,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,17669268,CREB1,SREBP-1c,Clenbuterol inhibits SREBP-1c expression by activating CREB1.,0.91,PMID.dPMID17669268.s7.p0,2,2,SREBP-1c|CREB1,CREB1|SREBP-1c,e
1.1.2.0.1,1385,9606,,GO:0045944,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,17669268,CREB1,SREBP-1c,"In the present study, we treated 293T and L-02 cells with clenbuterol and found that clenbuterol downregulates SREBP-1c expression and upregulates CREB1 expression.",0.53,PMID.dPMID17669268.s5.p0,2,2,SREBP-1c|CREB1,CREB1|SREBP-1c,n
1.1.2.0.1,1385,9606,,GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,16651533,cAMP-response element-binding protein,Stat3,The Stat3-mediated p100 processing to p52 requires activation of Stat3 by the acetyltransferase activity of cAMP-response element-binding protein (CREB)-binding protein (CBP)/p300.,0.39,PMID.dPMID16651533.s3.p2,5,4,Stat3|Stat3|cAMP-response element-binding protein|CBP|p300,cAMP-response element-binding protein|CBP|p300|Stat3,n
1.1.2.0.1,1385,9606,,GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19930465,CREB,p53,"Taken together, our present findings suggest that p53 is transcriptionally regulated by CREB/phospho-AMPKalpha complex and thereby contributing to the induction of apoptosis under carbon source depletion.",0.90,PMID.dPMID19930465.s0.p0,3,3,p53|CREB|AMPKalpha,AMPKalpha|CREB|p53,e
1.1.2.0.1,1385,9606,,GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19930465,cAMP-responsive element-binding protein,p53,Transcriptional regulation of tumor suppressor p53 by cAMP-responsive element-binding protein/AMP-activated protein kinase complex in response to glucose deprivation.,0.14,PMID.dPMID19930465.s9.p0,2,2,p53|cAMP-responsive element-binding protein,cAMP-responsive element-binding protein|p53,e
1.1.2.0.1,1385,9606,,GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,16652169,CREB,Foxp3,These results suggest an expanded role for Foxp3 in regulating NF-kappaB- and CREB-dependent cellular and viral gene expression.,0.17,PMID.dPMID16652169.s0.p0,2,2,Foxp3|CREB,CREB|Foxp3,e
1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,7624151,ATF-2,c-Fos,"Our data further suggest that c-Fos can act as a repressor of the c-Jun/ATF-2 binding site, revealing an important functional difference, with respect to canonical AP-1 elements.",0.12,PMID.dPMID7624151.s0.p1,3,3,c-Fos|c-Jun|ATF-2,ATF-2|c-Fos|c-Jun,-->
1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10327051,ATF2,c-jun,"Here, we present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2: (1) Over-expression of p300 was found to stimulate c-jun transcription both in the presence and absence of E1A.",0.31,PMID.dPMID10327051.s4.p2,5,3,p300|c-jun|ATF2|p300|c-jun,ATF2|c-jun|p300,e
1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10207054,ATF2,c-Jun,"Similarly, overexpression of c-Jun in 293T human embryo kidney cells increased ATF2 ubiquitination in vivo and reduced its half-life in a dose-dependent manner.",0.09,PMID.dPMID10207054.s4.p0,2,2,c-Jun|ATF2,ATF2|c-Jun,x
1.1.2.0.10,1388,9606,,,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,14559994,ATF6beta,ATF6alpha,"No UPR target genes that required ATF6beta were identified, nor, in contrast to XBP-1 and ATF6alpha, did the activity of the UPRE or ERSE promoters require ATF6beta, suggesting a minor role for it during the UPR.",0.26,PMID.dPMID14559994.s2.p5,4,3,ATF6beta|XBP-1|ATF6alpha|ATF6beta,ATF6alpha|ATF6beta|XBP-1,n
1.1.2.0.10,1388,9606,,,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,14973138,ATF6beta,ATF6alpha,"Although it is known that ATF6alpha is a potent activator of ERSRGs, the transcriptional potency and functions of ATF6beta remain to be explored.",0.14,PMID.dPMID14973138.s8.p0,2,2,ATF6alpha|ATF6beta,ATF6alpha|ATF6beta,x
1.1.2.0.10,1388,9606,,,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,11256944,ATF6beta,ATF6,"We thus concluded that the two related bZIP proteins are crucial transcriptional regulators of the mammalian UPR, and propose calling the ATF6 gene product ATF6alpha and the G13 gene product ATF6beta",0.01,PMID.dPMID11256944.s0.p3,4,2,ATF6|ATF6alpha|G13|ATF6beta,ATF6|ATF6alpha|ATF6beta|G13,x
1.1.2.0.3,1390,9606,,GO:0006355,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15204092,CREM,AP1,"This article will review the defective transcription regulation of IL-2 in SLE T cells, which is the result of decreased expression of the enhancers NF-kappa B and AP1 and the increased expression of the transcriptional repressor CREM",0.33,PMID.dPMID15204092.s0.p2,3,3,NF-kappa B|AP1|CREM,AP1|CREM|NF-kappa B,x
1.1.2.0.3,1390,9606,,GO:0006355,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,15204092,CREM,NF-kappa B,"This article will review the defective transcription regulation of IL-2 in SLE T cells, which is the result of decreased expression of the enhancers NF-kappa B and AP1 and the increased expression of the transcriptional repressor CREM",0.65,PMID.dPMID15204092.s0.p1,3,3,NF-kappa B|AP1|CREM,AP1|CREM|NF-kappa B,x
3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,19246878,Nkx2.5,GATA-4,GATA-4 expression of Nkx2.5+ hCPCs was higher than that of embryonic limb bud mesenchymal cells of the control group (p < 0.05).,0.87,PMID.dPMID19246878.s10.p0,2,2,GATA-4|Nkx2.5,GATA-4|Nkx2.5,x
3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,19479054,NKX2-5,GATA4,"Here, we studied regulation of beta-catenin and GATA4 by NKX2-5 in human fetal cardiac myocytes.",0.51,PMID.dPMID19479054.s5.p0,2,2,GATA4|NKX2-5,GATA4|NKX2-5,x
3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,19479054,NKX2-5,GATA4,"Using promoter-luciferase reporter assay combined with mutational analysis of the NKEs we demonstrated that the identified NKX2-5 binding sites were essential for the suppression of beta-catenin, and upregulation of GATA4 by NKX2-5.",0.45,PMID.dPMID19479054.s1.p2,3,2,NKX2-5|GATA4|NKX2-5,GATA4|NKX2-5,p
3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,6.5.3.0.5,57057,9606,,,19762328,NKX2-5,Tbx20,"Moreover, Tbx20-I121M resulted in a significantly enhanced transcriptional activity, which was further increased in the presence of co-transcription factors GATA4/5 and NKX2-5.",0.27,PMID.dPMID19762328.s3.p1,3,3,Tbx20|GATA4|NKX2-5,GATA4|NKX2-5|Tbx20,c
3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,3.1.10.11.1,84525,9606,,,14522464,Nkx2-5,Hop,"During embryogenesis, Hop is expressed in the myocardium of the developing heart and it functions downstream of Nkx2-5, an early cardiac-specific transcription factor.",0.01,PMID.dPMID14522464.s2.p0,2,2,Hop|Nkx2-5,Hop|Nkx2-5,x
1.1.4.2.1,1628,9606,GO:0003702,GO:0006357,1.1.4.2.4,4783,9606,,,18004209,DBP,E4BP4,"CONCLUSIONS: Results from this study suggest that DBP and E4BP4 might consist of a reciprocating mechanism in which DBP activates the transcription of the CYP3A4 gene during the time of day when DBP is abundant, and E4BP4 suppresses the transcription at other times of day.",0.03,PMID.dPMID18004209.s1.p7,6,3,DBP|E4BP4|DBP|CYP3A4|DBP|E4BP4,CYP3A4|DBP|E4BP4,x
1.1.4.2.1,1628,9606,GO:0003702,GO:0006357,1.1.4.2.3,7008,9606,GO:0003702,GO:0006357,17057225,DBP,TEF,"Furthermore, blockade of bcl-gS or TEF expression by a small interfering RNA strategy or transfection with tDBP significantly reduces the etoposide-mediated apoptotic cell death.",0.10,PMID.dPMID17057225.s1.p0,2,2,TEF|DBP,DBP|TEF,x
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,14630918,CHOP,ATF4,We show that inhibition of ATF2 or ATF4 expression impairs the transcriptional activation of CHOP by amino acid starvation.,1.04,PMID.dPMID14630918.s5.p2,3,3,ATF2|ATF4|CHOP,ATF2|ATF4|CHOP,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,17276738,CHOP,ATF4,"Furthermore, knockdown of ATF4 by RNA interference reduced CHOP and ASNS transcription in 2SD and NARP3-1 cells.",0.72,PMID.dPMID17276738.s1.p0,4,4,ATF4|CHOP|ASNS|NARP,ASNS|ATF4|CHOP|NARP,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,14630918,CHOP,ATF4,"Among all these transcription factors, only ATF4 and ATF2 are involved in the amino acid control of CHOP expression.",0.41,PMID.dPMID14630918.s6.p1,3,3,ATF4|ATF2|CHOP,ATF2|ATF4|CHOP,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,19922526,GADD153,ATF-4,CONCLUSION: Our results demonstrate the involvement of oxygen-dependent proteasomal degradation of ATF-4 in the hypoxia-induced expression of GADD153.,0.15,PMID.dPMID19922526.s1.p0,2,2,ATF-4|GADD153,ATF-4|GADD153,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,14630918,CHOP,ATF2,"Among all these transcription factors, only ATF4 and ATF2 are involved in the amino acid control of CHOP expression.",0.84,PMID.dPMID14630918.s6.p2,3,3,ATF4|ATF2|CHOP,ATF2|ATF4|CHOP,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,14630918,CHOP,ATF2,We show that inhibition of ATF2 or ATF4 expression impairs the transcriptional activation of CHOP by amino acid starvation.,0.51,PMID.dPMID14630918.s5.p1,3,3,ATF2|ATF4|CHOP,ATF2|ATF4|CHOP,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,10510472,GADD153,ETS1,Our results also demonstrate how ETS1 and FLI-1 specifically regulate GADD153 expression.,1.95,PMID.dPMID10510472.s2.p1,3,3,ETS1|FLI-1|GADD153,ETS1|FLI-1|GADD153,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,10510472,GADD153,ETS1,"The ETS1 and FLI-1 proteins provide a novel mechanism of activation for GADD153, allowing these two ETS genes to control its expression during cell growth and differentiation, rather than in response to oxidative stress.",0.35,PMID.dPMID10510472.s0.p1,3,3,ETS1|FLI-1|GADD153,ETS1|FLI-1|GADD153,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,10510472,GADD153,ETS1,"In addition, our data show that both ETS1 and FLI-1 strongly activate transcription of the GADD153 EBS linked to the CAT reporter gene.",0.10,PMID.dPMID10510472.s3.p1,4,4,ETS1|FLI-1|GADD153|CAT,CAT|ETS1|FLI-1|GADD153,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8670069,GADD153,AP-1,"Finally, both promoter-deletion analysis and point mutation of the AP-1 site in an otherwise intact promoter support a significant role for AP-1 in transcriptional activation of GADD153 by UVC or oxidant treatment.",0.83,PMID.dPMID8670069.s3.p2,3,2,AP-1|AP-1|GADD153,AP-1|GADD153,e
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12097658,CHOP,c-Jun,"Chalcone was the only phytochemical that activated all three transcription factors [Elk-1, 2.7-fold (P < 0.001); c-Jun, 2.7-fold (P = 0.025); CHOP, 3.0-fold (P = 0.002)], whereas apigenin stimulated CHOP (3.9-fold; P < 0.001), but inhibited phorbol myristoyl acetate-induced c-Jun activity (71%;P = 0.006).",0.76,PMID.dPMID12097658.s2.p4,5,3,Elk-1|c-Jun|CHOP|CHOP|c-Jun,CHOP|c-Jun|Elk-1,x
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11950812,gadd153,c-myc,"Among several genes selected by cDNA array screening, quantitative RT-PCR analysis confirmed downregulation of c-myc expression and upregulation of c-jun and gadd153 expression by 15d-PGJ2 and TGZ.",0.01,PMID.dPMID11950812.s3.p1,3,3,c-myc|c-jun|gadd153,c-jun|c-myc|gadd153,x
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18313712,CHOP,p53,"This decrease in Gal1 expression in Hs683 cells does not induce apoptotic or autophagic features, but is found to modulate p53 transcriptional activity and decrease p53-targeted gene expression including DDIT3/GADD153/CHOP, DUSP5 ATF3 and GADD45A.",0.26,PMID.dPMID18313712.s2.p4,4,2,p53|p53|DDIT3|CHOP,CHOP|DDIT3|p53,x
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18313712,DDIT3,p53,"This decrease in Gal1 expression in Hs683 cells does not induce apoptotic or autophagic features, but is found to modulate p53 transcriptional activity and decrease p53-targeted gene expression including DDIT3/GADD153/CHOP, DUSP5 ATF3 and GADD45A.",0.26,PMID.dPMID18313712.s2.p2,4,2,p53|p53|DDIT3|CHOP,CHOP|DDIT3|p53,x
1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,10958673,CHOP,ATF6,"We report here that overexpression of soluble ATF6 activates transcription of the CHOP and XBP-1 genes as well as of ER chaperone genes constitutively, whereas overexpression of a dominant negative mutant of ATF6 blocks the induction by ER stress.",0.23,PMID.dPMID10958673.s2.p0,4,3,ATF6|CHOP|XBP-1|ATF6,ATF6|CHOP|XBP-1,<--
3.1.2.5.5,1749,9606,GO:0016563,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19497851,DLX5,MYC,Here we demonstrate by luciferase assay that the MYC promoter is specifically activated by overexpression of DLX5 and that two DLX5 binding sites in the MYC promoter are important for transcriptional activation of MYC.,0.04,PMID.dPMID19497851.s4.p0,5,2,MYC|DLX5|DLX5|MYC|MYC,DLX5|MYC,p
3.1.2.5.5,1749,9606,GO:0016563,,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20808887,DLX5,p63,"We show that p63 binds to an enhancer element in the SHFM1 locus on chromosome 7q and that this element controls expression of DLX6 and possibly DLX5, both of which are important for limb development.",0.10,PMID.dPMID20808887.s3.p3,4,4,p63|SHFM1|DLX6|DLX5,DLX5|DLX6|p63|SHFM1,p
3.3.2.1.1,1869,9606,,GO:0000122,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,18687701,E2F1,E1AF,"Furthermore, disruption of E1AF expression by E1AF RNAi decreased E2F1-induced apoptosis in response to etoposide.",0.81,PMID.dPMID18687701.s1.p1,3,2,E1AF|E1AF|E2F1,E1AF|E2F1,x
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15944709,E2F1,c-Myc,c-Myc-regulated microRNAs modulate E2F1 expression.,2.21,PMID.dPMID15944709.s10.p0,2,2,c-Myc|E2F1,c-Myc|E2F1,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15944709,E2F1,c-Myc,"These findings expand the known classes of transcripts within the c-Myc target gene network, and reveal a mechanism through which c-Myc simultaneously activates E2F1 transcription and limits its translation, allowing a tightly controlled proliferative signal",1.44,PMID.dPMID15944709.s0.p2,3,2,c-Myc|c-Myc|E2F1,c-Myc|E2F1,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17784791,E2F1,myc,"""Myc'ed messages"": myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron.",1.27,PMID.dPMID17784791.s6.p0,2,2,myc|E2F1,E2F1|myc,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19806017,E2F1,Myc,Myc regulates entry into S phase by stimulating glucose and glutamine metabolism and mitochondrial biogenesis that are coupled to the regulation of E2F1 expression.,1.14,PMID.dPMID19806017.s4.p0,2,2,Myc|E2F1,E2F1|Myc,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19603422,E2F1,c-myc,PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells.,1.12,PMID.dPMID19603422.s6.p0,2,2,c-myc|E2F1,c-myc|E2F1,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11494151,E2F-1,c-Myc,"Furthermore, we describe a role for c-Myc in adhesion-mediated regulation of E2F-1",0.97,PMID.dPMID11494151.s0.p0,2,2,c-Myc|E2F-1,c-Myc|E2F-1,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8208548,E2F-1,MYC,"Using CAT reporter co-transfection assays we show here that transcription from the MYC P2 promoter is induced efficiently by E2F-1, but repressed by RB.",0.97,PMID.dPMID8208548.s4.p0,2,2,MYC|E2F-1,E2F-1|MYC,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8477845,E2F transcription factor,MYC,The promoter of the human proto-oncogene MYC has been the first cellular target shown to be subject to regulation by the E2F transcription factor.,0.91,PMID.dPMID8477845.s6.p0,2,2,MYC|E2F transcription factor,E2F transcription factor|MYC,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19603422,E2F1,c-myc,"Together, we demonstrate that PI3K-GSK3-dependent control of c-myc protein expression is connected to the transcription of the E2F1 gene in PDAC cells, leading to S-phase progression of the cell cycle.",0.82,PMID.dPMID19603422.s0.p0,2,2,c-myc|E2F1,c-myc|E2F1,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18345030,E2F1,Myc,A role for Myc in facilitating transcription activation by E2F1.,0.69,PMID.dPMID18345030.s5.p0,2,2,Myc|E2F1,E2F1|Myc,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11494151,E2F-1,c-Myc,"Restoration of c-Myc in non-adherent cells induces the expression of E2F-1, and hyperphosphorylation of pRb in response to EGF treatment.",0.58,PMID.dPMID11494151.s3.p0,3,3,c-Myc|E2F-1|EGF,c-Myc|E2F-1|EGF,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8208548,transcription factor E2F,MYC,Regulation of MYC promoter activity critically depends on the presence of a binding site for transcription factor E2F.,0.39,PMID.dPMID8208548.s6.p0,2,2,MYC|transcription factor E2F,MYC|transcription factor E2F,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8386381,transcription factor E2F,c-MYC,We have investigated the effects of deregulated expression of the human c-MYC protooncogene on cyclin gene expression and on the transcription factor E2F.,0.22,PMID.dPMID8386381.s4.p0,2,2,c-MYC|transcription factor E2F,c-MYC|transcription factor E2F,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18345030,E2F1,Myc,We now show that Myc is required to allow the interaction of the E2F1 protein with the E2F gene promoters.,0.11,PMID.dPMID18345030.s1.p0,2,2,Myc|E2F1,E2F1|Myc,-->
3.3.2.1.1,1869,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19629135,E2F1,c-MYC,"Here, we show that the c-MYC-interacting proapoptotic tumor suppressor, BIN1, is transcriptionally activated by E2F1 and mediates E2F1-induced apoptosis in response to DNA damage.",0.01,PMID.dPMID19629135.s7.p3,4,3,c-MYC|BIN1|E2F1|E2F1,BIN1|c-MYC|E2F1,-->
3.3.2.1.1,1869,9606,,GO:0000122,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,15313206,E2F1,Y box binding protein,"Transcription of dbpA, a Y box binding protein, is positively regulated by E2F1: implications in hepatocarcinogenesis.",0.88,PMID.dPMID15313206.s6.p0,2,2,Y box binding protein|E2F1,E2F1|Y box binding protein,e
3.3.2.1.1,1869,9606,,GO:0000122,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,7753559,E2F-1,Sp3,In contrast enforced expression of Sp3 fails to repress E2F-1/DP-1-mediated activation,0.68,PMID.dPMID7753559.s0.p0,3,3,Sp3|E2F-1|DP-1,DP-1|E2F-1|Sp3,<--
3.3.2.1.1,1869,9606,,GO:0000122,6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,12789260,E2F1,Hos,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.41,PMID.dPMID12789260.s0.p1,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,"wrong_Tf, Hos is a cell_line in that context"
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10619603,E2F-1,p53,It was found that p53 specifically inhibited activated transcription by E2F-5 but not by E2F-1.,0.88,PMID.dPMID10619603.s8.p1,3,3,p53|E2F-5|E2F-1,E2F-1|E2F-5|p53,x
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12909334,E2F1,p53,"However, this mutant retains its ability to stabilize and phosphorylate p53, suggesting that p53 is sufficient for the effect of E2F1.",0.80,PMID.dPMID12909334.s2.p2,3,2,p53|p53|E2F1,E2F1|p53,x
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9748148,E2F-1,p53,"To explain our growth assay findings on the basis of potential negative molecular interactions between E2F-1 and p53, Western and Northern blotting analyses were performed to investigate the differential expression of the downstream p53-transactivated genes, p21Waf1 and BAX, under various p53 and E2F-1 gene transfer conditions.",0.78,PMID.dPMID9748148.s4.p12,6,3,E2F-1|p53|p53|BAX|p53|E2F-1,BAX|E2F-1|p53,c
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20338640,E2F1,p53,"Analysis of the expression pattern of a key set of cell cycle regulators revealed that the expression of Zta and Rta substantially interfered with the cell cycle regulatory machinery in Raji cells, strongly inhibiting the expression of Rb and p53 and inducing the expression of E2F1.",0.76,PMID.dPMID20338640.s4.p5,4,4,Rta|Rb|p53|E2F1,E2F1|p53|Rb|Rta,x
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11689848,E2F transcription factor,p53,We have constructed a virus (01/PEME) containing a novel regulatory circuit in which p53-dependent expression of an antagonist of the E2F transcription factor inhibits viral replication in normal cells.,0.74,PMID.dPMID11689848.s2.p0,2,2,p53|E2F transcription factor,E2F transcription factor|p53,x
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16037820,E2F1,p53,"This regulation of p53 by E2F1 is cell cycle dependent, as the cellular distribution of Ser315 phosphorylated p53 is associated with the periodic expression of E2F and cyclin A throughout the cell cycle.",0.57,PMID.dPMID16037820.s1.p0,3,2,p53|E2F1|p53,E2F1|p53,x
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19035040,E2F-1,p53,"Effects of p53 in benzo (a) pyrene induced p21 and E2F-1 expression and cell cycle changes   OBJECTIVE: To investigate the roles of p53 in cell cycle changes on human embryo lung fibroblasts (HELF) induced by benzo(a) pyrene[ B(a) P], and relationships between p53 and p21, E2F-1.",0.45,PMID.dPMID19035040.s10.p1,7,3,p53|p21|E2F-1|p53|p53|p21|E2F-1,E2F-1|p21|p53,x
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10619603,E2F-1,p53,The results indicate that p53 differentially regulates the activities of two subclasses (E2F-1/-2/-3 vs. E2F-4/-5) of E2F transcription factors.,0.39,PMID.dPMID10619603.s4.p0,3,3,p53|E2F-1|E2F-4,E2F-1|E2F-4|p53,c
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11101847,E2F1,p53,Disruption of p73 function by a tumour-derived p53 mutant reduced E2F1-mediated apoptosis.,0.31,PMID.dPMID11101847.s1.p2,3,3,p73|p53|E2F1,E2F1|p53|p73,c
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15004518,E2F-1,p53,"Further, p53 appears to mediate TGF-beta1-induced apoptosis downstream of the pRb/E2F-1 pathway",0.20,PMID.dPMID15004518.s0.p1,3,3,p53|TGF-beta1|E2F-1,E2F-1|p53|TGF-beta1,c
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9769946,E2F-1,p53,"The Mdm2 protein is believed to be oncogenic by binding and inactivating the p53 and Rb tumor suppressor gene products and by activating the E2F-1/DP-1 transcription factors, thus promoting the G1 to S phase transition.",0.15,PMID.dPMID9769946.s5.p4,5,5,Mdm2|p53|Rb|E2F-1|DP-1,DP-1|E2F-1|Mdm2|p53|Rb,c
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16037820,E2F1,p53,Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315.,0.05,PMID.dPMID16037820.s5.p0,3,2,p53|E2F1|p53,E2F1|p53,n
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12789260,E2F1,p73,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.80,PMID.dPMID12789260.s0.p2,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12095638,E2F-1,p73,"Expression of p73beta was mediated by E2F-1, which was activated via release from pRB after exposure of cells to NA.",0.62,PMID.dPMID12095638.s2.p0,2,2,p73|E2F-1,E2F-1|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11988839,E2F1,p73,Our results suggest that regulation of p73 expression is primarily mediated through binding of E2F1 to target sites at -155 and -132.,0.48,PMID.dPMID11988839.s0.p0,2,2,p73|E2F1,E2F1|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14602923,E2F1,p73,DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. p73 is a member of the p53 family often overexpressed in human cancer.,0.40,PMID.dPMID14602923.s9.p0,4,3,p73|E2F1|p73|p53,E2F1|p53|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12095638,E2F-1,p73,Induction of p73beta by a naphthoquinone analog is mediated by E2F-1 and triggers apoptosis in HeLa cells.,0.39,PMID.dPMID12095638.s11.p0,2,2,p73|E2F-1,E2F-1|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17980704,E2F1,p73,"The results presented here suggested the cooperative transcriptional regulation of p73 by YY1 and E2F1, and might provide a new regulation mechanism by the YY1 network on tumorigenesis, differentiation and development",0.26,PMID.dPMID17980704.s0.p1,4,3,p73|YY1|E2F1|YY1,E2F1|p73|YY1,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16205639,E2F1,p73,We show that forced expression of p73 or activation of endogenous p73 by E2F1 results in the downregulation of telomerase activity.,0.26,PMID.dPMID16205639.s5.p2,3,2,p73|p73|E2F1,E2F1|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11101847,E2F1,p73,Disruption of p73 function by a tumour-derived p53 mutant reduced E2F1-mediated apoptosis.,0.04,PMID.dPMID11101847.s1.p1,3,3,p73|p53|E2F1,E2F1|p53|p73,-->
3.3.2.1.1,1869,9606,,GO:0000122,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,17980157,E2F1,LEF-1,LEF-1 activates the transcription of E2F1.,1.34,PMID.dPMID17980157.s2.p0,2,2,LEF-1|E2F1,E2F1|LEF-1,e
3.3.2.1.2,1870,9606,GO:0003702,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,17637753,E2F2,AP-1,"AP-1 blockade also led to reduced expression of E2F1 and E2F2, but not E2F4, at the mRNA and protein levels.",0.17,PMID.dPMID17637753.s4.p1,4,4,AP-1|E2F1|E2F2|E2F4,AP-1|E2F1|E2F2|E2F4,e
3.3.2.1.4,1874,9606,,,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18368381,E2F-4,PPARgamma,We also show that FBI-1 promotes terminal preadipocyte differentiation through a mechanism involving decreased levels of expression of the PPARgamma inhibitor E2F-4.,0.06,PMID.dPMID18368381.s7.p2,3,3,FBI-1|PPARgamma|E2F-4,E2F-4|FBI-1|PPARgamma,x
3.3.2.1.4,1874,9606,,,6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,12789260,E2F4,Hos,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.23,PMID.dPMID12789260.s0.p14,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,"wrong_Tf, Hos is a cell_line in that context"
3.3.2.1.4,1874,9606,,,6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,12789260,E2F4,Hos,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.07,PMID.dPMID12789260.s0.p10,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,"wrong_Tf, Hos is a cell_line in that context"
3.3.2.1.4,1874,9606,,,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,17121828,E2F4,TCF4,"We showed that both beta-catenin and TCF4 bind to the E2F4 3'-UTR site in vivo, inducing expression of an E2F4 antisense transcript.",0.34,PMID.dPMID17121828.s4.p1,3,2,TCF4|E2F4|E2F4,E2F4|TCF4,p
3.3.2.1.4,1874,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17656449,E2F4,p53,Downregulation of p53 expression by RNA interference attenuated cell death induced by E2F4-NLS.,0.83,PMID.dPMID17656449.s4.p0,2,2,p53|E2F4,E2F4|p53,x
3.3.2.1.4,1874,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10619603,E2F-4,p53,The results indicate that p53 differentially regulates the activities of two subclasses (E2F-1/-2/-3 vs. E2F-4/-5) of E2F transcription factors.,0.19,PMID.dPMID10619603.s4.p1,3,3,p53|E2F-1|E2F-4,E2F-1|E2F-4|p53,x
3.3.2.1.4,1874,9606,,,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12789260,E2F4,p73,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.48,PMID.dPMID12789260.s0.p11,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,e
3.3.2.1.5,1875,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10619603,E2F-5,p53,It was found that p53 specifically inhibited activated transcription by E2F-5 but not by E2F-1.,0.72,PMID.dPMID10619603.s8.p0,3,3,p53|E2F-5|E2F-1,E2F-1|E2F-5|p53,x
2.3.2.1.2,1958,9606,,GO:0045941,3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,18061571,Egr-1,Elk-1,Chromatin immunoprecipitation experiments revealed that Elk-1 binds in vivo to the 5'-upstream region of the Egr-1 gene in carbachol-stimulated neuroblastoma cells.,0.53,PMID.dPMID18061571.s5.p0,2,2,Elk-1|Egr-1,Egr-1|Elk-1,-->
2.3.2.1.2,1958,9606,,GO:0045941,3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,11121417,Egr-1,Elk-1,These results indicate that the Ras/MEK/Erk/Elk-1 pathway is necessary for TFP-induced Egr-1 expression.,0.09,PMID.dPMID11121417.s1.p0,2,2,Elk-1|Egr-1,Egr-1|Elk-1,-->
2.3.2.1.2,1958,9606,,GO:0045941,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,7690249,EGR-1,ara,The results demonstrate that ara-C inducibility of the EGR-1 gene is conferred by a region containing six serum response or CC(A/T)6GG (CArG) motifs.,0.44,PMID.dPMID7690249.s4.p0,2,2,ara|EGR-1,ara|EGR-1,e
2.3.2.1.2,1958,9606,,GO:0045941,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18844239,Egr-1,FoxO1,"Consistently, FoxO1silencing results in Egr-1-increased levels, indicating that FoxO1 behaves as a negative regulator of Egr-1 expression.",1.79,PMID.dPMID18844239.s1.p5,4,2,FoxO1|Egr-1|FoxO1|Egr-1,Egr-1|FoxO1,e
2.3.2.1.2,1958,9606,,GO:0045941,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18844239,Egr-1,FoxO1,"Consistently, FoxO1silencing results in Egr-1-increased levels, indicating that FoxO1 behaves as a negative regulator of Egr-1 expression.",0.84,PMID.dPMID18844239.s1.p3,4,2,FoxO1|Egr-1|FoxO1|Egr-1,Egr-1|FoxO1,e
2.3.2.1.2,1958,9606,,GO:0045941,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18844239,Egr-1,FoxO1,"Consistently, FoxO1silencing results in Egr-1-increased levels, indicating that FoxO1 behaves as a negative regulator of Egr-1 expression.",0.13,PMID.dPMID18844239.s1.p0,4,2,FoxO1|Egr-1|FoxO1|Egr-1,Egr-1|FoxO1,e
2.3.2.1.2,1958,9606,,GO:0045941,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12466969,Egr-1,Id-1,"Furthermore, treatment with antisense oligonucleotide complementary to Id-1 mRNA in PC-3 and DU145 cells resulted in a decreased Id-1 expression which was accompanied by decreased Egr-1 protein.",0.44,PMID.dPMID12466969.s1.p2,3,2,Id-1|Id-1|Egr-1,Egr-1|Id-1,e
2.3.2.1.2,1958,9606,,GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19940138,Egr-1,c-Jun,"c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.",2.18,PMID.dPMID19940138.s12.p0,2,2,c-Jun|Egr-1,c-Jun|Egr-1,x
2.3.2.1.2,1958,9606,,GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19940138,early growth response-1,c-Jun,Injury- and shear-inducible c-Jun controls early growth response-1.,2.02,PMID.dPMID19940138.s2.p0,2,2,c-Jun|early growth response-1,c-Jun|early growth response-1,x
2.3.2.1.2,1958,9606,,GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19837979,EGR-1,JUN,"Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib.",0.37,PMID.dPMID19837979.s0.p5,4,2,JUN|EGR-1|JUN|EGR-1,EGR-1|JUN,x
2.3.2.1.2,1958,9606,,GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9109500,EGR-1,Sp1,"Moreover, recent studies suggest that displaced Sp1 binds to and activates the endogenous Egr-1 gene, thereby leading to ""facilitated inhibition"" of Sp1 function by the resulting increased EGR-1.",1.16,PMID.dPMID9109500.s1.p3,4,2,Sp1|Egr-1|Sp1|EGR-1,Egr-1|EGR-1|Sp1,e
2.3.2.1.2,1958,9606,,GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9109500,EGR-1,Sp1,"Moreover, recent studies suggest that displaced Sp1 binds to and activates the endogenous Egr-1 gene, thereby leading to ""facilitated inhibition"" of Sp1 function by the resulting increased EGR-1.",1.03,PMID.dPMID9109500.s1.p5,4,2,Sp1|Egr-1|Sp1|EGR-1,Egr-1|EGR-1|Sp1,e
2.3.2.1.2,1958,9606,,GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11560779,Egr-1,Sp1,"The results showed that Sp1 plays a positive role for both basal and TPA-activated hMnSOD transcription, whereas overexpression of Egr-1 has a negative role in the basal promoter activity without any effect on TPA-mediated activation of hMnSOD transcription",0.05,PMID.dPMID11560779.s0.p0,2,2,Sp1|Egr-1,Egr-1|Sp1,c
2.3.2.1.2,1958,9606,,GO:0045941,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,12553721,Egr-1,Transcription factor,Transcription factor Egr-1 activates collagen expression in immortalized fibroblasts or fibrosarcoma cells.,0.14,PMID.dPMID12553721.s12.p0,2,2,Transcription factor|Egr-1,Egr-1|Transcription factor,w
2.3.2.1.2,1958,9606,,GO:0045941,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,7983016,egr-1,Transcription factor,Transcription factor egr-1 is involved in phorbol 12-myristate 13-acetate-induced megakaryocytic differentiation of K562 cells.,0.02,PMID.dPMID7983016.s7.p0,2,2,Transcription factor|egr-1,egr-1|Transcription factor,w
2.3.2.1.2,1958,9606,,GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11251186,Egr-1,p53,"A p53 mutant at codon 154 did not bind Egr-1, while p53 proteins with point mutations at residues 156, 246, 247, and 273 associated with this zinc finger transcription factor.",0.51,PMID.dPMID11251186.s3.p0,3,2,p53|Egr-1|p53,Egr-1|p53,c
2.3.2.1.2,1958,9606,,GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15548700,EGR1,p53,"One of the genes up-regulated in the presence of mutant p53 was EGR1, a transcription factor implicated in growth control, apoptosis, and cancer.",0.38,PMID.dPMID15548700.s4.p0,2,2,p53|EGR1,EGR1|p53,e
2.3.2.1.2,1958,9606,,GO:0045941,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14614448,EGR1,p73,"For instance, DeltaNp73alpha increased the expression of EGR1 and CDC6, whereas it decreased the mRNA levels of c-MYC, cyclin A2/CCNA2, NF-kappaB1, ODC1, and RET finger protein/RFP.",0.72,PMID.dPMID14614448.s3.p0,5,5,p73|EGR1|CDC6|c-MYC|CCNA2,CCNA2|CDC6|c-MYC|EGR1|p73,e
2.3.2.1.2,1958,9606,,GO:0045941,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17822668,Egr-1,p73,"Overall, our results provide direct evidence that Egr-1 positively regulated p73 expression by binding to its promoter in vivo, consistent with Egr-1 and p73 being involved in p53-independent tumor suppression",0.10,PMID.dPMID17822668.s0.p2,5,3,Egr-1|p73|Egr-1|p73|p53,Egr-1|p53|p73,p
2.3.2.1.2,1958,9606,,GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,1654597,EGR-1,WT1,"In transient transfection assays, the WT1 protein functioned as a repressor of transcription when bound to the EGR-1 site.",0.01,PMID.dPMID1654597.s1.p0,2,2,WT1|EGR-1,EGR-1|WT1,c
2.3.2.1.2,1958,9606,,GO:0045941,2.3.5.0.26,7716,9606,GO:0003704,GO:0006357,8035792,EGR1,DB1,"When DB1 was cotransfected with a Tax expression vector, transcription activity of the IL-3 promoter induced by Tax was significantly increased, while EGR1 and EGR2 were without effect.",0.07,PMID.dPMID8035792.s1.p1,4,4,DB1|IL-3|EGR1|EGR2,DB1|EGR1|EGR2|IL-3,c
2.3.2.1.3,1959,9606,,,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,16311519,Krox20,Sox10,"In addition, the enhancer-dependent synergism between these POU proteins and Sox10 suggests that Krox20 expression requires this combination of factors.",0.70,PMID.dPMID16311519.s1.p0,2,2,Sox10|Krox20,Krox20|Sox10,p
2.3.2.1.3,1959,9606,,,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,16311519,Krox20,Sox10,These results resolve previous controversy concerning the mechanism of action of Oct6 and Brn2 during myelination and provide an explanation for myelin deficiencies in Waardenberg-Hirschsprung disease patients whereby Sox10 mutations could lead to a loss of Krox20 expression,0.35,PMID.dPMID16311519.s0.p5,4,4,Oct6|Brn2|Sox10|Krox20,Brn2|Krox20|Oct6|Sox10,c
2.3.2.1.4,1960,9606,,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,15171706,EGR3,Transcription factor,Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells.,0.09,PMID.dPMID15171706.s10.p0,2,2,Transcription factor|EGR3,EGR3|Transcription factor,w
3.5.2.3.1,1997,9606,GO:0016563,GO:0045944,3.5.2.3.3,2000,9606,GO:0016563,GO:0006355|GO:0045944,8895518,elf-1,MEF,"MEF is a new member of the elf-1/E74 family of ETS proteins, that has DNA binding properties similar to elf-1 but distinct transcriptional activating effects in several hematopoietic cell lineages.",0.25,PMID.dPMID8895518.s0.p0,3,2,MEF|elf-1|elf-1,elf-1|MEF,x
3.5.2.3.1,1997,9606,GO:0016563,GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15907486,Elf-1,Sp1,Sp1-dependent regulation of Myeloid Elf-1 like factor in human epithelial cells.,0.53,PMID.dPMID15907486.s5.p0,2,2,Sp1|Elf-1,Elf-1|Sp1,c
3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,11121417,Elk-1,Egr-1,We propose that the calmodulin antagonist TFP stimulates Egr-1 gene expression by modulating Ras/MEK/Erk and activation of the Elk-1 pathway in human fibrosarcoma HT1080 cells,0.78,PMID.dPMID11121417.s0.p0,2,2,Egr-1|Elk-1,Egr-1|Elk-1,<--
3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,11835312,Elk1,Egr-1,"Moreover, these SREs are binding sites for Elk1, suggesting that NO activated Egr-1 gene transcription via activation of Elk1.",0.68,PMID.dPMID11835312.s2.p2,3,2,Elk1|Egr-1|Elk1,Egr-1|Elk1,<--
3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,18061571,Elk-1,Egr-1,"Transcriptional response to muscarinic acetylcholine receptor stimulation: regulation of Egr-1 biosynthesis by ERK, Elk-1, MKP-1, and calcineurin in carbachol-stimulated human neuroblastoma cells.",0.60,PMID.dPMID18061571.s8.p1,4,4,Egr-1|ERK|Elk-1|MKP-1,Egr-1|Elk-1|ERK|MKP-1,<--
3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,11121417,Elk-1,early growth response-1,Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells.,0.36,PMID.dPMID11121417.s10.p0,2,2,early growth response-1|Elk-1,early growth response-1|Elk-1,<--
3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,20236318,Elk-1,Ets-1,Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.,0.32,PMID.dPMID20236318.s11.p0,2,2,Ets-1|Elk-1,Elk-1|Ets-1,c
3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,8083237,Elk-1,TCF,"We conclude that p62TCF is composed of Elk-1, whereas the identities of the other identified TCFs (p60TCF, p62.5TCF, and p64TCF) are still unknown",0.32,PMID.dPMID8083237.s0.p0,6,2,TCF|Elk-1|TCF|TCF|TCF|TCF,Elk-1|TCF,x
3.1.2.7.2,2020,9606,,,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,11814686,En2,Pax2,"The Pax2/5/8 subfamily plays a key role in specification and/or maintenance of vertebrate mid-hindbrain boundary (MHB) region by directly regulating expression of other genes, most notably En2.",0.91,PMID.dPMID11814686.s9.p0,2,2,Pax2|En2,En2|Pax2,e
3.5.2.1.11,2077,9606,GO:0003706,GO:0006357,3.5.2.1.6,2313,9606,,,10975680,ERF,FLI1,"The FLI1/ERF repressor, like the wild-type ERF, is regulated by mitogen-activated protein kinase-dependent subcellular localization.",0.49,PMID.dPMID10975680.s1.p1,3,2,FLI1|ERF|ERF,ERF|FLI1,x
3.5.2.1.11,2077,9606,GO:0003706,GO:0006357,3.5.2.1.6,2313,9606,,,10975680,ERF,FLI1,"The FLI1/ERF repressor, like the wild-type ERF, is regulated by mitogen-activated protein kinase-dependent subcellular localization.",0.41,PMID.dPMID10975680.s1.p0,3,2,FLI1|ERF|ERF,ERF|FLI1,x
3.5.2.1.11,2077,9606,GO:0003706,GO:0006357,3.5.2.1.6,2313,9606,,,10975680,ERF,FLI1,"In this study, we demonstrate that the ES transformed phenotype can be suppressed by chimeric transcriptional repressors containing the DNA-binding domain of FLI1 and the regulatory and repressor domain of ERF, a transcription suppressor and member of the ets gene family.",0.20,PMID.dPMID10975680.s3.p0,2,2,FLI1|ERF,ERF|FLI1,x
3.5.2.1.7,2078,9606,,,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,18559874,ERG,WT1,"In multivariable analyses, WT1 mutations independently predicted worse DFS (P = .009; hazard ratio [HR] = 2.7) when controlling for CEBPA mutational status, ERG expression level, and FLT3-ITD/NPM1 molecular-risk group (ie, FLT3-ITD(negative)/NPM1(mutated) as low risk v FLT3-ITD(positive) and/or NPM1(wild-type) as high risk).",0.31,PMID.dPMID18559874.s3.p1,9,5,WT1|CEBPA|ERG|FLT3|NPM1|FLT3|NPM1|FLT3|NPM1,CEBPA|ERG|FLT3|NPM1|WT1,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.12.2,668,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0016481|GO:0045893|GO:0045944|GO:0051090,19797124,ERalpha,Foxl2,"We show that Foxl2 has no effect on classical ERalpha-mediated transcription, which occurs through canonical estrogen response elements.",0.01,PMID.dPMID19797124.s11.p0,2,2,Foxl2|ERalpha,ERalpha|Foxl2,n
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,17350616,ERalpha,Runx2,"Here, we investigate the role of Runx2 on the regulation of ERalpha expression by determining its interaction with the F promoter, one of the multiple promoters of the human ERalpha gene and the only one active in bone.",1.39,PMID.dPMID17350616.s7.p0,3,2,Runx2|ERalpha|ERalpha,ERalpha|Runx2,<--
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,16809346,ERalpha,FoxM1,"Together with the chromatin immunoprecipitation and biotinylated oligonucleotide pulldown data, the co-immunoprecipitation results also suggest the possibility that FoxM1 and FoxO3a cooperate to regulate ERalpha gene transcription",1.49,PMID.dPMID16809346.s0.p1,3,3,FoxM1|FoxO3a|ERalpha,ERalpha|FoxM1|FoxO3a,p
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,16809346,ERalpha,FoxM1,"In this study, we have identified the Forkhead transcription factor FoxM1 as a physiological regulator of estrogen receptor alpha (ERalpha) expression in breast carcinoma cells.",0.54,PMID.dPMID16809346.s8.p0,2,2,FoxM1|ERalpha,ERalpha|FoxM1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,16809346,ERalpha,FoxM1,"Furthermore, treatment of MCF-7 cells with the MEK inhibitor U0126, which blocks ERK1/2-dependent activation of FoxM1, also repressed ERalpha expression.",0.43,PMID.dPMID16809346.s5.p2,3,3,ERK1|FoxM1|ERalpha,ERalpha|ERK1|FoxM1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,16809346,ERalpha,FoxM1,"Consistent with this, silencing of FoxM1 expression in MCF-7 cells using small interfering RNA resulted in the almost complete abrogation of ERalpha expression.",0.31,PMID.dPMID16809346.s4.p0,2,2,FoxM1|ERalpha,ERalpha|FoxM1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,20208560,ERalpha,FOXM1,"In this study, we investigated the regulation of FOXM1 expression by estrogen receptor alpha (ERalpha) and its role in hormonal therapy and endocrine resistance.",0.19,PMID.dPMID20208560.s10.p0,2,2,FOXM1|ERalpha,ERalpha|FOXM1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,16809346,ERalpha,FoxM1,Our survey of a panel of 16 different breast cell lines showed a good correlation (13/16) between FoxM1 expression and expression of ERalpha at both protein and mRNA levels.,0.11,PMID.dPMID16809346.s7.p0,2,2,FoxM1|ERalpha,ERalpha|FoxM1,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,16809346,ERalpha,FoxO3a,"Together with the chromatin immunoprecipitation and biotinylated oligonucleotide pulldown data, the co-immunoprecipitation results also suggest the possibility that FoxM1 and FoxO3a cooperate to regulate ERalpha gene transcription",1.59,PMID.dPMID16809346.s0.p2,3,3,FoxM1|FoxO3a|ERalpha,ERalpha|FoxM1|FoxO3a,<--
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15367686,ERalpha,FOXO3a,"Thus, FOXO3a represents an important intracellular mediator of ERalpha expression, suggesting possible therapeutic intervention strategies for Her-2/neu-overexpressing refractory breast tumors",0.47,PMID.dPMID15367686.s0.p0,3,3,FOXO3a|ERalpha|Her-2/neu,ERalpha|FOXO3a|Her-2/neu,<--
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15367686,ERalpha,FOXO3a,"We identify for the first time the Forkhead box protein FOXO3a (formerly termed FKHRL-1), which is inactivated by Akt, as a key regulator of ERalpha gene transcription.",0.40,PMID.dPMID15367686.s7.p3,4,3,FOXO3a|FKHRL-1|Akt|ERalpha,Akt|ERalpha|FKHRL-1|FOXO3a,<--
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15367686,ERalpha,FOXO3a,"Ectopic FOXO3a expression induced ERalpha protein levels and promoter activity, while a dominant negative FOXO3a decreased ERalpha levels.",0.35,PMID.dPMID15367686.s5.p0,4,2,FOXO3a|ERalpha|FOXO3a|ERalpha,ERalpha|FOXO3a,<--
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15367686,ERalpha,FKHRL-1,"We identify for the first time the Forkhead box protein FOXO3a (formerly termed FKHRL-1), which is inactivated by Akt, as a key regulator of ERalpha gene transcription.",0.23,PMID.dPMID15367686.s7.p4,4,3,FOXO3a|FKHRL-1|Akt|ERalpha,Akt|ERalpha|FKHRL-1|FOXO3a,<--
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,17308128,ERalpha,c-fos,"Here, we show that, in ERalpha-positive BG-1 ovarian cancer cells, both E2 and the GPR30-selective ligand G-1 induced c-fos expression and estrogen-responsive element (ERE)-independent activity of a c-fos reporter gene, whereas only E2 stimulated an ERE-responsive reporter gene, indicating that GPR30 signaling does not activate ERalpha-mediated transcription.",0.03,PMID.dPMID17308128.s5.p18,7,4,ERalpha|BG-1|GPR30|c-fos|c-fos|GPR30|ERalpha,BG-1|c-fos|ERalpha|GPR30,-->
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,19902354,ERalpha,Gli1,"However, nuclear localization of Gli1 was predictive of a poorer cancer-specific survival in ERalpha-negative, including triple negative, cancers (P = 0.005), but not ERalpha-positive cancers.",0.70,PMID.dPMID19902354.s1.p0,3,2,Gli1|ERalpha|ERalpha,ERalpha|Gli1,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.1.1,3169,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051091,20501593,ERalpha,FOXA1,"Using breast cancer cell lines, we also demonstrate that FOXA1 regulates ERalpha expression, but not GATA3.",2.85,PMID.dPMID20501593.s1.p0,3,3,FOXA1|ERalpha|GATA3,ERalpha|FOXA1|GATA3,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.1.1,3169,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051091,20501593,ERalpha,FOXA1,FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.,0.36,PMID.dPMID20501593.s8.p0,2,2,FOXA1|ERalpha,ERalpha|FOXA1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.1.1,3169,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051091,20501593,ERalpha,FOXA1,"These data reveal that FOXA1 is necessary for hormonal responsiveness in the developing mammary gland and ERalpha-positive breast cancers, at least in part, through its control of ERalpha expression.",0.20,PMID.dPMID20501593.s0.p1,3,2,FOXA1|ERalpha|ERalpha,ERalpha|FOXA1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,16679312,ERalpha,AP-1,"Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.",2.15,PMID.dPMID16679312.s1.p20,10,3,JNK|c-Jun|JNK|c-Jun|ERalpha|AP-1|ERalpha|JNK|AP-1|ERalpha,AP-1|c-Jun|ERalpha|JNK,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10517669,ERalpha,AP-1,"Estrogen responses at AP-1 sites require the integrity of the ERalpha AF-1 and AF-2 activation surfaces and the complementary surfaces on the p160 coactivator GRIP1 (glucocorticoid receptor interacting protein 1), the NID/AF-1 region, and NR boxes.",0.42,PMID.dPMID10517669.s6.p0,3,3,AP-1|ERalpha|GRIP1,AP-1|ERalpha|GRIP1,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,18574464,ERalpha,MYB,"Moreover, recent evidence has strengthened the case that MYB is activated in colon and breast cancer: a block to MYB expression is overcome by mutation of the regulatory machinery in the former disease and by oestrogen receptor-alpha (ERalpha) in the latter.",0.01,PMID.dPMID18574464.s0.p1,3,2,MYB|MYB|ERalpha,ERalpha|MYB,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,17389747,ERalpha,NFATc1,"NFATc1 was specifically recruited ""in vivo"" at C and F distal promoters of ERalpha gene.",0.39,PMID.dPMID17389747.s3.p0,2,2,NFATc1|ERalpha,ERalpha|NFATc1,p
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,17389747,ERalpha,NFATc1,"In the present study, we demonstrated that NFATc1 was involved in the transcriptional regulation of human estrogen receptor alpha (ERalpha) gene in SaOS-2 osteoblastic like cells.",0.08,PMID.dPMID17389747.s4.p0,2,2,NFATc1|ERalpha,ERalpha|NFATc1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,17963131,ERalpha,NF-kappa B,The effects of xenoestrogens in transrepression of NF-kappa B by ERalpha were similar when 2 x NRE-CMV-Luc was employed as reporter.,0.25,PMID.dPMID17963131.s3.p0,2,2,NF-kappa B|ERalpha,ERalpha|NF-kappa B,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,19584059,ERalpha,NF-kappaB,"Increasing NF-kappaB expression by tumor necrosis factor-alpha reduced the expression of ERalpha, indicating that the NF-kappaB pathway inhibits expression of ERalpha in human cardiomyocytes.",0.25,PMID.dPMID19584059.s3.p0,4,2,NF-kappaB|ERalpha|NF-kappaB|ERalpha,ERalpha|NF-kappaB,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,18669446,ERalpha,NF-kappaB,"In summary, our results demonstrate that NF-kappaB pathway repression by HDAC is responsible for the low expression of IL-8 in ERalpha-positive breast cancer cells",0.12,PMID.dPMID18669446.s0.p3,4,4,NF-kappaB|HDAC|IL-8|ERalpha,ERalpha|HDAC|IL-8|NF-kappaB,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,17963131,ERalpha,NF-kappa B,"It is concluded that xenoestrogens, like estrogens, are capable of producing transrepression of NF-kappa B by hERalpha",0.11,PMID.dPMID17963131.s0.p0,2,2,NF-kappa B|ERalpha,ERalpha|NF-kappa B,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15870697,ERalpha,RARalpha,RARalpha and CRABPII proteins were either reduced or undetectable in T47D/C4:2W and MCF-7/ADR cells with lost expression of ERalpha.,0.11,PMID.dPMID15870697.s5.p1,3,3,RARalpha|CRABPII|ERalpha,CRABPII|ERalpha|RARalpha,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15111769,ERalpha,Sp1,In earlier studies we demonstrated an essential function for the Sp1 family of transcription factors in the regulation of ERalpha expression.,0.87,PMID.dPMID15111769.s5.p0,2,2,Sp1|ERalpha,ERalpha|Sp1,x
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19503094,ERalpha,p53,We also showed that activation of p53 decreased the transcriptional activity of ERalpha by elevating KLF4 expression.,1.28,PMID.dPMID19503094.s2.p0,3,3,p53|ERalpha|KLF4,ERalpha|KLF4|p53,-->
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10766163,ERalpha,p53,It is evident from these investigations that the ligand-independent protection of p53 by ERalpha is a novel role for this protein in addition to its classic regulatory function as a ligand-inducible transcription factor.,0.39,PMID.dPMID10766163.s1.p0,2,2,p53|ERalpha,ERalpha|p53,-->
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17699779,ERalpha,p53,"Transcriptional derepression of Survivin by ERalpha is dependent on the p53-binding site on the Survivin promoter, consistent with our observation that p53 is necessary for ERalpha to access the promoters.",0.10,PMID.dPMID17699779.s4.p5,4,2,ERalpha|p53|p53|ERalpha,ERalpha|p53,-->
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18765668,ERalpha,p53,Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter.,0.03,PMID.dPMID18765668.s7.p0,3,3,p53|ERalpha|BRCA2,BRCA2|ERalpha|p53,-->
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,18708366,ERalpha,WT1,"The expressions of ERalpha and its downstream target genes were significantly repressed following overexpression of WT1, whereas the down-regulation of WT1 by WT1 shRNA could enhance ERalpha expression and the sensitivity to tamoxifen treatment in ERalpha-negative MDA468 and HCC1954 cells that express high levels of WT1.",1.52,PMID.dPMID18708366.s2.p8,7,2,ERalpha|WT1|WT1|WT1|ERalpha|ERalpha|WT1,ERalpha|WT1,e
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,19011999,ERalpha,SXR,These results indicate that SXR augmented ER-mediated transcription by dissociating SMRT from ERalpha.,0.75,PMID.dPMID19011999.s1.p1,3,3,SXR|SMRT|ERalpha,ERalpha|SMRT|SXR,c 
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.8.1,8928,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045941|GO:0045944|GO:0051090,19711044,ERalpha,FoxH1,PKA-mediated stabilization of FoxH1 negatively regulates ERalpha activity.,1.54,PMID.dPMID19711044.s11.p0,2,2,FoxH1|ERalpha,ERalpha|FoxH1,c
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.8.1,8928,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045941|GO:0045944|GO:0051090,19711044,ERalpha,FoxH1,"In the present study, we examined the effects of PKA activation on the ability of FoxH1 to represses ERalpha transcriptional activity.",0.42,PMID.dPMID19711044.s3.p0,2,2,FoxH1|ERalpha,ERalpha|FoxH1,c
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19503094,ERalpha,KLF4,KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.,1.21,PMID.dPMID19503094.s10.p0,2,2,KLF4|ERalpha,ERalpha|KLF4,c
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19503094,ERalpha,KLF4,"Therefore, we examined the interaction between KLF4 and ERalpha, and found that KLF4 bound to the DNA-binding region of ERalpha.",0.15,PMID.dPMID19503094.s5.p5,4,2,KLF4|ERalpha|KLF4|ERalpha,ERalpha|KLF4,c
2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,18026833,ERalpha,FOXP1,"FOXP1 is not estrogen regulated and silencing FOXP1 expression, using siRNA, did not affect ERalpha, ERbeta or progesterone receptor expression, suggesting ER and FOXP1 co-expression may reflect a common regulatory mechanism",0.08,PMID.dPMID18026833.s0.p1,5,3,FOXP1|FOXP1|ERalpha|ERbeta|FOXP1,ERalpha|ERbeta|FOXP1,n
2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,16293641,ERbeta,c-Jun,"The recruitment pattern of c-Jun was also altered by ERbeta, although the expression levels of c-Jun were not.",0.15,PMID.dPMID16293641.s2.p0,3,2,c-Jun|ERbeta|c-Jun,c-Jun|ERbeta,n
2.1.1.2.3,2101,9606,,GO:0010552|GO:0034339,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,12914524,ERRalpha,PPARalpha,"At the cellular level, transcriptional activation driven by the PPARalpha/RXRalpha complex was counteracted by the expression of ERRalpha in HeLa cells.",0.02,PMID.dPMID12914524.s2.p0,2,2,PPARalpha|ERRalpha,ERRalpha|PPARalpha,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,12971829,Ets1,AML-1,"Some transcription factors, such as AML-1, regulate Ets1 by targeting its autoinhibitory module.",0.33,PMID.dPMID12971829.s8.p0,2,2,AML-1|Ets1,AML-1|Ets1,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19446338,Ets-1,RUNX1,"Chromatin immunoprecipitation assays revealed that RUNX1 constitutively occupies the CD6 promoter in vivo, and knockdown experiments demonstrated that the steady-state level of CD6 mRNA is dependent on the expression of RUNX1, RUNX3 and Ets-1 transcription factors.",0.21,PMID.dPMID19446338.s1.p10,6,4,RUNX1|CD6|CD6|RUNX1|RUNX3|Ets-1,CD6|Ets-1|RUNX1|RUNX3,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,10510472,ETS1,GADD153,Regulation of the human stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products.,0.43,PMID.dPMID10510472.s8.p0,3,3,GADD153|ETS1|FLI-1,ETS1|FLI-1|GADD153,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.5.2.1.2,2114,9606,,GO:0045893,2187191,ETS1,ETS2,Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1.,0.51,PMID.dPMID2187191.s5.p2,3,2,ETS1|ETS2|ETS1,ETS1|ETS2,x
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,8247540,ETS1,PEA3,The results of these studies indicate that PEA3 is a strong positive regulator of the ETS1 promoter and that other transcription factors increase the activity of the ETS1 promoter in an additive rather than synergistic fashion,0.85,PMID.dPMID8247540.s0.p0,3,2,PEA3|ETS1|ETS1,ETS1|PEA3,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.3.1.4.1,2297,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032582|GO:0045944|GO:0051090,9867825,Ets-1,FREAC-4,The kidney-expressed winged helix transcription factor FREAC-4 is regulated by Ets-1.,2.09,PMID.dPMID9867825.s7.p0,2,2,FREAC-4|Ets-1,Ets-1|FREAC-4,-->
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.3.1.4.1,2297,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032582|GO:0045944|GO:0051090,9867825,Ets-1,FREAC-4,"In this paper we show that the kidney-expressed winged helix transcription factor FREAC-4 is regulated by Ets-1, another kidney-expressed transcription factor.",1.87,PMID.dPMID9867825.s5.p0,2,2,FREAC-4|Ets-1,Ets-1|FREAC-4,-->
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,2.3.5.0.37,2672,9606,,GO:0000083|GO:0010553,17213822,ETS1,GFI1,"Luciferase (Luc) assays using artificial reporters showed that GFI1 repressed ETS1-mediated transcriptional activation and ETS1 repressed GFI1-mediated transcriptional activation, in a dose-dependent manner.",1.29,PMID.dPMID17213822.s5.p0,4,2,GFI1|ETS1|ETS1|GFI1,ETS1|GFI1,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15949416,Ets1,c-Jun,"CONCLUSION: The results suggest that transcription factor AP-1 and Ets play an crucial role in activation of MMP-9 transcription induced by LMP1, and cross-talk between c-Jun/Ets1 is involved in expression of MMP-9 mediated by LMP1",0.15,PMID.dPMID15949416.s0.p2,4,3,MMP-9|c-Jun|Ets1|MMP-9,c-Jun|Ets1|MMP-9,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18955504,ETS1,Smad2,We identified novel Smad binding sites in the CDKN1A gene where Smad2/3 binding was regulated by ETS1 and TFAP2A.,1.04,PMID.dPMID18955504.s3.p0,3,3,Smad2|ETS1|TFAP2A,ETS1|Smad2|TFAP2A,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,10558888,ETS-1,PPARgamma,"The luciferase assay showed that the activation of PPARgamma suppressed -249 to +330 c-MET promoter activity, driven by cotransfection of ETS-1 expression vector.",0.01,PMID.dPMID10558888.s2.p1,3,3,PPARgamma|c-MET|ETS-1,c-MET|ETS-1|PPARgamma,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17656364,Ets-1,Sp1,"To solve this problem, we examined the transcriptional regulation of the human Sp1 gene by Ets-1 and found that the gene expression and promoter activity of Sp1 are regulated by Ets-1 in cancer cells.",0.89,PMID.dPMID17656364.s2.p5,4,2,Sp1|Ets-1|Sp1|Ets-1,Ets-1|Sp1,p
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,15592518,ETS1,SP100,"Collectively, these data indicate that SP100 negatively modulates ETS1-dependent downstream biological processes",1.08,PMID.dPMID15592518.s0.p0,2,2,SP100|ETS1,ETS1|SP100,x
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,11909962,ETS-1,Sp100,"Sp100 strongly increases ETS-1 activation of natural and ets-focused promoters, through a mechanism involving the activation (C) domain of ETS-1 in addition to the interaction domains.",0.71,PMID.dPMID11909962.s2.p0,3,2,Sp100|ETS-1|ETS-1,ETS-1|Sp100,x
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,15592518,ETS1,SP100,SP100 directly antagonizes ETS1-mediated morphological changes in human umbilical vein endothelial cell (HUVEC) network formation and reduces HUVEC migration and invasion.,0.46,PMID.dPMID15592518.s4.p0,2,2,SP100|ETS1,ETS1|SP100,x
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,15592518,ETS1,SP100,"SP100 interacts with the ETS1 transcription factor, and we have previously shown that SP100 reduces ETS1-DNA binding and inhibits ETS1 transcriptional activity on the MMP1 and uPA promoters.",0.08,PMID.dPMID15592518.s7.p5,7,4,SP100|ETS1|SP100|ETS1|ETS1|MMP1|uPA,ETS1|MMP1|SP100|uPA,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,15592518,ETS1,SP100,"To further understand the functional relationship between ETS1 and SP100, cDNA microarray analysis was utilized to assess reprogramming of gene expression by ETS1 and SP100.",0.01,PMID.dPMID15592518.s3.p2,4,2,ETS1|SP100|ETS1|SP100,ETS1|SP100,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,1.3.1.0.1,7020,9606,,,12843180,Ets1,AP-2alpha,"As the transcription factor Ets1 is abundant in trophoblast cells, these investigations strongly suggest that AP-2alpha gene expression in the placenta is enhanced by a cis-acting element at nucleotides -1279 to -1139 that contains a critical Ets1-binding site",0.03,PMID.dPMID12843180.s0.p2,3,2,Ets1|AP-2alpha|Ets1,AP-2alpha|Ets1,-->
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14586398,ets-1,p53,An important implication of our findings is that the loss of p53-mediated negative control over ets-1-dependent transcription may lead to the acquisition of an invasive phenotype in tumor cells,0.52,PMID.dPMID14586398.s0.p0,2,2,p53|ets-1,ets-1|p53,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14586398,ets-1,Tumor suppressor p53,Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.,0.32,PMID.dPMID14586398.s8.p0,2,2,Tumor suppressor p53|ets-1,ets-1|Tumor suppressor p53,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,18212735,ETS-1,WT1,"On a molecular level, WT1 silencing diminished expression of the ETS-1 transcription factor.",0.80,PMID.dPMID18212735.s4.p0,2,2,WT1|ETS-1,ETS-1|WT1,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.1.10.1.1,8092,9606,GO:0016563,GO:0000122,20181745,Ets1,alx1,"An analysis of the upstream regulation of alx1 shows that this gene is regulated by MAPK signaling and by the transcription factor Ets1; however, these inputs influence only the maintenance of alx1 expression and not its activation, which occurs by a distinct mechanism.",0.06,PMID.dPMID20181745.s3.p0,3,2,alx1|Ets1|alx1,alx1|Ets1,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,8003962,ETS1,p51,"p51 ETS1 is characterized by a fast initial binding and conversion to a stable complex, whereas p42 ETS1 exhibits a slow initial binding and conversion to a stable complex.",0.39,PMID.dPMID8003962.s6.p0,3,2,p51|ETS1|ETS1,ETS1|p51,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,9266972,ETS1,p51,"Data presented in this paper indicate that the naturally occurring spliced variant protein, p42-ETS1, lacking the region encoded by ETS1 exon VII, represses the tumorigenicity, while p51-ETS1 reduces the tumorigenicity.",0.07,PMID.dPMID9266972.s2.p5,4,2,ETS1|ETS1|p51|ETS1,ETS1|p51,x
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.1.6.3.2,9839,9606,,GO:0016481,16391805,Ets-1,SIP1,Induced expression of Snail and SIP1 resulted in the increased expression of Ets-1 and DNA-binding activities of nuclear proteins to the Ets-1-binding site and strong Ets-1 expression was detected in highly invasive SCC cells.,0.13,PMID.dPMID16391805.s2.p3,4,2,SIP1|Ets-1|Ets-1|Ets-1,Ets-1|SIP1,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.1.6.3.2,9839,9606,,GO:0016481,19424592,ETS1,ZEB2,"Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB.",0.04,PMID.dPMID19424592.s14.p1,4,3,ZEB2|ZEB2|ETS1|HIF1alpha,ETS1|HIF1alpha|ZEB2,e
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,1.1.3.0.3,9935,9606,,,9566892,Ets-1,MafB,The MafB transcriptional activator plays a pivotal role in regulating lineage-specific gene expression during hematopoiesis by repressing Ets-1-mediated transcription of key erythroid-specific genes in myeloid cells.,1.33,PMID.dPMID9566892.s5.p0,2,2,MafB|Ets-1,Ets-1|MafB,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,1.1.3.0.3,9935,9606,,,10444328,ETS1,MAFB,The KRML (MAFB) transcriptional regulator plays a pivotal role in regulating lineage-specific hematopoiesis by repressing ETS1-mediated transcription of erythroid-specific genes in myeloid cells.,0.65,PMID.dPMID10444328.s7.p2,3,2,KRML|MAFB|ETS1,ETS1|KRML|MAFB,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,1.1.3.0.3,9935,9606,,,10444328,ETS1,KRML,The KRML (MAFB) transcriptional regulator plays a pivotal role in regulating lineage-specific hematopoiesis by repressing ETS1-mediated transcription of erythroid-specific genes in myeloid cells.,0.53,PMID.dPMID10444328.s7.p1,3,2,KRML|MAFB|ETS1,ETS1|KRML|MAFB,c
3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,3.5.2.6.2,51513,9606,GO:0003704,,11229456,Ets-1,transcription factor Ets-1,OBJECTIVE: To investigate the expression of the transcription factor Ets-1 in synovial tissue and cultured synovial fibroblasts from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and to study the regulation of Ets-1 expression and activation in synovial fibroblasts by proinflammatory cytokines.,0.27,PMID.dPMID11229456.s11.p0,2,2,transcription factor Ets-1|Ets-1,Ets-1|transcription factor Ets-1,x
3.5.2.1.2,2114,9606,,GO:0045893,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8660103,ets-2,c-jun,"Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis.",0.08,PMID.dPMID8660103.s9.p2,5,5,c-fos|c-jun|ets-2|metastasis suppressor|nm23-H1,c-fos|c-jun|ets-2|metastasis suppressor|nm23-H1,x
3.5.2.1.2,2114,9606,,GO:0045893,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,15064740,Ets-2,myb,"These results suggest that the myb gene family can be differentially modulated by Ets-2, and that the C-terminus is the domain that regulates this activity.",0.15,PMID.dPMID15064740.s0.p0,2,2,myb|Ets-2,Ets-2|myb,c
3.5.2.1.2,2114,9606,,GO:0045893,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20045441,ets2,Sp1,The triplex target sequence was located approximately 40-bp upstream of the transcription start site (TSS) and overlapped an Sp1 binding site relevant for ets2 transcription.,0.57,PMID.dPMID20045441.s4.p0,2,2,Sp1|ets2,ets2|Sp1,c
3.5.2.2.4,2115,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,17634427,ETV1,c-Jun,"Interestingly, c-Jun can transactivate the cloned ETV1 promoter also in the absence of ligand-activated AR, suggesting two mechanisms by which c-Jun can induce ETV1 expression.",0.74,PMID.dPMID17634427.s4.p5,4,2,c-Jun|ETV1|c-Jun|ETV1,c-Jun|ETV1,c
3.5.2.2.4,2115,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,17634427,ETV1,c-Jun,"In addition, both wild-type c-Jun and a transactivation-deficient mutant can enhance the transcriptional activity of ETV1, as measured by both reporter gene assay and endogenous expression of matrix metalloproteinase genes, well-known targets of Ets proteins.",0.53,PMID.dPMID17634427.s3.p0,2,2,c-Jun|ETV1,c-Jun|ETV1,c
3.5.2.1.3,2116,9606,,,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,19070576,Etv2,Ets protein,"We demonstrate that coexpression of the Forkhead protein FoxC2 and the Ets protein Etv2 induces ectopic expression of vascular genes in Xenopus embryos, and that combinatorial knockdown of the orthologous genes in zebrafish embryos disrupts vascular development.",0.01,PMID.dPMID19070576.s1.p0,2,2,Ets protein|Etv2,Ets protein|Etv2,x
3.5.2.1.9,2117,9606,,,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18959602,MetS,PPARG,CONCLUSIONS: Our data do not support a major role for the Pro12Ala variant of the PPARG gene in MetS and its individual components.,0.39,PMID.dPMID18959602.s1.p0,2,2,PPARG|MetS,MetS|PPARG,n
3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,3.3.2.1.1,1869,9606,,GO:0000122,18687701,E1AF,E2F1,"Here, we provided evidence the cell cycle and apoptosis regulator E2F1 induces E1AF expression at the transcriptional level.",2.12,PMID.dPMID18687701.s3.p0,2,2,E2F1|E1AF,E1AF|E2F1,e
3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,3.3.2.1.1,1869,9606,,GO:0000122,18687701,E1AF,E2F1,DNA damage by etoposide causes E2F1-dependent induction of E1AF expression at transcriptional level.,0.79,PMID.dPMID18687701.s2.p0,2,2,E2F1|E1AF,E1AF|E2F1,e
3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15754128,PEA3,AP-1,"Finally, AP-1 was determined via luciferase assays to be involved in regulating non-PEA3 dependent transcription.",0.64,PMID.dPMID15754128.s1.p0,2,2,AP-1|PEA3,AP-1|PEA3,x
3.5.2.2.6,2119,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7559555,ERM,c-Jun,"The synergy between c-Jun and ERM may be attributed to the enhancing effect of c-Jun on the transcription activity of ERM, because c-Jun increased ERM transcription activity by more than 20-fold in an assay system using a variety of fusion proteins between a Gal4 DNA-binding domain and a portion of ERM.",1.85,PMID.dPMID7559555.s1.p12,7,2,c-Jun|ERM|c-Jun|ERM|c-Jun|ERM|ERM,c-Jun|ERM,c
3.5.2.2.6,2119,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7559555,ERM,c-Jun,"The synergy between c-Jun and ERM may be attributed to the enhancing effect of c-Jun on the transcription activity of ERM, because c-Jun increased ERM transcription activity by more than 20-fold in an assay system using a variety of fusion proteins between a Gal4 DNA-binding domain and a portion of ERM.",1.29,PMID.dPMID7559555.s1.p5,7,2,c-Jun|ERM|c-Jun|ERM|c-Jun|ERM|ERM,c-Jun|ERM,c
3.5.2.2.6,2119,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7559555,ERM,c-Jun,"The synergy between c-Jun and ERM may be attributed to the enhancing effect of c-Jun on the transcription activity of ERM, because c-Jun increased ERM transcription activity by more than 20-fold in an assay system using a variety of fusion proteins between a Gal4 DNA-binding domain and a portion of ERM.",0.89,PMID.dPMID7559555.s1.p14,7,2,c-Jun|ERM|c-Jun|ERM|c-Jun|ERM|ERM,c-Jun|ERM,c
3.5.2.2.6,2119,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7559555,ERM,c-Jun,"The synergy between c-Jun and ERM may be attributed to the enhancing effect of c-Jun on the transcription activity of ERM, because c-Jun increased ERM transcription activity by more than 20-fold in an assay system using a variety of fusion proteins between a Gal4 DNA-binding domain and a portion of ERM.",0.89,PMID.dPMID7559555.s1.p10,7,2,c-Jun|ERM|c-Jun|ERM|c-Jun|ERM|ERM,c-Jun|ERM,c
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,9652733,TEL,AML1,Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1.,0.66,PMID.dPMID9652733.s10.p2,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,9671410,TEL,AML1,AML1 was found to be expressed but no normal TEL proteins were detected.,0.52,PMID.dPMID9671410.s5.p0,2,2,AML1|TEL,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,15837750,TEL,AML1,CONCLUSION: High AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL.,0.52,PMID.dPMID15837750.s0.p0,2,2,AML1|TEL,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11078523,TEL,AML1,"We also show that the leukemia-associated fusion protein TEL/AML1 is modified by SUMO-1 and found in the TEL bodies, in a pattern quite different from what we observe and report for AML1.",0.51,PMID.dPMID11078523.s2.p4,5,3,TEL|AML1|SUMO-1|TEL|AML1,AML1|SUMO-1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,9671410,TEL,AML1,"In t(12;21) samples, TEL-AML1 was detected as several protein species in the nuclei, whereas the AML1-TEL protein, was inconsistently expressed.",0.39,PMID.dPMID9671410.s6.p5,4,2,TEL|AML1|AML1|TEL,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,10488742,TEL,AML1,"The 12;21 chromosomal translocation occurs in leukemic cells from 20(30% of patients with B-lineage childhood acute lymphoblastic leukemia, the result being the TEL/AML1 fusion gene carrying a sequence different from TEL or AML1.",0.30,PMID.dPMID10488742.s6.p2,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,8653712,ETV6,AML1,"Moreover, it was shown that the AML1-ETV6 reciprocal chimeric transcript was not present in the malignant cells, and hence may not play a major role in leukemogenesis.",0.25,PMID.dPMID8653712.s1.p0,2,2,AML1|ETV6,AML1|ETV6,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,9031076,TEL,AML1,"The crucial chimeric gene, TEL-AML1, is transcribed from the der(21) and encodes the 336 NH2 aminoacics of TEL fused to the majority of the AML1 protein.",0.25,PMID.dPMID9031076.s2.p2,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,15837750,TEL,AML1,"The TEL-AML1 fusion product was expressed in all t(12;21)+ cases, whereas the reciprocal fusion product AML1-TEL was expressed in only 76%.",0.19,PMID.dPMID15837750.s4.p5,4,2,TEL|AML1|AML1|TEL,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,15837750,TEL,AML1,Multivariate analysis including age and WBC showed that only high AML1-TEL expression is an independent poor prognostic factor in t(12;21)+ childhood ALL.,0.15,PMID.dPMID15837750.s1.p0,2,2,AML1|TEL,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16038737,TEL,AML1,"Moreover, interphasic FISH using TEL and AML1 probes showed the loss of a second TEL at the time of relapse.",0.11,PMID.dPMID16038737.s2.p2,3,2,TEL|AML1|TEL,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,8751464,TEL,AML1,The reciprocal AML1/TEL transcripts were detected in 12 (86%) of the 14 cases expressing a TEL/AML1 transcript.,0.06,PMID.dPMID8751464.s10.p1,4,2,AML1|TEL|TEL|AML1,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11801462,TEL,AML1,DESIGN AND METHODS: The quantitative estimation of TEL-AML1 transcripts was performed in 10 P-ALL TEL-AML1-positive patients.,0.02,PMID.dPMID11801462.s9.p2,4,2,TEL|AML1|TEL|AML1,AML1|TEL,x
3.5.2.6.1,2120,9606,,,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,10023677,TEL,AML1,"Although AML1B (and a shorter AML1 isoform, AML1A) have transcriptional activating activity on the IL-3 promoter, fusion of the AML1 gene to the TEL gene generates a repressor of IL-3 expression.",0.01,PMID.dPMID10023677.s1.p14,7,3,AML1|AML1|AML1|IL-3|AML1|TEL|IL-3,AML1|IL-3|TEL,x
3.5.2.6.1,2120,9606,,,3.1.1.12.1,3110,9606,GO:0003702,GO:0006355|GO:0006357,18940475,ETV6,MNX1,MNX1-ETV6 fusion transcripts (previously HLXB9-ETV6) were rarely detected in AML patients having t(7;12)(q36;p13).,0.02,PMID.dPMID18940475.s6.p0,4,2,MNX1|ETV6|HLXB9|ETV6,ETV6|HLXB9|MNX1,x
3.5.2.6.1,2120,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,11165321,ETV6,MLL,"In AML, gene amplification by ring formation has been demonstrated only in another three patients (amplification of the MLL gene in two cases and of the ETV6 gene in one case).",0.14,PMID.dPMID11165321.s2.p0,2,2,MLL|ETV6,ETV6|MLL,x
3.5.2.6.1,2120,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,19579075,TEL,MLL,"For the ALL, the frequency of MLL/AF4 was 65.4%, for TEL-AML1 and that of BCR/ABL was 3.8%.",0.12,PMID.dPMID19579075.s3.p4,4,4,ALL|MLL|AF4|TEL,AF4|ALL|MLL|TEL,x
3.5.2.6.1,2120,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,15024455,ETV6,E2A,"Our aim is to develop a highly sensitive and specific method to screen simultaneously for the four most frequent fusion transcripts resulting from specific chromosomal translocations, namely, both the CML- and ALLtype BCR-ABL transcripts of t(9;22), E2A-PBX1 transcript of t(1;19), the MLL-AF4 transcript of t(4;11) and TEL-AML1 (also termed ETV6-CBFA2) of the cryptic t(12;21).",0.05,PMID.dPMID15024455.s3.p12,7,5,CML|BCR|E2A|MLL|TEL|ETV6|cryptic,BCR|CML|cryptic|E2A|ETV6|MLL|TEL,x
2.3.5.0.21,2122,9606,,GO:0016481|GO:0045892|GO:0045893,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11721451,MDS1-Evi-1,Evi-1,"RESULTS: Evi-1 expression was not detected in bone marrow samples of 8 normal controls, but low MDS1-Evi-1 expression levels (MDS1-Evi-1/GAPDH < 0.1) were detected in 3 of the 8 controls.",0.37,PMID.dPMID11721451.s6.p0,4,3,Evi-1|MDS1-Evi-1|MDS1-Evi-1|GAPDH,Evi-1|GAPDH|MDS1-Evi-1,x
2.3.5.0.21,2122,9606,,GO:0016481|GO:0045892|GO:0045893,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11243114,MDS1-Evi1,Evi1,"RESULTS: Evi1 expression was not detected in 8 normal controls, but low MDS1-Evi1 expression levels (MDS1-Evi1/GAPDH < 0.1) detected in 3 of the 8 controls.",0.30,PMID.dPMID11243114.s6.p0,4,3,Evi1|MDS1-Evi1|MDS1-Evi1|GAPDH,Evi1|GAPDH|MDS1-Evi1,x
2.3.5.0.21,2122,9606,,GO:0016481|GO:0045892|GO:0045893,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,11243114,MDS1-Evi1,Evi1,Study on expression of Evi1 and MDS1-Evi1 genes in myelodysplastic syndromes OBJECTIVE: To investigate expression of Evi1 and MDS1-Evi1 genes in myelodysplastic syndromes (MDS) and its role in pathogenesis of MDS.,0.10,PMID.dPMID11243114.s8.p3,4,2,Evi1|MDS1-Evi1|Evi1|MDS1-Evi1,Evi1|MDS1-Evi1,x
3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,3.3.1.6.1,2294,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0045893|GO:0051090,19220249,FOXC1,FOXF1,"The expression profiles of FOXF1 and FOXF2 suggest a role in epithelial to mesenchymal transition, while FOXA1 and FOXC1 expression is linked to androgen-associated growth status of cancer.",0.01,PMID.dPMID19220249.s0.p3,4,4,FOXF1|FOXF2|FOXA1|FOXC1,FOXA1|FOXC1|FOXF1|FOXF2,x
3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,17993506,FOXC1,FOXO1A,"Furthermore, FOXO1A expression is reduced in cultured human trabecular meshwork (TM) cells and in the zebrafish developing eye when FOXC1 expression is knocked down by siRNAs and morpholino antisense oliognucleotides, respectively.",0.02,PMID.dPMID17993506.s3.p0,2,2,FOXO1A|FOXC1,FOXC1|FOXO1A,e
3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2122229,ara,jun,Regulation of jun-B gene expression by 1-beta-D-arabinofuranosyl-cytosine in human myeloid leukemia cells.,0.55,PMID.dPMID2122229.s9.p0,2,2,jun|ara,ara|jun,x
3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1310062,ara,JUN,The binding of JUN/AP-1 was maximal at 1 hour of ara-C treatment and decreased to baseline levels at 12 hours.,0.39,PMID.dPMID1310062.s4.p0,2,2,JUN|ara,ara|JUN,x
3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2122980,ara,c-jun,Transcriptional regulation of c-jun gene expression by arabinofuranosylcytosine in human myeloid leukemia cells.,0.37,PMID.dPMID2122980.s9.p0,2,2,c-jun|ara,ara|c-jun,x
3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,3.1.10.19.2,5308,9606,,GO:0006355,16449236,FOXC1,PITX2,"Ultimately, PITX2 loss of function mutations have a compound effect: the reduced expression of PITX2-target genes coupled with the extensive activation of FOXC1-regulated targets.",0.13,PMID.dPMID16449236.s1.p2,3,2,PITX2|PITX2|FOXC1,FOXC1|PITX2,c
3.3.1.4.1,2297,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032582|GO:0045944|GO:0051090,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,9867825,FREAC-4,Ets-1,These results are compatible with the hypothesis that Ets-1 acts as an upstream regulator of FREAC-4 expression during kidney development,1.15,PMID.dPMID9867825.s0.p0,2,2,Ets-1|FREAC-4,Ets-1|FREAC-4,<--
3.3.1.4.4,2298,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,8825632,freac-5,freac-3,"The freac genes have been localized to the following positions: freac-1, 16q24; freac-3, 6p25; freac-4, 5q12-q13; freac-5, 9 pericen; freac-6, 5q34, and freac-8, 1p32",0.41,PMID.dPMID8825632.s0.p4,5,5,freac-1|freac-3|freac-4|freac-5|freac-8,freac-1|freac-3|freac-4|freac-5|freac-8,x
3.3.1.5.2,2301,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,3.2.1.2.2,5080,9606,,,11980846,FOXE3,PAX6,"In a small cohort (n = 13) of patients with Peters' anomaly, shown to be normal in the PAX6 locus, one individual was found to be heterozygous for a nonconservative missense mutation in FOXE3.",0.14,PMID.dPMID11980846.s3.p0,2,2,PAX6|FOXE3,FOXE3|PAX6,x
3.3.1.5.1,2304,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1.2.2.1.3,4617,9606,,GO:0006357,19192046,FOXE1,MYF-5,"CONCLUSIONS: In 45% of non-syndromic cleft palate patients, a novel homozygous polymorphism that prevented the binding of MYF-5 to FOXE1 promoter and affected the FOXE1 expression was found.",0.12,PMID.dPMID19192046.s1.p1,3,2,MYF-5|FOXE1|FOXE1,FOXE1|MYF-5,p
3.3.1.5.1,2304,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010553|GO:0045893|GO:0045944|GO:0051090,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,10944465,TTF-2,thyroid transcription factor,The thyroid transcription factor TTF-2 is a forkhead-containing protein involved in thyroid-specific gene expression and necessary for thyroid morphogenesis.,0.30,PMID.dPMID10944465.s3.p0,2,2,thyroid transcription factor|TTF-2,thyroid transcription factor|TTF-2,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20208560,FOXM1,ERalpha,Depletion of ERalpha by RNA interference (RNAi) in MCF-7 cells downregulated FOXM1 expression.,0.67,PMID.dPMID20208560.s8.p0,2,2,ERalpha|FOXM1,ERalpha|FOXM1,e
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17875680,FoxM1,ERalpha,TFAP2C regulates the expression of ERalpha directly by binding to the ERalpha promoter and indirectly via regulation of FoxM1.,0.47,PMID.dPMID17875680.s5.p4,4,3,TFAP2C|ERalpha|ERalpha|FoxM1,ERalpha|FoxM1|TFAP2C,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20208560,FOXM1,ERalpha,Reporter gene assays showed that ERalpha activates FOXM1 transcription through an estrogen-response element (ERE) located within the proximal promoter region.,0.38,PMID.dPMID20208560.s7.p0,2,2,ERalpha|FOXM1,ERalpha|FOXM1,p
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,19276163,FOXM1,FOXO3a,"We also showed that ectopic expression of an active FOXO3a represses FOXM1 expression, whereas knockdown of FOXO3a expression using small interfering RNA can up-regulate FOXM1 and its downstream targets polo-like kinase, cyclin B1, and CDC25B and rescue sensitive BT474 cells from gefitinib-induced cell proliferative arrest.",1.94,PMID.dPMID19276163.s3.p0,4,2,FOXO3a|FOXM1|FOXO3a|FOXM1,FOXM1|FOXO3a,e
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,16701100,FOXM1,GLI1,"Expression of transcription levels of GLI1 and FOXM1 correlated with SHh expression (SHh vs GLI1, r = 0.77, P < .0001; GLI1 vs FOXM1, r = 0.68, P < .0001; SHh vs FOXM1, r = 0.79, P < .0001).",0.18,PMID.dPMID16701100.s5.p9,6,2,GLI1|FOXM1|GLI1|GLI1|FOXM1|FOXM1,FOXM1|GLI1,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,3.3.1.1.1,3169,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051091,7862129,HNF-3,HNF-3 alpha,We also discuss the role of reduced HNF-3 alpha expression in mediating decreased transcription of HNF-3 target genes which respond negatively to cytokine signalling.,0.99,PMID.dPMID7862129.s0.p0,2,2,HNF-3 alpha|HNF-3,HNF-3|HNF-3 alpha,e
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20372080,FoxM1,Sp1,"Here we show that Sp1 binds to the FoxM1 promoter region and positively regulates FoxM1 transcription, while mithramycin, a chemotherapy drug that specifically binds GC rich sequences in the DNA and inhibits activities of Sp1, inhibits expression of FoxM1.",0.60,PMID.dPMID20372080.s3.p1,5,2,Sp1|FoxM1|FoxM1|Sp1|FoxM1,FoxM1|Sp1,p
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20372080,FoxM1,Sp1,Our data suggest that TZD mediated suppression of Sp1 is responsible for downregulation of FoxM1 gene expression.,0.57,PMID.dPMID20372080.s2.p0,2,2,Sp1|FoxM1,FoxM1|Sp1,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,16913845,FOXM1,Transcription factor,Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4.,0.72,PMID.dPMID16913845.s8.p0,3,3,Transcription factor|FOXM1|Cdk4,Cdk4|FOXM1|Transcription factor,c
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,1.3.1.0.3,7022,9606,,,17875680,FoxM1,TFAP2C,TFAP2C regulates the expression of ERalpha directly by binding to the ERalpha promoter and indirectly via regulation of FoxM1.,0.90,PMID.dPMID17875680.s5.p3,4,3,TFAP2C|ERalpha|ERalpha|FoxM1,ERalpha|FoxM1|TFAP2C,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,2.1.3.3.6,7026,9606,GO:0003706|GO:0016563,GO:0000122|GO:0006357|GO:0032582|GO:0043193|GO:0045941|GO:0060849,8441395,HNF-3,ARP-1,Data from cotransfection experiments in which ARP-1 is overexpressed in the absence of its binding site suggest that ARP-1 interacts either directly or via a mediator protein with proteins recognizing the HNF-3 site and that this interaction is sufficient to repress transcriptional activation by HNF-3.,0.28,PMID.dPMID8441395.s1.p4,4,2,ARP-1|ARP-1|HNF-3|HNF-3,ARP-1|HNF-3,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,8668179,HNF-3,TTF-1,Modulation of TTF-1 gene expression by members of the HNF-3/forkhead family members may provide a mechanism by which distinct HNF-3/forkhead family members influence respiratory epithelial cell gene expression and cell differentiation,0.63,PMID.dPMID8668179.s0.p0,3,2,TTF-1|HNF-3|HNF-3,HNF-3|TTF-1,"[3169-->7080, 3170-->7080]"
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19749794,FoxM1,p53,"Finally, our results indicate a potential contribution of p53-mediated repression of FoxM1 for maintenance of a stable G2 arrest",0.49,PMID.dPMID19749794.s0.p0,2,2,p53|FoxM1,FoxM1|p53,x
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19749794,FoxM1,p53,"In this study we show that p53 is required for the downregulation of FoxM1, an essential transcription factor that regulates many G2/M-specific genes and is overexpressed in a multitude of solid tumors.",0.35,PMID.dPMID19749794.s6.p0,2,2,p53|FoxM1,FoxM1|p53,e
3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19749794,FoxM1,p53,"After DNA damage, p53 facilitates the repression of FoxM1 mRNA, which is accompanied by a decrease in FoxM1 protein levels.",0.30,PMID.dPMID19749794.s5.p0,3,2,p53|FoxM1|FoxM1,FoxM1|p53,e
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,17993506,FOXO1A,FOXC1,FOXC1 regulates the expression of FOXO1A and binds to a conserved element in the FOXO1A promoter in vivo.,1.78,PMID.dPMID17993506.s5.p0,3,2,FOXC1|FOXO1A|FOXO1A,FOXC1|FOXO1A,p
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,17993506,FOXO1A,FOXC1,FOXC1 is required for cell viability and resistance to oxidative stress in the eye through the transcriptional regulation of FOXO1A.,0.46,PMID.dPMID17993506.s8.p0,2,2,FOXC1|FOXO1A,FOXC1|FOXO1A,e
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,17993506,FOXO1A,FOXC1,FOXC1 regulates the expression of FOXO1A and binds to a conserved element in the FOXO1A promoter in vivo.,0.08,PMID.dPMID17993506.s5.p1,3,2,FOXC1|FOXO1A|FOXO1A,FOXC1|FOXO1A,p
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18202312,FoxO1,FoxO3,"In primary atrial culture, targeting FoxO1 and FoxO3 with siRNA specifically reduces mRNA expression of FoxO1 and -O3 and KIR6.1.",0.44,PMID.dPMID18202312.s6.p2,3,2,FoxO1|FoxO3|FoxO1,FoxO1|FoxO3,e
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,20212266,FOXO1,HIF-1alpha,Gene knockdown of HIF-1alpha or FOXO1 by small-interfering RNAs abolishes hypoxia-induced expression of FOXO1 and SUR2A/B/Kir6.1.,1.00,PMID.dPMID20212266.s2.p1,4,3,HIF-1alpha|FOXO1|FOXO1|Kir6.1,FOXO1|HIF-1alpha|Kir6.1,e
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,12519792,FKHR,HNF-4,These results suggest that insulin regulates the transcriptional activity of HNF-4 via FKHR as a signal-regulated transcriptional inhibitor.,0.46,PMID.dPMID12519792.s0.p0,2,2,HNF-4|FKHR,FKHR|HNF-4,c
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.1.1.7.8,3207,9606,,,19727442,FOXO1A,HoxA-11,"While HoxA-11 alone is a repressor on the decidual prolactin promoter, it turns into an activator when combined with FOXO1A.",0.22,PMID.dPMID19727442.s5.p1,3,3,HoxA-11|prolactin|FOXO1A,FOXO1A|HoxA-11|prolactin,c
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,16282329,Foxo1,PDX-1,"Furthermore, adenovirus-mediated Foxo1 overexpression reduced the nuclear expression of PDX-1, whereas repression of Foxo1 by Foxo1-specific small interfering RNA retained the nuclear expression of PDX-1 under oxidative stress conditions.",0.22,PMID.dPMID16282329.s1.p2,5,2,Foxo1|PDX-1|Foxo1|Foxo1|PDX-1,Foxo1|PDX-1,e
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.2.1.2,4656,9606,,GO:0010552,10666368,FKHR,myogenin,One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts.,1.51,PMID.dPMID10666368.s5.p1,3,3,myogenin|Pax3|FKHR,FKHR|myogenin|Pax3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,10666368,FKHR,Pax3,One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts.,0.88,PMID.dPMID10666368.s5.p2,3,3,myogenin|Pax3|FKHR,FKHR|myogenin|Pax3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15688035,FKHR,Pax3,"Regulation of gene expression by Pax3 and Pax3/FKHR is, however, cell-type specific.",0.49,PMID.dPMID15688035.s2.p2,3,2,Pax3|Pax3|FKHR,FKHR|Pax3,c
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,20470941,FKHR,PAX3,"Correspondingly, using FISH, the t(2;13)/PAX3-FKHR was found positive in 19 cases (63.5%), one case (3%) revealed the t(1;13)/PAX7/FKHR and ten cases (33.5%) were fusion-negative by this method.",0.30,PMID.dPMID20470941.s6.p0,4,3,PAX3|FKHR|PAX7|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,9516963,FKHR,Pax3,"The objective of the study was to elucidate how DNA-damaging agents with different mechanisms of action were sensitized in the context of expression of the Pax3/FKHR fusion protein, a transformation event unique to alveolar rhabdomyosarcomas (ARMSs), and wild-type p53 (wtp53).",0.30,PMID.dPMID9516963.s7.p0,4,3,Pax3|FKHR|p53|p53,FKHR|p53|Pax3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15838707,FKHR,PAX3,Our study was directed at identifying antigenic T-lymphocyte epitopes at the PAX3/FKHR translocation point area.,0.28,PMID.dPMID15838707.s10.p0,2,2,PAX3|FKHR,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,9543674,FKHR,PAX3,"Molecular analysis with RT-PCR amplification of RNA isolated from the tumour demonstrated the presence of a PAX3/FKHR fusion transcript, product of a t(2;13) reciprocal translocation, a genetic marker specific for alveolar rhabdomyosarcoma.",0.26,PMID.dPMID9543674.s1.p0,2,2,PAX3|FKHR,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,17525748,FKHR,PAX3,We also found repression of skeletal muscle-specific genes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells.,0.20,PMID.dPMID17525748.s2.p0,2,2,PAX3|FKHR,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,19047133,FKHR,PAX3,"We previously showed that PAX3-FKHR expression in primary human myoblasts, cells that can give rise to RMS, cooperated with loss of p16INK4A to promote extended proliferation.",0.14,PMID.dPMID19047133.s5.p0,3,3,PAX3|FKHR|p16INK4A,FKHR|p16INK4A|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,19158934,FKHR,PAX3,Comparative analysis of paired- and homeodomain-specific roles in PAX3-FKHR oncogenesis.,0.14,PMID.dPMID19158934.s8.p0,2,2,PAX3|FKHR,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,18414034,FOXO1,PAX3,Experiments designed to determine how PAX3-FOXO1 expression contributes to the development of muscle cell-derived tumors resulted in the discovery that the fusion protein misregulates gene expression and interrupts myogenic differentiation through a unique gain of function mechanism.,0.13,PMID.dPMID18414034.s1.p0,3,3,PAX3|FOXO1|myogenic differentiation,FOXO1|myogenic differentiation|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15688035,FKHR,Pax3,"Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.",0.13,PMID.dPMID15688035.s0.p10,6,2,Pax3|FKHR|Pax3|Pax3|Pax3|FKHR,FKHR|Pax3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15688035,FKHR,Pax3,"Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.",0.12,PMID.dPMID15688035.s0.p14,6,2,Pax3|FKHR|Pax3|Pax3|Pax3|FKHR,FKHR|Pax3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,14697639,FOXO1A,PAX3,Alveolar rhabdomyosarcomas (ARMS) are soft-tissue tumors that are genetically characterized by the presence of reciprocal translocations that generate the fusion gene PAX3-FOXO1A or PAX7-FOXO1A.,0.11,PMID.dPMID14697639.s6.p0,4,3,PAX3|FOXO1A|PAX7|FOXO1A,FOXO1A|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,10871843,FKHR,PAX3,These results suggest that at least part of the anti-apoptotic effect of PAX3 and PAX3/FKHR is mediated through direct transcriptional modulation of the prominent anti-apoptotic protein BCL-XL.,0.07,PMID.dPMID10871843.s1.p2,4,3,PAX3|PAX3|FKHR|BCL-XL,BCL-XL|FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15838707,FKHR,PAX3,These results raise serious concerns about the success and applicability of future peptide-based vaccine immunotherapy directed at the PAX3/FKHR translocation point.,0.07,PMID.dPMID15838707.s0.p0,2,2,PAX3|FKHR,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,12414908,FKHR,PAX3,"PAX3/FKHR mutants with deletions in either the homeodomain (DeltaHD) or the FKHR-derived activation domain (DeltaFKHR), or in which the PAX3-derived paired domain (PD) was point-mutated (PD-R56L), were unable to activate GLUT4-P.",0.07,PMID.dPMID12414908.s4.p1,6,3,PAX3|FKHR|FKHR|FKHR|PAX3|GLUT4,FKHR|GLUT4|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,7862145,FKHR,PAX3,"The PAX3-FKHR protein was localized to the nucleus in Rh30 cells, as was wild-type PAX3, in t(2;13)-negative A673 cells.",0.05,PMID.dPMID7862145.s3.p0,3,2,PAX3|FKHR|PAX3,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,11496344,FKHR,PAX3,"CONCLUSIONS: We conclude that compared to PAX7-FKHR-containing tumors, ARMS that contain PAX3-FKHR transcript have (1) increased cell proliferation, consistent with greater loss of cell cycle regulation, and (2) apoptosis that is increased but insufficient to prevent tumor formation.",0.05,PMID.dPMID11496344.s2.p5,4,3,PAX7|FKHR|PAX3|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,18022385,FKHR,PAX3,The malignancy of alveolar rhabdomyosarcoma (ARMS) has been linked to expression of the PAX3-FKHR chimeric gene.,0.04,PMID.dPMID18022385.s3.p0,2,2,PAX3|FKHR,FKHR|PAX3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,17954266,FOXO1A,PAX7,"Previous studies have suggested that the expression of PAX7-FOXO1A is copy-number dependent, but that of PAX3-FOXO1A is not, which may be due to a weaker PAX7 than PAX3 promoter.",1.00,PMID.dPMID17954266.s3.p0,6,3,PAX7|FOXO1A|PAX3|FOXO1A|PAX7|PAX3,FOXO1A|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,11607823,FKHR,PAX7,The PAX7-FKHR fusion is overexpressed as a result of in vivo amplification while the PAX3-FKHR fusion is overexpressed due to a copy number-independent increase in transcriptional rate.,0.47,PMID.dPMID11607823.s3.p1,3,2,PAX7|FKHR|FKHR,FKHR|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,11496344,FKHR,PAX7,"RESULTS: Cell cycle parameters varied significantly: the number of nuclei that stained with either an immunohistochemical marker of proliferation (MIB1), or a TUNEL-based assay for apoptosis was significantly greater in tumors that expressed PAX3-FKHR compared to tumors that expressed PAX7-FKHR transcript.",0.30,PMID.dPMID11496344.s3.p5,4,3,PAX3|FKHR|PAX7|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,11496344,FKHR,PAX7,"PROCEDURE: We examined histology, immunohistochemical markers of differentiation, and cell cycle characteristics of a panel of ARMS containing either PAX3-FKHR or PAX7-FKHR transcript to determine if these features differ between the ARMS subsets.",0.10,PMID.dPMID11496344.s4.p5,4,3,PAX3|FKHR|PAX7|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,9479491,FKHR,PAX7,"Alveolar rhabdomyosarcomas are associated with unique chromosomal translocations t(2;13) and t(1;13), which arise from fusion of the genes for the paired box proteins PAX3 and PAX7, respectively, to the FKHR (forkhead in rhabdomyosarcoma) gene on chromosome 13q14.",0.08,PMID.dPMID9479491.s8.p0,2,2,PAX7|FKHR,FKHR|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,20470941,FKHR,PAX7,"Correspondingly, using FISH, the t(2;13)/PAX3-FKHR was found positive in 19 cases (63.5%), one case (3%) revealed the t(1;13)/PAX7/FKHR and ten cases (33.5%) were fusion-negative by this method.",0.07,PMID.dPMID20470941.s6.p5,4,3,PAX3|FKHR|PAX7|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,20470941,FKHR,PAX7,Only one case (3%) was positive to t(1;13)/PAX7-FKHR and nine cases (30%) were fusion-negative.,0.02,PMID.dPMID20470941.s7.p0,2,2,PAX7|FKHR,FKHR|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,11496344,FKHR,PAX7,Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions.,0.02,PMID.dPMID11496344.s7.p5,4,3,PAX3|FKHR|PAX7|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,9098647,FKHR,PAX7,The PAX3-FKHR and PAX7-FKHR gene fusions that result from chromosomal translocations in this tumor provide potential molecular diagnostic markers.,0.01,PMID.dPMID9098647.s6.p5,4,3,PAX3|FKHR|PAX7|FKHR,FKHR|PAX3|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.2.1.1.2,5081,9606,,,11607823,FKHR,PAX7,The PAX7-FKHR fusion is overexpressed as a result of in vivo amplification while the PAX3-FKHR fusion is overexpressed due to a copy number-independent increase in transcriptional rate.,0.00,PMID.dPMID11607823.s3.p0,3,2,PAX7|FKHR|FKHR,FKHR|PAX7,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,19049975,FoxO1,STAT3,"Our study suggests that leptin action could be inhibited at a step downstream of STAT3 phosphorylation and nuclear translocation, and provides a potential mechanism of leptin resistance in which an increased FoxO1 antagonizes STAT3-mediated leptin signaling.",0.23,PMID.dPMID19049975.s0.p4,6,3,leptin|STAT3|leptin|FoxO1|STAT3|leptin,FoxO1|leptin|STAT3,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.3.1.0.2,7021,9606,,GO:0006355|GO:0006357|GO:0045817,17525748,FKHR,TFAP2B,"Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR.",0.10,PMID.dPMID17525748.s1.p1,3,3,TFAP2B|PAX3|FKHR,FKHR|PAX3|TFAP2B,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17575126,Foxo1a,p73,These observations thus reveal a novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis especially when p53 is absent.,0.76,PMID.dPMID17575126.s0.p1,5,5,p73|Akt|Foxo1a|Bim|p53,Akt|Bim|Foxo1a|p53|p73,x
3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17575126,Foxo1a,p73,"A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A. Virtually all human cancers encounter disruption of the ""p53 network.""",0.62,PMID.dPMID17575126.s7.p1,5,5,p73|Akt|Foxo1a|Bim|p53,Akt|Bim|Foxo1a|p53|p73,x
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,19276163,FOXO3a,FOXM1,These results suggest that gefitinib represses FOXM1 expression via FOXO3a in breast cancer.,0.63,PMID.dPMID19276163.s2.p0,2,2,FOXM1|FOXO3a,FOXM1|FOXO3a,e
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,19276163,FOXO3a,FOXM1,Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.,0.24,PMID.dPMID19276163.s10.p0,2,2,FOXM1|FOXO3a,FOXM1|FOXO3a,e
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,19244250,FOXO3,FOXO1,"Altogether, our results suggest that the expression of FOXO1 and FOXO4 genes is stimulated by FOXO3 and possibly by other FOXO factors in a positive feedback loop, which is disrupted by growth factors.",0.68,PMID.dPMID19244250.s0.p1,3,3,FOXO1|FOXO4|FOXO3,FOXO1|FOXO3|FOXO4,e
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,20018872,FoxO3a,FoxO1,"Our findings provide evidence that FoxO1, hypoxia-stimulated expression of FoxO3a and its nuclear accumulation are required for the induction of CTGF by hypoxia in endothelial cells",0.14,PMID.dPMID20018872.s0.p0,2,2,FoxO1|FoxO3a,FoxO1|FoxO3a,x
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,19244250,FOXO3,FOXO1,"Using luciferase reporter assays and chromatin immunoprecipitations, we identified a conserved FOXO-binding site in the promoter of the FOXO1 gene, which was required for regulation by PDGF, and mediated the up-regulation of FOXO1 by itself and by FOXO3.",3.2522109511e-06,PMID.dPMID19244250.s1.p1,3,2,FOXO1|FOXO1|FOXO3,FOXO1|FOXO3,p
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.15.3,4303,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,19244250,FOXO3,FOXO4,"Altogether, our results suggest that the expression of FOXO1 and FOXO4 genes is stimulated by FOXO3 and possibly by other FOXO factors in a positive feedback loop, which is disrupted by growth factors.",1.02,PMID.dPMID19244250.s0.p2,3,3,FOXO1|FOXO4|FOXO3,FOXO1|FOXO3|FOXO4,c
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.6.7.5,4601,9606,,,17452451,FOXO3a,Mxi1,Silencing of Mxi1 by small interfering RNA (siRNA) reduced FOXO3a-mediated repression of a number of Myc target genes.,0.94,PMID.dPMID17452451.s4.p0,3,3,Mxi1|FOXO3a|Myc target,FOXO3a|Mxi1|Myc target,c
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.6.7.5,4601,9606,,,17452451,FOXO3a,Mxi1,Our results provide evidence of direct regulation of Mxi1 by FOXO3a and imply an additional mechanism through which the PI3-kinase/Akt/FOXO pathway can modulate Myc function,0.84,PMID.dPMID17452451.s0.p0,4,4,Mxi1|FOXO3a|Akt|Myc,Akt|FOXO3a|Mxi1|Myc,c
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.6.7.5,4601,9606,,,17452451,FOXO3a,Mxi1,The induction of Mxi1 by FOXO3a was specific to the Mxi1-SR alpha isoform and was mediated by three highly conserved FOXO binding sites within the first intron of the gene.,0.31,PMID.dPMID17452451.s6.p0,3,2,Mxi1|FOXO3a|Mxi1,FOXO3a|Mxi1,e
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.6.7.5,4601,9606,,,17452451,FOXO3a,Mxi1,Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.,0.28,PMID.dPMID17452451.s12.p0,3,3,Mxi1|FOXO3a|Myc,FOXO3a|Mxi1|Myc,e
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18393360,FOXO3a,c-Myc,c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.,2.08,PMID.dPMID18393360.s10.p0,4,4,c-Myc|FOXO3a|p27|Kip1,c-Myc|FOXO3a|Kip1|p27,x
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18393360,FOXO3a,c-Myc,"As ectopic c-Myc expression in these cells prevented anti-IgM induction of p27 and cell death, we hypothesized that c-Myc represses FOXO3a-mediated transcription.",1.99,PMID.dPMID18393360.s6.p5,4,3,c-Myc|p27|c-Myc|FOXO3a,c-Myc|FOXO3a|p27,c
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,20733005,FoxO3a,VDR,"In contrast, ablation of VDR expression enhances FoxO3a phosphorylation, as does knockdown of Sirt1, consistent with the coupling of FoxO acetylation and phosphorylation.",0.11,PMID.dPMID20733005.s3.p0,3,3,VDR|FoxO3a|Sirt1,FoxO3a|Sirt1|VDR,x
3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,19280712,Foxo3a,FoxP3,"hCDR1 increased the expression of transforming growth factor (TGF)-beta, FoxP3 and the negative regulators Foxj1 and Foxo3a.",0.26,PMID.dPMID19280712.s3.p0,2,2,FoxP3|Foxo3a,Foxo3a|FoxP3,x
3.5.2.1.6,2313,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8164678,FLI-1,c-myc,"We show that EWS-FLI-1 is a transactivator of the c-myc promoter, suggesting that upregulation of c-myc expression is under control of EWS-FLI-1",1.29,PMID.dPMID8164678.s0.p13,6,3,EWS|FLI-1|c-myc|c-myc|EWS|FLI-1,c-myc|EWS|FLI-1,e
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,11026560,c-fos,PGA1,"In this study, we revealed that PGA1 induces c-fos expression at least partly by increasing the binding between heat shock factor-1 and the HSE, and that PGA1 enhances activity of activating protein-1 (AP-1).",1.42,PMID.dPMID11026560.s3.p0,4,3,PGA1|c-fos|PGA1|AP-1,AP-1|c-fos|PGA1,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,11026560,c-fos,PGA1,"Because we recently found functional HSEs in the human and rodent c-fos promoters, we hypothesized that PGA1 might increase c-fos expression through the HSE.",0.74,PMID.dPMID11026560.s4.p2,3,2,c-fos|PGA1|c-fos,c-fos|PGA1,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,10100620,c-fos,acute myeloid leukemia 1,"These data suggest that acute myeloid leukemia 1 and acute myeloid leukemia 1-MTG8 reciprocally regulate the myeloid cell differentiation, possibly by the way of regulating c-fos gene transcription",0.54,PMID.dPMID10100620.s0.p1,3,2,acute myeloid leukemia 1|acute myeloid leukemia 1|c-fos,acute myeloid leukemia 1|c-fos,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,10100620,c-fos,acute myeloid leukemia 1,"These data suggest that acute myeloid leukemia 1 and acute myeloid leukemia 1-MTG8 reciprocally regulate the myeloid cell differentiation, possibly by the way of regulating c-fos gene transcription",0.51,PMID.dPMID10100620.s0.p2,3,2,acute myeloid leukemia 1|acute myeloid leukemia 1|c-fos,acute myeloid leukemia 1|c-fos,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,15156182,c-Fos,AML1,"Lastly, AML1/EVI-1 enhances AP-1 activity by activating the c-Fos promoter depending on the second zinc-finger domain of EVI-1, and promotes cell proliferation.",0.15,PMID.dPMID15156182.s1.p0,2,2,AML1|c-Fos,AML1|c-Fos,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.4.1.2,1051,9606,,,17129742,c-fos,C/EBPbeta,The acetylation of C/EBPbeta also contributes to its ability to activate c-fos transcription.,0.65,PMID.dPMID17129742.s6.p0,2,2,C/EBPbeta|c-fos,C/EBPbeta|c-fos,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.4.1.2,1051,9606,,,17129742,c-fos,C/EBPbeta,"Among the GH-regulated transcription factors on c-fos, C/EBPbeta appears to be key, since depletion of C/EBPbeta by RNA interference blocks the stimulation of c-fos by GH.",0.15,PMID.dPMID17129742.s8.p5,4,2,c-fos|C/EBPbeta|C/EBPbeta|c-fos,C/EBPbeta|c-fos,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.2.0.1,1385,9606,,GO:0045944,9382844,c-fos,CREB,Cells with anchored PKAII exhibited a threefold higher level of nuclear catalytic subunit content and 4-10-fold greater increments in phosphorylation of a regulatory serine residue in cAMP response element binding protein (CREB) and in phosphoCREB-stimulated transcription of the c-fos gene.,1.33,PMID.dPMID9382844.s2.p2,3,2,CREB|CREB|c-fos,c-fos|CREB,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.2.0.1,1385,9606,,GO:0045944,9140044,c-Fos,CREB,"Activation of the adenylate cyclase-coupled V2R in LLC-PK1 cells induced phosphorylation of adenosine 3',5'-cyclic monophosphate (cAMP) responsive element binding protein (CREB) and expression of c-Fos.",0.30,PMID.dPMID9140044.s2.p2,3,3,V2R|CREB|c-Fos,c-Fos|CREB|V2R,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.2.0.1,1385,9606,,GO:0045944,9382844,c-fos,CREB,Cells with anchored PKAII exhibited a threefold higher level of nuclear catalytic subunit content and 4-10-fold greater increments in phosphorylation of a regulatory serine residue in cAMP response element binding protein (CREB) and in phosphoCREB-stimulated transcription of the c-fos gene.,0.13,PMID.dPMID9382844.s2.p1,3,2,CREB|CREB|c-fos,c-fos|CREB,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.2.0.3,1390,9606,,GO:0006355,15322221,c-fos,CREM,We conclude that CREM represses the expression of c-fos and limits the activity of the enhancer AP-1.,1.37,PMID.dPMID15322221.s1.p0,3,3,CREM|c-fos|AP-1,AP-1|c-fos|CREM,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.2.0.3,1390,9606,,GO:0006355,17340624,c-fos,ICER,Inducible cAMP early repressor splice variants ICER I and IIgamma both repress transcription of c-fos and chromogranin A.,0.89,PMID.dPMID17340624.s10.p0,2,2,ICER|c-fos,c-fos|ICER,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,8168107,c-fos,GADD153,"Unlike GADD45, the response of other DNA damage-inducible genes to IR is not dependent on p53 based on the observation that induction in a panel of cell lines did not correlate with a normal p53 status; this included human GADD153, another member of the gadd (growth arrest and DNA damage inducible) group; MyD118, a gene related to GADD45; and the protooncogenes c-jun and c-fos.",0.08,PMID.dPMID8168107.s6.p18,7,5,GADD45|p53|p53|GADD153|MyD118|GADD45|c-fos,c-fos|GADD153|GADD45|MyD118|p53,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.3.2.1.2,1958,9606,,GO:0045941,8723988,c-fos,early growth response,OBJECTIVES: The aims of this study were to characterize the angiotensin II receptor subtype present on vascular smooth muscle cells from human saphenous vein and to assess the effect of angiotensin II on the expression of the early growth response gene c-fos and on DNA synthesis.,0.45,PMID.dPMID8723988.s7.p0,2,2,early growth response|c-fos,c-fos|early growth response,w
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.3.2.1.2,1958,9606,,GO:0045941,8723988,c-fos,early growth response,Effect of angiotension II on the expression of the early growth response gene c-fos and DNA synthesis in human vascular smooth muscle cells.,0.27,PMID.dPMID8723988.s8.p0,2,2,early growth response|c-fos,c-fos|early growth response,w
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.3.2.1.2,1958,9606,,GO:0045941,8541224,c-fos,early growth response,"The ER in SKOV3 cells was normal with respect to apparent Kd for binding with E2, E2 regulation of a transiently transfected ERE driven reporter gene, and E2 stimulation of expression of the early growth response genes c-myc and c-fos.",0.20,PMID.dPMID8541224.s2.p1,3,3,early growth response|c-myc|c-fos,c-fos|c-myc|early growth response,w
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,17950909,c-fos,Elk1,"Furthermore, ERK2-induced PARP-1 activation dramatically amplifies ERK-signals, enhancing ERK-induced phosphorylation of the transcription factor Elk1 and enhancing core histone acetylation and expression of the Elk1 target gene, c-fos.",0.43,PMID.dPMID17950909.s1.p20,7,4,ERK2|PARP-1|ERK|ERK|Elk1|Elk1|c-fos,c-fos|Elk1|ERK|ERK2|PARP-1,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.5.2.2.3,2005,9606,,,9734357,c-fos,SAP-1,SAP-1 is a member of the Ets transcription factors and cooperates with SRF protein to activate transcription of the c-fos protooncogene.,0.01,PMID.dPMID9734357.s4.p1,3,3,SAP-1|SRF|c-fos,c-fos|SAP-1|SRF,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.1.2.7.2,2020,9606,,,16900666,c-fos,EN2,"Besides the ontogenesis of the cerebellar cortex in man, we reported alterations of biopathological features (neuronal immaturity, altered apoptotic programs, negative expression of somatostatin and EN2 gene, intense c-fos expression positivity, astrogliosis) in the cortex and in the dentate nucleus of the 63% of sudden deaths, and only in 10% of the controls.",1.38,PMID.dPMID16900666.s2.p2,3,3,somatostatin|EN2|c-fos,c-fos|EN2|somatostatin,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17308128,c-fos,ERalpha,"Moreover, both GPR30 and ERalpha expression are required for c-fos stimulation and extracellular signal-regulated kinase (ERK) activation in response to either E2 or G-1.",0.03,PMID.dPMID17308128.s3.p2,4,4,GPR30|ERalpha|c-fos|ERK,c-fos|ERalpha|ERK|GPR30,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,19795350,c-fos,ERbeta,"These findings suggest a complex interrelation between estrogen signaling and c-fos transcriptional activity within the human testis, with the increase of ERbeta mRNA being putatively a compensatory mechanism for lower c-fos expression in infertile men with damaged spermatogenesis",0.25,PMID.dPMID19795350.s0.p2,3,2,c-fos|ERbeta|c-fos,c-fos|ERbeta,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.5.2.1.2,2114,9606,,GO:0045893,9500466,c-fos,Ets2,"We have also demonstrated that the expression of this Ets2 mutant is capable of interrupting the CSF-1R-regulated intracellular signaling pathways by inhibiting CSF-1-induced c-myc, c-fos, and c-jun expression in BT20 cells.",0.30,PMID.dPMID9500466.s1.p6,5,5,Ets2|CSF-1R|CSF-1|c-myc|c-fos,c-fos|c-myc|CSF-1|CSF-1R|Ets2,i
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.2.4,2355,9606,,GO:0006357,15811576,c-Fos,Fra-2,"In addition, G-120 increased the expression of c-Jun, Fra-1, and Fra-2, but did not affect the expression of c-Fos.",0.17,PMID.dPMID15811576.s2.p5,4,4,c-Jun|Fra-1|Fra-2|c-Fos,c-Fos|c-Jun|Fra-1|Fra-2,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,12944485,c-fos,TCF,"DN-MKL1 reduced the late stage of serum induction of endogenous c-fos expression, suggesting that the TCF- and RhoA-dependent pathways contribute to temporally distinct phases of c-fos expression.",0.45,PMID.dPMID12944485.s2.p8,5,4,MKL1|c-fos|TCF|RhoA|c-fos,c-fos|MKL1|RhoA|TCF,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.4.1.0.1,3297,9606,,,11189444,Fos,HSF1,"Therefore, besides its known function in the stress response, HSP70 also has the property of a corepressor and combines with HSF1 to antagonize Fos expression and may thus impact multiple aspects of cell regulation",0.44,PMID.dPMID11189444.s0.p2,3,3,HSP70|HSF1|Fos,Fos|HSF1|HSP70,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1708774,c-fos,AP-1,"This AP-1-like element, when cloned into the tk promoter, responds to the AP-1 activity of c-jun/c-fos products in both CV-1 and F-9 cells.",0.78,PMID.dPMID1708774.s6.p4,4,2,AP-1|AP-1|c-jun|c-fos,AP-1|c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1908239,c-fos,AP-1,It is concluded that a) the inhibition of transforming growth factor beta autostimulation by HDL3 plus LDL may involve reduced AP-1 activity via a reduction of c-fos expression by the lipoprotein combination and b) the ratio HDL3:LDL might influence the pathogenesis of arteriosclerosis via growth-related events in the arterial wall,0.78,PMID.dPMID1908239.s0.p2,4,3,HDL3|AP-1|c-fos|HDL3,AP-1|c-fos|HDL3,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11834005,c-fos,c-jun,"Expression patterns of c-fos and c-jun by in situ hybridization were markedly different; myocardial c-fos expression was diffuse and homogeneous, whereas c-jun expression was patchy with areas of intense focal localization.",0.74,PMID.dPMID11834005.s2.p2,4,2,c-fos|c-jun|c-fos|c-jun,c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15761212,c-Fos,c-Jun,E2 or E2-BSA enhanced DNA binding and transcriptional activity of AP-1 and generated c-Fos/c-Jun heterodimers by inducing c-Fos expression.,0.73,PMID.dPMID15761212.s5.p2,3,2,c-Fos|c-Jun|c-Fos,c-Fos|c-Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1325459,Fos,Jun,The action of Fos and Jun on PEPCK gene transcription involved each of the Fos/Jun-binding sites and was modulated by additional transcriptional regulatory elements within the PEPCK promoter.,0.69,PMID.dPMID1325459.s3.p4,6,3,Fos|Jun|PEPCK|Fos|Jun|PEPCK,Fos|Jun|PEPCK,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8608166,c-fos,AP-1,"Since FOS and JUN proteins form a transacting activator (AP-1) for expression of collagenase and stromelysin genes, PC may block the synthesis of both enzymes by inhibiting the transcription of c-fos and c-jun",0.68,PMID.dPMID8608166.s0.p8,5,3,FOS|JUN|AP-1|collagenase|c-fos,AP-1|c-fos|collagenase|FOS|JUN,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8065332,Fos,AP-1,The affinity of transcription factors for the AP-1 binding site depends on the redox state of a cysteine residue located close to the DNA-binding region of both Fos and Jun.,0.65,PMID.dPMID8065332.s6.p0,3,2,AP-1|Fos|Jun,AP-1|Fos|Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1708774,c-fos,AP-1,A 23-base pair DNA element containing the overlapping glucocorticoid-responsive element and AP-1 sites can be positively regulated by glucocorticoid receptor in the absence of c-jun/c-fos products.,0.32,PMID.dPMID1708774.s4.p1,3,2,AP-1|c-jun|c-fos,AP-1|c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19795388,c-Fos,AP-1,"Significant and quantitative changes were seen in the expression of six AP-1 transcription factor genes, FosB, c-Fos, Fra-1, c-Jun, JunB, and ATF3 from 1-8 h following OS.",0.32,PMID.dPMID19795388.s6.p1,4,4,AP-1|FosB|c-Fos|Fra-1,AP-1|c-Fos|FosB|Fra-1,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7533060,C-FOS,C-JUN,"The expression of C-FOS, C-JUN and phosphotyrosine gene products in lung cancer   An immunohistochemical study on C-FOS, C-JUN and phosphotyrosine (P-Tyr) cancer gene products was performed.",0.32,PMID.dPMID7533060.s8.p2,4,2,C-FOS|C-JUN|C-FOS|C-JUN,C-FOS|C-JUN,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,9523591,c-fos,jun,"On the other hand, preincubation with KN-62 attenuated the carbachol-induced increase in c-jun and junD expression by 70% but had no effect on c-fos, fosB, and junB mRNA levels.",0.28,PMID.dPMID9523591.s3.p2,5,3,c-jun|jun|c-fos|fosB|jun,c-fos|c-jun|fosB|jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,9681824,Fos,Jun,"Finally, we show that the formation of the previously described ternary complex Ergp55/Fos/jun is mediated by ETS domain and Jun protein, while the ternary complex Ergp49/Fos/Jun is mediated by Fos protein",0.26,PMID.dPMID9681824.s0.p14,6,2,Fos|jun|Jun|Fos|Jun|Fos,Fos|jun|Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8909793,c-fos,c-jun,"These signalling pathways, except that for bcl-2 pathway, appear to be mediated by multiple PTKs: p56lck is critical for the induction of the c-fos/c-jun genes, the activation of Syk PTKs results in the induction of the c-myc gene and Jak3 PTK is required for the induction of both c-fos and c-myc genes.",0.24,PMID.dPMID8909793.s1.p24,9,7,bcl-2|p56lck|c-fos|c-jun|Syk|c-myc|Jak3|c-fos|c-myc,bcl-2|c-fos|c-jun|c-myc|Jak3|p56lck|Syk,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8608166,c-fos,JUN,"Since FOS and JUN proteins form a transacting activator (AP-1) for expression of collagenase and stromelysin genes, PC may block the synthesis of both enzymes by inhibiting the transcription of c-fos and c-jun",0.23,PMID.dPMID8608166.s0.p7,5,3,FOS|JUN|AP-1|collagenase|c-fos,AP-1|c-fos|collagenase|FOS|JUN,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8422459,c-fos,c-jun,The inhibition of c-fos and c-jun expression by IL-4 in LPS-treated cells was shown to be due to a lower transcription rate of the c-fos and c-jun genes.,0.22,PMID.dPMID8422459.s3.p4,5,3,c-fos|c-jun|IL-4|c-fos|c-jun,c-fos|c-jun|IL-4,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1545132,c-fos,AP-1,The increase in AP-1-binding activity was accompanied by the marked stimulation of the transcription of c-fos but not that of c-jun.,0.20,PMID.dPMID1545132.s4.p0,2,2,AP-1|c-fos,AP-1|c-fos,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2498646,c-fos,AP1,"Although recent reports have shown that fos protein binds to AP1-binding sites through an interaction with AP1 protein and have raised the speculation that fos protein may negatively regulate expression of the c-fos gene via this interaction, we found no role for the AP1 consensus homology in the downregulation of c-fos expression following induction by epidermal growth factor and TPA",0.19,PMID.dPMID2498646.s0.p9,5,2,AP1|AP1|c-fos|AP1|c-fos,AP1|c-fos,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2511004,Fos,Jun,We conclude that in the Fos-Jun heterodimer the basic region of Fos contributes specific DNA-binding properties equivalent to those of Jun.,0.18,PMID.dPMID2511004.s1.p2,4,2,Fos|Jun|Fos|Jun,Fos|Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11736649,Fos,AP-1,The activator protein 1 (AP-1) transcription factor is composed of heterodimers of the Fos/activating transcription factor (ATF) and Jun subfamilies of basic-region leucine-zipper (B-ZIP) proteins.,0.17,PMID.dPMID11736649.s8.p0,3,2,AP-1|Fos|Jun,AP-1|Fos|Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7774103,c-Fos,c-Jun,"OBJECTIVE: To examine the relationship between the expression of c-Fos and c-Jun proteins and the METHODS: The expression of c-Fos and c-Jun proteins and the production of IL-1 beta in the PBMC of 11 patients with active RA was determine by Western blots and ELISA techniques, respectively.",0.17,PMID.dPMID7774103.s6.p2,4,2,c-Fos|c-Jun|c-Fos|c-Jun,c-Fos|c-Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19495976,c-Fos,c-Jun,"We investigated whether H. pylori in a Korean isolate (HP99), a cagA ( + ), vacA ( + ) strain, induces the expression of c-Fos and c-Jun for AP-1 activation to induce COX-2 and iNOS and whether HP99-induced expressions of COX-2 and iNOS are mediated by Ras and AP-1, determined by the expressions of c-Fos and c-Jun, in gastric epithelial AGS cells, using transfection with mutant genes for Ras (ras N-17) and c-Jun (TAM-67).",0.15,PMID.dPMID19495976.s3.p7,8,3,c-Fos|c-Jun|AP-1|AP-1|c-Fos|c-Jun|c-Jun|TAM,AP-1|c-Fos|c-Jun|TAM,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,17235455,c-fos,AP-1,"In this study, we investigated the possibility that PTEN mediates its effects through modulation of transcription factor AP-1, which is in part due to decrease in c-fos expression which was dependent on PI3kinase activity.",0.14,PMID.dPMID17235455.s5.p2,3,3,PTEN|AP-1|c-fos,AP-1|c-fos|PTEN,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8985358,c-fos,c-jun,"Since expression of the c-jun/c-fos gene family is tightly regulated during cellular differentiation, defined reorganization of a central viral transcription factor may represent a novel mechanism controlling the transcription of pathogenic HPVs during keratinocyte differentiation and in the progression to cervical cancer",0.12,PMID.dPMID8985358.s0.p0,2,2,c-jun|c-fos,c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7576299,Fos,Jun,Jun was detected in 14 of 20 (70%) and no significant relationship was observed between the expression of Jun and Fos or p53.,0.12,PMID.dPMID7576299.s2.p1,4,3,Jun|Jun|Fos|p53,Fos|Jun|p53,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,9973257,c-Fos,AP-1,AP-1 is a dimeric complex of the protooncoproteins c-Jun and c-Fos and directly regulates transcription of genes important for cellular growth.,0.12,PMID.dPMID9973257.s5.p1,3,2,AP-1|c-Jun|c-Fos,AP-1|c-Fos|c-Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11766607,c-fos,c-jun,The effects of triptolide on endothelial c-jun/c-fos mRNA expression were investigated by RT-PCR.,0.10,PMID.dPMID11766607.s4.p0,2,2,c-jun|c-fos,c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8100127,c-fos,c-jun,"Also a significant correlation between the c-fos and c-jun proteins and the expression of P-glycoprotein was found (c-fos p = 0.017, c-jun p = 0.036).",0.09,PMID.dPMID8100127.s3.p4,5,3,c-fos|c-jun|P-glycoprotein|c-fos|c-jun,c-fos|c-jun|P-glycoprotein,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8601460,Fos,Jun,"Moreover, analysis of the effect of AP-1 proteins on the collagenase and TIMP-1 promoters in gastric carcinoma KKLS cells revealed that c-Fos combined with any of the Jun-related proteins failed to stimulate the TIMP-1 promoter, though collagenase promoter was effectively activated by any Fos/Jun-related protein heterocomplex.",0.08,PMID.dPMID8601460.s1.p13,7,3,AP-1|TIMP-1|c-Fos|Jun|TIMP-1|Fos|Jun,AP-1|c-Fos|Fos|Jun|TIMP-1,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,16452503,Fos,AP-1,"AP-1 (Activating Protein 1) transcription factor activity is tightly regulated at multiple levels, including dimer formation (i.e., Fos/Jun).",0.07,PMID.dPMID16452503.s9.p0,3,2,AP-1|Fos|Jun,AP-1|Fos|Jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2498163,c-fos,c-jun,"Notably, c-fos and c-jun activation can be dissociated; whereas c-jun is coinduced with c-fos and jun-B after growth factor stimulation, membrane depolarization activates c-fos and jun-B without stimulating c-jun.",0.06,PMID.dPMID2498163.s4.p12,8,2,c-fos|c-jun|c-jun|c-fos|jun|c-fos|jun|c-jun,c-fos|c-jun|jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1708774,c-fos,AP-1,"This AP-1-like element, when cloned into the tk promoter, responds to the AP-1 activity of c-jun/c-fos products in both CV-1 and F-9 cells.",0.06,PMID.dPMID1708774.s6.p3,4,2,AP-1|AP-1|c-jun|c-fos,AP-1|c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18692824,cFos,AP-1,"Transcripts of related AP-1 genes, cJun and cFos, were significantly decreased by a mean of -29.57 for cJun and -23.78 for cFos, but there was no significant change in protein expression of the two transcription factors.",0.06,PMID.dPMID18692824.s2.p1,5,2,AP-1|cJun|cFos|cJun|cFos,AP-1|cFos|cJun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,17348214,c-fos,c-jun,"Expression and significance of hTERT, c-fos and c-jun in ameloblastoma   PURPOSE: To investigate the expression of c-fos, c-jun and hTERT mRNA in human ameloblastoma (AB) and to determine their clinicobiological significance.",0.05,PMID.dPMID17348214.s7.p2,4,2,c-fos|c-jun|c-fos|c-jun,c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1708774,c-fos,c-jun,A 23-base pair DNA element containing the overlapping glucocorticoid-responsive element and AP-1 sites can be positively regulated by glucocorticoid receptor in the absence of c-jun/c-fos products.,0.04,PMID.dPMID1708774.s4.p2,3,2,AP-1|c-jun|c-fos,AP-1|c-fos|c-jun,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3779660,c-fos,c-myb,"In most cell types, c-myc and c-myb expression is controlled primarily by posttranscriptional mechanisms, whereas c-fos expression is regulated primarily at the transcriptional level.",0.62,PMID.dPMID3779660.s4.p2,3,3,c-myc|c-myb|c-fos,c-fos|c-myb|c-myc,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3018359,c-fos,c-myb,"A correlation was evident between the potency of these compounds as inducers of differentiation demonstrated by nonspecific esterase activity, the degree of reduction in calmodulin concentration, the rate of the inhibition of DNA synthesis and of expression of c-myc and c-myb genes, and the induction of the expression of oncogenes c-fos and c-fms.",0.46,PMID.dPMID3018359.s1.p2,4,4,c-myc|c-myb|c-fos|c-fms,c-fms|c-fos|c-myb|c-myc,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2463066,c-fos,c-myc,"Since p53 and heat shock gene 70 were expressed at comparable levels in control and antisense cells, c-myc gene expression appears to be regulated by c-fos gene in F9 EC cells.",0.85,PMID.dPMID2463066.s1.p2,3,3,p53|c-myc|c-fos,c-fos|c-myc|p53,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3541926,c-fos,c-myc,"Induction of HL-60 cells by phorbol esters to undergo monocytic differentiation results in the suppression of c-myc, but the activation of c-fos gene transcription.",0.64,PMID.dPMID3541926.s4.p0,2,2,c-myc|c-fos,c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3137398,c-fos,c-myc,The same sample displayed a greatly reduced expression of c-myc accompanied by a concurrent 10-fold increased expression of c-fos.,0.53,PMID.dPMID3137398.s2.p0,2,2,c-myc|c-fos,c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3137398,c-fos,c-myc,"Expression of c-myc was completely abolished in U-937 and greatly reduced in HL-60 after a 3 day exposure to the drug, whereas specific c-fos transcripts were increased.",0.38,PMID.dPMID3137398.s6.p0,2,2,c-myc|c-fos,c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3779660,c-fos,c-myc,"In most cell types, c-myc and c-myb expression is controlled primarily by posttranscriptional mechanisms, whereas c-fos expression is regulated primarily at the transcriptional level.",0.25,PMID.dPMID3779660.s4.p1,3,3,c-myc|c-myb|c-fos,c-fos|c-myb|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3117047,c-fos,c-myc,"In lymphocytes stimulated with the mitogen phytohaemagglutinin, an inhibitor of the enzyme ADP-ribosyltransferase (ADPRT) completely blocks the proliferative response and the increase in expression of the proto-oncogene c-myc without affecting c-fos significantly.",0.24,PMID.dPMID3117047.s2.p2,3,3,ADPRT|c-myc|c-fos,ADPRT|c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1964112,c-fos,c-myc,"The mRNA expression of c-Ha-ras, c-Ki-ras, c-N-ras and c-myc oncogenes could be inhibited by 2 mmol/L sodium butyrate treatment, but this had no effect on the expression of c-fos.",0.19,PMID.dPMID1964112.s2.p5,4,4,c-Ha-ras|c-Ki-ras|c-myc|c-fos,c-fos|c-Ha-ras|c-Ki-ras|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18422165,c-fos,c-myc,Effects of intranasal budesonide on the expression of c-fos and c-myc in nasal polyps OBJECTIVE: To investigate the effect of intranasal glucocorticoids treatment on the expression of c-fos and c-myc nasal polyps.,0.15,PMID.dPMID18422165.s5.p2,4,2,c-fos|c-myc|c-fos|c-myc,c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3018359,c-fos,c-myc,"A correlation was evident between the potency of these compounds as inducers of differentiation demonstrated by nonspecific esterase activity, the degree of reduction in calmodulin concentration, the rate of the inhibition of DNA synthesis and of expression of c-myc and c-myb genes, and the induction of the expression of oncogenes c-fos and c-fms.",0.12,PMID.dPMID3018359.s1.p1,4,4,c-myc|c-myb|c-fos|c-fms,c-fms|c-fos|c-myb|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18422165,c-fos,c-myc,"RESULT: The rate of c-fos expressing cases was 15% and the rate of c-myc expressing cases was 20% in nasal polyps from topical steroid treated patients, but in untreated patients, the rate of c-fos expressing cases was 80% and the rate of c-myc expressing cases was 85%.",0.07,PMID.dPMID18422165.s3.p2,4,2,c-fos|c-myc|c-fos|c-myc,c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,14656381,c-fos,c-myc,"We find that FGF signaling inhibits cell cycle progression in two lines and surprisingly, reduces the expression of c-myc while turning on c-fos.",0.04,PMID.dPMID14656381.s2.p0,2,2,c-myc|c-fos,c-fos|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1688596,c-fos,c-myc,"The expression of the c-myc, c-fos, c-jun, c-erbB, and c-Ha-ras protooncogenes was compared by Northern blot analysis of total RNA extracted from keratome biopsies of normal skin and psoriatic plaques.",0.00,PMID.dPMID1688596.s7.p0,4,4,c-myc|c-fos|c-jun|c-Ha-ras,c-fos|c-Ha-ras|c-jun|c-myc,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.6.5.2,4613,9606,,GO:0006357,2039993,c-fos,N-myc,"We examined the genomic amplification of N-myc in 26 specimens of neuroblastomas and further analyzed 22 of the 26 cases for expression of N-myc, c-src, c-Ha-ras, and c-fos.",0.13,PMID.dPMID2039993.s2.p6,5,4,N-myc|N-myc|c-src|c-Ha-ras|c-fos,c-fos|c-Ha-ras|c-src|N-myc,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,17145886,c-fos,beta2,Constitutively activated PKCbeta1 and beta2 also enhanced the transcription of c-fos in transient transfection luciferase reporter assays.,0.34,PMID.dPMID17145886.s2.p0,2,2,beta2|c-fos,beta2|c-fos,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,9653115,Fos,NFAT1,The NFAT1-Fos-Jun complex induced a bend at the ARRE2 site that was distinct from the sum of the bends induced by NFAT1 and Fos-Jun separately.,0.03,PMID.dPMID9653115.s6.p3,4,2,NFAT1|Fos|NFAT1|Fos,Fos|NFAT1,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.1.10.20.1,5396,9606,,,16651408,c-FOS,PMX1,"In addition to many interesting features, we have found that the NUP98-PMX1 fusion protein exerts a repressive effect on PMX1 or serum response factor-mediated c-FOS activation, probably through the recruitment of a common corepressor histone deacetylase 1 by FG domains of the NUP98-PMX1 fusion protein.",0.28,PMID.dPMID16651408.s2.p4,6,3,NUP98|PMX1|PMX1|c-FOS|NUP98|PMX1,c-FOS|NUP98|PMX1,x
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,9671405,Fos,RARalpha,PMLRARalpha was also found to enhance the transcriptional activity of GAL4/Fos.,1.33,PMID.dPMID9671405.s2.p4,4,4,PML|RARalpha|GAL4|Fos,Fos|GAL4|PML|RARalpha,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.1.1.2.3,5966,9606,,,20562914,c-Fos,c-Rel,The inability of c-Rel to induce the expression of c-Fos and c-Jun contributes to its weaker oncogenic potential relative to v-Rel.,0.49,PMID.dPMID20562914.s5.p0,3,3,c-Rel|c-Fos|c-Jun,c-Fos|c-Jun|c-Rel,n
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,1547771,c-fos,SRF,These findings imply possible roles for SRF phosphorylation in the regulation of c-fos transcription,0.78,PMID.dPMID1547771.s0.p0,2,2,SRF|c-fos,c-fos|SRF,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,1924358,c-fos,SRF,"In the case of the human serum response factor (SRF), a transcription factor involved in the regulation of the c-fos protooncogene, the vaccinia-expressed histidine-tagged SRF (SRF-6His) could be purified solely by this step to greater than 95% purity.",0.29,PMID.dPMID1924358.s2.p0,4,2,SRF|c-fos|SRF|SRF,c-fos|SRF,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,3119326,c-fos,SRF,"A short DNA sequence element, the serum response element (SRE), which binds a nuclear protein, serum response factor (SRF), mediates transient transcriptional activation of c-fos and cytoskeletal actin genes in response to serum factors.",0.14,PMID.dPMID3119326.s4.p0,2,2,SRF|c-fos,c-fos|SRF,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,2928331,c-fos,SRF,"We conclude that band I in neonates represents a SRE-binding factor that is distinct from the SRF, which may be responsible for the neonatal induction of the c-fos gene.",0.12,PMID.dPMID2928331.s1.p0,2,2,SRF|c-fos,c-fos|SRF,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.2.1.0.1,6772,9606,,,19404962,c-Fos,STAT-1,STAT-1 and STAT-3 modulated the expression of c-Fos and directly transactivated the CCL2 promoter.,0.94,PMID.dPMID19404962.s6.p1,4,4,STAT-1|STAT-3|c-Fos|CCL2,CCL2|c-Fos|STAT-1|STAT-3,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,19404962,c-Fos,STAT-3,STAT-1 and STAT-3 modulated the expression of c-Fos and directly transactivated the CCL2 promoter.,0.91,PMID.dPMID19404962.s6.p2,4,4,STAT-1|STAT-3|c-Fos|CCL2,CCL2|c-Fos|STAT-1|STAT-3,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,8065335,c-Fos,TBP,"This inhibition (squelching) of c-Fos activity is relieved by the presence of excess TBP, indicating that TBP is a direct functional target of c-Fos.",0.46,PMID.dPMID8065335.s3.p5,4,2,c-Fos|TBP|TBP|c-Fos,c-Fos|TBP,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,8065335,c-Fos,TBP,High-affinity binding to TBP requires c-Fos activation modules which cooperate to activate transcription.,0.25,PMID.dPMID8065335.s8.p0,2,2,TBP|c-Fos,c-Fos|TBP,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10348347,c-fos,p53,"In addition, we show that (a) the level of endogenous p53 mRNA and (b) transcription from the strictly p53-dependent human mdm2 promoter are reduced in the presence of c-fos, c-jun, p50(NF-kappaB1), p65RelA or c-myc antisense oligonucleotides, underscoring the importance of these transcription factors for the expression of functional p53",0.38,PMID.dPMID10348347.s0.p4,6,4,p53|p53|mdm2|c-fos|c-myc|p53,c-fos|c-myc|mdm2|p53,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10082525,c-fos,p53,Overexpression of wt p53 induces c-fos mRNA and protein.,0.19,PMID.dPMID10082525.s4.p0,2,2,p53|c-fos,c-fos|p53,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1409626,c-FOS,p53,"The effect of wt p53 protein on the expression of four immediate-early genes (c-FOS, c-JUN, JUN-B, and c-MYC), one delayed-early gene (ornithine decarboxylase), and two late-G1/S-phase genes (B-MYB and DNA polymerase alpha) was also examined.",0.17,PMID.dPMID1409626.s2.p0,6,6,p53|c-FOS|c-JUN|c-MYC|ornithine decarboxylase|B-MYB,B-MYB|c-FOS|c-JUN|c-MYC|ornithine decarboxylase|p53,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8979269,c-fos,p53,"Finally, A253-p53 cells show reduced expression of c-fos, fibronectin, thrombospondin and parathyroid hormone-related protein (PTHrP) mRNAs.",0.11,PMID.dPMID8979269.s3.p0,6,5,p53|c-fos|fibronectin|thrombospondin|parathyroid hormone-related protein|PTHrP,c-fos|fibronectin|p53|parathyroid hormone-related protein|PTHrP|thrombospondin,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1652755,c-fos,p53,"The human p53 mutant derived from pC53-SCX3 was also less active than the wt protein in repressing the IL-6, c-fos, beta-actin, and MHC promoters, except that serum-induced IL-6/CAT expression was equally repressed by both human wt and mutant p53.",0.10,PMID.dPMID1652755.s2.p0,5,4,p53|c-fos|beta-actin|CAT|p53,beta-actin|CAT|c-fos|p53,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19320777,c-Fos,TP53,KRAS and TP53 mutations are commonly involved in sarcomagenesis whereby KRAS subsequently activates c-Fos.,0.04,PMID.dPMID19320777.s10.p0,2,2,TP53|c-Fos,c-Fos|TP53,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.2.7.0.2,7409,9606,,,11859076,c-fos,Vav1,"In this study, we have investigated the mechanisms by which Vav1 can regulate c-fos serum response element transcriptional activity.",0.30,PMID.dPMID11859076.s6.p0,2,2,Vav1|c-fos,c-fos|Vav1,e
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8266081,c-fos,YY1,"Yin-Yang-1 (YY1) regulates the transcription of many genes, including the oncogenes c-fos and c-myc.",0.82,PMID.dPMID8266081.s4.p2,4,3,Yin-Yang-1|YY1|c-fos|c-myc,c-fos|c-myc|Yin-Yang-1|YY1,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8266081,c-fos,Yin-Yang-1,"Yin-Yang-1 (YY1) regulates the transcription of many genes, including the oncogenes c-fos and c-myc.",0.47,PMID.dPMID8266081.s4.p1,4,3,Yin-Yang-1|YY1|c-fos|c-myc,c-fos|c-myc|Yin-Yang-1|YY1,<--
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1.1.1.2.3,8061,9606,,GO:0006357,15615716,c-Fos,Fos-related antigen-1,MEK1-dependent delayed expression of Fos-related antigen-1 counteracts c-Fos and p65 NF-kappaB-mediated interleukin-8 transcription in response to cytokines or growth factors.,0.50,PMID.dPMID15615716.s10.p2,3,3,MEK1|Fos-related antigen-1|c-Fos,c-Fos|Fos-related antigen-1|MEK1,-->
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8.1.1.0.2,9519,9606,,,15767669,c-fos,TLF,TATA-binding protein (TBP)-like factor (TLF) is a functional regulator of transcription: reciprocal regulation of the neurofibromatosis type 1 and c-fos genes by TLF/TRF2 and TBP.,0.42,PMID.dPMID15767669.s9.p2,6,3,TBP|TLF|c-fos|TLF|TRF2|TBP,c-fos|TBP|TLF|TRF2,c
1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3.5.2.4.1,26298,9606,,GO:0045893,18313906,c-Fos,EHF,"Movement restriction (40min) induced c-Fos protein expression primarily in cells with 10-50mum(2) sizes (associative type neurons) only in anterior hypothalamic nucleus and lateral hypothalamic area; while additional EHF-irradiation of acupuncture projection areas (under movement restriction) induced c-Fos expression in all hypothalamic structures and mostly in cells with 70-150mum(2) sizes (relay type neurons), i.e. changed the pattern of activated cell type distribution.",1.44,PMID.dPMID18313906.s1.p2,3,2,c-Fos|EHF|c-Fos,c-Fos|EHF,x
1.1.1.2.2,2354,9606,,GO:0000122,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19795388,FosB,AP-1,"Significant and quantitative changes were seen in the expression of six AP-1 transcription factor genes, FosB, c-Fos, Fra-1, c-Jun, JunB, and ATF3 from 1-8 h following OS.",0.30,PMID.dPMID19795388.s6.p0,4,4,AP-1|FosB|c-Fos|Fra-1,AP-1|c-Fos|FosB|Fra-1,x
1.1.1.2.4,2355,9606,,GO:0006357,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,11113393,fra-2,c-fos,"Expression of c-jun, junB, and c-fos peaked 30 minutes after the injection while fra-2 expression peaked 30 minutes later.",0.15,PMID.dPMID11113393.s8.p2,3,3,c-jun|c-fos|fra-2,c-fos|c-jun|fra-2,x
1.1.1.2.4,2355,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11113393,fra-2,c-jun,"Expression of c-jun, junB, and c-fos peaked 30 minutes after the injection while fra-2 expression peaked 30 minutes later.",0.04,PMID.dPMID11113393.s8.p1,3,3,c-jun|c-fos|fra-2,c-fos|c-jun|fra-2,x
1.1.1.2.4,2355,9606,,GO:0006357,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,16831953,Fra-2,NFATc1,"Furthermore, the specific inhibition of NFATc1 by siRNA increased Fra-2 expression in osteoblasts.",2.27,PMID.dPMID16831953.s1.p0,2,2,NFATc1|Fra-2,Fra-2|NFATc1,e
2.1.5.0.2,2494,9606,,GO:0034339|GO:0043193|GO:0045449|GO:0045941,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,19015525,LRH-1,Dax-1,"Here we report the structure of Dax-1 bound to one of its targets, liver receptor homolog 1 (LRH-1).",0.22,PMID.dPMID19015525.s3.p0,2,2,Dax-1|LRH-1,Dax-1|LRH-1,b
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,14580722,SF-1,DAX-1,WT1 and DAX-1 regulate SF-1-mediated human P450arom gene expression in gonadal cells.,2.08,PMID.dPMID14580722.s6.p2,4,4,WT1|DAX-1|SF-1|P450arom,DAX-1|P450arom|SF-1|WT1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11857908,SF-1,DAX-1,"Nuclear receptors in the pathophysiology of endocrine tumors   Nuclear orphan receptors COUP-TF and DAX-1 negatively regulate the transcriptional activity of SF-1, a steroidogenic cell-specific activator of various steroidogenic cytochrome P-450 genes.",1.75,PMID.dPMID11857908.s6.p2,3,3,COUP-TF|DAX-1|SF-1,COUP-TF|DAX-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,12081648,NR5A1,Dax-1,"Dax-1 gene transcription is regulated by Ad4BP/SF-1 (NR5A1), therefore we investigated the functional correlation between A4BP/SF-1 and AR.",1.30,PMID.dPMID12081648.s5.p3,5,2,Dax-1|Ad4BP|SF-1|NR5A1|SF-1,Ad4BP|Dax-1|NR5A1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11592817,SF-1,DAX-1,"COUP-TF and DAX-1 have been shown to negatively regulate the transcriptional activity of SF-1, a steroidogenic cell-specific activator of various steroidogenic cytochrome P450 genes.",1.06,PMID.dPMID11592817.s7.p2,3,3,COUP-TF|DAX-1|SF-1,COUP-TF|DAX-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,12081648,Ad4BP,Dax-1,"Dax-1 gene transcription is regulated by Ad4BP/SF-1 (NR5A1), therefore we investigated the functional correlation between A4BP/SF-1 and AR.",0.98,PMID.dPMID12081648.s5.p0,5,2,Dax-1|Ad4BP|SF-1|NR5A1|SF-1,Ad4BP|Dax-1|NR5A1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,12081648,SF-1,Dax-1,"Dax-1 gene transcription is regulated by Ad4BP/SF-1 (NR5A1), therefore we investigated the functional correlation between A4BP/SF-1 and AR.",0.98,PMID.dPMID12081648.s5.p1,5,2,Dax-1|Ad4BP|SF-1|NR5A1|SF-1,Ad4BP|Dax-1|NR5A1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,12081648,SF-1,Dax-1,"Interestingly, AR down-regulated the Dax-1 gene transcription mediated by Ad4BP/SF-1 in the presence of the ligand.",0.54,PMID.dPMID12081648.s4.p1,3,2,Dax-1|Ad4BP|SF-1,Ad4BP|Dax-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,12081648,Ad4BP,Dax-1,"Interestingly, AR down-regulated the Dax-1 gene transcription mediated by Ad4BP/SF-1 in the presence of the ligand.",0.54,PMID.dPMID12081648.s4.p0,3,2,Dax-1|Ad4BP|SF-1,Ad4BP|Dax-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,12959982,SF1,DAX1,DAX1 opposed SF1-activated transcription of many genes and abolished the GATA-6/SF1 ability to increase reporter activity.,0.54,PMID.dPMID12959982.s2.p0,4,3,DAX1|SF1|GATA-6|SF1,DAX1|GATA-6|SF1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,9232190,steroidogenic factor 1,DAX1,DAX1 gene expression upregulated by steroidogenic factor 1 in an adrenocortical carcinoma cell line.,0.54,PMID.dPMID9232190.s9.p0,2,2,DAX1|steroidogenic factor 1,DAX1|steroidogenic factor 1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11857908,SF-1,DAX-1,"In contrast, DAX-1 expression is increased and SF-1 expression is decreased in deoxycorticosterone-producing adrenocortical adenomas, where CYP17 expression is low.",0.41,PMID.dPMID11857908.s4.p0,3,3,DAX-1|SF-1|CYP17,CYP17|DAX-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,9232190,SF1,DAX1,"When cotransfected with 1550 bp of the DAX1 promoter, an SF1-containing expression vector increased the transcriptional activity of the DAX1 promoter by 4-fold.",0.36,PMID.dPMID9232190.s2.p0,3,2,DAX1|SF1|DAX1,DAX1|SF1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11196414,SF-1,DAX-1,"Another orphan receptor, DAX-1, is shown to act as a suppressor of SF-1-mediated transcription.",0.34,PMID.dPMID11196414.s4.p0,2,2,DAX-1|SF-1,DAX-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,17646707,SF-1,DAX-1,"We found that, upon transient cotransfection of human cells, nDAX-1 repressed the activity of tilapia SF-1 (nSF-1) but not that of human SF-1, although the physical interaction with human SF-1 was retained.",0.30,PMID.dPMID17646707.s3.p0,5,2,DAX-1|SF-1|SF-1|SF-1|SF-1,DAX-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,15829514,Sf1,Dax1,"Because Dax1 antagonizes Sf1-mediated transcription in vitro, we hypothesized that Dax1 deficiency would compensate for allelic loss of Sf1.",0.25,PMID.dPMID15829514.s8.p0,4,2,Dax1|Sf1|Dax1|Sf1,Dax1|Sf1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11990799,SF1,DAX1,Functional analysis showed that DAX1 acts as a repressor against SF1 through direct interaction between the repeated sequences at the N-terminus of DAX1 and a ligand-binding domain of SF1.,0.23,PMID.dPMID11990799.s1.p0,4,2,DAX1|SF1|DAX1|SF1,DAX1|SF1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11297612,SF-1,DAX-1,"DAX-1 is a repressor of StAR gene expression, and steroidogenic factor-1 (SF-1) is a regulator of CYP11A, DAX-1, and StAR gene.",0.22,PMID.dPMID11297612.s13.p3,7,4,DAX-1|StAR|steroidogenic factor-1|SF-1|CYP11A|DAX-1|StAR,CYP11A|DAX-1|SF-1|StAR|steroidogenic factor-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,11990799,SF1,DAX1,Functional analysis showed that DAX1 acts as a repressor against SF1 through direct interaction between the repeated sequences at the N-terminus of DAX1 and a ligand-binding domain of SF1.,0.21,PMID.dPMID11990799.s1.p3,4,2,DAX1|SF1|DAX1|SF1,DAX1|SF1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,15829514,Sf1,Dax1,"Because Dax1 antagonizes Sf1-mediated transcription in vitro, we hypothesized that Dax1 deficiency would compensate for allelic loss of Sf1.",0.08,PMID.dPMID15829514.s8.p5,4,2,Dax1|Sf1|Dax1|Sf1,Dax1|Sf1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,17646707,SF-1,DAX-1,"We found that, upon transient cotransfection of human cells, nDAX-1 repressed the activity of tilapia SF-1 (nSF-1) but not that of human SF-1, although the physical interaction with human SF-1 was retained.",0.04,PMID.dPMID17646707.s3.p1,5,2,DAX-1|SF-1|SF-1|SF-1|SF-1,DAX-1|SF-1,-->
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,11181509,SF-1,GATA-4,"We now report that GATA-4 differentially activates transcription of several genes expressed in the gonads that encode either steroidogenic enzymes (steroidogenic acute regulatory protein and aromatase), hormones (inhibin alpha and Mllerian inhibiting substance) and a transcription factor (SF-1) known to be essential for gonadal development and function.",0.13,PMID.dPMID11181509.s1.p1,3,3,GATA-4|aromatase|SF-1,aromatase|GATA-4|SF-1,e
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15129808,SF-1,Sp1,These results suggest that Sp1 interacts with SF-1 and that Sp1 enhances SF-1-DNA complex formation to regulate human StAR transcription,0.34,PMID.dPMID15129808.s0.p5,4,2,Sp1|SF-1|Sp1|SF-1,SF-1|Sp1,c
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,11857908,SF-1,COUP-TF,"Nuclear receptors in the pathophysiology of endocrine tumors Nuclear orphan receptors COUP-TF and DAX-1 negatively regulate the transcriptional activity of SF-1, a steroidogenic cell-specific activator of various steroidogenic cytochrome P-450 genes.",1.14,PMID.dPMID11857908.s6.p1,3,3,COUP-TF|DAX-1|SF-1,COUP-TF|DAX-1|SF-1,c
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,11592817,SF-1,COUP-TF,"COUP-TF and DAX-1 have been shown to negatively regulate the transcriptional activity of SF-1, a steroidogenic cell-specific activator of various steroidogenic cytochrome P450 genes.",0.88,PMID.dPMID11592817.s7.p1,3,3,COUP-TF|DAX-1|SF-1,COUP-TF|DAX-1|SF-1,c
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,14580722,SF-1,WT1,WT1 and DAX-1 regulate SF-1-mediated human P450arom gene expression in gonadal cells.,1.52,PMID.dPMID14580722.s6.p1,4,4,WT1|DAX-1|SF-1|P450arom,DAX-1|P450arom|SF-1|WT1,e
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12130543,Sf1,WT1,The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1.,1.12,PMID.dPMID12130543.s6.p2,3,2,Wilms tumor|WT1|Sf1,Sf1|Wilms tumor|WT1,x
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12130543,Sf1,Wt1,Our data suggest a pathway in which the products of the Wt1 and Lhx9 genes activate expression of Sf1 and thus mediate early gonadogenesis.,1.06,PMID.dPMID12130543.s0.p1,3,3,Wt1|Lhx9|Sf1,Lhx9|Sf1|Wt1,e
2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12130543,Sf1,Wilms tumor,The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1.,0.86,PMID.dPMID12130543.s6.p1,3,2,Wilms tumor|WT1|Sf1,Sf1|Wilms tumor|WT1,x
2.2.1.0.1,2623,9606,,GO:0006357,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19350569,GATA-1,RUNX1,"In this pathway, RUNX1 engages the erythro-megakaryocytic master regulator GATA-1 in a megakaryocytic transcriptional complex whose activity is highly dependent on the P-TEFb kinase complex.",0.78,PMID.dPMID19350569.s1.p0,2,2,RUNX1|GATA-1,GATA-1|RUNX1,c
2.2.1.0.1,2623,9606,,GO:0006357,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,12576332,GATA-1,RUNX1,"By contrast, the RUNX1-ETO leukemic fusion protein potently repressed GATA-1-mediated transactivation.",0.69,PMID.dPMID12576332.s4.p0,2,2,RUNX1|GATA-1,GATA-1|RUNX1,c
2.2.1.0.1,2623,9606,,GO:0006357,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,9067573,GATA-1,EVI1,"In addition, whereas EVI1 represses activation by the GATA-1 erythroid factor, MDS1/EVI1 does not, and is itself repressed by EVI1.",0.58,PMID.dPMID9067573.s4.p0,4,2,EVI1|GATA-1|EVI1|EVI1,EVI1|GATA-1,c
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,14695898,GATA-1,GATA-2,"Remarkably, at the GATA-2 gene, which is repressed by GATA-1, interaction with FOG-1 was dispensable for GATA-1 occupancy and was required for transcriptional inhibition and histone deacetylation.",0.62,PMID.dPMID14695898.s1.p0,4,3,GATA-2|GATA-1|FOG-1|GATA-1,FOG-1|GATA-1|GATA-2,e
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,19279013,GATA-1,GATA-2,"Interestingly, RNA silencing of GATA-1 alone had no impact on EDN expression; silencing of GATA-2 resulted in diminished expression of EDN, and also diminished expression of GATA-1 in both butyric acid-induced HL-60 clone 15 cells and in differentiating human eosinophils derived from CD34(+) hematopoietic progenitors.",0.26,PMID.dPMID19279013.s2.p8,6,4,GATA-1|EDN|GATA-2|EDN|GATA-1|CD34,CD34|EDN|GATA-1|GATA-2,x
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,1370462,GATA-binding protein,GATA-2,We propose that GATA-2 is the GATA-binding protein required for PPET-1 gene expression in endothelial cells,0.25,PMID.dPMID1370462.s0.p0,3,3,GATA-2|GATA-binding protein|PPET-1,GATA-2|GATA-binding protein|PPET-1,w
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,14695898,GATA-1,GATA-2,"Remarkably, at the GATA-2 gene, which is repressed by GATA-1, interaction with FOG-1 was dispensable for GATA-1 occupancy and was required for transcriptional inhibition and histone deacetylation.",0.23,PMID.dPMID14695898.s1.p3,4,3,GATA-2|GATA-1|FOG-1|GATA-1,FOG-1|GATA-1|GATA-2,e
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,10734088,GATA-1,GATA-2,These results suggest that GATA-1 is an activator and that GATA-2 is a relative competitive inhibitor of GATA-1 in the expression of the gp91(phox) gene in human eosinophils,0.03,PMID.dPMID10734088.s0.p2,3,2,GATA-1|GATA-2|GATA-1,GATA-1|GATA-2,c
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,16980610,GATA-1,Gata2,"Whereas Gata2 is preferentially transcribed early in hematopoiesis, elevated GATA-1 levels result in GATA-1 occupancy at sites upstream of the Gata2 locus and transcriptional repression.",0.01,PMID.dPMID16980610.s8.p1,4,2,Gata2|GATA-1|GATA-1|Gata2,GATA-1|Gata2,e
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,19212333,GATA-1,GATA-2,We showed that GATA-2 expression is a determinant of WT1 mRNA expression in both TYK-nu-cPr cells and HL60 cells without GATA-1 expression.,0.01,PMID.dPMID19212333.s1.p0,2,2,GATA-2|GATA-1,GATA-1|GATA-2,x
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,7791790,GATA-binding protein,GATA-4,"However, using ATL-16T nuclear extract, we demonstrated that GATA-4 is the only GATA-binding protein that forms a specific DNA-protein complex with the -70 GATA site.",0.15,PMID.dPMID7791790.s3.p0,2,2,GATA-4|GATA-binding protein,GATA-4|GATA-binding protein,w
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,9209438,GATA-binding protein,GATA-4,These results demonstrate the selective role of GATA-4 in the transcriptional regulation of the IL-5 gene in a circumstance where multiple members of the GATA-binding proteins are expressed,0.02,PMID.dPMID9209438.s0.p1,3,3,GATA-4|IL-5|GATA-binding protein,GATA-4|GATA-binding protein|IL-5,w
2.2.1.0.1,2623,9606,,GO:0006357,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,7791790,GATA-binding protein,GATA-4,These results demonstrate the selective role of GATA-4 in the transcriptional regulation of the IL-5 gene in a circumstance where multiple members of the GATA-binding proteins are expressed,0.02,PMID.dPMID7791790.s0.p1,3,3,GATA-4|IL-5|GATA-binding protein,GATA-4|GATA-binding protein|IL-5,w
2.2.1.0.1,2623,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15314183,GATA-1,Jun,Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2.,0.69,PMID.dPMID15314183.s8.p0,3,3,Jun|GATA-1|HERP2,GATA-1|HERP2|Jun,x
2.2.1.0.1,2623,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15314183,GATA-1,Jun,"In this study, we found that c-Jun blocks erythroid differentiation in primary human hematopoietic progenitors and, correspondingly, that Jun factors block transcriptional activation by GATA-1, the central regulator of erythroid differentiation.",0.53,PMID.dPMID15314183.s6.p2,3,2,c-Jun|Jun|GATA-1,c-Jun|GATA-1|Jun,c
2.2.1.0.1,2623,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15314183,GATA-1,c-Jun,Mutagenesis of c-Jun suggested that its repression of GATA-1 occurs through a transcriptional mechanism involving activation of downstream genes.,0.43,PMID.dPMID15314183.s5.p0,2,2,c-Jun|GATA-1,c-Jun|GATA-1,x
2.2.1.0.1,2623,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18838534,GATA1,Myc,Cotransfection experiments demonstrated that Myc-mediated inhibition of differentiation is partly dependent on the repression of Mad1 and GATA1.,0.72,PMID.dPMID18838534.s2.p0,2,2,Myc|GATA1,GATA1|Myc,x
2.2.1.0.1,2623,9606,,GO:0006357,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,18195733,GATA-1,Sp3,Involvement of Sp1/Sp3 in the activation of the GATA-1 erythroid promoter in K562 cells.,0.21,PMID.dPMID18195733.s11.p0,2,2,Sp3|GATA-1,GATA-1|Sp3,e
2.2.1.0.1,2623,9606,,GO:0006357,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,7579412,GATA-1,SCL,"SCL gene expression was usually accompanied by GATA-1 expression and was preferentially detected in patients with leukemia exhibiting megakaryocytic or erythrocytic phenotypes, while patients with monocytic leukemia were clustered in the group with no detectable GATA-1 expression.",0.98,PMID.dPMID7579412.s4.p0,3,2,SCL|GATA-1|GATA-1,GATA-1|SCL,-->
2.2.1.0.1,2623,9606,,GO:0006357,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19509292,GATA1,p73,"Furthermore, TAp73alpha induces GATA1 activity, and it is required for erythroid differentiation.",0.47,PMID.dPMID19509292.s2.p0,2,2,p73|GATA1,GATA1|p73,x
2.2.1.0.1,2623,9606,,GO:0006357,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,10360378,GATA-1,WT1,WT1 transcription is regulated in erythroid and myeloid lineages by the transcription factor GATA-1.,0.30,PMID.dPMID10360378.s6.p0,2,2,WT1|GATA-1,GATA-1|WT1,-->
2.2.1.0.1,2623,9606,,GO:0006357,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,16177182,GATA-1,Gfi-1B,"By further investigating the regulation of the Gfi-1B promoter, here we report that (i) Gfi-1B transcription is negatively regulated by its own gene product, (ii) GATA-1, instead of Gfi-1B, binds directly to the Gfi-1-like sites in the Gfi-1B promoter and (iii) Gfi-1B suppresses GATA-1-mediated stimulation of Gfi-1B promoter through their protein interaction.",0.68,PMID.dPMID16177182.s2.p2,9,3,Gfi-1B|Gfi-1B|GATA-1|Gfi-1B|Gfi-1|Gfi-1B|Gfi-1B|GATA-1|Gfi-1B,GATA-1|Gfi-1|Gfi-1B,p
2.2.1.0.1,2623,9606,,GO:0006357,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,16177182,GATA-1,Gfi-1B,"These results not only demonstrate that interaction of GATA-1 and Gfi-1B participates in a feedback regulatory pathway in controlling the expression of the Gfi-1B gene, but also provide the first evidence that Gfi-1B can exert its repression function by acting on GATA-1-mediated transcription without direct binding to the Gfi-1 site of the target genes.",0.55,PMID.dPMID16177182.s1.p9,6,3,GATA-1|Gfi-1B|Gfi-1B|Gfi-1B|GATA-1|Gfi-1,GATA-1|Gfi-1|Gfi-1B,x
2.2.1.0.1,2623,9606,,GO:0006357,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,16177182,GATA-1,Gfi-1B,"These results not only demonstrate that interaction of GATA-1 and Gfi-1B participates in a feedback regulatory pathway in controlling the expression of the Gfi-1B gene, but also provide the first evidence that Gfi-1B can exert its repression function by acting on GATA-1-mediated transcription without direct binding to the Gfi-1 site of the target genes.",0.49,PMID.dPMID16177182.s1.p8,6,3,GATA-1|Gfi-1B|Gfi-1B|Gfi-1B|GATA-1|Gfi-1,GATA-1|Gfi-1|Gfi-1B,x
2.2.1.0.1,2623,9606,,GO:0006357,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,16177182,GATA-1,Gfi-1B,"By further investigating the regulation of the Gfi-1B promoter, here we report that (i) Gfi-1B transcription is negatively regulated by its own gene product, (ii) GATA-1, instead of Gfi-1B, binds directly to the Gfi-1-like sites in the Gfi-1B promoter and (iii) Gfi-1B suppresses GATA-1-mediated stimulation of Gfi-1B promoter through their protein interaction.",0.48,PMID.dPMID16177182.s2.p22,9,3,Gfi-1B|Gfi-1B|GATA-1|Gfi-1B|Gfi-1|Gfi-1B|Gfi-1B|GATA-1|Gfi-1B,GATA-1|Gfi-1|Gfi-1B,p
2.2.1.0.1,2623,9606,,GO:0006357,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,17420275,GATA-1,Gfi-1B,These findings illuminate the role of Gfi-1B in GATA-1-mediated transcription in the survival aspect of erythroid cells.,0.30,PMID.dPMID17420275.s0.p0,2,2,Gfi-1B|GATA-1,GATA-1|Gfi-1B,x
2.2.1.0.1,2623,9606,,GO:0006357,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,16177182,GATA-1,Gfi-1B,"These results not only demonstrate that interaction of GATA-1 and Gfi-1B participates in a feedback regulatory pathway in controlling the expression of the Gfi-1B gene, but also provide the first evidence that Gfi-1B can exert its repression function by acting on GATA-1-mediated transcription without direct binding to the Gfi-1 site of the target genes.",0.14,PMID.dPMID16177182.s1.p7,6,3,GATA-1|Gfi-1B|Gfi-1B|Gfi-1B|GATA-1|Gfi-1,GATA-1|Gfi-1|Gfi-1B,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,20363750,GATA2,EVI1,"EVI1 is a member of a group of transcription factors with C-terminal binding protein (CtBP)-binding motifs that act as transcriptional co-repressors; however, we recently found that EVI1 directly activates GATA2 transcription, which is an important gene for the maintenance of hematopoietic stem cells.",1.46,PMID.dPMID20363750.s7.p2,3,2,EVI1|EVI1|GATA2,EVI1|GATA2,e
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,20363750,GATA2,EVI1,Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2.,1.17,PMID.dPMID20363750.s9.p0,2,2,EVI1|GATA2,EVI1|GATA2,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,20363750,GATA2,EVI1,"Acetylation at Lys(564), which is adjacent to the CtBP-binding consensus sequence of EVI1, was found to be important for transcriptional activation of GATA2.",0.87,PMID.dPMID20363750.s4.p0,2,2,EVI1|GATA2,EVI1|GATA2,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,20363750,GATA2,EVI1,Mutation of Lys(564) to alanine (K564A) markedly reduced the ability of EVI1 to bind DNA and activate transcription of GATA2.,0.23,PMID.dPMID20363750.s3.p0,2,2,EVI1|GATA2,EVI1|GATA2,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,10438731,GATA-2,GATA-1,"In our previous study, we demonstrated a major positive regulatory role for GATA-1 and a negative regulatory role for GATA-2 in MBP gene transcription.",0.72,PMID.dPMID10438731.s9.p0,3,3,GATA-1|GATA-2|MBP,GATA-1|GATA-2|MBP,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,14715908,GATA-2,GATA-1,"We showed previously that GATA-1 replaces GATA-2 at an upstream region of the GATA-2 locus, and that this GATA switch represses GATA-2.",0.67,PMID.dPMID14715908.s4.p1,4,2,GATA-1|GATA-2|GATA-2|GATA-2,GATA-1|GATA-2,e
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,16980610,Gata2,GATA-1,"Whereas Gata2 is preferentially transcribed early in hematopoiesis, elevated GATA-1 levels result in GATA-1 occupancy at sites upstream of the Gata2 locus and transcriptional repression.",0.57,PMID.dPMID16980610.s8.p4,4,2,Gata2|GATA-1|GATA-1|Gata2,GATA-1|Gata2,e
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,16980610,Gata2,GATA-1,"Whereas Gata2 is preferentially transcribed early in hematopoiesis, elevated GATA-1 levels result in GATA-1 occupancy at sites upstream of the Gata2 locus and transcriptional repression.",0.57,PMID.dPMID16980610.s8.p5,4,2,Gata2|GATA-1|GATA-1|Gata2,GATA-1|Gata2,e
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,14715908,GATA-2,GATA-1,"We showed previously that GATA-1 replaces GATA-2 at an upstream region of the GATA-2 locus, and that this GATA switch represses GATA-2.",0.30,PMID.dPMID14715908.s4.p3,4,2,GATA-1|GATA-2|GATA-2|GATA-2,GATA-1|GATA-2,e
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,11167015,GATA-2,GATA-1,"Increasing levels of GATA-1 also caused a decrease in the expression of endogenous GATA-2, while increased levels of GATA-2 had no effect on GATA-1 mRNA.",0.25,PMID.dPMID11167015.s2.p0,4,2,GATA-1|GATA-2|GATA-2|GATA-1,GATA-1|GATA-2,e
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,11167015,GATA-2,GATA-1,Levels of GATA-1/GATA-2 transcription factors modulate expression of embryonic and fetal hemoglobins.,0.23,PMID.dPMID11167015.s10.p0,2,2,GATA-1|GATA-2,GATA-1|GATA-2,c
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,9558404,GATA-2,GATA-1,"Our results provide the first evidence for a GATA-1 target gene in eosinophils, a negative regulatory role for GATA-2 in MBP expression, and possibly eosinophil gene transcription in general during myelopoiesis",0.18,PMID.dPMID9558404.s0.p0,3,3,GATA-1|GATA-2|MBP,GATA-1|GATA-2|MBP,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.2.1.0.1,2623,9606,,GO:0006357,14715908,GATA-2,GATA-1,"We showed previously that GATA-1 replaces GATA-2 at an upstream region of the GATA-2 locus, and that this GATA switch represses GATA-2.",0.17,PMID.dPMID14715908.s4.p0,4,2,GATA-1|GATA-2|GATA-2|GATA-2,GATA-1|GATA-2,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15468961,GATA-2,HIF-1,"While HIF-1 and HIF-2 activate the EPO gene, HIF-3, GATA-2 and NFkappaB are likely inhibitors of EPO gene transcription.",0.30,PMID.dPMID15468961.s6.p6,6,5,HIF-1|HIF-2|EPO|HIF-3|GATA-2|EPO,EPO|GATA-2|HIF-1|HIF-2|HIF-3,x
2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15254248,GATA-2,RARalpha,"Overexpression of RXRalpha inhibits RARalpha binding to the GATA-2-DNA complex, thus resulting in attenuation of the effects of RARalpha on GATA-2 activity.",0.47,PMID.dPMID15254248.s1.p5,4,2,RARalpha|GATA-2|RARalpha|GATA-2,GATA-2|RARalpha,c
2.2.1.0.3,2625,9606,,,3.3.1.1.1,3169,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051091,20501593,GATA3,Foxa1,"By contrast, Foxa1 null glands maintain GATA3 expression.",0.60,PMID.dPMID20501593.s3.p0,2,2,Foxa1|GATA3,Foxa1|GATA3,x
2.2.1.0.3,2625,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,20484083,GATA-3,c-Myb,"In primary T cells, c-Myb allows GATA-3 to autoactivate its own expression, an event that requires the direct interaction of c-Myb and GATA-3 on their respective binding sites in promoter of GATA-3.",0.90,PMID.dPMID20484083.s4.p0,5,2,c-Myb|GATA-3|c-Myb|GATA-3|GATA-3,c-Myb|GATA-3,e
2.2.1.0.3,2625,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,20484083,GATA-3,c-Myb,"In primary T cells, c-Myb allows GATA-3 to autoactivate its own expression, an event that requires the direct interaction of c-Myb and GATA-3 on their respective binding sites in promoter of GATA-3.",0.37,PMID.dPMID20484083.s4.p6,5,2,c-Myb|GATA-3|c-Myb|GATA-3|GATA-3,c-Myb|GATA-3,e
2.2.1.0.3,2625,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,20484083,GATA-3,c-Myb,"Therefore, c-Myb, GATA-3, and Menin form a core transcription complex that regulates GATA-3 expression and, with the recruitment of MLL, Th2 cell maturation in primary human peripheral blood T cells",0.24,PMID.dPMID20484083.s0.p1,3,2,c-Myb|GATA-3|GATA-3,c-Myb|GATA-3,e
2.2.1.0.3,2625,9606,,,3.5.2.5.2,6689,9606,GO:0003702,GO:0006357,16317090,GATA-3,Spi-B,"The ETS family member Spi-B is a key regulator of pDC development, whereas T-cell development is critically dependent on GATA-3.",0.90,PMID.dPMID16317090.s6.p0,2,2,Spi-B|GATA-3,GATA-3|Spi-B,x
2.2.1.0.3,2625,9606,,,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,17272506,Gata3,Gfi1b,"Gfi1b represses expression of Gata3, a transcription factor whose appropriate regulation is required for survival of lymphomas and T-lymphocyte progenitors.",1.46,PMID.dPMID17272506.s2.p0,2,2,Gfi1b|Gata3,Gata3|Gfi1b,e
2.2.1.0.3,2625,9606,,,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,17272506,Gata3,Gfi1b,"Therefore, we propose that E2A proteins prevent lymphoma cell expansion, at least in part through regulation of Gfi1b and modulation of Gata3 expression",0.92,PMID.dPMID17272506.s0.p2,3,3,E2A|Gfi1b|Gata3,E2A|Gata3|Gfi1b,x
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,19479054,GATA4,NKX2-5,NKX2-5 regulates the expression of beta-catenin and GATA4 in ventricular myocytes.,1.54,PMID.dPMID19479054.s8.p0,2,2,NKX2-5|GATA4,GATA4|NKX2-5,x
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,16607277,GATA4,GATA6,"In particular, GATA6 is lost or excluded from the nucleus in 85% of ovarian tumors and GATA4 expression is absent in majority of ovarian cancer cell lines.",0.50,PMID.dPMID16607277.s5.p0,2,2,GATA6|GATA4,GATA4|GATA6,x
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,15465926,GATA-4,HNF3beta,"Site-directed mutagenesis and transactivation analyses of the E1 promoter revealed that GATA-4 is probably a principal factor that regulates liver-specific expression of the E1 variant, with HNF3alpha and HNF3beta acting to negatively regulate GATA-4 function in hepatic cells",0.17,PMID.dPMID15465926.s0.p2,3,2,GATA-4|HNF3beta|GATA-4,GATA-4|HNF3beta,e
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,2.3.2.2.25,51621,9606,,,17053787,GATA-4,KLF13,"The data demonstrate that KLF13 is an important component of the transcription network required for heart development and suggest that KLF13 is a GATA-4 modifier; by analogy to other GATA-4 collaborators, mutations in KLF13 may be causative for congenital human heart disease",0.43,PMID.dPMID17053787.s0.p2,5,3,KLF13|KLF13|GATA-4|GATA-4|KLF13,GATA-4|KLF13,c
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,2.3.2.2.25,51621,9606,,,17053787,GATA-4,KLF13,"The data demonstrate that KLF13 is an important component of the transcription network required for heart development and suggest that KLF13 is a GATA-4 modifier; by analogy to other GATA-4 collaborators, mutations in KLF13 may be causative for congenital human heart disease",0.05,PMID.dPMID17053787.s0.p4,5,3,KLF13|KLF13|GATA-4|GATA-4|KLF13,GATA-4|KLF13,c
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,6.5.3.0.5,57057,9606,,,19762328,GATA4,Tbx20,"Moreover, Tbx20-I121M resulted in a significantly enhanced transcriptional activity, which was further increased in the presence of co-transcription factors GATA4/5 and NKX2-5.",0.11,PMID.dPMID19762328.s3.p0,3,3,Tbx20|GATA4|NKX2-5,GATA4|NKX2-5|Tbx20,c
2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,3.1.2.12.1,79923,9606,,GO:0006355,16391521,gata-4,nanog,"A reporter plasmid assay also showed that both variants of nanog modestly repressed transactivation of gata-4, whose expression is proposed to be inhibited by nanog, with comparable potency.",0.61,PMID.dPMID16391521.s1.p0,3,2,nanog|gata-4|nanog,gata-4|nanog,x
2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,12959982,GATA-6,SF1,DAX1 opposed SF1-activated transcription of many genes and abolished the GATA-6/SF1 ability to increase reporter activity.,0.51,PMID.dPMID12959982.s2.p2,4,3,DAX1|SF1|GATA-6|SF1,DAX1|GATA-6|SF1,x
2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,12959982,GATA-6,SF1,Transfection of HEK293 cells with both GATA-6 and SF1 significantly increased transcriptional activation of all reporter constructs above the effect of GATA-6 or SF1 alone.,0.04,PMID.dPMID12959982.s4.p2,4,2,GATA-6|SF1|GATA-6|SF1,GATA-6|SF1,c
2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,18227727,GATA-6,GATA-4,"We found that the majority of the carcinomas retained GATA-4 expression, whereas approximately two-thirds of the carcinomas had mislocalization or loss of GATA-6 expression.",0.21,PMID.dPMID18227727.s3.p0,2,2,GATA-4|GATA-6,GATA-4|GATA-6,x
2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,11889139,GATA-6,NFATc1,"Consistent with this, NFATc1 further potentiated GATA-6-activated Sm-MHC transcription.",0.17,PMID.dPMID11889139.s3.p0,2,2,NFATc1|GATA-6,GATA-6|NFATc1,c
2.3.5.0.37,2672,9606,,GO:0000083|GO:0010553,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,17213822,GFI1,ETS1,"Luciferase (Luc) assays using artificial reporters showed that GFI1 repressed ETS1-mediated transcriptional activation and ETS1 repressed GFI1-mediated transcriptional activation, in a dose-dependent manner.",1.08,PMID.dPMID17213822.s5.p5,4,2,GFI1|ETS1|ETS1|GFI1,ETS1|GFI1,e
2.3.5.0.37,2672,9606,,GO:0000083|GO:0010553,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,17213822,GFI1,ETS1,"Luciferase (Luc) assays using artificial reporters showed that GFI1 repressed ETS1-mediated transcriptional activation and ETS1 repressed GFI1-mediated transcriptional activation, in a dose-dependent manner.",0.92,PMID.dPMID17213822.s5.p4,4,2,GFI1|ETS1|ETS1|GFI1,ETS1|GFI1,e
2.3.5.0.37,2672,9606,,GO:0000083|GO:0010553,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,16177182,Gfi-1,Gfi-1B,"By further investigating the regulation of the Gfi-1B promoter, here we report that (i) Gfi-1B transcription is negatively regulated by its own gene product, (ii) GATA-1, instead of Gfi-1B, binds directly to the Gfi-1-like sites in the Gfi-1B promoter and (iii) Gfi-1B suppresses GATA-1-mediated stimulation of Gfi-1B promoter through their protein interaction.",0.47,PMID.dPMID16177182.s2.p7,9,3,Gfi-1B|Gfi-1B|GATA-1|Gfi-1B|Gfi-1|Gfi-1B|Gfi-1B|GATA-1|Gfi-1B,GATA-1|Gfi-1|Gfi-1B,-->
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,8076941,GLI,CHOP,"The CHOP/GADD153 gene, consistently translocated in myxoid liposarcomas, is located less than 55 kb from the putative oncogene GLI.",1.08,PMID.dPMID8076941.s1.p1,3,2,CHOP|GADD153|GLI,CHOP|GADD153|GLI,x
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,8076941,GLI,GADD153,"The CHOP/GADD153 gene, consistently translocated in myxoid liposarcomas, is located less than 55 kb from the putative oncogene GLI.",1.08,PMID.dPMID8076941.s1.p2,3,2,CHOP|GADD153|GLI,CHOP|GADD153|GLI,x
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,12183437,Gli1,FOXM1,"Expression of the Shh target glioma transcription factor-1 (Gli1) in primary keratinocytes and other cell lines caused a significant elevation of FOXM1 mRNA level and transcriptional activity, indicating that FOXM1 is a downstream target of Gli1.",0.51,PMID.dPMID12183437.s2.p5,4,2,Gli1|FOXM1|FOXM1|Gli1,FOXM1|Gli1,e
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,20712011,Gli,FoxM1,"To explore the role of Gli in the development and progression of hepatocellular carcinoma (HCC), we investigated the expression of Gli2 and FoxM1 (forkhead-box transcription factor M1) which is one of the Gli downstream target genes modulating cell cycle progression in 91 specimens of human HCCs with immunohistochemistry.",0.35,PMID.dPMID20712011.s7.p8,5,4,Gli|Gli2|FoxM1|M1|Gli,FoxM1|Gli|Gli2|M1,x
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,15175043,GLI1,GLI2,These data suggest that GLI2 directly activates GLI1 and that retrovirally expressed GLI2 induces expression of endogenous GLI1 in human primary keratinocytes.,1.57,PMID.dPMID15175043.s2.p0,4,2,GLI2|GLI1|GLI2|GLI1,GLI1|GLI2,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,18813803,GLI1,GLI2,"MAP3K10-induced DYRK2 phosphorylation combined with SUFU inhibition results in the stabilization and nuclear accumulation of GLI2 for transcriptional activation of GLI1, CCND1, CCND2, FOXA2, FOXC2, FOXP3, FOXQ1, RUNX2, and JAG2.",1.33,PMID.dPMID18813803.s11.p5,4,4,DYRK2|SUFU|GLI2|GLI1,DYRK2|GLI1|GLI2|SUFU,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,15175043,GLI1,GLI2,GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter.,0.85,PMID.dPMID15175043.s7.p0,2,2,GLI2|GLI1,GLI1|GLI2,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,16651270,Gli,Gli2,Stable Gli2 mutant is expressed in higher levels and is more potent in the activation of Gli-dependent transcription as compared with wild type Gli2.,0.50,PMID.dPMID16651270.s2.p0,3,2,Gli2|Gli|Gli2,Gli|Gli2,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,20024066,Gli1,Gli2,"This leads to the activation of Gli2, which regulates the transcription of target genes that include Gli1 and Ptch1.",0.28,PMID.dPMID20024066.s8.p0,3,3,Gli2|Gli1|Ptch1,Gli1|Gli2|Ptch1,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,12165851,GLI1,GLI2,"Detailed time course experiments monitoring the transcriptional response of keratinocytes either to GLI1 or to GLI2 suggest that GLI1 is a direct target of GLI2, while activation of GLI2 by GLI1 is likely to be indirect.",0.08,PMID.dPMID12165851.s2.p14,6,2,GLI1|GLI2|GLI1|GLI2|GLI2|GLI1,GLI1|GLI2,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,10574767,Gli1,Gli3,"Here, we have subjected the human proteins Gli1 and Gli3 to the precise and well-defined Hh signalling assay of Drosophila wing development and established that Gli1 functions as an activator and Gli3 as a repressor of Hh target genes; that the activating transcriptional activity of Gli1 and the repressing activity of Gli3 are both subject to Hh regulation in vivo; and that the combined activities of Gli1 and Gli3 can substitute for Ci in controlling Hh target gene expression during embryonic and larval development",0.82,PMID.dPMID10574767.s0.p40,12,3,Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh,Gli1|Gli3|Hh,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,18057099,Gli,Gli3,"In turn, Gli3, by acting as a transcriptional repressor, restricted graded Shh/Gli ventral activity to properly pattern the spinal cord.",0.70,PMID.dPMID18057099.s0.p1,3,3,Gli3|Shh|Gli,Gli|Gli3|Shh,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,10574767,Gli1,Gli3,"Here, we have subjected the human proteins Gli1 and Gli3 to the precise and well-defined Hh signalling assay of Drosophila wing development and established that Gli1 functions as an activator and Gli3 as a repressor of Hh target genes; that the activating transcriptional activity of Gli1 and the repressing activity of Gli3 are both subject to Hh regulation in vivo; and that the combined activities of Gli1 and Gli3 can substitute for Ci in controlling Hh target gene expression during embryonic and larval development",0.55,PMID.dPMID10574767.s0.p43,12,3,Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh,Gli1|Gli3|Hh,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19219074,GLI,JUN,Transcription of JUN is greatly enhanced in the presence of GLI and requires activated JUN protein.,0.30,PMID.dPMID19219074.s4.p0,3,2,JUN|GLI|JUN,GLI|JUN,c
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19219074,GLI,JUN,The synergistic effect of GLI and JUN extends to the activation of further GLI target genes as shown by shRNA-mediated knockdown of JUN in human keratinocytes.,0.03,PMID.dPMID19219074.s2.p2,4,2,GLI|JUN|GLI|JUN,GLI|JUN,c
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,17409199,GLI1,SOX9,"In silico studies identify a putative binding site within SOX9cre1 for GLI1, a downstream mediator of sonic hedgehog (SHH).",0.12,PMID.dPMID17409199.s4.p0,4,3,SOX9|GLI1|sonic hedgehog|SHH,GLI1|SHH|sonic hedgehog|SOX9,b
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.2.3.2.1,7291,9606,,,11948912,GLI1,Twist,"Twist mutations cause human birth defects and Twist is overexpressed in many rhabdomyosarcomas, suggesting that one of Twist's primary roles is the regulation of GLI1.",0.99,PMID.dPMID11948912.s0.p5,4,2,Twist|Twist|Twist|GLI1,GLI1|Twist,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.2.3.2.1,7291,9606,,,11948912,GLI1,Twist,"Twist mutations cause human birth defects and Twist is overexpressed in many rhabdomyosarcomas, suggesting that one of Twist's primary roles is the regulation of GLI1.",0.16,PMID.dPMID11948912.s0.p4,4,2,Twist|Twist|Twist|GLI1,GLI1|Twist,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,1.2.3.2.1,7291,9606,,,11948912,GLI1,Twist,Twist activates GLI1 reporter expression through E-box +482 but requires binding of USF proteins to E-box +157.,0.01,PMID.dPMID11948912.s1.p0,3,3,Twist|GLI1|USF,GLI1|Twist|USF,<--
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.3.2.3.7,7545,9606,,,18617531,Gli,Zic,"The zinc finger domain of all mammalian Zic genes is highly homologous with that of the Gli genes, which are transcriptional mediators of Shh signalling.",0.09,PMID.dPMID18617531.s6.p0,3,3,Zic|Gli|Shh,Gli|Shh|Zic,x
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,4.1.1.2.4,8403,9606,GO:0016564,GO:0000122,20074681,GLI1,SOX14,"Further, we have shown that human SOX14 expression is GLI1 dependent in U87MG cells and SHH-N dependent in U87MG and HepG2 cell lines.",0.06,PMID.dPMID20074681.s3.p0,3,3,SOX14|GLI1|SHH,GLI1|SHH|SOX14,e
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.1.6.0.2,8431,9606,,GO:0034339,20175750,Gli1,small heterodimer partner,In the present study we identified SHP (small heterodimer partner) as a nuclear receptor that decreased the expression of Gli target genes by repressing the transcriptional activity of Gli1.,1.05,PMID.dPMID20175750.s3.p4,4,2,SHP|small heterodimer partner|Gli|Gli1,Gli|Gli1|SHP|small heterodimer partner,e
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.1.6.0.2,8431,9606,,GO:0034339,20175750,Gli1,SHP,In the present study we identified SHP (small heterodimer partner) as a nuclear receptor that decreased the expression of Gli target genes by repressing the transcriptional activity of Gli1.,0.27,PMID.dPMID20175750.s3.p3,4,2,SHP|small heterodimer partner|Gli|Gli1,Gli|Gli1|SHP|small heterodimer partner,e
2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,2.1.6.0.2,8431,9606,,GO:0034339,20175750,Gli,SHP,"Finally, SHP overexpression decreased the expression of Gli target genes and SHP knockdown increased the expression of these genes.",0.17,PMID.dPMID20175750.s1.p0,3,2,SHP|Gli|SHP,Gli|SHP,e
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,3.3.1.6.1,2294,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0045893|GO:0051090,19049965,Gli2,Foxf1,"Furthermore, expression of both Foxf1 and Foxl1 is reduced in the Gli2/Gli3 mutant gut.",0.65,PMID.dPMID19049965.s1.p1,4,4,Foxf1|Foxl1|Gli2|Gli3,Foxf1|Foxl1|Gli2|Gli3,x
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,3.3.1.12.1,2300,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0051090,19049965,Gli2,Foxl1,"Furthermore, expression of both Foxf1 and Foxl1 is reduced in the Gli2/Gli3 mutant gut.",1.12,PMID.dPMID19049965.s1.p2,4,4,Foxf1|Foxl1|Gli2|Gli3,Foxf1|Foxl1|Gli2|Gli3,x
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,12165851,GLI2,GLI1,Expression of GLI1 in human keratinocytes induced the transcriptional activator isoforms GLI2alpha and GLI2beta.,0.73,PMID.dPMID12165851.s4.p0,3,2,GLI1|GLI2|GLI2,GLI1|GLI2,-->
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,12165851,GLI2,GLI1,Expression of GLI1 in human keratinocytes induced the transcriptional activator isoforms GLI2alpha and GLI2beta.,0.63,PMID.dPMID12165851.s4.p1,3,2,GLI1|GLI2|GLI2,GLI1|GLI2,-->
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,12165851,GLI2,GLI1,"Detailed time course experiments monitoring the transcriptional response of keratinocytes either to GLI1 or to GLI2 suggest that GLI1 is a direct target of GLI2, while activation of GLI2 by GLI1 is likely to be indirect.",0.38,PMID.dPMID12165851.s2.p5,6,2,GLI1|GLI2|GLI1|GLI2|GLI2|GLI1,GLI1|GLI2,-->
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10769232,Gli2,Gli1,"Gli1 is activated in response to Shh produced by the notochord, which also controls the dorsalization of Gli2 and Gli3 following their activation by Wnt signaling from the surface ectoderm and neural tube.",0.24,PMID.dPMID10769232.s2.p1,5,5,Gli1|Shh|Gli2|Gli3|Wnt,Gli1|Gli2|Gli3|Shh|Wnt,-->
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,12165851,GLI2,GLI1,"Detailed time course experiments monitoring the transcriptional response of keratinocytes either to GLI1 or to GLI2 suggest that GLI1 is a direct target of GLI2, while activation of GLI2 by GLI1 is likely to be indirect.",0.16,PMID.dPMID12165851.s2.p8,6,2,GLI1|GLI2|GLI1|GLI2|GLI2|GLI1,GLI1|GLI2,-->
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,9216996,Gli2,Gli3,"In contrast, Gli2 and Gli3 are absent from the neural plate midline with Gli2 expressed widely and Gli3 in a graded fashion with highest levels in lateral regions.",0.30,PMID.dPMID9216996.s5.p2,4,2,Gli2|Gli3|Gli2|Gli3,Gli2|Gli3,x
2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,10769232,Gli2,Gli3,This surface ectoderm/neural tube Wnt signaling has both negative and positive functions in Gli2 and Gli3 regulation: these signals repress Gli3 in segmental plate mesoderm prior to somite formation and then promote somite formation and the somite-specific activation of Gli2 and Gli3.,0.08,PMID.dPMID10769232.s1.p8,6,3,Wnt|Gli2|Gli3|Gli3|Gli2|Gli3,Gli2|Gli3|Wnt,x
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,3.3.1.6.1,2294,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0045893|GO:0051090,19049965,Gli3,Foxf1,"Furthermore, expression of both Foxf1 and Foxl1 is reduced in the Gli2/Gli3 mutant gut.",0.65,PMID.dPMID19049965.s1.p3,4,4,Foxf1|Foxl1|Gli2|Gli3,Foxf1|Foxl1|Gli2|Gli3,x
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,3.3.1.12.1,2300,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0051090,19049965,Gli3,Foxl1,"Furthermore, expression of both Foxf1 and Foxl1 is reduced in the Gli2/Gli3 mutant gut.",1.12,PMID.dPMID19049965.s1.p4,4,4,Foxf1|Foxl1|Gli2|Gli3,Foxf1|Foxl1|Gli2|Gli3,x
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10574767,GLI3,GLI,"Much attention has been devoted to the expression pattern of GLI genes; GLI1 is induced by Shh, whereas GLI3 transcription appears to be repressed by Shh signalling [13] [14] [15].",1.13,PMID.dPMID10574767.s3.p2,3,2,GLI|GLI|GLI3,GLI|GLI3,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,18057099,Gli3,Gli,Wnt canonical pathway restricts graded Shh/Gli patterning activity through the regulation of Gli3 expression.,1.08,PMID.dPMID18057099.s7.p2,3,3,Shh|Gli|Gli3,Gli|Gli3|Shh,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10574767,Gli3,Gli1,"Here, we have subjected the human proteins Gli1 and Gli3 to the precise and well-defined Hh signalling assay of Drosophila wing development and established that Gli1 functions as an activator and Gli3 as a repressor of Hh target genes; that the activating transcriptional activity of Gli1 and the repressing activity of Gli3 are both subject to Hh regulation in vivo; and that the combined activities of Gli1 and Gli3 can substitute for Ci in controlling Hh target gene expression during embryonic and larval development",0.83,PMID.dPMID10574767.s0.p48,12,3,Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh,Gli1|Gli3|Hh,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10574767,GLI3,GLI,"Much attention has been devoted to the expression pattern of GLI genes; GLI1 is induced by Shh, whereas GLI3 transcription appears to be repressed by Shh signalling [13] [14] [15].",0.40,PMID.dPMID10574767.s3.p1,3,2,GLI|GLI|GLI3,GLI|GLI3,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10574767,Gli3,Gli1,"Here, we have subjected the human proteins Gli1 and Gli3 to the precise and well-defined Hh signalling assay of Drosophila wing development and established that Gli1 functions as an activator and Gli3 as a repressor of Hh target genes; that the activating transcriptional activity of Gli1 and the repressing activity of Gli3 are both subject to Hh regulation in vivo; and that the combined activities of Gli1 and Gli3 can substitute for Ci in controlling Hh target gene expression during embryonic and larval development",0.32,PMID.dPMID10574767.s0.p51,12,3,Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh,Gli1|Gli3|Hh,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10574767,Gli3,Gli1,"Here, we have subjected the human proteins Gli1 and Gli3 to the precise and well-defined Hh signalling assay of Drosophila wing development and established that Gli1 functions as an activator and Gli3 as a repressor of Hh target genes; that the activating transcriptional activity of Gli1 and the repressing activity of Gli3 are both subject to Hh regulation in vivo; and that the combined activities of Gli1 and Gli3 can substitute for Ci in controlling Hh target gene expression during embryonic and larval development",0.28,PMID.dPMID10574767.s0.p24,12,3,Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh|Gli1|Gli3|Hh,Gli1|Gli3|Hh,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,10769232,Gli3,Gli1,"Gli1 is activated in response to Shh produced by the notochord, which also controls the dorsalization of Gli2 and Gli3 following their activation by Wnt signaling from the surface ectoderm and neural tube.",0.16,PMID.dPMID10769232.s2.p3,5,5,Gli1|Shh|Gli2|Gli3|Wnt,Gli1|Gli2|Gli3|Shh|Wnt,-->
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,10769232,Gli3,Gli2,This surface ectoderm/neural tube Wnt signaling has both negative and positive functions in Gli2 and Gli3 regulation: these signals repress Gli3 in segmental plate mesoderm prior to somite formation and then promote somite formation and the somite-specific activation of Gli2 and Gli3.,0.75,PMID.dPMID10769232.s1.p4,6,3,Wnt|Gli2|Gli3|Gli3|Gli2|Gli3,Gli2|Gli3|Wnt,x
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,9216996,Gli3,Gli2,"In contrast, Gli2 and Gli3 are absent from the neural plate midline with Gli2 expressed widely and Gli3 in a graded fashion with highest levels in lateral regions.",0.17,PMID.dPMID9216996.s5.p3,4,2,Gli2|Gli3|Gli2|Gli3,Gli2|Gli3,x
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,17436254,PHS,TCF4,We subsequently identified two de novo heterozygous missense mutations of a conserved amino acid in the basic region of the TCF4 gene in three additional subjects with PHS.,0.30,PMID.dPMID17436254.s2.p0,2,2,TCF4|PHS,PHS|TCF4,x
2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,17436254,PHS,TCF4,"These findings demonstrate that TCF4 anomalies are responsible for PHS and provide the first evidence of a human disorder related to class I basic helix-loop-helix transcription-factor defects (also known as ""E proteins"").",0.26,PMID.dPMID17436254.s1.p0,2,2,TCF4|PHS,PHS|TCF4,x
2.1.1.1.1,2908,9606,,GO:0034339,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2169352,GCR,c-Fos,"While the GCR is a potent inhibitor of AP-1 activity (Jun/Fos), both c-Jun and c-Fos are potent repressors of GCR activity.",0.55,PMID.dPMID2169352.s3.p20,7,3,GCR|AP-1|Jun|Fos|c-Jun|c-Fos|GCR,AP-1|c-Fos|c-Jun|Fos|GCR|Jun,<--
2.1.1.1.1,2908,9606,,GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2169352,GCR,c-Jun,"While the GCR is a potent inhibitor of AP-1 activity (Jun/Fos), both c-Jun and c-Fos are potent repressors of GCR activity.",0.38,PMID.dPMID2169352.s3.p19,7,3,GCR|AP-1|Jun|Fos|c-Jun|c-Fos|GCR,AP-1|c-Fos|c-Jun|Fos|GCR|Jun,e
3.1.2.8.1,3087,9606,GO:0016564,GO:0010552|GO:0010553|GO:0010621|GO:0010944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11726291,Hex,Sp1,"Thus, we conclude that Sp1 and Sp3 stimulate transcription of the Hex gene in both MH(1)C(1) and K562 cells.",0.77,PMID.dPMID11726291.s0.p1,3,3,Sp1|Sp3|Hex,Hex|Sp1|Sp3,e
3.1.2.8.1,3087,9606,GO:0016564,GO:0010552|GO:0010553|GO:0010621|GO:0010944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,11726291,Hex,Sp3,"Thus, we conclude that Sp1 and Sp3 stimulate transcription of the Hex gene in both MH(1)C(1) and K562 cells.",0.84,PMID.dPMID11726291.s0.p2,3,3,Sp1|Sp3|Hex,Hex|Sp1|Sp3,e
3.1.2.8.1,3087,9606,GO:0016564,GO:0010552|GO:0010553|GO:0010621|GO:0010944,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15062550,Hex,Pax8,"Therefore, we tested whether Pax8 regulates the transcriptional activity of Hex promoter.",0.93,PMID.dPMID15062550.s6.p0,2,2,Pax8|Hex,Hex|Pax8,e
3.1.2.8.1,3087,9606,GO:0016564,GO:0010552|GO:0010553|GO:0010621|GO:0010944,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15062550,Hex,Pax8,Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter.,0.59,PMID.dPMID15062550.s11.p0,2,2,Pax8|Hex,Hex|Pax8,e
3.1.2.8.1,3087,9606,GO:0016564,GO:0010552|GO:0010553|GO:0010621|GO:0010944,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15062550,Hex,Pax8,"Indeed, by using cotransfection experiments in non-thyroidal cells, we show that increasing doses of Pax8 expression vector elicited a dose-dependent increase of the transcriptional activity of Hex promoter.",0.14,PMID.dPMID15062550.s5.p0,2,2,Pax8|Hex,Hex|Pax8,e
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,14604972,HIF-1alpha,ATF-4,"By applying RNAi, ATF-4 induction in anoxia was shown to be independent of HIF-1alpha, and desferrioxamine mesylate (DFO) and cobalt chloride induced HIF-1alpha but not ATF-4 or GADD153.",0.05,PMID.dPMID14604972.s4.p0,5,3,ATF-4|HIF-1alpha|HIF-1alpha|ATF-4|GADD153,ATF-4|GADD153|HIF-1alpha,n
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,17684492,HIF-1,Runx1,"More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1.",1.53,PMID.dPMID17684492.s2.p9,7,2,Runx1|HIF-1|HIF-1|Runx1|HIF-1|Runx1|HIF-1,HIF-1|Runx1,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,17684492,HIF-1,Runx1,"More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1.",0.50,PMID.dPMID17684492.s2.p18,7,2,Runx1|HIF-1|HIF-1|Runx1|HIF-1|Runx1|HIF-1,HIF-1|Runx1,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,11708773,HIF-1,ETS-1,These results indicate that hypoxia induces ETS-1 via the activity of HIF-1,0.26,PMID.dPMID11708773.s0.p0,2,2,ETS-1|HIF-1,ETS-1|HIF-1,e
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18158893,HIF1,FOXO3a,"In fibroblasts as well as in breast cancer cells, FOXO3a inhibits HIF1-induced apoptosis by stimulating the transcription of CITED2, which results in reduced expression of the proapoptotic HIF1 target genes NIX and RTP801.",0.39,PMID.dPMID18158893.s1.p3,5,4,FOXO3a|HIF1|CITED2|HIF1|RTP801,CITED2|FOXO3a|HIF1|RTP801,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18158893,HIF1,FOXO3a,FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2.,0.33,PMID.dPMID18158893.s6.p0,3,3,FOXO3a|HIF1|CITED2,CITED2|FOXO3a|HIF1,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,17426247,HIF-1alpha,Id-1,"Furthermore, Id-1 enhanced nuclear translocation and the transcriptional activity of HIF-1alpha.",0.22,PMID.dPMID17426247.s3.p0,2,2,Id-1|HIF-1alpha,HIF-1alpha|Id-1,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,15983061,Hif1a,MITF,"Further, MITF ""silencing"" abrogates the cAMP effect on Hif1a expression, and overexpression of MITF in human melanoma cells is sufficient to stimulate HIF1A mRNA.",0.81,PMID.dPMID15983061.s3.p0,4,2,MITF|Hif1a|MITF|HIF1A,Hif1a|HIF1A|MITF,e
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,15983061,Hif1a,MITF,Our data demonstrate that Hif1a is a new MITF target gene and that MITF mediates the cAMP stimulation of Hif1a in melanocytes and melanoma cells.,0.53,PMID.dPMID15983061.s2.p5,4,2,Hif1a|MITF|MITF|Hif1a,Hif1a|MITF,e
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,3.3.1.15.3,4303,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,20136501,HIF-1alpha,FOXO4,FOXO4 induces human plasminogen activator inhibitor-1 gene expression via an indirect mechanism by modulating HIF-1alpha and CREB levels.,0.16,PMID.dPMID20136501.s9.p1,4,4,FOXO4|plasminogen activator inhibitor-1|HIF-1alpha|CREB,CREB|FOXO4|HIF-1alpha|plasminogen activator inhibitor-1,e
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11727934,HIF-1alpha,c-myc,"Whereas c-myc is a direct target for oncogenic mutations, expression of hypoxia-inducible factor 1 (HIF-1) is indirectly up-regulated via gain-of-function mutations in oncogenes and loss-of-function mutations in tumour suppressor genes that result increased HIF-1alpha protein expression and/or increased HIF-1 transcriptional activity in a cell-type-specific manner.",0.97,PMID.dPMID11727934.s2.p1,4,2,c-myc|HIF-1|HIF-1alpha|HIF-1,c-myc|HIF-1|HIF-1alpha,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11727934,HIF-1,c-myc,"Whereas c-myc is a direct target for oncogenic mutations, expression of hypoxia-inducible factor 1 (HIF-1) is indirectly up-regulated via gain-of-function mutations in oncogenes and loss-of-function mutations in tumour suppressor genes that result increased HIF-1alpha protein expression and/or increased HIF-1 transcriptional activity in a cell-type-specific manner.",0.72,PMID.dPMID11727934.s2.p3,4,2,c-myc|HIF-1|HIF-1alpha|HIF-1,c-myc|HIF-1|HIF-1alpha,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20404562,HIF-1,c-Myc,"In addition, our own results show that under normoxic conditions oncogenic c-Myc is required for constitutive high HIF-1 protein levels and activity in Multiple Myeloma (MM) cells, thereby influencing VEGF secretion and angiogenic activity within the bone marrow microenvironment.",0.16,PMID.dPMID20404562.s2.p0,3,3,c-Myc|HIF-1|VEGF,c-Myc|HIF-1|VEGF,e
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15780936,HIF-1alpha,Myc,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,0.02,PMID.dPMID15780936.s2.p11,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,14521756,HIF-1alpha,PPAR-alpha,"Conversely, the expressions of the mRNA and protein of PPAR-alpha were decreased after antisense oligonuclei of HIF-1alpha in group F, as compared with group E. CONCLUSIONS: The expressions of the mRNA and protein of PPAR-alpha and HIF-1alpha are increased by hypoxia, and PPAR-alpha may be regulated by HIF-1alpha",0.27,PMID.dPMID14521756.s0.p14,6,2,PPAR-alpha|HIF-1alpha|PPAR-alpha|HIF-1alpha|PPAR-alpha|HIF-1alpha,HIF-1alpha|PPAR-alpha,-->
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15780936,HIF-1alpha,Sp1,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,0.78,PMID.dPMID15780936.s2.p14,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15780936,HIF-1alpha,Sp1,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,0.44,PMID.dPMID15780936.s2.p12,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,19265129,HIF-1alpha,STAT3,"Interestingly, gene silencing of STAT3 by small interfering RNA resulted in HIF-1alpha inhibition and a significant restoration of target cell susceptibility to CTL-induced killing under hypoxic conditions by a mechanism involving at least in part down-regulation of AKT phosphorylation.",0.95,PMID.dPMID19265129.s4.p0,3,3,STAT3|HIF-1alpha|AKT,AKT|HIF-1alpha|STAT3,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,20164027,HIF-1,STAT3,STAT3 contributes to increase of EPO expression which is also HIF-1 dependent.,0.34,PMID.dPMID20164027.s13.p0,2,2,STAT3|HIF-1,HIF-1|STAT3,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,17597020,HIF-1,STAT3,STAT3 upregulates expression of HIF-1 induced EPO.,0.23,PMID.dPMID17597020.s15.p0,3,3,STAT3|HIF-1|EPO,EPO|HIF-1|STAT3,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18579174,HIF-1alpha,STAT3,Nuclear location was a proof of activity of STAT3 and HIF-1 and it was mainly characteristic for granular anti-STAT3 staining and rarely for diffuse HIF-1alpha expression.,0.20,PMID.dPMID18579174.s7.p1,3,2,STAT3|STAT3|HIF-1alpha,HIF-1alpha|STAT3,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18579174,HIF-1alpha,STAT3,Nuclear location was a proof of activity of STAT3 and HIF-1 and it was mainly characteristic for granular anti-STAT3 staining and rarely for diffuse HIF-1alpha expression.,0.09,PMID.dPMID18579174.s7.p2,3,2,STAT3|STAT3|HIF-1alpha,HIF-1alpha|STAT3,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9575138,HIF-1,p53,Here we demonstrate that p53 represses HIF-1-stimulated transcription.,2.01,PMID.dPMID9575138.s6.p0,2,2,p53|HIF-1,HIF-1|p53,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11375890,HIF-1,p53,"Albeit less potent than wild-type p53, all Arg175 p53 mutants retained partial ability to repress HIF-1-stimulated transcription.",1.71,PMID.dPMID11375890.s7.p2,3,2,p53|p53|HIF-1,HIF-1|p53,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14992692,HIF-1,p53,"In addition, low p53 expression repressed HIF-1 transactivation without affecting HIF-1alpha protein amount.",1.09,PMID.dPMID14992692.s4.p0,3,2,p53|HIF-1|HIF-1alpha,HIF-1|HIF-1alpha|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15170665,HIF-1,p53,Previous reports have suggested that the regulation of p53 and p21 is HIF-1-dependent.,0.78,PMID.dPMID15170665.s8.p1,3,3,p53|p21|HIF-1,HIF-1|p21|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14992692,HIF-1alpha,p53,"In addition, low p53 expression repressed HIF-1 transactivation without affecting HIF-1alpha protein amount.",0.68,PMID.dPMID14992692.s4.p1,3,2,p53|HIF-1|HIF-1alpha,HIF-1|HIF-1alpha|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14992692,HIF-1,p53,p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1).,0.37,PMID.dPMID14992692.s10.p2,3,3,p300|p53|HIF-1,HIF-1|p300|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15897903,HIF-1alpha,p53,"Given striking similarities between p53 and HIF-1alpha regulation, we previously suggested that HIF-1 transcriptionally initiates its own degradation and therefore inhibitors of transcription must induce HIF-1alpha.",0.36,PMID.dPMID15897903.s8.p3,4,2,p53|HIF-1alpha|HIF-1|HIF-1alpha,HIF-1|HIF-1alpha|p53,c
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17236590,HIF-1alpha,P53,"RESULTS: Under the condition of normal concentration oxygen, P53 was highly expressed in the placenta of pregnant women with ICP (P < 0.01), however the HIF-1alpha expression was not up to higher than in normal control.",0.27,PMID.dPMID17236590.s4.p0,2,2,P53|HIF-1alpha,HIF-1alpha|P53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18421307,HIF-1,p53,"Despite a close interaction between HIF-1 and p53 and that p53 mutation is seen in >50% of tumors, whether HIF-1 silencing by targeted therapy depends on tumor p53 status remains unknown.",0.22,PMID.dPMID18421307.s11.p5,5,2,HIF-1|p53|p53|HIF-1|p53,HIF-1|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15897903,HIF-1,p53,"Given striking similarities between p53 and HIF-1alpha regulation, we previously suggested that HIF-1 transcriptionally initiates its own degradation and therefore inhibitors of transcription must induce HIF-1alpha.",0.16,PMID.dPMID15897903.s8.p1,4,2,p53|HIF-1alpha|HIF-1|HIF-1alpha,HIF-1|HIF-1alpha|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15199132,HIF-1,p53,"In summary, our results demonstrate that the presence of wtp53 under hypoxic conditions has an insignificant effect on the stabilization of HIF-1alpha protein and HIF-1-dependent expression of CAIX.",0.16,PMID.dPMID15199132.s2.p1,3,2,p53|HIF-1alpha|HIF-1,HIF-1|HIF-1alpha|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11375890,HIF-1,p53,"Albeit less potent than wild-type p53, all Arg175 p53 mutants retained partial ability to repress HIF-1-stimulated transcription.",0.15,PMID.dPMID11375890.s7.p1,3,2,p53|p53|HIF-1,HIF-1|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19091459,HIF1,p53,p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway.,0.09,PMID.dPMID19091459.s5.p0,3,3,p53|HIF1|VEGF,HIF1|p53|VEGF,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20706634,HIF-1,p53,We conclude that p53 mutations in human tumors hold the potential to confound the efficacy of HIF-1-inhibitors in cancer therapy,0.03,PMID.dPMID20706634.s0.p0,2,2,p53|HIF-1,HIF-1|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16867872,HIF-1,p53,The aim of this study was therefore to explore the role of p53 and p300 in relation to overexpression of HIF-1alpha and activation of HIF-1 downstream genes in invasive breast cancer.,0.03,PMID.dPMID16867872.s9.p3,4,3,p53|p300|HIF-1alpha|HIF-1,HIF-1|HIF-1alpha|p300|p53,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,19549358,HIF-1alpha,Foxp3,"The Jurkat cells were incubated with hypoxia (1% O(>2)) and its simulant CoCl(2) for different times (0, 6, 12, 24 hours), the viability was measured by trypan blue staining, the expression of HIF-1alpha was detected by Western blot, the expression of Foxp3 was detected by real-time PCR, the expressions of HIF-1alpha and Foxp3 were assayed after HIF-1alpha in Jurkat cells was inhibited by using RNA interference technique.",0.59,PMID.dPMID19549358.s2.p7,5,2,HIF-1alpha|Foxp3|HIF-1alpha|Foxp3|HIF-1alpha,Foxp3|HIF-1alpha,x
1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,19549358,HIF-1alpha,Foxp3,"The Jurkat cells were incubated with hypoxia (1% O(>2)) and its simulant CoCl(2) for different times (0, 6, 12, 24 hours), the viability was measured by trypan blue staining, the expression of HIF-1alpha was detected by Western blot, the expression of Foxp3 was detected by real-time PCR, the expressions of HIF-1alpha and Foxp3 were assayed after HIF-1alpha in Jurkat cells was inhibited by using RNA interference technique.",0.34,PMID.dPMID19549358.s2.p2,5,2,HIF-1alpha|Foxp3|HIF-1alpha|Foxp3|HIF-1alpha,Foxp3|HIF-1alpha,x
3.1.1.12.1,3110,9606,GO:0003702,GO:0006355|GO:0006357,3.3.2.1.3,1871,9606,,,15772702,HLXB9,E2F3,Downstream analysis of PI3K revealed that E2F3 may mediate activation of HLXB9.,0.65,PMID.dPMID15772702.s1.p0,2,2,E2F3|HLXB9,E2F3|HLXB9,e
3.1.1.12.1,3110,9606,GO:0003702,GO:0006355|GO:0006357,3.5.2.6.1,2120,9606,,,18940475,MNX1,ETV6,MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines.,1.01,PMID.dPMID18940475.s8.p4,4,3,MNX1|ETV6|megakaryoblastic leukemia|MNX1,ETV6|megakaryoblastic leukemia|MNX1,x
1.1.4.2.2,3131,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,8065331,HLF,E2A,"Wild-type and chimeric HLF proteins also bound closely related sites identified previously for bZIP proteins of both the proline- and acidic amino acid-rich (PAR) and C/EBP subfamilies; however, E2A-HLF proteins were significantly less tolerant of certain deviations from the HLF consensus binding site.",0.45,PMID.dPMID8065331.s4.p4,4,2,HLF|E2A|HLF|HLF,E2A|HLF,x
1.1.4.2.2,3131,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,12111652,HLF,E2A,"The fusion E2A-HLF was amplified by RT-PCR and sequenced, giving a type I rearrangement with a long insertion (146 nucleotides) between E2A exon 13 and HLF exon 4.",0.24,PMID.dPMID12111652.s2.p0,4,2,E2A|HLF|E2A|HLF,E2A|HLF,x
1.1.4.2.2,3131,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,12111652,HLF,E2A,RT-PCR was used to detect the E2A-HLF transcript.,0.00,PMID.dPMID12111652.s5.p0,2,2,E2A|HLF,E2A|HLF,x
4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,4.1.2.0.11,3148,9606,GO:0016563|GO:0016565,GO:0006357|GO:0016481|GO:0045944,19223331,HMGB1,HMGB2,"The involvement of HMGB1 and its close relative, HMGB2, in modulation of activity of the topo IIalpha gene is further supported by knock-down of HMGB1/2, as evidenced by significantly decreased levels of topo IIalpha mRNA and protein.",0.44,PMID.dPMID19223331.s1.p2,3,2,HMGB1|HMGB2|HMGB1,HMGB1|HMGB2,c
4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11106654,HMG1,p53,Interaction between HMG1 and p53 required the HMG A box of HMG1 and amino acids 363-376 of p53.,0.46,PMID.dPMID11106654.s4.p2,4,2,HMG1|p53|HMG1|p53,HMG1|p53,p
4.1.2.0.11,3148,9606,GO:0016563|GO:0016565,GO:0006357|GO:0016481|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,9016958,HMG2,HMG1,Molecular phylogenetic analysis shows that LfHMG1 is descended from a gene ancestral to mammalian HMG1 and HMG2.,0.64,PMID.dPMID9016958.s3.p1,3,2,HMG1|HMG1|HMG2,HMG1|HMG2,x
4.1.2.0.11,3148,9606,GO:0016563|GO:0016565,GO:0006357|GO:0016481|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,7607539,HMG-2,HMG-1,Phylogenetic analysis indicated that the common ancestor of trout HMG-1/2 genes very likely diverged from the ancestor of the mammalian (or avian) HMG-1/2 genes before its separation into two distinct mammalian or (avian) HMG-1 and HMG-2 genes.,0.20,PMID.dPMID7607539.s1.p3,4,2,HMG-1|HMG-1|HMG-1|HMG-2,HMG-1|HMG-2,x
4.1.2.0.11,3148,9606,GO:0016563|GO:0016565,GO:0006357|GO:0016481|GO:0045944,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,12176321,HMGB2,YY1,"We show that an element within D4Z4 specifically binds a multiprotein complex consisting of YY1, a known transcriptional repressor, HMGB2, an architectural protein, and nucleolin.",0.24,PMID.dPMID12176321.s2.p0,3,3,YY1|HMGB2|nucleolin,HMGB2|nucleolin|YY1,c
8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20530667,HMGA1,p53,"Here, we report that HMGA1 antagonizes the p53-mediated transcriptional repression of another apoptosis-related gene, Bcl-2, suggesting a novel mechanism by which HMGA1 counteracts apoptosis.",0.21,PMID.dPMID20530667.s3.p4,4,3,HMGA1|p53|Bcl-2|HMGA1,Bcl-2|HMGA1|p53,c
2.1.4.0.1,3164,9606,,GO:0034339,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,17189400,Nur77,FOS,"Expression profiling of stably transfected HEK293 cells revealed specific up-regulation of the immediate early response genes EGR1/EGR2/EGR3 and FOS/FOSB, mediated by activation of the MEK/ERK5/Nur77 pathway.",0.06,PMID.dPMID17189400.s1.p25,8,8,early response|EGR1|EGR2|EGR3|FOS|FOSB|ERK5|Nur77,early response|EGR1|EGR2|EGR3|ERK5|FOS|FOSB|Nur77,x
2.1.4.0.1,3164,9606,,GO:0034339,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,10567637,nur77,JunD,This work suggests that JunD is involved in Tax-regulated TR3/nur77 expression,0.92,PMID.dPMID10567637.s0.p0,2,2,JunD|nur77,JunD|nur77,e
2.1.4.0.1,3164,9606,,GO:0034339,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,16264271,Nur77,JunD,Its dynamic regulation of histone modifiers with JunD is responsible for PKCq-synergistic effect on Nur77 expression in T cell.,0.51,PMID.dPMID16264271.s0.p0,2,2,JunD|Nur77,JunD|Nur77,x
2.1.4.0.1,3164,9606,,GO:0034339,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,16264271,Nur77,JunD,Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression.,0.20,PMID.dPMID16264271.s10.p2,3,3,Menin|JunD|Nur77,JunD|Menin|Nur77,x
2.1.4.0.1,3164,9606,,GO:0034339,5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,18079734,NUR77,MEF2C,"MEF2C consistently inhibits expression of NR4A1/NUR77, which regulates apoptosis via BCL2 transformation.",0.54,PMID.dPMID18079734.s1.p1,4,3,MEF2C|NR4A1|NUR77|BCL2,BCL2|MEF2C|NR4A1|NUR77,e
2.1.4.0.1,3164,9606,,GO:0034339,5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,18079734,NR4A1,MEF2C,"MEF2C consistently inhibits expression of NR4A1/NUR77, which regulates apoptosis via BCL2 transformation.",0.54,PMID.dPMID18079734.s1.p0,4,3,MEF2C|NR4A1|NUR77|BCL2,BCL2|MEF2C|NR4A1|NUR77,e
2.1.4.0.1,3164,9606,,GO:0034339,2.1.4.0.2,4929,9606,GO:0030528,GO:0034339,14645496,NGFIB,NURR1,KN93 partially inhibited the effect of Ang II on NURR1 mRNA levels but did not modify the effect on expression of NGFIB.,0.09,PMID.dPMID14645496.s2.p0,2,2,NURR1|NGFIB,NGFIB|NURR1,n
2.1.4.0.1,3164,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17139261,TR3,p53,p53 mediates the negative regulation of MDM2 by orphan receptor TR3.,0.94,PMID.dPMID17139261.s9.p1,3,3,p53|MDM2|TR3,MDM2|p53|TR3,c
2.1.4.0.1,3164,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17139261,TR3,p53,"Taken together, our findings demonstrate that p53 mediates the suppression of TR3 on MDM2 at both transcriptional and post-transcriptional level and suggest TR3 as a potential target to develop new anticancer agents that restrict MDM2-induced tumor progression",0.46,PMID.dPMID17139261.s0.p3,5,3,p53|TR3|MDM2|TR3|MDM2,MDM2|p53|TR3,c
2.1.4.0.1,3164,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17139261,TR3,p53,"Taken together, our findings demonstrate that p53 mediates the suppression of TR3 on MDM2 at both transcriptional and post-transcriptional level and suggest TR3 as a potential target to develop new anticancer agents that restrict MDM2-induced tumor progression",0.05,PMID.dPMID17139261.s0.p0,5,3,p53|TR3|MDM2|TR3|MDM2,MDM2|p53|TR3,c
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,10385407,HNF3beta,FKHR,"Southwestern blots, electromobility shift assays, and DNase I protection assays show that Escherichia coli-expressed GST-FKHR binds specifically to IREs from the IGFBP-1, PEPCK and TAT genes; however, unlike HNF3beta, another protein proposed to be the insulin regulated factor, GST-FKHR does not bind the insulin unresponsive G/C-A/C mutation of the IGFBP-1 IRE.",0.03,PMID.dPMID10385407.s2.p3,6,4,FKHR|IGFBP-1|TAT|HNF3beta|FKHR|IGFBP-1,FKHR|HNF3beta|IGFBP-1|TAT,b
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,15465926,HNF3beta,GATA-4,"Site-directed mutagenesis and transactivation analyses of the E1 promoter revealed that GATA-4 is probably a principal factor that regulates liver-specific expression of the E1 variant, with HNF3alpha and HNF3beta acting to negatively regulate GATA-4 function in hepatic cells",0.46,PMID.dPMID15465926.s0.p0,3,2,GATA-4|HNF3beta|GATA-4,GATA-4|HNF3beta,c
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,9118802,HNF-3beta,Gli,"Taken together, these findings suggest that Gli, and probably also Gli2, are good candidates for transcriptional activators of the HNF-3beta floor plate enhancer, and the binding site for Gli proteins is a key element for response to Shh signalling.",0.07,PMID.dPMID9118802.s1.p1,5,4,Gli|Gli2|HNF-3beta|Gli|Shh,Gli|Gli2|HNF-3beta|Shh,[2735-->2735]
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,9118802,HNF-3beta,Gli2,"Taken together, these findings suggest that Gli, and probably also Gli2, are good candidates for transcriptional activators of the HNF-3beta floor plate enhancer, and the binding site for Gli proteins is a key element for response to Shh signalling.",0.57,PMID.dPMID9118802.s1.p2,5,4,Gli|Gli2|HNF-3beta|Gli|Shh,Gli|Gli2|HNF-3beta|Shh,[2735-->2735]
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,10868948,HNF3B,MODY,We have tested this hypothesis by screening a panel of 57 unrelated Japanese subjects with a clinical diagnosis of MODY for mutations in HNF3B.,0.27,PMID.dPMID10868948.s5.p0,2,2,MODY|HNF3B,HNF3B|MODY,x
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,10868855,HNF-3beta,MODY,"RESEARCH DESIGN AND METHODS: The coding regions of the known MODY genes hepatocyte nuclear factor (HNF)-1alpha, HNF-4alpha, HNF-1beta, and insulin promoter factor 1 and the coding regions of two MODY candidate genes, HNF-3beta and the dimerization cofactor of HNF-1, were sequenced in genomic DNA from Pima Indians.",0.19,PMID.dPMID10868855.s5.p9,5,3,MODY|HNF-4alpha|HNF-1beta|MODY|HNF-3beta,HNF-1beta|HNF-3beta|HNF-4alpha|MODY,x
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,12509444,FoxA2,HNF-6,"Human hepatoma (HepG2) cotransfection assays demonstrated that HNF-6 synergistically stimulated FoxA2 but not FoxA1 or FoxA3 transcriptional activity, and protein-binding assays showed that this protein interaction required the HNF-6 Cut-Homeodomain and FoxA2 winged-helix DNA binding domains.",0.48,PMID.dPMID12509444.s5.p0,6,4,HNF-6|FoxA2|FoxA1|FoxA3|HNF-6|FoxA2,FoxA1|FoxA2|FoxA3|HNF-6,c
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,9915796,hnf-3beta,HNF-6,"Like HNF-6, OC-2 stimulates transcription of the hnf-3beta gene in transient transfection experiments, suggesting that OC-2 participates in the network of transcription factors required for liver differentiation and metabolism",0.03,PMID.dPMID9915796.s0.p1,4,3,HNF-6|OC-2|hnf-3beta|OC-2,hnf-3beta|HNF-6|OC-2,c
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.1.3.2,3213,9606,,,16003909,FoxA2,HoxB3,"These results suggest that HoxB3 may be a putative positive regulator of FoxA2 expression at the pre-differentiation stage, and those interactions of Fox factors and Hox factors could participate in Clara cell differentiation",1.95,PMID.dPMID16003909.s0.p0,2,2,HoxB3|FoxA2,FoxA2|HoxB3,e
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.1.3.2,3213,9606,,,16003909,FoxA2,HoxB3,HoxB3 is a putative upstream regulator that enhances FoxA2 expression at the pre-differentiation stage.,1.90,PMID.dPMID16003909.s2.p0,2,2,HoxB3|FoxA2,FoxA2|HoxB3,e
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.1.3.2,3213,9606,,,16003909,FoxA2,HoxB3,HoxB3 transfection induced FoxA2 expression transiently at the pre-differentiation stage.,0.56,PMID.dPMID16003909.s4.p0,2,2,HoxB3|FoxA2,FoxA2|HoxB3,e
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,11278466,HNF-3beta,PDX-1,"A pancreatic beta -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3beta (HNF-3beta ), HNF-1alpha, and SPs transcription factors.",1.00,PMID.dPMID11278466.s7.p1,3,2,PDX-1|hepatocyte nuclear factor 3beta|HNF-3beta,hepatocyte nuclear factor 3beta|HNF-3beta|PDX-1,-->
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,11278466,hepatocyte nuclear factor 3beta,PDX-1,"A pancreatic beta -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3beta (HNF-3beta ), HNF-1alpha, and SPs transcription factors.",0.39,PMID.dPMID11278466.s7.p0,3,2,PDX-1|hepatocyte nuclear factor 3beta|HNF-3beta,hepatocyte nuclear factor 3beta|HNF-3beta|PDX-1,-->
3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,3.1.7.1.2,9480,9606,GO:0003702,,9915796,hnf-3beta,OC-2,"Like HNF-6, OC-2 stimulates transcription of the hnf-3beta gene in transient transfection experiments, suggesting that OC-2 participates in the network of transcription factors required for liver differentiation and metabolism",0.85,PMID.dPMID9915796.s0.p2,4,3,HNF-6|OC-2|hnf-3beta|OC-2,hnf-3beta|HNF-6|OC-2,e
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,8083237,TCF,Elk-1,"One, p62TCF, was indistinguishable from the Ets protein Elk-1 in gel shift analyses, while none of the HeLa TCFs resembled the other cloned TCFs, SAP-1a and SAP-1b.",0.18,PMID.dPMID8083237.s3.p4,6,3,TCF|Elk-1|TCF|TCF|SAP|SAP,Elk-1|SAP|TCF,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,12519792,HNF-4,FKHR,"Therefore, a phosphorylation of FKHR by insulin followed by its dissociation from HNF-4 and the redistribution of FKHR from the nucleus to the cytoplasm would expect to induce the transcriptional activation of HNF-4 by facilitating to the access of HNF-4 to its DNA element.",0.53,PMID.dPMID12519792.s2.p5,5,2,FKHR|HNF-4|FKHR|HNF-4|HNF-4,FKHR|HNF-4,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,12519792,HNF-4,FKHR,"Therefore, a phosphorylation of FKHR by insulin followed by its dissociation from HNF-4 and the redistribution of FKHR from the nucleus to the cytoplasm would expect to induce the transcriptional activation of HNF-4 by facilitating to the access of HNF-4 to its DNA element.",0.06,PMID.dPMID12519792.s2.p8,5,2,FKHR|HNF-4|FKHR|HNF-4|HNF-4,FKHR|HNF-4,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,10868948,MODY,HNF-3beta,"The winged-helix transcription factor HNF-3beta has been implicated in the regulation of expression of each of these MODY genes, suggesting that mutations in the HNF-3beta gene (HNF3B) may also cause MODY.",1.86,PMID.dPMID10868948.s6.p0,5,2,HNF-3beta|MODY|HNF-3beta|HNF3B|MODY,HNF3B|HNF-3beta|MODY,e
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,10868948,MODY,HNF-3beta,"The winged-helix transcription factor HNF-3beta has been implicated in the regulation of expression of each of these MODY genes, suggesting that mutations in the HNF-3beta gene (HNF3B) may also cause MODY.",0.85,PMID.dPMID10868948.s6.p6,5,2,HNF-3beta|MODY|HNF-3beta|HNF3B|MODY,HNF3B|HNF-3beta|MODY,e
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,10868948,MODY,HNF3B,The results of our study suggest that mutations in HNF3B are not a common cause of MODY in Japanese subjects,0.14,PMID.dPMID10868948.s0.p0,2,2,HNF3B|MODY,HNF3B|MODY,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,11323086,MODY,HNF-6,We screened HNF-6 gene for mutations in 34 Japanese subjects with MODY/early-onset diabetes mellitus and 56 subjects with late-onset diabetes mellitus.,0.13,PMID.dPMID11323086.s2.p0,2,2,HNF-6|MODY,HNF-6|MODY,<--
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,17146436,TCF,AP-1,Physical and functional cooperation between AP-1 and beta-catenin for the regulation of TCF-dependent genes.,0.44,PMID.dPMID17146436.s10.p0,2,2,AP-1|TCF,AP-1|TCF,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,14694850,MODY,NeuroD1,On the other hand we confirmed that the Ala45Thr variant in NeuroD1/BETA2 may represent a susceptibility gene for type 1 diabetes but none of these genes revealed any MODY-specific mutations.,0.04,PMID.dPMID14694850.s2.p0,2,2,NeuroD1|MODY,MODY|NeuroD1,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11981036,HNF4,PPARalpha,"Because PPARalpha levels are elevated in tissues expressing the hepatocyte nuclear factor-4 (HNF4), such as liver, the regulation of hPPARalpha by HNF4 was examined.",0.74,PMID.dPMID11981036.s8.p5,4,2,PPARalpha|HNF4|PPARalpha|HNF4,HNF4|PPARalpha,-->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,18080173,HNF4alpha,SREBP2,RESULTS: Transfection of SREBP2 induced the transcriptional activities of NPC1L1 and additional transfection of HNF4alpha results in a marked stimulation of the activities.,0.32,PMID.dPMID18080173.s4.p0,2,2,SREBP2|HNF4alpha,HNF4alpha|SREBP2,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,12086873,TCF,ITF-2,"Human cancers with beta-catenin regulatory defects had elevated ITF-2 expression, and ITF-2 was repressed by restoring wild-type APC function or inhibiting TCF activity.",0.49,PMID.dPMID12086873.s2.p5,4,3,beta-catenin|ITF-2|ITF-2|TCF,beta-catenin|ITF-2|TCF,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,12086873,TCF,ITF-2,"Human cancers with beta-catenin regulatory defects had elevated ITF-2 expression, and ITF-2 was repressed by restoring wild-type APC function or inhibiting TCF activity.",0.30,PMID.dPMID12086873.s2.p4,4,3,beta-catenin|ITF-2|ITF-2|TCF,beta-catenin|ITF-2|TCF,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,8290348,HNF-4,HNF-1,In addition HNF-1 also repressed the activity of HNF-4 dependent ApoCIII and ApoAI promoters.,1.09,PMID.dPMID8290348.s5.p0,3,3,HNF-1|HNF-4|ApoCIII,ApoCIII|HNF-1|HNF-4,<->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,8257717,HNF-4,HNF-1,"On the contrary, HNF-1, whose expression is controlled by HNF-4, is not involved in the regulation of the reporter gene transcription through the -6700/+67 genome sequence.",0.41,PMID.dPMID8257717.s1.p0,2,2,HNF-1|HNF-4,HNF-1|HNF-4,<->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,19336507,MODY,HNF1A,CONCLUSION: This study suggests that mutations in the HNF1A gene comprise about 9% of clinically diagnosed MODY subjects in southern India and a novel Arg263His mutation cosegregates with MODY in one family,0.38,PMID.dPMID19336507.s0.p0,3,2,HNF1A|MODY|MODY,HNF1A|MODY,<->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,12627330,MODY,MODY3,"AIMS/HYPOTHESIS: The aim of this study was to examine the prevalence and nature of mutations in HNF4alpha/MODY1, GCK/MODY2 and HNF-1alpha/MODY3 genes in Czech subjects with clinical diagnosis of MODY.",0.18,PMID.dPMID12627330.s8.p9,5,3,MODY1|GCK|MODY2|MODY3|MODY,GCK|MODY|MODY1|MODY2|MODY3,<->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,16670373,HNF4,HNF1,"The mechanism by which HNF1-mediated activation occurs seems to be transcriptional, because the regulated expression of HNF4, which is known to control HNF1 expression, was also increased.",0.04,PMID.dPMID16670373.s7.p0,3,2,HNF1|HNF4|HNF1,HNF1|HNF4,<->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,17761837,HNF-4,hepatic nuclear factor,"Although hepatic nuclear factor HNF-4 is involved in the basal activity of DRA promoter, sodium butyrate induces its activity in LS174T cells via the binding of Yin Yang 1 (YY1) and GATA transcription factors to their respective cis-elements in promoter region.",0.02,PMID.dPMID17761837.s3.p0,2,2,hepatic nuclear factor|HNF-4,hepatic nuclear factor|HNF-4,<->
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,15928669,TCF,TCF4,"However, HOXB13 downregulated the expression of TCF4 and its target gene, c-myc, at the protein level and consequently inhibited beta-catenin/TCF-mediated signalling.",0.01,PMID.dPMID15928669.s3.p4,4,4,HOXB13|TCF4|c-myc|TCF,c-myc|HOXB13|TCF|TCF4,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,9852068,HNF-4,COUP-TF,"Taken together, these data imply that an interplay between COUP-TF and HNF-4 at a site within FP1 regulates human SHBG expression and that HNF-4 controls transcription from this TATA-less promoter by somehow substituting for TATA-binding protein in the recruitment of a transcription preinitiation complex",0.28,PMID.dPMID9852068.s0.p3,4,3,COUP-TF|HNF-4|SHBG|HNF-4,COUP-TF|HNF-4|SHBG,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,1312668,HNF-4,Ear3,"HNF-4 activation is abolished by increasing amounts of ARP-1 or Ear3/COUP-TF, and repression by ARP-1 or Ear3/COUP-TF is alleviated by increasing amounts of HNF-4.",0.16,PMID.dPMID1312668.s3.p26,8,3,HNF-4|ARP-1|Ear3|COUP-TF|ARP-1|Ear3|COUP-TF|HNF-4,ARP-1|COUP-TF|Ear3|HNF-4,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,1312668,HNF-4,COUP-TF,"HNF-4 activation is abolished by increasing amounts of ARP-1 or Ear3/COUP-TF, and repression by ARP-1 or Ear3/COUP-TF is alleviated by increasing amounts of HNF-4.",0.16,PMID.dPMID1312668.s3.p27,8,3,HNF-4|ARP-1|Ear3|COUP-TF|ARP-1|Ear3|COUP-TF|HNF-4,ARP-1|COUP-TF|Ear3|HNF-4,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,8810289,HNF4,COUP-TFI,"Additionally, COUP-TFI was shown to inhibit HNF4 stimulation of the CYP2D6 promoter in COS-7 cells, suggesting that COUP-TFI could attenuate the effect of HNF4 in HepG2 cells.",0.10,PMID.dPMID8810289.s2.p9,5,3,COUP-TFI|HNF4|CYP2D6|COUP-TFI|HNF4,COUP-TFI|CYP2D6|HNF4,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16895524,HNF4alpha,p53,Implications of the p53-mediated repression of HNF4alpha expression in response to cellular stress are discussed,1.78,PMID.dPMID16895524.s0.p0,2,2,p53|HNF4alpha,HNF4alpha|p53,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17929268,TCF,p53,"RESULTS: Overexpression of p53wt as well as p53(249Ser) (a structural mutant) and p53(273His) (a DNA-contact-mutant) almost completely inhibited beta-catenin-mediated transcriptional activity of the T-cell factor (TCF) whereas p53(175His), a structural mutant, and a p53-mutant with a C-terminal deletion in the tetramerization domain (Deltap53) were unable to do so.",0.30,PMID.dPMID17929268.s6.p5,7,2,p53|p53|p53|TCF|p53|p53|p53,p53|TCF,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.6.0.1,7343,9606,GO:0003701,GO:0006356|GO:0045943,12748295,TCF,UBF,"Downregulation of endogenous UBF expression using an RNA interference approach reduces transcriptional activation of a beta-catenin-LEF/TCF-responsive promoter by means of overexpressed beta-catenin, further implicating UBF as a transcriptional enhancer of the beta-catenin pathway",0.38,PMID.dPMID12748295.s0.p0,3,2,UBF|TCF|UBF,TCF|UBF,x
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12829997,HNF-4,WT1,"In conclusion, we show that WT1 is induced by TGF-beta and down-regulates HNF-4 in liver cells.",0.08,PMID.dPMID12829997.s1.p0,2,2,WT1|HNF-4,HNF-4|WT1,e
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,16455805,HNF4alpha,PXR,"Results suggest that PXR strongly induces CYP3A4 gene transcription by interacting with HNF4alpha, SRC-1, and PGC-1alpha.",0.18,PMID.dPMID16455805.s2.p1,5,5,PXR|CYP3A4|HNF4alpha|SRC-1|PGC-1alpha,CYP3A4|HNF4alpha|PGC-1alpha|PXR|SRC-1,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,16455805,HNF4alpha,PXR,"On the other hand, SHP reduced PXR recruitment of HNF4alpha and SRC-1 to the CYP3A4 chromatin.",0.00,PMID.dPMID16455805.s5.p2,5,5,SHP|PXR|HNF4alpha|SRC-1|CYP3A4,CYP3A4|HNF4alpha|PXR|SHP|SRC-1,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,15998435,TCF,LEF-1,"Nuclear LEF-1/TCF expression was observed in 52% of all cases, but was also present in 42% of cyclin D1(-) cases.",0.37,PMID.dPMID15998435.s4.p0,2,2,LEF-1|TCF,LEF-1|TCF,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,20028861,TCF,LEF1,Aberrant activations of LEF1/TCF-mediated transcription have been implicated in a variety of malignancies.,0.22,PMID.dPMID20028861.s4.p0,2,2,LEF1|TCF,LEF1|TCF,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,16741972,TCF,LEF-1,Wnt is a complex signaling pathway whose endpoint involves activation of transcription from LEF-1/TCF transcription factors and it is known to be involved in the development and progression of numerous human epithelial tumors including prostate cancer.,0.20,PMID.dPMID16741972.s5.p0,2,2,LEF-1|TCF,LEF-1|TCF,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,15998435,TCF,LEF-1,Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma.,0.16,PMID.dPMID15998435.s9.p0,2,2,LEF-1|TCF,LEF-1|TCF,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,16741972,TCF,LEF-1,"Finally, it was recently found that the human AR gene itself is a target of LEF-1/TCF-mediated transcription and that AR mRNA is highly upregulated by activation of Wnt signaling in prostate cancer cells.",0.09,PMID.dPMID16741972.s2.p0,2,2,LEF-1|TCF,LEF-1|TCF,c
2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,16474850,TCF,LEF-1,"These data indicate that the hAR gene is a direct target of LEF-1/TCF transcriptional regulation in PCa cells but also show that the expression of the hAR protein is suppressed by a degradation pathway regulated by cross-talk of Wnt to Akt that is likely mediated by Wnt-directed degradation of the B regulatory subunit of protein phosphatase, PP2A",0.06,PMID.dPMID16474850.s0.p0,4,4,LEF-1|TCF|Akt|PP2A,Akt|LEF-1|PP2A|TCF,c
3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,10333497,HNF-6,HNF-3,"Sequences were inserted at position -21, separating both HNF-3 binding sites from the HNF-1-HNF-6 binding site, and position -5, separating the HNF-3-HNF-1-HNF-6 complex from the transcription start site.",0.37,PMID.dPMID10333497.s5.p1,6,3,HNF-3|HNF-1|HNF-6|HNF-3|HNF-1|HNF-6,HNF-1|HNF-3|HNF-6,c
3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,12509444,HNF-6,FoxA2,"This was supported by the fact that FoxA2 transcriptional synergy with HNF-6 was dependent on retention of the HNF-6 Cut domain LXXLL sequence, which mediated recruitment of the p300/CBP proteins.",0.38,PMID.dPMID12509444.s3.p1,3,2,FoxA2|HNF-6|HNF-6,FoxA2|HNF-6,x
3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,15047618,HNF6,pdx-1,"The results showed that pdx-1 expression clearly enhanced the expression of the insulin 2, somatostatin, Kir6.2, glucokinase, neurogenin3, p48, Pax6, PC2, and HNF6 genes in the resulting differentiated cells.",0.04,PMID.dPMID15047618.s2.p6,5,5,pdx-1|somatostatin|Pax6|PC2|HNF6,HNF6|Pax6|PC2|pdx-1|somatostatin,
3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,2.1.6.0.2,8431,9606,,GO:0034339,18459945,HNF-6,SHP,"Using transient transfection assays, we have shown that SHP represses the transcriptional activity of HNF-6.",2.02,PMID.dPMID18459945.s5.p0,2,2,SHP|HNF-6,HNF-6|SHP,
3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,2.1.6.0.2,8431,9606,,GO:0034339,18459945,HNF-6,SHP,"In this study, we have investigated the function of SHP as a putative repressor of HNF-6.",0.79,PMID.dPMID18459945.s6.p0,2,2,SHP|HNF-6,HNF-6|SHP,
3.1.1.7.17,3195,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20618946,TLX1,MYC,"Gain- and loss-of-function experiments confirmed that MYC was an essential mediator of TLX1/NOTCH transcriptional output and growth promotion in ALL-SIL cells, with TLX1 contributing to the NOTCH-MYC regulatory axis by posttranscriptional enhancement of MYC protein levels.",0.24,PMID.dPMID20618946.s5.p0,5,2,MYC|TLX1|TLX1|MYC|MYC,MYC|TLX1,
3.1.1.1.1,3198,9606,GO:0003702,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18276758,HOXA1,STAT3,"The protein levels of STAT3 and 5B, but not STAT5A, and protein phosphorylation levels of STAT3 and 5B were significantly increased by forced expression of HOXA1.",0.26,PMID.dPMID18276758.s3.p2,3,2,STAT3|STAT3|HOXA1,HOXA1|STAT3,
3.1.1.2.1,3199,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,20085832,HOXA2,MLL,Here we show that CHD8 relocalizes to the promoter of the MLL regulated gene HOXA2 upon gene activation.,0.34,PMID.dPMID20085832.s3.p2,3,3,CHD8|MLL|HOXA2,CHD8|HOXA2|MLL,
3.1.1.4.1,3201,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,16230385,Hoxa4,MLL,"Thus, MLL-ENL is required to initiate and maintain immortalization of myeloid progenitors and may contribute to leukemogenesis by aberrantly sustaining the expression of a ""Hox code"" consisting of Hoxa4 to Hoxa11.",0.00,PMID.dPMID16230385.s0.p0,3,3,MLL|Hoxa4|Hoxa11,Hoxa11|Hoxa4|MLL,
3.1.1.7.1,3205,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17047146,HoxA9,MLL,"We conclude that MLL regulates endothelial-cell migration via HoxA9 and EphB4, whereas sprout formation requires MLL-dependent signals beyond HoxA9 and HoxD3",1.47,PMID.dPMID17047146.s0.p0,6,4,MLL|HoxA9|EphB4|MLL|HoxA9|HoxD3,EphB4|HoxA9|HoxD3|MLL,x
3.1.1.7.1,3205,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,20541477,Hoxa9,MLL,PAFc augments MLL and MLL-AF9 mediated transcriptional activation of Hoxa9.,0.82,PMID.dPMID20541477.s3.p2,3,2,MLL|MLL|Hoxa9,Hoxa9|MLL,
3.1.1.7.1,3205,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,15160920,HOXA9,MLL,"These results suggest that MLL aberrations may regulate MEIS1 and HOXA9 gene expression in ALL-derived cell lines, while AML-derived cell lines express these genes independently of the MLL status.",0.60,PMID.dPMID15160920.s0.p1,4,3,MLL|MEIS1|HOXA9|MLL,HOXA9|MEIS1|MLL,
3.1.1.7.1,3205,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,20541477,Hoxa9,MLL,PAFc augments MLL and MLL-AF9 mediated transcriptional activation of Hoxa9.,0.48,PMID.dPMID20541477.s3.p1,3,2,MLL|MLL|Hoxa9,Hoxa9|MLL,
3.1.1.7.1,3205,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17047146,HoxA9,MLL,"We conclude that MLL regulates endothelial-cell migration via HoxA9 and EphB4, whereas sprout formation requires MLL-dependent signals beyond HoxA9 and HoxD3",0.48,PMID.dPMID17047146.s0.p6,6,4,MLL|HoxA9|EphB4|MLL|HoxA9|HoxD3,EphB4|HoxA9|HoxD3|MLL,
3.1.1.7.1,3205,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,19056693,HOXA9,MLL,"Gene expression analyses demonstrate a distinct profile for MLL-rearranged leukemias with consistent high-level expression of select Homeobox genes, including HOXA9.",0.04,PMID.dPMID19056693.s6.p0,2,2,MLL|HOXA9,HOXA9|MLL,
3.1.1.7.5,3206,9606,,,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,17688409,HOXA10,Ets-1,"Mutation of the GATA-1 and the Ets-1 motifs amplified the expression of HOXA10 in HEL and K562 cells, confirming the importance of these cis-acting elements in regulating HOXA10 expression in megakaryocytic cells.",0.35,PMID.dPMID17688409.s2.p2,4,3,GATA-1|Ets-1|HOXA10|HOXA10,Ets-1|GATA-1|HOXA10,
3.1.1.7.5,3206,9606,,,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,12493691,HOXA10,FKHR,"A DNA binding-deficient FKHR mutant fails to stimulate promoter activity, even in the presence of HOXA10, and deletion or mutation of IRSs also disrupts the effect of FKHR and cooperativity with HOXA10.",0.07,PMID.dPMID12493691.s3.p0,5,3,FKHR|HOXA10|IRS|FKHR|HOXA10,FKHR|HOXA10|IRS,
3.1.1.7.5,3206,9606,,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,19188669,Hoxa10,MLL,"Here, we show that MLL normally regulates expression of mir-196b, a hematopoietic microRNA located within the HoxA cluster, in a pattern similar to that of the surrounding 5' Hox genes, Hoxa9 and Hoxa10, during embryonic stem (ES) cell differentiation.",0.17,PMID.dPMID19188669.s6.p1,3,3,MLL|mir-196b|Hoxa10,Hoxa10|mir-196b|MLL,
3.1.1.6.5,3217,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12697323,HOXB7,Sp1,"Cell transfection and site-specific mutagenesis demonstrated Sp1/Sp3, NF-Y, YY1 and USF-1 binding to be functional and fundamental in driving HOXB7 expression.",0.01,PMID.dPMID12697323.s2.p6,5,5,Sp1|Sp3|YY1|USF-1|HOXB7,HOXB7|Sp1|Sp3|USF-1|YY1,<--
3.1.1.6.5,3217,9606,,,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,12697323,HOXB7,Sp3,"Cell transfection and site-specific mutagenesis demonstrated Sp1/Sp3, NF-Y, YY1 and USF-1 binding to be functional and fundamental in driving HOXB7 expression.",0.01,PMID.dPMID12697323.s2.p7,5,5,Sp1|Sp3|YY1|USF-1|HOXB7,HOXB7|Sp1|Sp3|USF-1|YY1,<--
3.1.1.3.3,3232,9606,GO:0030528,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17047146,HoxD3,MLL,"In contrast, MLL knockdown effects on capillary sprouting were not rescued by HoxA9 or HoxD3 overexpression, indicating that MLL affects additional targets required for 3-dimensional sprout formation.",0.31,PMID.dPMID17047146.s1.p1,4,3,MLL|HoxA9|HoxD3|MLL,HoxA9|HoxD3|MLL,
3.1.1.3.3,3232,9606,GO:0030528,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17047146,HoxD3,MLL,"We conclude that MLL regulates endothelial-cell migration via HoxA9 and EphB4, whereas sprout formation requires MLL-dependent signals beyond HoxA9 and HoxD3",0.17,PMID.dPMID17047146.s0.p10,6,4,MLL|HoxA9|EphB4|MLL|HoxA9|HoxD3,EphB4|HoxA9|HoxD3|MLL,
1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,16753023,HES1,RUNX2,"Furthermore, both pRb and HES1 increase the amount of RUNX2 bound to promoter sites in vivo, pRb and HES1 synergistically activate a RUNX2-dependent reporter gene, and depletion of HES1 reduces RUNX2/pRb activity.",0.07,PMID.dPMID16753023.s1.p7,6,2,HES1|RUNX2|HES1|RUNX2|HES1|RUNX2,HES1|RUNX2,
1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,2.3.2.2.14,5978,9606,GO:0016564,GO:0006355,16253247,HES-1,REST,"In this study, we hypothesized that REST expression is controlled by hairy and enhancer of split 1 (HES-1), a transcriptional repressor that plays an important role in brain and pancreas development.",0.87,PMID.dPMID16253247.s3.p0,2,2,REST|HES-1,HES-1|REST,-->
1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,19322650,HES-1,SOX9,SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells.,0.48,PMID.dPMID19322650.s8.p0,2,2,SOX9|HES-1,HES-1|SOX9,
1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,19322650,HES-1,SOX9,We found an enhancer regulating HES-1 expression: two SOX9 binding sites upstream of the HES-1 gene that were capable of binding SOX9 in vitro.,0.39,PMID.dPMID19322650.s4.p2,4,2,HES-1|SOX9|HES-1|SOX9,HES-1|SOX9,
1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,19322650,HES-1,SOX9,"In reporter assays, transfection of a SOX9 expression plasmid increased the activity of the HES-1 enhancer.",0.36,PMID.dPMID19322650.s2.p0,2,2,SOX9|HES-1,HES-1|SOX9,
3.4.1.0.1,3297,9606,,,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,12468538,HSF1,c-fos,"Furthermore, we constructed dominant inhibitors of c-fos repression by HSF1, which also blocked the repression of c-fms and IL-1beta, suggesting a shared mechanism for repression of these genes by HSF1.",0.18,PMID.dPMID12468538.s2.p0,5,4,c-fos|HSF1|c-fms|IL-1beta|HSF1,c-fms|c-fos|HSF1|IL-1beta,
3.4.1.0.1,3297,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15152009,HSF1,p53,Inhibition of aneuploidy in p53 null PC-3 cells by DN-HSF1 expression was recapitulated by expression within the cells of wild type p53.,0.37,PMID.dPMID15152009.s3.p0,3,2,p53|HSF1|p53,HSF1|p53,
3.4.1.0.2,3298,9606,,,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9341107,heat shock factor 2,c-fos,This property was specific for heat shock factor 1; c-fos repression was not seen with the structurally related protein heat shock factor 2.,0.06,PMID.dPMID9341107.s2.p0,2,2,c-fos|heat shock factor 2,c-fos|heat shock factor 2,
3.5.3.0.8,3394,9606,,GO:0000122,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19958752,IRF8,MYC,"In addition, this subtype of t-AML is characterized by a unique expression profile (higher expression of genes) involved in cell cycle control (CCNA2, CCNE2, CDC2), checkpoints (BUB1), or growth (MYC), loss of expression of IRF8, and overexpression of FHL2.",0.07,PMID.dPMID19958752.s6.p2,4,4,BUB1|MYC|IRF8|FHL2,BUB1|FHL2|IRF8|MYC,
3.5.3.0.8,3394,9606,,GO:0000122,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,20237505,IRF8,WT1,"Upon overexpression in CD34+ progenitors, as well as in U937 cells, WT1 strongly downregulated IRF8 expression.",1.22,PMID.dPMID20237505.s4.p2,3,3,CD34|WT1|IRF8,CD34|IRF8|WT1,
3.5.3.0.8,3394,9606,,GO:0000122,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,20237505,IRF8,WT1,"Interestingly, IRF8 is known as a tumor suppressor in some leukemias and we investigated whether WT1 might repress IRF8 expression.",1.14,PMID.dPMID20237505.s6.p2,3,2,IRF8|WT1|IRF8,IRF8|WT1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.1.1.2.6,467,9606,,,12718878,Id1,ATF3,A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells.,0.35,PMID.dPMID12718878.s4.p0,2,2,ATF3|Id1,ATF3|Id1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.1.4.1.2,1051,9606,,,12574125,Id-1,C/EBPbeta,"Consistently, expression of an acetylation-resistant mutant of C/EBPbeta results in IL-3-independent expression of the Id-1 gene.",0.67,PMID.dPMID12574125.s1.p1,3,3,C/EBPbeta|IL-3|Id-1,C/EBPbeta|Id-1|IL-3,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,7828584,ID1,c-Fos,"Finally, squelching experiments suggest that c-Fos ID1 binds a limiting protein involved in inhibition.",0.06,PMID.dPMID7828584.s1.p0,2,2,c-Fos|ID1,c-Fos|ID1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17426247,Id-1,HIF-1alpha,"In addition, stability of the HIF-1alpha protein was enhanced in part by the reduced association of the HIF-1alpha protein with von Hippel-Lindau protein in the presence of Id-1.",0.01,PMID.dPMID17426247.s4.p2,3,2,HIF-1alpha|HIF-1alpha|Id-1,HIF-1alpha|Id-1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,7622574,Id,Id2,"The Id2 gene is one of several ""Id-like"" genes which encode helix-loop-helix proteins which dimerize with basic helix-loop-helix proteins and inhibit binding to the DNA enhancer element known as an E box.",0.78,PMID.dPMID7622574.s6.p0,2,2,Id2|Id,Id|Id2,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,11751402,Id1,Id2,"Expression of Id1 and to a lesser extent of Id2 was correlated with mitotic index (P = 0.005 for Id1; P = 0.042 for Id2) in human adenocarcinomas, and expression of all three Id proteins was correlated with p53 immunoreactivity (a marker of mutational 'inactivation' of p53 function; P = 0.002 for Id1; P = 0.006 for Id2; P = 0.016 for Id3).",0.25,PMID.dPMID11751402.s6.p22,10,4,Id1|Id2|Id1|Id2|Id|p53|p53|Id1|Id2|Id3,Id|Id1|Id2|Id3|p53,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,11751402,Id1,Id3,"In a series of 34 cases of primary human colorectal adenocarcinoma, immunoreactivity for Id1, Id2, and Id3 was found to be significantly elevated in tumor compared with normal mucosa (P = 0.001 for Id1 and Id2; P = 0.002 for Id3).",0.18,PMID.dPMID11751402.s8.p5,6,3,Id1|Id2|Id3|Id1|Id2|Id3,Id1|Id2|Id3,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,7.1.1.1.1,4086,9606,,,18436795,Id,Smad1,"Taken together, these findings indicate an important interaction between ERK1/2 and Smad1/5 in the regulation of Id genes.",0.99,PMID.dPMID18436795.s2.p2,3,3,ERK1|Smad1|Id,ERK1|Id|Smad1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,7.1.1.1.1,4086,9606,,,18436795,Id,Smad1,We provide evidence for an important interaction between Smad1/5 and ERK1/2 signaling in the regulation of Id gene expression.,0.47,PMID.dPMID18436795.s8.p1,3,3,Smad1|ERK1|Id,ERK1|Id|Smad1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15489884,Id1,c-Myc,"Inhibition of c-Myc function by siRNA, antisense oligonucleotides or a dominant repressor resulted in downregulation of Id1, while ectopic expression of c-Myc resulted in rapid induction of Id1, suggesting that Id1 may be downstream of c-Myc.",0.38,PMID.dPMID15489884.s1.p5,6,2,c-Myc|Id1|c-Myc|Id1|Id1|c-Myc,c-Myc|Id1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,20235117,Id1,MyoD,Affinity of synthetic peptide fragments of MyoD for Id1 protein and their biological effects in several cancer cells.,0.36,PMID.dPMID20235117.s12.p0,2,2,MyoD|Id1,Id1|MyoD,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,15163661,Id1,MyoD,These results thus demonstrate that in vivo MyoD modulates the rate of Id1 degradation and suggest a dynamic interplay of these factors.,0.10,PMID.dPMID15163661.s0.p0,2,2,MyoD|Id1,Id1|MyoD,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,18296633,Id1,MyoD,"Here, we demonstrate that, in differentiated myotubes, glucocorticoid, via the glucocorticoid receptor, selectively induces a decrease in protein abundance of MyoD, a master switch for muscle development and regeneration, but not that of its negative regulator Id1.",0.01,PMID.dPMID18296633.s5.p0,2,2,MyoD|Id1,Id1|MyoD,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,12526101,Id,BETA2,Inhibition of BETA2/NeuroD by Id2.,0.38,PMID.dPMID12526101.s10.p1,3,2,BETA2|NeuroD|Id,BETA2|Id|NeuroD,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,12526101,Id,NeuroD,Inhibition of BETA2/NeuroD by Id2.,0.38,PMID.dPMID12526101.s10.p2,3,2,BETA2|NeuroD|Id,BETA2|Id|NeuroD,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,11896613,Id-1,helix-loop-helix protein,"The helix-loop-helix protein Id-1 is a dominant negative regulator of basic helix-loop-helix transcription factors, and plays a key role in the control of breast epithelial cell growth, invasion and differentiation.",0.91,PMID.dPMID11896613.s6.p0,2,2,helix-loop-helix protein|Id-1,helix-loop-helix protein|Id-1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,10908559,Id-1,helix-loop-helix protein,"Recently it was reported that forced overexpression of the helix-loop-helix protein Id-1 was capable of immortalizing keratinocytes, secondary to activation of telomerase activity and suppression of p16/Rb-mediated growth arrest pathways.",0.43,PMID.dPMID10908559.s5.p0,4,4,helix-loop-helix protein|Id-1|p16|Rb,helix-loop-helix protein|Id-1|p16|Rb,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,9070860,Id-1,helix-loop-helix protein,The helix-loop-helix protein Id-1 regulates growth and differentiation in many mammalian cells.,0.42,PMID.dPMID9070860.s7.p0,2,2,helix-loop-helix protein|Id-1,helix-loop-helix protein|Id-1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,8934878,Id-1,helix-loop-helix protein,The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts.,0.38,PMID.dPMID8934878.s14.p0,3,3,helix-loop-helix protein|Id-1|retinoblastoma protein binding,helix-loop-helix protein|Id-1|retinoblastoma protein binding,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,15489884,Id1,helix-loop-helix protein,The helix-loop-helix protein Id1 has been implicated in regulating mammary epithelial cell proliferation and differentiation but the underlying molecular mechanisms are not well characterized.,0.27,PMID.dPMID15489884.s6.p0,2,2,helix-loop-helix protein|Id1,helix-loop-helix protein|Id1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,10728695,Id-1,helix-loop-helix protein,"The helix-loop-helix protein Id-1 inhibits the activity of basic helix-loop-helix transcription factors, and is an important regulator of cell growth and tissue-specific differentiation.",0.24,PMID.dPMID10728695.s10.p0,2,2,helix-loop-helix protein|Id-1,helix-loop-helix protein|Id-1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,12016143,Id-1,helix-loop-helix protein,It has been suggested that the helix-loop-helix protein Id-1 plays an important role in tumourigenesis in certain types of human cancer.,0.10,PMID.dPMID12016143.s7.p0,2,2,helix-loop-helix protein|Id-1,helix-loop-helix protein|Id-1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,12466969,Id-1,helix-loop-helix protein,The helix-loop-helix protein Id-1 has been suggested to play a positive role in cell proliferation and tumorigenesis of many types of human cancers.,0.09,PMID.dPMID12466969.s6.p0,2,2,helix-loop-helix protein|Id-1,helix-loop-helix protein|Id-1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.3.1.4,4807,9606,,,14755252,ID1,helix-loop-helix protein,The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers.,0.09,PMID.dPMID14755252.s7.p0,2,2,helix-loop-helix protein|ID1,helix-loop-helix protein|ID1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17490644,Id-1,Sp1,"Small interfering RNA directed against Sp1 reduced Id-1 expression and the upregulation of the promoter, indicating that Sp1 is required for Id-1 induction in E47- and Snail-expressing cells.",1.02,PMID.dPMID17490644.s1.p0,4,2,Sp1|Id-1|Sp1|Id-1,Id-1|Sp1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17490644,Id-1,Sp1,"Small interfering RNA directed against Sp1 reduced Id-1 expression and the upregulation of the promoter, indicating that Sp1 is required for Id-1 induction in E47- and Snail-expressing cells.",0.23,PMID.dPMID17490644.s1.p5,4,2,Sp1|Id-1|Sp1|Id-1,Id-1|Sp1,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,6.2.1.0.5,6776,9606,,GO:0006357,12574125,Id-1,STAT5,STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta.,0.39,PMID.dPMID12574125.s6.p0,4,4,STAT5|Id-1|HDAC1|C/EBPbeta,C/EBPbeta|HDAC1|Id-1|STAT5,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16037992,Id-1,p53,p53GOF-mediated regulation of Id-1 expression was validated by RT-PCR and dual-luciferase reporter assays.,2.50,PMID.dPMID16037992.s7.p0,2,2,p53|Id-1,Id-1|p53,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16037992,Id-1,p53,"To begin validating these genes as effectors of the p53 mutants, we evaluated one of the overexpressed genes, Id-1.",1.14,PMID.dPMID16037992.s4.p0,2,2,p53|Id-1,Id-1|p53,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19079342,Id-1,p53,"In promoter assay with serial deletion and chromatin immunoprecipitation assay, the binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation.",0.49,PMID.dPMID19079342.s4.p0,4,2,p53|Id-1|Id-1|p53,Id-1|p53,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18556654,ID1,p53 tumor suppressor,"Although the biological functions of the ID1 oncogene and the p53 tumor suppressor have been intensively investigated, little is known about the upstream regulators of ID1 and the cross-talk between ID1 and p53.",0.38,PMID.dPMID18556654.s7.p2,5,2,ID1|p53 tumor suppressor|ID1|ID1|p53,ID1|p53|p53 tumor suppressor,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19079342,Id-1,p53,"In promoter assay with serial deletion and chromatin immunoprecipitation assay, the binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation.",0.06,PMID.dPMID19079342.s4.p1,4,2,p53|Id-1|Id-1|p53,Id-1|p53,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,19098224,ID1,VDR,"Notably, SMRT mutants defective in the VDR interaction were also defective in the repression of endogenous VDR-target genes, indicating that the SMRT corepressor is directly involved in the VDR-mediated repression in vivo via an ID1-specific interaction with the VDR",0.20,PMID.dPMID19098224.s0.p12,7,3,SMRT|VDR|VDR|SMRT|VDR|ID1|VDR,ID1|SMRT|VDR,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,19098224,ID1,VDR,"Notably, SMRT mutants defective in the VDR interaction were also defective in the repression of endogenous VDR-target genes, indicating that the SMRT corepressor is directly involved in the VDR-mediated repression in vivo via an ID1-specific interaction with the VDR",0.08,PMID.dPMID19098224.s0.p14,7,3,SMRT|VDR|VDR|SMRT|VDR|ID1|VDR,ID1|SMRT|VDR,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,4.1.5.0.1,7468,9606,,,16115125,ID-1,MMSET,"As high levels of ID-1 are associated with cancer, our findings indicate that MMSET promotes oncogenic transformation in t(4;14)+ MM patients by transcriptional activation of ID-1 expression",0.65,PMID.dPMID16115125.s0.p2,3,2,ID-1|MMSET|ID-1,ID-1|MMSET,
1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,1.2.4.1.12,8553,9606,,GO:0006355,18556654,ID1,DEC1,"Interestingly, we found that DEC1, which was recently identified as a p53 target and mediates p53-dependent cell cycle arrest and senescence, is capable of inhibiting ID1 expression.",0.23,PMID.dPMID18556654.s5.p3,4,3,DEC1|p53|p53|ID1,DEC1|ID1|p53,
1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,18413820,Id2,Id,"CONCLUSION: Changed expression profiles of Id proteins may play important roles in malignant progression of SCLC, and the increased Id2 in cytoplasm is a novel prognostic factor to predict the patient outcomes.",0.41,PMID.dPMID18413820.s0.p0,2,2,Id|Id2,Id|Id2,
1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,11751402,Id2,Id1,"In a series of 34 cases of primary human colorectal adenocarcinoma, immunoreactivity for Id1, Id2, and Id3 was found to be significantly elevated in tumor compared with normal mucosa (P = 0.001 for Id1 and Id2; P = 0.002 for Id3).",0.04,PMID.dPMID11751402.s8.p6,6,3,Id1|Id2|Id3|Id1|Id2|Id3,Id1|Id2|Id3,
1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,11751402,Id2,Id3,"In a series of 34 cases of primary human colorectal adenocarcinoma, immunoreactivity for Id1, Id2, and Id3 was found to be significantly elevated in tumor compared with normal mucosa (P = 0.001 for Id1 and Id2; P = 0.002 for Id3).",0.03,PMID.dPMID11751402.s8.p8,6,3,Id1|Id2|Id3|Id1|Id2|Id3,Id1|Id2|Id3,
1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,3.5.2.5.2,6689,9606,GO:0003702,GO:0006357,18792017,Id2,Spi-B,"Notably, Spi-B was unable to overcome the Id2 enforced block in pDC development and moreover Spi-B transduced pDC expressed reduced Id2 levels.",0.52,PMID.dPMID18792017.s3.p5,4,2,Spi-B|Id2|Spi-B|Id2,Id2|Spi-B,
1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,15249128,Id2,E2-2,"Co-transfection of JEG-3 cells with E2-2 and Id2, and a luciferase reporter construct under the control of the human chorionic gonadotropin alpha-subunit promoter revealed that E2-2 had a negative effect on CGalpha-subunit transcription, which could be relieved by overexpression of Id2.",0.73,PMID.dPMID15249128.s2.p5,4,2,E2-2|Id2|E2-2|Id2,E2-2|Id2,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,17899540,ID3,ID1,"BMP-6 also induced phosphorylation of Smad1/5/8, followed by transcriptional increase in ID1-ID3 mRNA expression.",0.44,PMID.dPMID17899540.s2.p2,3,3,BMP-6|ID1|ID3,BMP-6|ID1|ID3,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,19515385,Id3,Id1,"In addition, Id1/Id3 double-knockdown caused decreased expression of integrins alpha3, alpha6, and beta1, and consequently reduced adhesion of tumor cells to laminin.",0.24,PMID.dPMID19515385.s2.p0,3,3,Id1|Id3|alpha6,alpha6|Id1|Id3,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,11751402,Id3,Id1,"In a series of 34 cases of primary human colorectal adenocarcinoma, immunoreactivity for Id1, Id2, and Id3 was found to be significantly elevated in tumor compared with normal mucosa (P = 0.001 for Id1 and Id2; P = 0.002 for Id3).",0.22,PMID.dPMID11751402.s8.p13,6,3,Id1|Id2|Id3|Id1|Id2|Id3,Id1|Id2|Id3,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,11751402,Id3,Id1,"In a series of 34 cases of primary human colorectal adenocarcinoma, immunoreactivity for Id1, Id2, and Id3 was found to be significantly elevated in tumor compared with normal mucosa (P = 0.001 for Id1 and Id2; P = 0.002 for Id3).",0.13,PMID.dPMID11751402.s8.p10,6,3,Id1|Id2|Id3|Id1|Id2|Id3,Id1|Id2|Id3,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,11751402,Id3,Id2,"In a series of 34 cases of primary human colorectal adenocarcinoma, immunoreactivity for Id1, Id2, and Id3 was found to be significantly elevated in tumor compared with normal mucosa (P = 0.001 for Id1 and Id2; P = 0.002 for Id3).",0.06,PMID.dPMID11751402.s8.p11,6,3,Id1|Id2|Id3|Id1|Id2|Id3,Id1|Id2|Id3,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,11751402,Id3,Id2,"Expression of Id1 and to a lesser extent of Id2 was correlated with mitotic index (P = 0.005 for Id1; P = 0.042 for Id2) in human adenocarcinomas, and expression of all three Id proteins was correlated with p53 immunoreactivity (a marker of mutational 'inactivation' of p53 function; P = 0.002 for Id1; P = 0.006 for Id2; P = 0.016 for Id3).",0.04,PMID.dPMID11751402.s6.p37,10,4,Id1|Id2|Id1|Id2|Id|p53|p53|Id1|Id2|Id3,Id|Id1|Id2|Id3|p53,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,16449966,Id3,Id2,"We have shown that while Id2 is induced by UVB in primary keratinocytes, Id3 is upregulated only in immortalized cells.",0.02,PMID.dPMID16449966.s10.p0,2,2,Id2|Id3,Id2|Id3,
1.2.8.0.3,3399,9606,GO:0016564,GO:0016481|GO:0043433,3.1.4.5.1,5460,9606,,GO:0006355|GO:0010552|GO:0090308,19815608,ID3,POU5F1,POU5F1 expression positively correlated with ID1 and ID3 expression (P < 0.05) but not with NANOG or SOX2 expression.,0.04,PMID.dPMID19815608.s4.p1,5,5,POU5F1|ID1|ID3|NANOG|SOX2,ID1|ID3|NANOG|POU5F1|SOX2,
1.2.8.0.4,3400,9606,GO:0016564,GO:0006357|GO:0016481,3.3.2.1.1,1869,9606,,GO:0000122,19783986,ID4,E2F1,The protein complex mutant p53-E2F1 assembles on specific regions of the ID4 promoter and positively controls ID4 expression.,0.61,PMID.dPMID19783986.s3.p4,4,3,p53|E2F1|ID4|ID4,E2F1|ID4|p53,
1.2.8.0.4,3400,9606,GO:0016564,GO:0006357|GO:0016481,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19783986,ID4,p53,The protein complex mutant p53-E2F1 assembles on specific regions of the ID4 promoter and positively controls ID4 expression.,0.61,PMID.dPMID19783986.s3.p3,4,3,p53|E2F1|ID4|ID4,E2F1|ID4|p53,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,9570134,RBP-J,HES1,"Recent studies indicate that HES1 expression is also controlled by RBP-J, a mammalian homologue of Suppressor of Hairless [Su(H)], and Notch, a key membrane protein that may regulate lateral specification through RBP-J during neural development.",1.14,PMID.dPMID9570134.s1.p0,3,2,HES1|RBP-J|RBP-J,HES1|RBP-J,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,9570134,RBP-J,HES1,"Recent studies indicate that HES1 expression is also controlled by RBP-J, a mammalian homologue of Suppressor of Hairless [Su(H)], and Notch, a key membrane protein that may regulate lateral specification through RBP-J during neural development.",0.24,PMID.dPMID9570134.s1.p1,3,2,HES1|RBP-J|RBP-J,HES1|RBP-J,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17434929,CBF1,c-myc,"Furthermore, the N1IC also bound to the promoter of human c-myc oncogene, a YY1 target gene, to elevate c-myc expression via a CBF1-independent pathway.",0.48,PMID.dPMID17434929.s5.p2,3,2,c-myc|c-myc|CBF1,CBF1|c-myc,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18490439,CBF1,c-myc,The complex of N1IC and transcription factor YY1 binds to the human c-myc promoter to enhance c-myc expression in a CBF1-independent manner.,0.02,PMID.dPMID18490439.s8.p5,4,3,YY1|c-myc|c-myc|CBF1,CBF1|c-myc|YY1,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20446924,RBP-Jkappa,p53,"Our reports, here and previously published, show that repression of p53 by RBP-Jkappa and activation of p53 by C/EBPbeta through differential binding of these two factors indicates a type of co-operative regulation in p53 expression.",0.24,PMID.dPMID20446924.s1.p0,5,3,p53|RBP-Jkappa|p53|C/EBPbeta|p53,C/EBPbeta|p53|RBP-Jkappa,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,2.3.5.0.49,59269,9606,GO:0016563,GO:0045941,15367343,RBP-J,KBP1,Effect of KyoT2 binding protein KBP1 on RBP-J-mediated transcriptional activity  AIM: To investigate the physical interaction between KyoT2 and KyoT2-binding protein 1 (KBP1) and the effect of KBP1 on RBP-J-mediated transcriptional activity.,0.99,PMID.dPMID15367343.s3.p9,5,2,KBP1|RBP-J|KBP1|KBP1|RBP-J,KBP1|RBP-J,
6.1.4.1.1,3516,9606,,GO:0007221|GO:0045892,2.3.5.0.49,59269,9606,GO:0016563,GO:0045941,15367343,RBP-J,KBP1,Effect of KyoT2 binding protein KBP1 on RBP-J-mediated transcriptional activity  AIM: To investigate the physical interaction between KyoT2 and KyoT2-binding protein 1 (KBP1) and the effect of KBP1 on RBP-J-mediated transcriptional activity.,0.51,PMID.dPMID15367343.s3.p0,5,2,KBP1|RBP-J|KBP1|KBP1|RBP-J,KBP1|RBP-J,
2.2.3.0.1,3642,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,12890672,IA-1,NeuroD1,"NeuroD1/E47 regulates the E-box element of a novel zinc finger transcription factor, IA-1, in developing nervous system.",0.17,PMID.dPMID12890672.s6.p0,2,2,NeuroD1|IA-1,IA-1|NeuroD1,
3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,16282329,PDX-1,Foxo1,"Furthermore, adenovirus-mediated Foxo1 overexpression reduced the nuclear expression of PDX-1, whereas repression of Foxo1 by Foxo1-specific small interfering RNA retained the nuclear expression of PDX-1 under oxidative stress conditions.",1.01,PMID.dPMID16282329.s1.p8,5,2,Foxo1|PDX-1|Foxo1|Foxo1|PDX-1,Foxo1|PDX-1,
3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,20353756,PDX-1,FoxO1,"On the contrary, the forkhead transcription factor FoxO1 inhibits PDX-1 gene transcription.",0.39,PMID.dPMID20353756.s8.p0,2,2,FoxO1|PDX-1,FoxO1|PDX-1,
3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,17007882,PDX-1,Transcription factor,BACKGROUND: Transcription factor PDX-1 is expressed by human pancreatic and breast cancers.,0.45,PMID.dPMID17007882.s15.p0,2,2,Transcription factor|PDX-1,PDX-1|Transcription factor,<--
3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,19065104,PDX-1,TTF-1,"All rectal carcinoids were negative for CDX-2 and TTF-1; 2/12 were positive for PDX-1, and 1/12 for NESP-55.",0.10,PMID.dPMID19065104.s6.p2,3,3,CDX-2|TTF-1|PDX-1,CDX-2|PDX-1|TTF-1,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,9181476,IRF-1,IRF-2,"Two well-studied members of this family, IRF-1 and IRF-2, have antagonistic roles in interferon-beta gene regulation: IRF-1 activates this gene, and IRF-2 represses the activation by IRF-1, IRF-1 and IRF-2 have more recently been linked to growth control by displaying tumor suppressor and oncogenic activities, respectively.",0.76,PMID.dPMID9181476.s2.p9,7,2,IRF-1|IRF-2|IRF-1|IRF-2|IRF-1|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,7687740,IRF-1,IRF-2,"IRF-1 functions as a transcriptional activator, while IRF-2 represses IRF-1 function.",0.74,PMID.dPMID7687740.s7.p2,3,2,IRF-1|IRF-2|IRF-1,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,9540062,IRF-1,IRF-2,We also analyzed the effect of over-expressing IRF-2 on CAT reporter gene expression driven by mutant H4 promoters and assessed H4 transcriptional control in cells nullizygous for IRF-1 and IRF-2.,0.73,PMID.dPMID9540062.s5.p1,4,3,IRF-2|CAT|IRF-1|IRF-2,CAT|IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,10609788,IRF-1,IRF-2,The structurally related IRF-2 represses the effects of IRF-1 by competitive binding to the same DNA sequence elements.,0.65,PMID.dPMID10609788.s5.p0,2,2,IRF-2|IRF-1,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,7507207,IRF-1,IRF-2,"Interestingly, one IRF binding site was found within the IRF-2 promoter, and expression of the IRF-2 gene was affected by both transient and stable IRF-1 expression.",0.62,PMID.dPMID7507207.s2.p5,4,3,IRF|IRF-2|IRF-2|IRF-1,IRF|IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,9181476,IRF-1,IRF-2,"Two well-studied members of this family, IRF-1 and IRF-2, have antagonistic roles in interferon-beta gene regulation: IRF-1 activates this gene, and IRF-2 represses the activation by IRF-1, IRF-1 and IRF-2 have more recently been linked to growth control by displaying tumor suppressor and oncogenic activities, respectively.",0.60,PMID.dPMID9181476.s2.p13,7,2,IRF-1|IRF-2|IRF-1|IRF-2|IRF-1|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,17363571,IRF-1,IRF-2,"Additionally, high levels of IRF-2 blocked the function of IRF-1 by preventing the latter from translocating into the nucleus; in contrast, knock down of IRF-2 by small interfering RNA permitted nuclear localization and activity of IRF-1.",0.56,PMID.dPMID17363571.s4.p5,4,2,IRF-2|IRF-1|IRF-2|IRF-1,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,10321737,IRF-1,IRF-2,"Therefore, the induction of IRF-1 by IFNs or other stimuli acts as a transactivator of genes involved in cell growth regulation, as well as of its own repressor IRF-2, thus providing autoinhibitory regulation of IRF-1 activated genes",0.47,PMID.dPMID10321737.s0.p2,3,2,IRF-1|IRF-2|IRF-1,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,9181476,IRF-1,IRF-2,"Two well-studied members of this family, IRF-1 and IRF-2, have antagonistic roles in interferon-beta gene regulation: IRF-1 activates this gene, and IRF-2 represses the activation by IRF-1, IRF-1 and IRF-2 have more recently been linked to growth control by displaying tumor suppressor and oncogenic activities, respectively.",0.47,PMID.dPMID9181476.s2.p11,7,2,IRF-1|IRF-2|IRF-1|IRF-2|IRF-1|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,9204971,IRF1,IRF2,"IRF1 functions as an activator for IFN and IFN-inducible genes, whereas IRF2 represses the action of IRF1.",0.40,PMID.dPMID9204971.s9.p2,3,2,IRF1|IRF2|IRF1,IRF1|IRF2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,9181476,IRF-1,IRF-2,"Two well-studied members of this family, IRF-1 and IRF-2, have antagonistic roles in interferon-beta gene regulation: IRF-1 activates this gene, and IRF-2 represses the activation by IRF-1, IRF-1 and IRF-2 have more recently been linked to growth control by displaying tumor suppressor and oncogenic activities, respectively.",0.36,PMID.dPMID9181476.s2.p7,7,2,IRF-1|IRF-2|IRF-1|IRF-2|IRF-1|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,18395009,IRF-1,IRF-2,"Interferon regulatory factor-2 (IRF-2), an antagonistic transcriptional repressor of IRF-1, evidences oncogenic potential, but little is currently known regarding the mechanism underlying the oncogenic activities of IRF-2.",0.31,PMID.dPMID18395009.s4.p0,3,2,IRF-2|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,2208287,IRF-1,IRF-2,"Furthermore, cDNA-directed IRF-1 produced in undifferentiated but not differentiated EC cells efficiently activates the transfected IFN-alpha and IFN-beta and endogenous IFN-alpha genes, whereas IRF-2 represses the IRF-1 effects.",0.25,PMID.dPMID2208287.s2.p14,6,4,IRF-1|IFN-alpha|IFN-beta|IFN-alpha|IRF-2|IRF-1,IFN-alpha|IFN-beta|IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,1630448,IRF-1,IRF-2,"Studies have shown that IRF-2 can block the activity of the transcriptional activator IRF-1, which also binds specifically to the IFN-beta gene promoter.",0.16,PMID.dPMID1630448.s1.p0,3,3,IRF-2|IRF-1|IFN-beta,IFN-beta|IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,16241857,IRF-1,IRF-2,"Further, tumors maintained expression of IRF-2 if there was coincident expression of IRF-1.",0.12,PMID.dPMID16241857.s1.p0,2,2,IRF-2|IRF-1,IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,7507207,IRF-1,IRF-2,"Interestingly, one IRF binding site was found within the IRF-2 promoter, and expression of the IRF-2 gene was affected by both transient and stable IRF-1 expression.",0.08,PMID.dPMID7507207.s2.p4,4,3,IRF|IRF-2|IRF-2|IRF-1,IRF|IRF-1|IRF-2,
3.5.3.0.1,3659,9606,,,3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,11524479,IRF-1,IRF-7,CONCLUSION: A preferential induction of IRF-7 in IFN beta-treated astrocytes and a predominant expression of IRF-1 in IFN gamma-exposed astrocytes might contribute to one of the molecular mechanisms underlying the clinically opposite effects of IFN beta and IFN gamma in MS,0.38,PMID.dPMID11524479.s0.p0,2,2,IRF-7|IRF-1,IRF-1|IRF-7,-->
3.5.3.0.1,3659,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,10739671,IRF-1,c-myb,"Together, these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which IRF-1 negatively regulates c-myb expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing",0.44,PMID.dPMID10739671.s0.p9,6,2,IRF-1|c-myb|IRF-1|c-myb|IRF-1|c-myb,c-myb|IRF-1,-->
3.5.3.0.1,3659,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,10739671,IRF-1,c-myb,"Together, these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which IRF-1 negatively regulates c-myb expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing",0.17,PMID.dPMID10739671.s0.p7,6,2,IRF-1|c-myb|IRF-1|c-myb|IRF-1|c-myb,c-myb|IRF-1,-->
3.5.3.0.1,3659,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,14576323,MAR,c-myc,The c-myc MAR is also matrix-associated in CEM cells while localizing to loop DNA in WI-38 cells.,0.54,PMID.dPMID14576323.s2.p0,2,2,c-myc|MAR,c-myc|MAR,
3.5.3.0.1,3659,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11739238,IRF-1,NFkappaB,These studies show that NFkappaB plays an important role in the regulation of IRF-1 induction in HUVECs.,0.32,PMID.dPMID11739238.s1.p0,2,2,NFkappaB|IRF-1,IRF-1|NFkappaB,
3.5.3.0.1,3659,9606,,,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,14656743,IRF-1,PPARgamma,"METHODS AND RESULTS: Using Northern and Western blot analyses, we documented that PPARgamma ligands, including ciglitazone, troglitazone, and GW7845, significantly increased IRF-1 expression in VSMCs; however, the PPARalpha ligand (Wy14643) and PPARdelta ligand (GW0742) did not affect its expression.",1.33,PMID.dPMID14656743.s5.p0,4,4,PPARgamma|IRF-1|PPARalpha|PPARdelta,IRF-1|PPARalpha|PPARdelta|PPARgamma,
3.5.3.0.1,3659,9606,,,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,14656743,IRF-1,PPARgamma,PPARgamma-induced IRF-1 expression was abrogated by pretreatment with the PPARgamma antagonist GW9662.,1.15,PMID.dPMID14656743.s4.p0,3,2,PPARgamma|IRF-1|PPARgamma,IRF-1|PPARgamma,
3.5.3.0.1,3659,9606,,,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,14656743,IRF-1,PPARgamma,"In contrast, adenoviral expression of PPARgamma in VSMCs dramatically increased IRF-1 level.",0.74,PMID.dPMID14656743.s3.p0,2,2,PPARgamma|IRF-1,IRF-1|PPARgamma,
3.5.3.0.1,3659,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,17202361,IRF1,STAT3,"Thus, STAT3 also plays a role in the recruitment of the transcriptional activators p65 and IRF1, and the displacement of the transcriptional repressors p50 and IRF2 from the CXCL11 promoter also appears to regulate the induction of CXCL11 gene transcription",0.04,PMID.dPMID17202361.s0.p1,6,5,STAT3|p65|IRF1|IRF2|CXCL11|CXCL11,CXCL11|IRF1|IRF2|p65|STAT3,<--
3.5.3.0.1,3659,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12732645,IRF1,tumor suppressor p53,"For comparison, the tumor suppressor p53 represses CDK2 promoter activity independently of IRF1 through sequences upstream of nt -68, and the CDP/cut/Cux1 homeodomain protein represses transcription down-stream of -31.",0.13,PMID.dPMID12732645.s6.p1,3,3,tumor suppressor p53|CDK2|IRF1,CDK2|IRF1|tumor suppressor p53,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,2.3.5.0.48,639,9606,,GO:0000122,1630448,IRF-2,PRDI-BFi,"Although the affinity of PRDI-BFc/IRF-2 for the IFN-beta promoter does not appear to be affected by the removal of C-terminal amino acids, the ability of PRDI-BFi to function as a repressor in cotransfection experiments is significantly less than that of intact IRF-2.",0.01,PMID.dPMID1630448.s2.p5,4,3,IRF-2|IFN-beta|PRDI-BFi|IRF-2,IFN-beta|IRF-2|PRDI-BFi,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,9054665,IRF-2,IRF-1,"In addition, IRF-1 activates the expression of IRF-2, a negative regulator of the type I interferon genes themselves.",1.60,PMID.dPMID9054665.s3.p0,2,2,IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,10321737,IRF-2,IRF-1,IRF-1 also induced expression of its homologous repressor IRF-2 as indicated by EMSA analysis using an IRF-E probe from the IRF-2 promoter; and by cotransfection of IRF-1 together with an IRF-2 promoter CAT construct.,1.59,PMID.dPMID10321737.s1.p0,6,3,IRF-1|IRF-2|IRF|IRF-2|IRF-1|IRF-2,IRF|IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,9181476,IRF-2,IRF-1,"Two well-studied members of this family, IRF-1 and IRF-2, have antagonistic roles in interferon-beta gene regulation: IRF-1 activates this gene, and IRF-2 represses the activation by IRF-1, IRF-1 and IRF-2 have more recently been linked to growth control by displaying tumor suppressor and oncogenic activities, respectively.",0.75,PMID.dPMID9181476.s2.p17,7,2,IRF-1|IRF-2|IRF-1|IRF-2|IRF-1|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,11559933,IRF2,IRF1,Alterations in IRF1/IRF2 expression in acute myelogenous leukemia.,0.65,PMID.dPMID11559933.s6.p0,2,2,IRF1|IRF2,IRF1|IRF2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,17073600,IRF2,IRF1,It appears that the tumour suppression function of IRF1 is abolished by IRF2.,0.59,PMID.dPMID17073600.s2.p0,2,2,IRF1|IRF2,IRF1|IRF2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,10321737,IRF-2,IRF-1,IRF-1 also induced expression of its homologous repressor IRF-2 as indicated by EMSA analysis using an IRF-E probe from the IRF-2 promoter; and by cotransfection of IRF-1 together with an IRF-2 promoter CAT construct.,0.48,PMID.dPMID10321737.s1.p3,6,3,IRF-1|IRF-2|IRF|IRF-2|IRF-1|IRF-2,IRF|IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,10321737,IRF-2,IRF-1,"Therefore, the induction of IRF-1 by IFNs or other stimuli acts as a transactivator of genes involved in cell growth regulation, as well as of its own repressor IRF-2, thus providing autoinhibitory regulation of IRF-1 activated genes",0.43,PMID.dPMID10321737.s0.p0,3,2,IRF-1|IRF-2|IRF-1,IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,17363571,IRF-2,IRF-1,"In our present work, IRF-1 expression was decreased and IRF-2 expression was increased in ESCCs compared with matched normal esophageal tissues.",0.25,PMID.dPMID17363571.s8.p0,2,2,IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,17073600,IRF2,IRF1,IRF1 acts to repress IRF2 function through the repression of cyclin-dependent kinase (CDK) inhibitor p21WAF1 critical for cell growth control.,0.13,PMID.dPMID17073600.s3.p0,2,2,IRF1|IRF2,IRF1|IRF2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,9181476,IRF-2,IRF-1,"Two well-studied members of this family, IRF-1 and IRF-2, have antagonistic roles in interferon-beta gene regulation: IRF-1 activates this gene, and IRF-2 represses the activation by IRF-1, IRF-1 and IRF-2 have more recently been linked to growth control by displaying tumor suppressor and oncogenic activities, respectively.",0.12,PMID.dPMID9181476.s2.p15,7,2,IRF-1|IRF-2|IRF-1|IRF-2|IRF-1|IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,3.5.3.0.1,3659,9606,,,8625321,IRF-2,IRF-1,The transcriptional activator IFN regulatory factor 1 (IRF-1) and its antagonistic repressor IRF-2 are regulators of the IFN system.,0.01,PMID.dPMID8625321.s5.p0,2,2,IRF-1|IRF-2,IRF-1|IRF-2,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18395009,IRF-2,RelA,"While the nuclear recruitment of RelA by IRF-2 augments TNFalpha-induced NF-kappaB dependent transcription, the N-terminal truncated mutant form of IRF-2 inhibits the nuclear localization of RelA, and thus interferes with NF-kappaB activation.",0.19,PMID.dPMID18395009.s2.p0,4,2,RelA|IRF-2|IRF-2|RelA,IRF-2|RelA,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,6.2.1.0.1,6772,9606,,,15778351,IRF-2,STAT1,Interaction of IRF-2 and STAT1 on the promoter depends on the DNA-binding domain of IRF-2.,0.03,PMID.dPMID15778351.s1.p2,3,2,IRF-2|STAT1|IRF-2,IRF-2|STAT1,
3.5.3.0.2,3660,9606,GO:0003702,GO:0000122|GO:0045449,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,17202361,IRF2,STAT3,"Thus, STAT3 also plays a role in the recruitment of the transcriptional activators p65 and IRF1, and the displacement of the transcriptional repressors p50 and IRF2 from the CXCL11 promoter also appears to regulate the induction of CXCL11 gene transcription",0.04,PMID.dPMID17202361.s0.p3,6,5,STAT3|p65|IRF1|IRF2|CXCL11|CXCL11,CXCL11|IRF1|IRF2|p65|STAT3,
3.5.3.0.3,3661,9606,GO:0003702,,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,10848607,IRF-3,ATF-2,We demonstrate that correct orientation of the ATF-2-c-jun binding site is required for virus induction of the IFN-beta gene and for IRF-3-dependent activation of a composite ATF-2- c-jun-IRF site in the IFN-beta promoter.,0.04,PMID.dPMID10848607.s4.p1,5,3,ATF-2|IFN-beta|IRF-3|ATF-2|IFN-beta,ATF-2|IFN-beta|IRF-3,
3.5.3.0.4,3662,9606,GO:0003702|GO:0016563,GO:0045941,6.1.1.2.3,5966,9606,,,17138822,IRF-4,c-Rel,"Elevated expression of the putative c-Rel target, interferon regulatory factor-4 (IRF-4), was observed in 10 (91%) of 11 nonresponders and in all tested patients with c-Rel+ tumors and occurred in the absence of the HTLV-1 oncoprotein Tax.",0.11,PMID.dPMID17138822.s5.p0,3,2,c-Rel|IRF-4|c-Rel,c-Rel|IRF-4,<--
3.5.3.0.4,3662,9606,GO:0003702|GO:0016563,GO:0045941,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,16428437,IRF-4,E2A,"In the absence of E2A, increased IRF-4 expression is not sufficient to promote Igkappa enhancer chromatin modification or transcription, suggesting that the sequential involvement of IRF-4 and E2A is necessary for the activation of the Igkappa locus.",1.01,PMID.dPMID16428437.s1.p0,4,3,E2A|IRF-4|IRF-4|E2A,E2A|IRF-4,
3.5.3.0.4,3662,9606,GO:0003702|GO:0016563,GO:0045941,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,16428437,IRF-4,E2A,"Furthermore, we show that increased E2A recruitment to kappaEi and kappaE3' correlates with activation of Igkappa in pre-B cells and that recruitment of E2A to kappaE3' is in part dependent on the transcription factor IRF-4.",0.12,PMID.dPMID16428437.s3.p2,3,2,E2A|E2A|IRF-4,E2A|IRF-4,
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,3.5.3.0.1,3659,9606,,,19433065,IRF-7,IRF-1,"In monocytic U937 cells, IRF-1 is activated by IFN-gamma but not by IFN-alpha/beta, whereas it is the reverse for IRF-7; in the latter cells, only IFN-gamma is capable of stimulating CD80 transcription emphasizing the essential role of IRF-1.",0.01,PMID.dPMID19433065.s3.p1,6,4,IRF-1|IFN-gamma|IRF-7|IFN-gamma|CD80|IRF-1,CD80|IFN-gamma|IRF-1|IRF-7,<--
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,3.5.3.0.3,3661,9606,GO:0003702,,19349300,IRF7,IRF-3,"Nucleotide substitutions in the C modules of other IFN-A genes disrupt IRF-3-mediated transcription, whereas a G/A substitution in the D modules enhances IRF7-mediated expression.",1.54,PMID.dPMID19349300.s3.p0,2,2,IRF-3|IRF7,IRF-3|IRF7,<--
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,3.5.3.0.3,3661,9606,GO:0003702,,14668346,IRF-7,IRF-3,Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7.,0.68,PMID.dPMID14668346.s12.p1,3,2,IRF-3|IRF-3|IRF-7,IRF-3|IRF-7,<--
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,3.5.3.0.3,3661,9606,GO:0003702,,11222729,IRF-7,IRF-3,"While the expression of IRF-3 alone was shown to be sufficient for induction of the IFNB gene, induction of all the IFNA subtypes in human cells required the presence of IRF-7.",0.50,PMID.dPMID11222729.s4.p1,3,3,IRF-3|IFNB|IRF-7,IFNB|IRF-3|IRF-7,<--
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,3.5.3.0.3,3661,9606,GO:0003702,,10924517,IRF-7,IRF-3,"Previous studies indicated that the virus-mediated transcription of type I interferon (IFN) genes required activation of two members of IFN regulatory factor (IRF) family, IRF-3 and IRF-7, where the expression of IRF-7 was found to be indispensable for the induction of IFNA genes.",0.34,PMID.dPMID10924517.s8.p13,7,4,IFN|IFN|IRF|IRF-3|IRF-7|IRF-7|IFN,IFN|IRF|IRF-3|IRF-7,<--
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11711629,IRF-7,NF-kappaB,"A superrepressor of IkappaB (sr-IkappaB) could block the induction of IRF-7 by LMP-1, and overexpression of NF-kappaB (p65 plus p50) could induce the expression of IRF-7.",0.71,PMID.dPMID11711629.s1.p5,4,3,IRF-7|LMP|NF-kappaB|IRF-7,IRF-7|LMP|NF-kappaB,<--
3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,6.2.1.0.1,6772,9606,,,16628196,IRF-7,STAT1,"Furthermore, STAT1-SOCS1 regulated poly(I:C)-induced TLR3 and IRF-7 expression.",0.82,PMID.dPMID16628196.s2.p3,4,4,STAT1|SOCS1|TLR3|IRF-7,IRF-7|SOCS1|STAT1|TLR3,<--
3.1.5.1.1,3670,9606,GO:0003702,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,18374087,Isl-1,Beta2,"mRNA expression for NeuroD/Beta2, Isl-1, Ras, Metalloproteinase-2 (MMP-2), -9 and -7 also were affected, with PLL inducing increased expression of NeuroD/Beta2 of Isl-1, and no difference between C and control.",0.19,PMID.dPMID18374087.s3.p20,7,3,NeuroD|Beta2|Isl-1|MMP-2|NeuroD|Beta2|Isl-1,Beta2|Isl-1|MMP-2|NeuroD,
3.1.5.1.1,3670,9606,GO:0003702,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,18374087,Isl-1,NeuroD,"mRNA expression for NeuroD/Beta2, Isl-1, Ras, Metalloproteinase-2 (MMP-2), -9 and -7 also were affected, with PLL inducing increased expression of NeuroD/Beta2 of Isl-1, and no difference between C and control.",0.19,PMID.dPMID18374087.s3.p19,7,3,NeuroD|Beta2|Isl-1|MMP-2|NeuroD|Beta2|Isl-1,Beta2|Isl-1|MMP-2|NeuroD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,12799773,AP-1,AhR,These results suggest that AhR can stimulate AP-1 expression resulting in inhibition of the binding of AR to ARE in the transcription regulatory region of target genes such as PSA.,1.55,PMID.dPMID12799773.s0.p0,3,3,AhR|AP-1|PSA,AhR|AP-1|PSA,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.12.2,668,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0016481|GO:0045893|GO:0045944|GO:0051090,19797124,AP1,Foxl2,We conclude that ERalpha and Foxl2 interact and that Foxl2 selectively suppresses ERalpha-mediated transcription of AP1-regulated genes.,0.10,PMID.dPMID19797124.s1.p8,5,3,ERalpha|Foxl2|Foxl2|ERalpha|AP1,AP1|ERalpha|Foxl2,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,12944913,c-jun,AML1,These data suggest a model in which AML1-ETO induces proto-oncogene c-jun expression via the proximal AP-1 site of the c-jun promoter in a JNK-dependent manner,0.75,PMID.dPMID12944913.s0.p0,4,3,AML1|c-jun|c-jun|JNK,AML1|c-jun|JNK,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.1,1050,9606,,GO:0045945,12522006,c-Jun,C/EBPalpha,Activation of C/EBPalpha-ER specifically reduced endogenous JunB RNA and protein and exogenous JunB levels without affecting endogenous or exogenous c-Jun.,0.27,PMID.dPMID12522006.s5.p3,4,3,C/EBPalpha|JunB|JunB|c-Jun,C/EBPalpha|c-Jun|JunB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.1,1050,9606,,GO:0045945,12879022,c-Jun,C/EBPalpha,Inactivation of C/EBPalpha by c-Jun is necessary for c-Jun to induce proliferation because c-Jun-induced proliferation can be prevented by ectopic overexpression of C/EBPalpha.,0.01,PMID.dPMID12879022.s3.p1,5,2,C/EBPalpha|c-Jun|c-Jun|c-Jun|C/EBPalpha,C/EBPalpha|c-Jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.2,1051,9606,,,18367585,c-Jun,C/EBPbeta,"Individual gene knockdown experiments demonstrate the direct regulation of C/EBPbeta expression by c-Jun, and the critical roles of both c-Jun and C/EBPbeta in shear-induced COX-2 synthesis.",1.12,PMID.dPMID18367585.s3.p0,4,2,C/EBPbeta|c-Jun|c-Jun|C/EBPbeta,C/EBPbeta|c-Jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.2,1051,9606,,,18367585,c-Jun,C/EBPbeta,"Individual gene knockdown experiments demonstrate the direct regulation of C/EBPbeta expression by c-Jun, and the critical roles of both c-Jun and C/EBPbeta in shear-induced COX-2 synthesis.",0.66,PMID.dPMID18367585.s3.p1,4,2,C/EBPbeta|c-Jun|c-Jun|C/EBPbeta,C/EBPbeta|c-Jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.2,1051,9606,,,9566900,c-Jun,C/EBPbeta,Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun.,0.20,PMID.dPMID9566900.s13.p0,2,2,C/EBPbeta|c-Jun,C/EBPbeta|c-Jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.2,1051,9606,,,17348037,c-jun,LAP,"All three stimuli increased PGHS-2 and IL-8 mRNA expression in a MAPK-dependent manner, but while the MAPK inhibitors reduced the IL-1beta-induced activation of activating transcription factor (ATF)-2, liver activating protein (LAP) and c-jun, the stretch-induced increase in LAP was unaffected by MAPK-inhibition and only JNK inhibition appeared to reduce c-jun activation.",0.09,PMID.dPMID17348037.s1.p26,8,6,PGHS-2|IL-8|IL-1beta|LAP|c-jun|LAP|JNK|c-jun,c-jun|IL-1beta|IL-8|JNK|LAP|PGHS-2,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,15378003,c-Jun,KLF6,"Here, we demonstrate that KLF6 behaves as a functional antagonist of the c-Jun proto-oncoprotein.",0.25,PMID.dPMID15378003.s5.p0,2,2,KLF6|c-Jun,c-Jun|KLF6,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,15378003,c-Jun,KLF6,"Thus, KLF6 overexpression downregulated c-Jun-dependent transcription and a physical interaction between c-Jun and KLF6 was detected.",0.02,PMID.dPMID15378003.s4.p0,4,2,KLF6|c-Jun|c-Jun|KLF6,c-Jun|KLF6,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.1,1385,9606,,GO:0045944,10064599,c-Jun,CREB,"Similar to CREB-mediated transcription, activation of c-Jun-mediated transcription by calcium signals requires calcium/ calmodulin-dependent protein kinases and is dependent on CBP function.",0.47,PMID.dPMID10064599.s1.p0,3,3,CREB|c-Jun|CBP,CBP|c-Jun|CREB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.1,1385,9606,,GO:0045944,8647095,jun,CREB-1,"Since CREB-1 can repress transcription of other target genes (including c-jun) via association with identical cis-acting CRE-like sequences, we suggest that the mechanism for the transcriptional down-regulation of t-PA by PMA in HT-1080 cells requires CREB-1 binding to the t-PACRE while ATF-2, by associating with the same site, plays a role in PMA-mediated induction of t-PA in HeLa cells",0.07,PMID.dPMID8647095.s0.p0,8,5,CREB-1|jun|t-PA|HT-1080|CREB-1|t-PA|ATF-2|t-PA,ATF-2|CREB-1|HT-1080|jun|t-PA,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,10327051,c-jun,ATF2,"Here, we present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2: (1) Over-expression of p300 was found to stimulate c-jun transcription both in the presence and absence of E1A.",1.07,PMID.dPMID10327051.s4.p8,5,3,p300|c-jun|ATF2|p300|c-jun,ATF2|c-jun|p300,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,18641343,c-Jun,ATF-2,"Additionally, ATF-2 controls expression of CREB and c-Jun during T cell activation",0.93,PMID.dPMID18641343.s0.p1,3,3,ATF-2|CREB|c-Jun,ATF-2|c-Jun|CREB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,15640148,c-Jun,ATF-2,PGE2 suppression of IL-17-induced ATF-2/c-Jun transactivation and DNA binding was dependent on Egr-1-mediated inhibition of induced c-Jun expression.,0.58,PMID.dPMID15640148.s1.p3,4,3,ATF-2|c-Jun|Egr-1|c-Jun,ATF-2|c-Jun|Egr-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,12751796,c-jun,ATF2,"In transient transfection experiments, this constitutively active ATF2 mutant stimulated c-jun, tumor necrosis factor alpha, and Fas ligand promoter activities.",0.44,PMID.dPMID12751796.s2.p0,2,2,ATF2|c-jun,ATF2|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.11,1386,9606,GO:0003702,GO:0051090,7624151,c-Jun,ATF-2,"In addition, in vivo studies suggest that ATF-2 can mediate, at the same time, the activation of the c-Jun/ATF-2 site and the repression of the canonical collagenase AP-1 site.",0.41,PMID.dPMID7624151.s2.p0,3,2,ATF-2|c-Jun|ATF-2,ATF-2|c-Jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.3,1390,9606,,GO:0006355,15322221,AP-1,CREM,We conclude that CREM represses the expression of c-fos and limits the activity of the enhancer AP-1.,1.94,PMID.dPMID15322221.s1.p1,3,3,CREM|c-fos|AP-1,AP-1|c-fos|CREM,"[1385-->2353, 1386-->2353, 1390-->2353]"
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.3,1390,9606,,GO:0006355,1429597,c-Jun,CREM,"We also show that c-Fos does not affect the inhibitory function of CREM on c-Jun and that the transcriptional activation elicited by the other members of the jun family (JunB, JunD, and v-Jun) is also down-regulated by CREM",0.65,PMID.dPMID1429597.s0.p2,7,4,c-Fos|CREM|c-Jun|Jun|JunD|Jun|CREM,c-Fos|c-Jun|CREM|Jun|JunD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.3,1390,9606,,GO:0006355,1429597,c-Jun,CREM,In this report we show that CREM antagonists are able to block the transcriptional activation elicited by c-Jun.,0.50,PMID.dPMID1429597.s4.p0,2,2,CREM|c-Jun,c-Jun|CREM,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.2.0.3,1390,9606,,GO:0006355,1429597,Jun,CREM,"We also show that c-Fos does not affect the inhibitory function of CREM on c-Jun and that the transcriptional activation elicited by the other members of the jun family (JunB, JunD, and v-Jun) is also down-regulated by CREM",0.05,PMID.dPMID1429597.s0.p4,7,4,c-Fos|CREM|c-Jun|Jun|JunD|Jun|CREM,c-Fos|c-Jun|CREM|Jun|JunD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,8670069,AP-1,GADD153,Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element.,0.54,PMID.dPMID8670069.s12.p0,2,2,GADD153|AP-1,AP-1|GADD153,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,10697568,AP-1,gadd153,"These results indicate that the activation of AP-1 binding by taxotere seems to be an important factor in determining its sensitivity in association with internucleosomal DNA ladders, and suggest that the induction of gadd153 gene could be a downstream target of AP-1-regulated genes involved in signal transduction pathways leading to apoptosis in gastric cancer cells",0.36,PMID.dPMID10697568.s0.p2,3,2,AP-1|gadd153|AP-1,AP-1|gadd153,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,10523647,AP-1,CHOP,"Thus, CHOP not only is a negative or a positive regulator of C/EBP target genes but also, when tethered to AP-1 factors, can activate AP-1 target genes.",0.31,PMID.dPMID10523647.s1.p1,3,2,CHOP|AP-1|AP-1,AP-1|CHOP,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.2.1.2,1958,9606,,GO:0045941,15640148,c-Jun,Egr-1,PGE2 suppression of IL-17-induced ATF-2/c-Jun transactivation and DNA binding was dependent on Egr-1-mediated inhibition of induced c-Jun expression.,0.69,PMID.dPMID15640148.s1.p5,4,3,ATF-2|c-Jun|Egr-1|c-Jun,ATF-2|c-Jun|Egr-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.2.1.2,1958,9606,,GO:0045941,19837979,JUN,EGR-1,"EGR-1 knockdown in MM cells abrogated JUN overexpression-induced MM cell death and growth inhibition, indicating that EGR-1 acts directly downstream of JUN.",0.13,PMID.dPMID19837979.s3.p5,4,2,EGR-1|JUN|EGR-1|JUN,EGR-1|JUN,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.5.2.4.2,1999,9606,GO:0016563|GO:0016564,,12682075,c-Jun,ESE-1,"Although ESE-1 synergistically activated c-Jun- and PMA-enhanced SPRR1B transcription, coexpression of Sp1 and ESE-1 showed no synergistic or additive effect on promoter activity, indicating an obligatory role for AP-1 proteins in such regulation.",1.36,PMID.dPMID12682075.s2.p0,5,4,ESE-1|c-Jun|SPRR1B|Sp1|ESE-1,c-Jun|ESE-1|Sp1|SPRR1B,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,19797124,AP1,ERalpha,We conclude that ERalpha and Foxl2 interact and that Foxl2 selectively suppresses ERalpha-mediated transcription of AP1-regulated genes.,1.09,PMID.dPMID19797124.s1.p9,5,3,ERalpha|Foxl2|Foxl2|ERalpha|AP1,AP1|ERalpha|Foxl2,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,12554755,AP-1,ERalpha,"In the presence of estradiol, estrogen receptor-alpha (ERalpha) increases transcription triggered by activator protein-1 (AP-1).",0.22,PMID.dPMID12554755.s8.p0,2,2,ERalpha|AP-1,AP-1|ERalpha,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,15509581,AP-1,ER alpha,"Taken together, these studies have helped to delineate the roles of ER alpha and ER beta in modulating transcription of genes containing AP-1 and Sp1 sites and define the effects of widely used, pharmacologic agents in target cells with distinct cellular environments",0.10,PMID.dPMID15509581.s0.p0,3,3,ER alpha|AP-1|Sp1,AP-1|ER alpha|Sp1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,18607069,c-Jun,ERbeta,"The administration of ICI impeded the JNK1-ERbeta1 interaction, increased c-Jun phosphorylation and cyclin D1 expression and allowed the cells to progress to late G1, where they became arrested.",0.11,PMID.dPMID18607069.s1.p2,3,3,JNK1|ERbeta|c-Jun,c-Jun|ERbeta|JNK1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.5.2.1.2,2114,9606,,GO:0045893,20554528,c-Jun,Ets2,"MKP3 induction relied on the activation of the Ets2 transcription factor, whereas DUSP5 induction depended on the activation of c-Jun.",0.23,PMID.dPMID20554528.s3.p4,4,4,MKP3|Ets2|DUSP5|c-Jun,c-Jun|DUSP5|Ets2|MKP3,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.5.2.2.4,2115,9606,,,17634427,c-Jun,ETV1,"In this report, we show that c-Jun can mediate AR induction of ETV1 expression independent of c-Jun transactivation function.",0.11,PMID.dPMID17634427.s5.p2,3,2,c-Jun|ETV1|c-Jun,c-Jun|ETV1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,8512587,jun,ara,"Taken together, these results demonstrate that ara-C induces expression of the jun-D gene and that this effect is regulated by transcriptional and posttranscriptional mechanisms",1.36,PMID.dPMID8512587.s0.p0,2,2,ara|jun,ara|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,8058058,c-jun,ara,"The present studies have examined the effects of ara-C on c-jun expression in a phorbol ester-resistant variant of the HL-60 myeloid leukemia cell line, designated HL-525, that is deficient in protein kinase C (PKC)-mediated signal transduction and fails to respond to 12-O-tetradecanoylphorbol-13-acetate with induction of c-jun transcripts.",1.17,PMID.dPMID8058058.s7.p0,4,3,ara|c-jun|PKC|c-jun,ara|c-jun|PKC,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,2122229,jun,ara,"These results, thus, demonstrate that ara-C induces expression of the jun-B gene in KG-1 cells and that this effect is mediated by transcriptional and posttranscriptional mechanisms",0.94,PMID.dPMID2122229.s0.p0,2,2,ara|jun,ara|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1310062,c-jun,ara,Previous studies have shown that 1-beta-D-arabinofuranosylcytosine (ara-C) induces transcription of the c-jun immediate early response gene in human myeloid leukemia cells.,0.85,PMID.dPMID1310062.s11.p2,4,3,ara|ara|c-jun|early response,ara|c-jun|early response,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,2122980,c-jun,ara,This work examines the effects of ara-C on c-jun gene expression in human KG-1 myeloid leukemia cells.,0.78,PMID.dPMID2122980.s6.p0,2,2,ara|c-jun,ara|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1310062,c-jun,ara,The results demonstrate that ara-C-induced c-jun transcription is mediated by an element between positions -74 and -20 upstream to the start site.,0.67,PMID.dPMID1310062.s8.p0,2,2,ara|c-jun,ara|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1310062,c-jun,ara,Previous studies have shown that 1-beta-D-arabinofuranosylcytosine (ara-C) induces transcription of the c-jun immediate early response gene in human myeloid leukemia cells.,0.64,PMID.dPMID1310062.s11.p1,4,3,ara|ara|c-jun|early response,ara|c-jun|early response,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,8512587,jun,ara,The present studies demonstrate that 1-beta-D-arabinofuranosylcytosine (ara-C) increases jun-D expression in HL-525 myeloid leukemia cells.,0.47,PMID.dPMID8512587.s5.p2,3,2,ara|ara|jun,ara|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1996082,c-jun,Ara,"Whereas KG-1 cells displayed only barely detectable amounts of c-jun transcripts when cultured in the presence of serum, Ara-C at concentrations of 1 to 50 microM induced c-jun transcripts in a dose-dependent fashion.",0.41,PMID.dPMID1996082.s5.p2,3,2,c-jun|Ara|c-jun,Ara|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,2122229,jun,ara,"Moreover, cycloheximide prolonged the half-life of ara-C-induced jun-B transcripts.",0.35,PMID.dPMID2122229.s1.p0,2,2,ara|jun,ara|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,2122229,jun,ara,The present studies have examined the effects of 1-beta-D-arabinofuranosylcytosine (ara-C) on jun-B expression in human KG-1 myeloid leukemia cells.,0.26,PMID.dPMID2122229.s7.p2,3,2,ara|ara|jun,ara|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1996082,c-jun,Ara,Time course studies showed that 10 microM Ara-C induced c-jun transcripts 6 hr after initiation of culture.,0.18,PMID.dPMID1996082.s4.p0,2,2,Ara|c-jun,Ara|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,2122980,c-jun,ara,"Furthermore, transcriptional run-on analysis has demonstrated that exposure to ara-C increases the rate of c-jun gene transcription.",0.13,PMID.dPMID2122980.s3.p0,2,2,ara|c-jun,ara|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1310062,JUN,ara,The finding that ara-C induces AP-1 binding in the absence of protein synthesis indicated that this agent activates already synthesized JUN/AP-1.,0.05,PMID.dPMID1310062.s3.p0,2,2,ara|JUN,ara|JUN,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,2122229,jun,ara,The results also demonstrate that ara-C-induced jun-B mRNA levels are regulated by a posttranscriptional mechanism.,0.04,PMID.dPMID2122229.s3.p0,2,2,ara|jun,ara|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,8732670,c-jun,ara,They also raise the possibility that separate aspects of the antiproliferative actions of ara-C may be differentially regulated by c-jun,0.04,PMID.dPMID8732670.s0.p2,3,2,ara|ara|c-jun,ara|c-jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.2,2354,9606,,GO:0000122,9523591,jun,fosB,"Inhibition of protein kinase C with GF109203X suppressed the carbachol-stimulated increase in mRNA levels of c-fos, fosB, and junB by approximately 70% but had only minor effects on the expression of c-jun and junD.",0.53,PMID.dPMID9523591.s4.p7,5,3,c-fos|fosB|jun|c-jun|jun,c-fos|c-jun|fosB|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.2,2354,9606,,GO:0000122,16401477,AP-1,FosB,"Real-time reverse-transcription polymerase chain reaction and Western blot analyses revealed quantitative increases in c-Jun, JunB, JunD, and FosB expression associated with increased AP-1 activity.",0.44,PMID.dPMID16401477.s4.p5,4,4,JunB|JunD|FosB|AP-1,AP-1|FosB|JunB|JunD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.2,2354,9606,,GO:0000122,11150324,AP-1,Fos-B,Immunostaining showed an increase in the expression of the Fos-B and c-Jun components of AP-1 in the injured cord.,0.14,PMID.dPMID11150324.s8.p0,2,2,Fos-B|AP-1,AP-1|Fos-B,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.2,2354,9606,,GO:0000122,9523591,c-jun,fosB,"Inhibition of protein kinase C with GF109203X suppressed the carbachol-stimulated increase in mRNA levels of c-fos, fosB, and junB by approximately 70% but had only minor effects on the expression of c-jun and junD.",0.13,PMID.dPMID9523591.s4.p4,5,3,c-fos|fosB|jun|c-jun|jun,c-fos|c-jun|fosB|jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.4,2355,9606,,GO:0006357,18219112,c-Jun,Fra-2,"RESULTS: Starting in immortal stages c-Fos, Fra-2 and JunB expression became up regulated towards tumorigenicity, whereas Fra-1, c-Jun, Notch1, Net and CADM1 became down regulated.",0.06,PMID.dPMID18219112.s4.p4,6,6,c-Fos|Fra-2|JunB|c-Jun|Notch1|CADM1,CADM1|c-Fos|c-Jun|Fra-2|JunB|Notch1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.4,2355,9606,,GO:0006357,8723999,AP-1,Fra-2,The analysis and determination of the function of Fra-2 will provide further information on the role of AP-1,0.01,PMID.dPMID8723999.s0.p0,2,2,Fra-2|AP-1,AP-1|Fra-2,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.2.1.0.1,2623,9606,,GO:0006357,8423810,AP-1,GATA-1,"Thus, GATA-1 regulates the response of the epsilon-globin gene to enhancers through a specific site in the promoter and requires enhancer AP-1/NF-E2 binding to transduce the enhancer effect on transcription",0.22,PMID.dPMID8423810.s0.p1,3,3,GATA-1|epsilon-globin|AP-1,AP-1|epsilon-globin|GATA-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,19219074,JUN,GLI,Transcription of JUN is greatly enhanced in the presence of GLI and requires activated JUN protein.,0.35,PMID.dPMID19219074.s4.p2,3,2,JUN|GLI|JUN,GLI|JUN,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,19219074,JUN,GLI1,"Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis.",0.19,PMID.dPMID19219074.s6.p1,3,3,GLI1|GLI2|JUN,GLI1|GLI2|JUN,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.2.3.2,2736,9606,GO:0016563,GO:0000122|GO:0045944,19219074,JUN,GLI2,"Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis.",0.16,PMID.dPMID19219074.s6.p2,3,3,GLI1|GLI2|JUN,GLI1|GLI2|JUN,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,19738058,c-Jun,HIF-1alpha,The stabilization of HIF-1alpha was dependent on the domains of c-Jun for DNA binding and heterodimerization but independent of the Ser(63/73) phosphorylation that is critical for transcriptional function.,0.12,PMID.dPMID19738058.s1.p0,2,2,HIF-1alpha|c-Jun,c-Jun|HIF-1alpha,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,19131506,JUN,TCF,"Finally, overexpression of TCFDN attenuates GnRH regulation of Cga promoter activity, a known downstream target of JUN.",0.52,PMID.dPMID19131506.s1.p0,2,2,TCF|JUN,JUN|TCF,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,7758976,c-Jun,Id2A,"Sequences of the 5'-flanking region of the human helix-loop-helix protein-encoding Id2A gene, and promoter activity regulated by serum and c-Jun/AP-1.",0.26,PMID.dPMID7758976.s2.p2,3,3,helix-loop-helix protein|Id2A|c-Jun,c-Jun|helix-loop-helix protein|Id2A,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1336108,cJun,JunB,"In addition JunB is not an efficient activator of the cJun and collagenase promoters although both cJun and JunB exhibit similar DNA binding properties, indicating that the differences in biological activity is due to differences in their activation domains.",0.41,PMID.dPMID1336108.s3.p0,4,2,JunB|cJun|cJun|JunB,cJun|JunB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,16401477,AP-1,JunB,"Real-time reverse-transcription polymerase chain reaction and Western blot analyses revealed quantitative increases in c-Jun, JunB, JunD, and FosB expression associated with increased AP-1 activity.",0.26,PMID.dPMID16401477.s4.p3,4,4,JunB|JunD|FosB|AP-1,AP-1|FosB|JunB|JunD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1316480,Jun,JunB,"However, in nuclear extracts prepared from human keratinocytes, JunB was the predominant Jun component bound to the DNA probe containing this cis element.",0.13,PMID.dPMID1316480.s1.p0,2,2,JunB|Jun,Jun|JunB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,8383624,c-Jun,JunB,"JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers.",0.08,PMID.dPMID8383624.s7.p0,3,2,JunB|c-Jun|c-Jun,c-Jun|JunB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,12052834,c-Jun,JunD,The JunD transcription factor is one member of the Jun family of proteins that also includes c-Jun and JunB.,0.17,PMID.dPMID12052834.s6.p0,2,2,JunD|c-Jun,c-Jun|JunD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1719551,AP-1,JunD,"We demonstrate that JunD, a component of the AP-1 transcription factor complex, activates transcription of the human proenkephalin gene in a fashion that is completely dependent upon the cAMP-dependent protein kinase, protein kinase A.",0.06,PMID.dPMID1719551.s5.p0,3,3,JunD|AP-1|proenkephalin,AP-1|JunD|proenkephalin,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,16401477,AP-1,JunD,"Real-time reverse-transcription polymerase chain reaction and Western blot analyses revealed quantitative increases in c-Jun, JunB, JunD, and FosB expression associated with increased AP-1 activity.",0.01,PMID.dPMID16401477.s4.p4,4,4,JunB|JunD|FosB|AP-1,AP-1|FosB|JunB|JunD,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,10871633,c-Jun,Smad3,"The repression obtained with a c-Jun mutant unable to activate transcription through AP-1 sites indicates that the inhibitory mechanism does not rely on the induction of a Smad3 repressor by c-Jun, suggesting that c-Jun could act as a Smad3 co-repressor.",1.19,PMID.dPMID10871633.s1.p2,5,2,c-Jun|Smad3|c-Jun|c-Jun|Smad3,c-Jun|Smad3,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,10220381,AP-1,Smad3,"Providing evidence for the importance of this interaction between Smad and Jun proteins, we demonstrate that Smad3 is required for the activation of concatamerized AP-1 sites in a reporter construct that has previously been characterized as unable to bind Smad proteins directly.",0.32,PMID.dPMID10220381.s1.p2,3,2,Jun|Smad3|AP-1,AP-1|Jun|Smad3,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,10995748,c-Jun,Smad3,Structural and functional characterization of the transforming growth factor-beta -induced Smad3/c-Jun transcriptional cooperativity.,0.20,PMID.dPMID10995748.s8.p0,2,2,Smad3|c-Jun,c-Jun|Smad3,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,10871633,c-Jun,Smad3,"The repression obtained with a c-Jun mutant unable to activate transcription through AP-1 sites indicates that the inhibitory mechanism does not rely on the induction of a Smad3 repressor by c-Jun, suggesting that c-Jun could act as a Smad3 co-repressor.",0.12,PMID.dPMID10871633.s1.p4,5,2,c-Jun|Smad3|c-Jun|c-Jun|Smad3,c-Jun|Smad3,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,18664273,AP1,Smad4,"RESULTS: Herein, we report that Smad4 mediates transcriptional regulation through three different mechanisms, namely through Smad4 binding to a functional SBE site exclusively in the LAMA3 promoter, Smad4 binding to AP1 (and Sp1) sites presumably via interaction with AP1 family components and lastly a Smad4 impact on transcription of AP1 factors.",0.34,PMID.dPMID18664273.s2.p35,9,4,Smad4|Smad4|LAMA3|Smad4|AP1|Sp1|AP1|Smad4|AP1,AP1|LAMA3|Smad4|Sp1,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.5.0.35,4150,9606,,,19028685,AP-1,SAF-1,We present evidence that knockdown of SAF-1 by small interfering RNAs inhibits AP-1-mediated increase of human MMP-1 expression.,0.71,PMID.dPMID19028685.s6.p0,3,3,SAF-1|AP-1|MMP-1,AP-1|MMP-1|SAF-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,5.1.1.1.1,4205,9606,,,20590529,c-Jun,MEF2A,"Interestingly, endogenous p300 only associates with MEF2A in differentiated macrophages, indicating that MEF2A/D could activate c-Jun expression in macrophages through a MEF2A/D-p300 activator complex.",1.48,PMID.dPMID20590529.s2.p5,6,3,p300|MEF2A|MEF2A|c-Jun|MEF2A|p300,c-Jun|MEF2A|p300,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,5.1.1.1.1,4205,9606,,,11877423,c-jun,MEF2A,Studying the c-jun enhancer in reporter gene assays we observed that the muscle transcription factors MEF2A and MyoD can contribute to robust transcriptional activation of the c-jun enhancer.,0.03,PMID.dPMID11877423.s4.p4,4,3,c-jun|MEF2A|MyoD|c-jun,c-jun|MEF2A|MyoD,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,9069290,c-jun,MEF2C,One consequence of MEF2C activation is increased c-jun gene transcription.,1.38,PMID.dPMID9069290.s1.p0,2,2,MEF2C|c-jun,c-jun|MEF2C,x
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9301678,c-jun,c-myc,"In contrast, exposure to 0.5 nM TPA decreased c-myc expression and increased c-jun transcripts only transiently between 4 and 8 h while little if any effect was detectable on c-fms mRNA expression and subsequent differentiation.",0.59,PMID.dPMID9301678.s1.p0,3,3,c-myc|c-jun|c-fms,c-fms|c-jun|c-myc,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1502888,c-jun,c-myc,There was no strong correlation between EGF-R/TGF-alpha and c-myc/c-jun expression,0.41,PMID.dPMID1502888.s0.p2,3,3,EGF-R|c-myc|c-jun,c-jun|c-myc|EGF-R,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15592835,c-jun,c-myc,"Salvicine induced a dose-dependent decrease in c-myc gene transcription, concomitant with an increase in c-jun expression.",0.37,PMID.dPMID15592835.s4.p0,2,2,c-myc|c-jun,c-jun|c-myc,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8462021,jun,c-myc,"The combined treatment of human myeloid leukemia cells by ara-C and LIF is associated with down-regulation of c-myc gene expression, transcriptional activation of jun/fos gene expression, and features of functional differentiation (e.g., the capability to reduce nitroblue tetrazolium, to express lysozyme, or to display differentiation-related surface receptors including C3bi and the c-fms protein).",0.33,PMID.dPMID8462021.s1.p2,5,5,LIF|c-myc|jun|lysozyme|c-fms,c-fms|c-myc|jun|LIF|lysozyme,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8422634,jun,myc,"The following results of messenger RNA analysis in ovarian cancer were observed: EGF-R, negative in 25%, low in 65%, and strongly positive in 10%; TGF-alpha, negative in 34%, low in 36%, and strongly positive in 30%; myc, negative in 8%, low in 64%, and strongly positive in 28%; jun, negative in 4%, low in 58%, and strong in 38%; and MT, low in 80% and strongly positive in 20%.",0.25,PMID.dPMID8422634.s6.p2,3,3,EGF-R|myc|jun,EGF-R|jun|myc,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1688596,c-jun,c-myc,"The expression of the c-myc, c-fos, c-jun, c-erbB, and c-Ha-ras protooncogenes was compared by Northern blot analysis of total RNA extracted from keratome biopsies of normal skin and psoriatic plaques.",0.17,PMID.dPMID1688596.s7.p1,4,4,c-myc|c-fos|c-jun|c-Ha-ras,c-fos|c-Ha-ras|c-jun|c-myc,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11457456,c-jun,c-myc,"Furthermore, the expression of some protooncogenes such as c-myc, c-fos and c-jun was examined, showing that salvicine produced a reduction in the transcription rate of c-myc in a dose-dependent manner and a marked induction of c-fos and c-jun expression was observed.",0.06,PMID.dPMID11457456.s1.p13,6,3,c-myc|c-fos|c-jun|c-myc|c-fos|c-jun,c-fos|c-jun|c-myc,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8746269,c-jun,c-myc,"However, an association was found between low c-myc expression (P = 0.0001) and high c-jun expression (P = 0.0001) and absence of tumoral response to neoadjuvant chemotherapy.",0.03,PMID.dPMID8746269.s7.p0,2,2,c-myc|c-jun,c-jun|c-myc,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.2.1.2,4656,9606,,GO:0010552,11753683,c-Jun,myogenin,"In addition, myogenin expression was a positive target of this cooperation and this regulation occurred through a stimulation of myogenin promoter activity: (1) whereas c-Fos or Fra2 co-expression abrogated c-Jun stimulatory activity on this promoter, ATF2 co-expression potentiated this influence; (2) using a dominant negative ATF2 mutant, we established that c-Jun transcriptional activity required functionality of endogenous ATF2.",0.02,PMID.dPMID11753683.s1.p6,6,4,myogenin|myogenin|c-Fos|Fra2|c-Jun|c-Jun,c-Fos|c-Jun|Fra2|myogenin,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,12176906,AP-1,NF-kappaB,"Bay 11-7082 rapidly and efficiently reduced the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulated the expression of the antiapoptotic gene, Bcl-x(L), regulated by NF-kappaB, whereas it had little effect on the DNA binding of another transcription factor, AP-1.",0.24,PMID.dPMID12176906.s3.p1,3,2,NF-kappaB|NF-kappaB|AP-1,AP-1|NF-kappaB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,9665319,AP-1,IkappaBalpha,"ETOH does not directly inhibit NFkappaB or AP-1, in vivo, but rather inhibits LPS-induced activation of the MEKK/MAP kinase system and inhibition of inhibitory protein IkappaBalpha required for formation of AP-1 and NFkappaB, respectively.",0.46,PMID.dPMID9665319.s7.p5,5,3,NFkappaB|AP-1|IkappaBalpha|AP-1|NFkappaB,AP-1|IkappaBalpha|NFkappaB,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.3.1.4,4807,9606,,,7758976,c-Jun,helix-loop-helix protein,"Sequences of the 5'-flanking region of the human helix-loop-helix protein-encoding Id2A gene, and promoter activity regulated by serum and c-Jun/AP-1.",0.03,PMID.dPMID7758976.s2.p1,3,3,helix-loop-helix protein|Id2A|c-Jun,c-Jun|helix-loop-helix protein|Id2A,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,17822788,AP-1,YB-1,YB-1 represses tumor promoter-induced MMP-13 promoter transactivation at the AP-1 site.,0.10,PMID.dPMID17822788.s1.p1,3,3,YB-1|MMP-13|AP-1,AP-1|MMP-13|YB-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10329471,AP1,RAR,"To gain insight into the molecular mechanism of RAR-AP1 interaction, we have identified the regions of the RAR required for AP1 antagonism.",0.60,PMID.dPMID10329471.s5.p5,4,2,RAR|AP1|RAR|AP1,AP1|RAR,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,9377582,c-jun,RAR,"Investigation of the RAR and retinoic acid X receptor expression level demonstrated that RAR alpha and RAR gamma RNA expression was reduced in the c-jun-transfected MCF7 cells, whereas RAR beta expression was up-regulated.",0.33,PMID.dPMID9377582.s3.p4,5,2,RAR|RAR|RAR|c-jun|RAR,c-jun|RAR,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10329471,AP1,RAR,Some of the therapeutic actions of retinoids can be ascribed to retinoic acid receptor (RAR)-mediated antagonism of AP1-dependent gene expression.,0.23,PMID.dPMID10329471.s8.p0,2,2,RAR|AP1,AP1|RAR,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,9377582,c-jun,RAR,"Investigation of the RAR and retinoic acid X receptor expression level demonstrated that RAR alpha and RAR gamma RNA expression was reduced in the c-jun-transfected MCF7 cells, whereas RAR beta expression was up-regulated.",0.08,PMID.dPMID9377582.s3.p5,5,2,RAR|RAR|RAR|c-jun|RAR,c-jun|RAR,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.2,5915,9606,,GO:0034339,12123542,AP-1,RARbeta,"RESULTS: Transient transfection of RARbeta expression vector into MKN-45 cells resulted in the RARbeta concentration dependent repression of AP-1 activity induced by 12-o-tetradecanoylphorbol-13-acetate (TPA), regardless of the presence of ATRA.",0.47,PMID.dPMID12123542.s5.p2,3,2,RARbeta|RARbeta|AP-1,AP-1|RARbeta,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.2,5915,9606,,GO:0034339,12009305,AP-1,RARbeta,This indicates the necessity for sufficient cellular RARalpha and/or RARbeta in order for AP-1 activity repression to occur.,0.05,PMID.dPMID12009305.s3.p2,3,3,RARalpha|RARbeta|AP-1,AP-1|RARalpha|RARbeta,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.1.2,5915,9606,,GO:0034339,12009305,AP-1,RARbeta,"Transient transfection of RARbeta expression vector into MKN-45 cells significantly resulted in direct repression of AP-1 activity in a receptor concentration-dependent manner, and this could be strengthened by ATRA.",0.01,PMID.dPMID12009305.s8.p0,2,2,RARbeta|AP-1,AP-1|RARbeta,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.1.1.2.3,5966,9606,,,20562914,c-Jun,c-Rel,The inability of c-Rel to induce the expression of c-Fos and c-Jun contributes to its weaker oncogenic potential relative to v-Rel.,1.19,PMID.dPMID20562914.s5.p1,3,3,c-Rel|c-Fos|c-Jun,c-Fos|c-Jun|c-Rel,x
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.1.1.2.3,5966,9606,,,8920856,AP-1,c-Rel,"In Jurkat TAg cells, overexpression of c-Rel increased AP-1 activation approximately 17-fold.",0.48,PMID.dPMID8920856.s5.p0,2,2,c-Rel|AP-1,AP-1|c-Rel,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15509581,AP-1,Sp1,"The ability of ligands to modulate transcription of AP-1- or Sp1-containing promoters was dependent on cell context, but the expression of AP-1 or Sp1 proteins was not necessarily related to transcriptional response.",0.28,PMID.dPMID15509581.s1.p2,4,2,AP-1|Sp1|AP-1|Sp1,AP-1|Sp1,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,8649405,c-jun,Sp1,In vitro DNase I footprinting analysis with purified Sp1 and c-jun proteins showed that Sp1 binding could facilitate binding of c-jun.,0.28,PMID.dPMID8649405.s1.p5,4,2,Sp1|c-jun|Sp1|c-jun,c-jun|Sp1,<--
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,10501656,AP-1,SPR1,"AP-1 is the cis element mediating the transcriptional activation of SPR1 by PMA, which induces the expression of AP-1 factors in 21MT-2 cells.",0.23,PMID.dPMID10501656.s3.p2,3,2,AP-1|SPR1|AP-1,AP-1|SPR1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,16494848,AP-1,Stat3,"However, Stat3 does not bind to the MMP7 promoter, but activates MMP7 gene expression indirectly via AP-1.",0.05,PMID.dPMID16494848.s2.p3,4,3,Stat3|MMP7|MMP7|AP-1,AP-1|MMP7|Stat3,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,12907627,c-Jun,Transcription factor,Transcription factor c-Jun activation represses mdr-1 gene expression.,0.00,PMID.dPMID12907627.s15.p0,3,3,Transcription factor|c-Jun|mdr-1,c-Jun|mdr-1|Transcription factor,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.6.1.0.1,7003,9606,,,11118054,AP-1,Ref-1,"In this study, the role of TRX and Ref-1 in the activation of the AP-1 complex was examined in HeLa and Jurkat cell lines exposed to ionizing radiation (IR).",0.28,PMID.dPMID11118054.s7.p0,2,2,Ref-1|AP-1,AP-1|Ref-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19584293,c-Jun,p53,"Furthermore, induction of p53 by p38 was dependent on c-Jun down-regulation.",0.92,PMID.dPMID19584293.s3.p1,3,3,p53|p38|c-Jun,c-Jun|p38|p53,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11325852,c-jun,p53,"Nonetheless, the ligation-mediated PCR technology was used here to demonstrate, at nucleotide resolution, that p53-/-p21+/+ DLD1 excises UVB-induced cyclobutane pyrimidine dimers from the c-jun proto-oncogene at a significantly lower rate than the isogenic p53-/-p21-/- derivative.",0.86,PMID.dPMID11325852.s2.p1,5,3,p53|p21|c-jun|p53|p21,c-jun|p21|p53,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18094076,c-Jun,p53,"In KB-3 cells, which have compromised p53 function, and in p53-null cells but not in p53 wild-type cells, vinblastine caused down-regulation of p21 expression concomitant with increased c-Jun expression, suggesting a role for c-Jun in negative regulation of the p21 promoter independent of p53.",0.33,PMID.dPMID18094076.s1.p4,6,2,p53|p53|p53|c-Jun|c-Jun|p53,c-Jun|p53,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18094076,c-Jun,p53,"In KB-3 cells, which have compromised p53 function, and in p53-null cells but not in p53 wild-type cells, vinblastine caused down-regulation of p21 expression concomitant with increased c-Jun expression, suggesting a role for c-Jun in negative regulation of the p21 promoter independent of p53.",0.28,PMID.dPMID18094076.s1.p5,6,2,p53|p53|p53|c-Jun|c-Jun|p53,c-Jun|p53,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18448277,c-Jun,p53,"Inhibition of p53 by either its inhibitor pifithrin-alpha or p53 siRNA markedly increased B(a)P-induced the activation of c-Jun, Akt and ERK in this context.",0.05,PMID.dPMID18448277.s1.p1,5,4,p53|p53|c-Jun|Akt|ERK,Akt|c-Jun|ERK|p53,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12775760,c-jun,p53,"Indeed, relative to an isogenic p53 wild-type counterpart, p53-deficient human lymphoblastoid strains were shown to remove CPD significantly less efficiently along both the transcribed and nontranscribed strands of the c-jun and hprt loci after exposure to polychromatic UVB (290-320 nm).",0.05,PMID.dPMID12775760.s3.p2,3,2,p53|p53|c-jun,c-jun|p53,-->
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.7.0.2,7409,9606,,,10706671,AP-1,Vav,We show that WIP has the ability to enhance Vav-mediated activation of NF-AT/AP-1 gene transcription.,0.32,PMID.dPMID10706671.s3.p2,3,3,WIP|Vav|AP-1,AP-1|Vav|WIP,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8794287,AP-1,YY1,YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity.,1.03,PMID.dPMID8794287.s7.p0,2,2,YY1|AP-1,AP-1|YY1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8794287,AP-1,YY1,We also provide data demonstrating that YY1 can bind the transcriptional coactivator CREB-binding protein and propose a potentially novel mechanism by which YY1 represses AP-1 activity as a result of this YY1-CREB-binding protein interaction,0.70,PMID.dPMID8794287.s0.p5,6,3,YY1|CREB-binding protein|YY1|AP-1|YY1|CREB-binding protein,AP-1|CREB-binding protein|YY1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,20430007,AP-1,YY1,"Furthermore, the repressive effect of YY1 was more evident than NFI on the iNOS promoter activity, resulting in a more marked reduction of iNOS expression via YY1/AP-1 than via NFI/AP-1 under the stimulation of cytomix.",0.48,PMID.dPMID20430007.s1.p3,4,2,YY1|YY1|AP-1|AP-1,AP-1|YY1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,15365249,c-Jun,YY-1,Nuclear protein directly bound to an oligonucleotide containing the repressive YY-1 sequence but the binding capacity of the sequence was decreased by the increased c-Jun levels.,0.40,PMID.dPMID15365249.s2.p0,2,2,YY-1|c-Jun,c-Jun|YY-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,20430007,AP-1,YY1,"Furthermore, the repressive effect of YY1 was more evident than NFI on the iNOS promoter activity, resulting in a more marked reduction of iNOS expression via YY1/AP-1 than via NFI/AP-1 under the stimulation of cytomix.",0.37,PMID.dPMID20430007.s1.p1,4,2,YY1|YY1|AP-1|AP-1,AP-1|YY1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8794287,AP-1,YY1,"The target for YY1-mediated repression was identified as being a highly conserved AP-1 site, and we propose that AP-1 may represent a common target for YY1 repression.",0.04,PMID.dPMID8794287.s1.p0,4,2,YY1|AP-1|AP-1|YY1,AP-1|YY1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.3,8061,9606,,GO:0006357,7721415,c-jun,fra-1,"In cardiac ventriculocytes, however, fra-1 effected a synergistic amplification of the c-jun response (a 2.5-fold increase over c-jun alone).",0.54,PMID.dPMID7721415.s4.p0,3,2,fra-1|c-jun|c-jun,c-jun|fra-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.3,8061,9606,,GO:0006357,9742208,AP-1,fra1,"Insulin-stimulated expression of c-fos, fra1 and c-jun accompanies the activation of the activator protein-1 (AP-1) transcriptional complex.",0.27,PMID.dPMID9742208.s5.p4,4,3,c-fos|fra1|c-jun|AP-1,AP-1|c-fos|c-jun|fra1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.3,8061,9606,,GO:0006357,9658402,AP-1,Fra-1,High Fra-1 concentration is crucial for the negative regulation of AP-1 activity by estradiol and thus may take part in estradiol-induced inhibition of cell proliferation in ER alpha- breast cancer cells transfected with ER alpha expression construct,0.15,PMID.dPMID9658402.s0.p0,2,2,Fra-1|AP-1,AP-1|Fra-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.3,8061,9606,,GO:0006357,7721415,c-jun,fra-1,"In cardiac ventriculocytes, however, fra-1 effected a synergistic amplification of the c-jun response (a 2.5-fold increase over c-jun alone).",0.12,PMID.dPMID7721415.s4.p1,3,2,fra-1|c-jun|c-jun,c-jun|fra-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,16860316,c-Jun,SRC3,"However, depletion of SRC1 or SRC3 instead reduced c-Jun expression.",1.38,PMID.dPMID16860316.s1.p0,2,2,SRC3|c-Jun,c-Jun|SRC3,x
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,18162290,AP-1,ACTR,Molecular analysis indicates that ACTR functions as a coactivator of AP-1 to up-regulate the expression of matrix metalloproteinases such as MMP-7 and MMP-10 and reduce cell adhesion to specific extracellular matrix proteins.,0.18,PMID.dPMID18162290.s1.p0,2,2,ACTR|AP-1,ACTR|AP-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.6.0.2,8431,9606,,GO:0034339,18307978,c-Jun,SHP,"In this study, we demonstrated that bile acid induced the expression of the SHP orphan nuclear receptor at the transcriptional level via c-Jun activation.",0.90,PMID.dPMID18307978.s2.p0,2,2,SHP|c-Jun,c-Jun|SHP,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.6.0.2,8431,9606,,GO:0034339,15292277,c-Jun,SHP,"Here, we show that SHP expression increases during monocytic differentiaton with exposure HL-60 leukemia cells to a 12-O-tetradecanoylphorbol-13-acetate (TPA) response element, whose treatment induced the SHP promoter activity dependent on c-Jun expression, which is well known to be involved in the commitment step in the TPA-induced differentiation of HL-60 leukemia cells.",0.74,PMID.dPMID15292277.s4.p2,3,2,SHP|SHP|c-Jun,c-Jun|SHP,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.6.0.2,8431,9606,,GO:0034339,15292277,c-Jun,SHP,"We also show that overexpression and activation signaling of c-Jun increase the SHP promoter activity, suggesting that the level of SHP expression is normally limiting for c-Jun-dependent monocytic differentiation.",0.31,PMID.dPMID15292277.s3.p5,4,2,c-Jun|SHP|SHP|c-Jun,c-Jun|SHP,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.6.0.2,8431,9606,,GO:0034339,18307978,c-Jun,SHP,"Bile acid also enhanced the protein interaction of NF-kappaB and SHP, thereby resulting in an increase in c-Jun expression and the production of the inflammatory cytokine, TNFalpha.",0.21,PMID.dPMID18307978.s1.p0,2,2,SHP|c-Jun,c-Jun|SHP,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20607803,c-jun,p63,Transcriptional activity of TAp63 promoter is regulated by c-jun.,1.19,PMID.dPMID20607803.s8.p0,2,2,p63|c-jun,c-jun|p63,p
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2.1.2.7.3,9971,9606,,GO:0034339,16357303,AP-1,FXR,"Electrophoretic mobility-shift and chromatin immunoprecipitation assays indicated that FXR reduced the binding activity of AP-1 transcriptional factors, suggesting that FXR may suppress ET-1 expression via negatively interfering with AP-1 signaling.",0.45,PMID.dPMID16357303.s1.p0,5,3,FXR|AP-1|FXR|ET-1|AP-1,AP-1|ET-1|FXR,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.7,10538,9606,GO:0003702,,10777209,AP-1,B-ATF,B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.,0.31,PMID.dPMID10777209.s9.p0,3,3,B-ATF|AP-1|Fos,AP-1|B-ATF|Fos,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.7,10538,9606,GO:0003702,,10777209,Jun,B-ATF,"B-ATF inhibits transcriptional activation of a reporter gene containing TRE sites in a dose-dependent manner, presumably by competing with Fos for Jun and forming transcriptionally inert Jun/B-ATF heterodimers.",0.27,PMID.dPMID10777209.s3.p1,5,3,B-ATF|Fos|Jun|Jun|B-ATF,B-ATF|Fos|Jun,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.2.4.1.8,23462,9606,,GO:0010553,15314183,c-Jun,HERP2,We identified the hairy-enhancer-of-split-related factor HERP2 as a novel gene upregulated by c-Jun.,0.14,PMID.dPMID15314183.s4.p0,2,2,HERP2|c-Jun,c-Jun|HERP2,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,3.5.2.6.2,51513,9606,GO:0003704,,16887814,AP-1,transcription factor Ets-1,"Interestingly, the transcription factor Ets-1 promotes AP-1-induced P2 activity but inhibits AP-1-induced P1 activity for which a 10-bp AP-1/Ets-1 composite site (CCTTCCTTCC) in P1 may be responsible",0.16,PMID.dPMID16887814.s0.p0,5,3,transcription factor Ets-1|AP-1|AP-1|AP-1|Ets-1,AP-1|Ets-1|transcription factor Ets-1,
1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1.1.1.2.5,122953,9606,,,12650714,jun,JDP-2,"JDP-2, initially defined as a repressor of jun and other bZIP transcription factors, also functions as a potent PR selective coactivator.",0.26,PMID.dPMID12650714.s3.p0,2,2,JDP-2|jun,JDP-2|jun,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1.1.4.1.1,1050,9606,,GO:0045945,12522006,JunB,C/EBPalpha,Activation of C/EBPalpha-ER specifically reduced endogenous JunB RNA and protein and exogenous JunB levels without affecting endogenous or exogenous c-Jun.,0.18,PMID.dPMID12522006.s5.p1,4,3,C/EBPalpha|JunB|JunB|c-Jun,C/EBPalpha|c-Jun|JunB,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1.1.4.1.1,1050,9606,,GO:0045945,12522006,JunB,C/EBPalpha,"Thus, C/EBPalpha-ER suppresses both JunB transcription and posttranscriptional protein generation or induction.",0.15,PMID.dPMID12522006.s3.p0,2,2,C/EBPalpha|JunB,C/EBPalpha|JunB,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18494816,JUNB,AP-1,A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS.,0.35,PMID.dPMID18494816.s9.p0,3,3,AP-1|JUNB|JUND,AP-1|JUNB|JUND,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,20060892,JunB,c-Jun,"Furthermore, unlike the antagonistic activities of c-Jun and JunB in the transcription of genes coding for major cell cycle regulators such as CyclinD or p16INK4A, the transcription of other cell cycle regulating genes is modified similarly by c-Jun or JunB.",0.27,PMID.dPMID20060892.s3.p3,4,2,c-Jun|JunB|c-Jun|JunB,c-Jun|JunB,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18494816,JUNB,AP-1,These findings suggest that deregulation of AP-1 expression in CTCL is the result of aberrant expression of JUNB and possible JUND resulting from genomic amplification and constitutive activation of ERK1/2 MAPK in this type of lymphoma.,0.15,PMID.dPMID18494816.s0.p0,4,4,AP-1|JUNB|JUND|ERK1,AP-1|ERK1|JUNB|JUND,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,8441422,JunB,NFAT-1,"Taken together, these results suggested that the JunB-Fra-1 heterodimer is the inducible nuclear component of the NFAT-1 binding activity and that JunB expression regulates the formation of the heterodimer.",0.09,PMID.dPMID8441422.s1.p2,3,2,JunB|NFAT-1|JunB,JunB|NFAT-1,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,17951530,JunB,STAT3,"These phenotypes are accompanied by decreased expression of several known STAT3 target genes, including c-Myc, JunB, and Mcl-1, and increased expression of the cell- cycle inhibitor p27.",0.10,PMID.dPMID17951530.s1.p1,4,4,STAT3|c-Myc|JunB|Mcl-1,c-Myc|JunB|Mcl-1|STAT3,
1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,1.1.1.2.3,8061,9606,,GO:0006357,15377346,JunB,Fra-1,"Furthermore, experiments revealed that the protein and mRNA expression of the AP-1 subunits c-Fos, Fra-1 and c-Jun was reduced in lesional psoriatic skin compared with nonlesional psoriatic skin, whereas the protein and mRNA expression of the subunit JunB was increased.",0.06,PMID.dPMID15377346.s2.p4,4,4,c-Fos|Fra-1|c-Jun|JunB,c-Fos|c-Jun|Fra-1|JunB,-->
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15492115,JunD,AP-1,"Resveratrol reduced both activator protein-1 (AP-1) DNA binding and transcriptional activities, and supershift assay revealed that AP-1 composition was shifted from c-Jun/JunD/Fra-1 to JunD/Fra-1/Fra-2, with markedly increased JunD, Fra-1, and Fra-2 protein expression levels in the nucleus.",0.73,PMID.dPMID15492115.s4.p22,10,4,AP-1|AP-1|JunD|Fra-1|JunD|Fra-1|Fra-2|JunD|Fra-1|Fra-2,AP-1|Fra-1|Fra-2|JunD,
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,20184865,JunD,c-Jun,"PKCdelta decreased c-Jun expression, whereas PKCeta increased JunD, which are positive regulators of loricrin transcription.",0.65,PMID.dPMID20184865.s1.p1,4,4,c-Jun|eta|JunD|loricrin,c-Jun|eta|JunD|loricrin,
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18494816,JUND,AP-1,These findings suggest that deregulation of AP-1 expression in CTCL is the result of aberrant expression of JUNB and possible JUND resulting from genomic amplification and constitutive activation of ERK1/2 MAPK in this type of lymphoma.,0.52,PMID.dPMID18494816.s0.p1,4,4,AP-1|JUNB|JUND|ERK1,AP-1|ERK1|JUNB|JUND,
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18494816,JUND,AP-1,A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS.,0.45,PMID.dPMID18494816.s9.p1,3,3,AP-1|JUNB|JUND,AP-1|JUNB|JUND,
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1719551,JunD,AP-1,These results demonstrate that the transcriptional activity of an AP-1-related protein is regulated by the cAMP-dependent second-messenger pathway and suggest that JunD and other AP-1-related proteins may play an important role in the regulation of gene expression by cAMP-dependent intracellular signaling pathways,0.34,PMID.dPMID1719551.s0.p0,3,2,AP-1|JunD|AP-1,AP-1|JunD,
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15486991,JunD,AP-1,"Paradoxically, while Fra-2 mRNA and protein levels continued to increase, binding of Fra-2 to the AP-1 site decreased over 96 hr, with a concomitant increase in JunD AP-1-binding and a marked increase in expression of the 35 kDa form of JunD.",0.33,PMID.dPMID15486991.s2.p14,6,3,Fra-2|Fra-2|AP-1|JunD|AP-1|JunD,AP-1|Fra-2|JunD,
1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1.1.1.2.3,8061,9606,,GO:0006357,15492115,JunD,Fra-1,"Resveratrol reduced both activator protein-1 (AP-1) DNA binding and transcriptional activities, and supershift assay revealed that AP-1 composition was shifted from c-Jun/JunD/Fra-1 to JunD/Fra-1/Fra-2, with markedly increased JunD, Fra-1, and Fra-2 protein expression levels in the nucleus.",0.25,PMID.dPMID15492115.s4.p24,10,4,AP-1|AP-1|JunD|Fra-1|JunD|Fra-1|Fra-2|JunD|Fra-1|Fra-2,AP-1|Fra-1|Fra-2|JunD,-->
1.2.6.7.1,4084,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19526459,MAD1,MYC,"MAX dimerization protein 1 (MAD1) is a transcription suppressor that antagonizes MYC-mediated transcription activation, and the inhibition mechanism occurs mainly through the competition of target genes' promoter MYC binding sites by MAD1.",0.19,PMID.dPMID19526459.s8.p5,4,2,MAD1|MYC|MYC|MAD1,MAD1|MYC,
7.1.1.1.1,4086,9606,,,6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,16547957,Smad1,Brachyury,When Brachyury meets Smad1: the evolution of bilateral symmetry during gastrulation.,0.41,PMID.dPMID16547957.s7.p0,2,2,Brachyury|Smad1,Brachyury|Smad1,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11371641,Smad2,c-Jun,"Interestingly, c-Jun directly binds to the nuclear transcriptional corepressor TGIF and is required for TGIF-mediated repression of Smad2 transcriptional activity.",0.89,PMID.dPMID11371641.s1.p3,4,3,c-Jun|TGIF|TGIF|Smad2,c-Jun|Smad2|TGIF,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.1.1,4086,9606,,,19819941,SMAD2,SMAD1,"These data suggest that the SMAD family, possibly through disruption of SMAD1/5 or activation of SMAD2/3 may contribute to the pathogenesis of JGCT in humans.",0.04,PMID.dPMID19819941.s0.p0,2,2,SMAD1|SMAD2,SMAD1|SMAD2,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,16253118,Smad2,Smad3,"TGFbeta1-induced increases in CTGF and decreases in E-cadherin expression were Smad3-dependent, whereas increases in MMP-2 expression were Smad2-dependent.",0.32,PMID.dPMID16253118.s3.p13,6,6,TGFbeta1|CTGF|E-cadherin|Smad3|MMP-2|Smad2,CTGF|E-cadherin|MMP-2|Smad2|Smad3|TGFbeta1,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,17144456,Smad2,Smad3,"Expressions of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids OBJECTIVE: To investigate the expression of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids, normal scars and normal skins.",0.20,PMID.dPMID17144456.s8.p4,6,3,Smad2|Smad3|Smad7|Smad2|Smad3|Smad7,Smad2|Smad3|Smad7,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,15623506,Smad2,Smad3,"Our findings indicate that Smad3 has a stronger potential to stimulate the SOX9-dependent transcriptional activity by modulating the interaction between SOX9 and CBP/p300, rather than Smad2.",0.16,PMID.dPMID15623506.s1.p3,4,4,Smad3|CBP|p300|Smad2,CBP|p300|Smad2|Smad3,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,12700238,Smad2,Smad3,Evidence for a role of Smad3 and Smad2 in stabilization of the tumor-derived mutant Smad2.Q407R.,0.03,PMID.dPMID12700238.s7.p1,3,2,Smad3|Smad2|Smad2,Smad2|Smad3,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,18310088,Smad2,Smad4,"Although the expression of the dominant-negative Smad4 blocked TGF-beta(1)/Smad2,3-signaling activity, the above-mentioned effects of Smad4 on beta-catenin stability were independent of the TGF-beta1/Smad2,3-signaling pathway.",0.82,PMID.dPMID18310088.s1.p12,6,4,Smad4|Smad2|Smad4|beta-catenin|TGF-beta1|Smad2,beta-catenin|Smad2|Smad4|TGF-beta1,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,11424093,Smad2,Smad4,"Increased levels of TGFbeta1-induced transcriptional activation of the P1 promoter by overexpression of Smad2 and/or Smad4 is greatly reduced in the presence of Smad2(3SA) and completely inhibited by Smad7, suggesting the participation of endogenous Smad2/Smad4 complexes.",0.52,PMID.dPMID11424093.s4.p5,7,4,TGFbeta1|Smad2|Smad4|Smad2|Smad7|Smad2|Smad4,Smad2|Smad4|Smad7|TGFbeta1,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,11304690,MADH2,MADH4,"None of the tumors showed mutations of MADH2 and MADH4 or loss of detectable transcripts from MADH2, MADH4, APM-1 and DCC.",0.31,PMID.dPMID11304690.s3.p2,5,3,MADH2|MADH4|MADH2|MADH4|DCC,DCC|MADH2|MADH4,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.1,4091,9606,,,18496506,Smad2,Smad6,The expression of inhibitory Smad6 and 7 was increased whereas the expression of active Smad2 and 3 was reduced in these mesangial cells by BMP-7.,0.31,PMID.dPMID18496506.s1.p0,3,3,Smad6|Smad2|BMP-7,BMP-7|Smad2|Smad6,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,10915727,Smad 2,Smad 7,"However, Smad 7 induced by TGF-beta negatively regulated Smad 2 action and rendered most Smad 2 proteins in the cytoplasm.",1.37,PMID.dPMID10915727.s1.p1,4,3,Smad 7|TGF-beta|Smad 2|Smad 2,Smad 2|Smad 7|TGF-beta,c
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,20087894,Smad 2,Smad 7,TGFbeta inducible early gene-1 activates the TGFbeta-Smad signaling pathway via repression of Smad 7 expression and activation of Smad 2 expression and activity.,0.91,PMID.dPMID20087894.s4.p0,2,2,Smad 7|Smad 2,Smad 2|Smad 7,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,10915727,Smad 2,Smad 7,"However, Smad 7 induced by TGF-beta negatively regulated Smad 2 action and rendered most Smad 2 proteins in the cytoplasm.",0.85,PMID.dPMID10915727.s1.p3,4,3,Smad 7|TGF-beta|Smad 2|Smad 2,Smad 2|Smad 7|TGF-beta,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,18201262,Smad2,Smad7,"RESULTS: Asiaticoside markedly enhanced the expression of inhibitory Smad7, but it had no effect on the expression of Smad2.",0.16,PMID.dPMID18201262.s2.p0,2,2,Smad7|Smad2,Smad2|Smad7,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,19861282,Smad2,Smad7,"The optimal dose of doxycycline for inducing Smad7 was determined, and the effects of Smad7 over-expression on the expressions of collagen I and alpha-SMA in the cells activated by TGF-beta1 and on Smad2/3 phosphorylation were evaluated using Western blotting.",0.05,PMID.dPMID19861282.s3.p4,4,3,Smad7|Smad7|TGF-beta1|Smad2,Smad2|Smad7|TGF-beta1,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,15183844,Smad2,Smad7,"We have also shown that Smad7 expression is stimulated by myostatin via the interaction between Smad2, Smad3, Smad4 and the SBE (Smad binding element) in the Smad7 promoter.",0.01,PMID.dPMID15183844.s1.p1,6,5,Smad7|myostatin|Smad2|Smad3|Smad4|Smad7,myostatin|Smad2|Smad3|Smad4|Smad7,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,18595660,Smad2,Tcf4,"Indeed, the enhancement of beta-catenin/Tcf4 transcriptional activity by activated Smad2 was negatively regulated by the presence of Smad4.",1.00,PMID.dPMID18595660.s2.p0,3,3,Tcf4|Smad2|Smad4,Smad2|Smad4|Tcf4,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,3.1.3.6.1,7050,9606,,GO:0000122,11371641,Smad2,TGIF,"Interestingly, c-Jun directly binds to the nuclear transcriptional corepressor TGIF and is required for TGIF-mediated repression of Smad2 transcriptional activity.",1.41,PMID.dPMID11371641.s1.p5,4,3,c-Jun|TGIF|TGIF|Smad2,c-Jun|Smad2|TGIF,c
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,3.1.3.6.1,7050,9606,,GO:0000122,11371641,Smad2,TGIF,"Interestingly, c-Jun directly binds to the nuclear transcriptional corepressor TGIF and is required for TGIF-mediated repression of Smad2 transcriptional activity.",0.42,PMID.dPMID11371641.s1.p4,4,3,c-Jun|TGIF|TGIF|Smad2,c-Jun|Smad2|TGIF,c
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17875924,SMAD2,p53,"Furthermore, we found that mutant p53 attenuates the TGF-beta1-induced transcription activity of SMAD2/3 proteins.",0.38,PMID.dPMID17875924.s2.p1,3,3,p53|TGF-beta1|SMAD2,p53|SMAD2|TGF-beta1,
7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,3.3.1.8.1,8928,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045941|GO:0045944|GO:0051090,16120611,Smad2,FoxH1,This action of FoxH1 was independent of its transactivation capacity and activin A but relieved by Smad2.Smad4.,0.11,PMID.dPMID16120611.s5.p0,2,2,FoxH1|Smad2,FoxH1|Smad2,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,11590145,Smad3,Ets1,"In comparison, Ets1 did not increase Smad3/TGF beta-induced stimulation of the TGF beta-responsive plasminogen activator inhibitor 1 (PAI-1) promoter.",0.51,PMID.dPMID11590145.s4.p0,3,3,Ets1|Smad3|PAI,Ets1|PAI|Smad3,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,19798702,smad3,Id-1,Transforming growth factor-beta suppressed Id-1 Expression in a smad3-dependent manner in LoVo cells.,0.07,PMID.dPMID19798702.s13.p0,2,2,Id-1|smad3,Id-1|smad3,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,19798702,smad3,Id-1,"However, the suppression of Id-1 by TGF-beta1 was recovered by smad3 siRNA but not smad2 or p38 MAPK siRNA.",0.03,PMID.dPMID19798702.s3.p1,3,3,Id-1|TGF-beta1|smad3,Id-1|smad3|TGF-beta1,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10995748,Smad3,c-Jun,Mutational analyses of the c-Jun protein and the AP-1 binding site in the promoter revealed that the interaction of c-Jun with DNA is necessary for transcriptional activation by TGF-beta and Smad3.,0.44,PMID.dPMID10995748.s3.p8,5,3,c-Jun|AP-1|c-Jun|TGF-beta|Smad3,AP-1|c-Jun|Smad3|TGF-beta,-->
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10871633,Smad3,c-Jun,"Moreover, overexpression of wild-type c-Jun inhibits Smad3-dependent transcription.",0.41,PMID.dPMID10871633.s3.p0,2,2,c-Jun|Smad3,c-Jun|Smad3,-->
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10871633,Smad3,c-Jun,c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity.,0.26,PMID.dPMID10871633.s10.p0,2,2,c-Jun|Smad3,c-Jun|Smad3,-->
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10903323,Smad3,c-Jun,"On the other hand, c-Jun and JunB, both induced by TNF-alpha, block Smad3-mediated transcription.",0.25,PMID.dPMID10903323.s6.p3,4,4,c-Jun|JunB|TNF-alpha|Smad3,c-Jun|JunB|Smad3|TNF-alpha,-->
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10871633,Smad3,c-Jun,"The repression obtained with a c-Jun mutant unable to activate transcription through AP-1 sites indicates that the inhibitory mechanism does not rely on the induction of a Smad3 repressor by c-Jun, suggesting that c-Jun could act as a Smad3 co-repressor.",0.22,PMID.dPMID10871633.s1.p9,5,2,c-Jun|Smad3|c-Jun|c-Jun|Smad3,c-Jun|Smad3,-->
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11423983,Smad3,AP-1,"Using both artificial constructs specific for either the Smad or AP-1 signaling pathways or natural promoters known to be TGF-beta-responsive, we have determined that Jun family members downregulate Smad3-mediated gene transactivation whereas AP-1-dependent promoters are synergistically activated by Smad3 and Jun proteins.",0.06,PMID.dPMID11423983.s1.p14,7,3,AP-1|TGF-beta|Jun|Smad3|AP-1|Smad3|Jun,AP-1|Jun|Smad3|TGF-beta,-->
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,10903323,Smad3,JunB,"On the other hand, c-Jun and JunB, both induced by TNF-alpha, block Smad3-mediated transcription.",0.28,PMID.dPMID10903323.s6.p4,4,4,c-Jun|JunB|TNF-alpha|Smad3,c-Jun|JunB|Smad3|TNF-alpha,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,12930890,Smad3,Smad2,"In contrast, Smad2 and ERK predominantly transmodulated regulation of both immediate-early and intermediate genes by TGF-beta/Smad3.",0.56,PMID.dPMID12930890.s1.p3,4,4,Smad2|ERK|TGF-beta|Smad3,ERK|Smad2|Smad3|TGF-beta,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,12384983,Smad3,Smad2,"ALK-5 and ALK-1 mediate TGF-beta signals through distinct Smad proteins, i.e., Smad2/Smad3 and Smad1/Smad5, respectively.",0.50,PMID.dPMID12384983.s9.p9,6,6,ALK-5|ALK-1|TGF-beta|Smad2|Smad3|Smad5,ALK-1|ALK-5|Smad2|Smad3|Smad5|TGF-beta,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,17144456,Smad3,Smad2,"Expressions of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids OBJECTIVE: To investigate the expression of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids, normal scars and normal skins.",0.41,PMID.dPMID17144456.s8.p6,6,3,Smad2|Smad3|Smad7|Smad2|Smad3|Smad7,Smad2|Smad3|Smad7,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,15068708,smad3,smad2,"The relative lack in expression of TGF-beta(1) and smad2 genes in skins from younger fetuses might contribute to fetal scar-less healing, in which the role of smad3 needs to be further investigated.",0.12,PMID.dPMID15068708.s0.p0,2,2,smad2|smad3,smad2|smad3,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,12411310,Smad3,Smad2,Exposure of HUVECs to hypoxia resulted in phosphorylation and nuclear transportation of Smad2 and Smad3 proteins as well as stimulation of transcriptional activities of Smad3 and the transcription factor hypoxia-inducible factor-1alpha and culminated in up-regulation of TGF-beta2 gene expression.,0.02,PMID.dPMID12411310.s1.p1,4,3,Smad2|Smad3|Smad3|TGF-beta2,Smad2|Smad3|TGF-beta2,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,12917425,Smad3,YB-1,"Altogether, the results provide a novel insight into the mechanism by which IFN-gamma/YB-1 counteracts TGF-beta/Smad3.",0.22,PMID.dPMID12917425.s1.p4,4,4,IFN-gamma|YB-1|TGF-beta|Smad3,IFN-gamma|Smad3|TGF-beta|YB-1,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,19538467,Smad3,PPARdelta,"The effect of PPARdelta on the expression of type III collagen was dually regulated by the direct binding of PPARdelta and Smad3 to a direct repeat-1 site and a Smad-binding element, respectively, of the type III gene promoter.",1.29,PMID.dPMID19538467.s1.p1,3,2,PPARdelta|PPARdelta|Smad3,PPARdelta|Smad3,w
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15294900,Smad3,PPAR-gamma,"These findings, along with the observations that cPLA2alpha activates PPAR-gamma and that PPAR-gamma binds Smad3, illustrate novel cPLA2alpha/COX-2/EP1 and cPLA2alpha/PPAR-gamma/Smad signaling pathways that counteract the mitoinhibition by TGF-beta in human cancer cells",0.01,PMID.dPMID15294900.s0.p2,6,4,PPAR-gamma|PPAR-gamma|Smad3|EP1|PPAR-gamma|TGF-beta,EP1|PPAR-gamma|Smad3|TGF-beta,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,14603262,Smad3,RAR,"We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists.",0.60,PMID.dPMID14603262.s3.p0,5,3,RAR|Smad3|Smad4|RAR|RAR,RAR|Smad3|Smad4,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,15623506,Smad3,Sox9,"Interestingly, the association between Sox9 and CBP/p300 was increased by Smad3 overexpression and was suppressed by si-Smad3.",0.53,PMID.dPMID15623506.s2.p3,5,4,Sox9|CBP|p300|Smad3|Smad3,CBP|p300|Smad3|Sox9,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,15623506,Smad3,Sox9,"Interestingly, the association between Sox9 and CBP/p300 was increased by Smad3 overexpression and was suppressed by si-Smad3.",0.19,PMID.dPMID15623506.s2.p6,5,4,Sox9|CBP|p300|Smad3|Smad3,CBP|p300|Smad3|Sox9,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11114293,Smad3,Sp1,"In a Gal4-LUC reporter assay system, Sp1 stimulated the TGF-beta1-induced transcriptional activity of Gal4-Smad3, Gal4-Smad4 (266), or both.",0.15,PMID.dPMID11114293.s3.p1,4,4,Sp1|TGF-beta1|Smad3|Smad4,Smad3|Smad4|Sp1|TGF-beta1,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,15527767,Smad3,SREBP-2,We found that SREBP-2 inhibited the transcriptional activity of Smad3 in luciferase reporter assays.,0.63,PMID.dPMID15527767.s0.p0,2,2,SREBP-2|Smad3,Smad3|SREBP-2,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,18714394,Smad3,SRF,"The pulmonary ASPS myofibroblasts synthesize serum response factor (SRF), a repressor of Smad3-mediated TGFbeta signaling essential for myofibroblast differentiation and Smad3.",0.04,PMID.dPMID18714394.s5.p0,3,2,SRF|Smad3|Smad3,Smad3|SRF,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,16819512,Smad3,SRF,SRF therefore acts as a nuclear repressor of Smad3-mediated TGF-beta1 signaling,0.02,PMID.dPMID16819512.s0.p0,3,3,SRF|Smad3|TGF-beta1,Smad3|SRF|TGF-beta1,
7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,20870174,Smad3,Foxp3,Positive and Negative Transcriptional Regulation of the Foxp3 Gene is Mediated by Access and Binding of the Smad3 Protein to Enhancer I.,0.23,PMID.dPMID20870174.s4.p0,2,2,Foxp3|Smad3,Foxp3|Smad3,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11854297,Smad4,AP-1,"The stimulation of AP-1 by BMP-2 and TGF-beta was dependent on Smad signaling, and anti-Smad4 antibody interfered with AP-1 activity.",0.03,PMID.dPMID11854297.s5.p3,5,4,AP-1|BMP-2|TGF-beta|Smad4|AP-1,AP-1|BMP-2|Smad4|TGF-beta,-->
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18595660,Smad4,Smad2,"Indeed, the enhancement of beta-catenin/Tcf4 transcriptional activity by activated Smad2 was negatively regulated by the presence of Smad4.",0.72,PMID.dPMID18595660.s2.p2,3,3,Tcf4|Smad2|Smad4,Smad2|Smad4|Tcf4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,8752209,DPC4,MADR2,"The gene for MADR2 was found to reside on chromosome 18q21, near DPC4, another MADR protein implicated in pancreatic cancer.",0.53,PMID.dPMID8752209.s3.p0,2,2,MADR2|DPC4,DPC4|MADR2,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18425078,Smad4,Smad2,Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival.,0.50,PMID.dPMID18425078.s11.p1,3,2,Smad2|Smad4|Smad4,Smad2|Smad4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,15184872,Smad4,Smad2,"By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-beta, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-beta induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4.",0.49,PMID.dPMID15184872.s3.p17,9,5,MUC4|TGF-beta|Smad2|Smad4|Smad4|TGF-beta|Smad4|Smad7|Smad4,MUC4|Smad2|Smad4|Smad7|TGF-beta,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,15184872,Smad4,Smad2,"By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-beta, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-beta induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4.",0.48,PMID.dPMID15184872.s3.p8,9,5,MUC4|TGF-beta|Smad2|Smad4|Smad4|TGF-beta|Smad4|Smad7|Smad4,MUC4|Smad2|Smad4|Smad7|TGF-beta,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,17960585,Smad4,Smad2,Transforming growth factor-beta (TGF-beta) signaling is known to depend on the formation of Smad2/3-Smad4 transcription regulatory complexes.,0.38,PMID.dPMID17960585.s8.p2,3,3,TGF-beta|Smad2|Smad4,Smad2|Smad4|TGF-beta,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,15280432,Smad4,Smad2,"In uninduced cells, GFPSmad2 is less mobile in the cytoplasm than is GFPSmad4, suggesting that it may be tethered there.",0.29,PMID.dPMID15280432.s2.p0,2,2,Smad2|Smad4,Smad2|Smad4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,9892110,SMAD4,SMAD2,These results suggest that functional abrogation of SMAD2 or SMAD3 and increased expression of SMAD6 or SMAD7 are infrequent in pancreatic carcinomas and further stress the particular importance of SMAD4 inactivation in pancreatic carcinogenesis,0.26,PMID.dPMID9892110.s0.p6,5,5,SMAD2|SMAD3|SMAD6|SMAD7|SMAD4,SMAD2|SMAD3|SMAD4|SMAD6|SMAD7,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18595660,Smad4,Smad2,Here we demonstrated that the Activin-like kinase 4 (Alk4)/Smad2 pathway facilitates the transcriptional activity of the oncogenic Wnt/beta-catenin/Tcf4 pathway through a novel Smad4-independent mechanism.,0.18,PMID.dPMID18595660.s5.p1,3,3,Smad2|Tcf4|Smad4,Smad2|Smad4|Tcf4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,11576339,Smad4,Smad2,"Smad2 and ERK1/2 were activated in response to TGF-beta; however, TGF-beta had little effect on the protein expression of Smad4.",0.15,PMID.dPMID11576339.s5.p6,5,4,Smad2|ERK1|TGF-beta|TGF-beta|Smad4,ERK1|Smad2|Smad4|TGF-beta,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,10480932,Smad4,Smad2,"Constitutive activation of the p38 pathway in the absence of TGF-beta induced the transcriptional activation, which was enhanced synergistically by coexpression of Smad2 and Smad4 and was inhibited by expression of the C-terminal truncated, dominant negative Smad4.",0.12,PMID.dPMID10480932.s3.p4,4,3,TGF-beta|Smad2|Smad4|Smad4,Smad2|Smad4|TGF-beta,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,9389648,Smad4,Smad2,Receptor-activated Smad2 takes Smad4 into the nucleus where they form a complex with FAST-1 that requires these three components to activate transcription.,0.03,PMID.dPMID9389648.s2.p0,3,3,Smad2|Smad4|FAST-1,FAST-1|Smad2|Smad4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,14603262,Smad4,RAR,"We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists.",0.60,PMID.dPMID14603262.s3.p1,5,3,RAR|Smad3|Smad4|RAR|RAR,RAR|Smad3|Smad4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,18595660,Smad4,Tcf4,"Indeed, the enhancement of beta-catenin/Tcf4 transcriptional activity by activated Smad2 was negatively regulated by the presence of Smad4.",0.52,PMID.dPMID18595660.s2.p1,3,3,Tcf4|Smad2|Smad4,Smad2|Smad4|Tcf4,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11751405,Smad4,p53,"p21(WAF1/CIP1) overexpression, independent of p53 and/or DPC4/Smad4 expression, may reflect increased Ras activity, either directly through activating K-ras mutations or as a consequence of HER-2/neu (ERBB2) overexpression, both of which are common in PC and in early events in the development of PanIN.",0.31,PMID.dPMID11751405.s1.p8,8,5,WAF1|CIP1|p53|DPC4|Smad4|K-ras|HER-2/neu|ERBB2,CIP1|DPC4|ERBB2|HER-2/neu|K-ras|p53|Smad4|WAF1,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11751405,DPC4,p53,"p21(WAF1/CIP1) overexpression, independent of p53 and/or DPC4/Smad4 expression, may reflect increased Ras activity, either directly through activating K-ras mutations or as a consequence of HER-2/neu (ERBB2) overexpression, both of which are common in PC and in early events in the development of PanIN.",0.31,PMID.dPMID11751405.s1.p5,8,5,WAF1|CIP1|p53|DPC4|Smad4|K-ras|HER-2/neu|ERBB2,CIP1|DPC4|ERBB2|HER-2/neu|K-ras|p53|Smad4|WAF1,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15043313,DPC4,p53,The three adenomas were p53 negative and showed loss of DPC4 expression.,0.26,PMID.dPMID15043313.s2.p0,2,2,p53|DPC4,DPC4|p53,
7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,3.3.1.8.1,8928,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045941|GO:0045944|GO:0051090,9702198,Smad4,hFAST-1,The hFAST-1-dependent activation of ARE was completely dependent on endogenous Smad4 and stimulation by a TGF beta-like ligand.,0.08,PMID.dPMID9702198.s3.p0,2,2,hFAST-1|Smad4,hFAST-1|Smad4,
7.1.1.3.1,4091,9606,,,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,20709030,Smad6,Smad2,"Western blot analysis revealed unchanged total Smad2/3 protein levels, but reduced phospho-Smad2/3 (p-Smad2/3) and increased Smad6/7 protein levels in the miR-106b stably transfected cell line.",0.50,PMID.dPMID20709030.s3.p4,4,2,Smad2|Smad2|Smad2|Smad6,Smad2|Smad6,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15579469,SMAD7,c-Jun,"Furthermore, overexpression of dominant negative c-Jun substantially reduced UV irradiation induction of SMAD7 transcription.",0.18,PMID.dPMID15579469.s1.p0,2,2,c-Jun|SMAD7,c-Jun|SMAD7,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,16944602,Smad7,Smad2,The increase of p-Smad2 expression stimulated by TGF-beta2 was inhibited in Smad7 overexpression clone by Western blot assay.,0.79,PMID.dPMID16944602.s5.p1,3,3,Smad2|TGF-beta2|Smad7,Smad2|Smad7|TGF-beta2,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,17144456,Smad7,Smad2,"Expressions of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids OBJECTIVE: To investigate the expression of TGF-betaR I, Smad2, Smad3 and Smad7 in keloids, normal scars and normal skins.",0.43,PMID.dPMID17144456.s8.p10,6,3,Smad2|Smad3|Smad7|Smad2|Smad3|Smad7,Smad2|Smad3|Smad7,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,15183844,Smad7,Smad2,"Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism.",0.08,PMID.dPMID15183844.s7.p3,4,4,Smad2|Smad3|Smad4|Smad7,Smad2|Smad3|Smad4|Smad7,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,20154264,Smad7,Smad2,TGF-beta1 also increased Smad2 and ERK1/2 phosphorylation but did not affect Smad7 expression.,0.07,PMID.dPMID20154264.s4.p4,4,4,TGF-beta1|Smad2|ERK1|Smad7,ERK1|Smad2|Smad7|TGF-beta1,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,9892110,SMAD7,SMAD2,These results suggest that functional abrogation of SMAD2 or SMAD3 and increased expression of SMAD6 or SMAD7 are infrequent in pancreatic carcinomas and further stress the particular importance of SMAD4 inactivation in pancreatic carcinogenesis,0.02,PMID.dPMID9892110.s0.p3,5,5,SMAD2|SMAD3|SMAD6|SMAD7|SMAD4,SMAD2|SMAD3|SMAD4|SMAD6|SMAD7,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18065393,Smad7,Smad2,"LPA elicited phosphorylation of Smad2/3, and siRNA-mediated depletion of endogenous Smad2/3 or adenoviral expression of Smad7, an inhibitory Smad, abrogated the LPA induced expression of alpha-SMA and phosphorylation of Smad2/3.",0.01,PMID.dPMID18065393.s4.p2,4,2,Smad2|Smad2|Smad7|Smad2,Smad2|Smad7,
7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16714330,Smad7,Sp1,"We found that in pancreatic cancer cells Smad proteins and Sp1 cooperatively regulate expression of a distinct set of TGFbeta target genes potentially involved in tumor progression, including MMP-11, cyclin D1 and Smad7.",0.75,PMID.dPMID16714330.s4.p0,2,2,Sp1|Smad7,Smad7|Sp1,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1323849,Max,c-Myc,"The recent discovery of Max, a basic helix-loop-helix leucine-zipper partner protein for c-Myc, suggests that the ability of c-Myc to regulate transcription is modulated by the presence of Max.",1.56,PMID.dPMID1323849.s4.p5,4,2,Max|c-Myc|c-Myc|Max,c-Myc|Max,x
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7731722,max,c-myc,"While the expression of c-myc is extensively regulated, no major changes in max expression have been reported so far with respect to differentiation.",1.55,PMID.dPMID7731722.s12.p0,2,2,c-myc|max,c-myc|max,n
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8222283,Max,Myc,The effects of Myc on both gene expression and cell growth are differentially regulated by the recently described Max and delta Max proteins that can either cooperate or compete with Myc for sequence-specific DNA binding,1.04,PMID.dPMID8222283.s0.p0,4,2,Myc|Max|Max|Myc,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11044429,Max,c-Myc,METHODS AND RESULTS: OxLDL enhanced c-Myc/Max expression and transcription by cotransfection assay and the nuclear activities of E2F and activator protein-2 by binding shift and supershift in coronary SMCs.,0.93,PMID.dPMID11044429.s4.p0,2,2,c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8222283,Max,Myc,The effects of Myc on both gene expression and cell growth are differentially regulated by the recently described Max and delta Max proteins that can either cooperate or compete with Myc for sequence-specific DNA binding,0.75,PMID.dPMID8222283.s0.p1,4,2,Myc|Max|Max|Myc,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11535131,Max,Myc,"Whereas the Myc and Mad genes and proteins are highly regulated, Max expression is constitutive and no post-translational regulation is known.",0.69,PMID.dPMID11535131.s10.p0,2,2,Myc|Max,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1644290,Max,Myc,"In addition, we observed a striking reduction in Myc cotransformation activity when a Max expression construct was added to myc/ras co-transfections.",0.66,PMID.dPMID1644290.s1.p0,3,2,Myc|Max|myc,Max|myc|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,16475822,Max,Myc,The Myc-Max-Mad network of proteins activates or represses gene transcription depending on whether the dimerization partner of Max is c-Myc or Mad.,0.63,PMID.dPMID16475822.s14.p1,4,2,Myc|Max|Max|c-Myc,c-Myc|Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7969121,Max,c-Myc,Here we demonstrate that the human p53 promoter is transactivated by high c-Myc expression and repressed by high Max expression.,0.61,PMID.dPMID7969121.s5.p2,3,3,p53|c-Myc|Max,c-Myc|Max|p53,"[4149-->7157, 4609-->7157]"
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19189276,Max,c-Myc,"On the other hand, the Mad proteins can compete with c-Myc for Max.",0.59,PMID.dPMID19189276.s6.p0,2,2,c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10579912,Max,c-myc,"The c-myc gene encodes the transcription factor c-Myc, which heterodimerizes with a partner protein, termed Max, to regulate gene expression.",0.40,PMID.dPMID10579912.s4.p1,3,2,c-myc|c-Myc|Max,c-myc|c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1323849,Max,c-Myc,"The recent discovery of Max, a basic helix-loop-helix leucine-zipper partner protein for c-Myc, suggests that the ability of c-Myc to regulate transcription is modulated by the presence of Max.",0.37,PMID.dPMID1323849.s4.p4,4,2,Max|c-Myc|c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9178892,max,c-myc,The expression of D106-143 and In373 c-myc mutants and the overexpression of max reduced the apoptosis mediated by okadaic acid.,0.32,PMID.dPMID9178892.s3.p0,2,2,c-myc|max,c-myc|max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9490791,Max,c-Myc,"Sp1 and c-Myc binding elements close to transcription start areas were positive regulators of both promoters, however, whereas overexpression in HeLa cells of Sp1 stimulated both promoters, c-Myc and c-Myc/Max overexpression had a suppressive effect.",0.31,PMID.dPMID9490791.s2.p3,4,2,c-Myc|c-Myc|c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10886373,Max,c-Myc,"RESULTS: We found that c-Myc directly bound to the N-terminal region of origin recognition complex-1 (ORC1), a region that is responsible for gene silencing, in a state of complex containing other ORC subunits and Max in vivo and in vitro.",0.30,PMID.dPMID10886373.s2.p0,2,2,c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8417337,Max,Myc,"The discovery of the specific cognate DNA-binding site for Myc and its specific heterodimerization partner, Max, enabled the use of direct experiments to elucidate how Myc functions in vivo and how this function is modulated by Max.",0.30,PMID.dPMID8417337.s5.p5,4,2,Myc|Max|Myc|Max,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10511314,Max,c-Myc,"This result is in contrast with the inhibition of erythroid differentiation of K562 exerted by c-Myc, suggesting divergent roles for c-Myc/Max, depending on the differentiation pathway.",0.29,PMID.dPMID10511314.s0.p2,3,2,c-Myc|c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8637719,Max,Myc,"In light of the evidence that ODC is transcriptionally regulated in vitro and in vivo by the Myc/Max protein complex and the potential role of Mxi1 and Mad as antagonists of Myc transactivation activity, we set out to determine if one of these Max associated proteins, Mxi1, could affect the regulation of ODC expression by Myc/Max and if this regulation was correlated to growth status.",0.25,PMID.dPMID8637719.s4.p24,8,3,Myc|Max|Mxi1|Myc|Max|Mxi1|Myc|Max,Max|Mxi1|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15258910,Max,Myc,In parallel experiments we also analyzed the Myc/Max/Mad expression and DNA binding capacity during induced differentiation in the MYCN single copy neuroblastoma cell line SH-SY5Y.,0.18,PMID.dPMID15258910.s4.p0,3,3,Myc|Max|MYCN,Max|Myc|MYCN,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1406955,Max,Myc,Here we use Saccharomyces cerevisiae as an in vivo model system to show that the Myc protein is a sequence-specific transcriptional activator whose DNA binding is strictly dependent on dimerization with Max.,0.17,PMID.dPMID1406955.s3.p0,2,2,Myc|Max,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9797456,Max,MYC,"AMY-1 by itself did not recognize the E-box element, the MYC/Max binding sequence, nor did it transactivate via the element, but stimulated the activation of E-box-regulated transcription by MYC/Max.",0.16,PMID.dPMID9797456.s3.p7,5,3,AMY-1|MYC|Max|MYC|Max,AMY-1|Max|MYC,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7577944,Max,c-Myc,"Their function is mediated by switches in the dimerization partners; c-Myc does not homodimerize in vivo but competes with Mad, another member of the subfamily, to form heterodimers with Max, leading to either activation or repression of transcription.",0.16,PMID.dPMID7577944.s8.p0,2,2,c-Myc|Max,c-Myc|Max,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17275176,Max,c-Myc,This repression occurs via a dynamic shift in occupancy from activating c-Myc/Max to repressive Mad1/Max and Mnt/Max complexes at the proximal promoters of both the MLH1 and MSH2 genes.,0.13,PMID.dPMID17275176.s2.p1,7,5,c-Myc|Max|Max|Mnt|Max|MLH1|MSH2,c-Myc|Max|MLH1|Mnt|MSH2,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11031250,Max,Myc,The Myc/Max/Mad network and the transcriptional control of cell behavior.,0.09,PMID.dPMID11031250.s7.p0,2,2,Myc|Max,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9308237,Max,Myc,Myc-transformed cells are also characterised by the loss of expression of a number of genes and this repressive effect of Myc on gene expression may not be mediated by the Myc/Max complex.,0.05,PMID.dPMID9308237.s3.p4,4,2,Myc|Myc|Myc|Max,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17217336,Max,Myc,"Max is a ubiquitous transcription factor with a bHLHZip [basic HLH (helix-loop-helix) leucine zipper] DNA-binding/dimerization domain and the central component of the Myc/Max/Mad transcription factor network that controls cell growth, proliferation, differentiation and apoptotic cell death in metazoans.",0.05,PMID.dPMID17217336.s11.p2,3,2,Max|Myc|Max,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17217336,Max,Myc,"Max is the obligatory DNA-binding and dimerization partner for all the bHLHZip regulators of the Myc/Max/Mad network, including the Myc family of oncoproteins and the Mad family of Myc antagonists, which recognize E-box DNA elements in the regulatory regions of target genes.",0.04,PMID.dPMID17217336.s10.p2,5,2,Max|Myc|Max|Myc|Myc,Max|Myc,
1.2.6.5.5,4149,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10734130,Max,c-Myc,"Further, FasL promoter activity in T cells is driven by overexpression of c-Myc and inhibited by expression of dominant-negative mutants of c-Myc and Max.",0.03,PMID.dPMID10734130.s1.p4,4,3,FasL|c-Myc|c-Myc|Max,c-Myc|FasL|Max,
1.2.6.5.5,4149,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10348347,Max,p53,"Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max.",0.06,PMID.dPMID10348347.s7.p3,4,3,p53|p53|Myc|Max,Max|Myc|p53,-->
1.2.6.5.5,4149,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15647429,Max,p53,"Intracellular p53 expression was significantly decreased in Max (25.5%) compared with Min (37%, p<0.01) OA or normal cartilage (41.5%, p<0.05).",0.03,PMID.dPMID15647429.s7.p0,2,2,p53|Max,Max|p53,-->
1.2.6.5.5,4149,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7969121,Max,p53 tumor suppressor,Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.,0.01,PMID.dPMID7969121.s10.p1,4,3,p53 tumor suppressor|c-Myc|Max|p53,c-Myc|Max|p53|p53 tumor suppressor,-->
2.3.5.0.35,4150,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12684688,MAZ,Sp1,"Both Sp1 and MAZ inhibited the expression of the gene for MAZ, while expression of the gene for eNOS was enhanced by Sp1 and repressed by MAZ.",0.60,PMID.dPMID12684688.s3.p1,6,3,Sp1|MAZ|MAZ|eNOS|Sp1|MAZ,eNOS|MAZ|Sp1,<--
2.3.5.0.35,4150,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,8626793,MAZ,Sp1,"This result suggests that MAZ and Sp1 both participate in regulating expression from the serotonin 1a receptor gene promoter, and it raises the possibility that MAZ may act at a variety of promoters through the guanosine-cytosine-rich sequences generally thought to serve as binding sites for the Sp1 family of transcription factors.",0.12,PMID.dPMID8626793.s2.p2,4,2,MAZ|Sp1|MAZ|Sp1,MAZ|Sp1,<--
2.3.5.0.35,4150,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12684688,MAZ,Sp1,"Both Sp1 and MAZ inhibited the expression of the gene for MAZ, while expression of the gene for eNOS was enhanced by Sp1 and repressed by MAZ.",0.02,PMID.dPMID12684688.s3.p10,6,3,Sp1|MAZ|MAZ|eNOS|Sp1|MAZ,eNOS|MAZ|Sp1,<--
5.1.1.1.1,4205,9606,,,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,20165829,MEF2A,ATF6,CONCLUSIONS/INTERPRETATION: In this work we show that glucosamine-induced ER stress causes insulin resistance in both human and rat myotubes and impairs GLUT4 production and insulin-induced glucose uptake via an ATF6-dependent decrease of the GLUT4 regulators MEF2A and PGC1alpha,0.77,PMID.dPMID20165829.s0.p4,5,4,GLUT4|ATF6|GLUT4|MEF2A|PGC1alpha,ATF6|GLUT4|MEF2A|PGC1alpha,
5.1.1.1.1,4205,9606,,,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,20165829,MEF2A,ATF6,"Finally, we showed that overproduction of ATF6 is sufficient to inhibit the expression of genes GLUT4, MEF2A and PGC1alpha and that ATF6 silencing with a specific small interfering RNA is sufficient to completely prevent glucosamine-induced inhibition of GLUT4, MEF2A and PGC1alpha in skeletal muscle cells.",0.01,PMID.dPMID20165829.s1.p1,8,6,ATF6|GLUT4|MEF2A|PGC1alpha|ATF6|GLUT4|MEF2A|PGC1alpha,ATF6|GLUT4|MEF2A|PGC1alpha,
5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,19584403,MEF2C,MLL,Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C.,0.68,PMID.dPMID19584403.s8.p1,3,3,MLL|ENL|MEF2C,ENL|MEF2C|MLL,
5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,1.2.5.3.2,10499,9606,,GO:0006355,15044954,MEF2C,GRIP-1,"In addition, Smad3 interacts with MEF2C, which requires its MADS domain, and disrupts its association with the SRC-family coactivator GRIP-1, thus diminishing the transcription activity of MEF2C.",0.07,PMID.dPMID15044954.s2.p5,4,3,Smad3|MEF2C|GRIP-1|MEF2C,GRIP-1|MEF2C|Smad3,
3.1.3.2.1,4211,9606,GO:0003702,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,15160920,MEIS1,MLL,"These results suggest that MLL aberrations may regulate MEIS1 and HOXA9 gene expression in ALL-derived cell lines, while AML-derived cell lines express these genes independently of the MLL status.",1.42,PMID.dPMID15160920.s0.p0,4,3,MLL|MEIS1|HOXA9|MLL,HOXA9|MEIS1|MLL,
3.1.3.2.1,4211,9606,GO:0003702,,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17671196,Meis1,MLL,"Blocking the MLL-menin interaction by the expression of a dominant negative inhibitor composed of amino terminal MLL sequences down-regulates Meis1 expression and inhibits cell proliferation, suggesting that targeting this interaction may be an effective therapeutic strategy for leukemias with MLL rearrangements",0.46,PMID.dPMID17671196.s0.p3,5,3,MLL|menin|MLL|Meis1|MLL,Meis1|menin|MLL,
3.1.3.2.2,4212,9606,GO:0003704,GO:0000122,3.1.3.6.1,7050,9606,,GO:0000122,10764806,Meis2,TGIF,"Among the five cloned splice variants of Meis2, isoforms Meis2a-d activate the D(1A) promoter in most cell types tested, whereas TGIF competes with Meis2 binding to DNA and represses Meis2-induced transcription activation.",0.07,PMID.dPMID10764806.s7.p8,5,2,Meis2|Meis2|TGIF|Meis2|Meis2,Meis2|TGIF,
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,1.1.2.0.2,466,9606,,,15884099,MITF,ATF1,Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma.,1.30,PMID.dPMID15884099.s8.p2,3,3,EWSR1|ATF1|MITF,ATF1|EWSR1|MITF,
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,1.1.2.0.2,466,9606,,,16766266,MITF,EWS-ATF1,"We show that EWS-ATF1 occupies the MITF promoter, mimicking melanocyte-stimulating hormone (MSH) signaling to induce expression of MITF, the melanocytic master transcription factor and an amplified oncogene in melanoma.",0.18,PMID.dPMID16766266.s3.p1,3,2,EWS-ATF1|MITF|MITF,EWS-ATF1|MITF,
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,1.1.2.0.1,1385,9606,,GO:0045944,15923629,Mitf,CREB,"However, constitutively active CREB(DIEDML) without PKA activation is insufficient for Mitf expression and melanogenesis, indicating PKA regulates additional aspects of Mitf transcription.",0.53,PMID.dPMID15923629.s2.p0,3,2,CREB|Mitf|Mitf,CREB|Mitf,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,9500554,MITF,PAX3,These results provide evidence that PAX3 directly regulates MITF and suggest that the failure of this regulation due to PAX3 mutations causes the auditory-pigmentary symptoms in at least some individuals with WS1,2.07,PMID.dPMID9500554.s0.p0,4,2,PAX3|MITF|PAX3|WS1,MITF|PAX3|WS1,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,10938265,MITF,Pax3,"WS1 and WS3 are caused by mutation in the gene encoding the transcription factor Pax3, which regulates MITF expression.",1.76,PMID.dPMID10938265.s5.p2,3,3,WS3|Pax3|MITF,MITF|Pax3|WS3,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,10644012,MITF,Pax3,"This suggests that additional factors, besides Pax3, are required for the MITF expression.",0.80,PMID.dPMID10644012.s2.p0,2,2,Pax3|MITF,MITF|Pax3,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,10536986,MITF,PAX3,"By analyzing the genes for Waardenburg syndrome, we showed that PAX3, the gene responsible for Waardenburg syndrome type 1, regulates MITF, the gene responsible for Waardenburg syndrome type 2.",0.75,PMID.dPMID10536986.s2.p0,3,3,PAX3|MITF|Waardenburg syndrome type 2,MITF|PAX3|Waardenburg syndrome type 2,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,19026785,Mitf,PAX3,The protein encoded by paired-box homeotic gene 3 (PAX3) is a key regulator of the microphthalmia-associated transcription factor (Mitf) in the melanocyte lineage.,0.49,PMID.dPMID19026785.s5.p0,2,2,PAX3|Mitf,Mitf|PAX3,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,10644012,MITF,Pax3,Pax3 transcription factor was reported earlier to regulate positively the melanocyte-specific promoter of the MITF gene.,0.15,PMID.dPMID10644012.s4.p0,2,2,Pax3|MITF,MITF|Pax3,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,12944398,microphthalmia-associated transcription factor,SOX10,A tissue-restricted cAMP transcriptional response: SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes.,2.01,PMID.dPMID12944398.s10.p0,2,2,SOX10|microphthalmia-associated transcription factor,microphthalmia-associated transcription factor|SOX10,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,19026785,Mitf,SOX10,The activation of p53-POMC/MSH-MC1R signaling is required for the UV-induced melanogenic response because PAX3 functions in synergy with SOX10 in a cAMP-response element (CRE)-dependent manner to regulate the transcription of Mitf.,0.50,PMID.dPMID19026785.s1.p9,5,5,p53|MSH|PAX3|SOX10|Mitf,Mitf|MSH|p53|PAX3|SOX10,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,15760336,Mitf,Sox10,"During specification, Sox10 activates the Mitf gene as the key regulator of melanocyte development.",0.48,PMID.dPMID15760336.s3.p0,2,2,Sox10|Mitf,Mitf|Sox10,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,10938265,MITF,WS4,"Finally, we show that three SOX10 mutations found in WS4 abolish the transcriptional activity of the resulting Sox10 proteins toward the MITF promoter.",0.38,PMID.dPMID10938265.s1.p4,4,2,SOX10|WS4|Sox10|MITF,MITF|Sox10|SOX10|WS4,<--
1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,10938265,MITF,SOX10,"Finally, we show that three SOX10 mutations found in WS4 abolish the transcriptional activity of the resulting Sox10 proteins toward the MITF promoter.",0.26,PMID.dPMID10938265.s1.p3,4,2,SOX10|WS4|Sox10|MITF,MITF|Sox10|SOX10|WS4,<--
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,15130940,MLL,AML1,"Chimeric RARalpha and acute myeloid leukemia 1 (AML1) proteins induce constitutive repression after the recruitment of corepressors, whereas inappropriate maintenance of target gene expression by mixed-lineage leukemia (MLL) chimeras may result from the recruitment of coactivators or the basal transcriptional machinery.",0.05,PMID.dPMID15130940.s1.p0,2,2,AML1|MLL,AML1|MLL,
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,3.1.2.5.3,1747,9606,,,17611665,MLL,DLX3,"Importantly, hypermethylation of DLX3 significantly reduces its expression in MLL-AF4 rearranged leukemias while methylation is almost absent in TEL-AML1 positive ALL specimens.",0.35,PMID.dPMID17611665.s1.p0,4,4,DLX3|MLL|TEL|ALL,ALL|DLX3|MLL|TEL,
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,10484978,MLL,ETS1,"Southern blot analysis confirmed the CGH findings and showed that the ETS1, FLI1, SRPR, NFRKB, and KCNJ5 genes located at 11q23-->24 were amplified, whereas the MLL at 11q23 was not amplified.",0.17,PMID.dPMID10484978.s2.p3,4,4,ETS1|NFRKB|KCNJ5|MLL,ETS1|KCNJ5|MLL|NFRKB,
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,3.1.1.7.1,3205,9606,,,19056693,MLL,HOXA9,HOXA9 is required for survival in human MLL-rearranged acute leukemias.,0.30,PMID.dPMID19056693.s8.p0,2,2,HOXA9|MLL,HOXA9|MLL,
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,3.1.1.7.15,3229,9606,GO:0003702,,19922474,MLL,HOXC13,"Overall, our studies have demonstrated that HOXC13 is transcriptionally regulated by E2 and MLLs, which, in coordination with ERalpha and ERbeta, play critical roles in this process.",0.20,PMID.dPMID19922474.s2.p0,4,4,HOXC13|MLL|ERalpha|ERbeta,ERalpha|ERbeta|HOXC13|MLL,
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,3.1.3.2.1,4211,9606,GO:0003702,,19109563,MLL,MEIS1,These results show that MEIS1 expression is important for MLL-rearranged leukemias and suggest that MEIS1 promotes cell-cycle entry.,0.20,PMID.dPMID19109563.s1.p0,3,2,MEIS1|MLL|MEIS1,MEIS1|MLL,
2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,1.1.1.1.9,4780,9606,,,15282410,Trx-1,Nrf-2,"Results showed that tert-butylhydroquinone (TBHQ), a transcriptional activator that functions through Nrf-2/ARE, promoted Nrf-2 nuclear translocation by a type I (thiylation) redox switch which was regulated by GSH not by Trx-1.",0.14,PMID.dPMID15282410.s2.p5,4,3,tert|Nrf-2|Nrf-2|Trx-1,Nrf-2|tert|Trx-1,
3.3.1.15.3,4303,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,1.1.2.0.1,1385,9606,,GO:0045944,20136501,FOXO4,CREB,"Chromatin immunoprecipitations showed that FOXO4 did not bind the PAI-1 promoter, whereas CREB binding was enhanced on FOXO4 overexpression.",0.18,PMID.dPMID20136501.s2.p5,4,3,FOXO4|PAI-1|CREB|FOXO4,CREB|FOXO4|PAI-1,
1.2.7.0.1,4335,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17419941,Mnt,Myc,This in turn leads to increased expression of the Myc/Mnt target gene cyclin D2.,0.23,PMID.dPMID17419941.s3.p0,2,2,Myc|Mnt,Mnt|Myc,
1.2.7.0.1,4335,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19086036,Mnt,c-Myc,"Following common bile duct ligation or left hepatic bile duct ligation, the expression of p53, c-Myc, and cyclin D1 increased markedly, whereas Mnt expression decreased.",0.14,PMID.dPMID19086036.s6.p4,4,4,p53|c-Myc|cyclin D1|Mnt,c-Myc|cyclin D1|Mnt|p53,
3.1.2.11.1,4487,9606,,,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,20004191,Msx1,YB1,"Furthermore, YB1/p32 cooperates with Msx1 in transcriptional repression and knocking down the expression of endogenous YB1 attenuates the effects of Msx1.",0.77,PMID.dPMID20004191.s1.p6,5,3,YB1|p32|Msx1|YB1|Msx1,Msx1|p32|YB1,
3.1.2.11.1,4487,9606,,,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,20004191,Msx1,YB1,"Furthermore, YB1/p32 cooperates with Msx1 in transcriptional repression and knocking down the expression of endogenous YB1 attenuates the effects of Msx1.",0.31,PMID.dPMID20004191.s1.p9,5,3,YB1|p32|Msx1|YB1|Msx1,Msx1|p32|YB1,
3.1.2.11.1,4487,9606,,,3.2.2.1.2,5083,9606,GO:0016564,GO:0006355|GO:0045892,16651263,Msx1,Pax9,Here we demonstrate that Pax9 is able to directly regulate Msx1 expression and interact with Msx1 at the protein level to enhance its ability to transactivate Msx1 and Bmp4 expression during tooth development.,1.73,PMID.dPMID16651263.s6.p0,5,3,Pax9|Msx1|Msx1|Msx1|Bmp4,Bmp4|Msx1|Pax9,e
3.1.2.11.1,4487,9606,,,3.2.2.1.2,5083,9606,GO:0016564,GO:0006355|GO:0045892,16651263,Msx1,Pax9,This suggests that Pax9 is critical for the regulation of Bmp4 expression through its paired domain rather than Msx1.,0.32,PMID.dPMID16651263.s2.p1,3,3,Pax9|Bmp4|Msx1,Bmp4|Msx1|Pax9,
3.1.2.11.1,4487,9606,,,3.2.2.1.2,5083,9606,GO:0016564,GO:0006355|GO:0045892,16651263,Msx1,Pax9,Here we demonstrate that Pax9 is able to directly regulate Msx1 expression and interact with Msx1 at the protein level to enhance its ability to transactivate Msx1 and Bmp4 expression during tooth development.,0.15,PMID.dPMID16651263.s6.p3,5,3,Pax9|Msx1|Msx1|Msx1|Bmp4,Bmp4|Msx1|Pax9,
3.1.2.11.2,4488,9606,GO:0016564,,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,11683913,Msx2,Runx2,CONCLUSION: These results suggest that regulation of the activity of Runx2 by Msx2 and Dlx5 plays an important role in the mammalian skull development,0.31,PMID.dPMID11683913.s0.p0,3,3,Runx2|Msx2|Dlx5,Dlx5|Msx2|Runx2,
1.2.6.7.5,4601,9606,,,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,17452451,Mxi1,FOXO3a,"Furthermore, FOXO3a activation induced expression of several members of the Mad/Mxd family of transcriptional repressors, most notably Mxi1.",0.51,PMID.dPMID17452451.s7.p0,2,2,FOXO3a|Mxi1,FOXO3a|Mxi1,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.1.1.2.10,468,9606,GO:0003702|GO:0003704|GO:0016563,GO:0006355|GO:0045944,17347301,c-Myb,ATF4,"In contrast, ATF4:C/EBPalpha dimers bound to the C/EBP sites in the G-CSFR and NE promoters, but transcriptional activation was inhibited by 30-80% in the presence or absence of c-Myb.",0.09,PMID.dPMID17347301.s1.p3,4,4,ATF4|C/EBPalpha|G-CSFR|c-Myb,ATF4|C/EBPalpha|c-Myb|G-CSFR,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,9694711,c-myb,Bcl-3,"These findings suggest that Bcl-3 may participate in the transcriptional regulation of certain kappaB-containing genes involved in hematopoiesis, including c-myb",0.16,PMID.dPMID9694711.s0.p0,2,2,Bcl-3|c-myb,Bcl-3|c-myb,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.3.2.1.1,1869,9606,,GO:0000122,15867358,c-myb,E2F1,"Taken together, these results suggest activation of a transcriptional cascade by which E2F1 regulates COX-2 expression through the c-myb oncogene.",0.18,PMID.dPMID15867358.s1.p0,2,2,E2F1|c-myb,c-myb|E2F1,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,3105625,c-myb,c-fos,These findings suggest that a switch in c-fos/c-myb expression is associated with the terminal differentiation of cells of the monocytic lineage,0.35,PMID.dPMID3105625.s0.p0,2,2,c-fos|c-myb,c-fos|c-myb,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.1.1.12.1,3110,9606,GO:0003702,GO:0006355|GO:0006357,15540222,MYB,HLXB9,"Detailed expression analysis suggested ectopic activation of HLXB9 occurred via juxtaposition with regions upstream of MYB, which was highly expressed in GDM-1.",0.03,PMID.dPMID15540222.s1.p0,3,3,HLXB9|MYB|GDM-1,GDM-1|HLXB9|MYB,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.1.1.7.1,3205,9606,,,18337761,c-Myb,HoxA9,Stimulation of HoxA9 activity resulted in increased expression of the c-Myb transcription factor and induction of insulin-like growth factor-1 receptor (IGF-1R) surface expression.,0.27,PMID.dPMID18337761.s4.p0,3,3,HoxA9|c-Myb|IGF-1R,c-Myb|HoxA9|IGF-1R,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.1.1.4.2,3214,9606,,GO:0006355,20599537,c-Myb,HoxB4,"Adding tPTD-HoxB4 fusion protein increased the gene expression of TpoR, Cyclin D1, Fog-1 and Fli-1 while it inhibited c-Myb expression.",0.93,PMID.dPMID20599537.s2.p3,4,4,HoxB4|TpoR|Fog-1|c-Myb,c-Myb|Fog-1|HoxB4|TpoR,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.1.1.4.2,3214,9606,,GO:0006355,20599537,c-Myb,HoxB4,Our data suggest that increased HoxB4 enhanced early megakaryocytic development in human TF1 cells and CD34 positively-selected cord blood cells primarily by upregulating TpoR and Fli-1 expression and downregulating c-Myb expression.,0.56,PMID.dPMID20599537.s1.p3,4,4,HoxB4|CD34|TpoR|c-Myb,CD34|c-Myb|HoxB4|TpoR,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.1.1.4.2,3214,9606,,GO:0006355,20599537,c-Myb,HoxB4,"We found that ectopic HoxB4 in TF1 cells increased the antigen expression of CD61and CD41a, increased the gene expression of thrombopoietin receptor (TpoR), Scl-1, Cyclin D1, Fog-1 and Fli-1 while it decreased c-Myb expression.",0.26,PMID.dPMID20599537.s5.p10,6,6,HoxB4|CD61|TpoR|Scl|Fog-1|c-Myb,CD61|c-Myb|Fog-1|HoxB4|Scl|TpoR,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.1.1.4.2,3214,9606,,GO:0006355,20599537,c-Myb,HoxB4,HoxB4 RNA silencing in TF1 cells decreased the expression of CD61 and CD41a and decreased Fli-1 expression while it increased the expression of c-Myb.,0.04,PMID.dPMID20599537.s4.p1,3,3,HoxB4|CD61|c-Myb,CD61|c-Myb|HoxB4,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.5.3.0.1,3659,9606,,,10739671,c-myb,IRF-1,"Together, these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which IRF-1 negatively regulates c-myb expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing",3.01,PMID.dPMID10739671.s0.p5,6,2,IRF-1|c-myb|IRF-1|c-myb|IRF-1|c-myb,c-myb|IRF-1,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.5.3.0.1,3659,9606,,,10739671,c-myb,IRF-1,"Together, these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which IRF-1 negatively regulates c-myb expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing",1.72,PMID.dPMID10739671.s0.p3,6,2,IRF-1|c-myb|IRF-1|c-myb|IRF-1|c-myb,c-myb|IRF-1,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.5.3.0.1,3659,9606,,,10739671,c-myb,IRF-1,"Together, these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which IRF-1 negatively regulates c-myb expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing",0.80,PMID.dPMID10739671.s0.p12,6,2,IRF-1|c-myb|IRF-1|c-myb|IRF-1|c-myb,c-myb|IRF-1,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.5.3.0.1,3659,9606,,,10739671,c-myb,IRF-1,"Together, these results are consistent with the existence of a functional relationship between IRF-1 and c-myb in which IRF-1 negatively regulates c-myb expression at the transcriptional level by a mechanism that may depend on the interaction of IRF-1 with a segment of the c-myb gene implicated in transcription pausing",0.26,PMID.dPMID10739671.s0.p10,6,2,IRF-1|c-myb|IRF-1|c-myb|IRF-1|c-myb,c-myb|IRF-1,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,1527086,c-myb,c-Jun,"Because T-lymphocytes induced to proliferate express c-jun and junD before c-myb, these data suggest a mechanism whereby c-Jun and JunD contribute to the transcriptional activation of c-myb that, in turn, is maintained at the G1/S transition and during S phase by positive autoregulation",0.41,PMID.dPMID1527086.s0.p4,4,3,c-myb|c-Jun|JunD|c-myb,c-Jun|c-myb|JunD,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,1527086,c-myb,JunD,"Because T-lymphocytes induced to proliferate express c-jun and junD before c-myb, these data suggest a mechanism whereby c-Jun and JunD contribute to the transcriptional activation of c-myb that, in turn, is maintained at the G1/S transition and during S phase by positive autoregulation",0.45,PMID.dPMID1527086.s0.p5,4,3,c-myb|c-Jun|JunD|c-myb,c-Jun|c-myb|JunD,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.1.3.0.1,4094,9606,GO:0003702,,9566892,c-Myb,Maf,"This pattern matched that of CD13/APN reporter gene expression, indicating that Maf modulation of c-Myb activity may be an important mechanism for the control of gene transcription during hematopoietic cell development.",0.16,PMID.dPMID9566892.s0.p5,4,3,CD13|APN|Maf|c-Myb,APN|CD13|c-Myb|Maf,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.5.1.0.3,4605,9606,,,2160970,c-MYB,B-MYB,The MBS-BI site was an enhancer element dependent on B-MYB and a very weakly dependent on c-MYB.,0.50,PMID.dPMID2160970.s1.p0,2,2,B-MYB|c-MYB,B-MYB|c-MYB,<--
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3756869,c-myb,c-myc,"We have found that six of 14 patients with acute leukemias have markedly high ratios of c-myc/H3, c-myc/p53, and c-myc/c-myb expression.",0.59,PMID.dPMID3756869.s4.p9,5,3,c-myc|c-myc|p53|c-myc|c-myb,c-myb|c-myc|p53,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2694722,c-myb,c-myc,"The other fourteen oncogene of c-myc was c-myb, c-abl and N-myc, showed no increases of gene content.",0.47,PMID.dPMID2694722.s2.p0,4,4,c-myc|c-myb|c-abl|N-myc,c-abl|c-myb|c-myc|N-myc,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18722373,c-Myb,c-Myc,Silencing c-Myc and E2F1 reduced PIK3CA/Akt and mTOR and completely abolished c-Myb and COX-2 expression in human HCC cell lines.,0.44,PMID.dPMID18722373.s2.p6,5,5,c-Myc|E2F1|PIK3CA|Akt|c-Myb,Akt|c-Myb|c-Myc|E2F1|PIK3CA,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1497659,c-Myb,c-myc,"Surprisingly, deletion of the six Myb-binding sites did not influence the transactivation of c-myc by c-Myb protein.",0.31,PMID.dPMID1497659.s3.p0,2,2,c-myc|c-Myb,c-Myb|c-myc,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1485708,c-myb,c-myc,"The number of responding cells was decreased during aging when the presence of the c-myc protein was taken as its measure; and this decrease was further accentuated, determining the expression of the c-myb protein.",0.12,PMID.dPMID1485708.s7.p0,2,2,c-myc|c-myb,c-myb|c-myc,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,7.1.2.0.2,4781,9606,,,19841262,MYB,NFIB,Our data indicate that the MYB-NFIB fusion is a hallmark of ACC and that deregulation of the expression of MYB and its target genes is a key oncogenic event in the pathogenesis of ACC.,0.54,PMID.dPMID19841262.s1.p2,3,2,MYB|NFIB|MYB,MYB|NFIB,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,3.2.2.2.2,5079,9606,,,18708755,c-Myb,Pax5,Here we demonstrate that the Pax5 oncoprotein downregulates the dleu2 gene and at the same time boosts expression of its own heterodimeric partner c-Myb.,0.51,PMID.dPMID18708755.s4.p1,3,3,Pax5|dleu2|c-Myb,c-Myb|dleu2|Pax5,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,11585920,c-Myb,RelA,"Interestingly, an amino-terminal deletion form of p300 lacking the C/H1 and KIX domains and unable to bind RelA retained the ability to stimulate c-Myb transcription and prevented NF-kappaB-mediated repression",0.56,PMID.dPMID11585920.s0.p2,3,3,p300|RelA|c-Myb,c-Myb|p300|RelA,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,2.3.5.0.2,6591,9606,,GO:0000122,20622260,c-Myb,Slug,Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.,1.89,PMID.dPMID20622260.s10.p0,2,2,Slug|c-Myb,c-Myb|Slug,e
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,2.3.5.0.2,6591,9606,,GO:0000122,20622260,c-Myb,Slug,"We show here that in embryonic kidney, colon carcinoma, chronic myeloid leukemia-blast crisis, and in neuroblastoma cells, expression of Slug is transcriptionally regulated by c-Myb via Myb binding sites in the 5'-flanking region and in the first intron of the slug gene.",0.70,PMID.dPMID20622260.s7.p0,3,2,Slug|c-Myb|slug,c-Myb|slug|Slug,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11500059,c-Myb,p53,"In addition, p53 stimulates the degradation of c-Myb, which is, at least partly, mediated by induction of Siah in certain types of cells.",0.26,PMID.dPMID11500059.s1.p0,2,2,p53|c-Myb,c-Myb|p53,
3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7559553,c-myb,WT1,We conclude that WT1 is a negative regulator of c-myb expression in both T and B cell lines,1.61,PMID.dPMID7559553.s0.p0,2,2,WT1|c-myb,c-myb|WT1,<--
3.5.1.0.3,4605,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,17242210,B-myb,c-Myb,"In addition, expression of c-Myb in HCT116 cells rescued cyclin B1 expression after B-myb expression was silenced with small interfering RNA.",0.14,PMID.dPMID17242210.s1.p0,2,2,c-Myb|B-myb,B-myb|c-Myb,-->
3.5.1.0.3,4605,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1594249,B-myb,c-myc,Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products.,0.22,PMID.dPMID1594249.s7.p1,3,3,c-myc|c-myb|B-myb,B-myb|c-myb|c-myc,
3.5.1.0.3,4605,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7937841,B-myb,p53,"p53-dependent G1 arrest is accompanied by decreased expression of the B-myb gene, a relative of the c-myb cellular oncogene.",0.72,PMID.dPMID7937841.s3.p0,2,2,p53|B-myb,B-myb|p53,
3.5.1.0.3,4605,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1409626,B-MYB,p53,"The effect of wt p53 protein on the expression of four immediate-early genes (c-FOS, c-JUN, JUN-B, and c-MYC), one delayed-early gene (ornithine decarboxylase), and two late-G1/S-phase genes (B-MYB and DNA polymerase alpha) was also examined.",0.04,PMID.dPMID1409626.s2.p10,6,6,p53|c-FOS|c-JUN|c-MYC|ornithine decarboxylase|B-MYB,B-MYB|c-FOS|c-JUN|c-MYC|ornithine decarboxylase|p53,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,16091746,c-Myc,AhR,"These results suggest that the AhR influences the expression of c-Myc, a protein critical to malignant transformation",0.87,PMID.dPMID16091746.s0.p0,2,2,AhR|c-Myc,AhR|c-Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,11114727,c-myc,AhR,Here we demonstrate a physical and functional association between the RelA subunit of NF-kappaB and AhR resulting in the activation of c-myc gene transcription in breast cancer cells.,0.85,PMID.dPMID11114727.s5.p2,3,3,RelA|AhR|c-myc,AhR|c-myc|RelA,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.48,639,9606,,GO:0000122,10713181,c-myc,Blimp-1,The functional importance of recruiting HDAC for Blimp-1-dependent repression of c-myc transcription is supported by two experiments.,1.51,PMID.dPMID10713181.s2.p0,2,2,Blimp-1|c-myc,Blimp-1|c-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.48,639,9606,,GO:0000122,18235046,c-MYC,PRDM1,PRDM1beta was associated with increased c-MYC expression.,1.32,PMID.dPMID18235046.s5.p0,2,2,PRDM1|c-MYC,c-MYC|PRDM1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.48,639,9606,,GO:0000122,17877160,c-myc,Blimp-1,CONCLUSION: Blimp-1 could directly repress the expression of c-myc in 2ME2-mediated differentiation induction of multiple myeloma cells.,0.99,PMID.dPMID17877160.s0.p0,2,2,Blimp-1|c-myc,Blimp-1|c-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.48,639,9606,,GO:0000122,11073970,c-myc,Blimp-1,"Our data show that Blimp-1-dependent repression of c-myc is required for BCL-1 differentiation, since constitutive expression of c-Myc blocked differentiation.",0.68,PMID.dPMID11073970.s3.p0,3,2,Blimp-1|c-myc|c-Myc,Blimp-1|c-myc|c-Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.48,639,9606,,GO:0000122,9887105,c-myc,Blimp-1,"The PRDI-BF1/Blimp-1 protein is a transcriptional repressor required for normal B-cell differentiation, and it has been implicated in the repression of beta-interferon (IFN-beta) and c-myc gene expression.",0.17,PMID.dPMID9887105.s7.p4,4,3,PRDI-BF1|Blimp-1|IFN-beta|c-myc,Blimp-1|c-myc|IFN-beta|PRDI-BF1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.48,639,9606,,GO:0000122,9887105,c-myc,PRDI-BF1,"The PRDI-BF1/Blimp-1 protein is a transcriptional repressor required for normal B-cell differentiation, and it has been implicated in the repression of beta-interferon (IFN-beta) and c-myc gene expression.",0.17,PMID.dPMID9887105.s7.p3,4,3,PRDI-BF1|Blimp-1|IFN-beta|c-myc,Blimp-1|c-myc|IFN-beta|PRDI-BF1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.20,688,9606,GO:0003702,,19684017,MYC,KLF5,"When TGFbeta was applied, however, whereas MYC expression was significantly inhibited, knockdown of KLF5 increased MYC expression.",1.78,PMID.dPMID19684017.s4.p2,3,2,MYC|KLF5|MYC,KLF5|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.20,688,9606,GO:0003702,,19684017,MYC,KLF5,Knockdown of KLF5 significantly reduced MYC expression in the HaCaT epidermal epithelial cells.,1.28,PMID.dPMID19684017.s5.p0,2,2,KLF5|MYC,KLF5|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.20,688,9606,GO:0003702,,19684017,MYC,KLF5,Opposing effects of KLF5 on the transcription of MYC in epithelial proliferation in the context of transforming growth factor beta.,1.26,PMID.dPMID19684017.s9.p0,2,2,KLF5|MYC,KLF5|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.20,688,9606,GO:0003702,,19684017,MYC,KLF5,In this study we investigated whether KLF5 directly regulates MYC transcription in epithelial cells in the context of TGFbeta.,1.06,PMID.dPMID19684017.s6.p0,2,2,KLF5|MYC,KLF5|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.4.1.0.3,864,9606,,GO:0006355,20442291,c-Myc,RUNX3,"Evidence is presented suggesting that RUNX3 downregulates c-Myc expression by two parallel pathways-directly at the transcriptional level and through attenuation of beta-catenin/TCFs, downstream of BMPs in colorectal cancer cells",1.76,PMID.dPMID20442291.s0.p0,2,2,RUNX3|c-Myc,c-Myc|RUNX3,p
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.4.1.0.3,864,9606,,GO:0006355,20442291,c-Myc,RUNX3,We show that upregulation of RUNX3 by BMP reduces c-Myc expression.,1.69,PMID.dPMID20442291.s1.p0,2,2,RUNX3|c-Myc,c-Myc|RUNX3,e
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.4.1.4,1052,9606,,,17471507,c-Myc,C/EBPdelta,"Finally, C/EBPdelta expression is repressed in proliferating mammary epithelial cells by c-Myc via a mechanism that involves the binding of c-Myc:Max dimers to C/EBPdelta promoter-bound Miz-1.",0.53,PMID.dPMID17471507.s1.p0,5,3,C/EBPdelta|c-Myc|c-Myc|Max|C/EBPdelta,C/EBPdelta|c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.4.1.4,1052,9606,,,17471507,c-Myc,C/EBPdelta,"Finally, C/EBPdelta expression is repressed in proliferating mammary epithelial cells by c-Myc via a mechanism that involves the binding of c-Myc:Max dimers to C/EBPdelta promoter-bound Miz-1.",0.14,PMID.dPMID17471507.s1.p1,5,3,C/EBPdelta|c-Myc|c-Myc|Max|C/EBPdelta,C/EBPdelta|c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.4.1.4,1052,9606,,,17471507,c-Myc,C/EBPdelta,"The mouse C/EBPdelta gene promoter is regulated by STAT3 and Sp1 transcriptional activators, chromatin remodeling and c-Myc repression.",0.03,PMID.dPMID17471507.s10.p3,4,4,C/EBPdelta|STAT3|Sp1|c-Myc,C/EBPdelta|c-Myc|Sp1|STAT3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.4.1.5,1053,9606,,,17094903,c-Myc,C/EBPepsilon,"This study was to detect the cell-specific expression of C/EBPepsilon, and to investigate the effect of C/EBPepsilon overexpression on c-Myc expression, cell cycle distribution, and cell differentiation of human myelomonocytic leukemia cell line U-937.",0.07,PMID.dPMID17094903.s7.p2,3,2,C/EBPepsilon|C/EBPepsilon|c-Myc,C/EBPepsilon|c-Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,16702959,c-myc,KLF6,KLF6-mediated changes in E-cadherin levels were accompanied by downstream changes in both the subcellular localization of beta-catenin and c-myc expression levels.,0.13,PMID.dPMID16702959.s2.p1,3,3,KLF6|E-cadherin|c-myc,c-myc|E-cadherin|KLF6,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,19101139,c-myc,KLF6,Functional studies confirmed that wtKLF6 suppressed proliferation of gastric cancer cells via transcriptional regulation of the cyclin-dependent kinase inhibitor p21 and the oncogene c-myc.,0.06,PMID.dPMID19101139.s3.p0,2,2,KLF6|c-myc,c-myc|KLF6,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.7.2.1,1523,9606,GO:0003702,GO:0006357,9178912,c-Myc,CUTL1,"The human Cut-like homeobox gene, CUTL1, is one of the genes localized to 7q22 and it was shown previously to encode a transcriptional repressor that down-modulates the expression of c-Myc.",1.31,PMID.dPMID9178912.s5.p0,2,2,CUTL1|c-Myc,c-Myc|CUTL1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.2.5.4,1748,9606,,GO:0006355,10402242,c-myc,DLX-7,DLX-7 homeobox gene regulates c-myc and GATA-1 gene expression in different stages respectively.,1.52,PMID.dPMID10402242.s5.p0,3,3,DLX-7|c-myc|GATA-1,c-myc|DLX-7|GATA-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.2.5.4,1748,9606,,GO:0006355,10402242,c-myc,DLX-7,These results suggest that DLX-7 may regulate c-myc and GATA-1 genes at transcriptional and post-transcriptional levels,1.46,PMID.dPMID10402242.s0.p0,3,3,DLX-7|c-myc|GATA-1,c-myc|DLX-7|GATA-1,e
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.2.5.4,1748,9606,,GO:0006355,10402242,c-myc,DLX-7,We have shown that inhibition of the DLX-7 homeobox gene by an antisense oligonucleotide decreased the expression of c-myc and GATA-1 genes.,0.16,PMID.dPMID10402242.s3.p0,3,3,DLX-7|c-myc|GATA-1,c-myc|DLX-7|GATA-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.2.5.5,1749,9606,GO:0016563,,19497851,MYC,DLX5,Here we demonstrate by luciferase assay that the MYC promoter is specifically activated by overexpression of DLX5 and that two DLX5 binding sites in the MYC promoter are important for transcriptional activation of MYC.,0.56,PMID.dPMID19497851.s4.p8,5,2,MYC|DLX5|DLX5|MYC|MYC,DLX5|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.2.1.1,1869,9606,,GO:0000122,18794899,c-MYC,E2F1,"E2F1 deregulation suppresses beta-catenin activity in an adenomatous polyposis coli (APC)/glycogen synthase kinase-3 (GSK3)-independent manner, reducing the expression of key beta-catenin targets including c-MYC.",0.52,PMID.dPMID18794899.s4.p0,2,2,E2F1|c-MYC,c-MYC|E2F1,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.2.1.1,1869,9606,,GO:0000122,10779353,Myc,E2F1,"Based on these results and past experiments, it appears that the E2F1, E2F2, and E2F3a genes are similarly regulated by growth stimulation, involving a combination of E2F-dependent negative control and Myc-mediated positive control.",0.39,PMID.dPMID10779353.s1.p3,4,4,E2F1|E2F2|E2F3|Myc,E2F1|E2F2|E2F3|Myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.2.1.1,1869,9606,,GO:0000122,7794791,c-myc,transcription factor E2F,A direct role of transcription factor E2F in c-myc gene expression during granulocytic and macrophage-like differentiation of HL60 cells.,0.19,PMID.dPMID7794791.s8.p0,2,2,transcription factor E2F|c-myc,c-myc|transcription factor E2F,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.2.1.2,1870,9606,GO:0003702,,10779353,Myc,E2F2,"Based on these results and past experiments, it appears that the E2F1, E2F2, and E2F3a genes are similarly regulated by growth stimulation, involving a combination of E2F-dependent negative control and Myc-mediated positive control.",0.14,PMID.dPMID10779353.s1.p4,4,4,E2F1|E2F2|E2F3|Myc,E2F1|E2F2|E2F3|Myc,<->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.2.1.3,1871,9606,,,10779353,Myc,E2F3,"Based on these results and past experiments, it appears that the E2F1, E2F2, and E2F3a genes are similarly regulated by growth stimulation, involving a combination of E2F-dependent negative control and Myc-mediated positive control.",0.24,PMID.dPMID10779353.s1.p5,4,4,E2F1|E2F2|E2F3|Myc,E2F1|E2F2|E2F3|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.2.1.5,1875,9606,,,10738311,MYC,E2F5,"This suggests that E2F5 behaves like a MYC-type cooperating oncogene in functional assays, prompting us to monitor potential amplifications of the E2F5 gene in primary human tumors.",0.65,PMID.dPMID10738311.s5.p0,3,2,E2F5|MYC|E2F5,E2F5|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.1.2,1958,9606,,GO:0045941,7784068,c-myc,early growth response,"In contrast to the transient expression of many other immediate early growth response genes, both FBP and c-myc expression were sustained for more than 24 h.",0.59,PMID.dPMID7784068.s1.p1,3,3,early growth response|FBP|c-myc,c-myc|early growth response|FBP,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.1.2,1958,9606,,GO:0045941,8541224,c-myc,early growth response,"The ER in SKOV3 cells was normal with respect to apparent Kd for binding with E2, E2 regulation of a transiently transfected ERE driven reporter gene, and E2 stimulation of expression of the early growth response genes c-myc and c-fos.",0.51,PMID.dPMID8541224.s2.p0,3,3,early growth response|c-myc|c-fos,c-fos|c-myc|early growth response,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.7,2034,9606,,GO:0045944,19061835,c-Myc,HIF-2alpha,"To determine whether opposing influences of HIF-1alpha and HIF-2alpha on c-Myc activity regulate human ccRCC progression, we analyzed VHL genotype and HIF-alpha expression in 160 primary tumors, which segregated into three groups with distinct molecular characteristics.",0.18,PMID.dPMID19061835.s3.p0,2,2,HIF-2alpha|c-Myc,c-Myc|HIF-2alpha,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.1.7,2078,9606,,,18542058,C-MYC,ERG,"TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.",0.13,PMID.dPMID18542058.s5.p0,2,2,ERG|C-MYC,C-MYC|ERG,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17825481,c-myc,ERalpha,"In cells expressing the ERalpha mutant, estrogen did not induce ERE-dependent gene expression but did induce AP-1- and Sp1-dependent gene expression and the cell cycle regulatory genes cyclin D1 and c-myc.",0.76,PMID.dPMID17825481.s2.p1,3,3,ERalpha|Sp1|c-myc,c-myc|ERalpha|Sp1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,14764652,c-myc,ERalpha,"Estrogen-induced transcriptional activities of both ERalpha and ERbeta and mRNA expression of estrogen-responsive genes, including pS2, c-myc, and cyclin D1, were suppressed by PP5 but enhanced by PP5 antisense oligonucleotide.",0.59,PMID.dPMID14764652.s2.p3,6,5,ERalpha|ERbeta|pS2|c-myc|PP5|PP5,c-myc|ERalpha|ERbeta|PP5|pS2,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,18193094,c-Myc,ERalpha,ERalpha silencing abolished the E2-stimulated c-Myc expression.,0.50,PMID.dPMID18193094.s4.p0,2,2,ERalpha|c-Myc,c-Myc|ERalpha,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,15808510,c-myc,ERalpha,"We demonstrated that IKKalpha, in conjunction with ERalpha and AIB1/SRC-3, is important in activating the transcription of estrogen-responsive genes, including cyclin D1 and c-myc, to result in the enhanced proliferation of breast cancer cells.",0.37,PMID.dPMID15808510.s2.p7,5,4,IKKalpha|ERalpha|AIB1|SRC-3|c-myc,AIB1|c-myc|ERalpha|IKKalpha|SRC-3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,19398483,c-Myc,ERalpha,This work revealed a cooperative role for ERalpha and c-Myc in estrogen regulation of VEGF and the ability of c-Myc to partially mimic estrogen regulation of angiogenesis.,0.02,PMID.dPMID19398483.s1.p3,4,3,ERalpha|c-Myc|VEGF|c-Myc,c-Myc|ERalpha|VEGF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,20176724,c-Myc,ERbeta,"The induction is temporal, as assessed by measuring kinetics of the association of ERbeta/Dvl2, protein expression of the beta-CTS targeted genes, c-Myc and cyclin D1, and cell growth.",0.56,PMID.dPMID20176724.s6.p0,2,2,ERbeta|c-Myc,c-Myc|ERbeta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,14764652,c-myc,ERbeta,"Estrogen-induced transcriptional activities of both ERalpha and ERbeta and mRNA expression of estrogen-responsive genes, including pS2, c-myc, and cyclin D1, were suppressed by PP5 but enhanced by PP5 antisense oligonucleotide.",0.01,PMID.dPMID14764652.s2.p4,6,5,ERalpha|ERbeta|pS2|c-myc|PP5|PP5,c-myc|ERalpha|ERbeta|PP5|pS2,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,18059336,myc,Ets-1,"Here, we observed that in breast cancer cells resistant and insensitive to endocrine treatment, the growth factor EGF induced Ets-2 but not Ets-1 transcriptional regulation of the oncogene myc.",0.82,PMID.dPMID18059336.s7.p5,4,4,EGF|Ets-2|Ets-1|myc,EGF|Ets-1|Ets-2|myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,17913746,c-myc,Ets1,Both SPBP and TopBP1 enhanced the transcriptional activity of Ets1 on the c-myc P1P2- and matrix metalloproteinase-3 (MMP3) promoters.,0.08,PMID.dPMID17913746.s5.p2,4,4,SPBP|Ets1|c-myc|MMP3,c-myc|Ets1|MMP3|SPBP,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.1.2,2114,9606,,GO:0045893,18059336,myc,Ets-2,Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3.,1.41,PMID.dPMID18059336.s6.p0,5,5,Ets-2|myc|p160|SRC-1|SRC-3,Ets-2|myc|p160|SRC-1|SRC-3,x
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.1.2,2114,9606,,GO:0045893,18059336,c-Myc,Ets-2,Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer.,1.01,PMID.dPMID18059336.s10.p1,3,3,Ets-2|p160|c-Myc,c-Myc|Ets-2|p160,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.1.2,2114,9606,,GO:0045893,18059336,myc,Ets-2,SRC-1 can utilize MAP kinase effector transcription factor Ets-2 to regulate the production of the oncogene myc.,0.37,PMID.dPMID18059336.s1.p2,3,3,SRC-1|Ets-2|myc,Ets-2|myc|SRC-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.2.6.1,2120,9606,,,9558390,Myc,TEL,A link between the function of the t(5;12)-encoded TEL/PDGFRbeta fusion protein and Myc expression is suggested by the fact that Myc is induced by PDGF and is essential for entry of cells into the S phase of the cell cycle.,0.12,PMID.dPMID9558390.s3.p1,4,3,TEL|PDGFRbeta|Myc|Myc,Myc|PDGFRbeta|TEL,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.1.15.2,2309,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,17452451,Myc,FOXO3a,Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.,0.42,PMID.dPMID17452451.s12.p2,3,3,Mxi1|FOXO3a|Myc,FOXO3a|Mxi1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9642304,c-myc,c-fos,METHODS: The c-fos/c-myc expression were analysed by Northern blot.,0.90,PMID.dPMID9642304.s4.p0,2,2,c-fos|c-myc,c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2498322,c-myc,c-fos,This same complex reacted strongly with anti-fos immunoglobulin suggesting a role for c-fos in governing c-myc expression.,0.87,PMID.dPMID2498322.s6.p0,2,2,c-fos|c-myc,c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,7565905,c-myc,c-fos,"The analysis of the of c-myc, c-Ha-ras and c-fos genes reveal no change in the c-myc expression, induction of the c-Ha-ras oncogene in CBP-6 and CBP-7 cells, and biochemistry and oncogene expression indicate that the acquired resistance to carboplatin is a complex, multifactorial process in these cells",0.78,PMID.dPMID7565905.s0.p5,5,3,c-myc|c-Ha-ras|c-fos|c-myc|c-Ha-ras,c-fos|c-Ha-ras|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8099529,c-myc,c-fos,"Expression of the c-fos protein was seen in 66% of the tumors; expression of the c-myc protein, in 50%; of the c-K-ras protein, in 16%; of the EGF-R protein, in 61%; and of the c-neu protein, in 54% of the tumors.",0.67,PMID.dPMID8099529.s4.p0,4,4,c-fos|c-myc|c-K-ras|EGF-R,c-fos|c-K-ras|c-myc|EGF-R,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2441504,c-myc,c-fos,"Expression of c-fos was not elevated in carcinoma compared to BPH, whereas expression of c-myc was elevated in carcinoma specimens of all grades of glandular differentiation, and expression of H-ras became increasingly elevated as differentiation was lost",0.66,PMID.dPMID2441504.s0.p0,3,3,c-fos|c-myc|H-ras,c-fos|c-myc|H-ras,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8909793,c-myc,c-fos,"These signalling pathways, except that for bcl-2 pathway, appear to be mediated by multiple PTKs: p56lck is critical for the induction of the c-fos/c-jun genes, the activation of Syk PTKs results in the induction of the c-myc gene and Jak3 PTK is required for the induction of both c-fos and c-myc genes.",0.57,PMID.dPMID8909793.s1.p12,9,7,bcl-2|p56lck|c-fos|c-jun|Syk|c-myc|Jak3|c-fos|c-myc,bcl-2|c-fos|c-jun|c-myc|Jak3|p56lck|Syk,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,2498162,MYC,FOS,These results raise the possibility that FOS and JUN participate in the regulation of MYC,0.57,PMID.dPMID2498162.s0.p1,3,3,FOS|JUN|MYC,FOS|JUN|MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9642304,c-myc,c-fos,Induction of c-fos/c-myc expression by epidermal growth factor decreases with alteration of their gene binding proteins in senescent fibroblasts.,0.27,PMID.dPMID9642304.s6.p0,2,2,c-fos|c-myc,c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,16552729,c-myc,c-fos,"The identified proteins included key regulators of signal transduction such as Rho GDP dissociation inhibitor (Rho GDI) alpha and beta members of the MAPK family, and proteins involved in the regulation of c-fos or c-myc expression.",0.18,PMID.dPMID16552729.s3.p0,2,2,c-fos|c-myc,c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,18422165,c-myc,c-fos,"RESULT: The rate of c-fos expressing cases was 15% and the rate of c-myc expressing cases was 20% in nasal polyps from topical steroid treated patients, but in untreated patients, the rate of c-fos expressing cases was 80% and the rate of c-myc expressing cases was 85%.",0.16,PMID.dPMID18422165.s3.p0,4,2,c-fos|c-myc|c-fos|c-myc,c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,14606069,c-myc,c-fos,"GBEP was able to elevate the apoptosis rate and expression of c-fos gene, but reduce the expression of c-myc and bcl-2 genes also in a dose-dependent manner.",0.13,PMID.dPMID14606069.s1.p0,3,3,c-fos|c-myc|bcl-2,bcl-2|c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,18422165,c-myc,c-fos,"RESULT: The rate of c-fos expressing cases was 15% and the rate of c-myc expressing cases was 20% in nasal polyps from topical steroid treated patients, but in untreated patients, the rate of c-fos expressing cases was 80% and the rate of c-myc expressing cases was 85%.",0.13,PMID.dPMID18422165.s3.p5,4,2,c-fos|c-myc|c-fos|c-myc,c-fos|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8909793,c-myc,c-fos,"These signalling pathways, except that for bcl-2 pathway, appear to be mediated by multiple PTKs: p56lck is critical for the induction of the c-fos/c-jun genes, the activation of Syk PTKs results in the induction of the c-myc gene and Jak3 PTK is required for the induction of both c-fos and c-myc genes.",0.10,PMID.dPMID8909793.s1.p30,9,7,bcl-2|p56lck|c-fos|c-jun|Syk|c-myc|Jak3|c-fos|c-myc,bcl-2|c-fos|c-jun|c-myc|Jak3|p56lck|Syk,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9642304,c-myc,c-fos,OBJECTIVE: To observe the changes of proto-oncogene c-fos/c-myc expression and its relation to specific transcription factors in human senescent fibroblast after epidermal growth factor (EGF) addition.,0.10,PMID.dPMID9642304.s5.p0,3,3,c-fos|c-myc|EGF,c-fos|c-myc|EGF,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,7605217,c-myc,c-fos,"Expression of c-fos was revealed in 79 of 138(59.4%) of proliferative and dysplastic changes of lung epithelium; c-jun in 40 of 61 (65.6%), c-ets-1 in 22 of 41 (53.7%), c-myc in 41 of 96(42.7%) and L-myc in 15 of 61 (24.6%), mainly in altered bronchial epithelium with a positive reaction to the antibodies against neuron specific enolase and S100 protein.",0.04,PMID.dPMID7605217.s1.p0,3,3,c-fos|c-myc|neuron specific enolase,c-fos|c-myc|neuron specific enolase,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,12713689,c-myc,c-fos,"The expression of the c-fos, H-ras and c-myc genes was immunohistochemically determined in biopsies from 12 patients with dilated cardiomyopathy, 24 patients with hypertrophic cardiomyopathy, and 4 patients with myocarditis.",0.01,PMID.dPMID12713689.s11.p1,3,3,c-fos|H-ras|c-myc,c-fos|c-myc|H-ras,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,12832487,c-myc,GATA-1,These effects were dependent on GATA-1-mediated repression of the c-myc (Myc) proto-oncogene.,0.41,PMID.dPMID12832487.s3.p0,3,2,GATA-1|c-myc|Myc,c-myc|GATA-1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,12832487,Myc,GATA-1,These effects were dependent on GATA-1-mediated repression of the c-myc (Myc) proto-oncogene.,0.14,PMID.dPMID12832487.s3.p1,3,2,GATA-1|c-myc|Myc,c-myc|GATA-1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,12832487,Myc,GATA-1,"GATA-1 inhibited Myc expression within 3 h, and chromatin immunoprecipitation studies indicated that GATA-1 occupies the Myc promoter in vivo, suggesting a direct mechanism for gene repression.",0.09,PMID.dPMID12832487.s2.p0,4,2,GATA-1|Myc|GATA-1|Myc,GATA-1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,20404562,c-Myc,HIF-1,"Specifically, under hypoxic conditions HIF-1-mediated regulation of oncogenic c-Myc plays a pivotal role in conferring metabolic advantages to tumor cells as well as adaptation to the tumorigenic micromilieu.",1.12,PMID.dPMID20404562.s3.p0,2,2,HIF-1|c-Myc,c-Myc|HIF-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15780936,Myc,HIF-1alpha,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,1.08,PMID.dPMID15780936.s2.p0,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17482131,C-MYC,HIF-1,"First, HIF-1 binds to and activates transcription of the MXI1 gene, which encodes a repressor of C-MYC transcriptional activity.",0.84,PMID.dPMID17482131.s2.p1,3,3,HIF-1|MXI1|C-MYC,C-MYC|HIF-1|MXI1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,19934275,c-Myc,HIF-1alpha,"Under arginine depletion conditions, HIF-1alpha was replaced by c-Myc in A2058 and SK-MEL-2 cells but not in A375 cells.",0.58,PMID.dPMID19934275.s4.p0,2,2,HIF-1alpha|c-Myc,c-Myc|HIF-1alpha,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15970707,Myc,HIF-1alpha,"In particular, the constitutively bound transcription factor Sp1 serves as a molecular switch by recruiting HIF-1alpha in hypoxia to displace the transcription activator Myc from the promoter.",0.30,PMID.dPMID15970707.s1.p0,2,2,HIF-1alpha|Myc,HIF-1alpha|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17785433,MYC,HIF-1,"As hypoxia signals a cellular deprivation state, HIF-1 has also been reported to counter the activity of MYC, which encodes a transcription factor that drives cell growth and proliferation.",0.23,PMID.dPMID17785433.s4.p0,2,2,HIF-1|MYC,HIF-1|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17671423,Myc,HIF-1alpha,"In accordance with the HIF-1alpha-Myc pathway, hypoxia requires HIF-1alpha for CDC25A repression, resulting in a selective displacement of an activating Myc from the CDC25A promoter without affecting a canonical Myc binding in the intron.",0.22,PMID.dPMID17671423.s2.p8,7,3,HIF-1alpha|Myc|HIF-1alpha|CDC25A|Myc|CDC25A|Myc,CDC25A|HIF-1alpha|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15071503,Myc,HIF-1alpha,"In keeping with its antagonism of Myc, HIF-1alpha also downregulates Myc-activated genes such as hTERT and BRCA1.",0.12,PMID.dPMID15071503.s1.p2,4,3,Myc|HIF-1alpha|Myc|BRCA1,BRCA1|HIF-1alpha|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15970707,Myc,HIF-1alpha,"Alternatively, HIF-1alpha regulates hypoxia-responsive genes by functionally antagonizing the oncoprotein Myc via protein-protein interactions.",0.10,PMID.dPMID15970707.s4.p0,2,2,HIF-1alpha|Myc,HIF-1alpha|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,17482131,C-MYC,HIF-1,HIF-1 mediates these effects by inhibiting C-MYC activity via two mechanisms.,0.08,PMID.dPMID17482131.s3.p0,2,2,HIF-1|C-MYC,C-MYC|HIF-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,19845622,c-Myc,HIF-1alpha,HIF-1alpha action via the HIF-1alpha-c-Myc axis is independent of its DNA-binding and transactivation domains; instead it requires the PAS-B domain to displace the transcription activator c-Myc from the target gene promoter for gene repression.,0.07,PMID.dPMID19845622.s3.p4,4,2,HIF-1alpha|HIF-1alpha|c-Myc|c-Myc,c-Myc|HIF-1alpha,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.4.0.1,3096,9606,,,2005901,c-myc,MBP-1,"Coexpression of the MBP-1 protein repress transcription from the human c-myc promoter, suggesting that MBP-1 may act as a negative regulatory factor for the human c-myc gene.",0.25,PMID.dPMID2005901.s0.p3,4,2,MBP-1|c-myc|MBP-1|c-myc,c-myc|MBP-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.4.0.1,3096,9606,,,2005901,c-myc,MBP-1,"Coexpression of the MBP-1 protein repress transcription from the human c-myc promoter, suggesting that MBP-1 may act as a negative regulatory factor for the human c-myc gene.",0.05,PMID.dPMID2005901.s0.p0,4,2,MBP-1|c-myc|MBP-1|c-myc,c-myc|MBP-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.4.0.2,3097,9606,,GO:0006355,12866954,c-myc,MIBP1,"Twelve differentiation-associated genes were cloned, including MIBP1 gene, which can regulate the c-myc gene expression and may be relevant with glioma cell differentiation.",0.30,PMID.dPMID12866954.s2.p0,2,2,MIBP1|c-myc,c-myc|MIBP1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,10891489,c-Myc,HMG-I,"HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene.",0.35,PMID.dPMID10891489.s6.p0,5,2,HMG-I|c-Myc|Myc|HMG-I|c-Myc,c-Myc|HMG-I|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,10891489,Myc,HMG-I,HMG-I/Y induction is decreased in Myc-deficient fibroblasts.,0.31,PMID.dPMID10891489.s5.p0,2,2,HMG-I|Myc,HMG-I|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,10891489,Myc,HMG-I,"HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene.",0.21,PMID.dPMID10891489.s6.p1,5,2,HMG-I|c-Myc|Myc|HMG-I|c-Myc,c-Myc|HMG-I|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,10891489,c-Myc,HMG-I,"HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene.",0.10,PMID.dPMID10891489.s6.p9,5,2,HMG-I|c-Myc|Myc|HMG-I|c-Myc,c-Myc|HMG-I|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,17132729,c-myc,TCF,These results support a previously unreported TGF-beta-independent function for Smad4 in cooperating with LEF/TCF to activate c-myc expression,0.97,PMID.dPMID17132729.s0.p5,4,4,TGF-beta|Smad4|TCF|c-myc,c-myc|Smad4|TCF|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,17132729,c-myc,TCF,We report that a peptide aptamer designed to inhibit the binding between Smad4 and LEF/TCF reduced c-myc expression and the growth rate of HepG2 cells.,0.88,PMID.dPMID17132729.s5.p2,3,3,Smad4|TCF|c-myc,c-myc|Smad4|TCF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,19966299,MYC,TCF,"Thus, we propose that a distinct chromatin architecture coordinated by beta-catenin/TCF-bound WREs accompanies transcriptional activation of MYC gene expression",0.51,PMID.dPMID19966299.s0.p0,2,2,TCF|MYC,MYC|TCF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,19966299,MYC,TCF,A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers.,0.45,PMID.dPMID19966299.s9.p0,2,2,TCF|MYC,MYC|TCF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,12414619,c-myc,TCF,"Increased transcriptional initiation of c-myc induced by the short-chain fatty acid, butyrate, consistent with elevated beta-catenin/TCF activity, was efficiently abrogated by a block to transcriptional elongation, resulting in decreased c-myc expression.",0.26,PMID.dPMID12414619.s3.p2,3,2,c-myc|TCF|c-myc,c-myc|TCF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,11470825,c-myc,TCF,"Also, 1alpha,25(OH)2D(3) inhibited expression of beta-catenin-TCF-4-responsive genes, c-myc, peroxisome proliferator-activated receptor delta, Tcf-1, and CD44, whereas it induced expression of ZO-1.",0.16,PMID.dPMID11470825.s1.p0,5,5,TCF|c-myc|Tcf-1|CD44|ZO-1,CD44|c-myc|TCF|Tcf-1|ZO-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.7.17,3195,9606,,,20618946,MYC,TLX1,"In addition, the TLX1/NOTCH/MYC transcriptional network coregulates genes involved in T cell development, such as CD1 and RAG family members, and therefore may prescribe the early cortical stage of differentiation arrest characteristic of the TLX1 subgroup of T-ALL",0.80,PMID.dPMID20618946.s0.p0,3,2,TLX1|MYC|TLX1,MYC|TLX1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.7.17,3195,9606,,,20618946,MYC,TLX1,Comparison of the dataset to publicly available biological databases indicated that the TLX1/NOTCH-coregulated genes are frequently targeted by MYC.,0.43,PMID.dPMID20618946.s6.p0,2,2,TLX1|MYC,MYC|TLX1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.7.17,3195,9606,,,20618946,MYC,TLX1,"CONCLUSIONS: We found that TLX1 and NOTCH synergistically regulate transcription in T-ALL, at least in part via the sharing of a TLE corepressor and by augmenting expression of MYC.",0.13,PMID.dPMID20618946.s2.p0,2,2,TLX1|MYC,MYC|TLX1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.4.2,3214,9606,,GO:0006355,10085075,c-myc,HOXB4,"Taken together, these results indicate that HOXB4 is one of the nuclear phosphoproteins involved in c-myc transcription elongation block during HL-60 cell differentiation by 1,25-(OH)2D3",0.71,PMID.dPMID10085075.s0.p0,2,2,HOXB4|c-myc,c-myc|HOXB4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.4.2,3214,9606,,GO:0006355,11250656,c-myc,HOXB4,"The data further establish that HOXB4 levels are regulated by 1,25-(OH)2D(3) and reveal that HOXB4 participates in the down-regulation of c-myc expression",0.59,PMID.dPMID11250656.s0.p2,3,2,HOXB4|HOXB4|c-myc,c-myc|HOXB4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.4.2,3214,9606,,GO:0006355,11250656,c-myc,HOXB4,HOXB4 binds to the c-my c gene at sites involved in blocking c-myc transcription elongation.,0.25,PMID.dPMID11250656.s5.p0,2,2,HOXB4|c-myc,c-myc|HOXB4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.4.2,3214,9606,,GO:0006355,11250656,c-myc,HOXB4,"In this study, a phosphorothioate antisense oligonucleotide targeted against HOXB4 was examined for its effect on 1,25-(OH)2D(3) inhibition of c-myc expression.",0.21,PMID.dPMID11250656.s4.p0,2,2,HOXB4|c-myc,c-myc|HOXB4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,18085637,myc,Id2,"CONCLUSIONS: Taken together, the current data suggest that Id2 commonly is overexpressed in highly proliferative T-cell lymphomas, and its expression may result from transcriptional activation of myc in these tumors.",1.32,PMID.dPMID18085637.s0.p1,3,3,Id2|T-cell lymphoma|myc,Id2|myc|T-cell lymphoma,e
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,20375148,Myc,Id2,Id2 expression has been found to depend on Myc-Max-Mad transcriptional complexes in mammary epithelial cells.,1.00,PMID.dPMID20375148.s5.p0,2,2,Id2|Myc,Id2|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,18085637,myc,helix-loop-helix protein Id2,The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.,0.59,PMID.dPMID18085637.s9.p0,3,3,helix-loop-helix protein Id2|myc|T-cell lymphoma,helix-loop-helix protein Id2|myc|T-cell lymphoma,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,16007217,c-Myc,Id2,Deletion analysis revealed that transactivation involves a 166 bp region immediately upstream to the Id2 transcriptional start site and is independent of c-Myc.,0.25,PMID.dPMID16007217.s5.p0,2,2,Id2|c-Myc,c-Myc|Id2,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,12545167,MYC,ID2,"Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma.",0.09,PMID.dPMID12545167.s7.p1,5,3,ID2|MYCN|MYC|ID2|MYCN,ID2|MYC|MYCN,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.14.1,3651,9606,GO:0003702|GO:0003704,,9722555,c-myc,IPF-1,IPF-1.c-myc expression also enhanced the response of the insulin promoter to elevations in extracellular glucose concentration.,0.09,PMID.dPMID9722555.s5.p0,2,2,IPF-1|c-myc,c-myc|IPF-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,2498162,MYC,JUN,These results raise the possibility that FOS and JUN participate in the regulation of MYC,0.65,PMID.dPMID2498162.s0.p2,3,3,FOS|JUN|MYC,FOS|JUN|MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8909793,c-myc,c-jun,"These signalling pathways, except that for bcl-2 pathway, appear to be mediated by multiple PTKs: p56lck is critical for the induction of the c-fos/c-jun genes, the activation of Syk PTKs results in the induction of the c-myc gene and Jak3 PTK is required for the induction of both c-fos and c-myc genes.",0.57,PMID.dPMID8909793.s1.p13,9,7,bcl-2|p56lck|c-fos|c-jun|Syk|c-myc|Jak3|c-fos|c-myc,bcl-2|c-fos|c-jun|c-myc|Jak3|p56lck|Syk,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7683227,c-myc,C-jun,This was temporally associated with a marked induction of C-jun expression but a significant repression in BCL-2 and c-myc expressions.,0.48,PMID.dPMID7683227.s2.p1,3,3,C-jun|BCL-2|c-myc,BCL-2|C-jun|c-myc,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8909793,c-myc,c-jun,"These signalling pathways, except that for bcl-2 pathway, appear to be mediated by multiple PTKs: p56lck is critical for the induction of the c-fos/c-jun genes, the activation of Syk PTKs results in the induction of the c-myc gene and Jak3 PTK is required for the induction of both c-fos and c-myc genes.",0.10,PMID.dPMID8909793.s1.p31,9,7,bcl-2|p56lck|c-fos|c-jun|Syk|c-myc|Jak3|c-fos|c-myc,bcl-2|c-fos|c-jun|c-myc|Jak3|p56lck|Syk,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.1,4084,9606,,,12821782,Myc,Mad protein,"Mad protein, a specific antagonist of Myc, repressed E6-mediated transactivation of the hTERT promoter and this repression was relieved by Myc overexpression.",0.66,PMID.dPMID12821782.s5.p1,3,2,Mad protein|Myc|Myc,Mad protein|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.1,4084,9606,,,19526459,MYC,MAD1,"MAX dimerization protein 1 (MAD1) is a transcription suppressor that antagonizes MYC-mediated transcription activation, and the inhibition mechanism occurs mainly through the competition of target genes' promoter MYC binding sites by MAD1.",0.25,PMID.dPMID19526459.s8.p0,4,2,MAD1|MYC|MYC|MAD1,MAD1|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.1,4084,9606,,,12821782,Myc,Mad protein,"Mad protein, a specific antagonist of Myc, repressed E6-mediated transactivation of the hTERT promoter and this repression was relieved by Myc overexpression.",0.12,PMID.dPMID12821782.s5.p0,3,2,Mad protein|Myc|Myc,Mad protein|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,15930298,c-myc,Smad3,The data indicate that SnoN-Smad3 complexes do not cause repression of c-myc transcription but rather prevent functionality of active repressor complexes.,0.60,PMID.dPMID15930298.s2.p2,3,3,SnoN|Smad3|c-myc,c-myc|Smad3|SnoN,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,12150994,c-myc,Smad3,"We defined how, in the same context, Smad3 can also mediate transcriptional repression of the growth-promoting gene c-myc.",0.57,PMID.dPMID12150994.s4.p0,2,2,Smad3|c-myc,c-myc|Smad3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,17934056,c-myc,Smad3,"By interacting with c-myc, Smad3 also represses the c-myc gene.",0.11,PMID.dPMID17934056.s2.p2,3,2,c-myc|Smad3|c-myc,c-myc|Smad3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,Smad4 cooperates with lymphoid enhancer-binding factor 1/T cell-specific factor to increase c-myc expression in the absence of TGF-beta signaling.,0.96,PMID.dPMID17132729.s9.p1,4,4,Smad4|lymphoid enhancer-binding factor 1|c-myc|TGF-beta,c-myc|lymphoid enhancer-binding factor 1|Smad4|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,Reduction of Smad4 levels by RNAi knockdown also reduced c-myc expression levels and sensitized hepatocytes to cell death by serum deprivation.,0.78,PMID.dPMID17132729.s2.p0,2,2,Smad4|c-myc,c-myc|Smad4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,These results support a previously unreported TGF-beta-independent function for Smad4 in cooperating with LEF/TCF to activate c-myc expression,0.59,PMID.dPMID17132729.s0.p4,4,4,TGF-beta|Smad4|TCF|c-myc,c-myc|Smad4|TCF|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,"Smad4 binding to the positive TBE1 c-myc element was reduced by TGF-beta, consistent with Smad4's inhibitory role on c-myc expression in response to TGF-beta.",0.46,PMID.dPMID17132729.s3.p10,7,4,Smad4|TBE1|c-myc|TGF-beta|Smad4|c-myc|TGF-beta,c-myc|Smad4|TBE1|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,"Further analysis demonstrated that, in the absence of TGF-beta, Smad4 was bound to the positive regulatory element TBE1 from the c-myc promoter and activated c-myc promoter activity.",0.18,PMID.dPMID17132729.s4.p7,5,4,TGF-beta|Smad4|TBE1|c-myc|c-myc,c-myc|Smad4|TBE1|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,"Further analysis demonstrated that, in the absence of TGF-beta, Smad4 was bound to the positive regulatory element TBE1 from the c-myc promoter and activated c-myc promoter activity.",0.18,PMID.dPMID17132729.s4.p4,5,4,TGF-beta|Smad4|TBE1|c-myc|c-myc,c-myc|Smad4|TBE1|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,Smad4,"Smad4 binding to the positive TBE1 c-myc element was reduced by TGF-beta, consistent with Smad4's inhibitory role on c-myc expression in response to TGF-beta.",0.01,PMID.dPMID17132729.s3.p14,7,4,Smad4|TBE1|c-myc|TGF-beta|Smad4|c-myc|TGF-beta,c-myc|Smad4|TBE1|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,15555279,c-myc,Smad7,"RESULTS: After BEP2D and BERP35T2 cells transfected with Smad7, the transcriptional activity of c-myc was significantly increased.",0.38,PMID.dPMID15555279.s2.p0,2,2,Smad7|c-myc,c-myc|Smad7,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,1406956,c-Myc,Max,Max-induced repression is relieved by overexpression of c-Myc.,1.33,PMID.dPMID1406956.s2.p0,2,2,Max|c-Myc,c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16475822,c-Myc,Max,The Myc-Max-Mad network of proteins activates or represses gene transcription depending on whether the dimerization partner of Max is c-Myc or Mad.,0.96,PMID.dPMID16475822.s14.p4,4,2,Myc|Max|Max|c-Myc,c-Myc|Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,17217336,Myc,Max,"Max is the obligatory DNA-binding and dimerization partner for all the bHLHZip regulators of the Myc/Max/Mad network, including the Myc family of oncoproteins and the Mad family of Myc antagonists, which recognize E-box DNA elements in the regulatory regions of target genes.",0.86,PMID.dPMID17217336.s10.p0,5,2,Max|Myc|Max|Myc|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,8637719,Myc,Max,"In light of the evidence that ODC is transcriptionally regulated in vitro and in vivo by the Myc/Max protein complex and the potential role of Mxi1 and Mad as antagonists of Myc transactivation activity, we set out to determine if one of these Max associated proteins, Mxi1, could affect the regulation of ODC expression by Myc/Max and if this regulation was correlated to growth status.",0.69,PMID.dPMID8637719.s4.p19,8,3,Myc|Max|Mxi1|Myc|Max|Mxi1|Myc|Max,Max|Mxi1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,10825189,Myc,Max,Myc-Max dimers transactivate whereas Mad-Max-mSin3 complexes repress Myc-mediated transcriptional activation.,0.64,PMID.dPMID10825189.s7.p5,4,2,Myc|Max|Max|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,8426752,Myc,max,The max gene encodes a heterodimeric partner of Myc.,0.62,PMID.dPMID8426752.s8.p0,2,2,max|Myc,max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,10672043,c-Myc,Max,The MSSP/Myc/Max ternary complex lost the binding activity to the E-box sequence-the recognition sequence of c-Myc/Max complex-thereby abrogating the E-box-dependent transcription activity of c-Myc.,0.53,PMID.dPMID10672043.s3.p14,6,3,MSSP|Myc|Max|c-Myc|Max|c-Myc,c-Myc|Max|MSSP|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,11535131,Myc,Max,"Taken together, our findings uncover three distinct processes, namely dephosphorylation and cleavage by caspase-5 and caspase-7, that target Max during Fas-mediated apoptosis, suggesting the regulation of the Myc/Max/Mad network through its central component",0.51,PMID.dPMID11535131.s0.p1,4,3,Max|Fas|Myc|Max,Fas|Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,7789959,Myc,Max,"The MXI1 gene encodes a protein interacting with Max, a regulatory factor of the Myc oncogene, and is located on chromosome 10q25, a region showing frequent loss of heterozygosity in malignant gliomas.",0.48,PMID.dPMID7789959.s4.p2,3,3,MXI1|Max|Myc,Max|MXI1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16128587,Myc,Max,"Looked at from the perspective of the Max protein, the binding of DNA to Max significantly reduces the affinity of the Max protein for the second monomer, whether the second monomer is Myc, Mad, or Max.",0.47,PMID.dPMID16128587.s1.p3,5,2,Max|Max|Max|Myc|Max,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,10339499,Myc,Max,"In addition to modulation of the expression of Myc/Max/Mad network proteins, posttranslational negative regulation of Myc by external signals may, therefore, be an alternative biologically important level of control with potential therapeutic relevance for hematopoietic and other tumors with deregulated Myc expression",0.43,PMID.dPMID10339499.s0.p4,4,2,Myc|Max|Myc|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,10378691,c-Myc,Max,"Recently described interactions between the CTD and other cellular proteins, including YY-1, AP-2, BRCA-1, TFII-I, and Miz-1, suggest levels of regulatory complexity beyond Max in controlling DNA recognition by c-Myc.",0.42,PMID.dPMID10378691.s4.p9,5,5,YY-1|TFII-I|Miz-1|Max|c-Myc,c-Myc|Max|Miz-1|TFII-I|YY-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,1644290,Myc,Max,"We have investigated the common and unique properties among the Myc family, as well as the physiological role of Max in the regulation of Myc family function.",0.39,PMID.dPMID1644290.s4.p2,3,2,Myc|Max|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,2006410,c-Myc,Max,"The interaction between Max and c-Myc was dependent on the integrity of the c-Myc HLH-Zip domain, but not on the basic region or other sequences outside the domain.",0.38,PMID.dPMID2006410.s3.p1,3,2,Max|c-Myc|c-Myc,c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,12747840,Myc,Max,Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression.,0.38,PMID.dPMID12747840.s8.p2,3,2,Myc|Max|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16620028,c-Myc,Max,"Although the molecular mechanisms by which c-Myc and its obligate partner, Max, regulate gene expression are becoming better defined, genes or transcriptomes that c-Myc regulate are just emerging from a variety of different experimental approaches.",0.33,PMID.dPMID16620028.s2.p2,3,2,c-Myc|Max|c-Myc,c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,10339499,Myc,Max,"In addition to modulation of the expression of Myc/Max/Mad network proteins, posttranslational negative regulation of Myc by external signals may, therefore, be an alternative biologically important level of control with potential therapeutic relevance for hematopoietic and other tumors with deregulated Myc expression",0.33,PMID.dPMID10339499.s0.p2,4,2,Myc|Max|Myc|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16475822,c-Myc,Max,The Myc-Max-Mad network of proteins activates or represses gene transcription depending on whether the dimerization partner of Max is c-Myc or Mad.,0.31,PMID.dPMID16475822.s14.p5,4,2,Myc|Max|Max|c-Myc,c-Myc|Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,1406956,Myc,Max,"Repression requires the DNA-binding domain of Max, whereas relief of repression requires the dimerization and transcriptional activation activities of Myc.",0.29,PMID.dPMID1406956.s1.p0,2,2,Max|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,11535131,Myc,Max,"Max is the central component of the Myc/Max/Mad network of transcription factors that regulate growth, differentiation and apoptosis.",0.26,PMID.dPMID11535131.s11.p0,3,2,Max|Myc|Max,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,15003254,Myc,Max,The analysis of the mechanisms by which the Myc:Max complex regulates transcription at the molecular level in vitro has been hampered by the difficulty in obtaining highly pure recombinant Myc:Max heterodimers that contain full-length Myc with its complete TAD domain and that have sequence-specific DNA-binding activity.,0.23,PMID.dPMID15003254.s3.p2,5,2,Myc|Max|Myc|Max|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,9797456,MYC,Max,"AMY-1 by itself did not recognize the E-box element, the MYC/Max binding sequence, nor did it transactivate via the element, but stimulated the activation of E-box-regulated transcription by MYC/Max.",0.16,PMID.dPMID9797456.s3.p5,5,3,AMY-1|MYC|Max|MYC|Max,AMY-1|Max|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16287840,Myc,Max,"While Max lacks a transcription regulatory domain, the N terminus of Myc contains a transcription activation domain (TAD) that recruits cofactor complexes containing the histone acetyltransferases (HATs) GCN5 and Tip60.",0.16,PMID.dPMID16287840.s6.p0,4,4,Max|Myc|GCN5|Tip60,GCN5|Max|Myc|Tip60,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,17217336,Myc,Max,"Max is the obligatory DNA-binding and dimerization partner for all the bHLHZip regulators of the Myc/Max/Mad network, including the Myc family of oncoproteins and the Mad family of Myc antagonists, which recognize E-box DNA elements in the regulatory regions of target genes.",0.13,PMID.dPMID17217336.s10.p3,5,2,Max|Myc|Max|Myc|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,1490382,Myc,Max,"Max repression is dependent on an intact DNA binding region, while Myc activation depends on both the N-terminal activation and the C-terminal dimerization domains.",0.12,PMID.dPMID1490382.s1.p0,2,2,Max|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,1490382,c-myc,max,"Similar overexpression of max results in a repression of reporter gene activity, an effect which is reversed by co-expression with c-myc.",0.11,PMID.dPMID1490382.s2.p0,2,2,max|c-myc,c-myc|max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16140957,c-Myc,Max,Expression of Max-U reduced both the abundance of endogenous c-Myc in and the proliferation rate of a Burkitt lymphoma cell line.,0.09,PMID.dPMID16140957.s2.p0,2,2,Max|c-Myc,c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,1565473,myc,max,max expression is identical in myc-induced tumor cell lines relative to other cells.,0.06,PMID.dPMID1565473.s2.p0,2,2,max|myc,max|myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,8425218,Myc,Max,"To determine whether Max mediates the function of regulatory proteins other than Myc, we screened a lambda gt11 expression library with radiolabeled Max protein.",0.06,PMID.dPMID8425218.s5.p0,3,2,Max|Myc|Max,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,16128587,Myc,Max,"Looked at from the perspective of the Max protein, the binding of DNA to Max significantly reduces the affinity of the Max protein for the second monomer, whether the second monomer is Myc, Mad, or Max.",0.03,PMID.dPMID16128587.s1.p5,5,2,Max|Max|Max|Myc|Max,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,19189276,c-Myc,Max,"For example, the specific heterodimerization between the b-HLH-LZ transcription factors c-Myc and Max is a prerequisite for c-Myc transcriptional activity that leads to cell growth, proliferation and tumorigenesis.",0.02,PMID.dPMID19189276.s7.p2,3,2,c-Myc|Max|c-Myc,c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,11422041,c-Myc,Max,"Max is the best known heterodimeric partner of c-Myc, interacting with its C-terminal domain, and Bin1 is an adaptor protein interacting with its N-terminal domain.",0.02,PMID.dPMID11422041.s9.p0,3,3,Max|c-Myc|Bin1,Bin1|c-Myc|Max,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.5,4149,9606,,,17217336,Myc,Max,"Max is the obligatory DNA-binding and dimerization partner for all the bHLHZip regulators of the Myc/Max/Mad network, including the Myc family of oncoproteins and the Mad family of Myc antagonists, which recognize E-box DNA elements in the regulatory regions of target genes.",0.02,PMID.dPMID17217336.s10.p6,5,2,Max|Myc|Max|Myc|Myc,Max|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.35,4150,9606,,,8844723,c-myc,MAZ,These findings are consistent with the established role for MAZ in regulating c-myc gene expression.,1.30,PMID.dPMID8844723.s1.p0,2,2,MAZ|c-myc,c-myc|MAZ,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.35,4150,9606,,,8844723,c-myc,MAZ,The MAZ protein has been shown to be a transcription regulator of the c-myc protooncogene.,0.71,PMID.dPMID8844723.s3.p0,2,2,MAZ|c-myc,c-myc|MAZ,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.35,4150,9606,,,9294605,c-myc,Myc-associated zinc finger protein,"To investigate whether MAZ (Myc-associated zinc finger protein) affects the expression of the c-myc gene during the retinoic acid-induced (RA-induced) neuroectodermal differentiation of P19 embryonal carcinoma (EC) cells, we introduced a CAT reporter construct, human c-myc promoter/CAT (pMyc2CAT), and a mutant CAT derivative that lacked an ME1a1 site (pMyc1CAT) into P19EC cells to monitor the promoter activity of the c-myc gene.",0.59,PMID.dPMID9294605.s4.p2,10,3,MAZ|Myc-associated zinc finger protein|c-myc|CAT|c-myc|CAT|CAT|CAT|CAT|c-myc,CAT|c-myc|MAZ|Myc-associated zinc finger protein,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.35,4150,9606,,,10448092,c-myc,MAZ,"Moreover, the mutated MAZ was unable to enhance the expression of luciferase encoded by a c-myc promoter/luciferase reporter gene in HeLa cells in the presence of CKII.",0.58,PMID.dPMID10448092.s1.p0,3,3,MAZ|c-myc|CKII,CKII|c-myc|MAZ,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.35,4150,9606,,,11777933,c-myc,Myc-associated zinc finger protein,A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.,0.46,PMID.dPMID11777933.s9.p0,2,2,Myc-associated zinc finger protein|c-myc,c-myc|Myc-associated zinc finger protein,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.35,4150,9606,,,9294605,c-myc,MAZ,"In addition, an electrophoretic mobility shift assay (EMSA) with ME1a1 DNA as probe demonstrated that the kinetics of the DNA-binding activity of MAZ were closely correlated with the changes in the expression of CAT from the c-myc promoter/CAT gene during the differentiation of P19EC cells.",0.14,PMID.dPMID9294605.s1.p1,4,3,MAZ|CAT|c-myc|CAT,CAT|c-myc|MAZ,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.7.0.1,4335,9606,,,17419941,Myc,Mnt,It is therefore possible that Myc function relies on its ability to overcome transcriptional repression by Mnt and that relief of Mnt-mediated transcriptional repression is of greater importance for regulation of target genes than the sole activation by Myc.,1.33,PMID.dPMID17419941.s2.p5,4,2,Myc|Mnt|Mnt|Myc,Mnt|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.7.0.1,4335,9606,,,16410546,Myc,Mnt,But Mnt-Max and Mxd-Max complexes are transcriptional repressors and can antagonize the transcriptional activation function of Myc-Max.,0.16,PMID.dPMID16410546.s2.p0,2,2,Mnt|Myc,Mnt|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.7.0.1,4335,9606,,,15519529,MYC,MNT,"Of 119 genes residing in this region, seven genes--14-3-3epsilon (YWHAE), HIC-1, ROX/MNT (a helix-loop-helix transcription factor and member of the MYC/MAX superfamily), KIAA0399, UBE2G1 (ubiquitin ligase), ALOX15, and MINK--encode proteins with potential links to cancer.",0.04,PMID.dPMID15519529.s4.p5,5,4,YWHAE|ROX|MNT|MYC|UBE2G1,MNT|MYC|ROX|UBE2G1|YWHAE,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.7.0.1,4335,9606,,,15519529,MYC,ROX,"Of 119 genes residing in this region, seven genes--14-3-3epsilon (YWHAE), HIC-1, ROX/MNT (a helix-loop-helix transcription factor and member of the MYC/MAX superfamily), KIAA0399, UBE2G1 (ubiquitin ligase), ALOX15, and MINK--encode proteins with potential links to cancer.",0.04,PMID.dPMID15519529.s4.p4,5,4,YWHAE|ROX|MNT|MYC|UBE2G1,MNT|MYC|ROX|UBE2G1|YWHAE,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,8603382,c-myc,MXI1,"The MXI1 gene, located at 10q24-q25, may serve to negatively regulate c-myc oncogene activity, and potentially has tumor suppressor function.",1.42,PMID.dPMID8603382.s6.p0,2,2,MXI1|c-myc,c-myc|MXI1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,8637719,Myc,Mxi1,"In light of the evidence that ODC is transcriptionally regulated in vitro and in vivo by the Myc/Max protein complex and the potential role of Mxi1 and Mad as antagonists of Myc transactivation activity, we set out to determine if one of these Max associated proteins, Mxi1, could affect the regulation of ODC expression by Myc/Max and if this regulation was correlated to growth status.",1.15,PMID.dPMID8637719.s4.p20,8,3,Myc|Max|Mxi1|Myc|Max|Mxi1|Myc|Max,Max|Mxi1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,17452451,Myc,Mxi1,Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.,1.15,PMID.dPMID17452451.s12.p1,3,3,Mxi1|FOXO3a|Myc,FOXO3a|Mxi1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,9669667,MYC,MXI1,"MXI1 encodes a basic-helix-loop-helix protein that suppresses the transcriptional activity of the MYC oncoprotein by competing for the common dimerization partner, MAX, and binding to identical DNA sites.",1.09,PMID.dPMID9669667.s6.p0,3,3,MXI1|MYC|MAX,MAX|MXI1|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,17482131,C-MYC,MXI1,"First, HIF-1 binds to and activates transcription of the MXI1 gene, which encodes a repressor of C-MYC transcriptional activity.",1.07,PMID.dPMID17482131.s2.p2,3,3,HIF-1|MXI1|C-MYC,C-MYC|HIF-1|MXI1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,10470286,Myc,Mxi1,Mxi1 is thought to negatively regulate Myc function and may therefore be a potential tumor suppressor gene.,0.76,PMID.dPMID10470286.s8.p0,2,2,Mxi1|Myc,Mxi1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,17697116,Myc,Mxi1,"Unlike Mxi1-SRbeta, Mxi1-SRalpha is not a potent suppressor of the cellular transformation activity of Myc.",0.20,PMID.dPMID17697116.s4.p2,3,2,Mxi1|Mxi1|Myc,Mxi1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,9354456,c-Myc,Mxi1,"The Mxi1 protein functions in a regulatory network with members of the c-Myc family, in which c-Myc activates transcription and stimulates cell proliferation, and Mxi1 negatively regulates these actions.",0.12,PMID.dPMID9354456.s8.p0,4,2,Mxi1|c-Myc|c-Myc|Mxi1,c-Myc|Mxi1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,11101889,Myc,Mxi,Members of the Mad/Mxi family of repressors play important roles in the transition between proliferation and differentiation by down-regulating the expression of genes that are activated by the proto-oncogene product Myc.,0.03,PMID.dPMID11101889.s5.p0,2,2,Mxi|Myc,Mxi|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.7.5,4601,9606,,,7789959,Myc,MXI1,"The MXI1 gene encodes a protein interacting with Max, a regulatory factor of the Myc oncogene, and is located on chromosome 10q25, a region showing frequent loss of heterozygosity in malignant gliomas.",0.01,PMID.dPMID7789959.s4.p1,3,3,MXI1|Max|Myc,Max|MXI1|Myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,19609274,MYC,MYB,These data highlight a cooperative function for MYB in the context of activated Wnt signaling and provide a molecular basis for the expression of MYC in CRC.,0.79,PMID.dPMID19609274.s0.p0,3,3,MYB|MYC|CRC,CRC|MYB|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1679531,c-myc,Myb,This result suggests that the Myb protein could participate in regulation of human c-myc gene expression,0.52,PMID.dPMID1679531.s0.p0,2,2,Myb|c-myc,c-myc|Myb,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,19609274,MYC,MYB,"We explored the relationship between activated Wnt signaling and MYB in regulating MYC and found activated beta-catenin in combination with MYB induces robust upregulation of MYC promoter activity, as well as endogenous MYC mRNA and protein expression, in human cells.",0.51,PMID.dPMID19609274.s2.p0,6,3,MYB|MYC|beta-catenin|MYB|MYC|MYC,beta-catenin|MYB|MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1376749,c-myc,c-myb,"We conclude that c-myb, B-myb, and c-myc are regulated independently from one another, that induction of c-myc and B-myb together is not sufficient to trigger B cell proliferation, and we suggest that expression of all three is a prerequisite for proliferation to occur",0.07,PMID.dPMID1376749.s0.p3,5,3,c-myb|B-myb|c-myc|c-myc|B-myb,B-myb|c-myb|c-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,2536917,c-myc,c-myb,"Surprisingly, in two cell lines with low neuroendocrine differentiation but without c-myc protein expression (SCLC-86M1 and NCI-H526) p75c-myb expression was observed which may therefore be able to substitute for the p64c-myc protein.",0.06,PMID.dPMID2536917.s7.p5,4,3,c-myc|SCLC|c-myb|c-myc,c-myb|c-myc|SCLC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,11259163,c-myc,Myb,Here we have used a conditionally myb-transformed myeloid cell line (ERMYB) to further examine Myb regulation of one candidate target gene--c-myc--that has the potential to affect cell proliferation.,0.01,PMID.dPMID11259163.s3.p2,3,2,myb|Myb|c-myc,c-myc|myb|Myb,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,1776859,c-myc,c-myb,"The effects of E2 and 4-OH Tam on the expression of the not-amplified c-mil and c-myb oncogenes were stronger than those observed on c-myc expression; however, the E2 reversal effect was identical either after short or long-term antiestrogen treatment.",0.00,PMID.dPMID1776859.s1.p2,3,3,Tam|c-myb|c-myc,c-myb|c-myc|Tam,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.3,4610,9606,,GO:0006355,8934535,c-myc,L-myc,"We have previously reported that all-trans-retinoic acid (RA) inhibits the growth of NCI-H82 SCLC cells in association with increased neuroendocrine differentiation, increased L-myc gene expression and decreased c-myc gene expression.",0.48,PMID.dPMID8934535.s6.p0,2,2,L-myc|c-myc,c-myc|L-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.3,4610,9606,,GO:0006355,12707044,c-MYC,L-MYC,"Using oligonucleotide microarrays, L-MYC was found to be more frequently overexpressed in OvCas than either c-MYC or N-MYC relative to ovarian surface epithelium.",0.13,PMID.dPMID12707044.s2.p0,3,3,L-MYC|c-MYC|N-MYC,c-MYC|L-MYC|N-MYC,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.3,4610,9606,,GO:0006355,2997622,myc,L-myc,"L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.",0.10,PMID.dPMID2997622.s11.p0,2,2,L-myc|myc,L-myc|myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,2669755,c-myc,N-myc,"In this report, we show that in IMR32 cells the expression of the N-myc gene is repressed by introduction of a c-myc expression vector (c-myc cDNA conjugated with an SR promoter).",1.77,PMID.dPMID2669755.s1.p0,3,2,N-myc|c-myc|c-myc,c-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,2669755,c-myc,N-myc,Transrepression of the N-myc expression by c-myc protein.,0.90,PMID.dPMID2669755.s3.p0,2,2,N-myc|c-myc,c-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,2997622,c-myc,N-myc,"The N-myc gene, first detected by its homology to the second exon of the c-myc gene, is amplified and/or expressed in tumours or cell lines derived from neuroblastoma, retinoblastoma and SCLC.",0.31,PMID.dPMID2997622.s9.p0,2,2,N-myc|c-myc,c-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,2068146,c-myc,N-myc,Antisense inhibition of N-myc reduces cell growth but does not affect c-myc expression in the neuroepithelioma cell line CHP100.,0.16,PMID.dPMID2068146.s0.p0,2,2,N-myc|c-myc,c-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,8707290,c-myc,N-myc,"Since the N-myc gene at 2p24 is amplified in NCI-H69 and the c-myc gene at 8q24 is amplified in NCI-H82, it is possible that these DNA fragments are co-amplified with N-myc or c-myc in these cell lines.",0.15,PMID.dPMID8707290.s4.p0,4,2,N-myc|c-myc|N-myc|c-myc,c-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,12733375,C-myc,N-myc,"Expression of C-myc and N-myc protein in adulthood and childhood medulloblastomas and prognostic analysis    OBJECTIVE: To detect the expression of C-myc and N-myc in medulloblastomas, the difference between adults and children, and the relation between expression and prognosis.",0.11,PMID.dPMID12733375.s7.p2,4,2,C-myc|N-myc|C-myc|N-myc,C-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,15013217,MYC,MYCN,MYCN is a member of the MYC family of oncogenes that encode nuclear proteins serving as transcription factors.,0.10,PMID.dPMID15013217.s5.p0,2,2,MYCN|MYC,MYC|MYCN,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,19946337,c-MYC,MYCN,MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.,0.06,PMID.dPMID19946337.s6.p0,4,2,MYCN|c-MYC|MYCN|c-MYC,c-MYC|MYCN,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,2669755,c-myc,N-myc,"In this report, we show that in IMR32 cells the expression of the N-myc gene is repressed by introduction of a c-myc expression vector (c-myc cDNA conjugated with an SR promoter).",0.06,PMID.dPMID2669755.s1.p1,3,2,N-myc|c-myc|c-myc,c-myc|N-myc,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2191300,c-myc,NF-kappa B,These results suggest the involvement of NF-kappa B-like factors in the regulation of c-myc transcription,1.15,PMID.dPMID2191300.s0.p0,2,2,NF-kappa B|c-myc,c-myc|NF-kappa B,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,7969136,c-myc,NF-kappa B,NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.,1.01,PMID.dPMID7969136.s10.p0,2,2,NF-kappa B|c-myc,c-myc|NF-kappa B,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,12894581,c-Myc,NF-kappa B,"IB-MECA treatment also induced down-modulation of the expression of NF-kappa B/p65, known to regulate the transcription of cyclin D1 and c-Myc.",0.86,PMID.dPMID12894581.s2.p0,2,2,NF-kappa B|c-Myc,c-Myc|NF-kappa B,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,12007958,c-myc,NFkappaB,"Activation of NFkappaB by the antioxidant WR-1065 is accompanied by a reduced expression of the oncogene c-myc and an enhanced expression of the antioxidant gene MnSOD, a gene whose expression in tumor cells is relatively low, but when overexpressed has been correlated with a suppression of the malignant phenotype.",0.66,PMID.dPMID12007958.s1.p0,2,2,NFkappaB|c-myc,c-myc|NFkappaB,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,7969136,c-myc,NF-kappa B,We conclude that the two NF-kappa B sites function as positive regulatory regions for the translocated c-myc gene in Burkitt's lymphoma,0.62,PMID.dPMID7969136.s0.p0,2,2,NF-kappa B|c-myc,c-myc|NF-kappa B,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10931834,c-myc,NF-kappa B,NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.,0.42,PMID.dPMID10931834.s12.p0,2,2,NF-kappa B|c-myc,c-myc|NF-kappa B,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11873516,c-myc,NF-kappa B,"For example, WR-1065 treatment activates binding of the redox-sensitive transcription factor NF-kappa B to DNA and affects expression of a number of genes, including thymidine kinase, c-myc, and manganese superoxide dismutase.",0.37,PMID.dPMID11873516.s3.p0,3,3,NF-kappa B|c-myc|superoxide dismutase,c-myc|NF-kappa B|superoxide dismutase,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,20190818,c-myc,YB-1,"Importantly, we show that there is a strong correlation between the expression of PTB-1, YB-1 and c-myc in MM-derived cell lines, suggesting that by reducing either PTB-1 or YB-1 protein levels it is possible to decrease c-myc expression and inhibit cell proliferation of MM-derived cell lines",0.17,PMID.dPMID20190818.s0.p11,6,3,PTB-1|YB-1|c-myc|PTB-1|YB-1|c-myc,c-myc|PTB-1|YB-1,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.2.1.2.1,5078,9606,,,15596543,c-myc,Pax4,We propose that Pax4 is implicated in beta-cell plasticity through the activation of c-myc and potentially protected from apoptosis through Bcl-xL gene expression,0.02,PMID.dPMID15596543.s0.p0,3,3,Pax4|c-myc|Bcl-xL,Bcl-xL|c-myc|Pax4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,11950812,c-myc,PPARgamma,"CONCLUSIONS: As c-myc is an important target gene of the adenomatous polyposis coli (APC)/beta-catenin and/or APC/gamma-catenin pathway, activation of PPARgamma signalling appears to compensate for deregulated c-myc expression caused by mutated APC.",0.57,PMID.dPMID11950812.s1.p2,3,2,c-myc|PPARgamma|c-myc,c-myc|PPARgamma,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,17462534,c-myc,PPARgamma,PPARgamma ligands inhibited c-myc expression.,0.55,PMID.dPMID17462534.s5.p0,2,2,PPARgamma|c-myc,c-myc|PPARgamma,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.3.3.0.1,5989,9606,,,10918054,myc,RFX1,"These findings suggest that nuclear translocation and binding of RFX1 to the X box cause the down-regulation of myc expression, which follows acute PKC activation in undifferentiated HL-60 cells",0.11,PMID.dPMID10918054.s0.p0,2,2,RFX1|myc,myc|RFX1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,7753559,c-myc,Sp1,"In addition, enforced expression of Sp3 repressed Sp1-mediated activation of c-myc.",0.60,PMID.dPMID7753559.s2.p2,3,3,Sp3|Sp1|c-myc,c-myc|Sp1|Sp3,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12565816,c-Myc,Sp1,At this time it is not entirely clear which Sp1-containing promoters will be repressed by c-Myc and what other modes of c-Myc transcriptional repression may exist.,0.37,PMID.dPMID12565816.s1.p1,3,2,Sp1|c-Myc|c-Myc,c-Myc|Sp1,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12565816,c-Myc,Sp1,At this time it is not entirely clear which Sp1-containing promoters will be repressed by c-Myc and what other modes of c-Myc transcriptional repression may exist.,0.36,PMID.dPMID12565816.s1.p0,3,2,Sp1|c-Myc|c-Myc,c-Myc|Sp1,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15761015,c-Myc,Sp1 transcription factor,"We further explored the mechanisms by which ROS affects gene regulation and found that the Sp1 transcription factor was oxidized by arsenic treatment, with a corresponding decrease in its in situ binding on the promoters of 3 genes, hTERT, C17, and c-Myc, whose expressions were significantly suppressed.",0.25,PMID.dPMID15761015.s1.p4,4,4,ROS|Sp1 transcription factor|C17|c-Myc,C17|c-Myc|ROS|Sp1 transcription factor,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,7753559,c-myc,Sp3,"In addition, enforced expression of Sp3 repressed Sp1-mediated activation of c-myc.",1.34,PMID.dPMID7753559.s2.p1,3,3,Sp3|Sp1|c-myc,c-myc|Sp1|Sp3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.2.1.0.1,6772,9606,,,12637327,c-Myc,Stat1,"Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells.",1.26,PMID.dPMID12637327.s7.p0,3,3,Stat1|c-Myc|p27Kip1,c-Myc|p27Kip1|Stat1,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,7880838,c-myc,TBP,"Since TBP binds in the minor groove, MBP-1 might inhibit c-myc transcription by preventing the formation of a functional preinitiation complex.",0.17,PMID.dPMID7880838.s8.p0,2,2,TBP|c-myc,c-myc|TBP,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,8662737,c-myc,TBP,"Conversely, a PNA complementary to a unique sequence of the c-myc gene did not inhibit transcription of the AR or TBP genes but did inhibit c-myc transcription.",0.15,PMID.dPMID8662737.s2.p2,3,2,c-myc|TBP|c-myc,c-myc|TBP,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,14506152,c-myc,TBP,Both enolase-alpha and MBP-1 can bind to the P2 element in the c-myc promoter and compete with TATA-box binding protein (TBP) to suppress transcription of c-myc.,0.06,PMID.dPMID14506152.s4.p5,4,2,c-myc|TATA-box binding protein|TBP|c-myc,c-myc|TATA-box binding protein|TBP,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,10080941,c-myc,Tcf4,"The elevated levels of Tcf4:beta-catenin result in increased transcription of genes, including c-myc, important for the growth of these tumor cells.",0.94,PMID.dPMID10080941.s5.p0,2,2,Tcf4|c-myc,c-myc|Tcf4,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,20133699,Myc,Tcf-4,We also demonstrate that one such enhancer element physically interacts with the Myc promoter via transcription factor Tcf-4 binding and acts in an allele specific manner to regulate Myc expression.,0.93,PMID.dPMID20133699.s0.p2,3,2,Myc|Tcf-4|Myc,Myc|Tcf-4,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,19895682,MYC,TCF7L2,These findings suggest that some splicing forms of TCF7L2 may be functionally important for regulation of MYC expression in colon tissue but this regulation is not directly dependent on rs6983267.,0.35,PMID.dPMID19895682.s0.p0,2,2,TCF7L2|MYC,MYC|TCF7L2,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,12591729,c-myc,TCF-4,"When TCF-4 was bound to this element, TGF-beta dissociated beta-catenin and repressed the transcriptional activity of the c-myc promoter.",0.01,PMID.dPMID12591729.s2.p1,3,3,TCF-4|TGF-beta|c-myc,c-myc|TCF-4|TGF-beta,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.3.1.0.1,7020,9606,,,20066163,c-MYC,AP-2,Chromatin immunoprecipitation assays demonstrated that AP-2 proteins bound to a cluster of AP-2 binding sites located within a 2 kb upstream regulatory region of c-myc These results suggest that the negative regulation of AP-2 on c-MYC activity was achieved through binding of AP-2 protein to the c-myc gene.,0.35,PMID.dPMID20066163.s1.p9,7,2,AP-2|AP-2|c-myc|AP-2|c-MYC|AP-2|c-myc,AP-2|c-myc|c-MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.3.1.0.1,7020,9606,,,20066163,c-myc,AP-2,Chromatin immunoprecipitation assays demonstrated that AP-2 proteins bound to a cluster of AP-2 binding sites located within a 2 kb upstream regulatory region of c-myc These results suggest that the negative regulation of AP-2 on c-MYC activity was achieved through binding of AP-2 protein to the c-myc gene.,0.29,PMID.dPMID20066163.s1.p16,7,2,AP-2|AP-2|c-myc|AP-2|c-MYC|AP-2|c-myc,AP-2|c-myc|c-MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.3.1.0.1,7020,9606,,,20066163,c-MYC,AP-2,The effects of AP-2 on c-MYC were active at several levels.,0.28,PMID.dPMID20066163.s5.p0,2,2,AP-2|c-MYC,AP-2|c-MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.3.1.0.1,7020,9606,,,20066163,c-MYC,AP-2,Chromatin immunoprecipitation assays demonstrated that AP-2 proteins bound to a cluster of AP-2 binding sites located within a 2 kb upstream regulatory region of c-myc These results suggest that the negative regulation of AP-2 on c-MYC activity was achieved through binding of AP-2 protein to the c-myc gene.,0.28,PMID.dPMID20066163.s1.p7,7,2,AP-2|AP-2|c-myc|AP-2|c-MYC|AP-2|c-myc,AP-2|c-myc|c-MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.3.1.0.1,7020,9606,,,20066163,c-myc,AP-2,Chromatin immunoprecipitation assays demonstrated that AP-2 proteins bound to a cluster of AP-2 binding sites located within a 2 kb upstream regulatory region of c-myc These results suggest that the negative regulation of AP-2 on c-MYC activity was achieved through binding of AP-2 protein to the c-myc gene.,0.17,PMID.dPMID20066163.s1.p2,7,2,AP-2|AP-2|c-myc|AP-2|c-MYC|AP-2|c-myc,AP-2|c-myc|c-MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.3.1.0.1,7020,9606,,,20066163,c-MYC,AP-2,"In addition, forced expression of AP-2 significantly decreased steady state levels of c-MYC mRNA and protein.",0.16,PMID.dPMID20066163.s3.p0,2,2,AP-2|c-MYC,AP-2|c-MYC,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19411072,c-Myc,p53,p53 ablates c-Myc expression via several mechanisms at the transcriptional and posttranscriptional level.,1.19,PMID.dPMID19411072.s3.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19202062,c-Myc,p53,p53 represses c-Myc through induction of the tumor suppressor miR-145.,1.18,PMID.dPMID19202062.s10.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19202062,c-Myc,tumor suppressor p53,"The tumor suppressor p53 negatively regulates a number of genes, including the proto-oncogene c-Myc, in addition to activating many other genes.",1.12,PMID.dPMID19202062.s9.p0,2,2,tumor suppressor p53|c-Myc,c-Myc|tumor suppressor p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8750149,c-myc,p53,CONCLUSION: We conclude that c-myc might induce p53 expression in human colorectal cancer and that wild-type but not mutant p53 might be involved in a negative feedback regulation of c-myc expression.,1.08,PMID.dPMID8750149.s1.p5,4,2,c-myc|p53|p53|c-myc,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19202062,c-Myc,p53,"However, it is not clear whether microRNAs (miRNAs) play a role in the p53-mediated posttranscriptional regulation of c-Myc.",1.08,PMID.dPMID19202062.s7.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16112647,c-myc,p53,We demonstrated that p53-repression of eIF4E was regulated by c-myc.,0.91,PMID.dPMID16112647.s2.p1,3,3,p53|eIF4E|c-myc,c-myc|eIF4E|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7969121,c-Myc,p53,We have addressed the possibility that elevated mutant p53 expression is due to deregulated c-Myc expression.,0.89,PMID.dPMID7969121.s6.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19696787,MYC,p53,p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.,0.70,PMID.dPMID19696787.s7.p0,2,2,p53|MYC,MYC|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9632756,c-myc,p53,"Here we report that (i) mutant p53 can regulate the expression of the endogenous c-myc gene and is a potent activator of the c-myc promoter; (ii) the region of mutant p53 responsiveness in the c-myc gene has been mapped to the 3' end of exon 1; (iii) the mutant p53 response region is position and orientation dependent and therefore does not function as an enhancer; and (iv) transactivation by mutant p53 requires the C terminus, which is not essential for wild-type p53 transactivation.",0.58,PMID.dPMID9632756.s2.p0,8,2,p53|c-myc|c-myc|p53|c-myc|p53|p53|p53,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7937596,c-myc,p53,A potential involvement of the oncosuppressor gene products p53 and Rb in the control of trophoblastic proliferation and of c-myc in the control of both the proliferative and differentiation pathways of trophoblastic cells is suggested,0.50,PMID.dPMID7937596.s0.p1,3,3,p53|Rb|c-myc,c-myc|p53|Rb,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11272469,c-myc,p53,"p53 is a key regulator of E1A and c-myc-induced apoptosis and, together with the oncoproteins, may transcriptionally activate numerous genes whose products influence, or are themselves, members of the core apoptotic machinery.",0.50,PMID.dPMID11272469.s1.p0,2,2,p53|c-myc,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9727619,c-myc,p53,"K-ras point mutations were analyzed by PCR-RFLP technique, followed by sequencing; p53 protein accumulation by immunohistochemistry; p53 gene mutations in exons 5-9 were studied by the SSCP and sequencing techniques, and c-myc overexpression by Northern blot.",0.49,PMID.dPMID9727619.s3.p5,4,3,K-ras|p53|p53|c-myc,c-myc|K-ras|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1844240,c-myc,p53,"Studies with other cell types have shown that another tumor suppressor gene, p53, can also regulate transcription of c-myc in transient assays.",0.44,PMID.dPMID1844240.s2.p0,2,2,p53|c-myc,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8750149,c-myc,p53,CONCLUSION: We conclude that c-myc might induce p53 expression in human colorectal cancer and that wild-type but not mutant p53 might be involved in a negative feedback regulation of c-myc expression.,0.40,PMID.dPMID8750149.s1.p4,4,2,c-myc|p53|p53|c-myc,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15242522,c-myc,p53,"CONCLUSIONS: Overexpression of PTTG activates the expression of p53 and modulates its function, with this action of PTTG being mediated through the regulation of c-myc expression.",0.39,PMID.dPMID15242522.s1.p4,4,4,PTTG|p53|PTTG|c-myc,c-myc|p53|PTTG,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16527552,c-Myc,p53,"Both Wortmannin and PD98059 elevated the level of p53 expression strikingly, however, only PD98059 suppressed the up-regulation trend of c-Myc expression induced by etoposide.",0.36,PMID.dPMID16527552.s2.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11148566,c-myc,p53,"CONCLUSIONS: Because c-myc is a known inducer of wild type p53, decreased c-myc expression may lead to uncontrolled cell growth because of the lack of p53 expression that normally induces apoptosis.",0.34,PMID.dPMID11148566.s1.p2,4,2,c-myc|p53|c-myc|p53,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19202062,c-Myc,p53,One mechanism of the p53-mediated c-Myc repression may involve transcriptional regulation.,0.28,PMID.dPMID19202062.s8.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9727619,c-myc,p53,"K-ras point mutations were analyzed by PCR-RFLP technique, followed by sequencing; p53 protein accumulation by immunohistochemistry; p53 gene mutations in exons 5-9 were studied by the SSCP and sequencing techniques, and c-myc overexpression by Northern blot.",0.27,PMID.dPMID9727619.s3.p4,4,3,K-ras|p53|p53|c-myc,c-myc|K-ras|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8523074,c-myc,TP53,"DNA derived from medulloblastoma biopsies was analyzed to determine if deletions of the 17p region, mutations of the TP53 gene, or amplification of the c-myc, N-myc, EGFR (epidermal growth factor receptor), or MDM2 (murine double-minute-2) genes was indicative of a poor prognosis.",0.27,PMID.dPMID8523074.s5.p0,4,4,TP53|c-myc|EGFR|MDM2,c-myc|EGFR|MDM2|TP53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16432227,Myc,p53,"Here we demonstrate that p53 induction in response to Myc overexpression requires the ataxia-telangiectasia mutated (ATM) kinase, a major regulator of the cellular response to DNA double-strand breaks.",0.25,PMID.dPMID16432227.s3.p0,3,3,p53|Myc|ATM,ATM|Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10023683,c-Myc,p53,"Although direct effects of E2 on the expression of p53 gene are not known, the steroid is a potent regulator of c-Myc transcription.",0.25,PMID.dPMID10023683.s12.p0,2,2,p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17613764,c-myc,p53,"All but one of MCL showed t(11:14) translocation and in 22/30 samples taken at diagnosis or first relapse, one or several cytogenetic changes were detected; 11 deletions of ATM, 13 p53 deletions, 8 numerical c-myc-aberrations and 6 delp16.",0.25,PMID.dPMID17613764.s2.p2,3,3,ATM|p53|c-myc,ATM|c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9196053,c-myc,p53,CAT assay using mutated T antigen lacking p53 or the RB binding site indicated that p53 or RB was not mainly involved in transcriptional activation of the c-myc gene.,0.18,PMID.dPMID9196053.s1.p5,4,3,CAT|p53|p53|c-myc,CAT|c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9820862,c-myc,p53,"Our research concentrated on genetic alterations in cell cycle regulator genes: mutations in the p53 gene and ras gene, loss of heterozygosity at the p53, p16 and Rb-locus, and amplification of the mdm2-gene and the c-myc-gene.",0.17,PMID.dPMID9820862.s5.p7,5,4,p53|p53|Rb|mdm2|c-myc,c-myc|mdm2|p53|Rb,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8821986,c-myc,p53,"Positive expression of c-myc and p53 products in two cases of pulmonary sclerosing hemangioma    The c-myc and p53 genes are thought to be an oncogene and a tumor suppressor gene, respectively.",0.16,PMID.dPMID8821986.s9.p2,4,2,c-myc|p53|c-myc|p53,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20587660,c-Myc,p53,"These results suggest that ascofuranone upregulates p21(WAF1/CIP1) through p53-independent suppression of c-Myc expression, leading to cytostatic G(1) arrest.",0.15,PMID.dPMID20587660.s1.p5,4,3,WAF1|CIP1|p53|c-Myc,CIP1|c-Myc|p53|WAF1,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2435565,c-myc,p53,"Here we show that p53, unlike the products of the c-myc and c-fos genes, is not induced by the signal generated by the interaction between epidermal growth factor (EGF) and its receptor.",0.13,PMID.dPMID2435565.s2.p0,4,4,p53|c-myc|c-fos|EGF,c-fos|c-myc|EGF|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14513581,c-myc,p53,"The experimental study on telomerase activity and expression of p53 and c-myc genes in tongue cancer    OBJECTIVE: To study telomerase activity and expression of oncogenes c-myc and p53 in tongue cancer, analyse the interaction among them, and assess their possible correlations with tongue cancer clinicopathological features.",0.13,PMID.dPMID14513581.s4.p1,4,2,p53|c-myc|c-myc|p53,c-myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15814658,c-myc,p53,"EXPERIMENTAL DESIGN: Using two p53 mutant melanoma models stably expressing an inducible c-myc antisense RNA, we have investigated whether Myc protein down-regulation could render melanoma cells more susceptible to radiotherapy, reestablishing apoptotic p53-independent pathway.",0.08,PMID.dPMID15814658.s6.p0,4,2,p53|c-myc|Myc|p53,c-myc|Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8523074,c-myc,TP53,"These results demonstrate that, while only rare medulloblastomas contain TP53 gene mutations or amplification of the c-myc gene, loss of heterozygosity on chromosome 17p is indicative of a significantly worse prognosis among patients with these tumors.",0.07,PMID.dPMID8523074.s1.p0,2,2,TP53|c-myc,c-myc|TP53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9218867,Myc,p53,"Thus, our data support a functional involvement of p53 in Myc-dependent apoptosis and implicate potential regulatory roles for JNK/SAPK and Mdm-2 pathways in the regulation of apoptosis in Myc-transformed tumor cells",0.07,PMID.dPMID9218867.s0.p6,5,4,p53|Myc|JNK|Mdm-2|Myc,JNK|Mdm-2|Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10348347,Myc,p53,"Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max.",0.06,PMID.dPMID10348347.s7.p1,4,3,p53|p53|Myc|Max,Max|Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11102893,c-myc,p53,SDNA was greater in p53-positive and bcl-2-negative cases; SDNP was greater in p53-positive cases; SHF was lower in p53- and c-myc-positive cases.,0.03,PMID.dPMID11102893.s4.p12,6,4,p53|bcl-2|p53|SHF|p53|c-myc,bcl-2|c-myc|p53|SHF,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7969121,c-Myc,p53 tumor suppressor,Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.,0.01,PMID.dPMID7969121.s10.p0,4,3,p53 tumor suppressor|c-Myc|Max|p53,c-Myc|Max|p53|p53 tumor suppressor,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14532990,c-Myc,p53,"In conclusion, these data suggest that p53 expression (e.g. p53 mutation) as well as c-Myc expression may have a role in regulation of telomerase activity in ovarian tumours",0.01,PMID.dPMID14532990.s0.p1,3,2,p53|p53|c-Myc,c-Myc|p53,-->
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14614448,c-MYC,p73,"For instance, DeltaNp73alpha increased the expression of EGR1 and CDC6, whereas it decreased the mRNA levels of c-MYC, cyclin A2/CCNA2, NF-kappaB1, ODC1, and RET finger protein/RFP.",0.52,PMID.dPMID14614448.s3.p3,5,5,p73|EGR1|CDC6|c-MYC|CCNA2,CCNA2|CDC6|c-MYC|EGR1|p73,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.2.1,7391,9606,,GO:0000430|GO:0000432|GO:0010551|GO:0010552|GO:0045990,15208653,c-Myc,USF,"In order to determine how these opposite functions correlate with the transcriptional activities of the two factors on particular downstream targets, we investigated the roles of USF and c-Myc in expression of CDK4, a known direct target of c-Myc.",0.49,PMID.dPMID15208653.s5.p3,4,3,USF|c-Myc|CDK4|c-Myc,CDK4|c-Myc|USF,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.6.2.1,7391,9606,,GO:0000430|GO:0000432|GO:0010551|GO:0010552|GO:0045990,10602473,Myc,USF,"Although USF-1 and -2 are the major proteins that bind to Myc-regulated E-box (CACGTG) elements in many cells, there is no clear role for USF during Myc-dependent gene regulation.",0.26,PMID.dPMID10602473.s5.p5,4,2,USF-1|Myc|USF|Myc,Myc|USF|USF-1,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,20493879,MYC,VDR,"In conclusion, our data suggest that dynamically composed protein complexes that dock via VDR to the two VDREs may explain the repression of the MYC gene.",0.77,PMID.dPMID20493879.s0.p2,3,2,VDR|VDR|MYC,MYC|VDR,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,20493879,MYC,VDR,"In conclusion, our data suggest that dynamically composed protein complexes that dock via VDR to the two VDREs may explain the repression of the MYC gene.",0.31,PMID.dPMID20493879.s0.p1,3,2,VDR|VDR|MYC,MYC|VDR,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,10775888,c-myc,VDR,"We have now determined if this association occurs in other leukemic cell lines, U937 and K562, and if VDR content is related to c-myc expression, which is also linked to cell growth state.",0.07,PMID.dPMID10775888.s5.p0,2,2,VDR|c-myc,c-myc|VDR,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15286719,c-myc,WT1,"Unlike other studies where WT1 is reported to be a negative regulator of c-myc, we found that both the - and + KTS forms of WT1 could act to enhance c-myc expression, depending on the cell type.",1.42,PMID.dPMID15286719.s3.p5,4,2,WT1|c-myc|WT1|c-myc,c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15286719,c-myc,WT1,"Unlike other studies where WT1 is reported to be a negative regulator of c-myc, we found that both the - and + KTS forms of WT1 could act to enhance c-myc expression, depending on the cell type.",1.41,PMID.dPMID15286719.s3.p3,4,2,WT1|c-myc|WT1|c-myc,c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7585606,c-myc,WT1,"This suggests that WT1 regulates bcl-2 and c-myc during renal development, and the loss of functional WT1 results in deregulation of bcl-2 and c-myc, contributing to tumor formation",1.30,PMID.dPMID7585606.s0.p1,6,3,WT1|bcl-2|c-myc|WT1|bcl-2|c-myc,bcl-2|c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15286719,c-myc,WT1,"To determine how WT1 affects c-myc expression in the context of breast cancer cells, we have examined the ability of both endogenous and exogenous WT1 proteins in breast cancer cells to bind to the c-myc promoter in vivo.",1.12,PMID.dPMID15286719.s5.p0,4,2,WT1|c-myc|WT1|c-myc,c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15286719,c-myc,WT1,"Unlike other studies where WT1 is reported to be a negative regulator of c-myc, we found that both the - and + KTS forms of WT1 could act to enhance c-myc expression, depending on the cell type.",0.92,PMID.dPMID15286719.s3.p0,4,2,WT1|c-myc|WT1|c-myc,c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,17634147,c-myc,WT1,"Moreover, WT1-ZF - KTS abrogated the transcriptional activation of c-myc mediated by all four predominant isoforms of WT1 (including or lacking alternatively spliced exons 5 and 9).",0.61,PMID.dPMID17634147.s3.p0,3,2,WT1|c-myc|WT1,c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7585606,c-myc,WT1,"This suggests that WT1 regulates bcl-2 and c-myc during renal development, and the loss of functional WT1 results in deregulation of bcl-2 and c-myc, contributing to tumor formation",0.54,PMID.dPMID7585606.s0.p10,6,3,WT1|bcl-2|c-myc|WT1|bcl-2|c-myc,bcl-2|c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,19050011,c-myc,WT1,"In contrast, the repressive WT1/BASP1 occupancy of the c-myc and Bak promoters is maintained and these genes are downregulated during the differentiation process.",0.31,PMID.dPMID19050011.s2.p1,3,3,WT1|BASP1|c-myc,BASP1|c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7585606,c-myc,WT1,We found that WT1 can repress transcription of both the bcl-2 and c-myc promoters.,0.24,PMID.dPMID7585606.s1.p1,3,3,WT1|bcl-2|c-myc,bcl-2|c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12802290,c-MYC,WT1,"Using the Atlas Human Cancer 1.2 cDNA arrays to quantitate gene expression in the 31 tumors, we found that the expression of one WT1 putative target gene, c-MYC, statistically significantly differed between the two sets of tumors and was upregulated in WT1-mutant tumors.",0.15,PMID.dPMID12802290.s3.p0,3,2,WT1|c-MYC|WT1,c-MYC|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15286719,c-myc,WT1,These observations strongly argue that in the case of breast cancer WT1 is functioning as an oncogene in part by stimulating the expression of c-myc,0.11,PMID.dPMID15286719.s0.p0,2,2,WT1|c-myc,c-myc|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,17634147,c-myc,WT1,"The expressions of WT1 target genes, including c-myc, Bcl-2, amphiregulin and TERT, were similarly suppressed by ZF - KTS.",0.05,PMID.dPMID17634147.s4.p0,5,5,WT1|c-myc|Bcl-2|amphiregulin|TERT,amphiregulin|Bcl-2|c-myc|TERT|WT1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8266081,c-myc,YY1,"Yin-Yang-1 (YY1) regulates the transcription of many genes, including the oncogenes c-fos and c-myc.",0.75,PMID.dPMID8266081.s4.p4,4,3,Yin-Yang-1|YY1|c-fos|c-myc,c-fos|c-myc|Yin-Yang-1|YY1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,15805285,c-Myc,YY1,"Whereas CHK had no significant effects on the expression of YY1, c-Myc, Max, and other YY1-binding proteins, CHK was found to modulate the YY1/c-Myc association.",0.58,PMID.dPMID15805285.s2.p13,6,3,YY1|c-Myc|Max|YY1|YY1|c-Myc,c-Myc|Max|YY1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,8266081,c-myc,Yin-Yang-1,"Yin-Yang-1 (YY1) regulates the transcription of many genes, including the oncogenes c-fos and c-myc.",0.42,PMID.dPMID8266081.s4.p3,4,3,Yin-Yang-1|YY1|c-fos|c-myc,c-fos|c-myc|Yin-Yang-1|YY1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,18490439,c-myc,YY1,The complex of N1IC and transcription factor YY1 binds to the human c-myc promoter to enhance c-myc expression in a CBF1-independent manner.,0.14,PMID.dPMID18490439.s8.p1,4,3,YY1|c-myc|c-myc|CBF1,CBF1|c-myc|YY1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.10,7555,9606,,GO:0006355,20394585,c-Myc,CNBP,"Several reports have demonstrated that CNBP enhances the transcription of c-Myc in vitro and in vivo; however, none of these reports have assessed the molecular mechanisms responsible for this control.",0.74,PMID.dPMID20394585.s2.p0,2,2,CNBP|c-Myc,c-Myc|CNBP,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.27,7799,9606,,GO:0006355,16356493,c-myc,RIZ2,Experiments of chromatin immunoprecipitation indicated that RIZ2 protein expression was controlled by estrogen receptor and RIZ1 had a direct repressor function on c-myc gene expression.,1.29,PMID.dPMID16356493.s2.p1,3,2,RIZ2|RIZ1|c-myc,c-myc|RIZ1|RIZ2,p
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.27,7799,9606,,GO:0006355,16356493,c-myc,RIZ1,Experiments of chromatin immunoprecipitation indicated that RIZ2 protein expression was controlled by estrogen receptor and RIZ1 had a direct repressor function on c-myc gene expression.,0.75,PMID.dPMID16356493.s2.p2,3,2,RIZ2|RIZ1|c-myc,c-myc|RIZ1|RIZ2,p
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,15808510,c-myc,SRC-3,"We demonstrated that IKKalpha, in conjunction with ERalpha and AIB1/SRC-3, is important in activating the transcription of estrogen-responsive genes, including cyclin D1 and c-myc, to result in the enhanced proliferation of breast cancer cells.",0.27,PMID.dPMID15808510.s2.p9,5,4,IKKalpha|ERalpha|AIB1|SRC-3|c-myc,AIB1|c-myc|ERalpha|IKKalpha|SRC-3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,15808510,c-myc,AIB1,"We demonstrated that IKKalpha, in conjunction with ERalpha and AIB1/SRC-3, is important in activating the transcription of estrogen-responsive genes, including cyclin D1 and c-myc, to result in the enhanced proliferation of breast cancer cells.",0.27,PMID.dPMID15808510.s2.p8,5,4,IKKalpha|ERalpha|AIB1|SRC-3|c-myc,AIB1|c-myc|ERalpha|IKKalpha|SRC-3,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,19522008,c-myc,Gfi-1B,"Surprisingly, this Gfi-1/GATA-2-Gfi-1B/GATA-1 switch observed at erythroblast stages is associated to an increase in the Gfi-1B transcription whereas it triggers repression of c-myc transcription.",1.01,PMID.dPMID19522008.s4.p14,6,5,Gfi-1|GATA-2|Gfi-1B|GATA-1|Gfi-1B|c-myc,c-myc|GATA-1|GATA-2|Gfi-1|Gfi-1B,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1.2.5.3.1,8648,9606,,,18193094,c-Myc,SRC-1,"E2 induced the recruitment of co-activators such as SRC-1, SRC-3 and CBP to the promoters of c-Myc and IGF-1, and SRC-1 silencing abolished both the E2-stimulated c-Myc expression and cell-cycle progression.",0.34,PMID.dPMID18193094.s3.p9,5,3,SRC-1|c-Myc|IGF-1|SRC-1|c-Myc,c-Myc|IGF-1|SRC-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.17,10365,9606,GO:0016563,,11477405,c-Myc,LKLF,"In addition, many effects of LKLF expression were mimicked by expression of the dominant-negative MadMyc protein and rescued by overexpression of c-Myc.",0.85,PMID.dPMID11477405.s1.p0,2,2,LKLF|c-Myc,c-Myc|LKLF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.17,10365,9606,GO:0016563,,11477405,c-Myc,LKLF,Forced expression of LKLF was associated with markedly decreased c-Myc expression.,0.43,PMID.dPMID11477405.s2.p0,2,2,LKLF|c-Myc,c-Myc|LKLF,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.7.14,10481,9606,,,15126340,c-myc,HOXB13,"Western blot analysis demonstrated that HOXB13 down-regulates the expression of TCF-4 and its responsive genes, c-myc and cyclin D1.",1.06,PMID.dPMID15126340.s3.p1,3,3,HOXB13|TCF-4|c-myc,c-myc|HOXB13|TCF-4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3.1.1.7.14,10481,9606,,,15928669,c-myc,HOXB13,"However, HOXB13 downregulated the expression of TCF4 and its target gene, c-myc, at the protein level and consequently inhibited beta-catenin/TCF-mediated signalling.",0.99,PMID.dPMID15928669.s3.p1,4,4,HOXB13|TCF4|c-myc|TCF,c-myc|HOXB13|TCF|TCF4,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.2.2.16,10661,9606,,,17974960,c-Myc,Kruppel-like factor,Cell growth inhibition by okadaic acid involves gut-enriched Kruppel-like factor mediated enhanced expression of c-Myc.,1.09,PMID.dPMID17974960.s11.p0,2,2,Kruppel-like factor|c-Myc,c-Myc|Kruppel-like factor,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,14503807,c-myc,CTCF,The CTCF gene encodes for a transcriptional repressor of the c-myc oncogene and has previously been mapped to one of the smallest regions of overlapping interstitial deletions on chromosome 16q22.1 in invasive breast cancer.,1.08,PMID.dPMID14503807.s8.p0,2,2,CTCF|c-myc,c-myc|CTCF,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,10906122,c-myc,CTCF,"Although expression of YB-1 alone had no effect, co-expression with CTCF resulted in a marked enhancement of CTCF-driven c-myc transcriptional repression.",0.98,PMID.dPMID10906122.s1.p5,4,3,YB-1|CTCF|CTCF|c-myc,c-myc|CTCF|YB-1,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,19568426,C-MYC,CTCF,Targeted deletion of multiple CTCF-binding elements in the human C-MYC gene reveals a requirement for CTCF in C-MYC expression.,0.97,PMID.dPMID19568426.s8.p5,4,3,CTCF|C-MYC|CTCF|C-MYC,C-MYC|CTCF,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,10037138,c-myc,CTCF,CTCF is a transcriptional repressor of the c-myc gene.,0.90,PMID.dPMID10037138.s4.p0,2,2,CTCF|c-myc,c-myc|CTCF,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,8649389,c-myc,CTCF,Mutational analysis of the P2-proximal CTCF binding site and transient-cotransfection experiments demonstrate that CTCF is a transcriptional repressor of the human c-myc gene.,0.27,PMID.dPMID8649389.s5.p2,3,3,CTCF|CTCF|c-myc,c-myc|CTCF,<--
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,17132729,c-myc,lymphoid enhancer-binding factor 1,Smad4 cooperates with lymphoid enhancer-binding factor 1/T cell-specific factor to increase c-myc expression in the absence of TGF-beta signaling.,0.46,PMID.dPMID17132729.s9.p2,4,4,Smad4|lymphoid enhancer-binding factor 1|c-myc|TGF-beta,c-myc|lymphoid enhancer-binding factor 1|Smad4|TGF-beta,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,17360796,c-myc,LEF-1,"We found that lymphoid enhancer-binding factor 1 (LEF-1) is a decisive transcription factor in granulopoiesis controlling proliferation, proper lineage commitment, and granulocytic differentiation via regulation of its target genes C/EBP-alpha, cyclin D1, c-myc, and survivin.",0.29,PMID.dPMID17360796.s4.p2,3,2,lymphoid enhancer-binding factor 1|LEF-1|c-myc,c-myc|LEF-1|lymphoid enhancer-binding factor 1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,16080193,c-myc,Lef-1,"In such treated cells, the association of beta-catenin with Lef-1 and the transcription of c-myc, cyclin-D1, CD44 and COX-2 were also reduced.",0.21,PMID.dPMID16080193.s1.p0,3,3,Lef-1|c-myc|CD44,CD44|c-myc|Lef-1,
1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,17360796,c-myc,lymphoid enhancer-binding factor 1,"We found that lymphoid enhancer-binding factor 1 (LEF-1) is a decisive transcription factor in granulopoiesis controlling proliferation, proper lineage commitment, and granulocytic differentiation via regulation of its target genes C/EBP-alpha, cyclin D1, c-myc, and survivin.",0.13,PMID.dPMID17360796.s4.p1,3,2,lymphoid enhancer-binding factor 1|LEF-1|c-myc,c-myc|LEF-1|lymphoid enhancer-binding factor 1,
1.2.6.5.3,4610,9606,,GO:0006355,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2545635,L-myc,c-myc,"In contrast to expression of the closely related c-myc gene, N-myc and L-myc expression is very restricted in adult tissues.",0.84,PMID.dPMID2545635.s4.p1,3,3,c-myc|N-myc|L-myc,c-myc|L-myc|N-myc,
1.2.6.5.2,4613,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12733375,N-myc,C-myc,"Expression of C-myc and N-myc protein in adulthood and childhood medulloblastomas and prognostic analysis    OBJECTIVE: To detect the expression of C-myc and N-myc in medulloblastomas, the difference between adults and children, and the relation between expression and prognosis.",0.83,PMID.dPMID12733375.s7.p3,4,2,C-myc|N-myc|C-myc|N-myc,C-myc|N-myc,
1.2.6.5.2,4613,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19351822,MYCN,MYC,Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.,0.55,PMID.dPMID19351822.s4.p0,2,2,MYC|MYCN,MYC|MYCN,
1.2.6.5.2,4613,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,2545635,N-myc,c-myc,"In contrast to expression of the closely related c-myc gene, N-myc and L-myc expression is very restricted in adult tissues.",0.45,PMID.dPMID2545635.s4.p0,3,3,c-myc|N-myc|L-myc,c-myc|L-myc|N-myc,
1.2.6.5.2,4613,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9674700,N-Myc,c-Myc,"The more complex expression pattern found for the Myc targets in neuroblastomas suggests that genes that were identified originally as targets for c-Myc regulation may be regulated by N-Myc, but other cell specific factors are also needed for transcription of the target genes",0.35,PMID.dPMID9674700.s0.p2,3,2,Myc|c-Myc|N-Myc,c-Myc|Myc|N-Myc,
1.2.6.5.2,4613,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9674700,N-Myc,Myc,"The more complex expression pattern found for the Myc targets in neuroblastomas suggests that genes that were identified originally as targets for c-Myc regulation may be regulated by N-Myc, but other cell specific factors are also needed for transcription of the target genes",0.04,PMID.dPMID9674700.s0.p1,3,2,Myc|c-Myc|N-Myc,c-Myc|Myc|N-Myc,
1.2.6.5.2,4613,9606,,GO:0006357,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11717865,N-myc,C-myc,The abnormal L-myc and C-myc gene were positive in 47% (15/32) of laryngeal cancers and 41% (13/32) of the cancers shown the N-myc gene amplification.,0.03,PMID.dPMID11717865.s3.p0,2,2,C-myc|N-myc,C-myc|N-myc,
1.2.6.5.2,4613,9606,,GO:0006357,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8428579,N-myc,NF-kappa B,These data indicate that the p50 subunit of NF-kappa B is involved in the regulation of MHC Class I antigen expression and that N-myc down-regulates MHC Class I gene expression primarily through suppression of p50 expression,0.78,PMID.dPMID8428579.s0.p0,2,2,NF-kappa B|N-myc,NF-kappa B|N-myc,
1.2.6.5.2,4613,9606,,GO:0006357,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,18335505,MYCN,PAX3,"In conclusion, we identified a selected set of biologically relevant genes modulated by PAX3-FKHR, and demonstrated that PAX3-FKHR contributes to the expression of MYCN and in turn MYCN collaborates with PAX3-FKHR in tumorigenesis",1.13,PMID.dPMID18335505.s0.p4,5,2,PAX3|PAX3|MYCN|MYCN|PAX3,MYCN|PAX3,
1.2.6.5.2,4613,9606,,GO:0006357,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,12095979,N-Myc,Pax-3,The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc.,1.05,PMID.dPMID12095979.s8.p0,2,2,Pax-3|N-Myc,N-Myc|Pax-3,
1.2.6.5.2,4613,9606,,GO:0006357,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,18335505,MYCN,PAX3,"In conclusion, we identified a selected set of biologically relevant genes modulated by PAX3-FKHR, and demonstrated that PAX3-FKHR contributes to the expression of MYCN and in turn MYCN collaborates with PAX3-FKHR in tumorigenesis",0.93,PMID.dPMID18335505.s0.p2,5,2,PAX3|PAX3|MYCN|MYCN|PAX3,MYCN|PAX3,
1.2.6.5.2,4613,9606,,GO:0006357,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,9334253,N-myc,RAR,"Any association of per se inactive RXR-selective with RAR-selective ligands efficiently regulates growth inhibition, differentiation (neurite extension), and expression of RARbeta, TrkB, and N-myc.",0.25,PMID.dPMID9334253.s3.p3,4,4,RAR|RARbeta|TrkB|N-myc,N-myc|RAR|RARbeta|TrkB,
1.2.6.5.2,4613,9606,,GO:0006357,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,14645238,MYCN,Sp1,"Our results define distinct chromatin states of the MYCN promoter, indicate that factors in addition to E2F and Sp1/Sp3 are required to activate MYCN in neuroblastomas, and provide evidence for a novel mechanism of controlling access of E2F to selected target genes",0.49,PMID.dPMID14645238.s0.p4,4,3,MYCN|Sp1|Sp3|MYCN,MYCN|Sp1|Sp3,<--
1.2.6.5.2,4613,9606,,GO:0006357,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,14645238,MYCN,Sp3,"Our results define distinct chromatin states of the MYCN promoter, indicate that factors in addition to E2F and Sp1/Sp3 are required to activate MYCN in neuroblastomas, and provide evidence for a novel mechanism of controlling access of E2F to selected target genes",0.49,PMID.dPMID14645238.s0.p5,4,3,MYCN|Sp1|Sp3|MYCN,MYCN|Sp1|Sp3,<--
1.2.6.5.2,4613,9606,,GO:0006357,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,11237058,N-myc,transcription factor E2a,The leukemogenic transcription factor E2a-Pbx1 induces expression of the putative N-myc and p53 target gene NDRG1 in Ba/F3 cells.,1.12,PMID.dPMID11237058.s7.p0,4,4,transcription factor E2a|N-myc|p53|NDRG1,NDRG1|N-myc|p53|transcription factor E2a,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20811720,MYCN,p53,"In addition, elevated p53 expression has a suppressive effect on MYCN expression in these cells.",0.60,PMID.dPMID20811720.s0.p0,2,2,p53|MYCN,MYCN|p53,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20145147,MYCN,p53,"Microarray analysis of Tet21N MYCN+/- cells identified several p53-regulated genes that were upregulated in the presence of MYCN, including MDM2 and PUMA, the levels of which were reduced by MYCN knockdown.",0.32,PMID.dPMID20145147.s1.p11,6,4,MYCN|p53|MYCN|MDM2|PUMA|MYCN,MDM2|MYCN|p53|PUMA,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15644444,MYCN,p53,The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.,0.31,PMID.dPMID15644444.s11.p1,3,3,p53|MDM2|MYCN,MDM2|MYCN|p53,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19526525,MYCN,p53,BACKGROUND: MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells.,0.19,PMID.dPMID19526525.s11.p2,3,3,MDM2|p53|MYCN,MDM2|MYCN|p53,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19649205,MYCN,p53 tumor suppressor,"Amplification of the MYCN oncogene correlates with the most clinically aggressive form of the cancer, and MDM2, a primary inhibitor of the p53 tumor suppressor, is a direct transcriptional target of, and positively regulated by, both MYCN and MYCC.",0.14,PMID.dPMID19649205.s6.p5,4,3,MYCN|MDM2|p53 tumor suppressor|MYCN,MDM2|MYCN|p53 tumor suppressor,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20811720,MYCN,p53,"Unexpectedly, co-transfection of TP53 and MYCN in IMR5 cells resulted in high p53 expression but a reduction of MYCN expression.",0.09,PMID.dPMID20811720.s2.p5,4,2,TP53|MYCN|p53|MYCN,MYCN|p53|TP53,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20145147,MYCN,p53,p53 is a direct transcriptional target of MYCN in neuroblastoma.,0.09,PMID.dPMID20145147.s11.p0,2,2,p53|MYCN,MYCN|p53,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20145147,MYCN,p53,"Microarray analysis of Tet21N MYCN+/- cells identified several p53-regulated genes that were upregulated in the presence of MYCN, including MDM2 and PUMA, the levels of which were reduced by MYCN knockdown.",0.05,PMID.dPMID20145147.s1.p2,6,4,MYCN|p53|MYCN|MDM2|PUMA|MYCN,MDM2|MYCN|p53|PUMA,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18583365,MYCN,p73,p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.,0.51,PMID.dPMID18583365.s6.p0,2,2,p73|MYCN,MYCN|p73,
1.2.6.5.2,4613,9606,,GO:0006357,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18583365,MYCN,p73,"Herein, using both ectopic expression and RNA interference-mediated silencing of p73 in MYCN amplified NB cells, we show that p73alpha isoforms inhibit MYCN expression at both transcript and protein levels, in spite of transactivator effects on MYCN promoter.",0.29,PMID.dPMID18583365.s2.p5,5,2,p73|MYCN|p73|MYCN|MYCN,MYCN|p73,
1.2.2.1.4,4618,9606,,GO:0006357|GO:0010552,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,12561432,MRF4,PAX3,"CONCLUSION: There is no obvious influence on biological character and differentiation in RD cells with transfection of PAX3-FKHR gene; PAX3-FKHR does not inhibit the expression of MRF4, but can reverse the effect of MRF4 on promoting the differentiation of RD cell",0.96,PMID.dPMID12561432.s0.p2,4,2,PAX3|PAX3|MRF4|MRF4,MRF4|PAX3,
1.2.2.1.4,4618,9606,,GO:0006357|GO:0010552,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,12561432,MRF4,PAX3,"CONCLUSION: There is no obvious influence on biological character and differentiation in RD cells with transfection of PAX3-FKHR gene; PAX3-FKHR does not inhibit the expression of MRF4, but can reverse the effect of MRF4 on promoting the differentiation of RD cell",0.83,PMID.dPMID12561432.s0.p4,4,2,PAX3|PAX3|MRF4|MRF4,MRF4|PAX3,
1.2.2.1.4,4618,9606,,GO:0006357|GO:0010552,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,12561432,MRF4,PAX3,This study was designed to observe the effects of fusion gene PAX3-FKHR transfection on expression of MRF4 and differentiation of cultured human rhabdomyosarcoma RD cells.,0.36,PMID.dPMID12561432.s5.p0,2,2,PAX3|MRF4,MRF4|PAX3,
1.2.2.1.4,4618,9606,,GO:0006357|GO:0010552,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,12561432,MRF4,PAX3,"Influences of PAX3-FKHR transfection on expression of MRF4 and differentiation of cultured human rhabdomyosarcoma RD cells BACKGROUND & OBJECTIVE: There were a few reports about the role of PAX3-FKHR fusion gene in the oncogenesis of alveolar rhabdomyosarcoma (ARMS); however, its effect on muscle-producing factor (MPF) is not clear.",0.12,PMID.dPMID12561432.s6.p0,4,3,PAX3|MRF4|PAX3|MPF,MPF|MRF4|PAX3,
1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,18414034,myogenic differentiation,FOXO1,Experiments designed to determine how PAX3-FOXO1 expression contributes to the development of muscle cell-derived tumors resulted in the discovery that the fusion protein misregulates gene expression and interrupts myogenic differentiation through a unique gain of function mechanism.,0.93,PMID.dPMID18414034.s1.p2,3,3,PAX3|FOXO1|myogenic differentiation,FOXO1|myogenic differentiation|PAX3,
1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,15163661,MyoD,Id1,Ubiquitin-Proteasome-mediated degradation of Id1 is modulated by MyoD.,0.71,PMID.dPMID15163661.s8.p0,2,2,Id1|MyoD,Id1|MyoD,
1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,15831463,myogenic differentiation,MEF2C,"When introduced into C2C12 myoblasts, the nonacetylatable MEF2C inhibits myogenic differentiation.",0.17,PMID.dPMID15831463.s1.p0,2,2,MEF2C|myogenic differentiation,MEF2C|myogenic differentiation,
1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,18414034,myogenic differentiation,PAX3,Experiments designed to determine how PAX3-FOXO1 expression contributes to the development of muscle cell-derived tumors resulted in the discovery that the fusion protein misregulates gene expression and interrupts myogenic differentiation through a unique gain of function mechanism.,0.93,PMID.dPMID18414034.s1.p1,3,3,PAX3|FOXO1|myogenic differentiation,FOXO1|myogenic differentiation|PAX3,
1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,12878168,MyoD1,PPARdelta,"Activation of PPARdelta by long chain fatty acids impairs the expression of the determination factor MyoD1 and alpha-actin, abolishes the development of multinucleated myotubes, and in parallel induces the expression of PPARgamma gene, a master regulator of adipogenesis.",0.69,PMID.dPMID12878168.s3.p0,4,4,PPARdelta|MyoD1|alpha-actin|PPARgamma,alpha-actin|MyoD1|PPARdelta|PPARgamma,
1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18631126,MyoD,p53,"In the present paper, we shall review the literature demonstrating the action of p68 and, where data are available, p72 as transcriptional co-regulators for a range of transcription factors, namely ERalpha (oestrogen receptor alpha), the tumour suppressor p53, the myogenic regulator MyoD and Runx2, a transcription factor essential for osteoblast development.",0.18,PMID.dPMID18631126.s1.p5,5,5,p72|ERalpha|p53|MyoD|Runx2,ERalpha|MyoD|p53|p72|Runx2,
1.2.2.1.2,4656,9606,,GO:0010552,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,11753683,myogenin,Fos,Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts.,0.13,PMID.dPMID11753683.s7.p1,3,3,Fos|c-Jun|myogenin,c-Jun|Fos|myogenin,
1.2.2.1.2,4656,9606,,GO:0010552,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11753683,myogenin,c-Jun,Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts.,0.72,PMID.dPMID11753683.s7.p2,3,3,Fos|c-Jun|myogenin,c-Jun|Fos|myogenin,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,8955077,basic helix-loop-helix transcription factor,HIF-1,"Hypoxia-inducible factor 1 (HIF-1) is a basic helix-loop-helix transcription factor which is expressed when mammalian cells are subjected to hypoxia and which activates transcription of genes encoding erythropoietin, vascular endothelial growth factor, and other proteins that are important for maintaining oxygen homeostasis.",0.20,PMID.dPMID8955077.s6.p0,4,4,HIF-1|basic helix-loop-helix transcription factor|erythropoietin|vascular endothelial growth factor,basic helix-loop-helix transcription factor|erythropoietin|HIF-1|vascular endothelial growth factor,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,8663540,basic helix-loop-helix transcription factor,HIF-1,Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription factor that regulates hypoxia-inducible genes including the human erythropoietin (EPO) gene.,0.16,PMID.dPMID8663540.s8.p0,4,3,HIF-1|basic helix-loop-helix transcription factor|erythropoietin|EPO,basic helix-loop-helix transcription factor|EPO|erythropoietin|HIF-1,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,14971644,basic helix-loop-helix transcription factor,HIF-1,"HIF-1 is a heterodimeric basic helix-loop-helix transcription factor, composed of HIF-1alpha and HIF-1beta/ARNT subunits; and is involved in tumor growth and angiogenesis.",0.07,PMID.dPMID14971644.s7.p0,5,3,HIF-1|basic helix-loop-helix transcription factor|HIF-1alpha|HIF-1beta|ARNT,ARNT|basic helix-loop-helix transcription factor|HIF-1|HIF-1alpha|HIF-1beta,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12952978,basic helix-loop-helix transcription factor,Id,Id proteins negatively regulate basic helix-loop-helix transcription factor function by disrupting subnuclear compartmentalization.,1.30,PMID.dPMID12952978.s8.p0,2,2,Id|basic helix-loop-helix transcription factor,basic helix-loop-helix transcription factor|Id,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12526101,NeuroD,Id,These results suggest that Id proteins may negatively regulate tissue specific gene expression induced by BETA2/NeuroD in neuroendocrine cells and the inhibitory role of Id proteins during differentiation may be conserved in various tissues.,1.16,PMID.dPMID12526101.s0.p1,4,2,Id|BETA2|NeuroD|Id,BETA2|Id|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12526101,BETA2,Id,These results suggest that Id proteins may negatively regulate tissue specific gene expression induced by BETA2/NeuroD in neuroendocrine cells and the inhibitory role of Id proteins during differentiation may be conserved in various tissues.,1.16,PMID.dPMID12526101.s0.p0,4,2,Id|BETA2|NeuroD|Id,BETA2|Id|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,18752043,basic helix-loop-helix transcription factor,Id1,"Inhibitor of DNA binding-1 (Id1) is a dominant-negative regulator of basic helix-loop-helix transcription factor, which control malignant cell behaviors in several types of carcinomas.",0.45,PMID.dPMID18752043.s11.p0,2,2,Id1|basic helix-loop-helix transcription factor,basic helix-loop-helix transcription factor|Id1,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12526101,NeuroD,Id,Id2 inhibited E-box mediated gene expression in a dose dependent manner in BETA2/NeuroD expressing HIT cells.,0.44,PMID.dPMID12526101.s2.p1,3,2,Id|BETA2|NeuroD,BETA2|Id|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12526101,BETA2,Id,Id2 inhibited E-box mediated gene expression in a dose dependent manner in BETA2/NeuroD expressing HIT cells.,0.44,PMID.dPMID12526101.s2.p0,3,2,Id|BETA2|NeuroD,BETA2|Id|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12526101,BETA2,Id,"In this study, we investigated the effect of Id on the function of BETA2/NeuroD, a bHLH transcription factor responsible for neuron and endocrine cell specific gene expression.",0.07,PMID.dPMID12526101.s6.p0,3,2,Id|BETA2|NeuroD,BETA2|Id|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12526101,NeuroD,Id,"In this study, we investigated the effect of Id on the function of BETA2/NeuroD, a bHLH transcription factor responsible for neuron and endocrine cell specific gene expression.",0.07,PMID.dPMID12526101.s6.p1,3,2,Id|BETA2|NeuroD,BETA2|Id|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.2.3.0.1,3642,9606,,,16569215,beta2,INSM1,A chromatin immunoprecipitation assay confirmed that in vivo INSM1 is situated on the promoter region of the neuroD/beta2 gene.,0.72,PMID.dPMID16569215.s7.p0,2,2,INSM1|beta2,beta2|INSM1,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.2.3.0.1,3642,9606,,,11842116,NeuroD,IA-1,"These findings suggest that the IA-1 protein may be auto-regulated and play a role in pancreas and neuronal development, specifically in the regulation of the NeuroD/beta2 gene",0.55,PMID.dPMID11842116.s0.p0,2,2,IA-1|NeuroD,IA-1|NeuroD,[3642-->3642]
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.2.3.0.1,3642,9606,,,16569215,beta2,INSM1,INSM1 functions as a transcriptional repressor of the neuroD/beta2 gene through the recruitment of cyclin D1 and histone deacetylases.,0.44,PMID.dPMID16569215.s10.p0,2,2,INSM1|beta2,beta2|INSM1,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11799123,NeuroD,c-Myc,"In conclusion, increased expression of c-Myc in beta-cells suppresses the insulin gene transcription by inhibiting NeuroD-mediated transcriptional activation.",0.72,PMID.dPMID11799123.s1.p0,2,2,c-Myc|NeuroD,c-Myc|NeuroD,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.4.2,4761,9606,,GO:0006357,11732772,NeuroD,NeuroD2,"The authors used in situ hybridization with full-length riboprobes for NeuroD1, NeuroD2, and NeuroD3 to describe the expression of the NeuroD homologues in a gestational sequence of human fetal brains.",0.32,PMID.dPMID11732772.s7.p4,4,3,NeuroD1|NeuroD2|NeuroD3|NeuroD,NeuroD|NeuroD1|NeuroD2|NeuroD3,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.4.5,4762,9606,,GO:0006357,11732772,NeuroD,NeuroD3,"The authors used in situ hybridization with full-length riboprobes for NeuroD1, NeuroD2, and NeuroD3 to describe the expression of the NeuroD homologues in a gestational sequence of human fetal brains.",0.67,PMID.dPMID11732772.s7.p5,4,3,NeuroD1|NeuroD2|NeuroD3|NeuroD,NeuroD|NeuroD1|NeuroD2|NeuroD3,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,3.2.1.2.2,5080,9606,,,19223471,NeuroD1,Pax6,"By binding and transactivation studies, we found that Pax6 indirectly regulates PC2 gene transcription through cMaf and Beta2/NeuroD1 while it activates the 7B2 gene both directly and indirectly through the same transcription factors, cMaf and Beta2/NeuroD1.",0.17,PMID.dPMID19223471.s1.p1,6,3,Pax6|Beta2|NeuroD1|7B2|Beta2|NeuroD1,7B2|Beta2|NeuroD1|Pax6,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,3.2.1.2.2,5080,9606,,,19223471,Beta2,Pax6,"By binding and transactivation studies, we found that Pax6 indirectly regulates PC2 gene transcription through cMaf and Beta2/NeuroD1 while it activates the 7B2 gene both directly and indirectly through the same transcription factors, cMaf and Beta2/NeuroD1.",0.17,PMID.dPMID19223471.s1.p0,6,3,Pax6|Beta2|NeuroD1|7B2|Beta2|NeuroD1,7B2|Beta2|NeuroD1|Pax6,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,11767003,beta2,RAR,"RAR beta2 expression is reduced or lost in many malignant tumors including breast cancer, however, whether LOH accounts for the loss of expression of RAR beta2 in breast cancer is unknown.",0.85,PMID.dPMID11767003.s6.p0,4,2,RAR|beta2|RAR|beta2,beta2|RAR,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10962564,beta2,RAR,"Upon bisulfite genomic sequencing, we found that 3 CpG sites in the beta2 RARE region were variably methylated in MCF-7 cells but were not methylated in MTSV1.7 cells or in 2 MDA-MB-231 subclones that differed in RARbeta2 expression (high in clone A2, low in clone A4).",0.72,PMID.dPMID10962564.s5.p5,4,2,beta2|RAR|RAR|beta2,beta2|RAR,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,11767003,beta2,RAR,RAR beta2 expression was lost in 42% (19/45) of these samples.,0.62,PMID.dPMID11767003.s2.p0,2,2,RAR|beta2,beta2|RAR,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,11497266,beta2,RAR,Hypermethylation of the retinoic acid receptor (RAR) beta2 has been detected in breast cancer cell lines and is known to repress the level of RAR beta2 transcription.,0.43,PMID.dPMID11497266.s4.p5,4,2,RAR|beta2|RAR|beta2,beta2|RAR,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,11767003,beta2,RAR,Our findings suggest that LOH of the RAR beta2 gene does not account for the frequent loss of RAR beta2 expression in breast cancer but the genomic structural alteration at or close to the RAR beta2 gene locus are likely to be associated with tumor progression and/or loss of hormonal dependency.,0.05,PMID.dPMID11767003.s0.p3,6,2,RAR|beta2|RAR|beta2|RAR|beta2,beta2|RAR,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,14725896,basic helix-loop-helix transcription factor,SCL,SCL is a basic helix-loop-helix transcription factor that is an essential regulator at several levels in the hematopoietic hierarchy and whose inappropriate regulation frequently contributes to the development of pediatric T-cell acute lymphoblastic leukemia.,0.35,PMID.dPMID14725896.s3.p0,2,2,SCL|basic helix-loop-helix transcription factor,basic helix-loop-helix transcription factor|SCL,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,14651981,basic helix-loop-helix transcription factor,TCL5,The Tal1 gene (also called Scl or TCL5) encodes a basic helix-loop-helix transcription factor required for hematopoiesis and vasculogenesis.,0.24,PMID.dPMID14651981.s8.p5,4,4,Tal1|Scl|TCL5|basic helix-loop-helix transcription factor,basic helix-loop-helix transcription factor|Scl|Tal1|TCL5,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,14984368,beta2,HNF-1,"In addition, overexpression of HNF-1alpha enhanced the endogenous beta2-GPI expression.",0.05,PMID.dPMID14984368.s1.p0,2,2,HNF-1|beta2,beta2|HNF-1,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1386162,basic helix-loop-helix transcription factor,E2A,"A t(17;19) chromosomal translocation in early B-lineage acute leukemia was shown to result in chimeric transcripts that contain sequences from the E2A basic helix-loop-helix transcription factor gene on chromosome 19, fused to sequences from a previously unidentified gene (HLF) on chromosome 17 that encodes a hepatic leukemia factor.",0.04,PMID.dPMID1386162.s2.p0,3,3,E2A|basic helix-loop-helix transcription factor|HLF,basic helix-loop-helix transcription factor|E2A|HLF,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.2.1,7291,9606,,,18504427,basic helix-loop-helix transcription factor,Twist,Twist is basic helix-loop-helix transcription factor that binds to E-boxes in gene promoters.,0.67,PMID.dPMID18504427.s7.p0,2,2,Twist|basic helix-loop-helix transcription factor,basic helix-loop-helix transcription factor|Twist,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.2.1,7291,9606,,,17236203,basic helix-loop-helix transcription factor,Twist,"Despite evidence that Twist, a highly conserved basic helix-loop-helix transcription factor, is a novel oncogene, there are no reports describing Twist expression in pancreatic cancer.",0.07,PMID.dPMID17236203.s8.p0,3,2,Twist|basic helix-loop-helix transcription factor|Twist,basic helix-loop-helix transcription factor|Twist,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.4.7,50674,9606,,,16855267,NEUROD1,NEUROG3,The injection of wild-type but not mutant NEUROG3 messenger RNA into xenopus embryos induced NEUROD1 expression.,0.99,PMID.dPMID16855267.s1.p0,2,2,NEUROG3|NEUROD1,NEUROD1|NEUROG3,
1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,1.2.3.4.6,63973,9606,,,17761887,NeuroD1,Ngn2,"Ngn2 is normally expressed in the anterior pituitary and frequently expressed in PA, but does not account for NeuroD1 overexpression where present.",0.30,PMID.dPMID17761887.s1.p0,2,2,Ngn2|NeuroD1,NeuroD1|Ngn2,
1.2.3.4.2,4761,9606,,GO:0006357,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,14732494,NEUROD2,NEUROD1,"In these assays, NEUROD1 was found to transiently transactivate NEUROD2 in trophoblast cells.",0.25,PMID.dPMID14732494.s4.p0,2,2,NEUROD1|NEUROD2,NEUROD1|NEUROD2,
1.2.3.4.2,4761,9606,,GO:0006357,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,14732494,NEUROD2,NEUROD1,NEUROD1 acts in vitro as an upstream regulator of NEUROD2 in trophoblast cells.,0.24,PMID.dPMID14732494.s7.p0,2,2,NEUROD1|NEUROD2,NEUROD1|NEUROD2,
6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,19028555,NFATc1,AhR,An AhR-activation by 10nM TCDD and HIF-1alpha activation by 5% oxygen induced activation of NFATc1.,0.45,PMID.dPMID19028555.s7.p0,2,2,AhR|NFATc1,AhR|NFATc1,
6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,16819284,NFATc1,c-Fos,"However, retrovirus-mediated overexpression of c-Fos induced the expression of NFATc1 despite the presence of tanshinone IIA and reversed the inhibitory effect of tanshinone IIA on osteoclast differentiation.",0.84,PMID.dPMID16819284.s2.p0,2,2,c-Fos|NFATc1,c-Fos|NFATc1,
6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,16931157,NFATc1,NFATc2,"NFATc2 is constitutively synthesized in T cells, whereas the expression of NFATc1/alphaA, the most prominent of six NFATc1 isoforms in peripheral T cells, is strongly induced following T-cell receptor and co-receptor stimulation and maintained by positive autoregulation.",0.24,PMID.dPMID16931157.s1.p1,3,2,NFATc2|NFATc1|NFATc1,NFATc1|NFATc2,
6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,16931157,NFATc1,NFATc2,"NFATc2 is constitutively synthesized in T cells, whereas the expression of NFATc1/alphaA, the most prominent of six NFATc1 isoforms in peripheral T cells, is strongly induced following T-cell receptor and co-receptor stimulation and maintained by positive autoregulation.",0.12,PMID.dPMID16931157.s1.p0,3,2,NFATc2|NFATc1|NFATc1,NFATc1|NFATc2,
6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9653115,NFAT1,Fos,The NFAT1-Fos-Jun complex induced a bend at the ARRE2 site that was distinct from the sum of the bends induced by NFAT1 and Fos-Jun separately.,0.26,PMID.dPMID9653115.s6.p2,4,2,NFAT1|Fos|NFAT1|Fos,Fos|NFAT1,
6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,11320240,NFAT1,Fos,The reorientation of Fos-Jun by NFAT1 was not inhibited by competitor oligonucleotides or heterodimers.,0.21,PMID.dPMID11320240.s6.p0,2,2,Fos|NFAT1,Fos|NFAT1,
6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,16407284,NFATc2,NFATc1,Dose-response CN binding experiments with GST fusion proteins of NFATc1 and NFATc2 showed that NFATc1 binds CN in vitro more efficiently than does NFATc2.,0.20,PMID.dPMID16407284.s7.p5,4,2,NFATc1|NFATc2|NFATc1|NFATc2,NFATc1|NFATc2,
6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,17463169,NFAT1,FOXP3,"By NFAT1 knockdown in CD4(+)CD25(+) T cells, FOXP3 expression was decreased when NFAT1 expression was decreased.",0.81,PMID.dPMID17463169.s2.p5,4,3,NFAT1|CD4|FOXP3|NFAT1,CD4|FOXP3|NFAT1,
6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,1.1.1.1.6,60468,9606,,,18769450,NFAT1,BACH2,"Thus, BACH2 expression is necessary to maintain IL-2 production when NFAT1 protein is reduced, potentially impacting UCB graft CD4(+) T-cell allogeneic responses",0.23,PMID.dPMID18769450.s0.p1,4,4,BACH2|IL-2|NFAT1|CD4,BACH2|CD4|IL-2|NFAT1,
1.1.1.1.7,4778,9606,GO:0030528,GO:0006357|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,20339092,NF-E2,AML1,RNAi-mediated suppression of either AML1 or of its binding partner CBF-beta significantly decreased NF-E2 expression.,0.82,PMID.dPMID20339092.s2.p1,3,3,AML1|CBF-beta|NF-E2,AML1|CBF-beta|NF-E2,
1.1.1.1.7,4778,9606,GO:0030528,GO:0006357|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,20339092,NF-E2,AML1,Our data identify NF-E2 as a novel AML1 target gene and delineate a role for aberrant AML1 expression in mediating elevated NF-E2 expression in MPN patients,0.11,PMID.dPMID20339092.s0.p5,4,2,NF-E2|AML1|AML1|NF-E2,AML1|NF-E2,
1.1.1.1.7,4778,9606,GO:0030528,GO:0006357|GO:0045941,1.1.3.0.6,4097,9606,,,9166829,p45 NF-E2,MafG,Human MafG is a functional partner for p45 NF-E2 in activating globin gene expression.,0.24,PMID.dPMID9166829.s8.p0,2,2,MafG|p45 NF-E2,MafG|p45 NF-E2,
1.1.1.1.7,4778,9606,GO:0030528,GO:0006357|GO:0045941,1.1.3.0.6,4097,9606,,,9195958,NFE2,hMAF,Thus variations in the expression of hMAF may account for the modulation in the activity of the genes that bear NFE2 recognition sites,0.20,PMID.dPMID9195958.s0.p0,2,2,hMAF|NFE2,hMAF|NFE2,
1.1.1.1.7,4778,9606,GO:0030528,GO:0006357|GO:0045941,1.2.6.2.1,7391,9606,,GO:0000430|GO:0000432|GO:0010551|GO:0010552|GO:0045990,20236933,NF-E2,USF,"Here we demonstrate that although USF is required for the efficient association of RNA polymerase II (Pol II) with immobilized LCR templates, USF and NF-E2 together regulate the association of Pol II with the adult beta-globin gene promoter.",0.09,PMID.dPMID20236933.s3.p1,4,4,USF|USF|NF-E2|beta-globin,beta-globin|NF-E2|USF,
7.1.2.0.2,4781,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,19841262,NFIB,MYB,Our findings also suggest that the gain-of-function activity resulting from the MYB-NFIB fusion is a candidate therapeutic target.,0.06,PMID.dPMID19841262.s0.p0,2,2,MYB|NFIB,MYB|NFIB,
7.1.2.0.3,4782,9606,,GO:0000122|GO:0010552|GO:0010553|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,15816857,NFI-C,Sp3,We conclude that RA induction of the secretin gene in neuronal cells is regulated by the combined actions of reducing Sp3 and increasing NFI-C expression.,0.23,PMID.dPMID15816857.s0.p2,3,3,secretin|Sp3|NFI-C,NFI-C|secretin|Sp3,
1.1.4.2.4,4783,9606,,,1.1.4.2.1,1628,9606,GO:0003702,GO:0006357,18004209,E4BP4,DBP,"CONCLUSIONS: Results from this study suggest that DBP and E4BP4 might consist of a reciprocating mechanism in which DBP activates the transcription of the CYP3A4 gene during the time of day when DBP is abundant, and E4BP4 suppresses the transcription at other times of day.",0.05,PMID.dPMID18004209.s1.p10,6,3,DBP|E4BP4|DBP|CYP3A4|DBP|E4BP4,CYP3A4|DBP|E4BP4,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,8198705,NF-kappa B,Bcl-3,Bcl-3-mediated nuclear regulation of the NF-kappa B trans-activating factor.,0.89,PMID.dPMID8198705.s3.p0,2,2,Bcl-3|NF-kappa B,Bcl-3|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,11387332,NF-kappa B,BCL-3,"Down-regulation of BCL-3 induction results in prolonged, enhanced NF-kappa B1 binding and increased NF-kappa B-dependent transcription.",0.48,PMID.dPMID11387332.s1.p1,3,2,BCL-3|NF-kappa B|NF-kappa B,BCL-3|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,11707390,NF-kappaB,Bcl-3,"Bcl-3 is an unusual IkappaB protein because it is primarily nucleoplasmic and can lead to enhanced NF-kappaB-dependent transcription, unlike the prototypical IkappaB protein IkappaBalpha, which inhibits NF-kappaB activity by retaining it in the cytoplasm.",0.35,PMID.dPMID11707390.s4.p0,4,3,Bcl-3|NF-kappaB|IkappaBalpha|NF-kappaB,Bcl-3|IkappaBalpha|NF-kappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,11387332,NF-kappa B,bcl-3,Two observations are interpreted to indicate that bcl-3 is transactivated by NF-kappa B/Rel A: 1) expression of a dominant negative NF-kappa B inhibitor blocks tumor necrosis factor-alpha-induced BCL-3 expression and 2) expression of constitutively active Rel A is sufficient to induce BCL-3 expression.,0.34,PMID.dPMID11387332.s3.p3,7,3,bcl-3|NF-kappa B|Rel|NF-kappa B|BCL-3|Rel|BCL-3,bcl-3|BCL-3|NF-kappa B|Rel,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,8196632,NF-kappa B,BCL3,BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins.,0.27,PMID.dPMID8196632.s10.p0,2,2,BCL3|NF-kappa B,BCL3|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,11387332,NF-kappa B,BCL-3,NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence.,0.21,PMID.dPMID11387332.s11.p2,3,2,NF-kappa B|BCL-3|NF-kappa B,BCL-3|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,8404857,NF-kappa B,Bcl-3,(i) Bcl-3 preferentially targets p50 homodimers over NF-kappa B heterodimers since the homodimers are completely dissociated from kappa B sites at concentrations of Bcl-3 which do not affect NF-kappa B.,0.03,PMID.dPMID8404857.s6.p6,5,3,Bcl-3|p50|NF-kappa B|Bcl-3|NF-kappa B,Bcl-3|NF-kappa B|p50,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,11387332,NF-kappa B,BCL-3,Here we examine the role of inducible cytoplasmic BCL-3 expression in terminating nuclear NF-kappa B1.,0.01,PMID.dPMID11387332.s7.p0,2,2,BCL-3|NF-kappa B,BCL-3|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.4.1.2,1051,9606,,,15048722,NF-kappa B,NF-IL6,"In this study, we show that the IL-4 promoter is synergistically activated by NF-kappa B, NF-AT and NF-IL6 at the NF-kappa B/NF-AT/NF-IL6 composite sites.",0.08,PMID.dPMID15048722.s4.p5,5,3,IL-4|NF-kappa B|NF-IL6|NF-kappa B|NF-IL6,IL-4|NF-IL6|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,15688424,NFkappaB,DDIT3,We demonstrate for the first time that DDIT3 and FUS-DDIT3 show opposite transcriptional regulation of IL8 and suggest that FUS-DDIT3 may affect the synergistic activation of promoters regulated by C/EBP beta and NFkappaB.,0.89,PMID.dPMID15688424.s0.p20,7,4,DDIT3|FUS|DDIT3|IL8|FUS|DDIT3|NFkappaB,DDIT3|FUS|IL8|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.3.2.1.1,1869,9606,,GO:0000122,9368006,NF-kappaB,E2F-1,In vitro transcription assay demonstrates that E2F-1 represses NF-kappaB mediated transcription in a cell-free system.,1.23,PMID.dPMID9368006.s2.p0,2,2,E2F-1|NF-kappaB,E2F-1|NF-kappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2.3.2.1.2,1958,9606,,GO:0045941,9053449,NF-kappa B,Egr-1,"Furthermore, Egr-1 induction was required for endogenous NF-kappa B1 gene expression, since PMA/PHA-stimulated T cell lines expressing antisense Egr-1 RNA were inhibited in their ability to upregulate NF-kappa B1 transcription.",0.72,PMID.dPMID9053449.s1.p5,4,2,Egr-1|NF-kappa B|Egr-1|NF-kappa B,Egr-1|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2.3.2.1.2,1958,9606,,GO:0045941,9053449,NF-kappa B,Egr-1,"Furthermore, Egr-1 induction was required for endogenous NF-kappa B1 gene expression, since PMA/PHA-stimulated T cell lines expressing antisense Egr-1 RNA were inhibited in their ability to upregulate NF-kappa B1 transcription.",0.34,PMID.dPMID9053449.s1.p3,4,2,Egr-1|NF-kappa B|Egr-1|NF-kappa B,Egr-1|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,8195192,NF-kappa B,ara,ara-C also increased expression of the transcription factor NF-kappa B which is related to the control of monocyte differentiation.,0.44,PMID.dPMID8195192.s1.p0,2,2,ara|NF-kappa B,ara|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,1732723,NF-kappa B,ara,"However, the finding that ara-C-induced binding of NF-kappa B to DNA occurs in the presence of cycloheximide indicates that this agent activates preexisting NF-kappa B protein.",0.06,PMID.dPMID1732723.s1.p0,3,2,ara|NF-kappa B|NF-kappa B,ara|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8849348,NF-kappa B,Fos,Different but overlapping distributions of nuclear p50 and p65 versus Jun and Fos indicate separate or divergent mechanisms for the activation of NF-kappa B and the expression of AP-1 proteins in rheumatoid synovium,0.02,PMID.dPMID8849348.s0.p2,3,3,p50|Fos|NF-kappa B,Fos|NF-kappa B|p50,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,12488445,NFkappaB,HIF-1alpha,"The ability of MDAs to induce HIF-1alpha is dependent upon activation of NFkappaB, since inhibition of NFkappaB either pharmacologically or by transfection of an NFkappaB super-repressor plasmid abrogated this induction.",0.52,PMID.dPMID12488445.s1.p0,4,2,HIF-1alpha|NFkappaB|NFkappaB|NFkappaB,HIF-1alpha|NFkappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,16118352,NFkappaB,HMGB1,HMGB1 increased NFkappaB activity and led to co-overexpression of the antiapoptotic NFkappaB target gene product c-IAP2 in vitro.,0.92,PMID.dPMID16118352.s4.p0,4,3,HMGB1|NFkappaB|NFkappaB|c-IAP2,c-IAP2|HMGB1|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,7520524,NF-kappa B,HMG-I(Y),We noted that one of the HMG-I(Y)-binding sites overlaps a sequence element (-127/-118) diverging at only one position from the NF-kappa B consensus binding sequence.,0.69,PMID.dPMID7520524.s8.p0,2,2,HMG-I(Y)|NF-kappa B,HMG-I(Y)|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,7520524,NF-kappa B,HMG-I(Y),We conclude that HMG-I(Y) mediates binding of a distinct NF-kappa B complex at two sites within the E-selectin promoter.,0.09,PMID.dPMID7520524.s2.p0,3,3,HMG-I(Y)|NF-kappa B|E-selectin,E-selectin|HMG-I(Y)|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,17638919,NFkappaB,Id-1,"Our results provide the first evidence that Id-1 induces the activation of PI3K/Akt/NFkappaB signaling pathway, and protects esophageal cancer cells from TNF-alpha-induced apoptosis in vitro.",0.51,PMID.dPMID17638919.s1.p1,4,4,Id-1|Akt|NFkappaB|TNF-alpha,Akt|Id-1|NFkappaB|TNF-alpha,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.5.3.0.1,3659,9606,,,10215868,NFkappaB,IRF-1,Here we report that IRF-1-mediated IFN-beta induction depends on NFkappaB activity.,0.31,PMID.dPMID10215868.s5.p1,3,3,IRF-1|IFN-beta|NFkappaB,IFN-beta|IRF-1|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.5.3.0.1,3659,9606,,,9336467,NFkappaB,IRF-1,The GAS/kappaB element may mediate synergistic transcriptional induction of IRF-1 by other pairs of ligands that together activate NFkappaB and STAT family members.,0.14,PMID.dPMID9336467.s1.p0,2,2,IRF-1|NFkappaB,IRF-1|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.5.3.0.1,3659,9606,,,10215868,NFkappaB,IRF-1,"IRF-1 by itself initiates NFkappaB activation by inducing a reduction in cellular MAD3/IkappaBalpha, an inhibitor of NFkappaB.",0.01,PMID.dPMID10215868.s4.p0,4,3,IRF-1|NFkappaB|IkappaBalpha|NFkappaB,IkappaBalpha|IRF-1|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.5.3.0.7,3665,9606,GO:0003704,GO:0000122,15265881,NF-kappa B,IRF-7,"In this study, we demonstrate that both LPS and HSV up-regulate the expression of IRF-7 in PDC, and that this enhancement of IRF-7 is dependent on NF-kappa B activation.",0.97,PMID.dPMID15265881.s4.p2,3,2,IRF-7|IRF-7|NF-kappa B,IRF-7|NF-kappa B,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10593895,NFkappaB,AP-1,"In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB.",0.44,PMID.dPMID10593895.s4.p2,3,3,CHP|AP-1|NFkappaB,AP-1|CHP|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19806201,NFkappaB,c-Jun,"Hypo-phosphorylated c-Jun accumulated to high levels following JNK2 silencing, auto-regulated its own expression and suppressed expression of Bcl-3, an unusual IkappaB protein and regulator of NFkappaB.",0.39,PMID.dPMID19806201.s5.p3,4,4,c-Jun|JNK2|Bcl-3|NFkappaB,Bcl-3|c-Jun|JNK2|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,14736953,NF-kappa B,AP-1,"TNF-alpha induced MCP-1 production appeared to be NF-kappa B and AP-1 interdependent, based on the following results. (i) TNF-alpha increased NF-kappa B and AP-1 binding activity.",0.33,PMID.dPMID14736953.s3.p13,7,4,TNF-alpha|MCP-1|NF-kappa B|AP-1|TNF-alpha|NF-kappa B|AP-1,AP-1|MCP-1|NF-kappa B|TNF-alpha,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18080803,NF-kappa B,AP-1,"In summary, we demonstrated that transfected IKK gamma, while inhibiting the NF-kappa B pathway, directly interacts with the AP-1 proteins and activates the AP-1 pathway independent of its effects on NF-kappa B.",0.16,PMID.dPMID18080803.s1.p9,5,3,IKK gamma|NF-kappa B|AP-1|AP-1|NF-kappa B,AP-1|IKK gamma|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18080803,NF-kappa B,AP-1,"In summary, we demonstrated that transfected IKK gamma, while inhibiting the NF-kappa B pathway, directly interacts with the AP-1 proteins and activates the AP-1 pathway independent of its effects on NF-kappa B.",0.14,PMID.dPMID18080803.s1.p8,5,3,IKK gamma|NF-kappa B|AP-1|AP-1|NF-kappa B,AP-1|IKK gamma|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.1.1.1.2,3726,9606,GO:0003702,GO:0006357,12145210,NF-kappa B,JunB,"Whereas c-Jun is up-regulated by an autoregulatory process, JunB is under control of NF-kappa B.",1.23,PMID.dPMID12145210.s3.p2,3,3,c-Jun|JunB|NF-kappa B,c-Jun|JunB|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.1.5.6.2,4010,9606,,GO:0006355,18996370,NF-kappa B,LMX1B,The LIM-homeodomain transcription factor LMX1B regulates expression of NF-kappa B target genes.,1.50,PMID.dPMID18996370.s9.p0,2,2,LMX1B|NF-kappa B,LMX1B|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1512542,NF-kappa B,c-myc,"Thus, IL-1 significantly induces c-myc expression through positive regulation by NF-kappa B, suggesting a role for this family of factors in activation of proliferation associated with wound healing",0.83,PMID.dPMID1512542.s0.p2,3,3,IL-1|c-myc|NF-kappa B,c-myc|IL-1|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12783888,NF-kappa B,c-myc,"Here we show that the NO donor, sodium nitroprusside (SNP), rapidly represses c-myc gene transcription in a protein synthesis-independent manner in P19 embryonal carcinoma cells by inactivation of NF-kappa B.",0.05,PMID.dPMID12783888.s8.p0,2,2,c-myc|NF-kappa B,c-myc|NF-kappa B,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,19414075,NF-kappaB,myogenic differentiation,"Studies in the past had suggested that two of these mesenchymal differentiation directions, the chondrogenic and the myogenic differentiation, are negatively regulated by the transcription factor NF-kappaB.",0.72,PMID.dPMID19414075.s9.p0,2,2,myogenic differentiation|NF-kappaB,myogenic differentiation|NF-kappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.1.2,4791,9606,,GO:0006355|GO:0051092,7541912,NF-kappa B,NFKB2,Co-transfection of NF-kappa B effector plasmids (NF-kappa Bp52 and RelA) with a reporter gene linked to P1 and P2 showed that the NFKB2 promoter regions are regulated by NF-kappa B factors.,0.14,PMID.dPMID7541912.s1.p9,5,3,NF-kappa B|NF-kappa B|RelA|NFKB2|NF-kappa B,NF-kappa B|NFKB2|RelA,"[4791-->4791, 5970-->4791]"
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,9514153,NF-kappaB,IkappaBalpha,"Taken together, these results indicate that induced IkappaBalpha expression accounts for only part of the repression of NF-kappaB activity by glucocorticoids and progestins.",1.00,PMID.dPMID9514153.s2.p0,2,2,IkappaBalpha|NF-kappaB,IkappaBalpha|NF-kappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,9572494,NF-kappaB,IkappaBalpha,In three Hodgkin cell lines examined each had abnormalities in expression of IkappaBalpha which could account for the deregulated NF-kappaB.,0.89,PMID.dPMID9572494.s5.p0,2,2,IkappaBalpha|NF-kappaB,IkappaBalpha|NF-kappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,12432072,NFkappaB,IkappaBalpha,These studies demonstrate for the first time that an IkappaBalphaY42F mutant can effectively modulate NFkappaB-mediated apoptosis in an injury-context-dependent manner.,0.67,PMID.dPMID12432072.s3.p0,2,2,IkappaBalpha|NFkappaB,IkappaBalpha|NFkappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,9514153,NF-kappaB,IkappaBalpha,"However, this enhanced IkappaBalpha synthesis did not cause repression of NF-kappaB DNA-binding activity.",0.66,PMID.dPMID9514153.s6.p0,2,2,IkappaBalpha|NF-kappaB,IkappaBalpha|NF-kappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,9665319,NFkappaB,IkappaBalpha,"ETOH does not directly inhibit NFkappaB or AP-1, in vivo, but rather inhibits LPS-induced activation of the MEKK/MAP kinase system and inhibition of inhibitory protein IkappaBalpha required for formation of AP-1 and NFkappaB, respectively.",0.27,PMID.dPMID9665319.s7.p8,5,3,NFkappaB|AP-1|IkappaBalpha|AP-1|NFkappaB,AP-1|IkappaBalpha|NFkappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,8631829,NFkappaB,IkappaBalpha,Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo.,0.18,PMID.dPMID8631829.s7.p0,2,2,IkappaBalpha|NFkappaB,IkappaBalpha|NFkappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,12356823,NFkappaB,IkappaBalpha,CONCLUSIONS; NaOCl oxidizes IkappaBalpha at methionine residues and thereby suppresses dissociation of IkappaBalpha from NFkappaB.,0.18,PMID.dPMID12356823.s2.p2,3,2,IkappaBalpha|IkappaBalpha|NFkappaB,IkappaBalpha|NFkappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,12356823,NFkappaB,IkappaBalpha,CONCLUSIONS; NaOCl oxidizes IkappaBalpha at methionine residues and thereby suppresses dissociation of IkappaBalpha from NFkappaB.,0.04,PMID.dPMID12356823.s2.p1,3,2,IkappaBalpha|IkappaBalpha|NFkappaB,IkappaBalpha|NFkappaB,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,16410078,NFkappaB,IkappaBalpha,"Instead, tyrosine phosphorylation of IkappaBalpha was observed following VEGF treatment, suggesting NFkappaB activation was mediated by degradation-independent dissociation of IkappaBalpha from NFkappaB.",0.00,PMID.dPMID16410078.s3.p9,5,3,IkappaBalpha|VEGF|NFkappaB|IkappaBalpha|NFkappaB,IkappaBalpha|NFkappaB|VEGF,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.7,4795,9606,,,15473256,NFkappaB,IKBL,IKBL encodes a protein resembling members of the IkappaB protein family that regulate bioavailability of NFkappaB.,0.86,PMID.dPMID15473256.s8.p0,2,2,IKBL|NFkappaB,IKBL|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,8709216,NF-kappa B,YB-1,"Functionally, YB-1 appears to act synergistically with p65 to control transcription from the NF-kappa B site.",0.41,PMID.dPMID8709216.s3.p1,3,3,YB-1|p65|NF-kappa B,NF-kappa B|p65|YB-1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,9748221,NFkappaB,PPARgamma,"Finally, PPARgamma inhibits the transcriptional activity of the NFkappaB p65/RelA subunit, suggesting that PPAR activators induce macrophage apoptosis by negatively interfering with the anti-apoptotic NFkappaB signaling pathway.",0.57,PMID.dPMID9748221.s1.p0,5,4,PPARgamma|NFkappaB|RelA|PPAR|NFkappaB,NFkappaB|PPAR|PPARgamma|RelA,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15387324,NFkappaB,PPARgamma,"(1) COX-2, PPARgamma, HGF, gastrin, and its receptor are significantly upregulated in BE, suggesting a possible role for these factors in Barrett's carcinogenesis; (2) the increased NFkappaB activity is probably linked to increased IL-8 and COX-2 expression; and (3) PPARgamma ligands might be useful as a new therapeutic option in the prevention and treatment of Barrett's carcinoma",0.54,PMID.dPMID15387324.s0.p3,6,5,PPARgamma|HGF|gastrin|NFkappaB|IL-8|PPARgamma,gastrin|HGF|IL-8|NFkappaB|PPARgamma,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.3,5966,9606,,,15188354,NF-kappa B,Rel,Rel/NF-kappa B was abundantly expressed in all samples.,0.26,PMID.dPMID15188354.s7.p0,2,2,Rel|NF-kappa B,NF-kappa B|Rel,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.3,5966,9606,,,10713713,NF-kappa B,Rel,I kappa B alpha is a dual regulator of Rel/NF-kappa B transcription factors.,0.23,PMID.dPMID10713713.s9.p0,2,2,Rel|NF-kappa B,NF-kappa B|Rel,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.3,5966,9606,,,9928378,NF-kappa B,c-rel,"Western blot studies showed an increased expression of the p50 and c-rel subunits of NF-kappa B; however, the most striking finding was an increased expression level of NF-kappa B p65 in patients with CD and UC.",0.18,PMID.dPMID9928378.s3.p0,4,3,c-rel|NF-kappa B|NF-kappa B|p65,c-rel|NF-kappa B|p65,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.3,5966,9606,,,9351352,NF-kappa B,Rel,"Nuclear factor-kappa B (NF-kappa B)/Rel transcription factors may be involved in atherosclerosis, as is suggested by the presence of activated NF-kappa B in human atherosclerotic lesions.",0.14,PMID.dPMID9351352.s6.p2,3,2,NF-kappa B|Rel|NF-kappa B,NF-kappa B|Rel,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.3,5966,9606,,,10602461,NF-kappaB,Rel,Activators and target genes of Rel/NF-kappaB transcription factors.,0.10,PMID.dPMID10602461.s7.p0,2,2,Rel|NF-kappaB,NF-kappaB|Rel,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.3,5966,9606,,,9299588,NF-kappa B,Rel,Rel/NF-kappa B transcription factors play fundamental roles in the immune system.,0.04,PMID.dPMID9299588.s4.p0,2,2,Rel|NF-kappa B,NF-kappa B|Rel,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,15988014,NF-kappaB,RelA,Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis.,1.17,PMID.dPMID15988014.s10.p0,2,2,RelA|NF-kappaB,NF-kappaB|RelA,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18201972,NFkappaB,RelA,"Functionally, phosphorylation of Ser-468 of RelA/p65 was required for the induced expression of a particular subset of proinflammatory NFkappaB-dependent genes.",0.86,PMID.dPMID18201972.s3.p1,3,3,RelA|p65|NFkappaB,NFkappaB|p65|RelA,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,14581467,NF-kappaB,RelA,"Using a range of functional assays, we have shown that microtubule depolymerization correlates with the activation of IKKalpha and IKKbeta; the phosphorylation, ubiquitination, and degradation of IkappaBalpha; the translocation of native p65 (RelA) into the nucleus; and increased NF-kappaB transcriptional activity.",0.37,PMID.dPMID14581467.s4.p5,4,4,IKKbeta|IkappaBalpha|RelA|NF-kappaB,IkappaBalpha|IKKbeta|NF-kappaB|RelA,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20385359,NFkappaB,Sp1,Sp1 enhances its own expression by participating in a NFkappaB/HDAC complex that further represses miR-29b transcription.,0.44,PMID.dPMID20385359.s3.p0,3,3,Sp1|NFkappaB|HDAC,HDAC|NFkappaB|Sp1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20385359,NFkappaB,Sp1,Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.,0.20,PMID.dPMID20385359.s6.p0,4,4,Sp1|NFkappaB|HDAC|KIT,HDAC|KIT|NFkappaB|Sp1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,16778171,NFKB1,TAL1,"Moreover, a significant negative correlation between NFKB1 and TAL1 or LMO1 was found in primary human TAL1/LMO1 double-positive T-ALL samples previously described by Ferrando et al. Thus, TAL1 modulates NFKB1 expression and an NF-kappaB-dependent transcriptional program in a subset of human T-cell leukemia cells",2.01,PMID.dPMID16778171.s0.p20,7,3,NFKB1|TAL1|LMO1|TAL1|LMO1|TAL1|NFKB1,LMO1|NFKB1|TAL1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,16778171,NFKB1,TAL1,"When TAL1 expression is reduced in CEM T leukemia cells, basal NFKB1 expression is increased, and the levels of p65:cRel complex and transcription of its target gene, such as intercellular adhesion molecule-1 (ICAM-1), are reduced in response to etoposide treatment.",0.48,PMID.dPMID16778171.s1.p0,5,4,TAL1|NFKB1|cRel|intercellular adhesion molecule-1|ICAM-1,cRel|ICAM-1|intercellular adhesion molecule-1|NFKB1|TAL1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,16778171,NFKB1,TAL1,"Moreover, a significant negative correlation between NFKB1 and TAL1 or LMO1 was found in primary human TAL1/LMO1 double-positive T-ALL samples previously described by Ferrando et al. Thus, TAL1 modulates NFKB1 expression and an NF-kappaB-dependent transcriptional program in a subset of human T-cell leukemia cells",0.20,PMID.dPMID16778171.s0.p16,7,3,NFKB1|TAL1|LMO1|TAL1|LMO1|TAL1|NFKB1,LMO1|NFKB1|TAL1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,16778171,NFKB1,TAL1,"Moreover, a significant negative correlation between NFKB1 and TAL1 or LMO1 was found in primary human TAL1/LMO1 double-positive T-ALL samples previously described by Ferrando et al. Thus, TAL1 modulates NFKB1 expression and an NF-kappaB-dependent transcriptional program in a subset of human T-cell leukemia cells",0.16,PMID.dPMID16778171.s0.p18,7,3,NFKB1|TAL1|LMO1|TAL1|LMO1|TAL1|NFKB1,LMO1|NFKB1|TAL1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,14965237,NF-kappa B,Transcription factor,Transcription factor NF-kappa B is reported to be the oxygen sensor in LPS induced endotoxemia.,0.18,PMID.dPMID14965237.s1.p0,2,2,Transcription factor|NF-kappa B,NF-kappa B|Transcription factor,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20160496,NFkappaB,p53,"Our further analysis of the effects of NFkappaB inhibition on p53 target gene expression revealed that while most target genes analysed where unaffected by blockade of NFkappaB, the p53-mediated induction of the pro-apoptotic gene p53AIP1 was significantly dependent on NFkappaB.",1.28,PMID.dPMID20160496.s2.p13,6,3,NFkappaB|p53|NFkappaB|p53|p53AIP1|NFkappaB,NFkappaB|p53|p53AIP1,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16684540,NF-kappaB,p53,"These data suggest that NF-kappaB-dependency of the PAF-induced increase in VEGF expression is due to decreased p53 activity, which is reciprocally regulated by increased NF-kappaB activity.",1.02,PMID.dPMID16684540.s0.p9,5,4,NF-kappaB|PAF|VEGF|p53|NF-kappaB,NF-kappaB|p53|PAF|VEGF,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15811878,NFkappaB,p53,"We first observed striking similarities in global gene expression profiles in human prostate cancer cells LNCaP transduced with p53 inhibitory genetic element or treated with TNF, suggesting that p53 inhibits transcription of TNF-inducible genes that are largely regulated by NFkappaB.",1.00,PMID.dPMID15811878.s3.p2,3,2,p53|p53|NFkappaB,NFkappaB|p53,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12887889,NF-kappa B,p53,p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor.,0.91,PMID.dPMID12887889.s6.p1,4,4,p53|Mdm2|NF-kappa B|ARF,ARF|Mdm2|NF-kappa B|p53,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8051093,NF-kappa B,p53,"Since NF-kappa B induction occurs as a response to stress and p53 arrests cells in G1/S, where repair may be initiated, activation of p53 by NF-kappa B could be a mechanism by which cells can recover from stress",0.53,PMID.dPMID8051093.s0.p5,4,2,NF-kappa B|p53|p53|NF-kappa B,NF-kappa B|p53,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20160496,NFkappaB,p53,p53-mediated induction of Noxa and p53AIP1 requires NFkappaB.,0.48,PMID.dPMID20160496.s10.p3,4,4,p53|Noxa|p53AIP1|NFkappaB,NFkappaB|Noxa|p53|p53AIP1,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11809417,NF-kappa B,p53,"We conclude from the study that p53, activated by NF-kappa B, is essential for H(2)O(2) induced apoptosis in glioma cells.",0.29,PMID.dPMID11809417.s0.p0,2,2,p53|NF-kappa B,NF-kappa B|p53,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16430884,NFkappaB,p53,"Over-expression of p53 suppressed the TAD-truncated p73alpha-mediated luciferase expression, suggesting that p53 interferes with the TAD-truncated p73alpha-mediated activation of NFkappaB.",0.26,PMID.dPMID16430884.s3.p8,5,3,p53|p73|p53|p73|NFkappaB,NFkappaB|p53|p73,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8051093,NF-kappa B,p53,Both p65 transactivation and TNF-alpha induction of the p53 promoter depended on an intact NF-kappa B site.,0.23,PMID.dPMID8051093.s3.p2,3,3,TNF-alpha|p53|NF-kappa B,NF-kappa B|p53|TNF-alpha,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17363555,NFkappaB,p53,Analysis of human head and neck tumors and lung tumors reveals a close correlation between the presence of abundant mutant p53 proteins and the constitutive activation of NFkappaB.,0.06,PMID.dPMID17363555.s1.p0,2,2,p53|NFkappaB,NFkappaB|p53,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20015865,NFkappaB,p53,"Gene expression profile in a glioma cell line resistant to cell death induced by the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53--the role of NFkappaB.",0.01,PMID.dPMID20015865.s11.p0,2,2,p53|NFkappaB,NFkappaB|p53,-->
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16430884,NFkappaB,p73,"Considering the inability of DeltaNp73beta, which is the C-terminus-truncated form of DeltaNp73alpha, to function, these results indicate that both the PRD and C-terminus are necessary for DeltaNp73alpha to can activate NFkappaB-responsive luciferase expression.",0.91,PMID.dPMID16430884.s4.p9,5,3,p73|p73|PRD|p73|NFkappaB,NFkappaB|p73|PRD,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16430884,NFkappaB,p73,"Inhibitors for NFkappaB activation reduced the TAD-truncated p73alpha-dependent NFkappaB-responsive gene expression, indicating that TAD-truncated p73alpha activates NFkappaB as does TNFalpha.",0.28,PMID.dPMID16430884.s2.p9,6,3,NFkappaB|p73|NFkappaB|p73|NFkappaB|TNFalpha,NFkappaB|p73|TNFalpha,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16430884,NFkappaB,p73,"Inhibitors for NFkappaB activation reduced the TAD-truncated p73alpha-dependent NFkappaB-responsive gene expression, indicating that TAD-truncated p73alpha activates NFkappaB as does TNFalpha.",0.20,PMID.dPMID16430884.s2.p2,6,3,NFkappaB|p73|NFkappaB|p73|NFkappaB|TNFalpha,NFkappaB|p73|TNFalpha,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,20195489,NF-kappa B,p73,Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B.,0.11,PMID.dPMID20195489.s8.p0,2,2,p73|NF-kappa B,NF-kappa B|p73,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.3.2.1,7291,9606,,,12695649,NF-kappa B,twist,A new twist on twist--modulation of the NF-kappa B pathway.,0.70,PMID.dPMID12695649.s0.p1,3,2,twist|twist|NF-kappa B,NF-kappa B|twist,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.3.2.1,7291,9606,,,12695649,NF-kappa B,twist,A new twist on twist--modulation of the NF-kappa B pathway.,0.07,PMID.dPMID12695649.s0.p2,3,2,twist|twist|NF-kappa B,NF-kappa B|twist,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.7.0.2,7409,9606,,,12626540,NF-kappa B,Vav-1,"Taken together, these data evidence that Vav-1 plays a key role in the control of NF-kappa B pathway by targeting IKK alpha in the T cell membrane and favoring its activation in response to CD28 stimulation",0.41,PMID.dPMID12626540.s0.p0,4,4,Vav-1|NF-kappa B|IKK alpha|CD28,CD28|IKK alpha|NF-kappa B|Vav-1,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,11094166,NF-kappa B,RAC3,We found that RAC3 functions as a coactivator by binding to the active form of NF-kappa B and that overexpression of RAC3 restores GR-dependent transcription neglecting GR/NF-kappa B transrepression.,0.29,PMID.dPMID11094166.s1.p5,4,2,RAC3|NF-kappa B|RAC3|NF-kappa B,NF-kappa B|RAC3,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,19487025,NFkappaB,FOXP1,FOXP1 is a transcriptional repressor that has been proposed to repress the expression of some NFkappaB-responsive genes.,1.30,PMID.dPMID19487025.s3.p0,2,2,FOXP1|NFkappaB,FOXP1|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.5,64332,9606,,,19707556,NFkappaB,IkappaBzeta,"Overall, our data suggests that IkappaBzeta positively regulates NFkappaB-mediated IFNgamma production in KG-1 cells.",1.53,PMID.dPMID19707556.s0.p0,3,3,IkappaBzeta|NFkappaB|IFNgamma,IFNgamma|IkappaBzeta|NFkappaB,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.5,64332,9606,,,19707556,NFkappaB,IkappaBzeta,IkappaBzeta is specifically induced by IL-1beta and several TLR ligands and positively regulates NFkappaB-mediated transcription of genes such as IL-6 and NGAL as an NFkappaB binding co-factor.,1.38,PMID.dPMID19707556.s8.p1,6,5,IkappaBzeta|IL-1beta|NFkappaB|IL-6|NGAL|NFkappaB,IkappaBzeta|IL-1beta|IL-6|NFkappaB|NGAL,
6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,6.1.2.1.5,64332,9606,,,19707556,NFkappaB,IkappaBzeta,"IkappaBzeta is a novel member of the IkappaB family of NFkappaB regulators, which modulates NFkappaB activity in the nucleus, rather than controlling its nuclear translocation.",0.89,PMID.dPMID19707556.s9.p1,3,2,IkappaBzeta|NFkappaB|NFkappaB,IkappaBzeta|NFkappaB,
6.1.1.1.2,4791,9606,,GO:0006355|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,2556265,H2TF1,NF-kappa B,"The second TC-II enhanson binding protein, TC-IIB, which could be clearly distinguished from the TC-IIA/NF-kappa B-like protein, by a number of differential properties, resembles the previously described KBF1/H2TF1 protein as it binds with a higher affinity to the H-2Kb enhanson than to the TC-II/kappa B enhanson, and its pattern of methylation interference on the H-2Kb and TC-II/kappa B enhansons is identical to that reported for the KBF1/H2TF1 protein",0.45,PMID.dPMID2556265.s0.p1,5,2,NF-kappa B|KBF1|H2TF1|KBF1|H2TF1,H2TF1|KBF1|NF-kappa B,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,9761780,I-kappaBalpha,PGA1,Induction of the stress response with PGA1 increased I-kappaBalpha mRNA expression in a time-dependent manner and increased I-kappaBalpha peptide expression.,0.92,PMID.dPMID9761780.s5.p1,3,2,PGA1|I-kappaBalpha|I-kappaBalpha,I-kappaBalpha|PGA1,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,9761780,I-kappaBalpha,PGA1,Induction of the stress response with PGA1 increased I-kappaBalpha mRNA expression in a time-dependent manner and increased I-kappaBalpha peptide expression.,0.85,PMID.dPMID9761780.s5.p0,3,2,PGA1|I-kappaBalpha|I-kappaBalpha,I-kappaBalpha|PGA1,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,9761780,I-kappaBalpha,PGA1,"Because the stress response can also be induced by nonthermal stimuli, we determined whether induction of the stress response with prostaglandin A1 (PGA1) would induce I-kappaBalpha gene expression.",0.42,PMID.dPMID9761780.s7.p0,2,2,PGA1|I-kappaBalpha,I-kappaBalpha|PGA1,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,11707390,IkappaBalpha,Bcl-3,"The two structures are highly similar over the central ankyrin repeats but differ in the N-terminal repeat and at the C-terminus, where Bcl-3 contains a seventh repeat in place of the acidic PEST region of IkappaBalpha.",1.24,PMID.dPMID11707390.s2.p0,2,2,Bcl-3|IkappaBalpha,Bcl-3|IkappaBalpha,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,17867593,IkappaBalpha,NFkappaB,"The NFkappaB regulated proteins IkappaBalpha, survivin, and cIAP1 were found in corresponding sites, again, at highest levels in islets surrounded by fibrosis.",0.98,PMID.dPMID17867593.s3.p0,3,3,NFkappaB|IkappaBalpha|cIAP1,cIAP1|IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,15814628,IkappaBalpha,NF-kappaB,"We also did luciferase reporter assay, Western blot analysis, and reverse transcription-PCR using the SNU-216 human gastric cancer cell line transduced with retroviral vectors containing constitutively active Akt or the NF-kappaB repressor mutant of IkappaBalpha.",0.79,PMID.dPMID15814628.s6.p2,3,3,Akt|NF-kappaB|IkappaBalpha,Akt|IkappaBalpha|NF-kappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,16271147,IkappaBalpha,NFkappaB,BACKGROUND: Activation-induced induction of transcription factor NFkappaB in T lymphocytes is regulated by its inhibitor IkappaBalpha.,0.55,PMID.dPMID16271147.s8.p0,2,2,NFkappaB|IkappaBalpha,IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,15265367,IkappaBalpha,NF-kappaB,The inhibition of NF-kappaB by mutant IkappaBalpha could provide a new approach that may enhance the anti-leukemia effects of TNF-alpha or even of other cytotoxic agents,0.39,PMID.dPMID15265367.s0.p0,3,3,NF-kappaB|IkappaBalpha|TNF-alpha,IkappaBalpha|NF-kappaB|TNF-alpha,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11845301,IkappaBalpha,NFkappaB,"Evidence suggests that activation of the nuclear factor kappa B (NFkappaB), which regulates the inflammatory gene transcription, depends on the degradation of the inhibitory factor IkappaBalpha.",0.34,PMID.dPMID11845301.s5.p0,2,2,NFkappaB|IkappaBalpha,IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10409681,IkappaBalpha,NFkappaB,"Activation of the transcription factor NFkappaB requires rapid degradation of its inhibitor, IkappaBalpha.",0.31,PMID.dPMID10409681.s9.p0,2,2,NFkappaB|IkappaBalpha,IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,9727009,IkappaBalpha,NFkappaB,Nuclear factor kappaB (NFkappaB) is a ubiquitously expressed transcription factor that is regulated by the cytoplasmic inhibitor protein IkappaBalpha.,0.25,PMID.dPMID9727009.s10.p0,2,2,NFkappaB|IkappaBalpha,IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,19325136,IkappaBalpha,NFkappaB,"Increasing TbetaRIII expression reduced NFkappaB-mediated transcriptional activation and IkappaBalpha degradation, whereas a TbetaRIII mutant unable to interact with beta-arrestin2, TbetaRIII-T841A, had no effect.",0.20,PMID.dPMID19325136.s3.p0,3,3,NFkappaB|IkappaBalpha|beta-arrestin2,beta-arrestin2|IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11069829,IkappaBalpha,NF-kappaB,"The reduced expression of nuclear NF-kappaB was not due to its inhibition by IkappaBalpha, as very low expression of IkappaBalpha, as well as low levels of p65 and p50 were found in the cytoplasm of PBMC from patients with sepsis and trauma when compared with control subjects.",0.19,PMID.dPMID11069829.s1.p0,4,3,NF-kappaB|IkappaBalpha|IkappaBalpha|p65,IkappaBalpha|NF-kappaB|p65,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10344280,IkappaBalpha,NFkappaB,"The model used in this study was a human lymphoblastoid cell line in which a functional repression of the transcription factors NFkappaB was obtained by induction of overexpression of IkappaBalpha, a physiological inhibitor of NFkappaB.",0.18,PMID.dPMID10344280.s9.p0,3,2,NFkappaB|IkappaBalpha|NFkappaB,IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11827262,IkappaBalpha,NFkappaB,"Additionally, we found that the inhibition of NFkappaB by Adv-SR-IkappaBalpha enhanced TNF-mediated caspase-8 and -3 activation.",0.14,PMID.dPMID11827262.s1.p0,2,2,NFkappaB|IkappaBalpha,IkappaBalpha|NFkappaB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,18204072,IkappaBalpha,NFkappaB,"The NFkappaB system is activated at labour and stimulates the IkappaBalpha gene, but the NFkappaB factors do not drive PGHS-2 transcription using consensus promoter sites in normal term amnion in vivo",0.01,PMID.dPMID18204072.s0.p0,4,3,NFkappaB|IkappaBalpha|NFkappaB|PGHS-2,IkappaBalpha|NFkappaB|PGHS-2,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11981037,IkappaBalpha,PPARalpha,"Here, we studied the molecular mechanisms by which PPARalpha controls IkappaBalpha expression.",2.20,PMID.dPMID11981037.s8.p0,2,2,PPARalpha|IkappaBalpha,IkappaBalpha|PPARalpha,p
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11981037,IkappaBalpha,PPARalpha,"Furthermore, cotransfection of increasing amounts of DRIP205 relieved this inhibition, suggesting that PPARalpha requires DRIP205 to regulate IkappaBalpha promoter activity.",1.62,PMID.dPMID11981037.s2.p4,4,3,DRIP205|PPARalpha|DRIP205|IkappaBalpha,DRIP205|IkappaBalpha|PPARalpha,p
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,12393563,IkappaB-alpha,PPAR-alpha,"First, PPAR-alpha increases IkappaB-alpha expression and thus prevents p50-NFkappaB translocation to the nucleus.",1.47,PMID.dPMID12393563.s2.p0,2,2,PPAR-alpha|IkappaB-alpha,IkappaB-alpha|PPAR-alpha,e
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11981037,IkappaBalpha,PPARalpha,"Taken together, these data provide a molecular basis for PPARalpha-mediated induction of IkappaBalpha and demonstrate, for the first time, that PPARalpha may positively regulate gene transcription in the absence of functional PPAR response elements.",0.27,PMID.dPMID11981037.s0.p0,3,2,PPARalpha|IkappaBalpha|PPARalpha,IkappaBalpha|PPARalpha,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11981037,IkappaBalpha,PPARalpha,Site-directed mutagenesis experiments revealed that PPARalpha activation of IkappaBalpha transcription requires the NF-kappaB and Sp1 sites within IkappaBalpha promoter.,0.27,PMID.dPMID11981037.s6.p0,4,3,PPARalpha|IkappaBalpha|Sp1|IkappaBalpha,IkappaBalpha|PPARalpha|Sp1,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,10980195,IkappaBalpha,PPARalpha,"Our results show that fibrates, synthetic PPARalpha activators, induced the expression of the inhibitory protein IkappaBalpha in human aortic smooth muscle cells as well as in primary human hepatocytes, whereas neither IkappaB-kinase activity nor the degradation rate of IkappaBalpha were affected.",0.23,PMID.dPMID10980195.s4.p0,4,3,PPARalpha|IkappaBalpha|IkappaB-kinase|IkappaBalpha,IkappaBalpha|IkappaB-kinase|PPARalpha,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,12191966,IkappaBalpha,PPAR,"In keeping with such an antiinflammatory role, it was found that several PPAR agonists, including Wy14,643, clofibrate, carbaprostacyclin, and ciglitazone inhibited NF-kappaB activity and increased IkappaBalpha levels in cytokine-stimulated mesangial cells (MC).",0.23,PMID.dPMID12191966.s9.p0,2,2,PPAR|IkappaBalpha,IkappaBalpha|PPAR,
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,12663663,IkappaBalpha,RelA,The data show that RelA regulation of NF-kappaB-IkappaBalpha complex formation is IkappaBalpha phosphorylation-dependent and that IkappaBalpha/NF-kappaB binding is dynamic and determined by concentration of the subunits.,0.86,PMID.dPMID12663663.s1.p0,4,2,RelA|IkappaBalpha|IkappaBalpha|IkappaBalpha,IkappaBalpha|RelA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,12663663,IkappaBalpha,RelA,The data show that RelA regulation of NF-kappaB-IkappaBalpha complex formation is IkappaBalpha phosphorylation-dependent and that IkappaBalpha/NF-kappaB binding is dynamic and determined by concentration of the subunits.,0.78,PMID.dPMID12663663.s1.p1,4,2,RelA|IkappaBalpha|IkappaBalpha|IkappaBalpha,IkappaBalpha|RelA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,12663663,IkappaBalpha,RelA,RelA control of IkappaBalpha phosphorylation: a positive feedback loop for high affinity NF-kappaB complexes.,0.49,PMID.dPMID12663663.s7.p0,2,2,RelA|IkappaBalpha,IkappaBalpha|RelA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,17899287,IkappaB-alpha,RelA,Correlation between RelA/IkappaB-alpha expression status and clinicopathological features of NSCLC was also analyzed.,0.33,PMID.dPMID17899287.s7.p0,2,2,RelA|IkappaB-alpha,IkappaB-alpha|RelA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,9417120,IkappaBalpha,RelA,Discrimination between RelA and RelB transcriptional regulation by a dominant negative mutant of IkappaBalpha.,0.32,PMID.dPMID9417120.s9.p1,3,3,RelA|RelB|IkappaBalpha,IkappaBalpha|RelA|RelB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,19129371,NFKBIA,RELA,"We analysed RELA, CHUK, NFKBIA and IL6 mRNA levels (RT-PCR); RELA, CHUK and NFKBIA proteins and p-NFKBIA/NFKBIA ratio (western blot); and NFKB binding (DNA shift assay) and IL6 concentration (ELISA) in endometrial explants.",0.27,PMID.dPMID19129371.s5.p25,10,4,RELA|CHUK|NFKBIA|IL6|RELA|CHUK|NFKBIA|NFKBIA|NFKBIA|IL6,CHUK|IL6|NFKBIA|RELA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,19129371,NFKBIA,RELA,"We analysed RELA, CHUK, NFKBIA and IL6 mRNA levels (RT-PCR); RELA, CHUK and NFKBIA proteins and p-NFKBIA/NFKBIA ratio (western blot); and NFKB binding (DNA shift assay) and IL6 concentration (ELISA) in endometrial explants.",0.27,PMID.dPMID19129371.s5.p32,10,4,RELA|CHUK|NFKBIA|IL6|RELA|CHUK|NFKBIA|NFKBIA|NFKBIA|IL6,CHUK|IL6|NFKBIA|RELA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,9573251,IkappaBalpha,RelA,"Although IkappaBalpha was resynthesized within 30 min following recombinant human TNFalpha treatment due to a robust 25-fold increase of IkappaBalpha mRNA expression (the RelA:IkappaBalpha positive feedback loop), following pRSV infection, there was no reaccumulation of IkappaBalpha protein, as infected cells produced only a 3-fold increase in IkappaBalpha mRNA at 24 h, indicating the RelA:IkappaBalpha positive feedback loop was insufficient to restore control IkappaBalpha levels.",0.09,PMID.dPMID9573251.s3.p34,9,2,IkappaBalpha|IkappaBalpha|RelA|IkappaBalpha|IkappaBalpha|IkappaBalpha|RelA|IkappaBalpha|IkappaBalpha,IkappaBalpha|RelA,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18550535,IkappaBalpha,RelA,"NF-kappaB is controlled by two pathways, a canonical pathway that releases sequestered RelA complexes from the IkappaBalpha inhibitor, and a second, the noncanonical pathway, that releases RelB from the 100-kDa NF-kappaB2 complex.",0.07,PMID.dPMID18550535.s8.p0,3,3,RelA|IkappaBalpha|RelB,IkappaBalpha|RelA|RelB,<--
6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15969767,IkappaBalpha,p53,Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.,0.22,PMID.dPMID15969767.s12.p0,3,2,p53|IkappaBalpha|p53,IkappaBalpha|p53,
4.2.1.0.1,4800,9606,,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16959611,NF-YA,p53,The recruitment of mutant p53 to the CCAAT sites is severely impaired upon abrogation of NF-YA expression.,0.13,PMID.dPMID16959611.s2.p0,2,2,p53|NF-YA,NF-YA|p53,-->
4.2.1.0.1,4800,9606,,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10514438,NF-YA,p53,"Consistently, a dominant negative mutant of the NF-YA subunit, NF-YAm29, decreases the cdc2 promoter, and p53 does not further decrease the promoter activity in the presence of NF-YAm29.",0.03,PMID.dPMID10514438.s1.p9,5,3,NF-YA|NF-YA|cdc2|p53|NF-YA,cdc2|NF-YA|p53,-->
4.2.1.0.3,4802,9606,GO:0003702,GO:0006355|GO:0006357,4.2.1.0.2,4801,9606,,GO:0006355,9813075,CBF-C,CBF-B,"None of the CBF-A and CBF-C subunits, which together formed a CBF-A/CBF-C heterodimer, were cross-linked without CBF-B; in contrast, CBF-B was cross-linked in the absence of CBF-A/CBF-C.",0.11,PMID.dPMID9813075.s6.p9,5,2,CBF-C|CBF-C|CBF-B|CBF-B|CBF-C,CBF-B|CBF-C,
4.2.1.0.3,4802,9606,GO:0003702,GO:0006355|GO:0006357,4.2.1.0.2,4801,9606,,GO:0006355,12401788,NF-YC,NF-YB,The NF-YB/NF-YC structure gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y.,0.04,PMID.dPMID12401788.s6.p0,2,2,NF-YB|NF-YC,NF-YB|NF-YC,
1.2.3.1.4,4807,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10779652,NSCL,p53,The available data do not support a clear role for p53 mutation as a prognostic marker in NSCLC.,0.28,PMID.dPMID10779652.s2.p0,2,2,p53|NSCL,NSCL|p53,
3.1.2.15.1,4821,9606,,,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,20711444,Nkx2.2,Gli,"Strikingly, in the embryonic neural tube, the forced expression of Pias1 increased Gli activity and induced the ectopic expression of the Gli dependent gene Nkx2.2.",0.58,PMID.dPMID20711444.s2.p5,4,3,Pias1|Gli|Gli|Nkx2.2,Gli|Nkx2.2|Pias1,
3.1.2.15.1,4821,9606,,,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,20711444,Nkx2.2,Gli,"Strikingly, in the embryonic neural tube, the forced expression of Pias1 increased Gli activity and induced the ectopic expression of the Gli dependent gene Nkx2.2.",0.35,PMID.dPMID20711444.s2.p4,4,3,Pias1|Gli|Gli|Nkx2.2,Gli|Nkx2.2|Pias1,
3.1.2.16.1,4824,9606,GO:0016564,GO:0006355|GO:0032582,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,16814806,NKX3.1,SRF,The importance of these linear motifs in the transcriptional interaction of NKX3.1 and SRF was demonstrated by targeted mutagenesis of an NKX3.1 expression vector in a SMGA reporter assay.,0.19,PMID.dPMID16814806.s1.p2,3,2,NKX3.1|SRF|NKX3.1,NKX3.1|SRF,
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12080043,Y-box-binding protein-1,c-Myc,p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression.,1.99,PMID.dPMID12080043.s10.p2,3,3,p73|c-Myc|Y-box-binding protein-1,c-Myc|p73|Y-box-binding protein-1,<--
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18504427,YB-1,p53,"Importantly, we found that p53-dependent growth suppression was canceled by the expression of either Twist or YB-1.",0.92,PMID.dPMID18504427.s1.p1,3,3,p53|Twist|YB-1,p53|Twist|YB-1,
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14738225,YB-1,p53,Including information about the histology and mutational status for p53 increased the prognostic value of nuclear YB-1.,0.26,PMID.dPMID14738225.s3.p0,2,2,p53|YB-1,p53|YB-1,
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14738225,YB-1,p53,"Representative samples from autopsied material of primary tumours from 77 patients with NSCLC were investigated by immunohistochemistry for subcellular distribution of YB-1 and p53, in order to evaluate the prognostic role of nuclear expression of YB-1.",0.21,PMID.dPMID14738225.s7.p2,3,2,YB-1|p53|YB-1,p53|YB-1,
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12743601,YB1,p53,Tumor-associated p53 mutants however are attenuated for YB1 nuclear localization as are mutants mutated in the proline-rich domain of p53.,0.04,PMID.dPMID12743601.s4.p0,3,2,p53|YB1|p53,p53|YB1,
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12080043,Y-box-binding protein-1,p73,p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression.,1.52,PMID.dPMID12080043.s10.p1,3,3,p73|c-Myc|Y-box-binding protein-1,c-Myc|p73|Y-box-binding protein-1,"[4149-->4904, 4609-->4904]"
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12080043,YB-1,p73,Our data suggest that p73 stimulates the transcription of the YB-1 promoter by enhancing recruitment of the c-Myc-Max complex to the E-box,0.30,PMID.dPMID12080043.s0.p0,4,4,p73|YB-1|c-Myc|Max,c-Myc|Max|p73|YB-1,"[4149-->4904, 4609-->4904]"
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,1.2.3.2.1,7291,9606,,,18172301,YB-1,Twist,"However, cotransfection of Twist expression plasmid could not increase colony formation when YB-1 expression was down-regulated.",0.48,PMID.dPMID18172301.s3.p0,2,2,Twist|YB-1,Twist|YB-1,
10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,10.1.1.3.1,51087,9606,,,10100484,Y-box-binding protein,Contrin,"By the criteria of northern and western blotting, Contrin appears to be testis specific and distinct from other mammalian Y-box-binding proteins.",0.40,PMID.dPMID10100484.s1.p0,2,2,Contrin|Y-box-binding protein,Contrin|Y-box-binding protein,
2.1.4.0.2,4929,9606,GO:0030528,GO:0034339,1.1.2.0.1,1385,9606,,GO:0045944,11884470,NURR1,CREB-1,"In summary, enhanced NF-kappaB- and CREB-1-binding activity on the NURR1 promoter by inflammatory mediators delineates novel mechanisms in the regulation of NURR1 transcription.",0.01,PMID.dPMID11884470.s1.p1,3,2,CREB-1|NURR1|NURR1,CREB-1|NURR1,<--
2.1.4.0.2,4929,9606,GO:0030528,GO:0034339,3.1.5.6.2,4010,9606,,GO:0006355,12846972,Nurr1,Lmx1b,Lmx1b is followed by the orphan steroid receptor Nurr1.,0.12,PMID.dPMID12846972.s6.p0,2,2,Lmx1b|Nurr1,Lmx1b|Nurr1,
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,3.2.1.2.2,5080,9606,,,12721955,PAX2,PAX6,Four of the detected mutations affected PAX6-mediated transcriptional repression of the PAX2 promoter in a reporter assay.,0.12,PMID.dPMID12721955.s1.p0,2,2,PAX6|PAX2,PAX2|PAX6,
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,19517575,PAX2,STAT3,"Moreover, analysis using pharmacological inhibitors against MEK1/2, ERK1/2, JAK-II, and phospho-STAT3 demonstrated that AT1R-mediated stimulatory effect of A-II on PAX2 expression was regulated in part by the phosphorylation of ERK1/2, JAK II, and STAT3 pathways.",0.53,PMID.dPMID19517575.s3.p2,5,3,ERK1|STAT3|PAX2|ERK1|STAT3,ERK1|PAX2|STAT3,
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20597068,PAX2,p53,"PAX2 (A)/p53 (N) SCOUTs were free of p53 mutations; however, 12 of 13 p53 signatures were PAX2 (A).",1.03,PMID.dPMID20597068.s4.p9,5,2,PAX2|p53|p53|p53|PAX2,p53|PAX2,-->
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19118900,PAX2,p53,"However, we have demonstrated that knock-down of PAX2 expression results in cell death independent of p53 status, thus suggesting that additional cell death pathways are negatively regulated by PAX2.",0.10,PMID.dPMID19118900.s3.p2,3,2,PAX2|p53|PAX2,p53|PAX2,-->
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,9916932,PAX2,WT1,"One target gene of WT1 is PAX2, the expression of which is down-regulated in podocytes during early stages of nephrogenesis.",0.86,PMID.dPMID9916932.s4.p0,2,2,WT1|PAX2,PAX2|WT1,-->
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,19401348,PAX2,WT1,Additional analyses indicated that PAX2 repressor WT1 and cancer-linked hypomethylation are not important for transcriptional regulation of PAX2 in ccRCC.,0.25,PMID.dPMID19401348.s1.p2,3,2,PAX2|WT1|PAX2,PAX2|WT1,-->
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,14531904,PAX2,WT1,Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias.,0.25,PMID.dPMID14531904.s10.p0,4,4,WT1|PAX2|PAX8|GATA-1,GATA-1|PAX2|PAX8|WT1,-->
3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12386275,Pax2,WT1,"To investigate the contribution of WT1 and Pax2 to the development of the CL in primary FSGS, immunohistological studies were performed using renal biopsy specimens on the expression of WT1, Pax2 and cytokeratin (CK), which is an epithelial marker but never found in normal podocytes.",0.01,PMID.dPMID12386275.s5.p3,4,2,WT1|Pax2|WT1|Pax2,Pax2|WT1,-->
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15688035,Pax3,FKHR,"By microarray analysis, we determined that Pax3/FKHR altered the expression of gene targets in a manner quantitatively and qualitatively distinct from Pax3.",1.12,PMID.dPMID15688035.s6.p2,3,2,Pax3|FKHR|Pax3,FKHR|Pax3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,7630639,PAX3,FKHR,"No functional role could be ascribed solely to the residual FKHR binding domain present in the fusion protein, but FKHR was found to contribute a strong carboxyl terminal activation domain replacing the one located in the unrearranged PAX3 gene.",0.77,PMID.dPMID7630639.s2.p2,3,2,FKHR|FKHR|PAX3,FKHR|PAX3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15688035,Pax3,FKHR,"Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.",0.48,PMID.dPMID15688035.s0.p2,6,2,Pax3|FKHR|Pax3|Pax3|Pax3|FKHR,FKHR|Pax3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15688035,Pax3,FKHR,"Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.",0.27,PMID.dPMID15688035.s0.p4,6,2,Pax3|FKHR|Pax3|Pax3|Pax3|FKHR,FKHR|Pax3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15688035,Pax3,FKHR,"Thus, our data reveal that Pax3/FKHR regulates a distinct but overlapping set of genes relative to Pax3 and that the global set of Pax3 and Pax3/FKHR gene targets is cell-type specific.",0.13,PMID.dPMID15688035.s0.p7,6,2,Pax3|FKHR|Pax3|Pax3|Pax3|FKHR,FKHR|Pax3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,7862145,PAX3,FKHR,The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.,0.11,PMID.dPMID7862145.s10.p2,3,2,PAX3|FKHR|PAX3,FKHR|PAX3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12095979,Pax-3,Myc,These results suggest that the Myc family of transcription factors may modulate Pax-3 expression in vivo,0.71,PMID.dPMID12095979.s0.p0,2,2,Myc|Pax-3,Myc|Pax-3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12095979,Pax-3,Myc,"Moreover, we show that Myc regulation of Pax-3 promoter activity is dependent upon a noncanonical E box site in the 5' promoter region of Pax-3.",0.69,PMID.dPMID12095979.s4.p1,3,2,Myc|Pax-3|Pax-3,Myc|Pax-3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12095979,Pax-3,Myc,"Moreover, we show that Myc regulation of Pax-3 promoter activity is dependent upon a noncanonical E box site in the 5' promoter region of Pax-3.",0.56,PMID.dPMID12095979.s4.p0,3,2,Myc|Pax-3|Pax-3,Myc|Pax-3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.6.5.2,4613,9606,,GO:0006357,18335505,PAX3,MYCN,"MYCN was one notable neural-related transcription factor-encoding gene identified in this set, and its regulation by PAX3-FKHR was further confirmed at the RNA and protein levels.",0.69,PMID.dPMID18335505.s3.p0,2,2,MYCN|PAX3,MYCN|PAX3,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.2.1.3,4617,9606,,GO:0006357,19756142,Pax3,Myf5,"Toxicity and MyoD/Myf5 expression changes were competitively reversed by overexpression of Pax3 or Pax7, implying mechanistic similarities with the anti-myogenic activity of human DUX4.",0.47,PMID.dPMID19756142.s3.p2,5,5,MyoD|Myf5|Pax3|Pax7|DUX4,DUX4|Myf5|MyoD|Pax3|Pax7,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,19756142,Pax3,MyoD,"Toxicity and MyoD/Myf5 expression changes were competitively reversed by overexpression of Pax3 or Pax7, implying mechanistic similarities with the anti-myogenic activity of human DUX4.",0.47,PMID.dPMID19756142.s3.p1,5,5,MyoD|Myf5|Pax3|Pax7|DUX4,DUX4|Myf5|MyoD|Pax3|Pax7,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.2.2.1.2,4656,9606,,GO:0010552,10666368,Pax3,myogenin,One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts.,1.51,PMID.dPMID10666368.s5.p0,3,3,myogenin|Pax3|FKHR,FKHR|myogenin|Pax3,x
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.2.1.1.2,5081,9606,,,15184910,PAX3,PAX7,"In addition, we found that expression of wild-type PAX3 is upregulated, whereas expression of wild-type PAX7 is downregulated by PAX3-FKHR.",0.65,PMID.dPMID15184910.s3.p2,3,2,PAX3|PAX7|PAX3,PAX3|PAX7,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.2.1.1.2,5081,9606,,,12039929,PAX3,PAX7,"However, in patients presenting with metastatic disease, there was a striking difference in outcome between PAX7-FKHR and PAX3-FKHR patient groups (estimated 4-year overall survival rate of 75% for PAX7-FKHR v 8% for PAX3-FKHR; P =.0015).",0.37,PMID.dPMID12039929.s3.p5,4,2,PAX7|PAX3|PAX7|PAX3,PAX3|PAX7,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.2.1.1.2,5081,9606,,,12930690,PAX3,PAX7,"Detection of PAX3/PAX7-FKHR fusion transcript in rhabdomyosarcoma by one-step RT-PCR    OBJECTIVE: To detect the PAX3-FKHR and PAX7-FKHR fusion transcripts in formalin-fixed, paraffin-embedded rhabdomyosarcoma tissues by one-step RT-PCR and discuss its diagnostic potential.",0.14,PMID.dPMID12930690.s3.p2,4,2,PAX3|PAX7|PAX3|PAX7,PAX3|PAX7,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,3.2.1.1.2,5081,9606,,,7527137,PAX-3,PAX-7,"PAX-7 was found to be weakly expressed in normal human myoblasts, while PAX-3 could not be detected in these cells at all.",0.14,PMID.dPMID7527137.s2.p0,2,2,PAX-7|PAX-3,PAX-3|PAX-7,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,1.3.1.0.2,7021,9606,,GO:0006355|GO:0006357|GO:0045817,17525748,PAX3,TFAP2B,"Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR.",0.10,PMID.dPMID17525748.s1.p0,3,3,TFAP2B|PAX3|FKHR,FKHR|PAX3|TFAP2B,
3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,18666806,PAX3,WT1,Loss of WT1 permits aberrant PAX3 expression in a subset of WTs with myogenic phenotype,0.34,PMID.dPMID18666806.s0.p0,2,2,WT1|PAX3,PAX3|WT1,
3.2.2.2.2,5079,9606,,,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,11796106,Pax-5,Ets-1,Ets-1 flips for new partner Pax-5.,0.25,PMID.dPMID11796106.s2.p0,2,2,Ets-1|Pax-5,Ets-1|Pax-5,
3.2.2.2.2,5079,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,8639790,Pax-5,E2A,"We further examined the expression of E2A and Id genes, because E2A and Id are considered to be positive and negative regulators in the expression of Pax-5 gene, respectively.",0.93,PMID.dPMID8639790.s2.p2,3,2,E2A|E2A|Pax-5,E2A|Pax-5,
3.2.2.2.2,5079,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,8639790,Pax-5,E2A,"We further examined the expression of E2A and Id genes, because E2A and Id are considered to be positive and negative regulators in the expression of Pax-5 gene, respectively.",0.31,PMID.dPMID8639790.s2.p1,3,2,E2A|E2A|Pax-5,E2A|Pax-5,
3.2.2.2.2,5079,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9808580,PAX-5,p53,"In both lymphomas, the J-chain gene, which is thought to be under negative control by BSAP, was not expressed, whereas transcription of the putative target gene p53 was unaffected by PAX-5 overexpression.",1.09,PMID.dPMID9808580.s1.p5,4,3,J-chain|BSAP|p53|PAX-5,BSAP|J-chain|p53|PAX-5,-->
3.2.2.2.2,5079,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8943844,PAX-5,p53,"When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.",0.88,PMID.dPMID8943844.s2.p2,3,2,PAX-5|p53|PAX-5,p53|PAX-5,-->
3.2.1.2.2,5080,9606,,,3.1.3.2.2,4212,9606,GO:0003704,GO:0000122,20523026,Pax6,Meis2,Animal studies on the Meis2 gene have revealed expression in the developing telencephalon and Meis2 is known to regulate the expression of Pax6 in the eye and pancreas.,1.17,PMID.dPMID20523026.s6.p2,3,2,Meis2|Meis2|Pax6,Meis2|Pax6,
3.2.1.2.2,5080,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,7838532,pax-6,c-myb,These observations suggest that the c-myb protein may be a regulator of Pax-QNR/pax-6.,0.56,PMID.dPMID7838532.s0.p0,2,2,c-myb|pax-6,c-myb|pax-6,
3.2.1.2.2,5080,9606,,,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,7838532,PAX6,C-Myb,C-Myb acts as transcriptional activator of the quail PAX6 (PAX-QNR) promoter through two different mechanisms.,0.03,PMID.dPMID7838532.s10.p0,2,2,C-Myb|PAX6,C-Myb|PAX6,
3.2.1.2.2,5080,9606,,,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,11707457,Pax6,PPARgamma,"These results suggest that PPARgamma in a ligand-dependent but DNA binding-independent manner inhibits Pax6 transcriptional activity, resulting in inhibition of glucagon gene transcription.",0.24,PMID.dPMID11707457.s1.p0,3,3,PPARgamma|Pax6|glucagon,glucagon|Pax6|PPARgamma,
3.2.1.2.2,5080,9606,,,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,16723452,PAX6,CTCF,CONCLUSIONS: These findings indicate that CTCF regulates PAX6 expression in response to stress-induced conditions and that the molecular base of CTCF controlling PAX6 expression is through five functional and specific motifs in the region upstream from the PAX6 P0 promoter in corneal epithelial cells,3.09,PMID.dPMID16723452.s0.p0,5,2,CTCF|PAX6|CTCF|PAX6|PAX6,CTCF|PAX6,p
3.2.1.2.2,5080,9606,,,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,16723452,PAX6,CTCF,CONCLUSIONS: These findings indicate that CTCF regulates PAX6 expression in response to stress-induced conditions and that the molecular base of CTCF controlling PAX6 expression is through five functional and specific motifs in the region upstream from the PAX6 P0 promoter in corneal epithelial cells,1.95,PMID.dPMID16723452.s0.p5,5,2,CTCF|PAX6|CTCF|PAX6|PAX6,CTCF|PAX6,p
3.2.1.2.2,5080,9606,,,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,16723452,PAX6,CTCF,Effect of CTCF-binding motif on regulation of PAX6 transcription.,1.11,PMID.dPMID16723452.s11.p0,2,2,CTCF|PAX6,CTCF|PAX6,
3.2.1.2.2,5080,9606,,,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,16723452,PAX6,CTCF,CONCLUSIONS: These findings indicate that CTCF regulates PAX6 expression in response to stress-induced conditions and that the molecular base of CTCF controlling PAX6 expression is through five functional and specific motifs in the region upstream from the PAX6 P0 promoter in corneal epithelial cells,0.77,PMID.dPMID16723452.s0.p3,5,2,CTCF|PAX6|CTCF|PAX6|PAX6,CTCF|PAX6,p
3.2.1.2.2,5080,9606,,,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,16723452,PAX6,CTCF,PURPOSE: Previous studies indicate that the CCCTC binding transcription factor (CTCF) regulates homeobox PAX6 gene transcription in corneal epithelial cells.,0.61,PMID.dPMID16723452.s10.p0,2,2,CTCF|PAX6,CTCF|PAX6,
3.2.1.2.2,5080,9606,,,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,15659382,Pax6,CTCF,EGF-induced CCCTC binding factor (CTCF) activation subsequently inhibited Pax6 expression by interacting with a CTCF-specific region upstream of the pax6 P0 promoter.,0.09,PMID.dPMID15659382.s5.p2,5,3,EGF|CTCF|Pax6|CTCF|pax6,CTCF|EGF|pax6|Pax6,
3.2.1.1.2,5081,9606,,,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,8889501,PAX7,FKHR,"Chromatin release studies suggested that the amplified sequences correlated with amplification of the PAX7-FKHR fusion gene which resulted from the insertion of PAX7 sequences into the first intron of FKHR gene, in keeping with the absence of cytogenetic evidence for derivative chromosomes.",0.29,PMID.dPMID8889501.s0.p2,4,2,PAX7|FKHR|PAX7|FKHR,FKHR|PAX7,
3.2.1.1.2,5081,9606,,,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,19047133,PAX7,FKHR,"aRMS tissues exhibit a number of genetic changes, including loss-of-function of the p53 and Rb tumor suppressor pathways, amplification of MYCN, stabilization of telomeres, and most characteristically, reciprocal translocation of loci involving the PAX and FKHR genes, generating the PAX7-FKHR or PAX3-FKHR fusion proteins.",0.03,PMID.dPMID19047133.s6.p9,8,6,p53|Rb|MYCN|FKHR|PAX7|FKHR|PAX3|FKHR,FKHR|MYCN|p53|PAX3|PAX7|Rb,
3.2.1.1.2,5081,9606,,,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,14706339,Pax7,Fos,"Moreover, Fos is able to repress Pax7 expression in rhabdomyosarcoma cell lines and primary myoblasts, suggesting a molecular link to genetic alterations involved in human rhabdomyosarcomas",1.33,PMID.dPMID14706339.s0.p0,2,2,Fos|Pax7,Fos|Pax7,
3.2.1.1.2,5081,9606,,,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15184910,PAX7,PAX3,"Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression.",1.39,PMID.dPMID15184910.s9.p3,4,3,PAX3|CXCR4|PAX3|PAX7,CXCR4|PAX3|PAX7,
3.2.1.1.2,5081,9606,,,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,15184910,PAX7,PAX3,"In addition, we found that expression of wild-type PAX3 is upregulated, whereas expression of wild-type PAX7 is downregulated by PAX3-FKHR.",0.18,PMID.dPMID15184910.s3.p0,3,2,PAX3|PAX7|PAX3,PAX3|PAX7,
3.2.1.1.2,5081,9606,,,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,17285543,PAX7,PAX3,"METHODS: One-step reverse transcription- polymerase chain reaction (RT-PCR) were used to detect the expression of the PAX3/PAX7-FKHR fusion transcrips in 16 cases of rhabdomyosarcoma (7 cases of ARMS, 9 cases of ERMS) and 16 specimens were compared to the surrounding normal tissue.",0.14,PMID.dPMID17285543.s6.p0,2,2,PAX3|PAX7,PAX3|PAX7,
3.2.1.1.2,5081,9606,,,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,17285543,PAX7,PAX3,Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma  OBJECTIVE: To detect the PAX3/PAX7-FKHR fusion transcripts to identify genetic alteration in embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) tissues.,0.10,PMID.dPMID17285543.s7.p0,4,2,PAX3|PAX7|PAX3|PAX7,PAX3|PAX7,
3.1.3.4.1,5087,9606,,GO:0043433,2.1.6.0.1,190,9606,GO:0003706|GO:0017163,GO:0016481|GO:0034339|GO:0043433|GO:0045892,18984668,PBX1,DAX1,The positive interaction between DAX1 and SF-1 in regulating PBX1 may be an important mechanism in this process.,0.31,PMID.dPMID18984668.s0.p1,3,3,DAX1|SF-1|PBX1,DAX1|PBX1|SF-1,
3.1.3.4.1,5087,9606,,GO:0043433,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,15684392,PBX1,FOXC1,FOXC1 transcriptional regulatory activity is impaired by PBX1 in a filamin A-mediated manner.,0.77,PMID.dPMID15684392.s8.p0,2,2,FOXC1|PBX1,FOXC1|PBX1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1520867,PBX1,E2A,"Sequence analysis showed an identical insertion of 27 bp at the E2A/PBX1 junction of the variant RNA species, the translation of which would result in the replacement of Val478 by 10 amino acids.",0.54,PMID.dPMID1520867.s3.p0,2,2,E2A|PBX1,E2A|PBX1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,16819510,Pbx1,E2a,E2a/Pbx1 is a fusion oncoprotein resulting from the t(1;19) translocation found in human pre-B acute lymphocytic leukemia and in a small number of acute T-lymphoid and myeloid leukemias.,0.36,PMID.dPMID16819510.s8.p0,2,2,E2a|Pbx1,E2a|Pbx1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,8757523,PBX1,E2A,The translocation t(1;19)(q23;p13) is found in 3-5% of all acute lymphoblastic leukaemias (ALL) and results in the expression of an E2A/PBX1 hybrid gene transcript.,0.16,PMID.dPMID8757523.s7.p0,2,2,E2A|PBX1,E2A|PBX1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,16800933,PBX1,E2A,Variant fusion transcript in ALL children with E2A-PBX1 fusion gene positive   The study was aimed to investigate the expression of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia (ALL).,0.14,PMID.dPMID16800933.s10.p7,6,3,ALL|E2A|PBX1|E2A|PBX1|ALL,ALL|E2A|PBX1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1520867,PBX1,E2A,The biologic significance of this additional E2A/PBX1 transcript is discussed,0.14,PMID.dPMID1520867.s0.p0,2,2,E2A|PBX1,E2A|PBX1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,7734349,PBX1,E2A,"We therefore show that the E2A-PBX1 transcript, although occurring predominantly in C mu+ pre-B ALL, also occurs in C mu- early pre-B ALL, sIg+ B-ALL and even in AML.",0.11,PMID.dPMID7734349.s1.p0,2,2,E2A|PBX1,E2A|PBX1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1672117,pbx1,E2A,Two E2A-pbx1 transcripts have been cloned.,0.02,PMID.dPMID1672117.s7.p0,2,2,E2A|pbx1,E2A|pbx1,
3.1.3.4.1,5087,9606,,GO:0043433,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,8255105,PBX1,E2A,"In seven cases diagnosed before 1986, cig analyses were not available, and consequently E2A/PBX1 expression could not be correlated to a particular immunological subtype of B-cell precursor ALL.",0.01,PMID.dPMID8255105.s1.p0,2,2,E2A|PBX1,E2A|PBX1,
3.1.3.4.3,5090,9606,,,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,8183558,PBX3,E2A,"Since homeodomains mediate DNA-binding, a potential model for the action of E2A-PBX1 is that it disrupts the transcriptional regulation of genes normally controlled by PBX1 or its closely-related family members PBX2 or PBX3.",0.60,PMID.dPMID8183558.s5.p0,2,2,E2A|PBX3,E2A|PBX3,
2.1.1.1.3,5241,9606,,GO:0034339,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,15987820,PGR,FOXO1A,"Reporter studies demonstrated that whereas liganded PGRA or PGRB increased a progesterone response element-linked reporter construct, pPRE/ GRE.E1b.Luc, coexpression of FOXO1A inhibited the PGRB response in HuF and synergistically increased PGRA and PGRB response in HEC-1B cells.",0.28,PMID.dPMID15987820.s4.p8,6,2,PGR|PGR|FOXO1A|PGR|PGR|PGR,FOXO1A|PGR,
2.1.1.1.3,5241,9606,,GO:0034339,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1325950,PgR,c-myc,All c-myc-amplified tumours were PgR-negative.,1.17,PMID.dPMID1325950.s3.p0,2,2,c-myc|PgR,c-myc|PgR,
2.1.1.1.3,5241,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10672061,PgR,p53,Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.,0.00,PMID.dPMID10672061.s16.p1,3,3,p53|chromogranin|PgR,chromogranin|p53|PgR,
3.1.10.19.1,5307,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,12296854,BFT,NF-kappaB,These results indicate that NF-kappaB can be a central regulator of chemokine gene expression in BFT-stimulated intestinal epithelial cells and may be an important regulator of neutrophil migration,0.61,PMID.dPMID12296854.s0.p0,2,2,NF-kappaB|BFT,BFT|NF-kappaB,
3.1.10.19.1,5307,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17762884,Pitx1,p53,Transcriptional activation of p53 by Pitx1.,0.75,PMID.dPMID17762884.s12.p0,2,2,p53|Pitx1,p53|Pitx1,
3.1.10.19.1,5307,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17762884,Pitx1,p53,"Thus, p53 is a direct transcriptional target gene of hPitx1.",0.29,PMID.dPMID17762884.s1.p0,2,2,p53|Pitx1,p53|Pitx1,
3.1.10.19.3,5309,9606,GO:0016563,GO:0045449,3.1.5.6.1,4009,9606,,,20643196,Pitx3,Lmx1a,"We found that Shh, FGF8 and Wnt1 induced the expression of Lmx1a and Otx2 in nmNSCs resulting in the differentiation of up to 39% of the nmNSCs into neurons expressing Pitx3.",0.02,PMID.dPMID20643196.s5.p13,6,6,Shh|FGF8|Wnt1|Lmx1a|Otx2|Pitx3,FGF8|Lmx1a|Otx2|Pitx3|Shh|Wnt1,
3.1.10.19.3,5309,9606,GO:0016563,GO:0045449,3.1.10.17.2,5015,9606,,GO:0006355,20643196,Pitx3,Otx2,"We found that Shh, FGF8 and Wnt1 induced the expression of Lmx1a and Otx2 in nmNSCs resulting in the differentiation of up to 39% of the nmNSCs into neurons expressing Pitx3.",0.26,PMID.dPMID20643196.s5.p14,6,6,Shh|FGF8|Wnt1|Lmx1a|Otx2|Pitx3,FGF8|Lmx1a|Otx2|Pitx3|Shh|Wnt1,
3.1.10.19.3,5309,9606,GO:0016563,GO:0045449,3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,20175877,Pitx3,FoxP1,FoxP1 promotes midbrain identity in embryonic stem cell-derived dopamine neurons by regulating Pitx3.,1.39,PMID.dPMID20175877.s7.p0,2,2,FoxP1|Pitx3,FoxP1|Pitx3,
3.1.10.19.3,5309,9606,GO:0016563,GO:0045449,3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,20175877,Pitx3,FoxP1,"Thus, this study demonstrates for the first time a transcription regulatory role for FoxP1 on the Pitx3 gene in mammalian stem cells",0.00,PMID.dPMID20175877.s0.p0,2,2,FoxP1|Pitx3,FoxP1|Pitx3,
2.3.5.0.42,5325,9606,,GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11360197,Zac1,p53,Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1.,0.66,PMID.dPMID11360197.s9.p0,2,2,p53|Zac1,p53|Zac1,
2.3.5.0.42,5325,9606,,GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20097304,Zac1,p53,"Other components of PML-NBs, such as CREB-binding protein (CBP), ubiquitin-conjugating enzyme 9, and p53, were also regulatory targets for Zac1, for whom the locations to mediate its regulatory functions were distinct from PML-NBs.",0.02,PMID.dPMID20097304.s2.p2,4,3,PML|p53|Zac1|PML,p53|PML|Zac1,
2.2.3.0.1,5424,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11375983,POLD1,p53,"When ectopic wild-type p53 expression was induced to a physiologically relevant level in ""tet-off"" cultured cells in which p53 expression was tightly regulated by tetracycline, it was found that POLD1 steady-state mRNA was repressed by about 65%.",0.49,PMID.dPMID11375983.s3.p2,3,2,p53|p53|POLD1,p53|POLD1,
3.1.4.1.1,5449,9606,,GO:0043193,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2181288,GHF-1,Sp1,"Still, Sp1 could compensate partially for the decreased stimulation of transcription seen at low GHF-1 concentrations",0.28,PMID.dPMID2181288.s0.p0,2,2,Sp1|GHF-1,GHF-1|Sp1,
3.1.4.1.1,5449,9606,,GO:0043193,1.2.6.6.3,51085,9606,GO:0016563|GO:0016564,GO:0006355|GO:0010552|GO:0045892|GO:0045893,19359385,Pit-1,ChREBP,"Insulin stimulates the expression of carbohydrate response element binding protein (ChREBP) by attenuating the repressive effect of Pit-1, Oct-1/Oct-2, and Unc-86 homeodomain protein octamer transcription factor-1.",0.73,PMID.dPMID19359385.s10.p0,3,3,ChREBP|Pit-1|Oct-1,ChREBP|Oct-1|Pit-1,
3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20215511,Oct-1,ERalpha,These results support a model whereby the regulation of ERalpha transcription by BRD7 is mediated by its recruitment of BRCA1 and Oct-1 to the ESR1 promoter.,0.33,PMID.dPMID20215511.s0.p3,5,4,ERalpha|BRD7|BRCA1|Oct-1|ESR1,BRCA1|BRD7|ERalpha|ESR1|Oct-1,
3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,3413485,OTF-1,Transcription factor,Transcription factor OTF-1 is functionally identical to the DNA replication factor NF-III.,0.24,PMID.dPMID3413485.s9.p0,3,3,Transcription factor|OTF-1|NF,NF|OTF-1|Transcription factor,
3.1.4.3.4,5456,9606,,,6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,18231833,DFN3,Tbx1,"In addition, Brn4-;Tbx1+/- mice displayed structural defects in the apical cochlea indicative of Mondini dysplasia found in patients with either VCFS/DGS or DFN3.",0.22,PMID.dPMID18231833.s1.p4,4,2,Brn4|Tbx1|DGS|DFN3,Brn4|DFN3|DGS|Tbx1,
3.1.4.4.1,5457,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12203124,Brn-3a,p53,"We have previously shown that the anti-apoptotic transcription factor, Brn-3a and the pro-apoptotic p53 factor have antagonistic effects on the promoter of the gene encoding the anti-apoptotic Bcl-2 protein, with p53 abolishing activation by Brn-3a.",0.59,PMID.dPMID12203124.s5.p9,5,3,Brn-3a|p53|Bcl-2|p53|Brn-3a,Bcl-2|Brn-3a|p53,
3.1.4.4.1,5457,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10329733,Brn-3a,p53,"In contrast, p53 mutants, which are incapable of binding to DNA, do not affect Brn-3a-mediated activation of the Bcl-2 p1 and p2 promoters.",0.51,PMID.dPMID10329733.s2.p0,3,3,p53|Brn-3a|Bcl-2,Bcl-2|Brn-3a|p53,
3.1.4.4.1,5457,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11713302,Brn-3a,p53,p53 therefore appears to specifically target the activation by Brn-3a of promoters derived from genes with an anti-apoptotic effect and this may be involved in the pro-apoptotic activity of p53,0.49,PMID.dPMID11713302.s0.p0,3,2,p53|Brn-3a|p53,Brn-3a|p53,
3.1.4.5.1,5460,9606,,GO:0006355|GO:0010552|GO:0090308,2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,18941526,Oct4,Gata-6,The model is based upon differential equations and makes two plausible assumptions; activation of Gata-6 by Oct4 and repression of Nanog by an Oct4-Gata-6 heterodimer.,0.18,PMID.dPMID18941526.s5.p0,5,3,Gata-6|Oct4|Nanog|Oct4|Gata-6,Gata-6|Nanog|Oct4,
3.1.4.5.1,5460,9606,,GO:0006355|GO:0010552|GO:0090308,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,8152920,Oct-4,RAR,"Specifically, important roles for ARP-1 and RAR in Oct-4 expression are indicated",0.56,PMID.dPMID8152920.s0.p0,2,2,RAR|Oct-4,Oct-4|RAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.2.3,406,9606,,GO:0045944,18317514,PPARalpha,BMAL1,We also found that CLOCK/BMAL1-mediated transcription of period (PER) and cryptochrome (CRY) was modulated by PPARalpha/RXRalpha.,0.95,PMID.dPMID18317514.s1.p2,3,3,CLOCK|BMAL1|PPARalpha,BMAL1|CLOCK|PPARalpha,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.2.3,406,9606,,GO:0045944,18317514,PPAR,BMAL1,"To investigate the interaction between the lipid metabolism system and the circadian system, we analyzed the effect of a CLOCK/BMAL1 heterodimer on the transcriptional regulation of PPAR-controlled genes through PPAR response elements (PPREs).",0.24,PMID.dPMID18317514.s3.p2,4,3,CLOCK|BMAL1|PPAR|PPAR,BMAL1|CLOCK|PPAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.2.3,406,9606,,GO:0045944,15828232,PPARalpha,BMAL1,"Recently, we showed that the CLOCK: BMAL1 heterodimer regulates the PPARalpha gene via promoter of PPARalpha.",0.21,PMID.dPMID15828232.s3.p4,4,3,CLOCK|BMAL1|PPARalpha|PPARalpha,BMAL1|CLOCK|PPARalpha,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.1.4.1.1,1050,9606,,GO:0045945,20110263,PPARalpha,C/EBPalpha,"Our data furthermore demonstrate interaction between PPARalpha and STAT transcription factors in PPARalpha-mediated transcriptional repression, and suggest interaction between PPARalpha and TBP, and PPARalpha and C/EBPalpha in PPARalpha-mediated transcriptional activation.",0.34,PMID.dPMID20110263.s1.p27,8,4,PPARalpha|STAT|PPARalpha|PPARalpha|TBP|PPARalpha|C/EBPalpha|PPARalpha,C/EBPalpha|PPARalpha|STAT|TBP,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,10678274,PPAR,c-fos,"Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.",0.23,PMID.dPMID10678274.s7.p2,3,2,PPAR|c-fos|PPAR,c-fos|PPAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,14521756,PPARalpha,HIF-1alpha,"Influence of hypoxia on peroxisome proliferator activated receptor alpha and its mechanisms   OBJECTIVE: To study the expressions of peroxisome proliferator activated receptor alpha (PPAR-alpha) and hypoxia-inducible factor-1alpha (HIF-1alpha) during different hypoxia states in lung cancer cell A549, and to investigate the mechanism of HIF-1alpha induced PPARalpha expression.",0.62,PMID.dPMID14521756.s6.p5,4,2,PPAR-alpha|HIF-1alpha|HIF-1alpha|PPARalpha,HIF-1alpha|PPARalpha|PPAR-alpha,<--
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,14521756,PPAR-alpha,HIF-1alpha,The influence of antisense oligonucleotide HIF-1alpha on PPAR-alpha was detected by RT-PCR and Western-blot.,0.27,PMID.dPMID14521756.s2.p0,2,2,HIF-1alpha|PPAR-alpha,HIF-1alpha|PPAR-alpha,<--
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15120605,PPARalpha,AP-1,These data suggest that AP-1 is likely to be located at the crossroads between LDL signaling and the regulation of IL-8 modulation by PPARalpha,1.19,PMID.dPMID15120605.s0.p1,3,3,AP-1|IL-8|PPARalpha,AP-1|IL-8|PPARalpha,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,5.1.1.1.3,4208,9606,GO:0003702,GO:0010552|GO:0010553,15356291,PPAR,MEF2C,"The reporter construct containing the PPRE and the MEF2C site was synergistically activated by co-expression of PPAR, retinoid X receptor (RXR) and MEF2C in non-muscle cells.",0.56,PMID.dPMID15356291.s2.p0,3,2,MEF2C|PPAR|MEF2C,MEF2C|PPAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12649303,PPAR,c-myc,"Moreover, the inhibition of c-myc expression by troglitazone may depend on a PPAR-independent mechanism",1.19,PMID.dPMID12649303.s0.p0,2,2,c-myc|PPAR,c-myc|PPAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,12843208,PPAR,MyoD,"Conversely, histone deacetylase-1 blunts MyoD-dependent expression of the UCP3 promoter and reduces PPAR-dependent responsiveness.",0.01,PMID.dPMID12843208.s3.p4,4,4,histone deacetylase-1|MyoD|UCP3|PPAR,histone deacetylase-1|MyoD|PPAR|UCP3,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,11981037,PPARalpha,IkappaBalpha,DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha.,0.58,PMID.dPMID11981037.s12.p0,2,2,IkappaBalpha|PPARalpha,IkappaBalpha|PPARalpha,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,17588807,PPAR,PPARdelta,"PPARdelta differs from the other two PPAR isotypes (alpha and gamma) by its more wide-spread tissue-specific expression pattern, its involvement in developmental processes and its profound impact on muscle and heart fat metabolism.",0.40,PMID.dPMID17588807.s4.p0,2,2,PPARdelta|PPAR,PPAR|PPARdelta,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,14566384,PPAR,PPARdelta,"PPARdelta is expressed ubiquitously and has been found to be effective in controlling dyslipidemia and cardiovascular diseases, while PPARgamma isotype is mainly expressed in adipose tissue where it stimulates adipogenesis and lipogenesis.",0.08,PMID.dPMID14566384.s2.p0,2,2,PPARdelta|PPAR,PPAR|PPARdelta,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,11819031,PPARalpha,PPARdelta,"L-165041, reported as a selective and potent PPARdelta ligand, displayed in this specified transactivation system, apart from its highly efficacious PPARdelta agonist activity, partial and full agonism at, respectively, PPARalpha and PPARgamma2 subtypes.",0.03,PMID.dPMID11819031.s1.p2,4,2,PPARdelta|PPARdelta|PPARalpha|PPAR,PPAR|PPARalpha|PPARdelta,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15661858,PPARalpha,PPARgamma,"In hepatocytes and adipocytes, both PPARalpha(mut) and the corresponding PPARgamma mutant were capable of inhibiting the expression of genes primarily regulated by PPARalpha, -gamma, or -delta ligands, albeit with some differences in potency.",1.13,PMID.dPMID15661858.s2.p8,5,3,PPARalpha|mut|PPARgamma|mut|PPARalpha,mut|PPARalpha|PPARgamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,12079871,PPAR,PPARgamma,"In protease protection assays, S-hexadecyl CoA increased the sensitivity of PPARalpha and PPARdelta towards chymotrypsin, whereas the action of chymotrypsin on PPARgamma was only marginally affected, suggesting distinct subtype-dependent differences in the effects of S-hexadecyl-CoA on conformation of the PPARs.",1.03,PMID.dPMID12079871.s1.p5,4,2,PPARalpha|PPAR|PPARgamma|PPAR,PPAR|PPARalpha|PPARgamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,10854698,PPAR,PPARgamma,"Therefore, hPPARgamma2Delta500 appears to repress PPAR activity by competing with wild type receptor to dimerize with RXR and bind the PPRE.",1.01,PMID.dPMID10854698.s4.p0,2,2,PPARgamma|PPAR,PPAR|PPARgamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,16412273,PPAR,PPARgamma,"RESULTS: C333H was determined to be a novel PPARalpha/gamma dual agonist because it strongly induced luciferase activity on human PPARalpha and PPARgamma, promoting the differentiation of preadipocytes to adipocytes, and functioning in upregulating the expression of some glucose and lipid metabolic target genes of the PPAR.",0.38,PMID.dPMID16412273.s2.p5,4,3,PPARalpha|PPARalpha|PPARgamma|PPAR,PPAR|PPARalpha|PPARgamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,17665979,PPAR,PPAR-gamma,"PPAR-gamma, one of the three PPAR subtypes, is expressed in many malignant and non-malignant cells and tissues.",0.22,PMID.dPMID17665979.s5.p0,2,2,PPAR-gamma|PPAR,PPAR|PPAR-gamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,9655393,PPARalpha,PPARgamma,"Whereas PPARgamma promotes lipid storage by regulating adipocyte differentiation, PPARalpha stimulates the beta-oxidative degradation of fatty acids.",0.13,PMID.dPMID9655393.s7.p0,2,2,PPARgamma|PPARalpha,PPARalpha|PPARgamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,19207680,PPARalpha,PPARgamma,"RESULTS: Concurrent with PPARgamma and SREBP-1 gene activation, steatosis extent was larger when cells were treated with oleic than with palmitic acid; the latter fatty acid was associated with increased PPARalpha expression.",0.12,PMID.dPMID19207680.s5.p1,3,3,PPARgamma|SREBP-1|PPARalpha,PPARalpha|PPARgamma|SREBP-1,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18092840,PPAR,PPARgamma,"This observation suggests the possibility that PPARalpha and PPARgamma activators, or compounds that positively regulate PPAR gene expression, may represent novel NSAIDs for the topical or systemic treatment of common inflammatory skin diseases such as atopic dermatitis, psoriasis, and allergic contact dermatitis.",0.03,PMID.dPMID18092840.s9.p2,3,2,PPARalpha|PPARgamma|PPAR,PPAR|PPARalpha|PPARgamma,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15949696,PPARalpha,PPARgamma,"The effect of norepinephrine on PPARgamma gene expression, at least in-vitro, is negative, PPARgamma-ablated brown adipose tissue can express UCP1, and PGC-1alpha coactivates other transcription factors (including PPARalpha); thus, the significance of PPARgamma for the physiological control of UCP1 gene expression is not settled.",0.03,PMID.dPMID15949696.s2.p6,7,4,PPARgamma|PPARgamma|UCP1|PGC-1alpha|PPARalpha|PPARgamma|UCP1,PGC-1alpha|PPARalpha|PPARgamma|UCP1,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.3.1.2,6257,9606,GO:0003706,GO:0034339,11840500,PPARA,RXRB,"A Val95Ala polymorphism of the RXRB gene, a Val227Ala polymorphism in the PPARA gene, and two synonymous single-nucleotide and CA repeat polymorphisms in the 5' region and 3' untranslated region of the NR4A2 gene were identified.",0.18,PMID.dPMID11840500.s2.p0,3,3,RXRB|PPARA|NR4A2,NR4A2|PPARA|RXRB,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,19207680,PPARalpha,SREBP-1,"RESULTS: Concurrent with PPARgamma and SREBP-1 gene activation, steatosis extent was larger when cells were treated with oleic than with palmitic acid; the latter fatty acid was associated with increased PPARalpha expression.",0.37,PMID.dPMID19207680.s5.p2,3,3,PPARgamma|SREBP-1|PPARalpha,PPARalpha|PPARgamma|SREBP-1,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,20139613,PPAR-alpha,SREBP1c,"Thus, AMPK mediated 95% EE induced suppression of SREBP1c and activation of PPAR-alpha respectively.",0.13,PMID.dPMID20139613.s1.p2,3,3,AMPK|SREBP1c|PPAR-alpha,AMPK|PPAR-alpha|SREBP1c,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,10958784,PPAR,PAX8,"PAX8-PPARgamma1 mRNA and protein were detected in 5 of 8 thyroid follicular carcinomas but not in 20 follicular adenomas, 10 papillary carcinomas, or 10 multinodular hyperplasias.",0.01,PMID.dPMID10958784.s2.p0,2,2,PAX8|PPAR,PAX8|PPAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19458633,PPARalpha,p63,Silencing of p63 by RNA interference and transient transfections showed that p63 represses PPARalpha through a functional region of promoter B.,1.08,PMID.dPMID19458633.s6.p2,3,2,p63|p63|PPARalpha,p63|PPARalpha,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,16243957,PPARalpha,PXR,"Further analysis of this regulatory region has shown that transcriptional activation of PXR by peroxisome proliferator-activated receptor alpha (PPARalpha) is via a binding site located approximately 1.3 kb upstream of the putative transcription start site, with ablation of this site preventing PPARalpha-mediated activation of PXR gene expression.",0.01,PMID.dPMID16243957.s1.p1,4,2,PXR|PPARalpha|PPARalpha|PXR,PPARalpha|PXR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.2.5,9575,9606,,GO:0006357|GO:0045944,18317514,PPARalpha,CLOCK,We also found that CLOCK/BMAL1-mediated transcription of period (PER) and cryptochrome (CRY) was modulated by PPARalpha/RXRalpha.,0.95,PMID.dPMID18317514.s1.p1,3,3,CLOCK|BMAL1|PPARalpha,BMAL1|CLOCK|PPARalpha,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.2.5,9575,9606,,GO:0006357|GO:0045944,18317514,PPAR,CLOCK,"To investigate the interaction between the lipid metabolism system and the circadian system, we analyzed the effect of a CLOCK/BMAL1 heterodimer on the transcriptional regulation of PPAR-controlled genes through PPAR response elements (PPREs).",0.24,PMID.dPMID18317514.s3.p1,4,3,CLOCK|BMAL1|PPAR|PPAR,BMAL1|CLOCK|PPAR,
2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,1.2.5.2.5,9575,9606,,GO:0006357|GO:0045944,15828232,PPARalpha,CLOCK,"Recently, we showed that the CLOCK: BMAL1 heterodimer regulates the PPARalpha gene via promoter of PPARalpha.",0.11,PMID.dPMID15828232.s3.p3,4,3,CLOCK|BMAL1|PPARalpha|PPARalpha,BMAL1|CLOCK|PPARalpha,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,16326050,PPARbeta,PPARalpha,We found that both human PPARalpha and PPARgamma were activated by MEHP whereas MEHP could not activate PPARbeta.,0.21,PMID.dPMID16326050.s2.p1,3,3,PPARalpha|PPARgamma|PPARbeta,PPARalpha|PPARbeta|PPARgamma,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,17152989,PPARdelta,PPARalpha,"Among 52 extracts nearly the half significantly activated PPARgamma and 14 activated PPARalpha in addition, whereas three of them were pan-PPAR activators, which also activated PPARdelta.",0.20,PMID.dPMID17152989.s2.p2,3,3,PPARgamma|PPARalpha|PPARdelta,PPARalpha|PPARdelta|PPARgamma,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,20032574,PPARdelta,PPAR,"Among Bitter melon extracts compounds, we focused on an extract known as momordin in the present study, to examine its effect on peroxisome-proliferator activated-receptor (PPAR) delta (also called PPARdelta in rodents) expression and promoter activity of the human PPARdelta gene.",0.05,PMID.dPMID20032574.s5.p0,3,2,PPAR|PPARdelta|PPARdelta,PPAR|PPARdelta,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,16326050,PPARbeta,PPARgamma,We found that both human PPARalpha and PPARgamma were activated by MEHP whereas MEHP could not activate PPARbeta.,0.12,PMID.dPMID16326050.s2.p2,3,3,PPARalpha|PPARgamma|PPARbeta,PPARalpha|PPARbeta|PPARgamma,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18037904,PPARdelta,RelA,"Interestingly, our results show that p65/RelA only represses PPARdelta-dependent transactivation when PPARdelta is bound to DNA via its DNA-binding domain.",1.00,PMID.dPMID18037904.s3.p0,3,2,RelA|PPARdelta|PPARdelta,PPARdelta|RelA,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18037904,PPARdelta,RelA,Recent studies have established that p65/RelA is a potent repressor of PPARdelta-mediated transactivation in human keratinocytes.,0.65,PMID.dPMID18037904.s6.p0,2,2,RelA|PPARdelta,PPARdelta|RelA,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18037904,PPARdelta,RelA,HDAC activity is required for p65/RelA-dependent repression of PPARdelta-mediated transactivation in human keratinocytes.,0.54,PMID.dPMID18037904.s9.p2,3,3,HDAC|RelA|PPARdelta,HDAC|PPARdelta|RelA,
2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,18037904,PPARdelta,RelA,"Interestingly, our results show that p65/RelA only represses PPARdelta-dependent transactivation when PPARdelta is bound to DNA via its DNA-binding domain.",0.08,PMID.dPMID18037904.s3.p1,3,2,RelA|PPARdelta|PPARdelta,PPARdelta|RelA,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.1.1.4,367,9606,GO:0016563,GO:0010552|GO:0034339,15694704,PPARgamma,AIS,"According to this categorization, responses of adipogenic markers to the stimulation of the master transcription factor, ADD1/SREBP-1c might be different in adipocytes: higher lipogenic enzymes activities in type I AIS, insufficient transactivation of leptin in type II AIS, failure in the expression of PPARgamma in type III AIS, and insufficient increases of lipogenic enzymes in type IV AIS.",0.08,PMID.dPMID15694704.s1.p14,8,5,ADD1|SREBP-1c|AIS|leptin|AIS|PPARgamma|AIS|AIS,ADD1|AIS|leptin|PPARgamma|SREBP-1c,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.3.2.2.20,688,9606,GO:0003702,,19551868,PPARgamma,KLF5,"CDXl, CDX2 and KLF5 expression was not modified by PPARgamma activation.",0.33,PMID.dPMID19551868.s5.p2,3,3,CDX2|KLF5|PPARgamma,CDX2|KLF5|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.1.1.8.1,1044,9606,,,19059241,PPARgamma,CDX1,"CDX1 enhanced the expression of PPARgamma gene, a master transcriptional regulator of intestinal differentiation, at the transcriptional level, via functional interaction with CCAAT/enhancer-binding protein alpha (C/EBPalpha).",0.85,PMID.dPMID19059241.s2.p0,3,3,CDX1|PPARgamma|C/EBPalpha,CDX1|C/EBPalpha|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.1.1.8.1,1044,9606,,,19059241,PPARgamma,CDX1,Homeodomain transcription factor CDX1 is required for the transcriptional induction of PPARgamma in intestinal cell differentiation.,0.18,PMID.dPMID19059241.s5.p0,2,2,CDX1|PPARgamma,CDX1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.1.1.8.2,1045,9606,,,19551868,PPARgamma,CDX2,"CDXl, CDX2 and KLF5 expression was not modified by PPARgamma activation.",0.01,PMID.dPMID19551868.s5.p1,3,3,CDX2|KLF5|PPARgamma,CDX2|KLF5|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.1.4.1.1,1050,9606,,GO:0045945,15711576,PPARgamma,C/EBPalpha,"Interestingly, expression of the mutant beta-catenin blocks expression of adiponectin and C/EBPalpha in response to the activation of PPARgamma.",0.38,PMID.dPMID15711576.s0.p2,3,3,adiponectin|C/EBPalpha|PPARgamma,adiponectin|C/EBPalpha|PPARgamma,<--
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.1.4.1.2,1051,9606,,,15711576,PPARgamma,C/EBPbeta,"Additionally, we have recently demonstrated that phosphorylation of C/EBPbeta at a consensus ERK/GSK3 site is required for the PPARgamma-associated expression of adiponectin during the terminal stages of adipogenesis.",0.68,PMID.dPMID15711576.s5.p0,3,3,C/EBPbeta|PPARgamma|adiponectin,adiponectin|C/EBPbeta|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.3.2.1.1,1869,9606,,GO:0000122,15711575,PPARgamma,E2F1,"E2F1 induces PPARgamma transcription during clonal expansion, whereas E2F4 represses PPARgamma expression during terminal adipocyte differentiation.",0.99,PMID.dPMID15711575.s6.p0,3,2,E2F1|PPARgamma|PPARgamma,E2F1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.3.2.1.1,1869,9606,,GO:0000122,15711575,PPARgamma,E2F1,"E2F1 induces PPARgamma transcription during clonal expansion, whereas E2F4 represses PPARgamma expression during terminal adipocyte differentiation.",0.48,PMID.dPMID15711575.s6.p1,3,2,E2F1|PPARgamma|PPARgamma,E2F1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.3.2.1.2,1958,9606,,GO:0045941,14662774,PPARgamma,EGR-1,"Our results suggest that EGR-1 induction is a unique property of TGZ, but is independent of PPARgamma activation.",0.24,PMID.dPMID14662774.s1.p1,3,3,EGR-1|TGZ|PPARgamma,EGR-1|PPARgamma|TGZ,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17363578,PPARgamma,ERalpha,"Here, we show that 15d-PGJ(2) inhibits both 17beta-estradiol (E(2))-dependent and E(2)-independent ERalpha transcriptional activity by PPARgamma-independent mechanism.",0.12,PMID.dPMID17363578.s4.p0,2,2,ERalpha|PPARgamma,ERalpha|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,16556873,PPARgamma,Ets-1,"Chromatin immunoprecipitation assays further demonstrated that PPARgamma ligands inhibit Ets-1 binding to the TERT promoter, which is mediated at least in part through an inhibition of Ets-1 expression by PPARgamma ligands.",0.30,PMID.dPMID16556873.s3.p9,5,3,PPARgamma|Ets-1|TERT|Ets-1|PPARgamma,Ets-1|PPARgamma|TERT,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,20519739,PPARgamma,ETV4,Stable overexpression of ETV4 promotes expression of PPARgamma and its downstream target genes and enhances morphological differentiation.,0.54,PMID.dPMID20519739.s2.p0,2,2,ETV4|PPARgamma,ETV4|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,20519739,PPARgamma,ETV4,Transient expression of ETV4 in preadipocytes enhances the expression of PPARgamma.,0.18,PMID.dPMID20519739.s3.p0,2,2,ETV4|PPARgamma,ETV4|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,20519739,PPARgamma,ETV4,"Finally, knockdown of PPARgamma expression by shRNA blocks the effects of phenamil on adipocyte differentiation and gene expression, but it does not block phenamil induction of ETV4, which suggests that ETV4 acts upstream of PPARgamma in differentiation processes.",0.12,PMID.dPMID20519739.s1.p5,4,2,PPARgamma|ETV4|ETV4|PPARgamma,ETV4|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,16670091,PPARgamma,FOXO1,We studied the effects of FOXO1 on human PPARgamma gene expression in primary rat adipocytes and found that both genes are endogenously expressed.,0.21,PMID.dPMID16670091.s6.p0,2,2,FOXO1|PPARgamma,FOXO1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,12615657,PPARgamma,GATA-6,GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells.,0.01,PMID.dPMID12615657.s8.p0,2,2,GATA-6|PPARgamma,GATA-6|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.3.1.1.1,3169,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051091,18688264,PPARgamma,FOXA1,FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation.,0.83,PMID.dPMID18688264.s7.p1,3,3,FOXA1|IRF-1|PPARgamma,FOXA1|IRF-1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,12613669,PPARgamma,Id2,"We hypothesized that downregulation of Id2 gene expression by thiazolidinediones (TZDs), a class of anti-diabetic drugs and peroxisome proliferator-activated receptor gamma (PPARgamma) activators, might contribute to the anti-atherosclerotic and anti-hypertensive effects of the PPARgamma.",0.23,PMID.dPMID12613669.s4.p1,3,2,Id2|PPARgamma|PPARgamma,Id2|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.5.3.0.1,3659,9606,,,18688264,PPARgamma,IRF-1,FOXA1 and IRF-1 intermediary transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation.,0.69,PMID.dPMID18688264.s7.p2,3,3,FOXA1|IRF-1|PPARgamma,FOXA1|IRF-1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.5.3.0.1,3659,9606,,,14656743,PPARgamma,IRF-1,"Finally, reducing IRF-1 expression by antisense technology attenuated PPARgamma-induced VSMC apoptosis through decreasing cyclin-dependent kinase inhibitor p21(cip1) and caspase-3 activity.",0.64,PMID.dPMID14656743.s1.p0,2,2,IRF-1|PPARgamma,IRF-1|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.3.5.0.35,4150,9606,,,19061500,PPARgamma,MAZ,Myc-associated zinc finger protein (MAZ) was identified as a transcriptional mediator of PPARgamma1 expression in these cells.,0.40,PMID.dPMID19061500.s6.p0,2,2,MAZ|PPARgamma,MAZ|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,16809887,PPARgamma,c-myc,"Moreover, the downregulation of c-myc expression by TGZ may depend on a PPARgamma-independent mechanism.",1.33,PMID.dPMID16809887.s1.p1,3,3,c-myc|TGZ|PPARgamma,c-myc|PPARgamma|TGZ,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,12878168,PPARgamma,MyoD1,"Activation of PPARdelta by long chain fatty acids impairs the expression of the determination factor MyoD1 and alpha-actin, abolishes the development of multinucleated myotubes, and in parallel induces the expression of PPARgamma gene, a master regulator of adipogenesis.",0.10,PMID.dPMID12878168.s3.p4,4,4,PPARdelta|MyoD1|alpha-actin|PPARgamma,alpha-actin|MyoD1|PPARdelta|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.3.5.0.42,5325,9606,,GO:0045944,17178896,PPARgamma,ZAC,"We show that in human colon carcinoma cells, ZAC activates expression of PPARgamma target genes in a PPARgamma-dependent manner.",0.76,PMID.dPMID17178896.s2.p1,3,2,ZAC|PPARgamma|PPARgamma,PPARgamma|ZAC,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.3.5.0.42,5325,9606,,GO:0045944,17178896,PPARgamma,ZAC,"We show that in human colon carcinoma cells, ZAC activates expression of PPARgamma target genes in a PPARgamma-dependent manner.",0.35,PMID.dPMID17178896.s2.p0,3,2,ZAC|PPARgamma|PPARgamma,PPARgamma|ZAC,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,10408502,PPARgamma,PPAR,Enhanced PPAR type alpha expression protects against cardiovascular disorders though the role of enhanced PPARgamma expression seems less favourable.,0.96,PMID.dPMID10408502.s2.p0,2,2,PPAR|PPARgamma,PPAR|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11443177,PPARgamma,PPARalpha,"In contrast, PPARalpha expression increased significantly at week 2 and further at week 4. 9- and 13-hydroxyoctadecanoic acid, products of linoleic acid peroxidation and agonists of PPARgamma, decreased during troglitazone therapy.",0.87,PMID.dPMID11443177.s2.p0,2,2,PPARalpha|PPARgamma,PPARalpha|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,10431661,PPAR-gamma,PPAR-alpha,"All PPARs are, albeit to different extents, activated by fatty acids and derivatives; PPAR-alpha binds the hypolipidemic fibrates whereas antidiabetic glitazones are ligands for PPAR-gamma.",0.69,PMID.dPMID10431661.s9.p0,2,2,PPAR-alpha|PPAR-gamma,PPAR-alpha|PPAR-gamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,19667161,PPARgamma,PPARalpha,"After treatment with corresponding ligands, the expression of the VDR, PPARalpha and PPARdelta was elevated up to 5-fold, while the PPARgamma expression was not significantly affected.",0.56,PMID.dPMID19667161.s14.p4,4,4,VDR|PPARalpha|PPARdelta|PPARgamma,PPARalpha|PPARdelta|PPARgamma|VDR,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,18221086,PPAR-gamma,PPAR-alpha,PPAR-alpha is the main metabolic regulator for catabolism whereas PPAR-gamma regulates anabolism or storage.,0.46,PMID.dPMID18221086.s8.p0,2,2,PPAR-alpha|PPAR-gamma,PPAR-alpha|PPAR-gamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,18095947,PPAR-gamma,PPAR-alpha,"PPAR-alpha is involved in the regulation of fatty acid (FA) uptake and oxidation, inflammation and vascular function, while PPAR-gamma participates in FA uptake and storage, glucose homeostasis and inflammation.",0.46,PMID.dPMID18095947.s10.p0,2,2,PPAR-alpha|PPAR-gamma,PPAR-alpha|PPAR-gamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11172467,PPARgamma,PPARalpha,"Troglitazone and pioglitazone, which are ligands/activators for PPARgamma, also induced PPARalpha gene and protein expression and increased CuZn-SOD gene expression and protein levels in addition to increasing PPARgamma gene and protein expression in endothelial cells.",0.34,PMID.dPMID11172467.s3.p2,3,2,PPARgamma|PPARalpha|PPARgamma,PPARalpha|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,19067734,PPAR-gamma,PPAR-alpha,"RESULTS: Using reverse transcriptase-polymerase chain reaction and Western blot, we found that incubation of TNF-alpha (50 ng mL(-1)) for 24 h decreased PPAR-alpha, but increased PPAR-gamma without altering PPAR-delta.",0.21,PMID.dPMID19067734.s7.p2,4,4,TNF-alpha|PPAR-alpha|PPAR-gamma|PPAR-delta,PPAR-alpha|PPAR-delta|PPAR-gamma|TNF-alpha,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,9748221,PPARgamma,PPARalpha,"Whereas PPARalpha is already present in undifferentiated monocytes, PPARgamma expression is induced upon differentiation into macrophages.",0.19,PMID.dPMID9748221.s6.p0,2,2,PPARalpha|PPARgamma,PPARalpha|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,20070029,PPAR-gamma,PPAR-alpha,"METHODS: In our angiographic and clinical study we assessed the association of gene polymorphisms of L162V for PPAR-alpha, C161T for PPAR-gamma and A(39526)AA for RXR-alpha with the risk of restenosis and cardiac events after coronary stenting.",0.12,PMID.dPMID20070029.s8.p0,2,2,PPAR-alpha|PPAR-gamma,PPAR-alpha|PPAR-gamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,11212240,PPARgamma,PPAR,We investigated the expression of peroxisome proliferator-activated receptor (PPAR) gamma in benign and malignant prostate tissues and the ability of 15S-HETE to activate PPARgamma-dependent transcription and modulate proliferation of the Pca cell line PC3.,0.08,PMID.dPMID11212240.s8.p0,3,3,PPAR|PPARgamma|PC3,PC3|PPAR|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,12679463,PPARgamma,PPAR,The aim was to study the effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue.,0.06,PMID.dPMID12679463.s10.p1,3,3,PPAR|gamma2|PPARgamma,gamma2|PPAR|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,12679463,PPARgamma,PPAR,Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects.,0.06,PMID.dPMID12679463.s11.p1,3,3,PPAR|gamma2|PPARgamma,gamma2|PPAR|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,14625208,PPARgamma,PPAR,"Whether other PPAR types can be found in human islets, how islet PPARgamma mRNA expression is regulated by the metabolic milieu, their role in insulin secretion, and the effects of a PPARgamma agonist are not known.",0.02,PMID.dPMID14625208.s9.p1,3,2,PPAR|PPARgamma|PPARgamma,PPAR|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,19814730,PPARgamma,PPAR,"Although peroxisome proliferator-activated receptor (PPAR)gamma activation reduces inflammation and atherosclerosis, expression of PPARgamma in cells and its modulation by smoking are poorly investigated.",0.01,PMID.dPMID19814730.s9.p0,2,2,PPAR|PPARgamma,PPAR|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,16288226,PPAR-g,PPAR-b,We tested (a) whether PPAR-b/d expression modulates PPAR-g activity in experimental models of the loss and gain of PPAR-b/d function in colon cancer cells and (b) whether 15-LOX-1 formation of 13-S-HODE influences the interaction between PPAR-b/d and PPAR-g.,0.75,PMID.dPMID16288226.s2.p0,6,3,PPAR-b|PPAR-g|PPAR-b|15-LOX-1|PPAR-b|PPAR-g,15-LOX-1|PPAR-b|PPAR-g,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,12878168,PPARgamma,PPARdelta,"Activation of PPARdelta by long chain fatty acids impairs the expression of the determination factor MyoD1 and alpha-actin, abolishes the development of multinucleated myotubes, and in parallel induces the expression of PPARgamma gene, a master regulator of adipogenesis.",0.51,PMID.dPMID12878168.s3.p3,4,4,PPARdelta|MyoD1|alpha-actin|PPARgamma,alpha-actin|MyoD1|PPARdelta|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,19667161,PPARgamma,PPARdelta,"After treatment with corresponding ligands, the expression of the VDR, PPARalpha and PPARdelta was elevated up to 5-fold, while the PPARgamma expression was not significantly affected.",0.39,PMID.dPMID19667161.s14.p5,4,4,VDR|PPARalpha|PPARdelta|PPARgamma,PPARalpha|PPARdelta|PPARgamma|VDR,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.6.1,6095,9606,,GO:0034339|GO:0045944,17545671,PPARgamma,RORalpha,"Our data identify cAspAT as a new member of glyceroneogenesis, transcriptionally regulated by TZD via the control of RORalpha expression by PPARgamma in adipocytes.",1.23,PMID.dPMID17545671.s0.p0,2,2,RORalpha|PPARgamma,PPARgamma|RORalpha,<--
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,10409739,PPARgamma,SREBP-2,The related transcription factor SREBP-2 likewise induced PPARgamma expression.,1.41,PMID.dPMID10409739.s4.p0,2,2,SREBP-2|PPARgamma,PPARgamma|SREBP-2,<--
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,14975242,PPARgamma,STAT3,"Interestingly, although inactivation of STAT3 by PPARgamma agonists is in a PPARgamma-dependent manner, the molecular mechanism by which two structurally distinct PPARgamma agonists suppress IL-6-activated STAT3 shows the divergent interactions between PPARgamma and STAT3 including direct or SMRT-mediated association",0.71,PMID.dPMID14975242.s0.p1,9,4,STAT3|PPARgamma|PPARgamma|PPARgamma|IL-6|STAT3|PPARgamma|STAT3|SMRT,IL-6|PPARgamma|SMRT|STAT3,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,14975242,PPARgamma,STAT3,"Interestingly, although inactivation of STAT3 by PPARgamma agonists is in a PPARgamma-dependent manner, the molecular mechanism by which two structurally distinct PPARgamma agonists suppress IL-6-activated STAT3 shows the divergent interactions between PPARgamma and STAT3 including direct or SMRT-mediated association",0.18,PMID.dPMID14975242.s0.p0,9,4,STAT3|PPARgamma|PPARgamma|PPARgamma|IL-6|STAT3|PPARgamma|STAT3|SMRT,IL-6|PPARgamma|SMRT|STAT3,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,6.2.1.0.6,6777,9606,,GO:0006357,16777921,PPARgamma,STAT5,CONCLUSIONS: Reduced activation of colonic STAT5 and expression of PPARgamma may contribute to persistent mucosal inflammation in colitis.,0.06,PMID.dPMID16777921.s1.p0,2,2,STAT5|PPARgamma,PPARgamma|STAT5,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,19667161,PPARgamma,VDR,"After treatment with corresponding ligands, the expression of the VDR, PPARalpha and PPARdelta was elevated up to 5-fold, while the PPARgamma expression was not significantly affected.",0.86,PMID.dPMID19667161.s14.p3,4,4,VDR|PPARalpha|PPARdelta|PPARgamma,PPARalpha|PPARdelta|PPARgamma|VDR,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,19667161,PPARgamma,VDR,"The strongest expression was found for the VDR, approximately 3-fold higher compared to the expression of PPARalpha or PPARdelta, and the weakest expression was for PPARgamma.",0.03,PMID.dPMID19667161.s15.p3,4,4,VDR|PPARalpha|PPARdelta|PPARgamma,PPARalpha|PPARdelta|PPARgamma|VDR,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15972966,PPARgamma,PAX8,"Moreover many genes involved in PAX8-PPARgamma expression profile presented a putative PPARgamma-promoter site, compatible with a direct activity of the fusion product.",1.19,PMID.dPMID15972966.s1.p0,3,2,PAX8|PPARgamma|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,16444351,PPARgamma,PAX8,"Therefore, there is no complete evidence that PAX8-PPARgamma is the cause of FTC.",0.64,PMID.dPMID16444351.s2.p0,2,2,PAX8|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15362967,PPARgamma,PAX8,"We investigated in a series of thyroid samples, including 14 normal, 13 hyperfunctioning tissues, 26 follicular adenomas, 21 follicular and 41 papillary carcinomas, both the frequency of the PAX8-PPARgamma1 rearrangement and the expression of the PAX8 and PPARgamma transcripts.",0.46,PMID.dPMID15362967.s8.p3,4,2,PAX8|PPARgamma|PAX8|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15972966,PPARgamma,PAX8,"Moreover many genes involved in PAX8-PPARgamma expression profile presented a putative PPARgamma-promoter site, compatible with a direct activity of the fusion product.",0.42,PMID.dPMID15972966.s1.p1,3,2,PAX8|PPARgamma|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,16179407,PPARgamma,PAX8,"Unexpectedly, PAX8-PPARgamma transcriptional function on a PPARgamma-responsive promoter was cell-type dependent; in HeLa cells, PAX8-PPARgamma dominantly inhibited expression of the PPARgamma-responsive promoter, whereas in FRTL-5 and immortalized human thyroid cells PAX8-PPARgamma stimulated this promoter.",0.32,PMID.dPMID16179407.s4.p13,8,5,PAX8|PPARgamma|PPARgamma|PAX8|PPARgamma|PPARgamma|PAX8|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,17651453,PPARgamma,PAX8,"OBJECTIVE: Follicular thyroid tumours present several genetic alterations such as aneuploidy, RAS mutations and PAX8/PPARgammarearrangements.",0.26,PMID.dPMID17651453.s10.p0,2,2,PAX8|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,15238980,PPARgamma,PAX8,"PAX8-PPARgamma fusion gene expression was found in 25% (six of 24) of follicular thyroid carcinomas (FTCs) and in 17% (six of 36) of follicular thyroid adenomas, but in none of the 10 normal tissues, 28 nodular hyperplasias, 38 papillary thyroid carcinomas (PTCs) and 11 poorly differentiated thyroid carcinomas (PDTCs).",0.14,PMID.dPMID15238980.s6.p0,2,2,PAX8|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,16444351,PPARgamma,PAX8,"A chromosomal translocation between the transcription factor PAX8 and the peroxisome proliferator-activated receptorgamma (PPARgamma) occurs in 30-50% of patients; however, the presence of PAX8-PPARgamma is also demonstrated in follicular adenomas.",0.08,PMID.dPMID16444351.s3.p5,4,2,PAX8|PPARgamma|PAX8|PPARgamma,PAX8|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.1.4.0.3,8013,9606,,GO:0034339,18855877,PPARG,NR4A3,The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.,0.39,PMID.dPMID18855877.s8.p2,3,3,EWSR1|NR4A3|PPARG,EWSR1|NR4A3|PPARG,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19551868,PPARgamma,KLF4,"We also demonstrate that PPARgamma activation leads to increased (p21WAF1/Cip1 and keratin 19) or decreased (cyclin D1) expression of known KLF4 targets, suggesting that KLF4 is a nodal player in a network of PPARgamma-regulated genes.",1.07,PMID.dPMID19551868.s0.p5,4,2,PPARgamma|KLF4|KLF4|PPARgamma,KLF4|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.1.2.0.6,64764,9606,,GO:0045941,18757431,PPARgamma,CREB3L2,The CREB3L2-PPARgamma fusion encodes a CREB3L2-PPARgamma fusion protein that is composed of the transactivation domain of CREB3L2 and all functional domains of PPARgamma1.,0.37,PMID.dPMID18757431.s7.p3,6,2,CREB3L2|PPARgamma|CREB3L2|PPARgamma|CREB3L2|PPARgamma,CREB3L2|PPARgamma,
2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,1.1.2.0.6,64764,9606,,GO:0045941,18757431,PPARgamma,CREB3L2,"CREB3L2-PPARgamma also inhibited 4-fold the expression of thyroglobulin, a native cAMP-responsive gene, in primary thyroid cells treated with thyroid-stimulating hormone.",0.19,PMID.dPMID18757431.s1.p0,3,3,CREB3L2|PPARgamma|thyroglobulin,CREB3L2|PPARgamma|thyroglobulin,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,16480812,RARalpha,AhR,"This, and the documented physical interaction between AhR and SMRT suggested that SMRT sequestration by AhR might activate RARalpha in the absence of ligand.",0.57,PMID.dPMID16480812.s4.p6,5,3,AhR|SMRT|SMRT|AhR|RARalpha,AhR|RARalpha|SMRT,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16832676,RAR,AML1,"In contrast, SAHA did not affect AML1-ETO levels and failed to induce RARbeta2 expression and maturation in Kasumi-1 cells.",0.35,PMID.dPMID16832676.s2.p0,2,2,AML1|RAR,AML1|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,10419474,RARalpha,AML2,Based on these studies we hypothesize that AML2 expression is normally regulated by retinoid/vitamin D nuclear receptors mainly through the RARalpha-dependent signaling pathway and that it may play a role in hematopoietic cell differentiation.,0.02,PMID.dPMID10419474.s0.p0,2,2,AML2|RARalpha,AML2|RARalpha,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.1.2.0.1,1385,9606,,GO:0045944,19416972,RAR,CREB1,"Interestingly, CREB1 complexes are regulated by all-trans-RA as are RAR complexes by forskolin.",0.21,PMID.dPMID19416972.s4.p0,2,2,CREB1|RAR,CREB1|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,12943740,RAR,ERalpha,"In this study, we generated cell lines stably expressing ERalpha-deletion mutants to elucidate the mechanism whereby ERalpha modulates RAR transcriptional activity.",1.27,PMID.dPMID12943740.s8.p2,3,2,ERalpha|ERalpha|RAR,ERalpha|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,12943740,RAR,ERalpha,"Moreover, the cross-talk between ERalpha and RAR does not seem to be mediated by sequestration of a number of common co-regulators, suggesting a novel mechanism whereby the N-terminal region of ERalpha modulates the transcriptional activity of RAR",1.11,PMID.dPMID12943740.s0.p5,4,2,ERalpha|RAR|ERalpha|RAR,ERalpha|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,15870697,RARalpha,ERalpha,Suppression of ERalpha by small interfering RNA (siRNA) reduced RARalpha and CRABPII gene expression and siRNA suppression of RARalpha reduced CRABPII expression while having no effect on ERalpha in T47D cells.,0.99,PMID.dPMID15870697.s2.p0,6,3,ERalpha|RARalpha|CRABPII|RARalpha|CRABPII|ERalpha,CRABPII|ERalpha|RARalpha,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,12943740,RAR,ERalpha,The effect of ERalpha is specific for RAR-mediated transcription and does not occur on promoters containing typical response elements for the Vitamin D or thyroid hormone receptors.,0.78,PMID.dPMID12943740.s1.p0,2,2,ERalpha|RAR,ERalpha|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,15870697,RARalpha,ERalpha,Suppression of ERalpha by small interfering RNA (siRNA) reduced RARalpha and CRABPII gene expression and siRNA suppression of RARalpha reduced CRABPII expression while having no effect on ERalpha in T47D cells.,0.67,PMID.dPMID15870697.s2.p3,6,3,ERalpha|RARalpha|CRABPII|RARalpha|CRABPII|ERalpha,CRABPII|ERalpha|RARalpha,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,12943740,RAR,ERalpha,"In this study, we generated cell lines stably expressing ERalpha-deletion mutants to elucidate the mechanism whereby ERalpha modulates RAR transcriptional activity.",0.34,PMID.dPMID12943740.s8.p1,3,2,ERalpha|ERalpha|RAR,ERalpha|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,18025157,RARalpha,ID2,"We show that the ID1 and ID2 promoters are activated by PML-RARalpha but, unexpectedly, not by wild-type RARalpha/RXR.",0.08,PMID.dPMID18025157.s1.p4,5,4,ID1|ID2|PML|RARalpha|RARalpha,ID1|ID2|PML|RARalpha,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10329471,RAR,AP1,"Retinoids, on the other hand, inhibit cell proliferation and affect differentiation, activities that possibly stem from an antagonism of AP1-mediated gene expression by RARs.",1.46,PMID.dPMID10329471.s6.p0,2,2,AP1|RAR,AP1|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10329471,RAR,AP1,"Therefore, CBP has been proposed as a common limiting cofactor that can account for inhibition of AP1-dependent gene expression by RARs.",1.03,PMID.dPMID10329471.s1.p0,2,2,AP1|RAR,AP1|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10573118,RAR,AP-1,"To determine whether activation of RAR-dependent gene transcription by atRA is necessary for growth inhibition, we tested the growth suppressive effect of a retinoid (BMS453) which binds RAR receptors and transrepresses AP-1 but does not activate RAR-dependent gene expression.",0.25,PMID.dPMID10573118.s5.p5,4,2,RAR|RAR|AP-1|RAR,AP-1|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12052862,RAR,AP1,"AP1 transrepression by retinoids was RAR and ligand dependent, but none of the functions required for RAR-mediated transactivation was necessary for AP1 transrepression.",0.08,PMID.dPMID12052862.s1.p0,4,2,AP1|RAR|RAR|AP1,AP1|RAR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,14603262,RAR,Smad3,"We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists.",0.34,PMID.dPMID14603262.s3.p4,5,3,RAR|Smad3|Smad4|RAR|RAR,RAR|Smad3|Smad4,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,14603262,RAR,Smad4,"We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists.",0.34,PMID.dPMID14603262.s3.p5,5,3,RAR|Smad3|Smad4|RAR|RAR,RAR|Smad3|Smad4,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.2.1.2,5915,9606,,GO:0034339,10328240,RAR,RARbeta,Oncogenicity was clearly decreased in only 1 of the 2 RARbeta-overexpressing clones (33% takes) and was unchanged in the 2 clones with increased RARgamma expression.,1.58,PMID.dPMID10328240.s2.p0,2,2,RARbeta|RAR,RAR|RARbeta,-->
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.2.1.2,5915,9606,,GO:0034339,16289102,RARalpha,RARbeta,"Moreover, the ATRA-induced expression of RARbeta was also mediated by RARalpha.",0.68,PMID.dPMID16289102.s2.p0,2,2,RARbeta|RARalpha,RARalpha|RARbeta,-->
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.2.1.2,5915,9606,,GO:0034339,10411930,RAR,RARbeta,"The structure and preliminary characterizations of human RARbeta(4), coupled with the observation that its expression is greatly elevated in breast tumor cell lines, support the hypothesis that RARbeta(4) functions as a dominant-negative repressor of RAR-mediated growth suppression",0.03,PMID.dPMID10411930.s0.p2,3,2,RARbeta|RARbeta|RAR,RAR|RARbeta,-->
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.2.1.3,5916,9606,,GO:0000122|GO:0034339|GO:0045944,1848877,RAR,RAR-gamma,"Blot hybridization analysis of total RNA extracted from keratome biopsies revealed that RAR-gamma was the predominant RAR species expressed in human epidermis, as RAR-alpha transcripts were detectable only at low levels and RAR-beta transcripts were undetectable.",0.29,PMID.dPMID1848877.s6.p0,4,3,RAR-gamma|RAR|RAR-alpha|RAR-beta,RAR|RAR-alpha|RAR-beta|RAR-gamma,-->
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,12420222,RAR,SOX9,SOX9 gene expression is rapidly stimulated by RAR-agonists in T-47D cells and other retinoid-inhibited breast cancer cell lines.,0.42,PMID.dPMID12420222.s5.p0,2,2,SOX9|RAR,RAR|SOX9,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,10361124,RAR,Sp1,"Furthermore, gel shift studies showed that the binding of Sp1 to the uPA GC box is significantly potentiated in the presence of RARs/RXRs.",0.25,PMID.dPMID10361124.s2.p1,3,3,Sp1|uPA|RAR,RAR|Sp1|uPA,<--
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,20159610,RARalpha,PU.1,PU.1-mediated transactivation was repressed by PML/RARalpha and restored by the addition of all-trans retinoic acid (ATRA).,0.79,PMID.dPMID20159610.s2.p1,3,3,PU.1|PML|RARalpha,PML|PU.1|RARalpha,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,6.2.1.0.6,6777,9606,,GO:0006357,11929749,RARalpha,Stat5,"The expression of Stat5-RARalpha causes the transcriptional repression of gene transcription, a process that requires the coiled-coil domain of Stat5 (amino acid positions 133-333).",0.60,PMID.dPMID11929749.s3.p0,3,2,Stat5|RARalpha|Stat5,RARalpha|Stat5,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,6.2.1.0.6,6777,9606,,GO:0006357,11929748,RARalpha,STAT5b,"To determine the molecular mechanisms of myeloid leukemogenesis and maturation arrest in STAT5b-RARalpha(+) APL and its unresponsiveness to ATRA, we examined the effect of STAT5b-RARalpha on the activity of myeloid transcription factors including RARalpha/retinoid X receptor (RXR) alpha, STAT3, and STAT5 as well as its molecular interactions with the nuclear receptor corepressor, SMRT, and nuclear receptor coactivator, TRAM-1.",0.12,PMID.dPMID11929748.s6.p8,7,4,STAT5b|RARalpha|STAT5b|RARalpha|RARalpha|STAT3|TRAM-1,RARalpha|STAT3|STAT5b|TRAM-1,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,6.2.1.0.6,6777,9606,,GO:0006357,11929749,RARalpha,Stat5,The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex.,0.01,PMID.dPMID11929749.s7.p0,2,2,Stat5|RARalpha,RARalpha|Stat5,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1316240,RAR,TFIID,"We demonstrate that the core domain of hTFIID is sufficient to mediate RAR-dependent transcription and that Drosophila, but not yeast, TFIID can substitute for hTFIID.",0.23,PMID.dPMID1316240.s2.p0,4,2,TFIID|RAR|TFIID|TFIID,RAR|TFIID,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.3.1.0.1,7020,9606,,,20195529,RARA,TFAP2A,"CONCLUSIONS/SIGNIFICANCE: Taken together, these results strongly suggest that NR2F2 is involved in villous CTB cell differentiation and that NR2F2 acts, at least in part, by directly activating TFAP2A gene expression and by potentiating the transactivation of TFAP2A by RARA and RXRA",0.10,PMID.dPMID20195529.s0.p9,5,3,NR2F2|NR2F2|TFAP2A|TFAP2A|RARA,NR2F2|RARA|TFAP2A,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10629053,RARalpha,COUP-TF,"In a transient transfection assay, COUP-TF strongly induced transcriptional activity of the RARbeta promoter in a RA- and RARalpha-dependent manner.",0.44,PMID.dPMID10629053.s3.p1,3,3,COUP-TF|RARbeta|RARalpha,COUP-TF|RARalpha|RARbeta,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,8394351,RAR,VDR,"In combination with all-trans-retinoic acid, however, vitamin D enhances VDR-RAR heterodimer-mediated gene expression.",0.39,PMID.dPMID8394351.s1.p0,2,2,VDR|RAR,RAR|VDR,
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,10342883,RAR,VDR,Incubation with vitamin D markedly reduced the response to RA caused by transcriptional interference of the vitamin D receptor (VDR) on the RARE.,0.00,PMID.dPMID10342883.s6.p0,2,2,VDR|RAR,RAR|VDR,"[5914-->5915, 6256-->5915, 7421-->5915]"
2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,19144644,RARalpha,SRC-3,We propose a model in which the ratio between SUG-1 and SRC-3 is crucial for the control of RARalpha functioning.,0.14,PMID.dPMID19144644.s1.p2,3,3,SUG-1|SRC-3|RARalpha,RARalpha|SRC-3|SUG-1,
2.1.2.1.2,5915,9606,,GO:0034339,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19623543,RARbeta,Myc,"METHODS: In this study, a benign prostate epithelial cell line RWPE1 was used as a model to study the epigenetic regulation of Myc on the RARbeta and PDLIM4 promoters.",0.07,PMID.dPMID19623543.s4.p0,3,3,Myc|RARbeta|PDLIM4,Myc|PDLIM4|RARbeta,
2.1.2.1.2,5915,9606,,GO:0034339,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19623543,RARbeta,Myc,A DNA methylation inhibitor 5-aza-2'-deoxycytidine reversed the epigenetic alteration effect of Myc on both RARbeta and PDLIM4.,0.05,PMID.dPMID19623543.s1.p0,3,3,Myc|RARbeta|PDLIM4,Myc|PDLIM4|RARbeta,
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10629053,RARbeta,RARalpha,"These results demonstrate that COUP-TF, by serving as an accessory protein for RARalpha to induce RARbeta expression, plays a critical role in regulating the anticancer activities of retinoids",1.19,PMID.dPMID10629053.s0.p2,3,3,COUP-TF|RARalpha|RARbeta,COUP-TF|RARalpha|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15189119,RARbeta,RAR,"We then focus on a discussion of RARalpha and acute promyelocytic leukemia followed by a discussion of the role of RARs, in particular RARbeta expression, in other cancer types.",0.62,PMID.dPMID15189119.s2.p1,3,2,RAR|RAR|RARbeta,RAR|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,9228081,RARbeta,RAR,"Activation of each of the endogenous RXR or RAR isoforms induces RARbeta gene expression, and blocks cellular proliferation.",0.47,PMID.dPMID9228081.s3.p0,2,2,RAR|RARbeta,RAR|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10344761,RAR-beta,RAR-alpha,"The expression of RAR-alpha and RAR-gamma remains positive in HEC specimens, but RAR-beta expression was detected in only 6 of 20 HEC specimens.",0.39,PMID.dPMID10344761.s1.p1,3,3,RAR-alpha|RAR-gamma|RAR-beta,RAR-alpha|RAR-beta|RAR-gamma,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10328240,RARbeta,RARalpha,"Sensitivity to 4HPR was increased in RARbeta-overexpressing clones, whereas it was slightly decreased in RARalpha transfectants (which had diminished RARbeta expression) and was unchanged in clones transfected with RARgamma.",0.38,PMID.dPMID10328240.s8.p2,4,2,RARbeta|RARalpha|RARbeta|RAR,RAR|RARalpha|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,12409228,RARbeta,RARalpha,Overexpression of VPAC1 in SKNSH cells resulted in upregulation of endogenous retinoic acid receptor expression for both RARalpha and RXRalpha with no change in expression of RARbeta.,0.20,PMID.dPMID12409228.s6.p4,4,4,VPAC1|RARalpha|RXRalpha|RARbeta,RARalpha|RARbeta|RXRalpha|VPAC1,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,12554770,RARbeta,RARalpha,"We report here that the three RAR isotypes display different transcriptional properties in the absence of hormone ligand; under these conditions, RARalpha is a strong repressor of target gene expression, whereas both RARbeta and RARgamma fail to repress and instead are able to mediate substantial levels of hormone-independent transcriptional activation.",0.16,PMID.dPMID12554770.s3.p2,4,2,RAR|RARalpha|RARbeta|RAR,RAR|RARalpha|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15189119,RARbeta,RAR,"We then focus on a discussion of RARalpha and acute promyelocytic leukemia followed by a discussion of the role of RARs, in particular RARbeta expression, in other cancer types.",0.07,PMID.dPMID15189119.s2.p2,3,2,RAR|RAR|RARbeta,RAR|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15808511,RARbeta,RAR,"We show that PARP-1 is indispensable to retinoic acid receptor (RAR)-mediated transcription from the RARbeta2 promoter in a highly purified, reconstituted transcription system and that RA-inducible expression of all RARbeta isoforms is abrogated in PARP-1(-/-) cells in vivo.",0.06,PMID.dPMID15808511.s7.p4,5,3,PARP-1|RAR|RARbeta|RARbeta|PARP,PARP|PARP-1|RAR|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,15255287,RARbeta,RARalpha,The hallmark of the study was the significant increase in expression of RARalpha and RXRalpha proteins and loss of expression of RARbeta protein in ESCCs in comparison with the distant normal epithelia,0.05,PMID.dPMID15255287.s0.p0,2,2,RARalpha|RARbeta,RARalpha|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10629053,RARbeta,COUP-TF,"In this study, we provide evidence that orphan receptor COUP-TF is required for induction of RARbeta expression, growth inhibition, and apoptosis by RA in cancer cells.",1.05,PMID.dPMID10629053.s6.p0,2,2,COUP-TF|RARbeta,COUP-TF|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10629053,RARbeta,COUP-TF,"These results demonstrate that COUP-TF, by serving as an accessory protein for RARalpha to induce RARbeta expression, plays a critical role in regulating the anticancer activities of retinoids",0.58,PMID.dPMID10629053.s0.p1,3,3,COUP-TF|RARalpha|RARbeta,COUP-TF|RARalpha|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10629053,RARbeta,COUP-TF,"In a transient transfection assay, COUP-TF strongly induced transcriptional activity of the RARbeta promoter in a RA- and RARalpha-dependent manner.",0.48,PMID.dPMID10629053.s3.p0,3,3,COUP-TF|RARbeta|RARalpha,COUP-TF|RARalpha|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10629053,RARbeta,COUP-TF,"In addition, stable expression of COUP-TF in COUP-TF-negative cancer cells restores induction of RARbeta expression, growth inhibition, and apoptosis by RA, whereas inhibition of COUP-TF by expression of COUP-TF antisense RNA represses the RA effects.",0.27,PMID.dPMID10629053.s4.p1,5,2,COUP-TF|COUP-TF|RARbeta|COUP-TF|COUP-TF,COUP-TF|RARbeta,<--
2.1.2.1.2,5915,9606,,GO:0034339,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,10629053,RARbeta,COUP-TF,"In addition, stable expression of COUP-TF in COUP-TF-negative cancer cells restores induction of RARbeta expression, growth inhibition, and apoptosis by RA, whereas inhibition of COUP-TF by expression of COUP-TF antisense RNA represses the RA effects.",0.17,PMID.dPMID10629053.s4.p2,5,2,COUP-TF|COUP-TF|RARbeta|COUP-TF|COUP-TF,COUP-TF|RARbeta,<--
2.1.2.1.3,5916,9606,,GO:0000122|GO:0034339|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,10782404,RAR-gamma,RAR-alpha,These results suggest that partial loss and abnormal localization of RAR-alpha expression as well as increased RAR-gamma expression may play a role in the etiology of non-neoplastic epithelial disorders of the vulva,1.39,PMID.dPMID10782404.s0.p0,2,2,RAR-alpha|RAR-gamma,RAR-alpha|RAR-gamma,<--
6.1.1.2.3,5966,9606,,,6.1.2.1.8,602,9606,GO:0030528,GO:0016481|GO:0045941,10830747,rel,bcl-3,"Structural alterations of the NF-kappaB/rel genes NFkappaB2, c-rel and bcl-3 have been shown to result in increased NF-kappaB/rel activity.",1.01,PMID.dPMID10830747.s6.p5,4,2,rel|c-rel|bcl-3|rel,bcl-3|c-rel|rel,
6.1.1.2.3,5966,9606,,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8920856,c-Rel,AP-1,"Moreover, AP-1 activity stimulated by anti-TCR Abs or PMA/ionomycin was further increased by c-Rel overexpression.",0.01,PMID.dPMID8920856.s4.p0,2,2,AP-1|c-Rel,AP-1|c-Rel,
6.1.1.2.3,5966,9606,,,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,17617603,c-rel,NFAT1,"Overall, these findings establish that disrupting actin cytoskeletal dynamics impairs TCR/CD28-mediated calcium flux required for NFAT1-mediated c-rel transcription and, thus, activation of the CD28RE/AP.",0.65,PMID.dPMID17617603.s0.p2,4,3,CD28|NFAT1|c-rel|CD28,CD28|c-rel|NFAT1,
6.1.1.2.3,5966,9606,,,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,17617603,c-rel,NFAT1,TCR/CD28-stimulated actin dynamics are required for NFAT1-mediated transcription of c-rel leading to CD28 response element activation.,0.35,PMID.dPMID17617603.s8.p2,4,3,CD28|NFAT1|c-rel|CD28,CD28|c-rel|NFAT1,
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,7843230,c-rel,NF-kappa B,"TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50.",0.84,PMID.dPMID7843230.s0.p4,5,4,TNF-alpha|NF-kappa B|c-rel|c-rel|p50,c-rel|NF-kappa B|p50|TNF-alpha,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,7843230,c-rel,NF-kappa B,"TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50.",0.59,PMID.dPMID7843230.s0.p2,5,4,TNF-alpha|NF-kappa B|c-rel|c-rel|p50,c-rel|NF-kappa B|p50|TNF-alpha,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8352966,rel,NF-kappa B,Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system.,0.47,PMID.dPMID8352966.s4.p0,2,2,NF-kappa B|rel,NF-kappa B|rel,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10684280,Rel,NFkappaB,"To date, several approaches attempting to correlate Tax activation of the CREB/activating transcription factor (ATF) or NFkappaB/Rel transcriptional activation pathway to cellular transformation have yielded conflicting results.",0.43,PMID.dPMID10684280.s5.p2,3,3,CREB|NFkappaB|Rel,CREB|NFkappaB|Rel,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8246997,Rel,NF-kappa B,"Taken together with prior in vivo transcription studies, these results suggest that the biological activities of p65 and p50 homodimers are independently regulated, thereby providing an integrated and flexible control mechanism for the rapid activation and repression of NF-kappa B/Rel-directed gene expression",0.40,PMID.dPMID8246997.s0.p2,3,3,p65|NF-kappa B|Rel,NF-kappa B|p65|Rel,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,18795655,C-Rel,NFkappaB,Promoter analysis suggests the implication of NFkappaB/C-Rel transcription factors in biliary atresia.,0.28,PMID.dPMID18795655.s9.p0,2,2,NFkappaB|C-Rel,C-Rel|NFkappaB,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8454856,Rel,NF-kappa B,The data demonstrate that the p50/p105 NF-kappa B gene is regulated by members of the NF-kappa B/Rel family and likely by other important transcription factors,0.20,PMID.dPMID8454856.s0.p4,4,3,p105|NF-kappa B|NF-kappa B|Rel,NF-kappa B|p105|Rel,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,12743820,Rel,NFkappaB,"For example, humans have two NFkappaB genes, three Rel genes, and five NFAT genes, while Ciona has one gene for each family.",0.20,PMID.dPMID12743820.s2.p0,2,2,NFkappaB|Rel,NFkappaB|Rel,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,7926759,rel,NF-kappa B,"As documented in the accompanying paper (Klug et al., this issue), an active v-abl protein also suppresses the activity of NF-kappa B/rel and expression controlled by the kappa intron enhancer.",0.12,PMID.dPMID7926759.s1.p2,3,3,v-abl|NF-kappa B|rel,NF-kappa B|rel|v-abl,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11591705,Rel,NF-kappa B,There are increasing lines of evidence that NF-kappa B/Rel activity is controlled to a great extent by its phosphorylation state.,0.06,PMID.dPMID11591705.s9.p0,2,2,NF-kappa B|Rel,NF-kappa B|Rel,<--
6.1.1.2.3,5966,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,9225998,Rel,NF-kappa B,"In this article, we summarise recent studies demonstrating that (1) chronic HIV-1 infection of human myelomonoblastic PLB-985 cells leads to constitutive NF-kappa B activity, activated in part due to enhanced I kappa B alpha turnover and increased NF-kappa B/Rel production; (2) HTLV-1 Tax protein physically associates with the I kappa B alpha protein in vivo and in vitro and also mediates a 20- to 40-fold stimulation of NF-kappa B DNA binding activity mediated via an enhancement of NF-kappa B dimer formation; (3) casein kinase II phosphorylates I kappa B alpha at multiple sites in the C-terminal PEST domains and regulates I kappa B alpha function; (4) transdominant forms of I kappa B alpha, mutated in critical Ser or Thr residues required for inducer-mediated (S32A,S36A) and/or constitutive phosphorylation block HIV LTR trans-activation and also effectively inhibit HIV-1 multiplication in a single cycle infection model; and (5) the amino-terminal 55aa of I kappa B alpha (NIK) interacts with the human homologue of dynein light chain 1, a small 9-kDa human homologue of the dynein light chain protein involved in microtubule and cytoskeletal dynamics.",0.01,PMID.dPMID9225998.s1.p2,8,4,NF-kappa B|NF-kappa B|Rel|NF-kappa B|NF-kappa B|NIK|dynein light chain|dynein light chain,dynein light chain|NF-kappa B|NIK|Rel,<--
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,3.1.7.2.1,1523,9606,GO:0003702,GO:0006357,10373529,RelA,p110,"Furthermore, by using a fusion protein containing the p65/RelA transactivation domain, we found that overexpression of the p110 catalytic subunit of PI3K induces p65/RelA-mediated transactivation and that the specific PI3K inhibitor LY294,002 represses this process.",0.03,PMID.dPMID10373529.s2.p2,3,2,RelA|p110|RelA,p110|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,16043358,RelA,ERalpha,"In transfection experiments, both ERalpha and ERbeta inhibited NF-kappaB-mediated expression in a hormone dependent manner with repression also dependent upon dimerization of RelA with p50.",0.19,PMID.dPMID16043358.s2.p1,4,4,ERalpha|ERbeta|RelA|p50,ERalpha|ERbeta|p50|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,3.5.3.0.1,3659,9606,,,18694960,RelA,IRF-1,The transcriptional activation of IRF-1 is controlled largely by the recruitment of p65 (RelA) NF-kappaB to the IRF-1 promoter following the engagement of a TAK1/IkappaB kinase beta/IkappaBalpha signaling pathway downstream of CD40.,0.28,PMID.dPMID18694960.s3.p0,4,3,IRF-1|RelA|IRF-1|CD40,CD40|IRF-1|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,3.1.1.13.2,4223,9606,,,20421348,RelA,MEOX2,CONCLUSION: Our results represent the first report of an interaction between a homeobox protein and IkappaBbeta and suggest that MEOX2 modulates the activity of the RelA complex through direct interaction with its components.,0.79,PMID.dPMID20421348.s1.p2,3,3,IkappaBbeta|MEOX2|RelA,IkappaBbeta|MEOX2|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8413215,RelA,NF-kappa B,"Furthermore, while providing a novel example of a kappa B-regulated promoter in which the classical NF-kappa B complex is unable to activate transcription from the kappa B element, these data provide direct evidence for the role of RelA in regulation of IL-8 gene expression",0.43,PMID.dPMID8413215.s0.p0,2,2,NF-kappa B|RelA,NF-kappa B|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,17113265,RelA,NFkappaB,Bandshift analysis using oligonucleotides spanning predicted NFkappaB sites within the SPP2 promoter and silencing of NFkappaB/RelA via RelA-directed siRNA demonstrated that SPP2 is an NFkappaB-dependent gene.,0.20,PMID.dPMID17113265.s3.p4,5,2,NFkappaB|NFkappaB|RelA|RelA|NFkappaB,NFkappaB|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,12827408,RelA,NF-kappa B,CONCLUSION: Our results suggest that increased expression of NF-kappa B/RelA contributes to tumor angiogenesis in colorectal cancer.,0.17,PMID.dPMID12827408.s1.p0,2,2,NF-kappa B|RelA,NF-kappa B|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8321192,RelA,NFKB1,Acquisition of NFKB1-selective DNA binding by substitution of four amino acid residues from NFKB1 into RelA.,0.11,PMID.dPMID8321192.s10.p2,3,2,NFKB1|NFKB1|RelA,NFKB1|RelA,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.1.1.2.2,5971,9606,,,11753650,RelA,RelB,"Thus, RelB is regulated at least at the level of transcription in a RelA and RelB dependent manner and may exert an important role in p21 regulation",0.99,PMID.dPMID11753650.s0.p0,3,2,RelB|RelA|RelB,RelA|RelB,
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9788595,RelA,p53,p53-mediated repression of RelA is relieved by p300 overexpression and the increased RelA activity conferred by p53-deficiency is counteracted by either transactivation domain-deficient p300 fragments that bind RelA or a transdominant mutant of IkappaB alpha.,0.99,PMID.dPMID9788595.s1.p3,7,3,p53|RelA|p300|RelA|p53|p300|RelA,p300|p53|RelA,-->
6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9788595,RelA,p53,p53-mediated repression of RelA is relieved by p300 overexpression and the increased RelA activity conferred by p53-deficiency is counteracted by either transactivation domain-deficient p300 fragments that bind RelA or a transdominant mutant of IkappaB alpha.,0.95,PMID.dPMID9788595.s1.p0,7,3,p53|RelA|p300|RelA|p53|p300|RelA,p300|p53|RelA,-->
6.1.1.2.2,5971,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11982761,RelB,NF-kappaB,"Fc(epsilon)RI-induced NF-kappaB complexes in monocytes and DC contain p50 and p65, but no other NF-kappaB subunits despite increased RelB expression during differentiation.",1.57,PMID.dPMID11982761.s3.p2,3,2,NF-kappaB|NF-kappaB|RelB,NF-kappaB|RelB,
6.1.1.2.2,5971,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,11982761,RelB,NF-kappaB,"Fc(epsilon)RI-induced NF-kappaB complexes in monocytes and DC contain p50 and p65, but no other NF-kappaB subunits despite increased RelB expression during differentiation.",0.61,PMID.dPMID11982761.s3.p1,3,2,NF-kappaB|NF-kappaB|RelB,NF-kappaB|RelB,
6.1.1.2.2,5971,9606,,,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,20185819,RelB,NFkappaB,"TRAF3 knock-down also increased mRNA and protein expression of several non-canonical NFkappaB components, including NFkappaB2/p100, RelB, and NIK, accompanied by processing of NFkappaB2/p100 into p52.",0.20,PMID.dPMID20185819.s3.p4,6,4,TRAF3|NFkappaB|NFkappaB|RelB|NIK|NFkappaB,NFkappaB|NIK|RelB|TRAF3,
6.1.1.2.2,5971,9606,,,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,20686703,RelB,RelA,"Moreover, RelB overexpression in microglial cells inhibited Tat-induced TNFalpha synthesis in a manner that involved transcriptional repression of the TNFalpha promoter, and increased phosphorylation of RelA at serine 276, a prerequisite for increased RelB/RelA protein interactions.",1.12,PMID.dPMID20686703.s5.p14,7,5,RelB|Tat|TNFalpha|TNFalpha|RelA|RelB|RelA,RelA|RelB|Tat|TNFalpha,
6.1.1.2.2,5971,9606,,,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,11753650,RelB,RelA,RelA is alone sufficient to induce RelB gene transcription and to mediate the stimuli-driven increase in RelB transcription.,1.03,PMID.dPMID11753650.s4.p0,3,2,RelA|RelB|RelB,RelA|RelB,
6.1.1.2.2,5971,9606,,,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,11753650,RelB,RelA,RelA is alone sufficient to induce RelB gene transcription and to mediate the stimuli-driven increase in RelB transcription.,0.22,PMID.dPMID11753650.s4.p1,3,2,RelA|RelB|RelB,RelA|RelB,
2.3.2.2.14,5978,9606,GO:0016564,GO:0006355,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,16253247,REST,HES-1,"Taken together, these results indicate that HES-1 is an upstream negative regulator of REST expression",1.88,PMID.dPMID16253247.s0.p0,2,2,HES-1|REST,HES-1|REST,<--
2.3.2.2.14,5978,9606,GO:0016564,GO:0006355,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,16253247,REST,HES-1,"Moreover, using a cells model that overexpress HES-1 and a combination of experimental approaches, we demonstrated that HES-1 reduces endogenous REST expression.",0.82,PMID.dPMID16253247.s1.p2,3,2,HES-1|HES-1|REST,HES-1|REST,<--
2.3.2.2.14,5978,9606,GO:0016564,GO:0006355,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,15197246,NRSF,TBP,These results indicate that the direct interaction between the NRSF C-terminal domain and TBP is essential for the C-terminal repression mechanism of NRSF.,0.28,PMID.dPMID15197246.s1.p2,3,2,NRSF|TBP|NRSF,NRSF|TBP,
2.3.2.2.14,5978,9606,GO:0016564,GO:0006355,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,12032298,REST,BHC,Chromatin-immunoprecipitation experiments demonstrate the recruitment of BHC by the neuronal repressor REST.,1.32,PMID.dPMID12032298.s2.p0,2,2,BHC|REST,BHC|REST,
3.3.3.0.1,5989,9606,,,3.3.1.10.1,2302,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032088,20690903,RFX,FOXJ1,"FOXJ1 is essential to allow for the assembly of motile cilia in vertebrates through the regulation of genes specific to motile cilia or necessary for basal body apical transport, whereas RFX proteins are necessary to assemble both primary and motile cilia in metazoans, in particular, by regulating genes involved in intraflagellar transport.",0.18,PMID.dPMID20690903.s2.p0,2,2,FOXJ1|RFX,FOXJ1|RFX,
2.1.2.6.1,6095,9606,,GO:0034339|GO:0045944,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15662020,RORalpha,PPARgamma,"In contrast, the synthetic PPARgamma ligand pioglitazone weakly induced RORalpha4 expression but did not affect RORalpha1 expression or TNF-alpha-induced gene expression.",0.61,PMID.dPMID15662020.s5.p0,4,3,PPARgamma|RORalpha|RORalpha|TNF-alpha,PPARgamma|RORalpha|TNF-alpha,-->
2.1.2.6.1,6095,9606,,GO:0034339|GO:0045944,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15662020,RORalpha,PPARgamma,"In contrast, the synthetic PPARgamma ligand pioglitazone weakly induced RORalpha4 expression but did not affect RORalpha1 expression or TNF-alpha-induced gene expression.",0.02,PMID.dPMID15662020.s5.p1,4,3,PPARgamma|RORalpha|RORalpha|TNF-alpha,PPARgamma|RORalpha|TNF-alpha,-->
1.2.5.1.4,6493,9606,,,3.3.1.9.1.1,326,9606,GO:0016563,GO:0006355,18083234,SIM,AIRE,The ability of PIAS1 to localize into NBs and interconnect with AIRE is neither dependent on the SP-RING domain nor the SIM.,1.08,PMID.dPMID18083234.s4.p2,3,3,PIAS1|AIRE|SIM,AIRE|PIAS1|SIM,
2.3.5.0.2,6591,9606,,GO:0000122,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,20622260,Slug,c-Myb,"In summary, we show here that the proto-oncogene c-Myb controls Slug transcription in tumor cells of different origin.",1.12,PMID.dPMID20622260.s1.p0,2,2,c-Myb|Slug,c-Myb|Slug,
2.3.5.0.2,6591,9606,,GO:0000122,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,20622260,Slug,c-Myb,c-Myb-dependent Slug expression was also essential for the homing of chronic myeloid leukemia K562 cells to the bone marrow.,0.99,PMID.dPMID20622260.s2.p0,2,2,c-Myb|Slug,c-Myb|Slug,
2.3.5.0.2,6591,9606,,GO:0000122,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17639499,SNAI2,p53,The p53-independent anti-apoptotic effect of Id2 was mediated in part by transcriptional repressor SNAI2.,0.71,PMID.dPMID17639499.s4.p1,3,3,p53|Id2|SNAI2,Id2|p53|SNAI2,
2.3.5.0.2,6591,9606,,GO:0000122,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20150431,Slug,p63,These data suggest that the disruption of p63 expression induced by Snail and Slug plays a crucial role in tumor progression.,0.03,PMID.dPMID20150431.s1.p0,2,2,p63|Slug,p63|Slug,
2.3.5.0.2,6591,9606,,GO:0000122,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,20128911,SLUG,Lef-1,"In a search for Lef-1 responsive genes in human osteoblasts, we focused on the transcriptional regulation of the SLUG, a zinc finger transcription factor belonging to the Snail family of developmental proteins.",0.33,PMID.dPMID20128911.s8.p0,2,2,Lef-1|SLUG,Lef-1|SLUG,
4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19716157,SOX2,p63,p63 was expressed in 96% of esophageal squamous cell carcinomas and 100% of anal canal squamous cell carcinomas; the single squamous cell carcinoma negative for p63 was strongly positive for SOX2.,1.00,PMID.dPMID19716157.s3.p2,3,2,p63|p63|SOX2,p63|SOX2,
4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19661786,Sox2,p63,Twenty-nine percent of ACA were at least focally p63+; 12% were Sox2+/p63+.,0.58,PMID.dPMID19661786.s4.p0,3,2,p63|Sox2|p63,p63|Sox2,
4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19716157,SOX2,p63,p63 was expressed in 96% of esophageal squamous cell carcinomas and 100% of anal canal squamous cell carcinomas; the single squamous cell carcinoma negative for p63 was strongly positive for SOX2.,0.18,PMID.dPMID19716157.s3.p1,3,2,p63|p63|SOX2,p63|SOX2,
4.1.1.3.1,6659,9606,,GO:0006355|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20400479,SOX4,p53,"In this study, we characterized the roles of SOX4 in regulation of the p53 transcription activity and evaluated the expression patterns and prognostic value of the transcription factor SOX4 in HCC.",0.05,PMID.dPMID20400479.s8.p2,4,3,SOX4|p53|SOX4|HCC,HCC|p53|SOX4,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,3.1.1.8.2,1045,9606,,,19795349,SOX9,CDX2,"In the intestine, Wnt signaling represses the expression of the tumor suppressor gene CDX2 via SOX9, a transcription factor, which is also expressed in the choroid plexus.",0.22,PMID.dPMID19795349.s9.p0,2,2,CDX2|SOX9,CDX2|SOX9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,16684505,Sox9,Ets-1,"Additionally, Ets-1 was shown to be a positive regulator of the integrin alpha10 expression whereas Sox9 was irrelevant.",0.71,PMID.dPMID16684505.s1.p1,3,3,Ets-1|integrin alpha10|Sox9,Ets-1|integrin alpha10|Sox9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,15383177,SOX9,SF1,"Basal expression of AMH is induced by SOX9; GATA4, SF1, and WT1 enhance SOX9-activated expression.",1.53,PMID.dPMID15383177.s5.p8,5,4,SOX9|GATA4|SF1|WT1|SOX9,GATA4|SF1|SOX9|WT1,x
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,15192080,Sox9,Ad4BP,"It has been established that the Mllerian inhibiting substance gene is transcribed predominantly under the control of Ad4BP/SF-1 and, moreover, its transcription is regulated synergistically with Sox9, Gata4, and Wt1.",0.04,PMID.dPMID15192080.s4.p1,3,2,Ad4BP|SF-1|Sox9,Ad4BP|SF-1|Sox9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.1.5.0.1,2516,9606,,GO:0034339|GO:0045944,15192080,Sox9,SF-1,"It has been established that the Mllerian inhibiting substance gene is transcribed predominantly under the control of Ad4BP/SF-1 and, moreover, its transcription is regulated synergistically with Sox9, Gata4, and Wt1.",0.04,PMID.dPMID15192080.s4.p2,3,2,Ad4BP|SF-1|Sox9,Ad4BP|SF-1|Sox9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,15383177,SOX9,GATA4,"Basal expression of AMH is induced by SOX9; GATA4, SF1, and WT1 enhance SOX9-activated expression.",1.89,PMID.dPMID15383177.s5.p7,5,4,SOX9|GATA4|SF1|WT1|SOX9,GATA4|SF1|SOX9|WT1,x
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,19790048,SOX9,HIF-1alpha,"RESULTS: We found that hypoxia and HIF-1alpha not only induced the expression of SOX9, COL2A1, and aggrecan, but they simultaneously inhibited the expression of COL1A1, COL1A2, and COL3A1.",0.94,PMID.dPMID19790048.s3.p0,6,6,HIF-1alpha|SOX9|COL2A1|aggrecan|COL1A1|COL1A2,aggrecan|COL1A1|COL1A2|COL2A1|HIF-1alpha|SOX9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,1.2.4.1.1,3280,9606,GO:0016564,GO:0000122,19322650,transcription factor SOX9,HES-1,Here we show that retinoic acid induces HES-1 expression via upregulation of transcription factor SOX9.,0.23,PMID.dPMID19322650.s6.p0,2,2,HES-1|transcription factor SOX9,HES-1|transcription factor SOX9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,19041414,Sox9,Smad3,Smad3 activates the Sox9-dependent transcription on chromatin.,0.83,PMID.dPMID19041414.s10.p0,2,2,Smad3|Sox9,Smad3|Sox9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,19041414,Sox9,Smad3,In vitro transcription and S1 nuclease assays showed that Smad3 and p300 cooperatively activated the Sox9-dependent transcription on chromatin template.,0.80,PMID.dPMID19041414.s2.p1,3,3,Smad3|p300|Sox9,p300|Smad3|Sox9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,19041414,Sox9,Smad3,We have previously reported that TGF-beta-regulated Smad3 induces chondrogenesis through the activation of Sox9-dependent transcription.,0.47,PMID.dPMID19041414.s7.p2,3,3,TGF-beta|Smad3|Sox9,Smad3|Sox9|TGF-beta,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,12420222,SOX9,RAR,RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition.,1.24,PMID.dPMID12420222.s10.p0,2,2,RAR|SOX9,RAR|SOX9,x
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Sox-9,Slug,"At the same time, Slug silencing potentiates the expression of Sox-9, a factor indispensable for chondrogenic development.",0.57,PMID.dPMID19756381.s2.p0,2,2,Slug|Sox-9,Slug|Sox-9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Sox-9,Slug,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.48,PMID.dPMID19756381.s1.p13,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Sox-9,Slug,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.40,PMID.dPMID19756381.s1.p1,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.3.5.0.2,6591,9606,,GO:0000122,19756381,Sox-9,Slug,"These data, with the finding that Slug is in vivo recruited by the promoters of Runx2 and Sox-9 genes, suggest that, in hOBs, Slug may act both as positive and negative transcriptional regulator of Runx2 and Sox-9 genes, respectively.",0.26,PMID.dPMID19756381.s1.p10,6,3,Slug|Runx2|Sox-9|Slug|Runx2|Sox-9,Runx2|Slug|Sox-9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,12840810,Sox9,Sry,"The timing of Sry and Sox9 expression is consistent with a role in testis determination: Sry expression begins at CS 16 in testes, followed by upregulation of Sox9 expression at CS 17.",0.85,PMID.dPMID12840810.s2.p5,4,2,Sry|Sox9|Sry|Sox9,Sox9|Sry,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,9541211,transcription factor Sox9,Sry,"Finally, the Sry-related transcription factor Sox9 is expressed in epithelial components and to a lesser degree in condensed mesenchyme of the developing teeth.",0.74,PMID.dPMID9541211.s1.p0,2,2,Sry|transcription factor Sox9,Sry|transcription factor Sox9,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,11990793,SOX9,SRY,"However, important pieces of the puzzle are still missing, such as the molecular nature of the sex switch in marsupials, monotremes and non-mammalian vertebrates; the target of SRY; the upstream regulators of SOX9; and the genes in the ovarian pathway.",0.57,PMID.dPMID11990793.s2.p0,2,2,SRY|SOX9,SOX9|SRY,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,12840810,Sox9,Sry,"In mammals, Sry might initiate testis induction by upregulating Sox9 expression; however, direct evidence supporting this hypothesis is lacking.",0.53,PMID.dPMID12840810.s7.p0,2,2,Sry|Sox9,Sox9|Sry,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,19875885,Sox9,Sry,"Initially, Sry with other factors upregulates Sox9 expression in XY individuals.",0.42,PMID.dPMID19875885.s6.p0,2,2,Sry|Sox9,Sox9|Sry,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,19513096,SOX9,SRY,The normal role of SRY in gonadal development is the upregulation of SOX9 expression.,0.22,PMID.dPMID19513096.s5.p0,2,2,SRY|SOX9,SOX9|SRY,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.1.1,6736,9606,GO:0016563,,15135034,SOX9,SRY,"They include the SRY-related gene, SOX9, which plays important roles in both sex determination and chondrogenesis, as well as genes responsible for the production of growth factors, i.e. fibroblast growth factor 9, platelet derived growth factor A, and the members of the insulin-receptor family of genes.",0.02,PMID.dPMID15135034.s7.p0,2,2,SRY|SOX9,SOX9|SRY,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15383177,SOX9,WT1,"Basal expression of AMH is induced by SOX9; GATA4, SF1, and WT1 enhance SOX9-activated expression.",1.67,PMID.dPMID15383177.s5.p9,5,4,SOX9|GATA4|SF1|WT1|SOX9,GATA4|SF1|SOX9|WT1,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,16877546,Sox9,Wt1,"The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis.",0.81,PMID.dPMID16877546.s7.p0,2,2,Wt1|Sox9,Sox9|Wt1,
4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,4.1.1.5.1,30812,9606,GO:0003702,GO:0045944,11483257,Sox9,Sox8,"Sox8 is a member of the E subgroup of Sox genes, the other members of which are Sox9 and Sox10, both of which are implicated in specific human disorders.",0.52,PMID.dPMID11483257.s5.p0,3,3,Sox8|Sox9|Sox10,Sox10|Sox8|Sox9,
4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,19422606,SOX10,MITF,"Our findings suggest that altered MITF function during melanomagenesis can be achieved by MITF amplification, MITF single base substitutions or by mutation of its regulator SOX10.",0.32,PMID.dPMID19422606.s0.p5,4,2,MITF|MITF|MITF|SOX10,MITF|SOX10,-->
4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,12944398,SOX10,MITF,"M-MITF promoter responsiveness to cAMP was found to depend upon SOX10, and reciprocally, SOX10 transactivation was dependent upon the CRE.",0.29,PMID.dPMID12944398.s3.p0,3,2,MITF|SOX10|SOX10,MITF|SOX10,-->
4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16921166,SOX10,Sp1,"However, unlike 482ins6 protein, S135T protein synergistically activated EDNRB promoter with a transcription factor Sp1, indicating that Sp1 could compensate the impaired function of a SOX10 mutant protein.",0.50,PMID.dPMID16921166.s1.p5,4,3,EDNRB|Sp1|Sp1|SOX10,EDNRB|SOX10|Sp1,
4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,4.1.1.5.1,30812,9606,GO:0003702,GO:0045944,11483257,Sox10,Sox8,"Sox8 is a member of the E subgroup of Sox genes, the other members of which are Sox9 and Sox10, both of which are implicated in specific human disorders.",0.18,PMID.dPMID11483257.s5.p1,3,3,Sox8|Sox9|Sox10,Sox10|Sox8|Sox9,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.48,639,9606,,GO:0000122,18604866,SP1,PRDM1,"Transcription of PRDM1, the master regulator for plasma cell differentiation, depends on an SP1/SP3/EGR-1 GC-box.",0.30,PMID.dPMID18604866.s7.p0,4,4,PRDM1|SP1|SP3|EGR-1,EGR-1|PRDM1|SP1|SP3,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.22,687,9606,,GO:0006357,12036432,Sp1,BTEB,Thus the identification of this protein expands the repertoire of BTEB-like members of the Sp1-like protein family involved in transcriptional repression.,0.38,PMID.dPMID12036432.s1.p0,2,2,BTEB|Sp1,BTEB|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.22,687,9606,,GO:0006357,12036432,Sp1,BTEB,"In the present study, we report the molecular and functional characterization of BTE-binding protein (BTEB) 4, a novel ubiquitously expressed member of the Sp1-like proteins family.",0.11,PMID.dPMID12036432.s6.p0,2,2,BTEB|Sp1,BTEB|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.1.1.8.2,1045,9606,,,16616718,Sp1,Cdx2,"Taken together, the present study suggests that Cdx2 plays a key role in the transcriptional regulation of the intestine-specific expression of PEPT1, possibly through interaction with Sp1",0.16,PMID.dPMID16616718.s0.p1,3,3,Cdx2|PEPT1|Sp1,Cdx2|PEPT1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.1.4.1.4,1052,9606,,,9528783,Sp1,C/EBPdelta,Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1.,0.37,PMID.dPMID9528783.s10.p1,3,3,C/EBPdelta|Stat3|Sp1,C/EBPdelta|Sp1|Stat3,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,9685731,Sp1,GBF,We also show that GBF belongs to a subgroup of Krppel-type zinc fingers distinct from Sp1.,0.29,PMID.dPMID9685731.s1.p0,2,2,GBF|Sp1,GBF|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,10446910,Sp1,E2F1,Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions.,0.85,PMID.dPMID10446910.s8.p0,2,2,E2F1|Sp1,E2F1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,10446910,Sp1,E2F1,"Thus, transcriptional activation of E2F1 gene expression in MCF-7 cells by E2 is regulated by multiprotein ER/Sp1-NF-Y interactions at GC-rich and two CCAAT elements in the proximal region of the E2F1 gene promoter.",0.79,PMID.dPMID10446910.s1.p0,3,2,E2F1|Sp1|E2F1,E2F1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,12368233,Sp1,E2F-1,Ectopic expression of E2F-1 repressed hTERT promoter activity by inhibiting Sp1 activation of the hTERT promoter.,0.51,PMID.dPMID12368233.s4.p0,2,2,E2F-1|Sp1,E2F-1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,12788094,Sp1,E2F1,"Cotransfection assays showed that activation of dhfr transcription by expression of E2F1/DP1 requires the reiterated Sp1 elements, whereas activation by Sp1 was enhanced by the deletion of the E2F element.",0.37,PMID.dPMID12788094.s2.p4,5,4,dhfr|E2F1|DP1|Sp1|Sp1,dhfr|DP1|E2F1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,18440323,Sp1,E2F1,Cotransfection of the luciferase reporter with either Sp1- or E2F1-expression plasmid further verified the role of Sp1 as a transcriptional activator and E2F1 as a transcriptional repressor in the human MCAK promoter,0.08,PMID.dPMID18440323.s0.p2,4,2,Sp1|E2F1|Sp1|E2F1,E2F1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,12637574,Sp1,Egr-1,Our results indicate that IL-1beta-induced activation of Egr-1 binding is required for inhibition of COL2A1 proximal promoter activity and suggest that Egr-1 acts as a repressor of a constitutively expressed collagen gene by preventing interactions between Sp1 and the general transcriptional machinery,0.37,PMID.dPMID12637574.s0.p9,5,4,IL-1beta|Egr-1|COL2A1|Egr-1|Sp1,COL2A1|Egr-1|IL-1beta|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,20121949,SP-1,EGR-1,More detailed deletion mapping and site-directed mutagenesis further concluded that the overlapping EGR-1/SP-1-binding site was required for TPA-induced p15-pro228 activation.,0.09,PMID.dPMID20121949.s5.p0,3,3,EGR-1|SP-1|p15,EGR-1|p15|SP-1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,16619504,transcription factor Sp1,Egr-1,"In addition, genistein treatment was associated with a significant increase in Egr-1 binding to the transcription factor Sp1.",0.08,PMID.dPMID16619504.s1.p0,2,2,Egr-1|transcription factor Sp1,Egr-1|transcription factor Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17825481,Sp1,ERalpha,"In cells expressing the ERalpha mutant, estrogen did not induce ERE-dependent gene expression but did induce AP-1- and Sp1-dependent gene expression and the cell cycle regulatory genes cyclin D1 and c-myc.",0.21,PMID.dPMID17825481.s2.p0,3,3,ERalpha|Sp1|c-myc,c-myc|ERalpha|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,12787135,Sp1,ERbeta,These results suggest that E2-bound ERbeta may inhibit MCP-1 gene expression by inhibiting Sp1 and AP-1 transcriptional activities in keratinocytes.,0.01,PMID.dPMID12787135.s1.p1,3,3,ERbeta|MCP-1|Sp1,ERbeta|MCP-1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,17656364,Sp1,Ets-1,"These results indicate that Ets-1 enhances expression of the beta-1,4-GalT V gene through activation of the Sp1 gene in cancer cells",0.79,PMID.dPMID17656364.s0.p0,2,2,Ets-1|Sp1,Ets-1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,11970950,Sp1,Ets-1,Ets-1 positively regulates Fas ligand transcription via cooperative interactions with Sp1.,0.47,PMID.dPMID11970950.s12.p1,3,3,Ets-1|Fas|Sp1,Ets-1|Fas|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.2.1.2,2114,9606,,GO:0045893,20045441,Sp1,ets2,"We found that the ets2-TFO prevented binding of Sp1, TAF(II)130 and TAF(II)250 to the ets2 promoter, while binding of RNA polymerase II and TBP were not affected.",0.06,PMID.dPMID20045441.s3.p0,5,4,ets2|Sp1|TAF(II)130|ets2|TBP,ets2|Sp1|TAF(II)130|TBP,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,17938207,Sp1,E1AF,"Biologically, E1AF functions as a positive invasion regulator in glioma in cooperation with Sp1 partly via up-regulation of GalT V.",0.03,PMID.dPMID17938207.s1.p0,2,2,E1AF|Sp1,E1AF|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9528985,Sp1,c-fos,Induction of c-fos protooncogene expression by E2 in MCF-7 cells is dependent on the formation of a transcriptionally active ER/Sp1 complex that binds to a GC-rich enhancer element,0.29,PMID.dPMID9528985.s0.p0,2,2,c-fos|Sp1,c-fos|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.5.0.2,2494,9606,,GO:0034339|GO:0043193|GO:0045449|GO:0045941,8009854,Sp1,CpF,"In contrast, binding sites for transcription factors located immediately upstream (CpE) and downstream (CpF) of the two Sp1-binding sites were shown to be important determinants of nucleocapsid promoter activity in the differentiated hepatoma cell lines, Huh7 and HepG2.",0.13,PMID.dPMID8009854.s3.p2,3,3,CpE|CpF|Sp1,CpE|CpF|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.2.1.0.3,2625,9606,,,18338249,Sp1,GATA-3,Transcription factor GATA-3 regulates the transcriptional activity of dopamine beta-hydroxylase by interacting with Sp1 and AP4.,0.36,PMID.dPMID18338249.s5.p1,3,3,GATA-3|dopamine beta-hydroxylase|Sp1,dopamine beta-hydroxylase|GATA-3|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.1.1.1,2908,9606,,GO:0034339,10329476,Sp-I,glucocorticoid-receptor,Upregulation of mineralocorticoid- and glucocorticoid-receptor gene expression by Sp-I.,0.98,PMID.dPMID10329476.s5.p0,2,2,glucocorticoid-receptor|Sp-I,glucocorticoid-receptor|Sp-I,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15780936,Sp1,HIF-1alpha,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,1.26,PMID.dPMID15780936.s2.p1,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,p
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15780936,Sp1,HIF-1alpha,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,0.57,PMID.dPMID15780936.s2.p6,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,p
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,10425220,Sp1,HIF1A,"Finally, we demonstrate that HIF1A gene transcription is dependent on Sp1 binding sites and that the 5'UTR sequence also contains other important cis-acting elements.",0.53,PMID.dPMID10425220.s0.p0,2,2,HIF1A|Sp1,HIF1A|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,14742449,Sp1,HIF-1,"However, HIF-1 alone was not sufficient to activate transcription in hypoxic conditions but, rather, required Sp1/Sp3, which binds to a cluster of GC-rich sequences adjacent to the HRE.",0.11,PMID.dPMID14742449.s2.p0,3,3,HIF-1|Sp1|Sp3,HIF-1|Sp1|Sp3,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,18513187,Sp1,HNF4alpha,"Overexpression of HNF4alpha led to a dramatic repression of the promoter activity and, in contrast, the activity was markedly elevated by overexpression of Sp1.",0.25,PMID.dPMID18513187.s8.p0,2,2,HNF4alpha|Sp1,HNF4alpha|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.1.1.6.5,3217,9606,,,12697323,Sp1,HOXB7,"HOXB7 expression is regulated by the transcription factors NF-Y, YY1, Sp1 and USF-1.",0.87,PMID.dPMID12697323.s8.p1,4,4,HOXB7|YY1|Sp1|USF-1,HOXB7|Sp1|USF-1|YY1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,17490644,Sp1,Id-1,"Small interfering RNA directed against Sp1 reduced Id-1 expression and the upregulation of the promoter, indicating that Sp1 is required for Id-1 induction in E47- and Snail-expressing cells.",0.03,PMID.dPMID17490644.s1.p2,4,2,Sp1|Id-1|Sp1|Id-1,Id-1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.3.0.1,3659,9606,,,12732645,SP1,IRF1,"Hence, IRF1 represses CDK2 gene expression by interfering with SP1-dependent transcriptional activation.",0.59,PMID.dPMID12732645.s1.p1,3,3,IRF1|CDK2|SP1,CDK2|IRF1|SP1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15509581,Sp1,AP-1,"The ability of ligands to modulate transcription of AP-1- or Sp1-containing promoters was dependent on cell context, but the expression of AP-1 or Sp1 proteins was not necessarily related to transcriptional response.",0.63,PMID.dPMID15509581.s1.p3,4,2,AP-1|Sp1|AP-1|Sp1,AP-1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.35,4150,9606,,,12684688,Sp1,MAZ,"Our results suggest, furthermore, that histone deacetylases are involved in autorepression of the gene for MAZ, while expression of DNA methyltransferase I is associated with suppression of the expression of the gene for MAZ by Sp1.",1.34,PMID.dPMID12684688.s1.p2,3,2,MAZ|MAZ|Sp1,MAZ|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.35,4150,9606,,,12684688,Sp1,MAZ,"Both Sp1 and MAZ inhibited the expression of the gene for MAZ, while expression of the gene for eNOS was enhanced by Sp1 and repressed by MAZ.",0.79,PMID.dPMID12684688.s3.p8,6,3,Sp1|MAZ|MAZ|eNOS|Sp1|MAZ,eNOS|MAZ|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.6.7.5,4601,9606,,,10497252,Sp1,MXI1,"Expression of MXI1, a Myc antagonist, is regulated by Sp1 and AP2.",1.03,PMID.dPMID10497252.s7.p1,3,3,MXI1|Myc|Sp1,MXI1|Myc|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.1.0.3,4605,9606,,,14613485,Sp1,B-Myb,"However, we found that B-Myb decreases Sp1 (specificity protein 1) and CBF (CCAAT-binding factor) binding for their specific sites localized in the 174 bp COL1A1 proximal promoter.",0.55,PMID.dPMID14613485.s4.p0,4,4,B-Myb|Sp1|CCAAT-binding factor|COL1A1,B-Myb|CCAAT-binding factor|COL1A1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.1.0.3,4605,9606,,,14613485,Sp1,B-Myb,B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts.,0.22,PMID.dPMID14613485.s11.p1,3,3,B-Myb|COL1A1|Sp1,B-Myb|COL1A1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.1.0.3,4605,9606,,,10022815,SP1,B-MYB,"These observations suggest that B-MYB functions as a coactivator of SP1, and that diverse combinations of myb and SP1 sites may dictate the responsiveness of myb-target genes to the various members of the myb family.",0.10,PMID.dPMID10022815.s0.p0,6,3,B-MYB|SP1|myb|SP1|myb|myb,B-MYB|myb|SP1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10497252,Sp1,Myc,"Expression of MXI1, a Myc antagonist, is regulated by Sp1 and AP2.",0.95,PMID.dPMID10497252.s7.p2,3,3,MXI1|Myc|Sp1,MXI1|Myc|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,3025632,transcription factor Sp1,c-myc,"In both cases, the region identified as the essential promoter element contained GGGCGG or GGCGGG,GC box-like sequences, suggesting that c-myc gene promoter activity may be controlled by transcription factor Sp1 binding in the microinjected oocytes",0.12,PMID.dPMID3025632.s0.p0,2,2,c-myc|transcription factor Sp1,c-myc|transcription factor Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19912441,Sp1,Myc,E-boxes for Myc/Mad/Max binding showed a higher activity than GC-boxes for Sp1.,0.04,PMID.dPMID19912441.s2.p0,2,2,Myc|Sp1,Myc|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.2.2.1.1,4654,9606,,GO:0006357|GO:0010552,2123467,Sp1,MyoD1,"Furthermore, expression of the promoter in embryonic Drosophila melanogaster cells that lack MyoD1 and Sp1 is strictly dependent on all three sites remaining intact and on the presence of exogenously supplied Sp1 and MyoD1.",0.13,PMID.dPMID2123467.s1.p1,4,2,MyoD1|Sp1|Sp1|MyoD1,MyoD1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,4.2.1.0.1,4800,9606,,GO:0006355,16024108,Sp1,NF-YA,Overexpression of NF-YA had a synergistic effect on Sp1 overexpression and an additive effect on Sp3 overexpression.,0.27,PMID.dPMID16024108.s2.p0,3,3,NF-YA|Sp1|Sp3,NF-YA|Sp1|Sp3,<--
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.1.5.0.2,4899,9606,,GO:0006357,9108165,Sp1,NRF-1,NRF-1 was required for stable binding of Sp1.,0.28,PMID.dPMID9108165.s3.p0,2,2,NRF-1|Sp1,NRF-1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.2.3.0.1,5424,9606,,,11375983,Sp1,POLD1,Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1.,0.44,PMID.dPMID11375983.s6.p1,3,3,POLD1|p53 tumor suppressor|Sp1,p53 tumor suppressor|POLD1|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,20160399,Sp1,PPARbeta,PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1.,0.84,PMID.dPMID20160399.s13.p1,3,3,PPARbeta|SIRT1|Sp1,PPARbeta|SIRT1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,20160399,Sp1,PPARdelta,"Furthermore, the effects of PPARdelta seem to be mediated by Sp1.",0.17,PMID.dPMID20160399.s1.p0,2,2,PPARdelta|Sp1,PPARdelta|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,17272513,transcription factor Sp1,RARalpha,"In searching for additional regulatory elements in the human MRP3 promoter, we have now identified nuclear receptor retinoic X receptor-alpha:retinoic acid receptor-alpha (RXRalpha:RARalpha) as a repressor of MRP3 activation by transcription factor Sp1.",0.89,PMID.dPMID17272513.s6.p4,4,3,MRP3|RARalpha|MRP3|transcription factor Sp1,MRP3|RARalpha|transcription factor Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,19401466,Sp1,RARalpha,"Further, RARalpha was shown to be recruited by Sp1 and to form a transcriptional regulation complex with Sp1 in the Sp1-binding sites of natural MAO B promoter.",0.36,PMID.dPMID19401466.s1.p0,4,2,RARalpha|Sp1|Sp1|Sp1,RARalpha|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,19401466,Sp1,RARalpha,"Further, RARalpha was shown to be recruited by Sp1 and to form a transcriptional regulation complex with Sp1 in the Sp1-binding sites of natural MAO B promoter.",0.33,PMID.dPMID19401466.s1.p1,4,2,RARalpha|Sp1|Sp1|Sp1,RARalpha|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,19401466,Sp1,RARalpha,"Further, RARalpha was shown to be recruited by Sp1 and to form a transcriptional regulation complex with Sp1 in the Sp1-binding sites of natural MAO B promoter.",0.31,PMID.dPMID19401466.s1.p3,4,2,RARalpha|Sp1|Sp1|Sp1,RARalpha|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,17272513,Sp1,RARalpha,"Site mutations and gel shift assays have identified a Sp1 binding GC box motif at -113 to -108 nts upstream from the MRP3 translation start site, where RXRalpha:RARalpha specifically reduced Sp1 binding to this site.",0.01,PMID.dPMID17272513.s4.p5,4,3,Sp1|MRP3|RARalpha|Sp1,MRP3|RARalpha|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,8621476,Sp1,Sp3,"Previous studies have shown that Sp3 repressed Sp1-mediated transcriptional activation, suggesting that Sp3 is an inhibitory member of the Sp family.",1.87,PMID.dPMID8621476.s4.p0,3,2,Sp3|Sp1|Sp3,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,15118068,Sp1,Sp3,"In addition, overexpression of Sp3 resulted in a dose-dependent repression of the Sp1-mediated transactivation.",1.19,PMID.dPMID15118068.s6.p0,2,2,Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,7753559,Sp1,Sp3,"In addition, enforced expression of Sp3 repressed Sp1-mediated activation of c-myc.",1.18,PMID.dPMID7753559.s2.p0,3,3,Sp3|Sp1|c-myc,c-myc|Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,8523525,Sp1,Sp3,"However, in HeLa and Drosophila SL-2 cells, Sp1 acted as a transcriptional activator of the LTRs, while Sp3 acted as a repressor of Sp1-mediated transcriptional activation.",1.11,PMID.dPMID8523525.s2.p2,3,2,Sp1|Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,10984499,Sp1,Sp3,ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene.,0.89,PMID.dPMID10984499.s9.p2,3,3,ZIC2|Sp3|Sp1,Sp1|Sp3|ZIC2,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,9610763,Sp1,Sp3,"Sp1 but not Sp3 activates the human LCAT promoter and when Sp1 is co-transfected along with Sp3, Sp3 functions as a dose-dependent repressor of Sp1-mediated activation.",0.79,PMID.dPMID9610763.s1.p20,7,3,Sp1|Sp3|LCAT|Sp1|Sp3|Sp3|Sp1,LCAT|Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,9632663,Sp1,Sp3,"Co-transfection studies using Sp1 and/or Sp3 expression plasmids revealed that while Sp1 stimulated, Sp3 repressed Sp1-mediated transactivation of TC II transcription.",0.79,PMID.dPMID9632663.s2.p9,5,2,Sp1|Sp3|Sp1|Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,12972613,Sp1,Sp3,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.77,PMID.dPMID12972613.s0.p24,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,12972613,Sp1,Sp3,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.76,PMID.dPMID12972613.s0.p13,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,12509426,Sp1,Sp3,"Additionally, in Gal4-Sp1/-Sp3-Gal4-luciferase assays, oxidative stress increased Sp1 but not Sp3 transactivating capacity, indicating additional mechanism(s) of VEGF-A gene regulation.",0.58,PMID.dPMID12509426.s2.p2,5,3,Sp1|Sp3|Sp1|Sp3|VEGF,Sp1|Sp3|VEGF,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,11337507,Sp1,Sp3,"Supershift assays showed no effect of the anti-Sp1 antibody on complex formation, whereas the anti-Sp3 antibody had a strong effect on protein.DNA complex formation, suggesting that Sp3 is one of the main factors binding to this Sp1 site.",0.51,PMID.dPMID11337507.s2.p5,4,2,Sp1|Sp3|Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,17511886,Sp1,Sp3,"Sp1 and Sp3 were transcriptional activators and repressors respectively, with Sp3 repression being dominant over Sp1-mediated activation.",0.46,PMID.dPMID17511886.s3.p4,4,2,Sp1|Sp3|Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,1454515,transcription factor Sp1,SPR-2,SPR-1 and SPR-2 are homologues of the transcription factor Sp1.,0.40,PMID.dPMID1454515.s5.p2,3,3,SPR-1|SPR-2|transcription factor Sp1,SPR-1|SPR-2|transcription factor Sp1,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,9224612,Sp1,Sp3,"We have also previously determined that Sp3 and Sp1, two members of the Sp family of transcription factors, encode the 115 and 95 kDa RCPs respectively and that Rb stimulates Sp1/Sp3-mediated transcription in vivo.",0.37,PMID.dPMID9224612.s4.p3,5,3,Sp3|Sp1|Rb|Sp1|Sp3,Rb|Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,17511886,Sp1,Sp3,"Sp1 and Sp3 were transcriptional activators and repressors respectively, with Sp3 repression being dominant over Sp1-mediated activation.",0.27,PMID.dPMID17511886.s3.p5,4,2,Sp1|Sp3|Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,12378384,SP1,SP3,An inhibitory activity of SP3 on the stimulatory effect of SP1 could be confirmed in LRA by contransfection experiments in adipocytes.,0.24,PMID.dPMID12378384.s4.p0,2,2,SP3|SP1,SP1|SP3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,11447232,Sp1,Sp3,Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes.,0.20,PMID.dPMID11447232.s9.p0,3,3,Sp3|Sp1|COL2A1,COL2A1|Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,15024015,Sp1,Sp3,These results showed that TIEG2 and Sp3 were repressors at the CACCC element but were activators at proximal Sp1 overlapping sites of MAO B.,0.04,PMID.dPMID15024015.s4.p2,3,3,TIEG2|Sp3|Sp1,Sp1|Sp3|TIEG2,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,9278495,Sp1,Sp3,The results of this study demonstrate that Sp3 is as potent an activator of the human alpha2(I) collagen promoter as is Sp1 and that a transcriptional activity of the human alpha2(I) promoter is dependent on both proteins,0.03,PMID.dPMID9278495.s0.p0,2,2,Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,10362515,Sp1,Sp3,"Expression of Btk was found in ES cells and levels of expression were the same as in ES cells with a targeted deletion of the Sp1 gene, suggesting that Sp3 acts as a positive regulator of Btk in vivo, in the absence of Sp1",0.02,PMID.dPMID10362515.s0.p8,5,3,Btk|Sp1|Sp3|Btk|Sp1,Btk|Sp1|Sp3,<->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,1454515,transcription factor Sp1,SPR-1,SPR-1 and SPR-2 are homologues of the transcription factor Sp1.,0.30,PMID.dPMID1454515.s5.p1,3,3,SPR-1|SPR-2|transcription factor Sp1,SPR-1|SPR-2|transcription factor Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.2.1.0.5,6776,9606,,GO:0006357,17922009,SP1,STAT5A,"The DNA methylation is induced by NPM1-ALK itself via STAT3, and is associated with binding to the promoter of the gene encoding MeCP2 capping protein and with lack of binding of the STAT5A gene transcription activator SP1.",0.62,PMID.dPMID17922009.s3.p9,5,5,NPM1|STAT3|MeCP2|STAT5A|SP1,MeCP2|NPM1|SP1|STAT3|STAT5A,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,12569092,Sp1,TAF1,"Here we provide evidence that TAF1 serves two independent functions, one at the core promoter and one at the upstream activating Sp1 sites of the cyclin D1 gene.",0.14,PMID.dPMID12569092.s6.p0,2,2,TAF1|Sp1,Sp1|TAF1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,10896937,Sp1,TFIID,Functional analysis of partial TFIID complexes formed in vivo indicated that hTAF(II)130 was required for transcriptional activation by Sp1 in vitro.,0.21,PMID.dPMID10896937.s3.p1,3,3,TFIID|TAF(II)130|Sp1,Sp1|TAF(II)130|TFIID,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,17483474,Sp1,TFIID,"TBP-associated factor 4 (TAF4), an essential subunit of the TFIID complex acts as a coactivator for multiple transcriptional regulators, including Sp1 and CREB.",0.18,PMID.dPMID17483474.s5.p2,3,3,TAF4|TFIID|Sp1,Sp1|TAF4|TFIID,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1820211,Sp1,TFIID,"First, it demonstrates that heat-treated extracts are not appropriate for examination of the involvement of TFIID in the transcription of Sp1-activated promoters.",0.05,PMID.dPMID1820211.s1.p0,2,2,TFIID|Sp1,Sp1|TFIID,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.5.4.0.1,6909,9606,GO:0016564,GO:0045892,18640248,Sp1,Tbx2,Functional characterization of cis-acting elements involved in basal transcription of the human Tbx2 gene: a new insight into the role of Sp1 in transcriptional regulation.,0.62,PMID.dPMID18640248.s4.p0,2,2,Tbx2|Sp1,Sp1|Tbx2,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.3.1.0.1,7020,9606,,,10393330,Sp1,AP-2,AP-2 enhances Sp1-dependent activation of the growth-regulated human ATP/ADP translocator.,0.35,PMID.dPMID10393330.s7.p0,2,2,AP-2|Sp1,AP-2|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,1.3.1.0.3,7022,9606,,,12733991,Sp1,AP-2gamma,Characterization of the human activator protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast tumour cells.,0.66,PMID.dPMID12733991.s9.p0,3,3,AP-2gamma|Sp1|Sp3,AP-2gamma|Sp1|Sp3,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.7.2.0.1,7024,9606,,GO:0006357,2819862,Sp1,LSF,"Thus, LSF is distinguishable from Sp1 in both its transcriptional and DNA-binding properties.",0.52,PMID.dPMID2819862.s1.p0,2,2,LSF|Sp1,LSF|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,12972613,Sp1,EAR3,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.32,PMID.dPMID12972613.s0.p21,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,12972613,Sp1,EAR3,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.24,PMID.dPMID12972613.s0.p10,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.3.2.2.1,7027,9606,,GO:0006357,12788094,Sp1,DP1,"Cotransfection assays showed that activation of dhfr transcription by expression of E2F1/DP1 requires the reiterated Sp1 elements, whereas activation by Sp1 was enhanced by the deletion of the E2F element.",0.37,PMID.dPMID12788094.s2.p5,5,4,dhfr|E2F1|DP1|Sp1|Sp1,dhfr|DP1|E2F1|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.25,7071,9606,,GO:0000122,9748269,Sp1,TIEG,We and others have recently reported that the transforming growth factor (TGF)-beta-regulated gene TIEG encodes a new Sp1-like protein that inhibits cell growth in cultured cells.,0.06,PMID.dPMID9748269.s6.p0,2,2,TIEG|Sp1,Sp1|TIEG,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11278953,Sp1,p53,"Together, these results suggest a model in which p53 requires the cooperation of Sp1 or a Sp1-like factor to mediate transcriptional activation of the human BAX promoter.",0.70,PMID.dPMID11278953.s0.p1,4,3,p53|Sp1|Sp1|BAX,BAX|p53|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11278953,Sp1,p53,"Together, these results suggest a model in which p53 requires the cooperation of Sp1 or a Sp1-like factor to mediate transcriptional activation of the human BAX promoter.",0.60,PMID.dPMID11278953.s0.p0,4,3,p53|Sp1|Sp1|BAX,BAX|p53|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15710382,Sp1 transcription factor,p53,This suggests that wild-type p53 mediates transcriptional repression of cyclin B1 through the Sp1 transcription factor.,0.51,PMID.dPMID15710382.s0.p0,2,2,p53|Sp1 transcription factor,p53|Sp1 transcription factor,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15249123,Sp1,p53,"Further, over-expression of p53 strongly suppressed the stimulating effect of Sp1 on hGR promoter activity.",0.38,PMID.dPMID15249123.s2.p0,2,2,p53|Sp1,p53|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11559575,transcription factor Sp1,p53,p53 significantly inhibited the transcription of VPF/VEGF involving the transcription factor Sp1.,0.22,PMID.dPMID11559575.s5.p3,4,3,p53|VPF|VEGF|transcription factor Sp1,p53|transcription factor Sp1|VEGF|VPF,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15249123,Sp1,p53,"We concluded that Sp1 activates the hGR gene promoter, at least in part, by acting on the first GC box in promoter 1C, while p53 suppresses the transactivation by Sp1.",0.16,PMID.dPMID15249123.s1.p2,3,2,Sp1|p53|Sp1,p53|Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15302882,Sp1,p53,Expression of p53 further enhanced the level of Vpr-Sp1-mediated transcription activation of p21 through the sequence spanning -84 to -74 and increased the DNA binding activity of Sp1 in the presence of Vpr.,0.05,PMID.dPMID15302882.s2.p1,5,3,p53|Vpr|Sp1|Sp1|Vpr,p53|Sp1|Vpr,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,14712219,transcription factor Sp1,p53,"These deletions cause the losses of p53-dependent transcriptional repression binding site, transcription factor Sp1 binding site, and growth-suppressive effect domain, leading to cell proliferation and transformation.",0.05,PMID.dPMID14712219.s1.p0,2,2,p53|transcription factor Sp1,p53|transcription factor Sp1,-->
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15737644,Sp1 transcription factor,p73,This suggests that p73 mediates transcriptional repression through the Sp1 transcription factor.,0.74,PMID.dPMID15737644.s0.p0,2,2,p73|Sp1 transcription factor,p73|Sp1 transcription factor,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,20528922,Sp1,p73,"Treatment of cells with Sp1 RNAi and Sp1 inhibitor functionally suppress TAp73 expression, indicating positive regulation of P1 by the Sp1 protein.",0.63,PMID.dPMID20528922.s3.p5,4,2,Sp1|Sp1|p73|Sp1,p73|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16234237,Sp1,p73,"Mutations in the Sp1 transcription factor-binding sites of the proximal core promoter region significantly abolished p73-induced repression, suggesting that the effect is mediated by Sp1.",0.45,PMID.dPMID16234237.s2.p2,3,2,Sp1 transcription factor|p73|Sp1,p73|Sp1|Sp1 transcription factor,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15737644,Sp1,p73,p73-mediated attenuation of the cyclin B1 promoter is dependent on the presence of functional Sp1-binding sites and is independent of the NF-Y-binding sites.,0.15,PMID.dPMID15737644.s1.p0,2,2,p73|Sp1,p73|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,16518840,Sp1,VDR,"Taken together, our results suggest that VDR functions as the transactivation component of the VDR/Sp1 complex to trigger gene expression.",0.05,PMID.dPMID16518840.s0.p1,3,2,VDR|VDR|Sp1,Sp1|VDR,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,9199306,Sp1,YY1,"In contrast, physical interaction is not necessary for YY1 to repress Sp1- and CREB-mediated transcription.",0.55,PMID.dPMID9199306.s2.p0,3,3,YY1|Sp1|CREB,CREB|Sp1|YY1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.3,7546,9606,,,10984499,Sp1,ZIC2,ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene.,0.68,PMID.dPMID10984499.s9.p1,3,3,ZIC2|Sp3|Sp1,Sp1|Sp3|ZIC2,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.3,7546,9606,,,10984499,Sp1,Zic2,"On the other hand, Zic2 and Sp3 inhibit Sp1-induced activation of the D(1A) gene in an AR1-dependent manner.",0.01,PMID.dPMID10984499.s2.p1,4,4,Zic2|Sp3|Sp1|AR1,AR1|Sp1|Sp3|Zic2,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,9144414,Sp1,ZBP-89,"Immunocytochemical studies confirmed that ZBP-89 expression is elevated in neoplastic tissue and chronic gastritis, whereas Sp1 expression was nearly unchanged.",0.18,PMID.dPMID9144414.s1.p0,2,2,ZBP-89|Sp1,Sp1|ZBP-89,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.23,8462,9606,,GO:0000122,15531587,Sp1,KLF11,KLF11-mediated repression antagonizes Sp1/sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signaling.,1.32,PMID.dPMID15531587.s7.p0,3,3,KLF11|Sp1|caveolin-1,caveolin-1|KLF11|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.23,8462,9606,,GO:0000122,17479246,Sp1,TIEG2,"AIMS/HYPOTHESIS: The Krppel-like factor 11 (KLF11; TIEG2), a pancreas-enriched Sp1-like transcription factor, is a known negative regulator of pancreatic exocrine cell growth.",0.63,PMID.dPMID17479246.s9.p2,3,2,KLF11|TIEG2|Sp1,KLF11|Sp1|TIEG2,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.23,8462,9606,,GO:0000122,15531587,Sp1,KLF11,The displacement of KLF11 results from both a down-regulation of its expression and competition by Sp1 for DNA binding.,0.31,PMID.dPMID15531587.s1.p0,2,2,KLF11|Sp1,KLF11|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.23,8462,9606,,GO:0000122,15024015,Sp1,TIEG2,These results showed that TIEG2 and Sp3 were repressors at the CACCC element but were activators at proximal Sp1 overlapping sites of MAO B.,0.25,PMID.dPMID15024015.s4.p1,3,3,TIEG2|Sp3|Sp1,Sp1|Sp3|TIEG2,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,17085651,Sp1,KLF4,"Enforced KLF4 expression repressed Sp1 expression at the promoter activity, mRNA, and protein levels.",1.88,PMID.dPMID17085651.s3.p0,2,2,KLF4|Sp1,KLF4|Sp1,p
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,17085651,Sp1,KLF4,CONCLUSIONS: Our data suggests that disruption of KLF4-mediated negative regulation contributes to the molecular events of Sp1 overexpression and to the development and progression of human gastric cancer,1.25,PMID.dPMID17085651.s0.p0,2,2,KLF4|Sp1,KLF4|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,3.5.3.0.9,10379,9606,,,14645369,transcription factor Sp1,p48,"We now have purified KBP from HeLa cell nuclear extracts by ion-exchange and DNA-affinity chromatography steps and then identified four constituent proteins of the KBP complex by mass spectrometry and immunochemistry: KBP120 and KBP45 are the damaged DNA-binding protein subunits, p127 DDB1 and p48 DDB2, respectively; KBP100 is the transcription factor Sp1; and KBP35 is the heterogeneous nuclear ribonucleoprotein A1.",0.11,PMID.dPMID14645369.s4.p25,9,4,KBP|KBP|KBP|KBP|p48|DDB2|KBP|transcription factor Sp1|KBP,DDB2|KBP|p48|transcription factor Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2.3.2.2.26,28999,9606,,,20141633,Sp1,KLF15,"Using Drosophila SL2 cells, we showed that KLF15 and Sp1 trans-activated the LRP5 promoter in a manner dependent on the presence of Sp1-binding and KLF15-binding motifs.",0.26,PMID.dPMID20141633.s2.p3,5,3,KLF15|Sp1|LRP5|Sp1|KLF15,KLF15|LRP5|Sp1,
2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,6.5.2.0.3,30009,9606,,GO:0006355,17705132,Sp1,T-BET,Transcriptional control of human T-BET expression: the role of Sp1.,0.71,PMID.dPMID17705132.s9.p0,2,2,T-BET|Sp1,Sp1|T-BET,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.5.0.48,639,9606,,GO:0000122,18604866,SP3,PRDM1,"Transcription of PRDM1, the master regulator for plasma cell differentiation, depends on an SP1/SP3/EGR-1 GC-box.",0.30,PMID.dPMID18604866.s7.p1,4,4,PRDM1|SP1|SP3|EGR-1,EGR-1|PRDM1|SP1|SP3,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.2.1.2,1958,9606,,GO:0045941,11316810,Sp3,Egr-1,"Whereas binding of either Sp1 or Sp3 induced promoter function, Egr-1 repressed Sp3-mediated PTP1B promoter activation.",0.12,PMID.dPMID11316810.s2.p5,5,4,Sp1|Sp3|Egr-1|Sp3|PTP1B,Egr-1|PTP1B|Sp1|Sp3,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20382698,Sp3,ERalpha,RNA interference studies confirmed that basal expression of ERalpha was dependent on Sp1 but not Sp3 or Sp4 in MCF-7 cells.,0.18,PMID.dPMID20382698.s4.p0,3,3,ERalpha|Sp3|Sp4,ERalpha|Sp3|Sp4,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,16300938,Sp3,Ets-1,"EMSAs and supershift assays showed that Sp1 and Sp3 both bind to the Sp1/Sp3 binding sites, whereas occupation of the Ets-1 binding site appears to be Sp3-dependent.",0.39,PMID.dPMID16300938.s6.p14,6,3,Sp1|Sp3|Sp1|Sp3|Ets-1|Sp3,Ets-1|Sp1|Sp3,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,14742449,Sp3,HIF-1,"However, HIF-1 alone was not sufficient to activate transcription in hypoxic conditions but, rather, required Sp1/Sp3, which binds to a cluster of GC-rich sequences adjacent to the HRE.",0.11,PMID.dPMID14742449.s2.p1,3,3,HIF-1|Sp1|Sp3,HIF-1|Sp1|Sp3,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,14767471,Sp3,JunD,JunD binding was abolished on mutation of the AP-1 site and Sp3 binding was abolished on mutation of the 7 bp at -861/-855; binding of the purified Sp3 protein to the 25 bp probe was similarly abolished on mutation of the newly discovered Sp3 binding site (TGCTGCA).,0.02,PMID.dPMID14767471.s2.p3,5,3,JunD|AP-1|Sp3|Sp3|Sp3,AP-1|JunD|Sp3,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,15044214,Sp3,SMAD3,"Analysis of the human SMAD3 promoter demonstrates that isoprenoid regulation of SMAD3 expression is dependent on Sp1/Sp3 activity, although farnesyl-mediated pathways may be acting through a secondary mechanism as well.",1.00,PMID.dPMID15044214.s1.p2,3,2,SMAD3|SMAD3|Sp3,SMAD3|Sp3,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,4.2.1.0.1,4800,9606,,GO:0006355,16024108,Sp3,NF-YA,Overexpression of NF-YA had a synergistic effect on Sp1 overexpression and an additive effect on Sp3 overexpression.,0.07,PMID.dPMID16024108.s2.p1,3,3,NF-YA|Sp1|Sp3,NF-YA|Sp1|Sp3,<--
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9224612,Sp3,Sp1,"We have also previously determined that Sp3 and Sp1, two members of the Sp family of transcription factors, encode the 115 and 95 kDa RCPs respectively and that Rb stimulates Sp1/Sp3-mediated transcription in vivo.",0.83,PMID.dPMID9224612.s4.p9,5,3,Sp3|Sp1|Rb|Sp1|Sp3,Rb|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12972613,Sp3,Sp1,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.76,PMID.dPMID12972613.s0.p17,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11004694,Sp3,Sp1,These data suggest that a high Sp1/Sp3 expression ratio and a peculiar expression pattern of the Ets transcription factors are involved in the overexpression of CD30 and might contribute to the transformation of CD30(+) tumour cells,0.55,PMID.dPMID11004694.s0.p0,4,3,Sp1|Sp3|CD30|CD30,CD30|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9867805,Sp3,Sp1,"Neither Sp3 nor Sp4 was able to activate transcription in those cells, and transcriptional activation by Sp1 was repressed by Sp3 or Sp4.",0.53,PMID.dPMID9867805.s2.p5,5,3,Sp3|Sp4|Sp1|Sp3|Sp4,Sp1|Sp3|Sp4,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15857802,Sp3,Sp1,Identification of the promoter of human transcription factor Sp3 and evidence of the role of factors Sp1 and Sp3 in the expression of Sp3 protein.,0.52,PMID.dPMID15857802.s8.p4,4,2,Sp3|Sp1|Sp3|Sp3,Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17150965,Sp3,Sp1,These findings suggest that Sp1/Sp3 is involved in controlling the HU/IL-6-induced reactivation of HIV-1 in latently infected cells,0.46,PMID.dPMID17150965.s0.p0,3,3,Sp1|Sp3|IL-6,IL-6|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12513689,Sp3,Sp1,"Whereas overexpression of NF-Y or E2F had an additive effect on Sp1 overexpression, the activation of Sp1 transcription due to Sp1 was counteracted by Sp3 overexpression.",0.46,PMID.dPMID12513689.s2.p8,5,3,NF|Sp1|Sp1|Sp1|Sp3,NF|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16943418,Sp3,Sp1,"Trichostatin A (TSA) induced histone acetylation and gene activation in JAR cells that prevailed in the absence of changes in Sp1/Sp3 expression, their binding activity, disassociation of the histone deacetylase/mSin3A complex from the Sp1 site, or demethylation of the promoter.",0.40,PMID.dPMID16943418.s9.p2,4,3,TSA|Sp1|Sp3|Sp1,Sp1|Sp3|TSA,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9242631,Sp3,Sp1,"Finally, a combination of cell transfections and DNA-binding assays excluded that COL1A2 transactivation involves the retinoblastoma gene product (pRb), an activator of Sp1, the pRb-related protein p107, an inhibitor of Sp1, or the Sp1-related repressor, Sp3",0.37,PMID.dPMID9242631.s0.p9,5,3,COL1A2|Sp1|Sp1|Sp1|Sp3,COL1A2|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12513689,Sp3,Sp1,"These results help to explain the complex regulation of the Sp1 gene, which depends on the relative amounts of Sp1, Sp3, E2F and NF-Y proteins in the cell.",0.36,PMID.dPMID12513689.s0.p1,4,3,Sp1|Sp1|Sp3|NF,NF|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,10649433,Sp3,Sp1,Differential role for Sp1/Sp3 transcription factors in the regulation of the promoter activity of multiple cyclin-dependent kinase inhibitor genes.,0.28,PMID.dPMID10649433.s8.p0,2,2,Sp1|Sp3,Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,14551190,Sp3,Sp1,"Western blot analysis demonstrated decreased expression of transcriptional activators (pCREB-1, pATF-1, USF-1, c-Fos, c-Jun, Sp1, and Sp3) and/or increased expression of repressors (short Sp3 isoforms), whereas normal AP2alpha levels were retained.",0.25,PMID.dPMID14551190.s2.p4,4,3,USF-1|Sp1|Sp3|Sp3,Sp1|Sp3|USF-1,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15247906,Sp3,Sp1,Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells.,0.23,PMID.dPMID15247906.s9.p0,4,3,Sp1|Sp3|15-lipoxygenase 2|15-LOX2,15-lipoxygenase 2|15-LOX2|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15951564,Sp3,Sp1,"In this study, the roles of Sp1/Sp3 transcription factors in the regulation of the activity of human telomerase reverse transcriptase (hTERT) promoter in response to ceramide were examined in the A549 human lung adenocarcinoma cells.",0.22,PMID.dPMID15951564.s8.p0,3,3,Sp1|Sp3|telomerase reverse transcriptase,Sp1|Sp3|telomerase reverse transcriptase,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12513689,Sp3,Sp1,"Whereas overexpression of NF-Y or E2F had an additive effect on Sp1 overexpression, the activation of Sp1 transcription due to Sp1 was counteracted by Sp3 overexpression.",0.19,PMID.dPMID12513689.s2.p9,5,3,NF|Sp1|Sp1|Sp1|Sp3,NF|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12888570,Sp3,Sp1,"Because we demonstrated previously that Sp1 was a strong activator of COL2A1 gene expression via the -63/+1 promoter region, whereas Sp3 overexpression blocked Sp1-induced promoter activity and inhibited COL2A1 gene transcription, we conclude that IL-1 beta down-regulation of that gene, as we found previously for transforming growth factor-beta 1, is mediated by an increase in the Sp3/Sp1 ratio.",0.15,PMID.dPMID12888570.s3.p1,7,3,Sp1|COL2A1|Sp3|Sp1|COL2A1|Sp3|Sp1,COL2A1|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12972613,Sp3,Sp1,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.12,PMID.dPMID12972613.s0.p5,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15706661,Sp3,Sp1,"In Drosophila S2 cells, both Sp1 and Sp3 activated the basal SOD2 promoter (88.1 +/- 39.4 fold vs. 10.3 +/- 3.5 fold, respectively), demonstrating a positive, yet lower transcriptional regulatory function for Sp3.",0.10,PMID.dPMID15706661.s4.p3,4,3,Sp1|Sp3|SOD2|Sp3,SOD2|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12513689,Sp3,Sp1,"Whereas overexpression of NF-Y or E2F had an additive effect on Sp1 overexpression, the activation of Sp1 transcription due to Sp1 was counteracted by Sp3 overexpression.",0.08,PMID.dPMID12513689.s2.p7,5,3,NF|Sp1|Sp1|Sp1|Sp3,NF|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12151347,Sp3,Sp1,"Thus, our observations have uncovered an antiproliferative pathway for DIM that implicates Sp1/Sp3-induced expression of p21 as a target for cell cycle control in human breast cancer cells",0.07,PMID.dPMID12151347.s0.p0,3,3,Sp1|Sp3|p21,p21|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,8523525,Sp3,Sp1,"However, in HeLa and Drosophila SL-2 cells, Sp1 acted as a transcriptional activator of the LTRs, while Sp3 acted as a repressor of Sp1-mediated transcriptional activation.",0.06,PMID.dPMID8523525.s2.p0,3,2,Sp1|Sp3|Sp1,Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9224612,Sp3,Sp1,"We have also previously determined that Sp3 and Sp1, two members of the Sp family of transcription factors, encode the 115 and 95 kDa RCPs respectively and that Rb stimulates Sp1/Sp3-mediated transcription in vivo.",0.05,PMID.dPMID9224612.s4.p7,5,3,Sp3|Sp1|Rb|Sp1|Sp3,Rb|Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15951564,Sp3,Sp1,"Treatment with C6-ceramide inhibited the trans-activation function of overexpressed Sp1, whereas it induced the repressor effects of exogenous Sp3 on the hTERT promoter.",0.01,PMID.dPMID15951564.s5.p0,2,2,Sp1|Sp3,Sp1|Sp3,<->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,7559627,Sp3,Sp4,"Furthermore, we show that Sp4-mediated transcriptional activation can be repressed by Sp3.",1.03,PMID.dPMID7559627.s1.p0,2,2,Sp4|Sp3,Sp3|Sp4,
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,1.3.1.0.3,7022,9606,,,12733991,Sp3,AP-2gamma,Characterization of the human activator protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast tumour cells.,0.66,PMID.dPMID12733991.s9.p1,3,3,AP-2gamma|Sp1|Sp3,AP-2gamma|Sp1|Sp3,-->
2.3.1.0.4,6670,9606,GO:0016563|GO:0016564,GO:0006355|GO:0016481,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,12972613,Sp3,EAR3,"Such cross talk among EAR3, TFIIB, and Sp1/Sp3 reveals repression of hLHR gene transcription by nuclear orphan receptors is achieved via perturbation of communication between Sp1/Sp3 at the Sp1-1 site and the basal transcription initiator complex",0.24,PMID.dPMID12972613.s0.p15,8,5,EAR3|TFIIB|Sp1|Sp3|LHR|Sp1|Sp3|Sp1,EAR3|LHR|Sp1|Sp3|TFIIB,
2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20382698,Sp4,ERalpha,RNA interference studies confirmed that basal expression of ERalpha was dependent on Sp1 but not Sp3 or Sp4 in MCF-7 cells.,0.34,PMID.dPMID20382698.s4.p1,3,3,ERalpha|Sp3|Sp4,ERalpha|Sp3|Sp4,
2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10501656,SPR1,AP-1,"AP-1 is the cis element mediating the transcriptional activation of SPR1 by PMA, which induces the expression of AP-1 factors in 21MT-2 cells.",0.43,PMID.dPMID10501656.s3.p0,3,2,AP-1|SPR1|AP-1,AP-1|SPR1,
2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10501656,SPR1,AP-1,Mutation of the AP-1 site abolishes the induction of SPR1 expression by PMA.,0.13,PMID.dPMID10501656.s2.p0,2,2,AP-1|SPR1,AP-1|SPR1,
2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9867805,Sp4,Sp1,"Neither Sp3 nor Sp4 was able to activate transcription in those cells, and transcriptional activation by Sp1 was repressed by Sp3 or Sp4.",0.52,PMID.dPMID9867805.s2.p8,5,3,Sp3|Sp4|Sp1|Sp3|Sp4,Sp1|Sp3|Sp4,
2.3.1.0.5,6671,9606,GO:0003702,GO:0006357,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,19853299,SP-4,SP-1,"Additionally EGF induced binding activity to SP-1, but reduced the expression of SP-1 and SP-4.",0.09,PMID.dPMID19853299.s3.p4,4,3,EGF|SP-1|SP-1|SP-4,EGF|SP-1|SP-4,
5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,15592518,SP100,ETS1,"To further understand the functional relationship between ETS1 and SP100, cDNA microarray analysis was utilized to assess reprogramming of gene expression by ETS1 and SP100.",0.41,PMID.dPMID15592518.s3.p3,4,2,ETS1|SP100|ETS1|SP100,ETS1|SP100,
5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,15592518,SP100,ETS1,"As ETS1 is functionally important in promoting angiogenesis, we tested the hypothesis that ETS1 activity is negatively modulated by SP100 in endothelial cells.",0.09,PMID.dPMID15592518.s5.p2,3,2,ETS1|ETS1|SP100,ETS1|SP100,
3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,16149049,PU.1,Runx1,Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1.,0.72,PMID.dPMID16149049.s10.p0,2,2,Runx1|PU.1,PU.1|Runx1,
3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,2.2.1.0.2,2624,9606,GO:0030528,GO:0010552|GO:0045944,19620289,Sfpi1,GATA-2,"Surprisingly, GATA-2 also negatively regulates the expression of crucial myeloid transcription factors, such as Sfpi1 and Cebpa.",0.10,PMID.dPMID19620289.s3.p0,3,3,GATA-2|Sfpi1|Cebpa,Cebpa|GATA-2|Sfpi1,
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,2.3.2.2.20,688,9606,GO:0003702,,18774944,SREBP-1,KLF5,KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.,0.07,PMID.dPMID18774944.s8.p0,3,3,KLF5|SREBP-1|fatty acid synthase,fatty acid synthase|KLF5|SREBP-1,
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,1.1.2.0.1,1385,9606,,GO:0045944,17669268,SREBP-1c,CREB1,"The data from our experiments indicate that CREB1 overexpression inhibits SREBP-1c transcription, and that this action is antagonized by CREB2, a competitive inhibitor of CREB1.",0.30,PMID.dPMID17669268.s2.p0,3,2,CREB1|SREBP-1c|CREB1,CREB1|SREBP-1c,
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,17669268,SREBP-1c,PPAR,"Furthermore, since PPARs are able to repress SREBP-1c transcription, we investigated whether clenbuterol and CREB1 function via a pathway involving PPAR activation.",0.52,PMID.dPMID17669268.s1.p0,4,3,PPAR|SREBP-1c|CREB1|PPAR,CREB1|PPAR|SREBP-1c,
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,10409739,SREBP-1,PPARgamma,"We investigated whether PPARgamma expression is dependent on the activity of adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1 (ADD-1/SREBP-1), another transcription factor associated with both adipocyte differentiation and cholesterol homeostasis.",0.21,PMID.dPMID10409739.s6.p1,3,3,PPARgamma|ADD-1|SREBP-1,ADD-1|PPARgamma|SREBP-1,-->
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,15881188,SREBP-1c,SREBP-2,"While SREBP-2 regulates expression of genes involved in cholesterol biosynthesis and LDL receptor, SREBP-1c controls fatty acid synthesis.",1.46,PMID.dPMID15881188.s5.p0,2,2,SREBP-2|SREBP-1c,SREBP-1c|SREBP-2,
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,2.1.2.7.2,7376,9606,,GO:0010552|GO:0016481|GO:0034339,11504730,SREBP-1c,NR1H2,"The nuclear receptors liver X receptor alpha (LXRalpha) (NR1H3) and LXRbeta (NR1H2) are important regulators of genes involved in lipid metabolism, including ABCA1, ABCG1, and sterol regulatory element-binding protein-1c (SREBP-1c).",0.54,PMID.dPMID11504730.s7.p7,5,5,NR1H3|NR1H2|ABCA1|ABCG1|SREBP-1c,ABCA1|ABCG1|NR1H2|NR1H3|SREBP-1c,
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,2.1.6.0.2,8431,9606,,GO:0034339,15123650,SREBP-1,SHP,"Herein, we report that the human SHP promoter (hSHP) is activated by sterol regulatory element-binding protein-1 (SREBP-1), which regulates the expression of various genes involved in cholesterol and fatty acid synthesis.",0.06,PMID.dPMID15123650.s9.p1,3,3,SHP|SHP|SREBP-1,SHP|SREBP-1,-->
1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,2.1.2.7.1,10062,9606,,GO:0010552|GO:0034339|GO:0043193,11504730,SREBP-1c,NR1H3,"The nuclear receptors liver X receptor alpha (LXRalpha) (NR1H3) and LXRbeta (NR1H2) are important regulators of genes involved in lipid metabolism, including ABCA1, ABCG1, and sterol regulatory element-binding protein-1c (SREBP-1c).",0.03,PMID.dPMID11504730.s7.p6,5,5,NR1H3|NR1H2|ABCA1|ABCG1|SREBP-1c,ABCA1|ABCG1|NR1H2|NR1H3|SREBP-1c,
1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,7862668,SREBP-2,SREBP-1,These findings suggest that SREBP-1 is responsible for basal transcription of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl CoA synthase genes in hamster liver and that SREBP-2 is responsible for the increased transcription that follows sterol depletion with a bile acid-binding resin and a cholesterol synthesis inhibitor.,0.19,PMID.dPMID7862668.s0.p0,2,2,SREBP-1|SREBP-2,SREBP-1|SREBP-2,
1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,20385828,SREBP-2,SREBP-1c,Here we demonstrate that macrophage colony-stimulating factor (M-CSF)-dependent differentiation of primary human monocytes from healthy volunteers induces transcription of SREBP-1c target genes required for fatty acid (FA) biosynthesis and impairs transcription of SREBP-2 target genes required for cholesterol synthesis.,0.15,PMID.dPMID20385828.s5.p0,2,2,SREBP-1c|SREBP-2,SREBP-1c|SREBP-2,
1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,14765107,SREBP2,ATF6,ATF6 modulates SREBP2-mediated lipogenesis.,1.44,PMID.dPMID14765107.s11.p0,2,2,ATF6|SREBP2,ATF6|SREBP2,x
1.2.6.3.2,6721,9606,GO:0003702,GO:0045944,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,14765107,SREBP2,ATF6,Our results provide a novel mechanism by which ATF6 antagonizes SREBP2 to regulate the homeostasis of lipid and glucose,0.02,PMID.dPMID14765107.s0.p0,2,2,ATF6|SREBP2,ATF6|SREBP2,
5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,3.5.2.2.1,2002,9606,GO:0016563,GO:0045893|GO:0045941|GO:0045944,12599056,SRF,Elk1,"HBx activated the transcriptional ability of Elk1, whereas LHDAg activated the transcriptional ability of SRF.",0.12,PMID.dPMID12599056.s2.p0,2,2,Elk1|SRF,Elk1|SRF,<->
5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,3.5.3.0.6,3664,9606,,GO:0045941,17303098,SRF,LPS,"LPS does not affect the activity of SRF, but it potently inhibits both basal and inducible TCE activation.",0.54,PMID.dPMID17303098.s1.p0,2,2,LPS|SRF,LPS|SRF,
5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1909174,SRF,TFIID,"Also of interest was the finding that recombinant human TFIID expressed in bacteria cannot mediate SRF-activated transcription, although it does support basal transcription.",0.71,PMID.dPMID1909174.s1.p0,2,2,TFIID|SRF,SRF|TFIID,
5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,1.2.7.0.2,7409,9606,,,11859076,SRF,Vav,"Interestingly, Vav2 also enhances SRF through Rho GTPases, suggesting that Vav proteins are general regulators of SRF activation in lymphocytes.",0.61,PMID.dPMID11859076.s1.p5,4,3,Vav2|SRF|Vav|SRF,SRF|Vav|Vav2,
5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,9271374,SRF,ATF6,"More strikingly, an antisense ATF6 construct reduced serum induction of a c-fos reporter gene, suggesting that ATF6 is involved in activation of transcription by SRF.",1.05,PMID.dPMID9271374.s2.p5,4,3,ATF6|c-fos|ATF6|SRF,ATF6|c-fos|SRF,
4.1.1.1.1,6736,9606,GO:0016563,,2.2.1.0.4,2626,9606,GO:0003702|GO:0003704,GO:0006355|GO:0043193|GO:0045893|GO:0045944,17986281,SRY,GATA-4,"RESULTS: RT-PCR and immunohistochemical studies revealed that SOX9, DAX-1, Ad4BP/SF-1, WT-1, GATA-4 and MIS were expressed in testicular tissues of SRY-negative XX males.",0.03,PMID.dPMID17986281.s4.p19,7,6,SOX9|DAX-1|Ad4BP|SF-1|GATA-4|MIS|SRY,Ad4BP|DAX-1|GATA-4|MIS|SF-1|SOX9|SRY,
4.1.1.1.1,6736,9606,GO:0016563,,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,15084848,Sry,SOX9,These findings suggest that SOX9 expression probably plays some role in Sry-independent testicular differentiation in ovarian Sertoli-stromal cell tumors,0.50,PMID.dPMID15084848.s0.p0,2,2,SOX9|Sry,SOX9|Sry,
4.1.1.1.1,6736,9606,GO:0016563,,4.1.1.5.2,6662,9606,GO:0003702|GO:0003704,GO:0006357,15385158,Sry,Sox9,The related autosomal gene Sox9 is up-regulated shortly after the onset of Sry transcription and is thought essential for the differentiation of Sertoli cells.,0.35,PMID.dPMID15385158.s7.p0,2,2,Sox9|Sry,Sox9|Sry,
4.1.1.1.1,6736,9606,GO:0016563,,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,11278460,SRY,WT1,"These observations, together with the overlapping expression patterns of WT1 and SRY in human gonads, led us to propose that WT1 regulates SRY in the initial sex determination process in humans and activates a cascade of genes ultimately leading to the complete organogenesis of the testis.",1.94,PMID.dPMID11278460.s0.p5,4,2,WT1|SRY|WT1|SRY,SRY|WT1,<--
4.1.1.1.1,6736,9606,GO:0016563,,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,15665984,SRY,WT1,"The WT1 transcription factor regulates SRY expression during the initial steps of the sex determination process in humans, activating a gene cascade leading to testis differentiation.",1.76,PMID.dPMID15665984.s10.p0,2,2,WT1|SRY,SRY|WT1,<--
4.1.1.1.1,6736,9606,GO:0016563,,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,12970737,SRY,WT1,"Wildtype WT1 is recruited to SRY-binding sites in an SRY-dependent manner, whereas DDS mutants are not recruited as efficiently.",0.11,PMID.dPMID12970737.s1.p1,3,2,WT1|SRY|SRY,SRY|WT1,<--
4.1.1.1.1,6736,9606,GO:0016563,,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,11278460,SRY,WT1,"These observations, together with the overlapping expression patterns of WT1 and SRY in human gonads, led us to propose that WT1 regulates SRY in the initial sex determination process in humans and activates a cascade of genes ultimately leading to the complete organogenesis of the testis.",0.11,PMID.dPMID11278460.s0.p3,4,2,WT1|SRY|WT1|SRY,SRY|WT1,<--
6.2.1.0.1,6772,9606,,,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,15996661,STAT1,Ets-1,"In contrast, Ets-1 siRNA decreased the expression of STAT1 and Nmi proteins.",0.71,PMID.dPMID15996661.s2.p0,3,3,Ets-1|STAT1|Nmi,Ets-1|Nmi|STAT1,
6.2.1.0.1,6772,9606,,,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,12705898,STAT1,c-fos,"Thus, under overexpression of c-fos gene, c-Fos inactivates STAT1 to down-regulate p21waf1/cip1 gene expression in the lymphocytes of patients with RA, and in this way may enhance proliferation of lymphocytes.",0.36,PMID.dPMID12705898.s0.p1,4,3,c-fos|c-Fos|STAT1|cip1,c-fos|c-Fos|cip1|STAT1,-->
6.2.1.0.1,6772,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17211884,STAT1,c-MYC,"Using a cell line in which EBNA2 and c-myc can be regulated at will, we show that c-MYC negatively regulates STAT1, the central player linking the Type-I and Type-II interferon response.",1.67,PMID.dPMID17211884.s3.p2,3,2,c-myc|c-MYC|STAT1,c-myc|c-MYC|STAT1,-->
6.2.1.0.1,6772,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10625620,Stat1,c-Myc,"Interestingly, both IL-3 and IFN-gamma induce expression of the c-Myc gene that is not dependent on the Stat1 activity.",0.56,PMID.dPMID10625620.s2.p5,4,4,IL-3|IFN-gamma|c-Myc|Stat1,c-Myc|IFN-gamma|IL-3|Stat1,-->
6.2.1.0.1,6772,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,20185553,STAT1,STAT3,"Consistent with a role for endogenous A(2A)ARs in regulating STAT protein levels, prolonged exposure of endogenous A(2A)ARs in endothelial cells with ZM241385 in vitro triggered the up-regulation of STAT3, whereas deletion of the A(2A)AR in vivo potentiated STAT1 expression and phosphorylation.",0.34,PMID.dPMID20185553.s1.p2,3,3,STAT|STAT3|STAT1,STAT|STAT1|STAT3,
6.2.1.0.1,6772,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,11171987,Stat1,Stat3,Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1.,0.18,PMID.dPMID11171987.s8.p0,2,2,Stat3|Stat1,Stat1|Stat3,
6.2.1.0.1,6772,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,10753837,STAT1,STAT3,"In interleukin-6 (IL-6)-dependent KT-3 cells, STAT3 was found to be conjugated by exogenous biotinylated Ub and to be degraded in a proteasome-dependent manner, whereas expression levels of STAT1, STAT5, or mitogen-activated protein kinase were not affected.",0.10,PMID.dPMID10753837.s4.p2,3,3,IL-6|STAT3|STAT1,IL-6|STAT1|STAT3,
6.2.1.0.1,6772,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,19626047,STAT1,STAT3,"Here, the function of STAT3 in the negative regulation of STAT1 apoptotic pathway was investigated by RNA interference-mediated STAT3 silencing in human malignant T lymphocytes.",0.05,PMID.dPMID19626047.s4.p0,3,2,STAT3|STAT1|STAT3,STAT1|STAT3,
6.2.1.0.1,6772,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,19476491,STAT1,STAT3,"This effect was counteracted by the STAT3 oligodeoxynucleotide, which was found to efficiently inhibit STAT1.",0.04,PMID.dPMID19476491.s1.p0,2,2,STAT3|STAT1,STAT1|STAT3,
6.2.1.0.1,6772,9606,,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,11109966,STAT1,Transcription factor,Transcription factor STAT1 is bound to proteasomes in A-431 cells.,0.30,PMID.dPMID11109966.s0.p0,2,2,Transcription factor|STAT1,STAT1|Transcription factor,
6.2.1.0.1,6772,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17085014,STAT1,p53,"However, non-transcriptional mechanisms such as STAT1 interaction with TRADD, p53, or HDAC have been implicated in the regulation of cell death by STAT1.",0.45,PMID.dPMID17085014.s2.p8,5,4,STAT1|TRADD|p53|HDAC|STAT1,HDAC|p53|STAT1|TRADD,
6.2.1.0.1,6772,9606,,,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,19124747,STAT1,foxp3,Regulation of the foxp3 gene by the Th1 cytokines: the role of IL-27-induced STAT1.,0.18,PMID.dPMID19124747.s7.p0,2,2,foxp3|STAT1,foxp3|STAT1,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,3.1.6.4.2,463,9606,GO:0016564,GO:0000122|GO:0006355,14715251,STAT3,ATBF1,We present here experimental evidence that ATBF1 is a new regulatory factor for STAT3-mediated signal transduction through its interaction with PIAS3.,0.58,PMID.dPMID14715251.s4.p0,3,3,ATBF1|STAT3|PIAS3,ATBF1|PIAS3|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,3.1.6.4.2,463,9606,GO:0016564,GO:0000122|GO:0006355,14715251,STAT3,ATBF1,"In the luciferase assay, ATBF1 was found to have no influence on STAT3 signaling induced by IL-6 stimulation, but it did synergistically enhance PIAS3 inhibition of activated STAT3.",0.14,PMID.dPMID14715251.s1.p6,5,4,ATBF1|STAT3|IL-6|PIAS3|STAT3,ATBF1|IL-6|PIAS3|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.4.1.4,1052,9606,,,9528783,Stat3,C/EBPdelta,Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1.,0.20,PMID.dPMID9528783.s10.p0,3,3,C/EBPdelta|Stat3|Sp1,C/EBPdelta|Sp1|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,12456685,STAT3,FKHR,"Since Akt is known to regulate gene expression through inactivation of the transcription factor FKHR (forkhead in rhabdomyosarcoma), we examined the effect of FKHR on STAT3-mediated transcriptional regulation.",1.03,PMID.dPMID12456685.s4.p5,4,3,Akt|FKHR|FKHR|STAT3,Akt|FKHR|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,12456685,STAT3,FKHR,The effect of FKHR required the presence of functional STAT3 and was abrogated by the expression of dominant negative STAT3 mutants.,0.96,PMID.dPMID12456685.s2.p1,3,2,FKHR|STAT3|STAT3,FKHR|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,12456685,STAT3,FKHR,The effect of FKHR required the presence of functional STAT3 and was abrogated by the expression of dominant negative STAT3 mutants.,0.41,PMID.dPMID12456685.s2.p0,3,2,FKHR|STAT3|STAT3,FKHR|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,18292576,STAT3,c-Fos,"The augmentative effect of c-Fos required the presence of STAT3 and 3'-hepatocyte NF-1 (HNF-1) RE, which were eliminated by dominant negative STAT3 and HNF-1alpha, respectively.",0.45,PMID.dPMID18292576.s4.p0,3,2,c-Fos|STAT3|STAT3,c-Fos|STAT3,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,12536605,Stat3,c-fos,"The expressive intensity of c-fos and c-jun proteins was positively related to p-Stat3 expression in HCCs, whereas the positive correlation of expressive intensity was only observed between c-jun protein and p-Stat3 in pericarcinomatous tissues.",0.41,PMID.dPMID12536605.s1.p1,5,3,c-fos|c-jun|Stat3|c-jun|Stat3,c-fos|c-jun|Stat3,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,18292576,STAT3,c-Fos,"Because human fetus liver cells failed to express c-Fos/STAT3/HNF-1alpha showed no CRP production, transcriptional complex formation of c-Fos/STAT3/HNF-1alpha is essential for the synergistic induction of CRP gene expression by IL-1 plus IL-6.",0.10,PMID.dPMID18292576.s1.p5,5,3,c-Fos|STAT3|c-Fos|STAT3|IL-6,c-Fos|IL-6|STAT3,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,18292576,STAT3,c-Fos,"The augmentative effect of c-Fos required the presence of STAT3 and 3'-hepatocyte NF-1 (HNF-1) RE, which were eliminated by dominant negative STAT3 and HNF-1alpha, respectively.",0.08,PMID.dPMID18292576.s4.p1,3,2,c-Fos|STAT3|STAT3,c-Fos|STAT3,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8977235,STAT3,c-fos,"Our data show that, whereas c-fos is regulated through a pathway independent of STAT activation, oncostatin M, IRF-1, and egr-1 are regulated by an STAT5-dependent pathway and fibrinogen is regulated by an STAT3-dependent pathway.",0.04,PMID.dPMID8977235.s1.p3,4,4,c-fos|STAT|STAT5|STAT3,c-fos|STAT|STAT3|STAT5,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12536605,Stat3,c-jun,"The expressive intensity of c-fos and c-jun proteins was positively related to p-Stat3 expression in HCCs, whereas the positive correlation of expressive intensity was only observed between c-jun protein and p-Stat3 in pericarcinomatous tissues.",0.26,PMID.dPMID12536605.s1.p2,5,3,c-fos|c-jun|Stat3|c-jun|Stat3,c-fos|c-jun|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,17384650,Stat3,MITF,The results were also consistent with a role for AP-2 and MITF in regulation of Bcl-2 and pStat3 in regulation of Bcl-XL.,0.05,PMID.dPMID17384650.s1.p4,5,5,AP-2|MITF|Bcl-2|Stat3|Bcl-XL,AP-2|Bcl-2|Bcl-XL|MITF|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15677471,STAT3,Myc,"Reduction in Myc protein level results in defective recruitment of the CREB-binding protein, Cdk9, and RNA polymerase complexes, indicating that Myc is necessary for STAT3 transcription.",0.92,PMID.dPMID15677471.s4.p5,4,3,Myc|CREB-binding protein|Myc|STAT3,CREB-binding protein|Myc|STAT3,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12438313,STAT3,myc,Opposite regulation of myc and p21waf1 transcription by STAT3 proteins.,0.25,PMID.dPMID12438313.s10.p1,3,3,myc|waf1|STAT3,myc|STAT3|waf1,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19259613,STAT3,MYC,"Furthermore, IL-6 up-regulated the expression of MYC via STAT3 phosphorylation and MYC bound to the promoter region of the CEBPA gene followed by the down-regulation of CEBPA expression.",0.12,PMID.dPMID19259613.s2.p2,6,4,IL-6|MYC|STAT3|MYC|CEBPA|CEBPA,CEBPA|IL-6|MYC|STAT3,-->
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.6.5.2,4613,9606,,GO:0006357,17710228,STAT3,MYCN,"Unlike other oncogenes, MYCN repressed chemokine expression in a STAT3-independent manner, requiring an E-box element in the CCL2 promoter to mediate transcriptional repression.",0.93,PMID.dPMID17710228.s2.p0,3,3,MYCN|STAT3|CCL2,CCL2|MYCN|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.1.2.5.2,5467,9606,GO:0016563|GO:0016564,GO:0000122|GO:0006357|GO:0034339,17461989,STAT3,PPARdelta,CONCLUSIONS: These findings indicate that agonist-activated PPARdelta interferes with interleukin-6-induced acute phase reaction in the liver by inhibiting the transcriptional activity of STAT3.,0.50,PMID.dPMID17461989.s1.p1,3,3,PPARdelta|interleukin-6|STAT3,interleukin-6|PPARdelta|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,12584566,STAT3,RARalpha,"Studies comparing NuMA-RARalpha with NuMA-RARalpha(deltaCC) demonstrated that the dimerization or alpha-helical coiled-coil domain of NuMA was required for homodimer formation, transcriptional repression of wild-type RARalpha, transcriptional activation of STAT3, and stability of the NuMA-RARalpha/SMRT complex.",0.92,PMID.dPMID12584566.s5.p5,5,2,RARalpha|RARalpha|RARalpha|STAT3|RARalpha,RARalpha|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,19913854,STAT3,SREBP-1c,"Consistent with these findings, we found that the human SREBP-1c promoter was positively regulated by insulin and negatively regulated by STAT3.",0.51,PMID.dPMID19913854.s1.p0,2,2,SREBP-1c|STAT3,SREBP-1c|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.1,6772,9606,,,8662591,APRF,STAT1,We further present evidence that STAT1 is activated independently from APRF suggesting that gp130 contains multiple independent STAT binding sites.,0.80,PMID.dPMID8662591.s3.p0,4,4,STAT1|APRF|gp130|STAT,APRF|gp130|STAT|STAT1,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.1,6772,9606,,,16148108,Stat3,Stat1,The increase in Stat1 expression during priming provides a mechanism by which physiological regulation of the relative abundance of Stat1 and Stat3 impacts on gene expression.,0.51,PMID.dPMID16148108.s1.p1,3,2,Stat1|Stat1|Stat3,Stat1|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.1,6772,9606,,,19502801,Stat3,Stat1,"Site-specific Stat1 phosphorylation also controls the transcriptional activities of Stat3 and Stat5 and is capable of orchestrating a complex regulatory network that influences the expression of genes involved in cell cycle control, cell-cell adhesion and signal transduction.",0.47,PMID.dPMID19502801.s1.p0,2,2,Stat1|Stat3,Stat1|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.1,6772,9606,,,18941537,Stat3,Stat1,Stat1 induces p27 Kip1 expression in Ras transformed cells at the transcriptional level through mechanisms that depend on Stat1 phosphorylation at tyrosine 701 and activation of Stat3.,0.01,PMID.dPMID18941537.s3.p1,3,2,Stat1|Stat1|Stat3,Stat1|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.6,6777,9606,,GO:0006357,10356357,STAT3,STAT5,"Consequently, a carboxyl-terminal truncated STAT5 is capable of blocking STAT3-mediated transcription of an IREtkCAT reporter construct.",0.42,PMID.dPMID10356357.s1.p0,2,2,STAT5|STAT3,STAT3|STAT5,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.6,6777,9606,,GO:0006357,8977235,STAT3,STAT5,"Our data show that, whereas c-fos is regulated through a pathway independent of STAT activation, oncostatin M, IRF-1, and egr-1 are regulated by an STAT5-dependent pathway and fibrinogen is regulated by an STAT3-dependent pathway.",0.41,PMID.dPMID8977235.s1.p5,4,4,c-fos|STAT|STAT5|STAT3,c-fos|STAT|STAT3|STAT5,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.2.1.0.6,6777,9606,,GO:0006357,8977235,STAT3,STAT5,"Gel mobility shift and immunoprecipitation/Western analysis showed that STAT5 is rapidly activated by G-CSF in cells expressing the wt G-CSF receptor, in addition to the previously reported STAT3 and STAT1.",0.17,PMID.dPMID8977235.s7.p0,3,3,STAT5|STAT3|STAT1,STAT1|STAT3|STAT5,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.3.1.0.1,7020,9606,,,17384650,Stat3,AP-2,The results were also consistent with a role for AP-2 and MITF in regulation of Bcl-2 and pStat3 in regulation of Bcl-XL.,0.50,PMID.dPMID17384650.s1.p3,5,5,AP-2|MITF|Bcl-2|Stat3|Bcl-XL,AP-2|Bcl-2|Bcl-XL|MITF|Stat3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19825993,STAT3,p53,We further observed that p53 knockdown induced the downregulation of STAT3 protein.,0.04,PMID.dPMID19825993.s4.p0,2,2,p53|STAT3,p53|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.3.2.1,7291,9606,,,18353781,STAT3,Twist,Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function.,0.40,PMID.dPMID18353781.s12.p0,3,2,Twist|STAT3|STAT3,STAT3|Twist,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.3.2.1,7291,9606,,,18353781,STAT3,Twist,Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function.,0.16,PMID.dPMID18353781.s12.p1,3,2,Twist|STAT3|STAT3,STAT3|Twist,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,9531608,Stat3,WT1,"These results demonstrated that WT1 expression competed with the differentiation-inducing signal mediated by G-CSFR and constitutively activated Stat3, resulting in the blocking of differentiation and subsequent proliferation.",0.45,PMID.dPMID9531608.s1.p1,3,3,WT1|G-CSFR|Stat3,G-CSFR|Stat3|WT1,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,9531608,Stat3,WT1,"Thus, WT1 expression constitutively activated both Stat3alpha and Stat3beta.",0.14,PMID.dPMID9531608.s4.p0,3,2,WT1|Stat3|Stat3,Stat3|WT1,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,9531608,Stat3,WT1,"As for signal transduction mediated by G-CSF receptor (G-CSFR), Stat3alpha was constitutively activated in wild-type WT1-infected 32D cl3 in response to G-CSF, whereas, in WT1-uninfected 32D cl3, activation of Stat3alpha was only transient.",0.01,PMID.dPMID9531608.s6.p9,5,3,G-CSFR|Stat3|WT1|WT1|Stat3,G-CSFR|Stat3|WT1,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,14712222,Stat3,ZBP-89,"In the light of these results, we propose that the interaction of Stat3 and ZBP-89 may be crucial for overcoming the effects of the repressor ZBP-89, which suggests a novel mode for Stat3 gene activation",0.05,PMID.dPMID14712222.s0.p5,4,2,Stat3|ZBP-89|ZBP-89|Stat3,Stat3|ZBP-89,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,2.1.6.0.2,8431,9606,,GO:0034339,16871283,STAT3,SHP1,Our findings support the concept that loss of SHP1 contributes to the constitutive activation of JAK3/STAT3 in ALK+ ALCL cells.,0.00,PMID.dPMID16871283.s1.p1,4,4,SHP1|JAK3|STAT3|ALK,ALK|JAK3|SHP1|STAT3,
6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,1.2.5.3.1,8648,9606,,,19203349,STAT3,SRC-1,Co-activator SRC-1 is dispensable for transcriptional control by STAT3.,1.59,PMID.dPMID19203349.s11.p0,2,2,SRC-1|STAT3,SRC-1|STAT3,
6.2.1.0.5,6776,9606,,GO:0006357,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,12574125,STAT5,Id-1,"The interleukin-3 (IL-3)-dependent expression of the Id-1 gene, encoding a helix-loop-helix (HLH) transcriptional inhibitor, is activated by both C/EBPbeta and STAT5 transcription factors bound to its pro-B-cell enhancer (PBE), but is inhibited by HDAC inhibitors in Ba/F3 cells.",0.59,PMID.dPMID12574125.s3.p8,7,6,interleukin-3|IL-3|Id-1|C/EBPbeta|STAT5|PBE|HDAC,C/EBPbeta|HDAC|Id-1|IL-3|interleukin-3|PBE|STAT5,
6.2.1.0.5,6776,9606,,GO:0006357,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,19036881,Stat5a,c-Myb,"Taken together, these results indicate that c-Myb potentiates Stat5a-driven gene expression, possibly functioning as a Stat5a coactivator, in human breast cancer.",0.46,PMID.dPMID19036881.s0.p0,3,2,c-Myb|Stat5a|Stat5a,c-Myb|Stat5a,
6.2.1.0.5,6776,9606,,GO:0006357,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18431514,STAT5A,PPARgamma,"Further, PPARgamma agonists mimicked Nef activity by inhibiting STAT5A and STAT5B expression and hampering the functionality of hematopoietic progenitors both ex vivo and in vivo.",0.43,PMID.dPMID18431514.s2.p0,3,3,PPARgamma|STAT5A|STAT5B,PPARgamma|STAT5A|STAT5B,
6.2.1.0.5,6776,9606,,GO:0006357,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,11861304,STAT5,STAT3,"We also found that STAT3 is a substrate for calpain in vivo and in vitro, indicating that calpain-mediated cleavage is a common feature of STAT3 and STAT5.",0.36,PMID.dPMID11861304.s1.p1,3,2,STAT3|STAT3|STAT5,STAT3|STAT5,
6.2.1.0.6,6777,9606,,GO:0006357,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18431514,STAT5B,PPARgamma,"Further, PPARgamma agonists mimicked Nef activity by inhibiting STAT5A and STAT5B expression and hampering the functionality of hematopoietic progenitors both ex vivo and in vivo.",0.54,PMID.dPMID18431514.s2.p1,3,3,PPARgamma|STAT5A|STAT5B,PPARgamma|STAT5A|STAT5B,
6.2.1.0.6,6777,9606,,GO:0006357,2.1.2.1.1,5914,9606,GO:0016563,GO:0032582|GO:0034339|GO:0043193|GO:0045941|GO:0045944,11929749,Stat5,RARalpha,"The expression of Stat5-RARalpha causes the transcriptional repression of gene transcription, a process that requires the coiled-coil domain of Stat5 (amino acid positions 133-333).",0.01,PMID.dPMID11929749.s3.p2,3,2,Stat5|RARalpha|Stat5,RARalpha|Stat5,
6.2.1.0.6,6777,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9806359,Stat5,p53,"p53 repressed the prolactin induction of the Stat5 mediated transcription of the beta-casein promoter-luciferase reporter gene, but did not affect IFN-gamma induced, Stat1 dependent transcription of the IRF-1 promoter.",0.39,PMID.dPMID9806359.s6.p1,6,6,p53|prolactin|Stat5|beta-casein|IFN-gamma|IRF-1,beta-casein|IFN-gamma|IRF-1|p53|prolactin|Stat5,
6.2.1.0.6,6777,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9806359,Stat5,p53,"The repressive function of p53 on Stat5 activity is independent of the amino-terminal transactivation domain, but requires a functional DNA binding domain and the carboxyl-terminal domain.",0.33,PMID.dPMID9806359.s2.p0,2,2,p53|Stat5,p53|Stat5,
6.2.1.0.7,6778,9606,,GO:0006357,3.3.1.10.1,2302,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032088,17541011,STAT-6,foxj1,"Within the foxj1 promoter, a STAT-binding element was identified and inhibition of foxj1 expression by STAT-6 and IL-13 was demonstrated.",0.40,PMID.dPMID17541011.s3.p2,4,3,foxj1|foxj1|STAT-6|IL-13,foxj1|IL-13|STAT-6,
4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11316804,TAF(II)250,c-Jun,We hypothesized that c-Jun is capable of derepressing the effect of the TAF(II)250 N terminus on TFIID-driven transcription.,0.77,PMID.dPMID11316804.s3.p0,3,3,c-Jun|TAF(II)250|TFIID,c-Jun|TAF(II)250|TFIID,
4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,7724524,TAFII250,Sp1,The stimulation of Sp1-mediated transcription by RB in ts13 cells at the nonpermissive temperature could be restored by the introduction of wild-type human TAFII250.,0.74,PMID.dPMID7724524.s2.p0,2,2,Sp1|TAFII250,Sp1|TAFII250,
4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,8450888,CCG1,TFIID,The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle regulatory protein CCG1.,0.72,PMID.dPMID8450888.s6.p2,3,2,p250|TFIID|CCG1,CCG1|p250|TFIID,
4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15053879,TAF1,p53,"Thus, phosphorylation and the resultant degradation of p53 provide a mechanism for regulation of the cell cycle by TAF1.",0.48,PMID.dPMID15053879.s1.p0,2,2,p53|TAF1,p53|TAF1,
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,2.2.1.0.1,2623,9606,,GO:0006357,7678994,tal-1,GATA-1,"Altogether our results strongly suggest that GATA-1 modulates the transcription of tal-1 during the differentiation of the erythroid, megakaryocytic, and basosophilic lineages.",2.03,PMID.dPMID7678994.s0.p0,2,2,GATA-1|tal-1,GATA-1|tal-1,<--
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,2.2.1.0.1,2623,9606,,GO:0006357,18082606,SCL,GATA-1,"Here, we show that NLI/Ldb1 and erythroid-binding partners GATA-1/SCL/LMO2 bind in vivo to the beta-globin locus control region (LCR).",0.48,PMID.dPMID18082606.s3.p5,5,4,NLI|Ldb1|GATA-1|SCL|LMO2,GATA-1|Ldb1|LMO2|NLI|SCL,<--
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,2.2.1.0.1,2623,9606,,GO:0006357,20566737,TAL1,GATA1,"Finally, analysis of recruitment of GATA1, a protein partner of TAL1, to sequences occupied by TAL1 suggests that TAL1's binding is necessary prior or simultaneous to that of GATA1.",0.13,PMID.dPMID20566737.s1.p3,5,2,GATA1|TAL1|TAL1|TAL1|GATA1,GATA1|TAL1,<--
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,2.2.1.0.1,2623,9606,,GO:0006357,20566737,TAL1,GATA1,"Finally, analysis of recruitment of GATA1, a protein partner of TAL1, to sequences occupied by TAL1 suggests that TAL1's binding is necessary prior or simultaneous to that of GATA1.",0.04,PMID.dPMID20566737.s1.p1,5,2,GATA1|TAL1|TAL1|TAL1|GATA1,GATA1|TAL1,<--
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,2.2.1.0.3,2625,9606,,,9020185,TAL1,GATA3,"In this context, we carried out preliminary evaluation of a potential role of the T cell-specific GATA-binding protein, GATA3, in the transcriptional activity of TAL1 and RBTN.",0.52,PMID.dPMID9020185.s2.p0,2,2,GATA3|TAL1,GATA3|TAL1,<--
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,9687522,SCL,basic helix-loop-helix transcription factor,"In normal hemopoietic cells that are dependent on specific growth factors for cell survival, the expression of the basic helix-loop-helix transcription factor SCL/Tal1 correlates with that of c-Kit, the receptor for Steel factor (SF) or stem cell factor.",0.10,PMID.dPMID9687522.s7.p0,4,3,basic helix-loop-helix transcription factor|SCL|Tal1|c-Kit,basic helix-loop-helix transcription factor|c-Kit|SCL|Tal1,
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,9687522,Tal1,basic helix-loop-helix transcription factor,"In normal hemopoietic cells that are dependent on specific growth factors for cell survival, the expression of the basic helix-loop-helix transcription factor SCL/Tal1 correlates with that of c-Kit, the receptor for Steel factor (SF) or stem cell factor.",0.10,PMID.dPMID9687522.s7.p1,4,3,basic helix-loop-helix transcription factor|SCL|Tal1|c-Kit,basic helix-loop-helix transcription factor|c-Kit|SCL|Tal1,
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,11118214,SCL,basic helix-loop-helix transcription factor,P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL.,0.01,PMID.dPMID11118214.s6.p4,4,4,P/CAF|basic helix-loop-helix transcription factor|TAL1|SCL,basic helix-loop-helix transcription factor|P/CAF|SCL|TAL1,
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,3.1.7.3.1,6304,9606,,GO:0000122,15677454,Tal1,SATB1,"In addition, SATB1 bound EEGS chromatin and promoted Tal1/SCL EEGS-dependent repression.",0.04,PMID.dPMID15677454.s2.p0,3,3,SATB1|Tal1|SCL,SATB1|SCL|Tal1,
1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,16298389,TAL-1,PU.1,"In summary, our study shows that PU.1, in addition to its positive role in TAL-1 expression in early hematopoietic progenitors, may also act as a mediator of TAL-1 silencing in some hematopoietic lineages",0.35,PMID.dPMID16298389.s0.p0,3,2,PU.1|TAL-1|TAL-1,PU.1|TAL-1,<--
6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,3.1.10.9.2,2928,9606,,GO:0006357,9441739,VCFS,GSCL,"Due to its location in the critical region on 22q11, GSCL is an excellent candidate gene for VCFS/DGS.",0.59,PMID.dPMID9441739.s5.p0,3,2,GSCL|VCFS|DGS,DGS|GSCL|VCFS,
6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,3.1.10.9.2,2928,9606,,GO:0006357,9441739,DGS,GSCL,"Due to its location in the critical region on 22q11, GSCL is an excellent candidate gene for VCFS/DGS.",0.59,PMID.dPMID9441739.s5.p1,3,2,GSCL|VCFS|DGS,DGS|GSCL|VCFS,
6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,3.1.10.9.2,2928,9606,,GO:0006357,9811926,VCFS,Gscl,"Thus, the genomic location of Gscl and its expression in a subset of the tissues affected in DGS/VCFS patients suggest that Gscl may contribute to the pathogenesis of DGS/VCFS.",0.04,PMID.dPMID9811926.s6.p13,6,2,Gscl|DGS|VCFS|Gscl|DGS|VCFS,DGS|Gscl|VCFS,
6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,3.1.10.9.2,2928,9606,,GO:0006357,9811926,DGS,Gscl,"Thus, the genomic location of Gscl and its expression in a subset of the tissues affected in DGS/VCFS patients suggest that Gscl may contribute to the pathogenesis of DGS/VCFS.",0.04,PMID.dPMID9811926.s6.p9,6,2,Gscl|DGS|VCFS|Gscl|DGS|VCFS,DGS|Gscl|VCFS,
6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,3.1.4.3.4,5456,9606,,,18231833,Tbx1,Brn4,"Furthermore, expression of Brn4 is reduced in Tbx1 null mutants, suggesting a possible genetic interaction between these genes.",1.23,PMID.dPMID18231833.s4.p0,2,2,Brn4|Tbx1,Brn4|Tbx1,
6.5.3.0.1,6899,9606,GO:0003702,GO:0006357,6.5.5.0.1,6911,9606,,,20692252,Tbx1,Tbx6,"Tbx6 knockdown also reduced the expression of Tbx1, another T-box gene expressed in more anterior paraxial structures.",1.11,PMID.dPMID20692252.s3.p0,2,2,Tbx6|Tbx1,Tbx1|Tbx6,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,3.3.1.6.2,2295,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0045893|GO:0051090,9722567,TBP,FREAC-2,The target site for FREAC-2 on TBP was localized to the N-terminal repeat in the core domain of TBP.,0.01,PMID.dPMID9722567.s5.p0,3,2,FREAC-2|TBP|TBP,FREAC-2|TBP,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11316804,TFIID,c-Jun,We hypothesized that c-Jun is capable of derepressing the effect of the TAF(II)250 N terminus on TFIID-driven transcription.,1.20,PMID.dPMID11316804.s3.p1,3,3,c-Jun|TAF(II)250|TFIID,c-Jun|TAF(II)250|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11454854,TBP,AP-1,"These findings suggest that in macrophages, the p38 MAP kinase regulates AP-1-driven transcription by modulating the activation of TBP",1.15,PMID.dPMID11454854.s0.p2,3,3,p38|AP-1|TBP,AP-1|p38|TBP,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11316804,TBP,c-Jun,"Moreover, c-Jun blocked the repression of TBP DNA binding caused by the N terminus of TAF(II)250.",0.52,PMID.dPMID11316804.s1.p0,3,3,c-Jun|TBP|TAF(II)250,c-Jun|TAF(II)250|TBP,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11316804,TFIID,c-Jun,"In support of this hypothesis, we found that c-Jun increased levels of TFIID-driven transcription in vitro when added at high concentrations to a DNA template lacking activator protein 1 (AP-1) sites.",0.42,PMID.dPMID11316804.s2.p0,2,2,c-Jun|TFIID,c-Jun|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15087451,TFIID,c-Jun,"Interestingly, the isolated basic leucine zipper domain of c-Jun was able to derepress TFIID-directed basal transcription in vitro.",0.28,PMID.dPMID15087451.s3.p0,2,2,c-Jun|TFIID,c-Jun|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,2194667,TFIID,Sp1,"In reconstituted reactions, Sp1 stimulates transcription at TATA-containing promoters in the presence of semipurified TFIID fractions from either human or Drosophila cells, but is unable to do so when these fractions are replaced by purified, cloned Drosophila or yeast TFIID.",0.66,PMID.dPMID2194667.s3.p0,3,2,Sp1|TFIID|TFIID,Sp1|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9989412,TFIID,Sp1,"Transcriptional activation by enhancer-binding factors such as Sp1 requires TFIID, but the identity of other necessary cofactors has remained unknown.",0.60,PMID.dPMID9989412.s7.p0,2,2,Sp1|TFIID,Sp1|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9584164,TFIID,Sp1,Transcriptional activation by NF-kappaB and Sp1 requires both TFIID and the USA fraction.,0.28,PMID.dPMID9584164.s6.p0,2,2,Sp1|TFIID,Sp1|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,1909174,TFIID,SRF,This supports a model in which SRF activates transcription by affecting the conformation of TFIID bound to the promoter.,0.08,PMID.dPMID1909174.s2.p0,2,2,SRF|TFIID,SRF|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,11686293,TBP,TAF(II)250,"TAF(II)250 is a scaffold for assembly of other TAF(II)s and TBP into TFIID, TAF(II)250 binds activators to recruit TFIID to particular promoters, TAF(II)250 regulates binding of TBP to DNA, TAF(II)250 binds core promoter initiator elements, TAF(II)250 binds acetylated lysine residues in core histones, and TAF(II)250 possesses protein kinase, ubiquitin-activating/conjugating and acetylase activities that modify histones and GTFs.",0.72,PMID.dPMID11686293.s1.p20,10,2,TAF(II)250|TBP|TFIID|TAF(II)250|TFIID|TAF(II)250|TBP|TAF(II)250|TAF(II)250|TAF(II)250,TAF(II)250|TBP|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,11686293,TBP,TAF(II)250,"TAF(II)250 is a scaffold for assembly of other TAF(II)s and TBP into TFIID, TAF(II)250 binds activators to recruit TFIID to particular promoters, TAF(II)250 regulates binding of TBP to DNA, TAF(II)250 binds core promoter initiator elements, TAF(II)250 binds acetylated lysine residues in core histones, and TAF(II)250 possesses protein kinase, ubiquitin-activating/conjugating and acetylase activities that modify histones and GTFs.",0.60,PMID.dPMID11686293.s1.p18,10,2,TAF(II)250|TBP|TFIID|TAF(II)250|TFIID|TAF(II)250|TBP|TAF(II)250|TAF(II)250|TAF(II)250,TAF(II)250|TBP|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,11316804,TFIID,TAF(II)250,We hypothesized that c-Jun is capable of derepressing the effect of the TAF(II)250 N terminus on TFIID-driven transcription.,0.50,PMID.dPMID11316804.s3.p2,3,3,c-Jun|TAF(II)250|TFIID,c-Jun|TAF(II)250|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,11564872,TBP,TAF(II)250,"From a functional standpoint, hTAF(II)135 has been found to interact strongly and directly with hTFIIA and (within a complex that also contains hTBP and hTAF(II)250) to specifically cooperate with TFIIA to relieve TAF(II)250-mediated repression of TBP binding and function on core promoters.",0.03,PMID.dPMID11564872.s2.p9,5,3,TAF(II)135|TBP|TAF(II)250|TAF(II)250|TBP,TAF(II)135|TAF(II)250|TBP,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,7479778,TFIID,Transcription factor,Transcription factor TFIID is a direct functional target of the adenovirus E1A transcription-repression domain.,0.28,PMID.dPMID7479778.s9.p0,2,2,Transcription factor|TFIID,TFIID|Transcription factor,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17996705,TFIID,p53,An acetylation switch in p53 mediates holo-TFIID recruitment.,0.19,PMID.dPMID17996705.s6.p0,2,2,p53|TFIID,p53|TFIID,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12438576,TBP,p53,"BZLF1 substantially reduced the level of cellular TATA binding protein (TBP) in both normal human fibroblasts and A549 cells, and the inhibitory effects of BZLF1 on p53 transcriptional function could be partially rescued by the overexpression of TBP.",0.18,PMID.dPMID12438576.s1.p2,3,2,TBP|p53|TBP,p53|TBP,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9257185,TBP,p53,"Our data suggest that p300/CBP and TBP but not the pocket proteins, pRb, p107, and pRb2/p130 are functional targets of E1A in transcriptional regulation and that p53 transactivation requires the function of the p300/TBP/TFIIB complex, thus delineating a new pathway by which E1A may exert its transforming activity",0.06,PMID.dPMID9257185.s0.p19,8,6,p300|CBP|TBP|p107|p53|p300|TBP|TFIIB,CBP|p107|p300|p53|TBP|TFIIB,
8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,16575000,TATA box binding protein,WT1,"WT1 copy number was normalized by TATA box binding protein gene transcripts and expressed as WT1/TBP x 1,000 ratio.",0.28,PMID.dPMID16575000.s7.p0,3,2,WT1|TATA box binding protein|WT1,TATA box binding protein|WT1,
6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12789260,Hos,p73,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.43,PMID.dPMID12789260.s0.p7,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,
1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,2.3.2.3.3,2737,9606,GO:0016564,GO:0000122|GO:0010552|GO:0045944,18781613,TCF4,PHS,"PHS was shown to be caused by de novo heterozygous mutations of the TCF4 gene, located in 18q21.",0.74,PMID.dPMID18781613.s5.p0,2,2,PHS|TCF4,PHS|TCF4,
1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,18627065,TCF4,basic helix-loop-helix transcription factor,"Breakpoint-mapping by fluorescence in situ hybridization indicated that on chromosome 18, the basic helix-loop-helix transcription factor TCF4 gene is disrupted by the breakpoint.",0.32,PMID.dPMID18627065.s6.p0,2,2,basic helix-loop-helix transcription factor|TCF4,basic helix-loop-helix transcription factor|TCF4,
1.2.1.0.2,6925,9606,GO:0016566|GO:0016986,GO:0016481|GO:0045893|GO:0045944,3.5.2.5.2,6689,9606,GO:0003702,GO:0006357,18792017,E2-2,Spi-B,This might indicate that Spi-B contributes to pDC development by promoting E2-2 activity.,0.32,PMID.dPMID18792017.s2.p0,2,2,Spi-B|E2-2,E2-2|Spi-B,
6.5.4.0.2,6926,9606,GO:0003702|GO:0016564|GO:0016565,GO:0006357|GO:0045892,6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,18451335,TBX3,TBX5,We speculate that the gain-of-function mechanism underlies the mild skeletal phenotype and paroxysmal atrial fibrillation and suggest a possible role of TBX5 in the development of (paroxysmal) atrial fibrillation based on a gain-of-function either through a direct stimulation of target genes via TBX5 or indirectly via TBX5 stimulated TBX3.,0.10,PMID.dPMID18451335.s1.p5,4,2,TBX5|TBX5|TBX5|TBX3,TBX3|TBX5,
6.5.4.0.2,6926,9606,GO:0003702|GO:0016564|GO:0016565,GO:0006357|GO:0045892,6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,18451335,TBX3,TBX5,We speculate that the gain-of-function mechanism underlies the mild skeletal phenotype and paroxysmal atrial fibrillation and suggest a possible role of TBX5 in the development of (paroxysmal) atrial fibrillation based on a gain-of-function either through a direct stimulation of target genes via TBX5 or indirectly via TBX5 stimulated TBX3.,0.06,PMID.dPMID18451335.s1.p4,4,2,TBX5|TBX5|TBX5|TBX3,TBX3|TBX5,
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,3.1.1.8.2,1045,9606,,,18656622,HNF1,CDX2,GATA-5 and CDX2 also regulate SGLT1 promoter activity and show cooperativity with the HNF1s.,0.18,PMID.dPMID18656622.s1.p4,4,4,GATA-5|CDX2|SGLT1|HNF1,CDX2|GATA-5|HNF1|SGLT1,
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,10333497,HNF-1,HNF-3,"Sequences were inserted at position -21, separating both HNF-3 binding sites from the HNF-1-HNF-6 binding site, and position -5, separating the HNF-3-HNF-1-HNF-6 complex from the transcription start site.",0.37,PMID.dPMID10333497.s5.p0,6,3,HNF-3|HNF-1|HNF-6|HNF-3|HNF-1|HNF-6,HNF-1|HNF-3|HNF-6,
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,3.3.1.1.3,3171,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,19074951,HNF1A,HNF3G,"In exploring the DNA regions and TRFs involved in combinatorial transcriptional regulation, we noted that individual knockdown of a set of human liver-enriched TRFs such as HNF1A, HNF3A, HNF3B, HNF3G and HNF4A resulted in perturbation of the expression of several single TRF genes, such as HNF1A, HNF3G and CEBPA genes.",0.14,PMID.dPMID19074951.s5.p2,5,3,HNF1A|HNF3G|HNF1A|HNF3G|CEBPA,CEBPA|HNF1A|HNF3G,
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,8491780,HNF1,HNF4,"Since recent evidence indicates that HNF4 controls HNF1 expression, it can be proposed that the HNF4 gene is the primary target of the pleiotropic extinguisher",2.61,PMID.dPMID8491780.s0.p0,3,2,HNF4|HNF1|HNF4,HNF1|HNF4,<->
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,15337761,HNF-1,HNF-4,This suggests that HNF-4 regulates MTP gene expression either directly or indirectly through elevated HNF-1 levels.,1.06,PMID.dPMID15337761.s4.p1,3,3,HNF-4|MTP|HNF-1,HNF-1|HNF-4|MTP,<->
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,8866553,MODY3,MODY,"One form of maturity-onset diabetes of the young (MODY) results from mutations in a gene, designated MODY3, located on chromosome 12 in band q24.",0.72,PMID.dPMID8866553.s13.p0,2,2,MODY|MODY3,MODY|MODY3,<->
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,16670373,HNF1,HNF4,"The mechanism by which HNF1-mediated activation occurs seems to be transcriptional, because the regulated expression of HNF4, which is known to control HNF1 expression, was also increased.",0.70,PMID.dPMID16670373.s7.p2,3,2,HNF1|HNF4|HNF1,HNF1|HNF4,<->
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,8290348,HNF-1,HNF-4,"Both factors repressed HNF-4 induced transcription of the ApoCIII and HNF-1 genes in HeLa cells, arguing against the requirement of a hepatocyte specific function.",0.33,PMID.dPMID8290348.s1.p1,3,3,HNF-4|ApoCIII|HNF-1,ApoCIII|HNF-1|HNF-4,<->
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,8290348,HNF-1,HNF-4,"Recent studies have revealed that hepatocyte nuclear factor 4 (HNF-4) is an essential positive regulator of another liver enriched transcription factor HNF-1, defining a transcriptional hierarchy between the two factors operating in hepatocytes.",0.12,PMID.dPMID8290348.s8.p0,2,2,HNF-4|HNF-1,HNF-1|HNF-4,<->
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,3.1.4.7.2,6928,9606,,GO:0045893,15522234,MODY3,HNF-1beta,"We studied the effects of 13 HNF-1alpha mutants and 2 HNF-1beta mutants on human SI gene transcription, which were identified in subjects with MODY3 and MODY5, respectively.",0.31,PMID.dPMID15522234.s4.p0,3,2,HNF-1beta|MODY3|MODY5,HNF-1beta|MODY3|MODY5,
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,3.1.4.7.2,6928,9606,,GO:0045893,11106484,HNF-1,HNF-1beta,Conserved core residues in the dimerization domain of the homologous transcriptional regulator HNF-1beta rationalize the functional heterodimerization of the HNF-1alpha and HNF-1beta proteins.,0.12,PMID.dPMID11106484.s1.p0,3,2,HNF-1beta|HNF-1|HNF-1beta,HNF-1|HNF-1beta,
3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,2.2.1.0.5,140628,9606,,GO:0045944,18656622,HNF1,GATA-5,GATA-5 and CDX2 also regulate SGLT1 promoter activity and show cooperativity with the HNF1s.,0.04,PMID.dPMID18656622.s1.p3,4,4,GATA-5|CDX2|SGLT1|HNF1,CDX2|GATA-5|HNF1|SGLT1,
3.1.4.7.2,6928,9606,,GO:0045893,1.1.1.1.7,4778,9606,GO:0030528,GO:0006357|GO:0045941,19951713,transcription factor 2,NF-E2,Expression of the NF-E2-related transcription factor 2 (Nrf2) protein was analyzed by Western blotting.,0.14,PMID.dPMID19951713.s4.p0,2,2,NF-E2|transcription factor 2,NF-E2|transcription factor 2,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,2524598,E2A,transcription factor E2f,The cellular transcription factor E2f requires viral E1A and E4 gene products for increased DNA-binding activity and functions to stimulate adenovirus E2A gene expression.,0.89,PMID.dPMID2524598.s7.p0,2,2,transcription factor E2f|E2A,E2A|transcription factor E2f,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,9029153,E2A,Id2,Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors.,0.70,PMID.dPMID9029153.s7.p0,2,2,Id2|E2A,E2A|Id2,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.2.1.2,4656,9606,,GO:0010552,1317849,E2A,myogenin,We show that repression by TGF-beta is directed at the basic-HLH motif of myogenin and is independent of E2A products.,1.03,PMID.dPMID1317849.s3.p2,3,3,TGF-beta|myogenin|E2A,E2A|myogenin|TGF-beta,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.2.1.2,4656,9606,,GO:0010552,1646392,E2A,myogenin,Inefficient homooligomerization contributes to the dependence of myogenin on E2A products for efficient DNA binding.,0.79,PMID.dPMID1646392.s9.p0,2,2,myogenin|E2A,E2A|myogenin,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.2.1.2,4656,9606,,GO:0010552,1317849,E2A,myogenin,Repression of myogenin function by TGF-beta 1 is targeted at the basic helix-loop-helix motif and is independent of E2A products.,0.61,PMID.dPMID1317849.s6.p1,3,3,myogenin|TGF-beta 1|E2A,E2A|myogenin|TGF-beta 1,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.2.1.2,4656,9606,,GO:0010552,8065355,E2A,myogenin,Phosphorylation of myogenin at these sites was mediated by the bHLH region of E2A products and was dependent on dimerization but not on DNA binding.,0.34,PMID.dPMID8065355.s3.p0,2,2,myogenin|E2A,E2A|myogenin,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.2.1.2,4656,9606,,GO:0010552,1646392,E2A,myogenin,"Although myogenin alone binds DNA inefficiently, in the presence of the widely expressed HLH proteins E12 and E47 (encoded by the E2A gene), it forms heterooligomers that bind with high affinity to a DNA sequence known as a kappa E-2 site.",0.20,PMID.dPMID1646392.s7.p0,2,2,myogenin|E2A,E2A|myogenin,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,3.1.3.4.1,5087,9606,,GO:0043433,8327485,E2A,Pbx1,Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia.,0.86,PMID.dPMID8327485.s6.p0,2,2,Pbx1|E2A,E2A|Pbx1,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,3.1.3.4.1,5087,9606,,GO:0043433,16800933,E2A,PBX1,Variant fusion transcript in ALL children with E2A-PBX1 fusion gene positive   The study was aimed to investigate the expression of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia (ALL).,0.14,PMID.dPMID16800933.s10.p5,6,3,ALL|E2A|PBX1|E2A|PBX1|ALL,ALL|E2A|PBX1,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,16819510,E2a,PU.1,"Finally, additional experiments suggested that PU.1 and eight twenty-one transcriptional regulators might be implicated in the mechanisms of oncogenesis by E2a/Pbx1",0.42,PMID.dPMID16819510.s0.p0,3,3,PU.1|E2a|Pbx1,E2a|Pbx1|PU.1,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,9927512,E2A,Tal1,"In the Jurkat T cell line, originally derived from a patient with T-ALL, Tal1 is complexed with E2A proteins and the transcriptional activity of E2A is very low.",0.22,PMID.dPMID9927512.s1.p1,3,2,Tal1|E2A|E2A,E2A|Tal1,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,16621969,E2A,TAL1,"Using RNA interference, we demonstrated that TAL1 is required for the maintenance of the leukemic phenotype in Jurkat cells and showed that TAL1 binding can be associated with either repression or activation of genes whose promoters occupied by TAL1, E2A, and HEB.",0.14,PMID.dPMID16621969.s2.p4,5,3,TAL1|TAL1|TAL1|E2A|HEB,E2A|HEB|TAL1,
1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,17272506,E2A,Gfi1b,Gfi1b expression in primary T-lymphocyte progenitors is dependent on E2A and excess Gfi1b prevents the outgrowth of T lymphocyte progenitors in vitro.,0.58,PMID.dPMID17272506.s3.p0,3,2,Gfi1b|E2A|Gfi1b,E2A|Gfi1b,
4.1.3.0.1,6932,9606,GO:0003702,GO:0006357,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,11470825,Tcf-1,TCF,"Also, 1alpha,25(OH)2D(3) inhibited expression of beta-catenin-TCF-4-responsive genes, c-myc, peroxisome proliferator-activated receptor delta, Tcf-1, and CD44, whereas it induced expression of ZO-1.",0.23,PMID.dPMID11470825.s1.p1,5,5,TCF|c-myc|Tcf-1|CD44|ZO-1,CD44|c-myc|TCF|Tcf-1|ZO-1,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,11149923,Tcf-4,Tcf,Inhibition of beta-catenin/Tcf transcription by expression of the dominant-negative mutant of Tcf-4 blocked Wnt-1-mediated cell survival and rendered cells sensitive to apoptotic stimuli.,0.47,PMID.dPMID11149923.s1.p0,3,3,Tcf|Tcf-4|Wnt-1,Tcf|Tcf-4|Wnt-1,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18595660,Tcf4,Smad2,Here we demonstrated that the Activin-like kinase 4 (Alk4)/Smad2 pathway facilitates the transcriptional activity of the oncogenic Wnt/beta-catenin/Tcf4 pathway through a novel Smad4-independent mechanism.,0.01,PMID.dPMID18595660.s5.p0,3,3,Smad2|Tcf4|Smad4,Smad2|Smad4|Tcf4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11973610,Tcf-4,c-myc,Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity.,0.48,PMID.dPMID11973610.s8.p0,2,2,c-myc|Tcf-4,c-myc|Tcf-4,-->
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11973610,Tcf-4,c-Myc,They showed neither induction of apoptosis nor down-regulation of the c-Myc expression via blockade of the Tcf-4 activity after troglitazone treatment.,0.39,PMID.dPMID11973610.s1.p0,2,2,c-Myc|Tcf-4,c-Myc|Tcf-4,-->
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9727977,Tcf-4,c-MYC,"Expression of c-MYC was shown to be repressed by wild-type APC and activated by beta-catenin, and these effects were mediated through Tcf-4 binding sites in the c-MYC promoter.",0.06,PMID.dPMID9727977.s1.p1,4,3,c-MYC|APC|Tcf-4|c-MYC,APC|c-MYC|Tcf-4,-->
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16690926,TCF-4,Sp1,Human immunodeficiency virus type 1 Tat prevents dephosphorylation of Sp1 by TCF-4 in astrocytes.,0.37,PMID.dPMID16690926.s10.p2,3,3,Tat|Sp1|TCF-4,Sp1|Tat|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20122174,TCF-4,p53,"It has been reported that beta-catenin promotes and p53 inhibits TCF-4 transcription, respectively.",0.46,PMID.dPMID20122174.s14.p0,2,2,p53|TCF-4,p53|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20122174,TCF-4,p53,These results indicate that p53 is not required for Axin-mediated downregulation of TCF-4.,0.24,PMID.dPMID20122174.s4.p1,3,3,p53|Axin|TCF-4,Axin|p53|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20122174,TCF-4,p53,"Expression of Axin or AxinDeltap53 downregulates beta-catenin and TCF-4, and knock-down of beta-catenin upregulates TCF-4 in BE1 cells.",0.01,PMID.dPMID20122174.s11.p8,5,3,Axin|Axin|p53|TCF-4|TCF-4,Axin|p53|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15928669,TCF4,HOXB13,TCF4 promoter analysis showed that HOXB13 does not regulate TCF4 at the transcriptional level.,1.81,PMID.dPMID15928669.s4.p2,3,2,TCF4|HOXB13|TCF4,HOXB13|TCF4,n
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15928669,TCF4,HOXB13,"In prostate cancers, HOXB13 negatively regulates beta-catenin/TCF4-mediated transactivation and subsequently inhibits cell growth.",1.32,PMID.dPMID15928669.s7.p0,2,2,HOXB13|TCF4,HOXB13|TCF4,c
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15928669,TCF4,HOXB13,"However, HOXB13 downregulated the expression of TCF4 and its target gene, c-myc, at the protein level and consequently inhibited beta-catenin/TCF-mediated signalling.",1.22,PMID.dPMID15928669.s3.p0,4,4,HOXB13|TCF4|c-myc|TCF,c-myc|HOXB13|TCF|TCF4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15126340,TCF-4,HOXB13,"Western blot analysis demonstrated that HOXB13 down-regulates the expression of TCF-4 and its responsive genes, c-myc and cyclin D1.",0.76,PMID.dPMID15126340.s3.p0,3,3,HOXB13|TCF-4|c-myc,c-myc|HOXB13|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15126340,TCF-4,HOXB13,"This study suggests that HOXB13, a transcription factor, functions as a cell growth suppressor by negatively regulating the expression of TCF-4, which eventually provides negative signals for cell proliferation.",0.64,PMID.dPMID15126340.s1.p0,2,2,HOXB13|TCF-4,HOXB13|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15126340,TCF-4,HOXB13,"Because cyclin D1 is mainly regulated by beta-catenin/T-cell factor (TCF), TCF-4 response element was used in a reporter gene transcription assay, demonstrating that HOXB13 significantly inhibits TCF-4-mediated transcriptional activity in both prostate and nonprostate cells.",0.14,PMID.dPMID15126340.s5.p5,4,3,TCF|TCF-4|HOXB13|TCF-4,HOXB13|TCF|TCF-4,
4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,3.1.1.7.14,10481,9606,,,15928669,TCF4,HOXB13,This is the first description of the downregulation of HOXB13 in CRC and its mechanism of action is mediated through the regulation of TCF4 protein stability.,0.04,PMID.dPMID15928669.s1.p0,2,2,HOXB13|TCF4,HOXB13|TCF4,
3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,7876544,negative regulator of IL-2,ETS1,"Taken together, these results suggest the possibility that ETS1 may act as a negative regulator of IL-2 gene transcription and provide a rational approach toward engineering the endogenous expression of IL-2 in T cells.",0.21,PMID.dPMID7876544.s0.p0,3,3,ETS1|negative regulator of IL-2|IL-2,ETS1|IL-2|negative regulator of IL-2,
3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19194497,ZEB1,p73,"Employing histological, tissue culture, and molecular biological read-outs, we show that this novel pro-survival response, initiated through the rapid induction of p63, is mediated ultimately by the transcriptional repression of a pro-apoptotic isoform of p73 by ZEB1.",0.48,PMID.dPMID19194497.s4.p2,3,3,p63|p73|ZEB1,p63|p73|ZEB1,-->
3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11713281,ZEB,p73,"The p73 intronic fragment contains six consensus binding sites for transcriptional repressor ZEB, which binds these sites in vitro and in vivo.",0.11,PMID.dPMID11713281.s2.p0,2,2,p73|ZEB,p73|ZEB,-->
3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,16804902,ZEB1,VDR,"For instance, vitamin D receptor (VDR), which activates CDH1 expression upon ligand binding, is repressed by SNAIL but induced by ZEB1.",0.19,PMID.dPMID16804902.s9.p1,3,3,VDR|CDH1|ZEB1,CDH1|VDR|ZEB1,
3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19194497,ZEB1,p63,"Employing histological, tissue culture, and molecular biological read-outs, we show that this novel pro-survival response, initiated through the rapid induction of p63, is mediated ultimately by the transcriptional repression of a pro-apoptotic isoform of p73 by ZEB1.",0.47,PMID.dPMID19194497.s4.p1,3,3,p63|p73|ZEB1,p63|p73|ZEB1,
1.2.1.0.3,6938,9606,GO:0003702,GO:0006357,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,15193261,HEB,TAL1,TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB.,0.84,PMID.dPMID15193261.s6.p1,3,3,TAL1|E47|HEB,E47|HEB|TAL1,
1.2.1.0.3,6938,9606,GO:0003702,GO:0006357,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,15193261,HEB,tal1,These data demonstrate that tal1/scl induces leukemia by repressing E47/HEB and suggest that HDAC inhibitors may prove efficacious in T-ALL patients who express TAL1/SCL,0.82,PMID.dPMID15193261.s0.p1,5,4,tal1|E47|HEB|HDAC|TAL1,E47|HDAC|HEB|tal1|TAL1,
1.2.1.0.3,6938,9606,GO:0003702,GO:0006357,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,8163514,HTF4,TAL1,"Support for this hypothesis was obtained by transient expression analyses where TAL1 was found to inhibit the activation effects produced by E2-5 and HTF4a on a reporter gene construct containing repeated microE2 and microE5 motifs, derived from the immunoglobulin gene enhancer",0.01,PMID.dPMID8163514.s0.p0,2,2,TAL1|HTF4,HTF4|TAL1,
3.6.1.0.1,7003,9606,,,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,14630715,Ref-1,PAX8,"The PAX8-independent effect of APE/Ref-1 was specific for the NIS promoter, resulting not present for the promoter of the thyroperoxidase (TPO) gene.",0.22,PMID.dPMID14630715.s4.p0,5,4,PAX8|Ref-1|NIS|thyroperoxidase|TPO,NIS|PAX8|Ref-1|thyroperoxidase|TPO,
3.6.1.0.1,7003,9606,,,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,14630715,Ref-1,PAX8,"However, restoring the PAX8-APE/Ref-1 expression in tumor cells may not be sufficient to obtain adequate levels of NIS gene expression",0.03,PMID.dPMID14630715.s0.p0,3,3,PAX8|Ref-1|NIS,NIS|PAX8|Ref-1,
1.3.1.0.1,7020,9606,,,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18955504,TFAP2A,Smad2,We identified novel Smad binding sites in the CDKN1A gene where Smad2/3 binding was regulated by ETS1 and TFAP2A.,1.08,PMID.dPMID18955504.s3.p1,3,3,Smad2|ETS1|TFAP2A,ETS1|Smad2|TFAP2A,
1.3.1.0.1,7020,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20066163,AP-2,c-myc,Chromatin immunoprecipitation assays demonstrated that AP-2 proteins bound to a cluster of AP-2 binding sites located within a 2 kb upstream regulatory region of c-myc These results suggest that the negative regulation of AP-2 on c-MYC activity was achieved through binding of AP-2 protein to the c-myc gene.,0.10,PMID.dPMID20066163.s1.p5,7,2,AP-2|AP-2|c-myc|AP-2|c-MYC|AP-2|c-myc,AP-2|c-myc|c-MYC,-->
1.3.1.0.1,7020,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11912921,AP-2,SP-1,"Whereas SP-1 plays a positive role, which is absolutely essential for transcription from the human MnSOD promoter, AP-2 appears to play a negative role in this process.",0.54,PMID.dPMID11912921.s5.p0,2,2,SP-1|AP-2,AP-2|SP-1,
1.3.1.0.1,7020,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20525283,TFAP2A,SP1,"In an attempt to identify TFs that could cooperate with TFAP2A, a statistically significant enrichment for SP1 binding sites was found for TFAP2A-activated but not repressed genes.",0.49,PMID.dPMID20525283.s3.p2,3,2,TFAP2A|SP1|TFAP2A,SP1|TFAP2A,
1.3.1.0.1,7020,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16260418,AP-2alpha,Sp1,"Together, our results indicate that AP-2alpha and Sp1 are strong transcriptional regulators of KiSS-1 and that loss or decreased expression of AP-2alpha in breast cancer may account for the loss of tumor metastasis suppressor KiSS-1 expression and thus increased cancer metastasis",0.23,PMID.dPMID16260418.s0.p4,5,3,AP-2alpha|Sp1|KiSS-1|AP-2alpha|KiSS-1,AP-2alpha|KiSS-1|Sp1,
1.3.1.0.1,7020,9606,,,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11853549,AP-2,Sp1,"Direct mutagenesis analysis of Sp1- and AP-2-binding sites showed that Sp1 is essential for transcription of the human SOD2 gene, whereas AP-2 plays a negative role in the transcription.",0.12,PMID.dPMID11853549.s4.p8,5,3,Sp1|AP-2|Sp1|SOD2|AP-2,AP-2|SOD2|Sp1,
1.3.1.0.1,7020,9606,,,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,20195529,AP-2alpha,NR2F2,"To examine whether NR2F2 is involved in the regulation of villous CTB cell differentiation, studies were performed to determine whether NR2F2 regulates the expression of TFAP2A (AP-2alpha), a transcription factor that is critical for the terminal differentiation of these cells to a STB phenotype.",0.93,PMID.dPMID20195529.s4.p4,4,2,NR2F2|NR2F2|TFAP2A|AP-2alpha,AP-2alpha|NR2F2|TFAP2A,
1.3.1.0.1,7020,9606,,,2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,20195529,TFAP2A,NR2F2,"To examine whether NR2F2 is involved in the regulation of villous CTB cell differentiation, studies were performed to determine whether NR2F2 regulates the expression of TFAP2A (AP-2alpha), a transcription factor that is critical for the terminal differentiation of these cells to a STB phenotype.",0.55,PMID.dPMID20195529.s4.p2,4,2,NR2F2|NR2F2|TFAP2A|AP-2alpha,AP-2alpha|NR2F2|TFAP2A,
1.3.1.0.3,7022,9606,,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,15623634,AP-2gamma,Transcription factor,Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors.,0.53,PMID.dPMID15623634.s13.p0,2,2,Transcription factor|AP-2gamma,AP-2gamma|Transcription factor,
1.2.6.4.1,7023,9606,GO:0016563|GO:0016564|GO:0016566,GO:0016481|GO:0032582|GO:0043922|GO:0043923|GO:0045893|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19270520,TFAP4,c-MYC,"Recently, we reported a novel mechanism which allows c-MYC to repress p21: c-MYC triggers a transcriptional cascade by directly inducing the gene encoding the bHLH-LZ transcription factor AP4 (TFAP4), which binds to recognition motifs located in the vicinity of the p21 promoter and mediates transcriptional repression of p21.",0.67,PMID.dPMID19270520.s3.p5,6,3,c-MYC|p21|c-MYC|TFAP4|p21|p21,c-MYC|p21|TFAP4,
1.2.6.4.1,7023,9606,GO:0016563|GO:0016564|GO:0016566,GO:0016481|GO:0032582|GO:0043922|GO:0043923|GO:0045893|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19270520,TFAP4,c-MYC,"Recently, we reported a novel mechanism which allows c-MYC to repress p21: c-MYC triggers a transcriptional cascade by directly inducing the gene encoding the bHLH-LZ transcription factor AP4 (TFAP4), which binds to recognition motifs located in the vicinity of the p21 promoter and mediates transcriptional repression of p21.",0.03,PMID.dPMID19270520.s3.p3,6,3,c-MYC|p21|c-MYC|TFAP4|p21|p21,c-MYC|p21|TFAP4,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,10620335,COUP-TF,AHR,The specific interaction of COUP-TF with XREs and AHR together with the inhibition of TCDD-induced gene expression by COUP-TF suggests that COUP-TF may regulate AHR action both by direct DNA binding competition and through protein-protein interactions,0.29,PMID.dPMID10620335.s0.p4,5,2,COUP-TF|AHR|COUP-TF|COUP-TF|AHR,AHR|COUP-TF,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,2.1.3.3.7,2063,9606,,GO:0000122|GO:0034339,2905047,ear-3,ear-2,"Hybridization analysis of DNAs from sorted chromosomes shows that the ear-2 gene is located on chromosome 19 and ear-3 on chromosome 5, indicating that the two genes are clearly different from each other",0.06,PMID.dPMID2905047.s0.p0,2,2,ear-2|ear-3,ear-2|ear-3,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,8810289,COUP-TFI,HNF4,"However, when HNF4 levels were increased in HepG2 cells by co-transfection, it resulted in the enhancement of CYP2D6 promoter activity, indicating that HNF4 could overcome the repressive effect of COUP-TFI.",0.93,PMID.dPMID8810289.s1.p5,4,3,HNF4|CYP2D6|HNF4|COUP-TFI,COUP-TFI|CYP2D6|HNF4,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,3.1.10.17.2,5015,9606,,GO:0006355,20147377,COUP-TF,Otx2,"Using ChIP assay, siRNA treatment and transient transfection in ARPE-19 cells in vitro, we demonstrate that Pax6 and Otx2 are directly regulated by COUP-TFs.",1.00,PMID.dPMID20147377.s1.p2,3,3,Pax6|Otx2|COUP-TF,COUP-TF|Otx2|Pax6,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,3.2.1.2.2,5080,9606,,,20147377,COUP-TF,Pax6,"Using ChIP assay, siRNA treatment and transient transfection in ARPE-19 cells in vitro, we demonstrate that Pax6 and Otx2 are directly regulated by COUP-TFs.",0.81,PMID.dPMID20147377.s1.p1,3,3,Pax6|Otx2|COUP-TF,COUP-TF|Otx2|Pax6,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12972613,EAR3,Sp1,The Sp1(I) site was identified as critical for the repression since its mutation reduced the inhibition by EAR2 and abolished the inhibition by EAR3.,0.27,PMID.dPMID12972613.s11.p0,2,2,Sp1|EAR3,EAR3|Sp1,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,12972613,EAR3,Sp1,"Moreover, perturbation of the association of TFIIB with Sp1 by EAR3 was reflected in the reduced recruitment of RNA polymerase II to the promoter.",0.14,PMID.dPMID12972613.s3.p2,3,3,TFIIB|Sp1|EAR3,EAR3|Sp1|TFIIB,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,1.2.5.3.1,8648,9606,,,10652338,COUP-TFI,SRC-1,"Finally, overexpression of GRIP1 or SRC-1 does not convert COUP-TFI from a transcriptional repressor into a transcriptional activator in HeLa cells",0.44,PMID.dPMID10652338.s0.p2,3,3,GRIP1|SRC-1|COUP-TFI,COUP-TFI|GRIP1|SRC-1,
2.1.3.3.5,7025,9606,GO:0003706,GO:0000122|GO:0034339,1.2.5.3.2,10499,9606,,GO:0006355,10652338,COUP-TFI,GRIP1,"Finally, overexpression of GRIP1 or SRC-1 does not convert COUP-TFI from a transcriptional repressor into a transcriptional activator in HeLa cells",0.05,PMID.dPMID10652338.s0.p1,3,3,GRIP1|SRC-1|COUP-TFI,COUP-TFI|GRIP1|SRC-1,
3.3.2.2.1,7027,9606,,GO:0006357,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9769946,DP-1,p53,"The Mdm2 protein is believed to be oncogenic by binding and inactivating the p53 and Rb tumor suppressor gene products and by activating the E2F-1/DP-1 transcription factors, thus promoting the G1 to S phase transition.",0.15,PMID.dPMID9769946.s5.p7,5,5,Mdm2|p53|Rb|E2F-1|DP-1,DP-1|E2F-1|Mdm2|p53|Rb,
1.2.6.1.1,7030,9606,,GO:0010552,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,15050900,Tfe3,Mitf,"Mitf is a member of the basic/helix-loop-helix/leucine zipper (b-HLH-ZIP) transcription factor subfamily named MiT, which also includes Tfe3.",0.49,PMID.dPMID15050900.s4.p0,2,2,Mitf|Tfe3,Mitf|Tfe3,
1.2.6.1.1,7030,9606,,GO:0010552,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,1899229,TFE3,ITF-1,"Second, binding of ITF-1 physically displaces a repressor that normally blocks the stimulatory activity of TFE3, which binds the neighboring microE3 motif.",0.45,PMID.dPMID1899229.s2.p0,2,2,ITF-1|TFE3,ITF-1|TFE3,
3.1.3.6.1,7050,9606,,GO:0000122,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11371641,TGIF,c-Jun,"Interestingly, c-Jun directly binds to the nuclear transcriptional corepressor TGIF and is required for TGIF-mediated repression of Smad2 transcriptional activity.",0.16,PMID.dPMID11371641.s1.p1,4,3,c-Jun|TGIF|TGIF|Smad2,c-Jun|Smad2|TGIF,
2.1.2.2.1,7067,9606,GO:0016564|GO:0016988,GO:0010551|GO:0017055|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8393159,c-erbA-alpha,p53,We also show that p53 activates transcription of the c-erbA-alpha gene through a DNA element that consists of the p53 quarter-sites and GC3 elements.,0.76,PMID.dPMID8393159.s1.p0,3,2,p53|c-erbA-alpha|p53,c-erbA-alpha|p53,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,3.1.1.8.2,1045,9606,,,18091383,TTF-1,CDX-2,"In conclusion, CDX-2 expression is highly specific in identifying NETs of intestinal origin and TTF-1 expression is helpful in identifying NETs of pulmonary origin, which can be quite useful in the diagnosis of metastatic NETs of unknown origin.",0.07,PMID.dPMID18091383.s0.p0,2,2,CDX-2|TTF-1,CDX-2|TTF-1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,3.1.1.8.2,1045,9606,,,17922593,TTF-1,CDX2,"RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.",0.03,PMID.dPMID17922593.s2.p296,31,5,TTF-1|CDX2|CK7|TTF-1|CDX2|CK7|CK7|MUC5AC|TTF-1|CDX2|GCDFP-15|GCDFP-15|TTF-1|CDX2|CK7|TTF-1|CDX2|MUC5AC|TTF-1|TTF-1|CDX2|CK7|GCDFP-15|MUC5AC|TTF-1|CDX2|CK7|MUC5AC|TTF-1|CDX2|CK7,CDX2|CK7|GCDFP-15|MUC5AC|TTF-1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,3.3.1.5.1,2304,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010553|GO:0045893|GO:0045944|GO:0051090,10944465,TTF-1,TTF-2,We suggest that TTF-2 is able to interfere with a specific cofactor required for TTF-1 and Pax-8 activity,0.42,PMID.dPMID10944465.s0.p0,2,2,TTF-2|TTF-1,TTF-1|TTF-2,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,11733512,TTF-1,GATA-6,"GATA-6, a member of the GATA family of zinc finger domain containing transcription factors, is expressed in endodermally derived tissues including the lung, where GATA-6 influences the transcription of target genes, TTF-1, and surfactant proteins.",0.77,PMID.dPMID11733512.s7.p2,3,2,GATA-6|GATA-6|TTF-1,GATA-6|TTF-1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,19060016,thyroid transcription factor-1,GATA-6,"Expression of GATA-6 was examined in relation to thyroid transcription factor-1 expression, survival, proliferation and apoptosis.",0.36,PMID.dPMID19060016.s4.p0,2,2,GATA-6|thyroid transcription factor-1,GATA-6|thyroid transcription factor-1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,3.1.2.16.1,4824,9606,GO:0016564,GO:0006355|GO:0032582,18296735,NK2,Nkx3.1,"Nkx3.1 is a member of the NK2 class of homeodomain proteins and is expressed in development, being an early marker of the sclerotome and prostate gland.",0.39,PMID.dPMID18296735.s12.p0,2,2,Nkx3.1|NK2,NK2|Nkx3.1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20418387,TTF-1,Sp1,"DETA-NO decreased TTF-1, but not Sp1, levels, suggesting that reduced TTF-1 expression contributes to reduced TTF-1 binding activity.",0.41,PMID.dPMID20418387.s7.p2,4,2,TTF-1|Sp1|TTF-1|TTF-1,Sp1|TTF-1,<--
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,16680154,TTF-1,p63,All (13/13) small-cell lung carcinomas were negative for p63 and 92% (12/13) were positive for TTF-1.,0.09,PMID.dPMID16680154.s5.p0,2,2,p63|TTF-1,p63|TTF-1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12760288,TTF-1,p63,"All 23 SCLCs were negative or, rarely, equivocal for p63; 20 (87%) of 23 were TTF-1+; nuclear staining ranged from strong and/or frequent to weak and/or uncommon.",0.03,PMID.dPMID12760288.s4.p0,2,2,p63|TTF-1,p63|TTF-1,
3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,1.2.5.3.1,8648,9606,,,11713256,TTF-1,SRC-1,Role of CBP/p300 and SRC-1 in transcriptional regulation of the pulmonary surfactant protein-A (SP-A) gene by thyroid transcription factor-1 (TTF-1).,0.17,PMID.dPMID11713256.s11.p12,6,5,CBP|p300|SRC-1|SP-A|thyroid transcription factor-1|TTF-1,CBP|p300|SP-A|SRC-1|thyroid transcription factor-1|TTF-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.1,196,9606,,GO:0006355|GO:0006357,11191113,p53,AhR,These findings suggest that the AhR mediated the inverse expression patterns of BRCA-1 and p53 upon exposure to B[a]P.,0.24,PMID.dPMID11191113.s3.p1,3,3,AhR|BRCA-1|p53,AhR|BRCA-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.2.3,406,9606,,GO:0045944,19277210,p53 tumor suppressor,ARNTL,A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.,0.96,PMID.dPMID19277210.s12.p0,2,2,ARNTL|p53 tumor suppressor,ARNTL|p53 tumor suppressor,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.2.0.2,466,9606,,,11709699,p53,EWS-ATF-1,"Here, we demonstrate that EWS-ATF-1 represses p53/CBP-mediated trans-activation function.",1.14,PMID.dPMID11709699.s3.p0,3,3,EWS-ATF-1|p53|CBP,CBP|EWS-ATF-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,17599613,p53,ATF3,"Taken together, our results suggest that ATF3 is under control of p53 in part and that the ATF3 downregulation via p53 degradation may contribute to effective viral production as a modulation mechanism of CVB3 infection-induced cell death",1.71,PMID.dPMID17599613.s0.p0,4,2,ATF3|p53|ATF3|p53,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,12372430,p53,ATF3,These results clearly show that the human ATF3 gene is one of the target genes directly activated by p53 and may suggest a functional link between stress-inducible transcriptional repressor ATF3 and p53,0.68,PMID.dPMID12372430.s0.p0,4,2,ATF3|p53|ATF3|p53,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,16628010,p53,ATF3,ATF3 regulates the stability of p53: a link to cancer.,0.67,PMID.dPMID16628010.s9.p0,2,2,ATF3|p53,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,12161427,p53,ATF3,"Furthermore, the cell-protecting effect of ATF3 was remarkably reduced in p53-deficient cells.",0.57,PMID.dPMID12161427.s2.p0,2,2,ATF3|p53,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,12833146,p53,ATF3,"Using specific inhibitors, we found that the ATM- and Nibrin1-dependent activation of ATF3 does neither require p53 nor reactive oxygen species, but is dependent on the p38 and JNK MAPkinases.",0.35,PMID.dPMID12833146.s3.p0,3,3,ATF3|p53|JNK,ATF3|JNK|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,12372430,p53,ATF3,These results clearly show that the human ATF3 gene is one of the target genes directly activated by p53 and may suggest a functional link between stress-inducible transcriptional repressor ATF3 and p53,0.35,PMID.dPMID12372430.s0.p3,4,2,ATF3|p53|ATF3|p53,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,17599613,p53,ATF3,"CVB3 infection markedly reduced ATF3 expression at mRNA and protein levels in parallel with p53 degradation, and preservation of p53 expression rescued CVB3 infection-induced ATF3 downregulation.",0.27,PMID.dPMID17599613.s3.p1,4,2,ATF3|p53|p53|ATF3,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,20167600,p53,ATF3,"Consistent with its role as a potent E6 antagonist, ATF3 expressed enforcedly in HPV-positive SiHa cells activated p53, leading to expression of p53-target genes (e.g. p21 and PUMA), cell cycle arrest and apoptotic cell death.",0.27,PMID.dPMID20167600.s3.p0,3,2,ATF3|p53|p53,ATF3|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,16847457,p53,ATF3,"Thus, this study demonstrates that the regulation of ATF3 under anoxia is independent of 2-oxoglutarate dioxygenase, HIF-1 and p53, presumably involving multiple regulatory pathways",0.23,PMID.dPMID16847457.s0.p1,3,3,ATF3|HIF-1|p53,ATF3|HIF-1|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.6,467,9606,,,12386811,p53,ATF3,"In addition, ATF3 promoter can be activated by MEKK1, an upstream activator of the ERK and JNK kinase pathway, but not induced following p53 expression.",0.20,PMID.dPMID12386811.s3.p6,5,5,ATF3|MEKK1|ERK|JNK|p53,ATF3|ERK|JNK|MEKK1|p53,<->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.48,639,9606,,GO:0000122,17264218,p53,BLIMP1,BLIMP1 regulates cell growth through repression of p53 transcription.,1.53,PMID.dPMID17264218.s8.p0,2,2,BLIMP1|p53,BLIMP1|p53,e
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.48,639,9606,,GO:0000122,17264218,p53,BLIMP1,Here we report that BLIMP1 acts in an autoregulatory feedback loop that controls p53 activity through repression of p53 transcription.,0.97,PMID.dPMID17264218.s6.p1,3,2,BLIMP1|p53|p53,BLIMP1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.20,688,9606,GO:0003702,,17603560,p53,Kruppel-like factor 5,Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells.,0.85,PMID.dPMID17603560.s10.p0,3,3,Kruppel-like factor 5|p53|Pim1,Kruppel-like factor 5|p53|Pim1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.20,688,9606,GO:0003702,,17603560,p53,KLF5,"Here, we describe a novel role for KLF5 in a p53-independent apoptotic pathway.",0.14,PMID.dPMID17603560.s8.p0,2,2,KLF5|p53,KLF5|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,20353948,p53,RUNX3,Forced expression of RUNX3 enhanced p53-mediated transcriptional activation.,1.08,PMID.dPMID20353948.s4.p0,2,2,RUNX3|p53,p53|RUNX3,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.4.1.0.3,864,9606,,GO:0006355,20353948,p53,RUNX3,"Thus, our present results strongly suggest that RUNX3 acts as a novel co-activator for p53 through regulating its DNA damage-induced phosphorylation at Ser-15 and also provide a clue to understanding the molecular mechanisms underlying RUNX3-mediated tumor suppression",0.59,PMID.dPMID20353948.s0.p0,3,2,RUNX3|p53|RUNX3,p53|RUNX3,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.2,1051,9606,,,16227626,p53,C/EBPbeta,Here we report that C/EBPbeta in turn represses the transcriptional activity of p53.,1.76,PMID.dPMID16227626.s5.p0,2,2,C/EBPbeta|p53,C/EBPbeta|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.2,1051,9606,,,19075931,p53,C/EBPbeta,We conclude from these findings that C/EBPbeta-2 plays a central role in regulating p53 transcription during the transition into S-phase.,0.93,PMID.dPMID19075931.s1.p0,2,2,C/EBPbeta|p53,C/EBPbeta|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,18174288,p53,KLF6,"Stimulation of KLF6 expression by IGF-I in a p53-dependent manner may constitute a novel mechanism of action of IGF-I, with implications in normal cell cycle progression and cancer biology.",0.80,PMID.dPMID18174288.s0.p1,4,3,KLF6|IGF-I|p53|IGF-I,IGF-I|KLF6|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,18174288,p53,Kruppel-like factor-6,Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner.,0.78,PMID.dPMID18174288.s10.p0,2,2,Kruppel-like factor-6|p53,Kruppel-like factor-6|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.36,1316,9606,GO:0016563,GO:0006355,18174288,p53,KLF6,Small interfering RNA against p53 and KLF6 was used to assess the role of p53 in regulation of KLF6 expression by IGF-I and to evaluate KLF6 involvement in cell cycle control.,0.34,PMID.dPMID18174288.s2.p2,6,3,p53|KLF6|p53|KLF6|IGF-I|KLF6,IGF-I|KLF6|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.2.0.1,1385,9606,,GO:0045944,15967108,p53,CREB,"Transcriptional analysis with luciferase reporters driven by SAK promoter deletion fragments identified SP-1 and CREB binding sites, which together conferred a two-fold SAK repression by p53.",0.40,PMID.dPMID15967108.s4.p8,5,4,SAK|SP-1|CREB|SAK|p53,CREB|p53|SAK|SP-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.2.0.1,1385,9606,,GO:0045944,10848610,p53,CREB,"Although coactivator competition is an emerging theme in transcriptional regulation, we have made the fortuitous observation that protein kinase A-phosphorylated CREB strongly enhances p53 association with KIX.",0.17,PMID.dPMID10848610.s5.p0,2,2,CREB|p53,CREB|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.2.0.1,1385,9606,,GO:0045944,19930465,p53,CREB,"Additionally, glucose deprivation led to an efficient recruitment of CREB onto the promoter region of p53 gene carrying the canonical CREB-binding site, indicating that CREB has an ability to bind to the promoter region of p53 gene and transactivate p53.",0.00,PMID.dPMID19930465.s2.p0,6,2,CREB|p53|CREB|CREB|p53|p53,CREB|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,16205645,p53,GADD153,Additional experiments with CHOP/GADD153 siRNA knockdown strongly suggested that CHOP/GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null).,0.60,PMID.dPMID16205645.s1.p9,6,2,CHOP|GADD153|CHOP|GADD153|p53|p53,CHOP|GADD153|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,16205645,p53,CHOP,Additional experiments with CHOP/GADD153 siRNA knockdown strongly suggested that CHOP/GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null).,0.60,PMID.dPMID16205645.s1.p8,6,2,CHOP|GADD153|CHOP|GADD153|p53|p53,CHOP|GADD153|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,16205645,p53,CHOP,Additional experiments with CHOP/GADD153 siRNA knockdown strongly suggested that CHOP/GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null).,0.37,PMID.dPMID16205645.s1.p12,6,2,CHOP|GADD153|CHOP|GADD153|p53|p53,CHOP|GADD153|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,16205645,p53,GADD153,Additional experiments with CHOP/GADD153 siRNA knockdown strongly suggested that CHOP/GADD153 may play a positive role in upregulating the expression of p21(WAF) in a p53-independent manner (PC-3 cells are p53 null).,0.37,PMID.dPMID16205645.s1.p13,6,2,CHOP|GADD153|CHOP|GADD153|p53|p53,CHOP|GADD153|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,15316935,p53,GADD153,"However, the upregulation of GADD34, GADD45, and GADD153 mRNA expression apparently did not require p53, based on the finding that DOC increased expression of all three GADD genes in HCT-15 colonocytes, which express mutant p53.",0.30,PMID.dPMID15316935.s4.p5,5,4,GADD34|GADD45|GADD153|p53|p53,GADD153|GADD34|GADD45|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,10760820,p53,CHOP,"Immunoblotting techniques were used on microdissected fresh frozen tumor specimens, and expression of C/EBPalpha, C/EBPbeta and C/EBPzeta (CHOP) was analyzed in addition to that of the cell-cycle regulator p53 and the proliferation marker PCNA.",0.16,PMID.dPMID10760820.s5.p9,5,4,C/EBPalpha|C/EBPbeta|C/EBPzeta|CHOP|p53,C/EBPalpha|C/EBPbeta|C/EBPzeta|CHOP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,15316935,p53,GADD153,"However, mRNA expression of GADD153 was increased most markedly in DOC-treated HCT-116 colonocytes, which express wild-type p53.",0.11,PMID.dPMID15316935.s5.p0,2,2,GADD153|p53,GADD153|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.1.6,1649,9606,,GO:0043433|GO:0043620,10459501,p53,GADD153,Dysplastic naevi had significantly lower GADD34 and GADD153 expression as well as higher p53 expression in relation to the other naevi groups.,0.01,PMID.dPMID10459501.s1.p2,3,3,GADD34|GADD153|p53,GADD153|GADD34|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,11034215,p53,E2F-1,Here we show that E2F-1 induces the transcription of the p53 homologue p73.,1.27,PMID.dPMID11034215.s2.p0,3,3,E2F-1|p53|p73,E2F-1|p53|p73,e
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,15706352,p53,E2F1,"We show that E2F1 upregulates the expression of four proapoptotic cofactors of p53--ASPP1, ASPP2, JMY and TP53INP1--through a direct transcriptional mechanism.",0.74,PMID.dPMID15706352.s4.p0,4,4,E2F1|p53|JMY|TP53INP1,E2F1|JMY|p53|TP53INP1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,11853884,p53,E2F-1,"However, as experiments in p53 deficient cell lines indicated, the decrease of pRb and E2F-1 is independent of p53 and p21 expression.",0.72,PMID.dPMID11853884.s2.p5,5,4,p53|Rb|E2F-1|p53|p21,E2F-1|p21|p53|Rb,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,9864390,p53,E2F-1,"The E2F-1 protein is able to induce generalized apoptosis in gliomas independently of the p53, p16 or Rb status.",0.54,PMID.dPMID9864390.s3.p0,4,4,E2F-1|p53|p16|Rb,E2F-1|p16|p53|Rb,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,9032231,p53,E2F-1,"Although E2F-1 alone induces moderate levels of p53 and treatment with drugs markedly increased p53, the deleterious effects of etoposide in E2F-1-overexpressing cells were independent of p53 accumulation.",0.49,PMID.dPMID9032231.s5.p1,5,2,E2F-1|p53|p53|E2F-1|p53,E2F-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,16617145,p53,E2F1,"Although it has been well documented that E2F1 is able to induce p53-dependent apoptosis via raising ARF activity, the mechanism by which E2F induces p53-independent apoptosis remains unclear.",0.44,PMID.dPMID16617145.s6.p0,4,3,E2F1|p53|ARF|p53,ARF|E2F1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,15190206,p53,E2F1,E2F1 function is crucial for responding to loss of proper Rb-mediated growth control to activate p53 and the apoptotic program.,0.38,PMID.dPMID15190206.s2.p1,3,3,E2F1|Rb|p53,E2F1|p53|Rb,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,15731768,p53,E2F-1,"We show here that E2F-1 binds in vivo the promoters of ASPP1 and ASPP2 genes, two activators of p53-mediated apoptosis, E2F-1, E2F-2 and E2F-3 all activate the isolated ASPP1 and ASPP2 promoters.",0.33,PMID.dPMID15731768.s2.p3,9,6,E2F-1|ASPP1|ASPP2|p53|E2F-1|E2F-2|E2F-3|ASPP1|ASPP2,ASPP1|ASPP2|E2F-1|E2F-2|E2F-3|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,16434972,p53,E2F1,"Deregulation of the Rb/E2F pathway in human fibroblasts results in an E2F1-mediated apoptosis dependent on Atm, Nbs1, Chk2 and p53.",0.30,PMID.dPMID16434972.s7.p11,6,6,Rb|E2F1|Atm|Nbs1|Chk2|p53,Atm|Chk2|E2F1|Nbs1|p53|Rb,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,16617145,p53,E2F1,"Although it has been well documented that E2F1 is able to induce p53-dependent apoptosis via raising ARF activity, the mechanism by which E2F induces p53-independent apoptosis remains unclear.",0.27,PMID.dPMID16617145.s6.p3,4,3,E2F1|p53|ARF|p53,ARF|E2F1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,9266962,p53,E2F-1,"Several observations indicate MG-132 alleviates squelching by influencing the conformation of newly synthesized p53 and E2F-1:MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107.",0.21,PMID.dPMID9266962.s2.p4,8,3,p53|E2F-1|p53|p53|p53|p53|E2F-1|p107,E2F-1|p107|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,15517862,p53,E2F-1,However ectopic E2F-1 overexpression activates p53 and inhibits growth.,0.21,PMID.dPMID15517862.s6.p0,2,2,E2F-1|p53,E2F-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,11101847,p53,E2F1,"Here we provide evidence that E2F1 directly activates transcription of TP73, leading to activation of p53-responsive target genes and apoptosis.",0.16,PMID.dPMID11101847.s2.p1,3,3,E2F1|TP73|p53,E2F1|p53|TP73,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,8524253,p53,E2F-1,E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis.,0.08,PMID.dPMID8524253.s9.p1,3,3,E2F-1|DP-1|p53,DP-1|E2F-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,10828878,p53,E2F-1,"However, stress signals can induce E2F-1 expression independently of p53 and Rb.",0.07,PMID.dPMID10828878.s2.p0,3,3,E2F-1|p53|Rb,E2F-1|p53|Rb,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,16617145,p53,E2F1,"These results may suggest a novel mechanism by which E2F1 promotes p53-independent apoptosis through directly regulating its downstream mitochondrial apoptosis-inducing factors, such as Smac/DIABLO",0.07,PMID.dPMID16617145.s0.p0,4,3,E2F1|p53|Smac|DIABLO,DIABLO|E2F1|p53|Smac,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,15140942,p53,E2F1,"Deregulation of the Rb-E2F1 pathway also results in the activation of p53 and the promotion of apoptosis, and this contributes to the suppression of tumor development.",0.06,PMID.dPMID15140942.s7.p0,2,2,E2F1|p53,E2F1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,15993550,p53,E2F-1,Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.,0.04,PMID.dPMID15993550.s16.p0,3,2,E2F-1|p53|p53,E2F-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,17690688,p53,E2F1,"Therefore, our studies have revealed a previously unidentified pathway through which the activity of E2F1 may be guarded by activated p53.",0.04,PMID.dPMID17690688.s0.p0,2,2,E2F1|p53,E2F1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.1,1869,9606,,GO:0000122,7561751,p53,E2F-1,Here we test in transfection assays whether EBNA-LP expression has any functional consequence for repression of E2F-1 activity by pRb or p107 or for activation of transcription by the p53 protein.,0.00,PMID.dPMID7561751.s3.p1,3,3,E2F-1|p107|p53,E2F-1|p107|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.2,1870,9606,GO:0003702,,11172602,p53,E2F-2,"Finally, the expression of E2F-2 in D-54 MG cells suppressed the expression of the apoptotic molecule mdm-2 induced by exogenous p53 in these cells.",0.33,PMID.dPMID11172602.s1.p1,3,3,E2F-2|D-54|p53,D-54|E2F-2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.3,1871,9606,,,15177020,p53,E2F3,E2F3-a novel repressor of the ARF/p53 pathway.,0.59,PMID.dPMID15177020.s2.p1,3,3,E2F3|ARF|p53,ARF|E2F3|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.3,1871,9606,,,20428827,P53,E2F3,"Similarly, BCL2 and E2F3 were down-regulated when P53 expression was elevated by ASO treatment.",0.54,PMID.dPMID20428827.s1.p2,3,3,BCL2|E2F3|P53,BCL2|E2F3|P53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.4,1874,9606,,,17981789,p53,E2F4,"Adoptive overexpression of p53, p21 (CIP1/WAF1), and E2F4 down-regulated transcription from the PLK1 and TTK promoters in ATC cells, suggesting that these genes might be under the negative control of tumor suppressors of the p53 and pRB families.",0.67,PMID.dPMID17981789.s3.p25,8,5,p53|p21|CIP1|WAF1|E2F4|PLK1|TTK|p53,CIP1|E2F4|p21|p53|PLK1|TTK|WAF1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.1.4,1874,9606,,,11032828,p53,E2F4,p130/E2F4 binds to and represses the cdc2 promoter in response to p53.,0.30,PMID.dPMID11032828.s5.p2,3,3,p130|E2F4|p53,E2F4|p130|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,15548700,p53,EGR1,Functional assays indicate that induction of EGR1 by mutant p53 contributes to enhanced transformed properties and resistance to apoptosis.,0.96,PMID.dPMID15548700.s1.p0,2,2,EGR1|p53,EGR1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,17822668,p53,Egr-1,"Overall, our results provide direct evidence that Egr-1 positively regulated p73 expression by binding to its promoter in vivo, consistent with Egr-1 and p73 being involved in p53-independent tumor suppression",0.79,PMID.dPMID17822668.s0.p6,5,3,Egr-1|p73|Egr-1|p73|p53,Egr-1|p53|p73,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.1.2,1958,9606,,GO:0045941,16138117,p53,Egr1,"The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.",0.27,PMID.dPMID16138117.s6.p3,5,5,Egr1|TGFbeta1|PTEN|p53|fibronectin,Egr1|fibronectin|p53|PTEN|TGFbeta1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20696891,p53,ERalpha,Sequential ChIP assays demonstrated that ERalpha represses p53-mediated transcriptional activation in human breast cancer cells by recruiting nuclear receptor corepressors (NCoR and SMRT) and histone deacetylase 1 (HDAC1).,1.14,PMID.dPMID20696891.s6.p0,4,4,ERalpha|p53|NCoR|SMRT,ERalpha|NCoR|p53|SMRT,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,16469747,p53,ERalpha,Knocking down p53 and ERalpha by small interfering RNA elicits opposite effects on p53-target gene expression and cell cycle progression.,0.72,PMID.dPMID16469747.s3.p2,3,2,p53|ERalpha|p53,ERalpha|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17699779,p53,ERalpha,"Importantly, mutagenic conversion of this site to an activation element enabled ERalpha to repress p53-mediated transcriptional activation.",0.69,PMID.dPMID17699779.s3.p0,2,2,ERalpha|p53,ERalpha|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17699779,p53,ERalpha,"Chromatin immunoprecipitation assays reveal that ERalpha interacts in vivo with p53 bound to promoters of Survivin and multidrug resistance gene 1, both targets for transcriptional repression by p53.",0.65,PMID.dPMID17699779.s6.p1,3,2,ERalpha|p53|p53,ERalpha|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,10766163,p53,ERalpha,Our results indicate that ERalpha protects p53 from being deactivated by hdm2.,0.54,PMID.dPMID10766163.s2.p0,3,3,ERalpha|p53|hdm2,ERalpha|hdm2|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,17699779,p53,ERalpha,"Here, we report that ERalpha inhibits p53-mediated transcriptional repression.",0.47,PMID.dPMID17699779.s7.p0,2,2,ERalpha|p53,ERalpha|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,12490973,p53,ESR,"LOH was determined by polymerase chain reaction (PCR) using primers TP53, D3S1038, D17S855, and ESR for p53, VHL, BRCA1, and ER genes, respectively.",0.46,PMID.dPMID12490973.s11.p2,6,4,TP53|ESR|p53|VHL|BRCA1|ER,BRCA1|ER|ESR|p53|TP53|VHL,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20696891,p53,ERalpha,These results suggest that ERalpha uses dual strategies to promote abnormal cellular proliferation: enhancing the transcription of ERE-containing proproliferative genes and repressing the transcription of p53-responsive antiproliferative genes.,0.46,PMID.dPMID20696891.s2.p0,2,2,ERalpha|p53,ERalpha|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,19524422,p53,ERalpha,"Considering that MCF-7 cells express functional Estrogen receptor alpha (ERalpha) and wild-type p53, whereas MDA-MB-231 cells which are ERalpha-negative express mutant p53, the anti-proliferation effect of triptolide on MCF-7 and MDA-MB-231 cells were examined, the apoptotic effect and cell cycle arrest caused by triptolide were investigated, ERalpha and p53 expression were also observed in this paper.",0.19,PMID.dPMID19524422.s7.p5,6,2,ERalpha|p53|ERalpha|p53|ERalpha|p53,ERalpha|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,14586398,p53,ets-1,Negative interference with ets-1 transcription requires functional p53 and is lost in mutant p53 proteins.,0.48,PMID.dPMID14586398.s2.p1,3,2,ets-1|p53|p53,ets-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,14586398,p53,ets-1,Negative interference with ets-1 transcription requires functional p53 and is lost in mutant p53 proteins.,0.45,PMID.dPMID14586398.s2.p0,3,2,ets-1|p53|p53,ets-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,15469934,p53,ETS-1,"Furthermore, ETS-1 mediated activation of IKKalpha is negatively regulated by p53 binding to ETS-1.",0.04,PMID.dPMID15469934.s7.p1,4,3,ETS-1|IKKalpha|p53|ETS-1,ETS-1|IKKalpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.2.1.2,2114,9606,,GO:0045893,10510472,p53,ETS2,"We have previously shown that ETS transcription factors, regulate cell growth and differentiation, and ETS1 and ETS2 are able to transcriptionally regulate wt p53 gene expression.",0.63,PMID.dPMID10510472.s7.p2,3,3,ETS1|ETS2|p53,ETS1|ETS2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.2.1.2,2114,9606,,GO:0045893,12554679,p53,ETS2,"Therefore, we conclude that overexpression of human chromosome 21-encoded ETS2 induces apoptosis that is dependent on p53.",0.17,PMID.dPMID12554679.s1.p0,2,2,ETS2|p53,ETS2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,10769646,p53,ara,"The cell treatment with 0.1, 1 and 10 microM ara-C for 48 hours showed increased p53 protein expression in most of these lines.",1.99,PMID.dPMID10769646.s7.p0,2,2,ara|p53,ara|p53,x
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.1.3.1,2296,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0045893|GO:0045944|GO:0051090,9365241,p53 tumor suppressor,ara,The expression of c-Abl (K-R) blocked ara-C-induced apoptosis by a mechanism that is at least in part independent of the p53 tumor suppressor.,0.24,PMID.dPMID9365241.s2.p2,3,3,c-Abl|ara|p53 tumor suppressor,ara|c-Abl|p53 tumor suppressor,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,19235838,p53,FoxM1,"Taken together, the FoxM1 gene is aberrantly activated in gastric cancer and its inhibition triggers p53- and p16-independent senescence of cancer cells by regulating the expression of p27(kip1) and other targets.",0.24,PMID.dPMID19235838.s1.p0,3,3,FoxM1|p53|p16,FoxM1|p16|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8817002,p53,c-fos,"In this study we determined whether the repression of c-fos at M1 was downstream of the p53 or pRB-like ""arms"" of the M1 mechanism.",0.55,PMID.dPMID8817002.s8.p0,2,2,c-fos|p53,c-fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,7576299,p53,Fos,Fos was expressed in 21 of 25 (84%) and four negative cases were all p53-positive; this negative correlation between p53 and Fos staining was statistically significant (P < 0.01).,0.53,PMID.dPMID7576299.s3.p0,4,2,Fos|p53|p53|Fos,Fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,8524298,p53,c-Fos,The data suggest that c-Fos protein plays a causal role in the activation of apoptosis in a p53-dependent manner.,0.45,PMID.dPMID8524298.s1.p0,2,2,c-Fos|p53,c-Fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,10082525,p53,c-fos,Identification of c-fos as a specific target for transcriptional activation by p53 establishes a direct link between these two pivotal regulatory proteins and raises the possibility that c-fos contributes to some of the biological effects of p53,0.26,PMID.dPMID10082525.s0.p0,4,2,c-fos|p53|c-fos|p53,c-fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,7576299,p53,Fos,These data suggest the possibility of down regulation of Fos expression by high levels of p53 protein.,0.24,PMID.dPMID7576299.s1.p0,2,2,Fos|p53,Fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,9108200,p53,c-fos,"In other tissues, e.g. muscle and bone, c-fos was found together with p53, suggesting an antagonistic action of these proliferative and antiproliferative factors.",0.15,PMID.dPMID9108200.s2.p0,2,2,c-fos|p53,c-fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,1652755,p53,c-fos,"The human p53 mutant derived from pC53-SCX3 was also less active than the wt protein in repressing the IL-6, c-fos, beta-actin, and MHC promoters, except that serum-induced IL-6/CAT expression was equally repressed by both human wt and mutant p53.",0.00,PMID.dPMID1652755.s2.p7,5,4,p53|c-fos|beta-actin|CAT|p53,beta-actin|CAT|c-fos|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,19214186,p53,GLI1,"Mechanistically, p53 inhibits the activity, nuclear localisation and levels of GLI1 and in turn, GLI1 represses p53, establishing an inhibitory loop.",1.35,PMID.dPMID19214186.s2.p5,4,2,p53|GLI1|GLI1|p53,GLI1|p53,c
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,20581802,p53,GLI1,"However, GLI1 also requires NANOG activity forming a positive loop, which is negatively controlled by p53 and vice versa.",0.92,PMID.dPMID20581802.s3.p0,2,2,GLI1|p53,GLI1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15780936,p53,HIF-1alpha,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,1.35,PMID.dPMID15780936.s2.p3,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,p
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,16736613,p53,HIF-1alpha,"RESULTS: With the scar maturation, the expression of HIF-1alpha gradually decreased while the expression of p53 gradually increased within one year.",0.57,PMID.dPMID16736613.s3.p2,3,3,scar|HIF-1alpha|p53,HIF-1alpha|p53|scar,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,10469629,p53,HIF-1,"Since non-functional p53 was expressed in both HOS and SA-8 cells, acute Ni treatment induced HIF-1alpha protein and HIF-1-dependent transcription without affecting p53.",0.56,PMID.dPMID10469629.s4.p5,4,2,p53|HIF-1alpha|HIF-1|p53,HIF-1|HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,20706634,p53,HIF-1alpha,"CONCLUSION AND SIGNIFICANCE: In summary, we identified HIF-1alpha as a potent regulator of p53 and NF-kappaB activity under conditions of genotoxic stress.",0.52,PMID.dPMID20706634.s1.p0,2,2,HIF-1alpha|p53,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,16951228,p53,HIF-1alpha,"When stratified for HIF-1alpha and p53 positivity, the patients who were p53-negative and HIF-1alpha-negative had the most favorable prognosis, whereas patients who were p53-positive and HIF-1alpha-positive had the worst prognosis (P=0.0018).",0.39,PMID.dPMID16951228.s2.p1,6,2,HIF-1alpha|p53|p53|HIF-1alpha|p53|HIF-1alpha,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,20479887,p53,HIF-1alpha,"In this study we demonstrate that the inhibitory effect of mitomycin C on HIF-1alpha protein expression is not dependent on p53 and protein degradation, but also involves HIF-1alpha translational regulation.",0.34,PMID.dPMID20479887.s5.p0,3,2,HIF-1alpha|p53|HIF-1alpha,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,12060345,p53,HIF-1alpha,No correlation was found between the presence of HIF-1alpha protein and immunohistochemical expression of p53 protein.,0.29,PMID.dPMID12060345.s1.p0,2,2,HIF-1alpha|p53,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,16294025,p53,Hif-1alpha,Forced expression of Hif-1alpha is also surprisingly a potent inducer of apoptosis in wild-type p53 expressing H460 cells and further promotes TRAIL-induced apoptosis.,0.28,PMID.dPMID16294025.s4.p0,3,3,Hif-1alpha|p53|TRAIL,Hif-1alpha|p53|TRAIL,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,14992692,p53,HIF-1alpha,"Destruction of HIF-1alpha by p53 was corroborated in the present study by using pVHL-deficient RCC4 (renal carcinoma) cells, supporting the notion of a pVHL-independent degradation process.",0.20,PMID.dPMID14992692.s5.p0,4,3,HIF-1alpha|p53|pVHL|pVHL,HIF-1alpha|p53|pVHL,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,11059752,p53,HIF-1,"Therefore, high inducibility of HIF-1-dependent genes, loss of p53 functions with high ratio of HIF-1-dependent:p53-dependent transcription, and loss of sensitivity to p21 inhibition is a part of hypoxic phenotype associated with aggressive cancer behavior",0.12,PMID.dPMID11059752.s0.p0,5,3,HIF-1|p53|HIF-1|p53|p21,HIF-1|p21|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,16951228,p53,HIF-1alpha,"When stratified for HIF-1alpha and p53 positivity, the patients who were p53-negative and HIF-1alpha-negative had the most favorable prognosis, whereas patients who were p53-positive and HIF-1alpha-positive had the worst prognosis (P=0.0018).",0.09,PMID.dPMID16951228.s2.p6,6,2,HIF-1alpha|p53|p53|HIF-1alpha|p53|HIF-1alpha,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,15592500,p53,HIF-1,"Further, we provide genetic evidence that induction of Ero1-L alpha by hypoxia and hypoglycemia is mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1) but is independent of p53.",0.09,PMID.dPMID15592500.s3.p0,2,2,HIF-1|p53,HIF-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,10469629,p53,HIF-1alpha,"Since non-functional p53 was expressed in both HOS and SA-8 cells, acute Ni treatment induced HIF-1alpha protein and HIF-1-dependent transcription without affecting p53.",0.08,PMID.dPMID10469629.s4.p4,4,2,p53|HIF-1alpha|HIF-1|p53,HIF-1|HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,18069627,p53,HIF-1alpha,"Additionally, apigenin inhibited the expression of HIF-1alpha and p-AKT, induced the expression of p53, but had no effect on the expression of p-ERK1/2.",0.06,PMID.dPMID18069627.s1.p0,2,2,HIF-1alpha|p53,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,18574470,p53,HIF-1alpha,PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.,0.05,PMID.dPMID18574470.s8.p2,3,3,PCAF|HIF-1alpha|p53,HIF-1alpha|p53|PCAF,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,12213583,p53,HIF-1alpha,"More severe or prolonged hypoxia rather induces apoptosis that is, at least in part, initiated by the direct association of HIF-1alpha and p53 and p53-induced gene expression.",0.01,PMID.dPMID12213583.s2.p1,3,2,HIF-1alpha|p53|p53,HIF-1alpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,12799451,p53,HMGB-1,The acidic C-terminal domain and A-box of HMGB-1 regulates p53-mediated transcription.,2.95,PMID.dPMID12799451.s8.p0,2,2,HMGB-1|p53,HMGB-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,12799451,p53,High Mobility Group protein B-1,"The architectural DNA- binding protein, High Mobility Group protein B-1 is a unique activator of p53.",1.26,PMID.dPMID12799451.s6.p0,2,2,High Mobility Group protein B-1|p53,High Mobility Group protein B-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,9472015,p53,HMG-1,"Unexpectedly, HMG-1 also stimulates DNA binding by p53Delta30, a carboxy-terminally deleted form of the protein that is considered to be constitutively active, suggesting that HMG-1 stimulates p53 by a mechanism that is distinct from other known activators of p53.",0.79,PMID.dPMID9472015.s2.p5,5,2,HMG-1|p53|HMG-1|p53|p53,HMG-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,9472015,p53,HMG-1,"HMG-1 promotes the assembly of higher order p53 nucleoprotein structures, and these data, along with the fact that HMG-1 is capable of bending DNA, suggest that HMG-1 may activate p53 DNA binding by a novel mechanism involving a structural change in the target DNA",0.49,PMID.dPMID9472015.s0.p9,5,2,HMG-1|p53|HMG-1|HMG-1|p53,HMG-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,9472015,p53,HMG-1,High mobility group protein-1 (HMG-1) is a unique activator of p53.,0.46,PMID.dPMID9472015.s8.p0,2,2,HMG-1|p53,HMG-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,12799451,p53,HMGB-1,"In conclusion, these results elucidate the role of acidic C-terminal domain and A-box of HMGB-1 in p53-mediated transcriptional activation and its further downstream effect.",0.42,PMID.dPMID12799451.s0.p0,2,2,HMGB-1|p53,HMGB-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,11106654,p53,HMG1,Interaction between HMG1 and p53 required the HMG A box of HMG1 and amino acids 363-376 of p53.,0.36,PMID.dPMID11106654.s4.p3,4,2,HMG1|p53|HMG1|p53,HMG1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,12215537,p53,HMGB1,"Moreover, HMGB1 augmented binding to the linear DNA but not to the microcircle, suggesting that HMGB1 works by providing prebent DNA to p53.",0.36,PMID.dPMID12215537.s5.p2,3,2,HMGB1|HMGB1|p53,HMGB1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,9472015,p53,HMG-1,"Unexpectedly, HMG-1 also stimulates DNA binding by p53Delta30, a carboxy-terminally deleted form of the protein that is considered to be constitutively active, suggesting that HMG-1 stimulates p53 by a mechanism that is distinct from other known activators of p53.",0.35,PMID.dPMID9472015.s2.p8,5,2,HMG-1|p53|HMG-1|p53|p53,HMG-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,9472015,p53,HMG-1,"HMG-1 promotes the assembly of higher order p53 nucleoprotein structures, and these data, along with the fact that HMG-1 is capable of bending DNA, suggest that HMG-1 may activate p53 DNA binding by a novel mechanism involving a structural change in the target DNA",0.13,PMID.dPMID9472015.s0.p8,5,2,HMG-1|p53|HMG-1|HMG-1|p53,HMG-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.2.0.10,3146,9606,,GO:0000122|GO:0006357|GO:0017055|GO:0045944,12799451,p53,HMGB-1,Here we report that both the C-terminal domain and A-box of HMGB-1 are critical for stimulation of p53-mediated DNA binding to its cognate site.,0.07,PMID.dPMID12799451.s4.p0,2,2,HMGB-1|p53,HMGB-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,16540646,p53,HMGA1,"Moreover, inhibition of HMGA1 expression in thyroid cancer cells resulted in increased p53 oligomerization in response to the DNA-damaging agent doxorubicin.",0.79,PMID.dPMID16540646.s2.p0,2,2,HMGA1|p53,HMGA1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,17290307,p53,HMGA1,"HIPK2 depletion by RNA interference suppressed the antiapoptotic effect of HMGA1, which indicates that HIPK2 is the target required for HMGA1 to repress the apoptotic activity of p53.",0.65,PMID.dPMID17290307.s2.p9,5,3,HIPK2|HMGA1|HIPK2|HMGA1|p53,HIPK2|HMGA1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,16341121,p53,HMGA1,"We found that HMGA1 binds p53 in vitro and in vivo, and both proteins are present in the same complexes bound to the Bax gene promoter.",0.57,PMID.dPMID16341121.s4.p0,3,3,HMGA1|p53|Bax,Bax|HMGA1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,20530667,p53,HMGA1,"Here, we report that HMGA1 antagonizes the p53-mediated transcriptional repression of another apoptosis-related gene, Bcl-2, suggesting a novel mechanism by which HMGA1 counteracts apoptosis.",0.57,PMID.dPMID20530667.s3.p0,4,3,HMGA1|p53|Bcl-2|HMGA1,Bcl-2|HMGA1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,20530667,p53,HMGA1,"By this mechanism, HMGA1 modulates the transcription of p53 target genes such as Mdm2, p21(waf1), and Bax, inhibiting apoptosis.",0.56,PMID.dPMID20530667.s4.p0,4,4,HMGA1|p53|Mdm2|Bax,Bax|HMGA1|Mdm2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,16540646,p53,HMGA1,"These results indicate a new function of HMGA1 in the regulation of p53 family members, thus providing new mechanistic insights in tumor progression",0.55,PMID.dPMID16540646.s0.p0,2,2,HMGA1|p53,HMGA1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,16540646,p53,HMGA1,"We now show that in thyroid cancer cells, HMGA1 down-regulation by small interfering RNA and antisense techniques results in enhanced transcriptional activity of p53, TAp63alpha, TAp73alpha, and, consequently, increased apoptosis.",0.38,PMID.dPMID16540646.s4.p0,2,2,HMGA1|p53,HMGA1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.1,3159,9606,,GO:0006345|GO:0045941,16341121,p53,HMGA1,HMGA1 interferes with the p53-mediated transcription of p53 effectors Bax and p21(waf1) while cooperates with p53 in the transcriptional activation of the p53 inhibitor mdm2.,0.18,PMID.dPMID16341121.s3.p15,8,5,HMGA1|p53|p53|Bax|waf1|p53|p53|mdm2,Bax|HMGA1|mdm2|p53|waf1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.4.0.1,3164,9606,,GO:0034339,9659517,p53,N10,"Consequently, immunocytochemistry, Western blotting and flow cytometry revealed that N10 expressed a higher level of mutant p53 protein than did parental KB, suggesting the involvement of mutant p53 protein in radioresistance of N10",0.71,PMID.dPMID9659517.s0.p0,4,2,N10|p53|p53|N10,N10|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.4.0.1,3164,9606,,GO:0034339,17139261,p53,TR3,"Here, we present the first evidence that inhibition of TR3 on MDM2 is mediated by p53.",0.60,PMID.dPMID17139261.s5.p1,3,3,TR3|MDM2|p53,MDM2|p53|TR3,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.4.0.1,3164,9606,,GO:0034339,17139261,p53,TR3,"TR3 downregulates p53 transcriptional activity by blocking its acetylation, leading to a decrease on the transcription level of MDM2.",0.39,PMID.dPMID17139261.s3.p0,3,3,TR3|p53|MDM2,MDM2|p53|TR3,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,17929268,p53,TCF,Down-regulation of TCF-signalling by p53wt and p53(273His) was accompanied by a reduction in beta-catenin protein level.,0.11,PMID.dPMID17929268.s4.p0,3,2,TCF|p53|p53,p53|TCF,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.5.1,3202,9606,,GO:0045944,17167183,p53,HOXA5,Recent evidence has indicated that HOXA5 regulates both p53 and progesterone receptor expression levels in breast cancer cells.,1.70,PMID.dPMID17167183.s8.p0,2,2,HOXA5|p53,HOXA5|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.5.1,3202,9606,,GO:0045944,20042682,p53,HOXA5,It has been suggested that HOXA5 possesses growth-suppressive properties through activation of p53 expression in human breast tissue.,0.96,PMID.dPMID20042682.s7.p0,2,2,HOXA5|p53,HOXA5|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.5.1,3202,9606,,GO:0045944,10875927,p53,HOXA5,"Thus, HOXA5 may behave as a transcriptional regulator of multiple target genes, two among which are p53 and the progesterone receptor.",0.58,PMID.dPMID10875927.s0.p0,2,2,HOXA5|p53,HOXA5|p53,[3202-->5241]
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.5.1,3202,9606,,GO:0045944,16756717,p53,HOXA5,"Although HOXA5 has been shown to regulate the expression of the tumor-suppressor protein p53, its role in breast tumorigenesis is not well understood.",0.47,PMID.dPMID16756717.s7.p0,2,2,HOXA5|p53,HOXA5|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.7.5,3206,9606,,,15044858,p53,HOXA10,HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells.,3.59,PMID.dPMID15044858.s10.p0,2,2,HOXA10|p53,HOXA10|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.7.5,3206,9606,,,15044858,p53,HOXA10,The mechanism by which estrogen and other estrogen receptor modulators influence both normal breast development as well as breast cancer may involve the regulation of developmental control genes such as HOXA10; HOXA10 in turn regulates expression of key downstream genes such as p53 and regulates tumor cell functional phenotype,1.38,PMID.dPMID15044858.s0.p2,3,2,HOXA10|HOXA10|p53,HOXA10|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.7.5,3206,9606,,,15044858,p53,HOXA10,"BT20 cells, which are ER (-) and do not endogenously express HOXA10, were used to assay the effect of increased HOXA10 expression on p53 expression and on the invasive phenotype.",1.35,PMID.dPMID15044858.s3.p2,3,2,HOXA10|HOXA10|p53,HOXA10|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.1.7.5,3206,9606,,,15044858,p53,HOXA10,Constitutively expressing HOXA10 in BT20 cells increased p53 protein expression.,0.36,PMID.dPMID15044858.s2.p0,2,2,HOXA10|p53,HOXA10|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.4.1.0.1,3297,9606,,,19295133,p53,HSF1,"Analysis of natural and synthetic cis elements demonstrates that HSF1 can enhance p53-mediated transcription, whilst depletion of HSF1 reduces the expression of p53-responsive transcripts.",1.57,PMID.dPMID19295133.s3.p5,4,2,HSF1|p53|HSF1|p53,HSF1|p53,c
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.4.1.0.1,3297,9606,,,19295133,p53,HSF1,"Analysis of natural and synthetic cis elements demonstrates that HSF1 can enhance p53-mediated transcription, whilst depletion of HSF1 reduces the expression of p53-responsive transcripts.",0.57,PMID.dPMID19295133.s3.p0,4,2,HSF1|p53|HSF1|p53,HSF1|p53,c
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.4.1.0.1,3297,9606,,,20180806,p53,HSF1,"Furthermore, in HepG2 cells, induced Hsp70 is regulated by both p53 and heat shock transcription factor 1 (HSF1) wherein HSF1 levels are modulated by p53.",0.15,PMID.dPMID20180806.s3.p9,5,3,Hsp70|p53|HSF1|HSF1|p53,HSF1|Hsp70|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,19079342,p53,Id-1,Id-1 negatively regulated both p53 and PTEN at the transcriptional level.,1.62,PMID.dPMID19079342.s5.p0,2,2,Id-1|p53,Id-1|p53,e
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.8.0.1,3397,9606,GO:0016564,GO:0010621|GO:0016481|GO:0043433,19079342,p53,Id-1,"In promoter assay with serial deletion and chromatin immunoprecipitation assay, the binding of p53 to the PTEN promoter was reduced by Id-1, suggesting that Id-1 regulates PTEN transcription through its p53 modulation.",1.17,PMID.dPMID19079342.s4.p5,4,2,p53|Id-1|Id-1|p53,Id-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,18701504,p53,Id2,"To confirm this, Northern blot analysis was performed and showed that the expression level of Id2 was regulated by various mutant p53s in multiple cell lines.",1.31,PMID.dPMID18701504.s4.p0,2,2,Id2|p53,Id2|p53,e
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,18701504,p53,Id2,"Consistent with these observations, expression of endogenous Id2 was found to be inhibited by exogenous mutant p53 in p53-null HCT116 cells.",0.67,PMID.dPMID18701504.s2.p1,3,2,Id2|p53|p53,Id2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.8.0.2,3398,9606,,GO:0016481|GO:0043433,18701504,p53,Id2,"Consistent with these observations, expression of endogenous Id2 was found to be inhibited by exogenous mutant p53 in p53-null HCT116 cells.",0.67,PMID.dPMID18701504.s2.p0,3,2,Id2|p53|p53,Id2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.1,3659,9606,,,11390621,p53,IRF1,vIRF1 suppresses p53-dependent transcription and deregulates its apoptotic activity.,0.80,PMID.dPMID11390621.s1.p0,2,2,IRF1|p53,IRF1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.1,3659,9606,,,15548708,p53,IRF-1,Immunoblotting analyses supported the contention that ectopic expression of the IRF-1 protein results in down-regulation of survivin protein expression that is independent of p53.,0.45,PMID.dPMID15548708.s5.p1,3,3,IRF-1|survivin|p53,IRF-1|p53|survivin,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.1,3659,9606,,,17651018,p53,IRF-1,"Expression of IRF-1 was induced and expression of active caspase-3 was promoted by IFN-gamma treatment, but IFN-gamma did not affect the expression of IFNGR and p53.",0.44,PMID.dPMID17651018.s0.p6,5,4,IRF-1|IFN-gamma|IFN-gamma|IFNGR|p53,IFN-gamma|IFNGR|IRF-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.1,3659,9606,,,11390621,p53,IRF1,These results suggest that vIRF1 may regulate cellular function by inhibiting p53,0.31,PMID.dPMID11390621.s0.p0,2,2,IRF1|p53,IRF1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.1,3659,9606,,,15365257,p53,IRF-1,"Up-regulation of p21WAF1 and IRF-1 expression is transcriptional, but independent of p53.",0.20,PMID.dPMID15365257.s6.p0,2,2,IRF-1|p53,IRF-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.1,3659,9606,,,7579440,p53,IRF-1,"Possible IRF-1 binding sequence elements have been located in the promoter regions of several genes, including p53, inducible nitric oxide synthase, and cyclin D1.",0.14,PMID.dPMID7579440.s10.p0,2,2,IRF-1|p53,IRF-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.3.0.5,3663,9606,,,11973653,p53,IRF-5,"These results suggest that IRF-5 is a novel p53-target, and that it might mediate the p53-dependent immune response.",0.29,PMID.dPMID11973653.s0.p0,3,2,IRF-5|p53|p53,IRF-5|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15817159,p53,AP-1,"Activated Notch1 in these cells represses viral E6/E7 expression through AP-1 down-modulation, resulting in increased p53 expression and a block of pRb hyperphosphorylation.",1.45,PMID.dPMID15817159.s5.p2,3,3,Notch1|AP-1|p53,AP-1|Notch1|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18094076,p53,c-Jun,"In KB-3 cells, which have compromised p53 function, and in p53-null cells but not in p53 wild-type cells, vinblastine caused down-regulation of p21 expression concomitant with increased c-Jun expression, suggesting a role for c-Jun in negative regulation of the p21 promoter independent of p53.",1.36,PMID.dPMID18094076.s1.p14,6,2,p53|p53|p53|c-Jun|c-Jun|p53,c-Jun|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8714126,p53,AP-1,Transcription factors C-EBP and AP-1 modulate the promotor activity of the regulatory region of human p53 gene,0.51,PMID.dPMID8714126.s0.p0,2,2,AP-1|p53,AP-1|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18094076,p53,c-Jun,"In KB-3 cells, which have compromised p53 function, and in p53-null cells but not in p53 wild-type cells, vinblastine caused down-regulation of p21 expression concomitant with increased c-Jun expression, suggesting a role for c-Jun in negative regulation of the p21 promoter independent of p53.",0.49,PMID.dPMID18094076.s1.p13,6,2,p53|p53|p53|c-Jun|c-Jun|p53,c-Jun|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11867732,p53,c-Jun,Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.,0.44,PMID.dPMID11867732.s10.p1,3,2,c-Jun|p53|p53,c-Jun|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,18374905,p53,c-jun,Inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) represses the expression of presenilin-1 by a p53-dependent mechanism.,0.37,PMID.dPMID18374905.s16.p3,4,4,c-jun|JNK|presenilin-1|p53,c-jun|JNK|p53|presenilin-1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,7576299,p53,Jun,Jun was detected in 14 of 20 (70%) and no significant relationship was observed between the expression of Jun and Fos or p53.,0.35,PMID.dPMID7576299.s2.p3,4,3,Jun|Jun|Fos|p53,Fos|Jun|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19920812,p53,c-Jun,"The model predicted three dominant transcriptional activity profiles-an early response controlled by NFkappaB and c-Jun, a delayed response controlled by p53, and a late response related to cell cycle re-entry.",0.27,PMID.dPMID19920812.s5.p2,3,3,NFkappaB|c-Jun|p53,c-Jun|NFkappaB|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11325852,p53,c-jun,"Nonetheless, the ligation-mediated PCR technology was used here to demonstrate, at nucleotide resolution, that p53-/-p21+/+ DLD1 excises UVB-induced cyclobutane pyrimidine dimers from the c-jun proto-oncogene at a significantly lower rate than the isogenic p53-/-p21-/- derivative.",0.21,PMID.dPMID11325852.s2.p5,5,3,p53|p21|c-jun|p53|p21,c-jun|p21|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,8264230,p53,JUN,"CONCLUSIONS: We conclude that independent expression of RAS, JUN, and FOS occurred significantly more often in large tubulovillous adenomas and adenocarcinomas while p53 expression occurred primarily in adenocarcinomas.",0.17,PMID.dPMID8264230.s2.p1,3,3,JUN|FOS|p53,FOS|JUN|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,10357405,p53,DPC4,"Mutation analysis of the p53, p16, DPC4, and K-ras genes showed only a polymorphism at codon 72 of the p53 gene and no mutations in any of the genes.",0.17,PMID.dPMID10357405.s1.p8,5,4,p53|p16|DPC4|K-ras|p53,DPC4|K-ras|p16|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.3.0.1,4094,9606,GO:0003702,,12149651,p53,Maf,This was in contrast to the role of c-Maf in the activation of Maf recognition element (MARE) mediated p53 gene expression.,0.01,PMID.dPMID12149651.s9.p1,3,2,Maf|Maf|p53,Maf|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.5,4149,9606,,,7969121,p53,Max,Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.,0.19,PMID.dPMID7969121.s10.p5,4,3,p53 tumor suppressor|c-Myc|Max|p53,c-Myc|Max|p53|p53 tumor suppressor,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,12773566,p53,MLL,"Finally, our results demonstrate that MLL-ELL requires the presence of intact ELL(eCT) in order to disrupt p53 interactions with p300/CBP coactivator and thus significantly reduce p53 acetylation in vivo.",0.61,PMID.dPMID12773566.s1.p3,7,5,MLL|ELL|ELL|p53|p300|CBP|p53,CBP|ELL|MLL|p300|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,17062917,P53,MLL,We have recently found that the MLL leukemic fusions can abolish the activity of P53 tumor suppressor protein that actively guards against the appearance of cancer by instructing damaged cells to self-destruct.,0.54,PMID.dPMID17062917.s2.p0,2,2,MLL|P53,MLL|P53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,12773566,p53,MLL,"Finally, our results demonstrate that MLL-ELL requires the presence of intact ELL(eCT) in order to disrupt p53 interactions with p300/CBP coactivator and thus significantly reduce p53 acetylation in vivo.",0.50,PMID.dPMID12773566.s1.p15,7,5,MLL|ELL|ELL|p53|p300|CBP|p53,CBP|ELL|MLL|p300|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,15921626,p53,MLL,"The rearrangement of MLL gene, deletion of p53 gene, and translocation between chromosomes 6 and 11 were revealed by FISH.",0.10,PMID.dPMID15921626.s8.p0,2,2,MLL|p53,MLL|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.1.0.3,4605,9606,,,19383908,p53,B-MYB,B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.,0.90,PMID.dPMID19383908.s7.p0,2,2,B-MYB|p53,B-MYB|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.1.0.3,4605,9606,,,19383908,p53,B-MYB,"We find that B-MYB fails to dissociate from LINC in p53 mutant cells, that this contributes to increased G(2)-M gene expression in response to DNA damage in these cells, and, importantly, that B-MYB is required for recovery from the G(2) DNA damage checkpoint in p53-negative cells.",0.21,PMID.dPMID19383908.s2.p5,4,2,B-MYB|p53|B-MYB|p53,B-MYB|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.1.0.3,4605,9606,,,7937841,p53,B-myb,In this study we show that B-myb expression is required for cells to progress from G1 into S phase and that high levels of ectopic B-myb expression uncoupled from cell cycle regulation rescues cells from p53-induced G1 arrest even in the presence of Waf1/Cip1 transactivation and inhibition of cyclin E/Cdk2 kinase activity.,0.04,PMID.dPMID7937841.s2.p2,4,3,B-myb|B-myb|p53|Cip1,B-myb|Cip1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7969121,p53,c-Myc,"Taken together, our findings support a direct role for c-Myc in elevating expression of the mutant p53 gene in some tumors",1.15,PMID.dPMID7969121.s0.p0,2,2,c-Myc|p53,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1334053,p53,c-myc,"The c-myc-positive tumors had a significantly higher level of p53 expression, judged by PAb 1801 and PAb 240, than c-myc-negative tumors.",0.94,PMID.dPMID1334053.s4.p0,3,2,c-myc|p53|c-myc,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9632756,p53,c-myc,Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain.,0.90,PMID.dPMID9632756.s6.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20587660,p53,c-Myc,"Chromatin immunoprecipitation assay and RNA interference studies with cells deficient in p53 and p21 show that ascofuranone induces p21(WAF1/CIP1) expression and subsequent G(1) arrest through the release of p21(WAF1/CIP1) promoter from c-Myc-mediated transcriptional repression, independent of p53.",0.82,PMID.dPMID20587660.s3.p20,7,3,p53|WAF1|CIP1|WAF1|CIP1|c-Myc|p53,CIP1|c-Myc|p53|WAF1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8460477,p53,c-Myc,"We conclude that c-Myc is regulated at the transcriptional level, whereas p53 is regulated at the post-translational level in adenovirus transformants",0.77,PMID.dPMID8460477.s0.p0,2,2,c-Myc|p53,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19202062,p53,c-Myc,"Together, these results define the role of miR-145 in the posttranscriptional regulation of c-Myc by p53 and suggest that, as a new member of the p53 regulatory network, miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network",0.69,PMID.dPMID19202062.s0.p0,5,2,c-Myc|p53|p53|p53|c-Myc,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12748190,p53,c-Myc,Overexpressed c-Myc reduced the transcription of p21/CDKN1A and impaired p53-mediated repression but did not abolish repression by ectopic p21.,0.69,PMID.dPMID12748190.s1.p3,5,3,c-Myc|p21|CDKN1A|p53|p21,CDKN1A|c-Myc|p21|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8750149,p53,c-myc,CONCLUSION: We conclude that c-myc might induce p53 expression in human colorectal cancer and that wild-type but not mutant p53 might be involved in a negative feedback regulation of c-myc expression.,0.68,PMID.dPMID8750149.s1.p0,4,2,c-myc|p53|p53|c-myc,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,16169462,p53,MYC,"Acute MYC expression increases p53 or ARF levels and induces apoptosis, and previous transgenic animal studies revealed frequent inactivating mutations of p53 or p19ARF in transgenic Myc-induced lymphomas.",0.60,PMID.dPMID16169462.s2.p0,5,3,MYC|p53|ARF|p53|p19ARF,ARF|MYC|p19ARF|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,16953238,p53,c-myc,"Several reports implicate hnRNP K having a role in tumorigenesis, for instance hnRNP K increases transcription of the oncogene c-myc and hnRNP K expression is regulated by the p53/MDM 2 pathway.",0.56,PMID.dPMID16953238.s7.p8,5,3,hnRNP K|hnRNP K|c-myc|hnRNP K|p53,c-myc|hnRNP K|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,20150224,p53,c-myc,"The c-myc was significantly induced by the chloroform extract at the earlier phase of treatment, followed by p53 and caspase-3.",0.52,PMID.dPMID20150224.s3.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8845569,p53,c-myc,"The high levels of c-myc transcripts and protein could regulate myeloma cell proliferation and apoptotic death by controlling p53 expression and, through it, the expression of the Rb and BAX genes.",0.50,PMID.dPMID8845569.s2.p0,4,4,c-myc|p53|Rb|BAX,BAX|c-myc|p53|Rb,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10822369,p53,c-Myc,"Expression of c-Myc significantly attenuated apoptosis and impaired the transcriptional activity of p53 on p21WAF1, Bax and cytomegalovirus promoters.",0.40,PMID.dPMID10822369.s4.p0,3,3,c-Myc|p53|Bax,Bax|c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8203922,p53,c-myc,"Among the squamous cell carcinoma cases, there were one case (11%) of c-myc expression and one case (11%) of p53 expression.",0.36,PMID.dPMID8203922.s4.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15547708,p53,c-Myc,"Similarly, mRNA encoding c-Myc, a well-known regulator of p53, was decreased in NaBu-treated cells, while p21(Waf1/Cip1) mRNA was increased.",0.32,PMID.dPMID15547708.s5.p0,4,3,c-Myc|p53|Waf1|Cip1,Cip1|c-Myc|p53|Waf1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10037186,p53,c-myc,"Suppression of c-myc using antisense oligodeoxynucleotides (in the absence of p53) was sufficient to trigger apoptosis in Tu-138 cells, raising the possibility that the reduction of c-myc may be involved in at least one of the cell death pathways mediated by p53.",0.31,PMID.dPMID10037186.s5.p5,4,2,c-myc|p53|c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11148566,p53,c-myc,"CONCLUSIONS: Because c-myc is a known inducer of wild type p53, decreased c-myc expression may lead to uncontrolled cell growth because of the lack of p53 expression that normally induces apoptosis.",0.29,PMID.dPMID11148566.s1.p0,4,2,c-myc|p53|c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18976801,p53,c-myc,Adjustments for Cox-2 and c-myc had the strongest impact on VEGF as a prognosis predictor and LRIG1 was most influenced by adjustment for p53.,0.26,PMID.dPMID18976801.s2.p3,4,4,c-myc|VEGF|LRIG1|p53,c-myc|LRIG1|p53|VEGF,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8961277,p53,c-Myc,c-Myc is capable of abrogating p53-induced G1 arrest by interfering with the inhibitory action of p21 on cyclin-dependent kinases.,0.26,PMID.dPMID8961277.s5.p0,2,2,c-Myc|p53,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19202062,p53,c-Myc,"Together, these results define the role of miR-145 in the posttranscriptional regulation of c-Myc by p53 and suggest that, as a new member of the p53 regulatory network, miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network",0.25,PMID.dPMID19202062.s0.p3,5,2,c-Myc|p53|p53|p53|c-Myc,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9174110,p53,c-myc,Northern blot analysis indicated that the c-myc overexpression is concomitant to DRB-induced DNA fragmentation and that the increased mp53 protein level was mainly a posttranscriptional event.,0.24,PMID.dPMID9174110.s2.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8821986,p53,c-myc,"Positive expression of c-myc and p53 products in two cases of pulmonary sclerosing hemangioma    The c-myc and p53 genes are thought to be an oncogene and a tumor suppressor gene, respectively.",0.24,PMID.dPMID8821986.s9.p3,4,2,c-myc|p53|c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9674700,p53,c-Myc,"Among the target genes for c-Myc regulation are ECA39, p53, ornithine decarboxylase (ODC), alpha-prothymosin and Cdc25A.",0.23,PMID.dPMID9674700.s8.p1,4,4,c-Myc|ECA39|p53|ornithine decarboxylase,c-Myc|ECA39|ornithine decarboxylase|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9298807,p53,c-myc,Her-2/neu overexpression is not characteristic of this sequence; c-myc amplification/overexpression is common to both p53-associated sequences.,0.21,PMID.dPMID9298807.s2.p2,3,3,Her-2/neu|c-myc|p53,c-myc|Her-2/neu|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,14513581,p53,c-myc,RESULTS: A high telomerase activity existed in lower differentiated tongue cancer (P < 0.05); the positive expression of c-myc increased significantly in lower grade tongue cancer (P < 0.05) and the positive expression of p53 decreased increasingly in tongue cancer accompanied with lymph node metastasis (P < 0.05).,0.19,PMID.dPMID14513581.s2.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7969121,p53,c-Myc,Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.,0.19,PMID.dPMID7969121.s10.p4,4,3,p53 tumor suppressor|c-Myc|Max|p53,c-Myc|Max|p53|p53 tumor suppressor,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10822369,p53,c-Myc,c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells.,0.18,PMID.dPMID10822369.s10.p0,2,2,c-Myc|p53,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15780936,p53,Myc,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,0.18,PMID.dPMID15780936.s2.p4,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,14513581,p53,c-myc,"The experimental study on telomerase activity and expression of p53 and c-myc genes in tongue cancer    OBJECTIVE: To study telomerase activity and expression of oncogenes c-myc and p53 in tongue cancer, analyse the interaction among them, and assess their possible correlations with tongue cancer clinicopathological features.",0.17,PMID.dPMID14513581.s4.p4,4,2,p53|c-myc|c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12133541,p53,c-myc,"The effect of the AGP at the molecular level was associated with the low protein expression of the c-myc and bcl-2 genes and the high protein expression of the p53, bax, fas and fas-L genes, as well as the cell factor TGF beta(1).",0.15,PMID.dPMID12133541.s4.p1,5,5,c-myc|bcl-2|p53|bax|fas-L,bax|bcl-2|c-myc|fas-L|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8702238,p53,c-myc,"Analysis (subsequent to treatment) demonstrated that among the genes for which it was possible to detect expression, namely c-erb-B1, c-myc and p53, only the expression of the p53 gene varied significantly.",0.15,PMID.dPMID8702238.s1.p1,3,2,c-myc|p53|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,1436095,p53,c-myc,"The c-myc does not inhibit the activity of another tumour supressor, p53 (ref.",0.13,PMID.dPMID1436095.s2.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,19202062,p53,c-Myc,"Together, these results define the role of miR-145 in the posttranscriptional regulation of c-Myc by p53 and suggest that, as a new member of the p53 regulatory network, miR-145 provides a direct link between p53 and c-Myc in this gene regulatory network",0.12,PMID.dPMID19202062.s0.p1,5,2,c-Myc|p53|p53|p53|c-Myc,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8152906,p53,c-myc,No down-regulation of c-myc was observed in p53 expressing clones when shifted to the permissive temperature.,0.11,PMID.dPMID8152906.s3.p0,2,2,c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11454424,P53,C-MYC,C-MYC gene amplification and loss of the P53 gene could be ruled out by locus-specific probes for the common gain of 8q and for losses of 17p.,0.10,PMID.dPMID11454424.s2.p0,2,2,C-MYC|P53,C-MYC|P53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,9816266,p53,c-myc,The better prognosis seen in patients who overexpress c-myc was offset when c-myc overexpression was coupled with a point mutated p53 gene.,0.06,PMID.dPMID9816266.s1.p1,3,2,c-myc|c-myc|p53,c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,10209447,p53,c-myc,There was no evidence to suggest that c-myc was modulated by upregulation of Bcl-2 or p53 inactivation/mutation.,0.06,PMID.dPMID10209447.s1.p1,3,3,c-myc|Bcl-2|p53,Bcl-2|c-myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11865060,p53,c-Myc,The c-Myc-induced alteration of the G(1)/S checkpoint was also compared to the effects of expression of MycS (N-terminally truncated c-Myc) and p53DD (a dominant negative p53) in the HMECs.,0.06,PMID.dPMID11865060.s2.p3,4,2,c-Myc|c-Myc|p53|p53,c-Myc|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8104920,p53,c-myc,"Amplification of c-erbB-2, c-myc, and int-2, and expression of RB, p53(mutant), and NDP kinase were determined in 77 primary breast cancer specimens.",0.02,PMID.dPMID8104920.s6.p1,3,3,c-myc|int-2|p53,c-myc|int-2|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.3,4610,9606,,GO:0006355,11955646,p53,L-myc,"As both L-myc and p53 polymorphisms were analyzed for their prognostic value, the patients with an S allele of the L-myc gene and a Pro/Pro variant genotype of the p53 gene had significantly poorer prognoses compared with other patients (P=0.004, by the log rank test).",0.03,PMID.dPMID11955646.s1.p5,4,2,L-myc|p53|L-myc|p53,L-myc|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.2,4613,9606,,GO:0006357,20145147,p53,MYCN,"Based on observations of nuclear p53 accumulation in neuroblastoma, we hypothesized that MYCN may regulate p53 in this setting.",0.82,PMID.dPMID20145147.s8.p2,3,2,p53|MYCN|p53,MYCN|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.2,4613,9606,,GO:0006357,17363562,p53,MYCN,Herein we show that MYCN mediates centrosome amplification in a p53-dependent manner.,0.71,PMID.dPMID17363562.s4.p0,2,2,MYCN|p53,MYCN|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.2,4613,9606,,GO:0006357,20145147,p53,MYCN,We concluded that MYCN transcriptionally upregulates p53 in neuroblastoma and uses p53 to mediate a key mechanism of apoptosis,0.42,PMID.dPMID20145147.s0.p0,3,2,MYCN|p53|p53,MYCN|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.2,4613,9606,,GO:0006357,20145147,p53,MYCN,"In MYCN-amplified neuroblastoma cell lines, MYCN knockdown decreased p53 expression.",0.41,PMID.dPMID20145147.s5.p2,3,2,MYCN|MYCN|p53,MYCN|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.2,4613,9606,,GO:0006357,9212845,p53,MYCN,"Molecular analysis revealed, both MYCN gene amplification and a point mutation of the p53 tumor supressor gene.",0.16,PMID.dPMID9212845.s1.p0,2,2,MYCN|p53,MYCN|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.6.5.2,4613,9606,,GO:0006357,20145147,p53,MYCN,"In MYCN-amplified neuroblastoma cell lines, MYCN knockdown decreased p53 expression.",0.01,PMID.dPMID20145147.s5.p1,3,2,MYCN|MYCN|p53,MYCN|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,7.1.2.0.3,4782,9606,,GO:0000122|GO:0010552|GO:0010553|GO:0045944,16264274,p53,CCAAT-binding transcription factor,Transcription repression of a CCAAT-binding transcription factor CBF/HSP70 by p53.,0.58,PMID.dPMID16264274.s11.p3,4,4,CCAAT-binding transcription factor|CBF|HSP70|p53,CBF|CCAAT-binding transcription factor|HSP70|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,8051093,p53,NF-kappa B,"Thus, we show that NF-kappa B activates p53 and that this activation is inducible by TNF-alpha.",0.77,PMID.dPMID8051093.s1.p0,3,3,NF-kappa B|p53|TNF-alpha,NF-kappa B|p53|TNF-alpha,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,20160496,p53,NFkappaB,"We found in agreement with a recent report showing that NFkappaB is required for the efficient activation of the BH3-only protein Noxa by the p53 family member p73, that p53's ability to induce Noxa is also impeded by inhibition of NFkappaB.",0.23,PMID.dPMID20160496.s4.p1,7,4,NFkappaB|Noxa|p53|p73|p53|Noxa|NFkappaB,NFkappaB|Noxa|p53|p73,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,16684540,p53,NF-kappaB,"These data suggest that NF-kappaB-dependency of the PAF-induced increase in VEGF expression is due to decreased p53 activity, which is reciprocally regulated by increased NF-kappaB activity.",0.22,PMID.dPMID16684540.s0.p3,5,4,NF-kappaB|PAF|VEGF|p53|NF-kappaB,NF-kappaB|p53|PAF|VEGF,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,16430884,p53,NFkappaB,Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells.,0.17,PMID.dPMID16430884.s9.p1,3,3,NFkappaB|p73|p53,NFkappaB|p53|p73,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,20160496,p53,NFkappaB,"In addition, since both Noxa and p53AIP1 have been shown to be important components of p53-mediated cell death responses, these findings may also indicate critical points where NFkappaB plays a pro-apoptotic role downstream of p53",0.07,PMID.dPMID20160496.s0.p9,5,4,Noxa|p53AIP1|p53|NFkappaB|p53,NFkappaB|Noxa|p53|p53AIP1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,10698490,p53,NF-kappaB,A Western blot analysis of nuclear extracts demonstrated that NF-kappaB protein levels in the nuclei were suppressed by the transient expression of the wt-p53 in a dose-dependent manner.,0.00,PMID.dPMID10698490.s5.p0,2,2,NF-kappaB|p53,NF-kappaB|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.1.1,4792,9606,,GO:0010552|GO:0032088|GO:0051092,15969767,p53,IkappaBalpha,"We also determined that IkappaBalpha and p53 bind in vitro through a specific interaction in part involving the DNA binding region of p53, or a region proximal to it, and the amino terminus of IkappaBalpha independently or cooperatively with the ankyrin 3 domain of IkappaBalpha In cotransfection experiments, kappaBalpha could significantly inhibit the transcriptional activity of p53.",0.02,PMID.dPMID15969767.s5.p20,7,3,IkappaBalpha|p53|p53|IkappaBalpha|ankyrin|IkappaBalpha|p53,ankyrin|IkappaBalpha|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.2.1.0.1,4800,9606,,GO:0006355,11420680,p53,NF-YA,Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage.,0.24,PMID.dPMID11420680.s12.p2,4,4,Oct-1|NF-YA|p53|GADD45,GADD45|NF-YA|Oct-1|p53,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.2.16.1,4824,9606,GO:0016564,GO:0006355|GO:0032582,17202838,p53,NKX3.1,We found that NKX3.1 expression is down-regulated by over-expression of wild type (wt) p53 in prostate cancer LNCaP cells.,0.18,PMID.dPMID17202838.s4.p0,2,2,NKX3.1|p53,NKX3.1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,12743601,p53,YB1,Nuclear localization of Y-box factor YB1 requires wild-type p53.,1.01,PMID.dPMID12743601.s10.p0,2,2,YB1|p53,p53|YB1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,16963428,p53,YB-1,It has been demonstrated that YB-1 represses transcription of the p53 promoter in a sequence-specific manner using specifically reporter assays.,0.57,PMID.dPMID16963428.s3.p0,2,2,YB-1|p53,p53|YB-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,18258596,p53,YB1,"Chromatin immunoprecipitation and RNA interference analyses further confirmed that the recruitment of YB1, PURalpha, and H1.2 to the p53 target gene Bax is required for repression of p53-induced transcription.",0.17,PMID.dPMID18258596.s1.p6,5,4,YB1|H1.2|p53|Bax|p53,Bax|H1.2|p53|YB1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.4.0.2,4929,9606,GO:0030528,GO:0034339,19671681,p53,Nurr1,"Furthermore, Nurr1 represses p53 transcriptional activity in interaction-dependent and dose-dependent manners.",1.13,PMID.dPMID19671681.s2.p0,2,2,Nurr1|p53,Nurr1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.2.2.2.2,5079,9606,,,8521821,p53,PAX5,We have identified a direct role for PAX5 in the control of p53 transcription.,0.97,PMID.dPMID8521821.s5.p0,2,2,PAX5|p53,p53|PAX5,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.2.2.2.2,5079,9606,,,8943844,p53,PAX-5,"When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.",0.32,PMID.dPMID8943844.s2.p0,3,2,PAX-5|p53|PAX-5,p53|PAX-5,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.19.1,5307,9606,,,17762884,p53,Pitx1,A hPitx1 mutant (hPitx1-R141P) acting as a dominant inhibitor repressed p53 transcription.,0.97,PMID.dPMID17762884.s6.p1,3,2,Pitx1|Pitx1|p53,p53|Pitx1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.19.1,5307,9606,,,17762884,p53,Pitx1,"Here, we report that the human pituitary homeobox 1 (hPitx1) transcription factor increases the expression of p53 at the mRNA and protein levels in human mammary carcinoma (MCF-7) cells.",0.60,PMID.dPMID17762884.s10.p0,2,2,Pitx1|p53,p53|Pitx1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.19.1,5307,9606,,,17762884,p53,Pitx1,The predominant consensus element utilized by hPitx1 to stimulate p53 transcription was located within the first exon of the p53 gene.,0.55,PMID.dPMID17762884.s7.p0,3,2,Pitx1|p53|p53,p53|Pitx1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.19.1,5307,9606,,,17762884,p53,Pitx1,A hPitx1 mutant (hPitx1-R141P) acting as a dominant inhibitor repressed p53 transcription.,0.37,PMID.dPMID17762884.s6.p2,3,2,Pitx1|Pitx1|p53,p53|Pitx1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.19.1,5307,9606,,,17762884,p53,Pitx1,"Furthermore, hPitx1 stimulated the transcription of p53 target genes involved in cell-cycle arrest and apoptosis (p21 and PTGF-beta), again in a p53-dependent manner.",0.11,PMID.dPMID17762884.s4.p0,5,4,Pitx1|p53|p21|PTGF-beta|p53,p21|p53|Pitx1|PTGF-beta,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.19.1,5307,9606,,,17762884,p53,Pitx1,Depletion of endogenous hPitx1 by small interfering RNA (siRNA) in MCF-7 cells resulted in decreased basal expression of p53 and consequently of p21 and placental transforming growth factor beta (PTGF-beta).,0.01,PMID.dPMID17762884.s3.p0,4,4,Pitx1|p53|p21|PTGF-beta,p21|p53|Pitx1|PTGF-beta,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.42,5325,9606,,GO:0045944,11360197,p53,Zac1,"Since these activities are common to Zac1 and p53, we tested for a functional interaction between these two proteins by investigating possible effects of Zac1 on the transcriptional activator function of p53.",0.82,PMID.dPMID11360197.s7.p5,4,2,Zac1|p53|Zac1|p53,p53|Zac1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.42,5325,9606,,GO:0045944,11360197,p53,Zac1,These results indicate that Zac1 served as a transcriptional coactivator for p53.,0.41,PMID.dPMID11360197.s3.p0,2,2,Zac1|p53,p53|Zac1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.42,5325,9606,,GO:0045944,11360197,p53,Zac1,"The same promoters were not activated by Zac1 in cells lacking functional p53, but the Zac1 effect was restored by co-expression of p53.",0.13,PMID.dPMID11360197.s5.p5,4,2,Zac1|p53|Zac1|p53,p53|Zac1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.42,5325,9606,,GO:0045944,11360197,p53,Zac1,Zac1 specifically enhanced the activity of p53-responsive promoters in cells expressing wild type p53.,0.08,PMID.dPMID11360197.s6.p1,3,2,Zac1|p53|p53,p53|Zac1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.2.3.0.1,5424,9606,,,11375983,p53 tumor suppressor,POLD1,Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1.,0.50,PMID.dPMID11375983.s6.p0,3,3,POLD1|p53 tumor suppressor|Sp1,p53 tumor suppressor|POLD1|Sp1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.4.4.1,5457,9606,,GO:0006357,12203124,p53,Brn-3a,"In contrast, Brn-3a and p53 co-operative to induce maximal activation of another p53 target gene encoding the cyclin dependent kinase inhibitor, p21(CIP1/Waf1).",0.63,PMID.dPMID12203124.s3.p1,5,3,Brn-3a|p53|p53|CIP1|Waf1,Brn-3a|CIP1|p53|Waf1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.4.4.1,5457,9606,,GO:0006357,12203124,p53,Brn-3a,These differential effects of Brn-3a on p53-inducible genes involved in apoptosis or growth arrest are paralleled by its effects on these processes themselves.,0.21,PMID.dPMID12203124.s2.p0,2,2,Brn-3a|p53,Brn-3a|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,16887883,p53,Peroxisome proliferator-activated receptor-gamma,Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells.,0.24,PMID.dPMID16887883.s7.p0,2,2,Peroxisome proliferator-activated receptor-gamma|p53,p53|Peroxisome proliferator-activated receptor-gamma,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,12495476,p53,PPAR-gamma,"This study showed that PPAR-gamma ligands were able to induce growth suppression in anaplastic thyroid cancer cells via a p53-independent, but p21- and p27-dependent cytostatic pathway.",0.01,PMID.dPMID12495476.s1.p0,2,2,PPAR-gamma|p53,p53|PPAR-gamma,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,15671037,p53,RelA,We previously showed that RelA-NF-kappaB functioned as a proapoptotic factor by activating the p53-signaling pathway in response to doxycycline-induced superoxide.,0.08,PMID.dPMID15671037.s7.p0,2,2,RelA|p53,p53|RelA,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.34,6239,9606,GO:0016563,GO:0006355,19558368,p53,RREB-1,"Notably, disruption of RREB-1-mediated p53 transcription suppresses the expression of the p53 target genes.",1.14,PMID.dPMID19558368.s2.p0,3,2,RREB-1|p53|p53,p53|RREB-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.34,6239,9606,GO:0016563,GO:0006355,19558368,p53,RREB-1,Silencing of RREB-1 significantly reduces p53 expression at both the mRNA and the protein levels.,1.07,PMID.dPMID19558368.s3.p0,2,2,RREB-1|p53,p53|RREB-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.34,6239,9606,GO:0016563,GO:0006355,19558368,p53,RREB-1,"Notably, disruption of RREB-1-mediated p53 transcription suppresses the expression of the p53 target genes.",0.94,PMID.dPMID19558368.s2.p1,3,2,RREB-1|p53|p53,p53|RREB-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.34,6239,9606,GO:0016563,GO:0006355,19558368,p53,RREB-1,These findings provide evidence that RREB-1 participates in modulating p53 transcription in response to DNA damage.,0.84,PMID.dPMID19558368.s0.p0,2,2,RREB-1|p53,p53|RREB-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.34,6239,9606,GO:0016563,GO:0006355,19558368,p53,RREB-1,"We also show that, upon exposure to genotoxic stress, RREB-1 controls apoptosis in a p53-dependent manner.",0.48,PMID.dPMID19558368.s1.p0,2,2,RREB-1|p53,p53|RREB-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.2,6591,9606,,GO:0000122,20332115,p53,Slug,"In addition, knockdown of Slug and Zeb-1 expression diminished p53-mediated E-cadherin repression.",0.33,PMID.dPMID20332115.s5.p1,3,3,Slug|Zeb-1|p53,p53|Slug|Zeb-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.2,6591,9606,,GO:0000122,19448627,p53,Slug,Downregulation of Slug by wtp53 or MDM2 enhances E-cadherin expression and represses cancer cell invasiveness.,0.14,PMID.dPMID19448627.s2.p0,4,4,Slug|p53|MDM2|E-cadherin,E-cadherin|MDM2|p53|Slug,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.1.3.1,6659,9606,,GO:0006355|GO:0045893,20400479,p53,SOX4,"In this study, we characterized the roles of SOX4 in regulation of the p53 transcription activity and evaluated the expression patterns and prognostic value of the transcription factor SOX4 in HCC.",1.03,PMID.dPMID20400479.s8.p0,4,3,SOX4|p53|SOX4|HCC,HCC|p53|SOX4,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.1.3.1,6659,9606,,GO:0006355|GO:0045893,20400479,p53,SOX4,Conclusion: These results suggest that SOX4 contributes to hepatocarcinogenesis by inhibiting p53-mediated apoptosis and that its overexpression might be a useful prognostic marker for survival after surgical resection.,0.54,PMID.dPMID20400479.s0.p0,2,2,SOX4|p53,p53|SOX4,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.1.3.1,6659,9606,,GO:0006355|GO:0045893,19234109,p53,SOX4,"Here, we show that SOX4, a new DNA damage sensor, is required for the activation of p53 tumor suppressor in response to DNA damage.",0.34,PMID.dPMID19234109.s4.p0,2,2,SOX4|p53,p53|SOX4,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,9774636,p53,Sp1,Sp1-mediated transcription of the Werner helicase gene is modulated by Rb and p53.,1.68,PMID.dPMID9774636.s8.p1,3,3,Sp1|Rb|p53,p53|Rb|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15780936,p53,Sp1,HIF-1alpha displaces the transcriptional activator Myc from Sp1 binding to repress MutSalpha expression in a p53-dependent manner; Sp1 serves as a molecular switch by recruiting HIF-1alpha to the gene promoter under hypoxia.,0.64,PMID.dPMID15780936.s2.p5,6,4,HIF-1alpha|Myc|Sp1|p53|Sp1|HIF-1alpha,HIF-1alpha|Myc|p53|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,7649977,p53,Sp1,"The presence of Sp1 increased p53 binding to its recognition sequence in the HIV-1 LTR, and experiments in Drosophila cells show that Sp1 is necessary for full transactivation by mutant p53.",0.52,PMID.dPMID7649977.s2.p0,4,2,Sp1|p53|Sp1|p53,p53|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,19846904,p53,Sp1,"Taken together, these results suggest that sequestration of Sp1 could be one of the mechanisms by which p53 negatively regulates MGMT expression, thus enhancing sensitivity of tumor cells to O(6)-alkylguanine generating drugs.",0.31,PMID.dPMID19846904.s0.p0,3,3,Sp1|p53|MGMT,MGMT|p53|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,7649977,p53,Sp1,"The presence of Sp1 increased p53 binding to its recognition sequence in the HIV-1 LTR, and experiments in Drosophila cells show that Sp1 is necessary for full transactivation by mutant p53.",0.27,PMID.dPMID7649977.s2.p5,4,2,Sp1|p53|Sp1|p53,p53|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,18814047,p53,Sp1,"A functional MDM2 single nucleotide polymorphism (SNP309) in the promoter region increases the affinity of transcription activator Sp1 for the MDM2 gene promoter, resulting in higher expression of MDM2 and thus inhibition of p53 transcriptional activity.",0.21,PMID.dPMID18814047.s8.p7,5,3,MDM2|Sp1|MDM2|MDM2|p53,MDM2|p53|Sp1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15967108,p53,SP-1,"Transcriptional analysis with luciferase reporters driven by SAK promoter deletion fragments identified SP-1 and CREB binding sites, which together conferred a two-fold SAK repression by p53.",0.15,PMID.dPMID15967108.s4.p7,5,4,SAK|SP-1|CREB|SAK|p53,CREB|p53|SAK|SP-1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,14647468,p53,Sp100,Here we demonstrate that HIPK2 and the PML-NB resident protein Sp100 synergize for the activation of p53-dependent gene expression.,0.95,PMID.dPMID14647468.s4.p5,4,4,HIPK2|PML|Sp100|p53,HIPK2|p53|PML|Sp100,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,5.3.5.2.1,6672,9606,GO:0016565,GO:0000122|GO:0016481|GO:0032897|GO:0043433|GO:0045893|GO:0051091,14647468,p53,Sp100,Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression.,0.36,PMID.dPMID14647468.s6.p1,3,3,Sp100|homeodomain-interacting protein kinase-2|p53,homeodomain-interacting protein kinase-2|p53|Sp100,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.5.2.5.1,6688,9606,,GO:0000122|GO:0043193,18193090,p53 tumor suppressor,PU.1,We demonstrate that PU.1 reduces the transcriptional activity of the p53 tumor suppressor family and thus inhibits activation of genes important for cell cycle regulation and apoptosis.,1.19,PMID.dPMID18193090.s2.p0,2,2,PU.1|p53 tumor suppressor,p53 tumor suppressor|PU.1,c
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.2.1.0.1,6772,9606,,,20567883,p53,STAT1,"This shows that SPE B activates the bax promoter via p38/p53 signal pathways through the Fas receptor, and that STAT1 acts as a coactivator of p53.",0.21,PMID.dPMID20567883.s2.p9,5,4,bax|p53|Fas|STAT1|p53,bax|Fas|p53|STAT1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18941194,p53,STAT3,"PSTAT3 is a transcriptional repressor of p53, and therefore IL-24 induction of p53 secondary to PSTAT3 dephosphorylation may be sensed as a stress signal and promote apoptosis in cycling cells.",0.84,PMID.dPMID18941194.s1.p0,5,3,STAT3|p53|IL-24|p53|STAT3,IL-24|p53|STAT3,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,20546595,p53,STAT3,High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene expression in human heart failure.,0.04,PMID.dPMID20546595.s9.p0,2,2,STAT3|p53,p53|STAT3,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.5.1.0.1,6862,9606,,,18600528,p53,TFT,Conclusion: sensitivity to TFT is not dependent on the expression of wt p53.,0.93,PMID.dPMID18600528.s0.p0,2,2,TFT|p53,p53|TFT,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,15053879,p53,TAF1,We found that TAF1 induces G1 progression in a p53-dependent manner.,0.52,PMID.dPMID15053879.s5.p0,2,2,TAF1|p53,p53|TAF1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,7559631,p53,TBP,Our results suggest that at least TBP is a direct target for p53 TAD and that the binding strength of TAD to TBP (TFIID) is an important parameter controlling activity of p53 TAD.,0.41,PMID.dPMID7559631.s1.p0,5,2,TBP|p53|TBP|TFIID|p53,p53|TBP|TFIID,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,8497252,p53,TBP,We conclude that TBP binding is necessary for p53 transcriptional activation and that p53 sequences outside the TBP binding domain modulate the level of activation,0.30,PMID.dPMID8497252.s0.p0,4,2,TBP|p53|p53|TBP,p53|TBP,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.5.4.0.1,6909,9606,GO:0016564,GO:0045892,19216023,p53,TBX2,"In carcinogenesis, TBX2 regulates the cell cycle by suppressing the expression of cyclin-dependent kinase (CDK) inhibitors and destabilizes p53 by suppressing expression of ARF.",0.56,PMID.dPMID19216023.s11.p0,3,3,TBX2|p53|ARF,ARF|p53|TBX2,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.1.0.1,6929,9606,GO:0016563,GO:0006355|GO:0010552|GO:0045893|GO:0045944,11237058,p53,transcription factor E2a,The leukemogenic transcription factor E2a-Pbx1 induces expression of the putative N-myc and p53 target gene NDRG1 in Ba/F3 cells.,0.47,PMID.dPMID11237058.s7.p1,4,4,transcription factor E2a|N-myc|p53|NDRG1,NDRG1|N-myc|p53|transcription factor E2a,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,20122174,p53,TCF-4,CONCLUSIONS: Axin downregulates TCF-4 transcription via beta-catenin and independently of p53.,0.25,PMID.dPMID20122174.s1.p2,3,3,Axin|TCF-4|p53,Axin|p53|TCF-4,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,14990988,p53,Tcf-4,"Furthermore, since Tcf-4 is expressed in many tissues and downregulation of Tcf-4 by p53 is seen in several different cell types, this regulation likely plays a role in proliferation control of all tissues that can express p53 and Tcf-4.",0.24,PMID.dPMID14990988.s0.p2,5,2,Tcf-4|Tcf-4|p53|p53|Tcf-4,p53|Tcf-4,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,14990988,p53,Tcf-4,"Furthermore, since Tcf-4 is expressed in many tissues and downregulation of Tcf-4 by p53 is seen in several different cell types, this regulation likely plays a role in proliferation control of all tissues that can express p53 and Tcf-4.",0.08,PMID.dPMID14990988.s0.p4,5,2,Tcf-4|Tcf-4|p53|p53|Tcf-4,p53|Tcf-4,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,19194497,p53,ZEB1,"Beyond the context of stroke, the finding that ZEB1 is regulated by a member of the p53 family has implications for cell survival in other tissue and cellular environments subjected to ischemia, such as the myocardium and, in particular, tumor masses",1.00,PMID.dPMID19194497.s0.p0,2,2,ZEB1|p53,p53|ZEB1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,20332115,p53,Zeb-1,"In addition, knockdown of Slug and Zeb-1 expression diminished p53-mediated E-cadherin repression.",0.78,PMID.dPMID20332115.s5.p2,3,3,Slug|Zeb-1|p53,p53|Slug|Zeb-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.6.1.0.1,7003,9606,,,10523305,p53,Ref-1,"Finally, we observed that Ref-1 cooperates with a DNA-damaging compound, camptothecin, to stimulate the transcriptional activity of p53.",1.29,PMID.dPMID10523305.s1.p0,2,2,Ref-1|p53,p53|Ref-1,c
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.6.1.0.1,7003,9606,,,10523305,p53,Ref-1,Together these data indicate that Ref-1 is a key cellular regulator of p53.,0.89,PMID.dPMID10523305.s0.p0,2,2,Ref-1|p53,p53|Ref-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.6.1.0.1,7003,9606,,,10523305,p53,Ref-1,Ref-1 was discovered to be a potent activator of p53 DNA binding in vitro.,0.43,PMID.dPMID10523305.s7.p0,2,2,Ref-1|p53,p53|Ref-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.6.1.0.1,7003,9606,,,10523305,p53,Ref-1,"To address the physiological significance of the effects of Ref-1 on p53, we have analyzed its role in regulating p53 function in vivo.",0.19,PMID.dPMID10523305.s6.p0,3,2,Ref-1|p53|p53,p53|Ref-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.6.1.0.1,7003,9606,,,10523305,p53,Ref-1,Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo.,0.05,PMID.dPMID10523305.s9.p0,2,2,Ref-1|p53,p53|Ref-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.1.4.2.3,7008,9606,GO:0003702,GO:0006357,17057225,p53,TEF,"Consistently, transfection of TEF induces the expression of endogenous bcl-gS in cancer cells, and this induction is independent of p53.",0.01,PMID.dPMID17057225.s4.p0,2,2,TEF|p53,p53|TEF,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.3.1.0.1,7020,9606,,,16636674,p53,AP-2,"Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation",0.61,PMID.dPMID16636674.s0.p5,4,2,AP-2|p53|AP-2|p53,AP-2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.3.1.0.1,7020,9606,,,16636674,p53,AP-2,"Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation",0.48,PMID.dPMID16636674.s0.p3,4,2,AP-2|p53|AP-2|p53,AP-2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.3.1.0.1,7020,9606,,,16636674,p53,AP-2,"Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation",0.46,PMID.dPMID16636674.s0.p0,4,2,AP-2|p53|AP-2|p53,AP-2|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.3.1.0.3,7022,9606,,,16636674,p53,AP-2gamma,Expression microarray results in human breast carcinoma cells with forced p53 expression revealed AP-2gamma as a putative transcriptional target of p53.,0.04,PMID.dPMID16636674.s7.p2,3,2,p53|AP-2gamma|p53,AP-2gamma|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.2.2.1,7027,9606,,GO:0006357,8524253,p53,DP-1,E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis.,0.74,PMID.dPMID8524253.s9.p2,3,3,E2F-1|DP-1|p53,DP-1|E2F-1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,12923324,p53,TTF-1,"In NSCLC, TTF-1 expression was inversely correlated with Ki-67 proliferative activity and independent of p53 overexpression.",0.54,PMID.dPMID12923324.s2.p1,3,3,TTF-1|Ki-67|p53,Ki-67|p53|TTF-1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12934105,p53,p73,The fact that an ectopic expression of p73alphaR292H leads to both accumulation of p53 and stimulation of p53 target gene expression strongly suggests that p73alpha is able to induce activation of p53.,1.40,PMID.dPMID12934105.s2.p9,5,2,p73|p53|p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12095638,p53,p73,"The p73 protein activates the transcription of genes downstream of p53 and induces apoptosis when overexpressed in several cell lines, similar to the tumor suppressor p53.",1.16,PMID.dPMID12095638.s9.p0,3,2,p73|p53|tumor suppressor p53,p53|p73|tumor suppressor p53,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14614448,p53,p73,DeltaNp73 can modulate the expression of various genes in a p53-independent fashion.,1.11,PMID.dPMID14614448.s10.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19291793,p53,p73,"We found imatinib up-regulated phosphorylation of p38 mitogen-activated protein kinase (MAPK), checkpoint kinase 2 (chk2) and transactivation-competent (TA) p73; expression of pml and bax; formation of PML-nuclear body (NB); and co-localization of TAp73/PML-NB in p53-nonfunctioning K562 and p53(mutant) Meg-01 CML cells, but not in BCR-ABL(-) HL60 cells.",1.08,PMID.dPMID19291793.s7.p15,10,6,p73|pml|bax|PML|p73|PML|p53|p53|Meg|CML,bax|CML|Meg|p53|p73|pml|PML,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19861536,p53,p73,"On the contrary, when the cells are arrested in G(0)-G(1), p73 detaches from the REs and it is replaced by p53, which represses the expression of these genes.",0.99,PMID.dPMID19861536.s3.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18234963,p53,p73,"Indeed, depletion of p73 by small interfering RNA in thyroid cancer cells resulted in a reduced transcriptional activity of p53.",0.97,PMID.dPMID18234963.s7.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15450420,p53,p73,"The p16INK4a gene is involved in regulation of the G1/S transition, and when overexpressed, the p73 gene activates transcription of p53-responsive genes and promotes apoptosis.",0.96,PMID.dPMID15450420.s7.p2,3,3,p16INK4a|p73|p53,p16INK4a|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17304243,p53,p73,"In contrast to TA-p73, deltaN-p73 is a negative regulator of p53-induced and p73-induced autophagy, but does not affect autophagy induced by amino-acid starvation.",0.95,PMID.dPMID17304243.s1.p2,4,2,p73|p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14614448,p53,p73,"Rather, DeltaNp73alpha can regulate the expression of a variety of genes independently of p53",0.89,PMID.dPMID14614448.s0.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19777343,p53,p73,"DeltaNp73 was dramatically induced by p53 in a TAp73-dependent manner, and silencing p73 suppressed the transcriptional activation of alphaB-crystallin by p53.",0.87,PMID.dPMID19777343.s2.p13,6,3,p73|p53|p73|p73|alphaB-crystallin|p53,alphaB-crystallin|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18418051,p53,p73,"Although TAp73 positively regulates an overlapping repertoire of genes regulated by p53, TAp73 has been observed to be paradoxically overexpressed in a number of tumor cell types arousing much interest in the post-translational regulation of TAp73 transcriptional activity.",0.83,PMID.dPMID18418051.s3.p0,4,2,p73|p53|p73|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12101410,p53,p73,We show here that the expression of p73 Delta N is induced by p53 on the mRNA and protein level.,0.82,PMID.dPMID12101410.s6.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15846087,p53,p73,"In contrast to the differences between p53 and GAL4-VP16, p63 and p73 both regulated transcription in vitro under similar conditions as did p53.",0.80,PMID.dPMID15846087.s2.p9,5,4,p53|GAL4|p63|p73|p53,GAL4|p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16849542,p53,p73,Silencing of p53 or p73 by RNA interference significantly suppresses p53 transcription under physiologic conditions or in response to cellular stress.,0.79,PMID.dPMID16849542.s4.p2,3,2,p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11753569,p53,p73,Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53.,0.74,PMID.dPMID11753569.s14.p1,3,2,p73|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11314010,p53,p73,"Taken together, these data suggest that p73 is transcriptionally regulated by DNA damage and p53, and is autoregulated",0.74,PMID.dPMID11314010.s0.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10769197,p53,p73,"Indeed, p73 can activate p53-regulated genes and suppress growth or induce apoptosis.",0.73,PMID.dPMID10769197.s9.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19291793,p53,p73,"We found imatinib up-regulated phosphorylation of p38 mitogen-activated protein kinase (MAPK), checkpoint kinase 2 (chk2) and transactivation-competent (TA) p73; expression of pml and bax; formation of PML-nuclear body (NB); and co-localization of TAp73/PML-NB in p53-nonfunctioning K562 and p53(mutant) Meg-01 CML cells, but not in BCR-ABL(-) HL60 cells.",0.71,PMID.dPMID19291793.s7.p21,10,6,p73|pml|bax|PML|p73|PML|p53|p53|Meg|CML,bax|CML|Meg|p53|p73|pml|PML,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19777343,p53,p73,"DeltaNp73 was dramatically induced by p53 in a TAp73-dependent manner, and silencing p73 suppressed the transcriptional activation of alphaB-crystallin by p53.",0.70,PMID.dPMID19777343.s2.p0,6,3,p73|p53|p73|p73|alphaB-crystallin|p53,alphaB-crystallin|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,20160513,p53,p73,The p63 and p73 proteins activate the transcription of a number of p53 target genes.,0.69,PMID.dPMID20160513.s9.p2,3,3,p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12944917,p53,p73,"In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels.",0.68,PMID.dPMID12944917.s5.p1,3,3,p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15598310,p53,p73,The p73 gene is a member of the p53 gene family and the structure and functions of p73 protein are similar to those of p53.,0.67,PMID.dPMID15598310.s4.p0,4,2,p73|p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15548364,p53,p73,"Besides, p73 was shown to be activated by only a subset of signals that activate p53, such as gamma-irradiation and cisplatin, but not by other common genotoxic stress-inducing agents such as ultraviolet (UV) irradiation, although many of these signals are also capable of inducing p53-independent cell death.",0.67,PMID.dPMID15548364.s4.p0,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15734740,p53,p73,"Finally, knockdown of p73 in MCF7 cells resulted in increased p53 protein levels and a concomitant decrease in hTERT levels.",0.67,PMID.dPMID15734740.s1.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12095638,tumor suppressor p53,p73,"The p73 protein activates the transcription of genes downstream of p53 and induces apoptosis when overexpressed in several cell lines, similar to the tumor suppressor p53.",0.66,PMID.dPMID12095638.s9.p1,3,2,p73|p53|tumor suppressor p53,p53|p73|tumor suppressor p53,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16835297,p53,p73,"Some of the compounds activate a p53 response by increasing p73 expression, and knockdown of transactivating isoforms of p73 by small interfering RNA reduces their induction of p53-responsive transcriptional activity.",0.64,PMID.dPMID16835297.s3.p5,4,2,p53|p73|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11245471,p53,p73,Expression of p73 resulted in a reduction of the ectopically expressed p53 in transient transfections or of the endogenous p53 induced by Adriamycin- or UV-mediated damage.,0.61,PMID.dPMID11245471.s2.p0,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16430884,p53,p73,"Using p53 null cell lines, we examined whether or not DeltaNp73 can regulate gene expression in a p53-independent manner.",0.61,PMID.dPMID16430884.s7.p2,3,2,p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16205639,p53,p73,"We show that DeltaNp73 antagonizes the repressive effect of the proapoptotic p53 family members on hTERT expression and, in addition, induces hTERT expression in telomerase-negative cells by interfering with E2F-RB-mediated repression of the hTERT core promoter.",0.59,PMID.dPMID16205639.s1.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12761493,p53,p73,"Ectopic overexpression of RACK1 in SAOS-2 cells reduced the p73alpha-mediated transcription from the p53/p73-responsive promoters, and inhibited the p73alpha-dependent apoptosis.",0.55,PMID.dPMID12761493.s3.p2,5,3,RACK1|p73|p53|p73|p73,p53|p73|RACK1,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11314010,p53,p73,"p73 is transcriptionally regulated by DNA damage, p53, and p73.",0.55,PMID.dPMID11314010.s8.p0,3,2,p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17822668,p53,p73,"Overall, our results provide direct evidence that Egr-1 positively regulated p73 expression by binding to its promoter in vivo, consistent with Egr-1 and p73 being involved in p53-independent tumor suppression",0.55,PMID.dPMID17822668.s0.p7,5,3,Egr-1|p73|Egr-1|p73|p53,Egr-1|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12716888,p53 tumor suppressor,p73,The p73alpha protein is a functional homolog of the p53 tumor suppressor.,0.54,PMID.dPMID12716888.s7.p0,2,2,p73|p53 tumor suppressor,p53 tumor suppressor|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14602923,p53,p73,DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1.   p73 is a member of the p53 family often overexpressed in human cancer.,0.53,PMID.dPMID14602923.s9.p3,4,3,p73|E2F1|p73|p53,E2F1|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,20298673,p53,p73,"p73 and p63 regulate the expression of fibroblast growth factor receptor 3.  p53, p63 and p73 make a family of transcription factors that play a vital role in development and cancer.",0.53,PMID.dPMID20298673.s7.p1,5,3,p73|p63|p53|p63|p73,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10606650,p53,p73,The results suggest that p73 can modulate p53 function by inhibiting its DNA binding and that overexpression of p73 in tumors might be a novel mechanism of inactivation of p53,0.53,PMID.dPMID10606650.s0.p0,4,2,p73|p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11925430,p53,p73,Overexpression of HIPK2 stabilized the p53 protein and greatly increased the p73- and p53-induced transcriptional repression of multidrug-resistant and collagenase promoters in Saos2 cells but had little effect on the p73- or p53-mediated transcriptional activation of synthetic p53-responsive and p21WAF1 promoters.,0.53,PMID.dPMID11925430.s3.p17,7,4,HIPK2|p53|p73|p53|p73|p53|p53,HIPK2|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19835284,p53,p73,p73 also shares some common functions with p53 protein indicating that p73 gene is a p53-like tumor suppressor.,0.52,PMID.dPMID19835284.s6.p5,4,2,p73|p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18801697,p53,p73,Therapeutic prospects for p73 and p63: rising from the shadow of p53.,0.50,PMID.dPMID18801697.s5.p1,3,3,p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14701724,p53,p73,"Furthermore, we found that DeltaNp73beta is capable of inducing some p53 target genes, albeit to a lesser extent than does p73beta.",0.49,PMID.dPMID14701724.s4.p0,3,2,p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15741235,p53,p73,"The fact that DeltaNp73alpha may either inhibit or stimulate wt-p53 transcriptional activity, depending on both the p53 target gene and the cellular context, was confirmed by real-time quantitative PCR.",0.47,PMID.dPMID15741235.s3.p0,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11103943,p53,p73,"The p73 gene is a p53 homologue located at 1p36-33, a region submitted to deletions in breast cancer (BC) and putatively imprinted.",0.44,PMID.dPMID11103943.s10.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11925430,p53,p73,Overexpression of HIPK2 stabilized the p53 protein and greatly increased the p73- and p53-induced transcriptional repression of multidrug-resistant and collagenase promoters in Saos2 cells but had little effect on the p73- or p53-mediated transcriptional activation of synthetic p53-responsive and p21WAF1 promoters.,0.43,PMID.dPMID11925430.s3.p19,7,4,HIPK2|p53|p73|p53|p73|p53|p53,HIPK2|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16087678,p53,p73,"The p73 gene, a member of the p53 family, encodes several variants through differential splicing and use of alternative promoters.",0.43,PMID.dPMID16087678.s9.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12944917,p53,p73,"The DeltaNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity.",0.41,PMID.dPMID12944917.s7.p1,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14614448,p53,p73,Semiquantitative reverse transcription-PCR confirmed these results and further revealed that the influence of DeltaNp73alpha on the regulation of these genes differs from other p73 isoforms and p53.,0.41,PMID.dPMID14614448.s2.p1,3,2,p73|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14614448,p53,p73,We conclude that the impact of DeltaNp73alpha on gene expression is not limited to p53-responsive genes.,0.38,PMID.dPMID14614448.s1.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17952118,p53,p73,DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function.,0.38,PMID.dPMID17952118.s7.p1,3,3,p73|MDR1|p53,MDR1|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12619104,p53,TP73,"Based on gene sequence homologies, a p53 (TP53) gene family become apparent with the addition of the most recently identified p63 (TP73L; formerly TP63) and p73 (TP73) genes to the already known p53.",0.37,PMID.dPMID12619104.s7.p27,8,3,p53|TP53|p63|TP73L|TP63|p73|TP73|p53,p53|p63|p73|TP53|TP63|TP73|TP73L,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18234963,p53,p73,"Taken together, these results indicate that in thyroid cancer cells, TAp73alpha is able to increase p53 protein level and function by interfering with Mdm2-mediated p53 degradation.",0.37,PMID.dPMID18234963.s1.p0,4,3,p73|p53|Mdm2|p53,Mdm2|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10815895,p53,p73,The p73 gene located at 1p36.3 encodes for a protein with significant similarity to p53.,0.36,PMID.dPMID10815895.s7.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18234963,p53,p73,The enhancing effect of TAp73alpha on p53 activity is Mdm2 dependent because it is prevented by Mdm2 depletion by small interfering RNA.,0.36,PMID.dPMID18234963.s5.p0,4,3,p73|p53|Mdm2|Mdm2,Mdm2|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15737644,p53,p73,"p73 is a p53-independent, Sp1-dependent repressor of cyclin B1 transcription.",0.34,PMID.dPMID15737644.s8.p0,3,3,p73|p53|Sp1,p53|p73|Sp1,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15175114,p53 tumor suppressor,p73,"BACKGROUND: The p73 protein, a paralogue of the p53 tumor suppressor, is essential for normal development and survival of neurons.",0.34,PMID.dPMID15175114.s9.p0,2,2,p73|p53 tumor suppressor,p53 tumor suppressor|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10419905,p53,p73,"The p73 gene, a member of the p53 family, is a new candidate tumor suppressor gene.",0.33,PMID.dPMID10419905.s8.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16234237,p53,p73,"Our findings provide additional evidence that p73 mimics p53 in many aspects in cells lacking functional p53, thereby contributing to tumor surveillance.",0.30,PMID.dPMID16234237.s0.p0,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17822668,p53,p73,"Transcriptional regulation of the p73 gene, a member of the p53 family, by early growth response-1 (Egr-1).",0.30,PMID.dPMID17822668.s6.p0,3,3,p73|p53|Egr-1,Egr-1|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12934105,p53,p73,"We thus conclude that p73alpha protein was able to both stabilize and activate wt-p53 protein, independent of the p73alpha transcriptional activity",0.29,PMID.dPMID12934105.s0.p0,3,2,p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10435630,p53,p73,"Thus, we find that p73 shows a degree of specificity for the promoters of target genes that is quantitatively distinct from the response mediated by p53.",0.28,PMID.dPMID10435630.s4.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12101410,p53,p73,"Thus, the induction of p73 Delta N expression by p53 establishes an autoregulatory feedback loop that keeps the trigger of cell death under tight control",0.28,PMID.dPMID12101410.s0.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11051237,p53,p73,"Thep73 gene, a homology of p53, is a new candidate of imprinting and tumor suppressor gene.",0.27,PMID.dPMID11051237.s11.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12944917,p53,p73,"The DeltaNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity.",0.24,PMID.dPMID12944917.s7.p0,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16814250,p53,p73,"Taken together, our present results strongly suggest that p73-dependent induction of 14-3-3sigma plays an important role in the regulation of chemo-sensitivity of breast cancers bearing p53 mutation",0.24,PMID.dPMID16814250.s0.p1,3,3,p73|14-3-3sigma|p53,14-3-3sigma|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12880969,p53,p73,"The p73 gene is a p53 homologue localized at 1p36.3, a chromosomal region frequently deleted in neuroblastoma.",0.24,PMID.dPMID12880969.s5.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11470228,p53,p73,p73 has been identified as a transcription factor that can regulate p53-dependent transcriptional targets.,0.22,PMID.dPMID11470228.s4.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18418051,p53,p73,"p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1. Trans-activating (TA) p73 is a member of the p53 family of transcription factors and has been implicated in cell cycle regulation, apoptosis and developmental processes.",0.21,PMID.dPMID18418051.s4.p2,3,2,p73|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18039564,p53,p73,The TAp73 levels in stage III biopsies differed by 100-fold depending on the p53 status and overall survival appears to be significantly related to DeltaNp73 expression.,0.20,PMID.dPMID18039564.s3.p0,3,2,p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12969350,p53,p73,"Differential expressions of p63, p73 and p53 proteins in the carcinoma samples were: p63+/p73+/p53 + (n = 28; 70%); p63+/p73+/p53- (n = 4; 10%); p63+/p73-/p53- (n = 8; 20%), respectively; and p63+/p73+/p53- for normal mucosa (n = 10; 100%).",0.20,PMID.dPMID12969350.s3.p65,15,3,p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12934105,p53,p73,"Using the adenoviral system, we report that an overexpression of either wt-p73alpha or one of the two transcriptional inactive mutants, deltaNp73alpha or p73alphaR292H, induces an accumulation of the endogenous wt-p53 expressed in the three transformed cell lines, SK-N-SH, MCF-7 and U-2OS, without stimulating the p53 gene transcription.",0.19,PMID.dPMID12934105.s4.p3,5,2,p73|p73|p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14602923,p53,p73,DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1.   p73 is a member of the p53 family often overexpressed in human cancer.,0.19,PMID.dPMID14602923.s9.p5,4,3,p73|E2F1|p73|p53,E2F1|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12619104,p53,p73,The lack of p63/p73 mutations in human cancers rule out a typical TSG role for either of the p53 homologues.,0.19,PMID.dPMID12619104.s1.p4,4,4,p63|p73|TSG|p53,p53|p63|p73|TSG,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19291793,p53,p73,"We found imatinib up-regulated phosphorylation of p38 mitogen-activated protein kinase (MAPK), checkpoint kinase 2 (chk2) and transactivation-competent (TA) p73; expression of pml and bax; formation of PML-nuclear body (NB); and co-localization of TAp73/PML-NB in p53-nonfunctioning K562 and p53(mutant) Meg-01 CML cells, but not in BCR-ABL(-) HL60 cells.",0.18,PMID.dPMID19291793.s7.p19,10,6,p73|pml|bax|PML|p73|PML|p53|p53|Meg|CML,bax|CML|Meg|p53|p73|pml|PML,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10362118,p53,p73,Our results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function.,0.17,PMID.dPMID10362118.s1.p5,4,2,p73|p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12969350,p53,p73,"Differential expressions of p63, p73 and p53 proteins in the carcinoma samples were: p63+/p73+/p53 + (n = 28; 70%); p63+/p73+/p53- (n = 4; 10%); p63+/p73-/p53- (n = 8; 20%), respectively; and p63+/p73+/p53- for normal mucosa (n = 10; 100%).",0.17,PMID.dPMID12969350.s3.p35,15,3,p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18234963,p53,p73,"Second, a TAp73alpha mutant (G264W), which is devoid of DNA binding capability, is still able to increase p53 protein levels by competing with p53 for Mdm2 protein binding.",0.16,PMID.dPMID18234963.s2.p0,4,3,p73|p53|p53|Mdm2,Mdm2|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10648616,p53,p73,The newly identified p53 homolog p73 mimics the transcriptional function of p53.,0.15,PMID.dPMID10648616.s9.p2,3,2,p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11314010,p53,p73,p73 is a member of the p53 family.,0.13,PMID.dPMID11314010.s7.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17304243,p53,p73,"In contrast to TA-p73, deltaN-p73 is a negative regulator of p53-induced and p73-induced autophagy, but does not affect autophagy induced by amino-acid starvation.",0.13,PMID.dPMID17304243.s1.p1,4,2,p73|p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12920125,p53,p73,p73 is a p53 paralog that encodes proapoptotic (transactivation-competent (TA)) and antiapoptotic (dominant negative) isoforms.,0.13,PMID.dPMID12920125.s9.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,9802988,p53,p73,"At the functional level, p73gamma is significantly less efficient in activating transcription of the p21(Waf1/Cip1) promoter than p53 or p73beta, whereas the effect of p73delta is intermediate and comparable to that of p73alpha.",0.13,PMID.dPMID9802988.s3.p3,7,3,p73|Waf1|Cip1|p53|p73|p73|p73,Cip1|p53|p73|Waf1,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,14501821,p53,TP73,The TP73 gene is a member of the p53 family and through differential promoter usage and alternative splicing can encode a number of different isoforms that have distinct properties.,0.10,PMID.dPMID14501821.s8.p0,2,2,TP73|p53,p53|TP73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,16965670,p53,p73,The p53 family member p73 is a p53 homolog.,0.10,PMID.dPMID16965670.s15.p2,3,2,p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12427762,p53,p73,Full-length p73 expressed in the transformed leukemia cell line Jurkat behaves as a specific dominant negative transcriptional repressor of the cell cycle inhibitor gene p21 and blocks p53-mediated apoptosis.,0.09,PMID.dPMID12427762.s1.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15893728,p53,p73,YAP imparts selectivity to p73 by promoting the activation of a subset of p53 and/or p73 target promoters.,0.08,PMID.dPMID15893728.s4.p2,4,3,YAP|p73|p53|p73,p53|p73|YAP,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17637683,p53,p73,"p53, p63 and p73 are members of the p53 gene family involved in development, differentiation and response to cellular stress.",0.08,PMID.dPMID17637683.s9.p5,4,3,p53|p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10972855,p53,p73,"Besides structural similarities, the fact that p73 functions in the regulation of the cell cycle and apoptosis promotes the expansion of the research field concerning p53-associated tumor progression.",0.07,PMID.dPMID10972855.s2.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10802655,p53,p73,"The p73 protein, a homologue of the tumour-suppressor protein p53, can activate p53-responsive promoters and induce apoptosis in p53-deficient cells.",0.07,PMID.dPMID10802655.s5.p1,4,2,p73|p53|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12726864,p53,p73,A polymorphism encoding either arginine (72R) or proline (72P) at codon 72 of p53 influences inhibition of p73 by a range of p53 mutants identified in squamous cancers.,0.06,PMID.dPMID12726864.s2.p2,3,2,p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10207051,p53,p73,The newly identified p53 homolog p73 can mimic the transcriptional activation function of p53.,0.06,PMID.dPMID10207051.s6.p2,3,2,p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15741235,p53,p73,"The fact that DeltaNp73alpha may either inhibit or stimulate wt-p53 transcriptional activity, depending on both the p53 target gene and the cellular context, was confirmed by real-time quantitative PCR.",0.05,PMID.dPMID15741235.s3.p1,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11172610,p53,p73,p73 has been shown to transcriptionally activate genes positively responsive to wild-type p53.,0.05,PMID.dPMID11172610.s9.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18234963,p53,p73,"Ectopic coexpression of both p53 and TAp73alpha in thyroid cancer cells resulted in increased transcription and tumor suppressor function compared with p53 or TAp73alpha alone, as well as in increased p53 protein levels.",0.05,PMID.dPMID18234963.s6.p9,5,2,p53|p73|p53|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18579560,p53,p73,p73 was found to be upregulated by serum starvation and mediate PUMA induction through the p53-binding sites in the PUMA promoter.,0.03,PMID.dPMID18579560.s3.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,9296498,p53,p73,"Here we show that p73 can, at least when overproduced, activate the transcription of p53-responsive genes and inhibit cell growth in a p53-like manner by inducing apoptosis (programmed cell death)",0.03,PMID.dPMID9296498.s0.p0,3,2,p73|p53|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11313982,p53,p73,This was further substantiated by suppression of p53 transactivation of the effector gene p21/Waf1 in p73Deltaexon2 transfected cells and by inhibition of expression of a reporter gene under the control of the p53 promoter.,0.02,PMID.dPMID11313982.s3.p5,4,3,p53|Waf1|p73|p53,p53|p73|Waf1,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19777343,p53,p73,"DeltaNp73 was dramatically induced by p53 in a TAp73-dependent manner, and silencing p73 suppressed the transcriptional activation of alphaB-crystallin by p53.",0.02,PMID.dPMID19777343.s2.p10,6,3,p73|p53|p73|p73|alphaB-crystallin|p53,alphaB-crystallin|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11753569,p53,p73,"In this study, we report the cloning and characterisation of the human Delta Np73 isoforms, their regulation by p53 and their possible role in carcinogenesis.",0.02,PMID.dPMID11753569.s8.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11101847,p53,p73,Disruption of p73 function by a tumour-derived p53 mutant reduced E2F1-mediated apoptosis.,0.01,PMID.dPMID11101847.s1.p0,3,3,p73|p53|E2F1,E2F1|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10404087,tp53,tp73,"The tp73 gene, a tp53 homologue, has been sub-regionally mapped at 1p36.3, a chromosomal region frequently deleted in neuroblastoma.",0.01,PMID.dPMID10404087.s11.p0,2,2,tp73|tp53,tp53|tp73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12841870,p53,p73,"Moreover, the expression of p21 was highly correlated with p73 expression irrespective of the p53 mutation status.",0.01,PMID.dPMID12841870.s1.p2,3,3,p21|p73|p53,p21|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18566213,p53,p73,Pretreatment of resistant A2780 CIS cells with the histone deacetylase inhibitor trichostatin A overcomes apoptosis resistance to CDDP by restoring both p73 and Bax but not p53 expression.,0.01,PMID.dPMID18566213.s1.p1,3,3,p73|Bax|p53,Bax|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12782576,p53,p73,p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement.,0.01,PMID.dPMID12782576.s5.p0,2,2,p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18418051,p53,p73,"p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1. Trans-activating (TA) p73 is a member of the p53 family of transcription factors and has been implicated in cell cycle regulation, apoptosis and developmental processes.",0.01,PMID.dPMID18418051.s4.p1,3,2,p73|p73|p53,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,19952113,p53,p73,"Chromatin immunoprecipitation showed that cisplatin removed DeltaNp73 from the PDGFRB promoter and recruited p53 and p73, leading to binding of histone deacetylase 4.",0.00,PMID.dPMID19952113.s1.p0,3,2,p73|p53|p73,p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,15849742,p53,p73,"TA-p73/p63 demonstrate p53-like properties including gene transactivation and cell death promotion, whereas DeltaN-p73/p63 lack these p53-like functions.",0.00,PMID.dPMID15849742.s8.p1,6,3,p73|p63|p53|p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.3.2.1,7291,9606,,,15118411,p53,twist,"These results demonstrate that MDM2, rather than p53, is the substrate for HAUSP under physiologic conditions and document a fascinating and unexpected twist to the regulation of the p53/MDM2 axis",1.08,PMID.dPMID15118411.s0.p9,6,4,MDM2|p53|HAUSP|twist|p53|MDM2,HAUSP|MDM2|p53|twist,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.3.2.1,7291,9606,,,16671355,tumor suppressor p53,twist,"A new twist in the concept became evident while studying the degradation of the tumor suppressor p53, a protein that appeared to satisfy this principle.",0.10,PMID.dPMID16671355.s2.p0,2,2,twist|tumor suppressor p53,tumor suppressor p53|twist,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.3.2.1,7291,9606,,,15684615,p53,twist,A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.,0.02,PMID.dPMID15684615.s14.p1,3,3,twist|MDM2|p53,MDM2|p53|twist,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,16651407,p53,VDR,"VDR is induced by p53 as well as several other p53 family members, and analysis of chromatin immunoprecipitation showed that p53 protein binds to conserved intronic sequences of the VDR gene in vivo.",0.51,PMID.dPMID16651407.s3.p0,5,2,VDR|p53|p53|p53|VDR,p53|VDR,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,16741990,p53,VDR,"Additionally, transfection of p53-null ALVA-31 PCa cells with a p53 expression plasmid, and expression of dominant negative p53 in LNCaP PCa cells, show that the ability of VDR to induce PDF requires functional p53.",0.19,PMID.dPMID16741990.s2.p13,6,3,p53|p53|p53|VDR|PDF|p53,p53|PDF|VDR,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,8702877,p53,WT-1,"Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with mutated p53, and a 4-fold repression with wild-type p53.",0.54,PMID.dPMID8702877.s2.p15,7,2,WT-1|WT-1|p53|p53|WT-1|p53|p53,p53|WT-1,[7490-->2297]
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,11852808,P53,WT1,Involvement of WT1 gene expression in regulation of P53 and MDM2 proteins function in acute lymphoblastic leukemia   Using sensitive techniques such as reverse transcription polymerase chain reaction (RT-PCR) the expression of WT1 gene in acute lymphoblastic leukemias (ALL) is indicated.,0.36,PMID.dPMID11852808.s9.p0,5,4,WT1|P53|MDM2|WT1|ALL,ALL|MDM2|P53|WT1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,8702877,p53,WT-1,"Cotransfections with plasmids expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex pattern of regulation with a 3-fold induction with WT-1, a 7-fold induction with mutated p53, and a 4-fold repression with wild-type p53.",0.32,PMID.dPMID8702877.s2.p10,7,2,WT-1|WT-1|p53|p53|WT-1|p53|p53,p53|WT-1,[7490-->2297]
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7910152,p53,WT1,"Finally, WT1 expression data were evaluated in conjunction with immunohistochemical data on p53.",0.15,PMID.dPMID7910152.s1.p0,2,2,WT1|p53,p53|WT1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,10744705,p53,WT1,"Several proteins bind to and alter the transcription regulatory properties of the WT1 proteins, including the product of the tumor suppressor gene p53.",0.12,PMID.dPMID10744705.s5.p0,2,2,WT1|p53,p53|WT1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7927908,p53,WT1,"Co-expression of the wt1 and the PDGF-A chain genes was observed in 2 melanoma cell lines with mutated p53 but not in 2 melanoma cell lines with wild-type p53; this result is consistent with a previous report showing that, in the context of absent or mutated p53, WT1 acts as a transcriptional activator, whereas in the presence of wild-type p53 it acts as a repressor",0.07,PMID.dPMID7927908.s0.p14,6,2,wt1|p53|p53|p53|WT1|p53,p53|wt1|WT1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,9108440,p53,WT1,"WT1-mediated induction of p21 is independent of p53, another tumor suppressor gene known to regulate p21 expression.",0.00,PMID.dPMID9108440.s2.p1,4,3,WT1|p21|p53|p21,p21|p53|WT1,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,15210108,p53,YY1,"Importantly, the tumor suppressor p14ARF compromises the Hdm2-YY1 interaction, which is important for YY1 regulation of p53.",1.14,PMID.dPMID15210108.s1.p5,4,3,Hdm2|YY1|YY1|p53,Hdm2|p53|YY1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,10787423,p53,YY1,"Overexpression of YY1 reverses the repressive effect of p53, suggesting a functional antagonism between p53 and YY1.",0.87,PMID.dPMID10787423.s5.p0,4,2,YY1|p53|p53|YY1,p53|YY1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,15295102,p53 tumor suppressor,YY1,YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.,0.29,PMID.dPMID15295102.s10.p0,2,2,YY1|p53 tumor suppressor,p53 tumor suppressor|YY1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,15210108,p53,YY1,"Taken together, these findings identify YY1 as a potential cofactor for Hdm2 in the regulation of p53 homeostasis and suggest a possible role for YY1 in tumorigenesis",0.21,PMID.dPMID15210108.s0.p1,4,3,YY1|Hdm2|p53|YY1,Hdm2|p53|YY1,<--
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,14963412,p53,ZBP-89,ZBP-89-induced apoptosis is p53-independent and requires JNK.,0.26,PMID.dPMID14963412.s12.p0,3,3,ZBP-89|p53|JNK,JNK|p53|ZBP-89,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,8.2.1.0.2,8091,9606,,,20228781,p53,HMGA2,"In this study, we collected six different types of ovarian cancer and examined HMGA2 expression by immunohistochemistry, along with HMGA1, p53 and Ki-67.",0.28,PMID.dPMID20228781.s4.p0,3,3,HMGA2|p53|Ki-67,HMGA2|Ki-67|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,16084947,p53,AIB1,"The status of the number of AIB1 copies, p53 expression, and DNA ploidy was also analyzed.",0.19,PMID.dPMID16084947.s8.p0,2,2,AIB1|p53,AIB1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.6.0.2,8431,9606,,GO:0034339,19749791,p53,SHP-1,Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.,0.39,PMID.dPMID19749791.s17.p0,3,3,SHP-1|p53|trkA,p53|SHP-1|trkA,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.4.1.12,8553,9606,,GO:0006355,18025081,p53,DEC1,"Taken together, our data provided strong evidence that DEC1 is one of the effectors downstream of p53 to promote premature senescence",0.73,PMID.dPMID18025081.s0.p0,2,2,DEC1|p53,DEC1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.4.1.12,8553,9606,,GO:0006355,18025081,p53,DEC1,"Specifically, we showed that DEC1 is induced by the p53 family and DNA damage in a p53-dependent manner.",0.31,PMID.dPMID18025081.s6.p1,3,2,DEC1|p53|p53,DEC1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.4.1.12,8553,9606,,GO:0006355,18025081,p53,DEC1,"Specifically, we showed that DEC1 is induced by the p53 family and DNA damage in a p53-dependent manner.",0.29,PMID.dPMID18025081.s6.p0,3,2,DEC1|p53|p53,DEC1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,1.2.4.1.12,8553,9606,,GO:0006355,18025081,p53,DEC1,"Here, we found that DEC1 is a novel target gene of the p53 family and mediates p53-dependent premature senescence.",0.13,PMID.dPMID18025081.s7.p0,3,2,DEC1|p53|p53,DEC1|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,16445626,tumor suppressor p53,p63,The p63 is a homologue gene of the tumor suppressor p53.,1.32,PMID.dPMID16445626.s8.p0,2,2,p63|tumor suppressor p53,p63|tumor suppressor p53,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12944917,p53,p63,"In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels.",1.23,PMID.dPMID12944917.s5.p2,3,3,p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18626511,p53,p63,"In this report, we studied the effects of naturally occurring TAp63gamma mutants on the regulation of p53/p63 and p63 specific target genes.",1.05,PMID.dPMID18626511.s5.p0,4,2,p63|p53|p63|p63,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20663147,p53,p63,DeltaNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation.,1.02,PMID.dPMID20663147.s9.p1,3,3,p63|ATM|p53,ATM|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19272371,p53,p63,"Furthermore, we show that mesodermal induction after down-regulation of DeltaNp63 is dependent on p53.",0.96,PMID.dPMID19272371.s3.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20160513,p53,p63,The p63 and p73 proteins activate the transcription of a number of p53 target genes.,0.91,PMID.dPMID20160513.s9.p1,3,3,p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p63,"The p51/p63 gene is a homologue of p53, the product of which acts as a transcriptional activator by binding to p53-responsive elements in the promoter regions of several p53 downstream genes.",0.79,PMID.dPMID10606233.s5.p2,5,2,p51|p63|p53|p53|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p51,"The p51/p63 gene is a homologue of p53, the product of which acts as a transcriptional activator by binding to p53-responsive elements in the promoter regions of several p53 downstream genes.",0.79,PMID.dPMID10606233.s5.p1,5,2,p51|p63|p53|p53|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p63,"The p51/p63 gene is a homologue of p53, the product of which acts as a transcriptional activator by binding to p53-responsive elements in the promoter regions of several p53 downstream genes.",0.77,PMID.dPMID10606233.s5.p7,5,2,p51|p63|p53|p53|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p51,"The p51/p63 gene is a homologue of p53, the product of which acts as a transcriptional activator by binding to p53-responsive elements in the promoter regions of several p53 downstream genes.",0.77,PMID.dPMID10606233.s5.p6,5,2,p51|p63|p53|p53|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,16616891,p53,p63,This suggests that DeltaNp63alpha plays an anti-apoptotic role regardless of the p53 status.,0.70,PMID.dPMID16616891.s1.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,15846087,p53,p63,"In contrast to the differences between p53 and GAL4-VP16, p63 and p73 both regulated transcription in vitro under similar conditions as did p53.",0.66,PMID.dPMID15846087.s2.p8,5,4,p53|GAL4|p63|p73|p53,GAL4|p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20613985,p53,p63,BACKGROUND: p63 is a member of the p53 transcription factor family.,0.65,PMID.dPMID20613985.s13.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10637430,p53,p51,"However, the protein-protein interactions analyzed by a yeast two-hybrid assay between p51 and p53, between p51 and p73, and between p51 and oncoproteins showed that p51 is functionally rather distant from p53.",0.63,PMID.dPMID10637430.s2.p20,7,3,p51|p53|p51|p73|p51|p51|p53,p51|p53|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17935121,p53,p63,"p63 can activate or repress transcription of p53 and p73 target genes, but also has unique transcriptional targets and, unlike other p53 family members, is required for normal development and differentiation of squamous epithelia.",0.61,PMID.dPMID17935121.s6.p0,4,3,p63|p53|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20298673,p53,p63,"p73 and p63 regulate the expression of fibroblast growth factor receptor 3.   p53, p63 and p73 make a family of transcription factors that play a vital role in development and cancer.",0.60,PMID.dPMID20298673.s7.p2,5,3,p73|p63|p53|p63|p73,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,11494153,p53,p63,"Like p53, p63 is able to induce p53 target genes and it was shown to be able to cause cell cycle arrest and apoptosis.",0.60,PMID.dPMID11494153.s1.p2,3,2,p53|p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18626511,p53,p63,We observed significant differences among p63 mutants to regulate the p53/p63 and p63 specific target genes.,0.59,PMID.dPMID18626511.s4.p0,4,2,p63|p53|p63|p63,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12185332,p53 tumor suppressor,p63,BACKGROUND: p63 is a homologue of the p53 tumor suppressor gene and its protein is selectively expressed in the basal cells of a variety of epithelial tissues.,0.55,PMID.dPMID12185332.s6.p0,2,2,p63|p53 tumor suppressor,p53 tumor suppressor|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p51,Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.,0.51,PMID.dPMID10606233.s6.p1,3,2,p51|p63|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p63,Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.,0.51,PMID.dPMID10606233.s6.p2,3,2,p51|p63|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18801697,p53,p63,Therapeutic prospects for p73 and p63: rising from the shadow of p53.,0.47,PMID.dPMID18801697.s5.p2,3,3,p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12446784,p53,p63,We have systematically compared the activities of the wild-type p63 isoforms and of the natural mutants in activation and repression assays on three promoters modulated by p53.,0.43,PMID.dPMID12446784.s5.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18315848,p53,p63,"In contrast, reverse mutations, where p63 and p73 were mutated by replacing the Phe238 and Ile255 by Tyr and Thr respectively (as in p53), showed reduced conformational sampling although the change for p63 was much smaller than that for p73.",0.37,PMID.dPMID18315848.s7.p1,5,3,p63|p73|p53|p63|p73,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12379767,p53,p63,p63 is a p53-related gene that encodes for multiple mRNA transcripts with (TA-p63) or without (DeltaN-p63) transactivating properties on p53-responsive genes.,0.36,PMID.dPMID12379767.s10.p0,5,2,p63|p53|p63|p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,11681414,p53,p51,"The p51/p63 gene, a novel member of the p53 gene family, has recently been identified at 3q27-9.",0.35,PMID.dPMID11681414.s13.p1,3,2,p51|p63|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,11681414,p53,p63,"The p51/p63 gene, a novel member of the p53 gene family, has recently been identified at 3q27-9.",0.35,PMID.dPMID11681414.s13.p2,3,2,p51|p63|p53,p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17909026,p53,p63,"p63 is a member of the p53 family and regulates crucial events in the formation of epithelial structures, but the role of p63 in tumor is unclear.",0.31,PMID.dPMID17909026.s8.p0,3,2,p63|p53|p63,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20613985,p53,p63,"The DeltaNp63 isoforms are dominant-negative variants opposing the activities of p53, TAp63 and TAp73.",0.29,PMID.dPMID20613985.s10.p0,3,2,p63|p53|p63,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12429996,p53,p63,p63 is a known homologue of p53.,0.27,PMID.dPMID12429996.s9.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,15988026,p53,p63,"Taken together, these data suggest a feedback loop for p63 regulation, analogous to the p53-MDM2 feedback loop",0.25,PMID.dPMID15988026.s0.p0,3,3,p63|p53|MDM2,MDM2|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12357472,p53,P63,The P63 gene is a recently discovered member of the p53 family.,0.24,PMID.dPMID12357472.s7.p0,2,2,P63|p53,p53|P63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,16322335,p53,p63,"Moreover, TAp63alpha antagonizes the effect of p53 on target genes, cell viability and foci formation, and p63 gene silencing by small interfering (si) RNA results in improved p53 activity.",0.22,PMID.dPMID16322335.s2.p5,4,2,p63|p53|p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,11714701,p53,p63,These data indicate that p63 can be activated by HDM2 under conditions in which p53 is inhibited.,0.20,PMID.dPMID11714701.s1.p1,3,3,p63|HDM2|p53,HDM2|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,16322335,p53,p63,"Moreover, TAp63alpha antagonizes the effect of p53 on target genes, cell viability and foci formation, and p63 gene silencing by small interfering (si) RNA results in improved p53 activity.",0.20,PMID.dPMID16322335.s2.p0,4,2,p63|p53|p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,11727253,p53,p63,p63 is a p53-related DNA-binding protein that helps regulate differentiation and proliferation in epithelial progenitor cells.,0.20,PMID.dPMID11727253.s15.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,11714701,p53,p63,"Therefore, HDM2 expression could support p63-specific transcriptional functions on a common set of genes, keeping interference by p53 at a minimum.",0.20,PMID.dPMID11714701.s0.p2,3,3,HDM2|p63|p53,HDM2|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12969350,p53,p63,"Differential expressions of p63, p73 and p53 proteins in the carcinoma samples were: p63+/p73+/p53 + (n = 28; 70%); p63+/p73+/p53- (n = 4; 10%); p63+/p73-/p53- (n = 8; 20%), respectively; and p63+/p73+/p53- for normal mucosa (n = 10; 100%).",0.20,PMID.dPMID12969350.s3.p64,15,3,p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17297296,p53,p63,"We found that p63 is capable of activating gene expression through binding to specific cis-elements, RE1 and RE2, with the latter being more specific for p63 than for p53.",0.19,PMID.dPMID17297296.s1.p1,3,2,p63|p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12619104,p53,p63,The lack of p63/p73 mutations in human cancers rule out a typical TSG role for either of the p53 homologues.,0.19,PMID.dPMID12619104.s1.p3,4,4,p63|p73|TSG|p53,p53|p63|p73|TSG,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19272371,p53,p63,DeltaNp63 antagonizes p53 to regulate mesoderm induction in Xenopus laevis.,0.18,PMID.dPMID19272371.s8.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19267405,p53,p63,p63 is a member of the p53 family and DeltaNp63alpha is the dominant-expressing isoform of p63 in basal layer of normal stratified epithelium and human squamous cell carcinoma (SCC) cells.,0.17,PMID.dPMID19267405.s9.p0,4,2,p63|p53|p63|p63,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18615329,p53,p63,p63 is a p53 homologue and a marker expressed in replicating keratinocytes.,0.17,PMID.dPMID18615329.s9.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12969350,p53,p63,"Differential expressions of p63, p73 and p53 proteins in the carcinoma samples were: p63+/p73+/p53 + (n = 28; 70%); p63+/p73+/p53- (n = 4; 10%); p63+/p73-/p53- (n = 8; 20%), respectively; and p63+/p73+/p53- for normal mucosa (n = 10; 100%).",0.17,PMID.dPMID12969350.s3.p34,15,3,p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17332760,p53,p63,"The relatives and evolutionary predecessors of p53 - p63 and p73 - share the tumour-suppressor activity of p53 to some extent, but also have essential functions in embryonic development and differentiation control.",0.15,PMID.dPMID17332760.s1.p4,4,3,p53|p63|p73|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p63,"Although most of the p51/p63 missense mutations at the p53 hotspot residues were unable to transactivate the promoters used in this study, the tumor-derived p51/p63 missense mutations retained their ability to transactivate the MDM2 and/or the BAX promoter but not the p21/WAF1 promoter.",0.15,PMID.dPMID10606233.s1.p2,7,4,p51|p63|p53|p51|p63|MDM2|BAX,BAX|MDM2|p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10606233,p53,p51,"Although most of the p51/p63 missense mutations at the p53 hotspot residues were unable to transactivate the promoters used in this study, the tumor-derived p51/p63 missense mutations retained their ability to transactivate the MDM2 and/or the BAX promoter but not the p21/WAF1 promoter.",0.15,PMID.dPMID10606233.s1.p1,7,4,p51|p63|p53|p51|p63|MDM2|BAX,BAX|MDM2|p51|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18296650,p53,p63,p73 and p63 are members of the p53 gene family and have been shown to play an important role in development and homeostasis mainly by regulating the transcription of a variety of genes.,0.11,PMID.dPMID18296650.s10.p2,3,3,p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19103865,p53,p63,"BACKGROUND: p63 gene is a p53 homologue that encodes proteins with transactivation, DNA-binding and tetramerisation domains.",0.10,PMID.dPMID19103865.s7.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17688405,p53,p63,The p63 gene belongs to the p53 gene family and encodes for sequence-specific transcription factors.,0.09,PMID.dPMID17688405.s5.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10918601,p53,p63,We suggest that deltaN-p63 is a good candidate as a suppressor of wild type p53 function in these tumours and also that it may prove to be a valuable diagnostic marker for undifferentiated NPC,0.08,PMID.dPMID10918601.s0.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,18037962,p53,p63,"We showed that TAp63 isoforms are capable of inducing p53-responsive genes, inhibiting cell proliferation and promoting apoptosis.",0.07,PMID.dPMID18037962.s6.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12379768,p53,p63,"Products of the p63 gene, a recently described member of the p53 family, are constitutively expressed in the basal cells of human bronchi and bronchioli.",0.05,PMID.dPMID12379768.s6.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10695992,p53,p51,The p51 gene encodes a protein with significant homology to p53.,0.04,PMID.dPMID10695992.s4.p0,2,2,p51|p53,p51|p53,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17477357,p53 tumor suppressor,p63,p63 is a member of a gene family also including the p53 tumor suppressor and p73.,0.02,PMID.dPMID17477357.s7.p0,3,3,p63|p53 tumor suppressor|p73,p53 tumor suppressor|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,15846104,p53,p63,"DeltaNp63alpha, a homologue of the tumor suppressor p53, acts as a transcriptional repressor with dominant negative effects towards p53.",0.02,PMID.dPMID15846104.s8.p1,3,2,p63|tumor suppressor p53|p53,p53|p63|tumor suppressor p53,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19047897,p53,p63,MGA and carcinomas arising from MGA were typically negative for p63 and positive for S-100 and Ki-67 and occasionally positive for p53.,0.01,PMID.dPMID19047897.s6.p1,3,3,p63|Ki-67|p53,Ki-67|p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19829080,p53,p63,"p63 is a member of the p53 family involved in skin and limb development, as well as in the homeostasis of mature epidermis.",0.01,PMID.dPMID19829080.s3.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19461509,p53,p63,"CD117 (c-kit) was positive in 6 of 8 cases (75%), p63 was positive in 7 of 8 cases (88%), p53 was positive in 7 of 8 cases (88%), ranging from <10% to 90%, CD5 was focally positive in 3 of 8 cases (38%), collagen type IV was positive in 4 of 8 cases (50%), and proliferative index, as estimated by Ki67, ranged from <1% to approximately 15%.",0.01,PMID.dPMID19461509.s7.p0,2,2,p63|p53,p53|p63,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,15849742,p53,p63,"TA-p73/p63 demonstrate p53-like properties including gene transactivation and cell death promotion, whereas DeltaN-p73/p63 lack these p53-like functions.",0.00,PMID.dPMID15849742.s8.p2,6,3,p73|p63|p53|p73|p63|p53,p53|p63|p73,-->
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,8649855,p53,SAR,Specific binding of MAR/SAR DNA-elements by mutant p53.,0.59,PMID.dPMID8649855.s8.p0,2,2,SAR|p53,p53|SAR,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,8649855,p53,SAR,"The MAR/SAR-binding region of mutant p53 maps to a bipartite domain consisting of the mutated core region and the C-terminal 60 amino acids, carrying the unspecific DNA-binding domain and the oligomerization motif.",0.21,PMID.dPMID8649855.s2.p0,2,2,SAR|p53,p53|SAR,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,17308127,p53,KLF4,Previous work has shown that the Kruppel-like factor 4 (KLF4) transcription factor represses p53 transcription by binding to the PE21 element.,0.85,PMID.dPMID17308127.s3.p2,3,2,Kruppel-like factor 4|KLF4|p53,KLF4|Kruppel-like factor 4|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19826046,p53,KLF4,"KLF4 is activated by p53 following cytostatic, mild DNA damage, whereas it is strongly repressed via enhanced turnover of mRNA on severe DNA damage that irreversibly drives cells to apoptosis.",0.69,PMID.dPMID19826046.s2.p0,2,2,KLF4|p53,KLF4|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,17308127,p53,Kruppel-like factor 4,Previous work has shown that the Kruppel-like factor 4 (KLF4) transcription factor represses p53 transcription by binding to the PE21 element.,0.55,PMID.dPMID17308127.s3.p1,3,2,Kruppel-like factor 4|KLF4|p53,KLF4|Kruppel-like factor 4|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19503094,p53,KLF4,Earlier studies have reported that KLF4 is transcriptionally activated by p53 following DNA damage.,0.46,PMID.dPMID19503094.s3.p0,2,2,KLF4|p53,KLF4|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19826046,p53,KLF4,"Blocking the repression of KLF4 on severe DNA damage suppresses p53-mediated apoptosis, whereas ablation of the KLF4 induction on mild DNA damage shifts the p53 response from cell cycle arrest to cell death.",0.06,PMID.dPMID19826046.s1.p0,4,2,KLF4|p53|KLF4|p53,KLF4|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,17962299,p53,CTCF,"Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.",0.76,PMID.dPMID17962299.s9.p6,5,3,CTCF|brother of the regulator of imprinted sites|BORIS|CTCF|p53,BORIS|brother of the regulator of imprinted sites|CTCF|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,20101205,p53,CTCF,This evidence suggests that CTCF protects the p53 gene promoter against repressive histone marks.,0.45,PMID.dPMID20101205.s3.p0,2,2,CTCF|p53,CTCF|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,15489900,p53,iASPP,"The effect upon subcellular localization of the longer N-terminus of iASPP means that this new, longer form of the molecule may be subject to greater regulation and provides another layer in the control of p53-induced apoptosis.",0.42,PMID.dPMID15489900.s0.p0,2,2,iASPP|p53,iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,16964264,p53,iASPP,"iASPP is one of the most evolutionarily conserved inhibitors of p53, whereas ASPP1 and ASPP2 are activators of p53.",0.41,PMID.dPMID16964264.s3.p0,5,4,iASPP|p53|ASPP1|ASPP2|p53,ASPP1|ASPP2|iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,12524540,p53,iASPP,"iASPP is an evolutionarily conserved inhibitor of p53; inhibition of iASPP by RNA-mediated interference or antisense RNA in C. elegans or human cells, respectively, induces p53-dependent apoptosis.",0.40,PMID.dPMID12524540.s4.p5,4,2,iASPP|p53|iASPP|p53,iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,12524540,p53,iASPP,iASPP expression is upregulated in human breast carcinomas expressing wild-type p53 and normal levels of ASPP.,0.37,PMID.dPMID12524540.s1.p0,2,2,iASPP|p53,iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,16964264,p53,iASPP,"iASPP is one of the most evolutionarily conserved inhibitors of p53, whereas ASPP1 and ASPP2 are activators of p53.",0.25,PMID.dPMID16964264.s3.p6,5,4,iASPP|p53|ASPP1|ASPP2|p53,ASPP1|ASPP2|iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,19299014,p53,iASPP,The results indicated that down-regulation of endogenous iASPP increased p53-dependent apoptosis of leukemia cells.,0.18,PMID.dPMID19299014.s1.p0,2,2,iASPP|p53,iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.1.2.2.1,10848,9606,,,16964264,p53,iASPP,iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53.,0.07,PMID.dPMID16964264.s4.p0,3,2,iASPP|p53|p53,iASPP|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.7.1.1.1,29841,9606,,,18220473,p53,NH32,"We also examined the role of p53 (TP53) in these processes by using cells of three human lymphoblastoid cell lines from the same donor but with differing p53 status (TK6 is p53 wild-type, NH32 is p53 null, and WTK1 is p53 mutant).",0.45,PMID.dPMID18220473.s7.p14,7,2,p53|TP53|p53|p53|NH32|p53|p53,NH32|p53|TP53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,6.7.1.1.1,29841,9606,,,12376471,p53,NH32,"The global cellular response to UV-induced DNA damage has been analyzed in the p53-proficient human lymphoblastoid strain TK6 versus two isogenic derivatives wherein p53 activity was abrogated by diverse experimental approaches: (i) NH32, carrying a homozygous genetic knockout of p53; and (ii) TK6-5E, expressing the human papillomavirus E6 oncoprotein which binds and functionally inactivates p53 protein.",0.00,PMID.dPMID12376471.s6.p5,5,2,p53|p53|NH32|p53|p53,NH32|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,20075077,p53,Foxp3,"Here, we demonstrate that Foxp3 up-regulation requires p53 function, showing that Foxp3 expression is directly regulated by p53 upon DNA damage responses in human breast and colon carcinoma cells.",1.30,PMID.dPMID20075077.s4.p5,4,2,Foxp3|p53|Foxp3|p53,Foxp3|p53,e
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,20075077,p53,Foxp3,These results suggest that induction of Foxp3 in the context of tumor suppression is regulated in a p53-dependent manner and implicate Foxp3 as a key determinant of cell fate in p53-dependent DNA damage responses.,0.68,PMID.dPMID20075077.s0.p0,4,2,Foxp3|p53|Foxp3|p53,Foxp3|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,20075077,p53,Foxp3,Foxp3 expression in p53-dependent DNA damage responses.,0.17,PMID.dPMID20075077.s7.p0,2,2,Foxp3|p53,Foxp3|p53,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.4.0.1,55193,9606,,,20660729,p53,BAF180,Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence.,0.62,PMID.dPMID20660729.s7.p5,4,3,Polybromo|BRD7|BAF180|p53,BAF180|BRD7|p53|Polybromo,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,4.1.4.0.1,55193,9606,,,20660729,p53,Polybromo,Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence.,0.28,PMID.dPMID20660729.s7.p3,4,3,Polybromo|BRD7|BAF180|p53,BAF180|BRD7|p53|Polybromo,
6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,3.1.10.9.1,145258,9606,,,17523278,p53,GSC,Only two carcinomas (1 IPGC and 1 GSC) harboring a p53 mutation did not show any p53 expression.,0.71,PMID.dPMID17523278.s4.p1,3,2,GSC|p53|p53,GSC|p53,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,1.1.1.2.6,467,9606,,,18644986,p73,ATF3,"In contrast, paclitaxel-induced ATF3 expression did not change in TAp73beta-overexpressed or TAp73beta siRNA-cotransfected cells.",0.25,PMID.dPMID18644986.s7.p0,3,2,ATF3|p73|p73,ATF3|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,11101847,TP73,E2F1,"Here we provide evidence that E2F1 directly activates transcription of TP73, leading to activation of p53-responsive target genes and apoptosis.",1.30,PMID.dPMID11101847.s2.p0,3,3,E2F1|TP73|p53,E2F1|p53|TP73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19523927,p73,E2F-1,E2F-1 acts as a transcriptional regulator for p73.,1.15,PMID.dPMID19523927.s6.p0,2,2,E2F-1|p73,E2F-1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,11034215,p73,E2F-1,Here we show that E2F-1 induces the transcription of the p53 homologue p73.,1.06,PMID.dPMID11034215.s2.p1,3,3,E2F-1|p53|p73,E2F-1|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,15601819,p73,E2F1,We demonstrate as well that E2F1 directs p73 expression in the presence and absence of DNA damage.,1.03,PMID.dPMID15601819.s3.p0,2,2,E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19576172,p73,E2F1,"Taken together, our present study indicates that E2F1 has a dual role in the regulation of p73",0.91,PMID.dPMID19576172.s0.p0,2,2,E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19576172,p73,E2F1,It has been shown that E2F1 acts as a transcriptional activator for p73.,0.84,PMID.dPMID19576172.s5.p0,2,2,E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19576172,p73,E2F1,"Additionally, the deletion analysis showed that E2F1(1-117) has an undetectable effect on p73, whereas E2F1(1-285) and E2F1(1-414) have an ability to promote degradation of p73 and inhibition of p73 transcriptional activity, suggesting that the region of E2F1 between amino acid residues 118 and 285 has a critical role in the regulation of p73.",0.81,PMID.dPMID19576172.s1.p27,8,2,E2F1|p73|E2F1|E2F1|p73|p73|E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,14602923,p73,E2F1,DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. p73 is a member of the p53 family often overexpressed in human cancer.,0.72,PMID.dPMID14602923.s9.p2,4,3,p73|E2F1|p73|p53,E2F1|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,14602923,p73,E2F1,"Furthermore, by using different p73 promoter fragments, we found a role for E2F1 in mediating transcription of p73.",0.58,PMID.dPMID14602923.s6.p2,3,2,p73|E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,15450420,p73,E2F-1,"These pathways are related, for instance, p73 is also downstream of E2F-1, since E2F-1 induces p73-mediated apoptosis in the absence of p53.",0.57,PMID.dPMID15450420.s6.p5,5,3,p73|E2F-1|E2F-1|p73|p53,E2F-1|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19576172,p73,E2F1,Immunoprecipitation experiments demonstrated that E2F1 forms a complex with p73 and inhibits the transcriptional activity of p73.,0.45,PMID.dPMID19576172.s3.p1,3,2,E2F1|p73|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19576172,p73,E2F1,"In this study, we have found that deregulated expression of E2F1 increases the mRNA level of p73, however, E2F1 promotes the degradation of p73.",0.21,PMID.dPMID19576172.s4.p0,4,2,E2F1|p73|E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.3.2.1.1,1869,9606,,GO:0000122,19576172,p73,E2F1,"In this study, we have found that deregulated expression of E2F1 increases the mRNA level of p73, however, E2F1 promotes the degradation of p73.",0.10,PMID.dPMID19576172.s4.p5,4,2,E2F1|p73|E2F1|p73,E2F1|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.2.1.2,1958,9606,,GO:0045941,17822668,p73,Egr-1,"Overall, our results provide direct evidence that Egr-1 positively regulated p73 expression by binding to its promoter in vivo, consistent with Egr-1 and p73 being involved in p53-independent tumor suppression",3.29,PMID.dPMID17822668.s0.p0,5,3,Egr-1|p73|Egr-1|p73|p53,Egr-1|p53|p73,p
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.2.1.2,1958,9606,,GO:0045941,17822668,p73,Egr-1,"Overall, our results provide direct evidence that Egr-1 positively regulated p73 expression by binding to its promoter in vivo, consistent with Egr-1 and p73 being involved in p53-independent tumor suppression",0.50,PMID.dPMID17822668.s0.p3,5,3,Egr-1|p73|Egr-1|p73|p53,Egr-1|p53|p73,p
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.4.1.0.1,3297,9606,,,15081420,p73,HSF1,Regulation of HSF1-responsive gene expression by N-terminal truncated form of p73alpha.,0.68,PMID.dPMID15081420.s7.p0,2,2,HSF1|p73,HSF1|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,11844794,p73,c-Myc,"More importantly, we found that c-Myc was physically associated with p73 alpha and significantly impaired the transcriptional activity of p73 alpha on Bax and p21(waf1) promoters.",0.01,PMID.dPMID11844794.s2.p1,5,4,c-Myc|p73|p73|Bax|waf1,Bax|c-Myc|p73|waf1,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,1.2.6.5.2,4613,9606,,GO:0006357,12192602,p73,N-myc,N-myc modulates expression of p73 in neuroblastoma.,1.62,PMID.dPMID12192602.s11.p0,2,2,N-myc|p73,N-myc|p73,x
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,1.2.6.5.2,4613,9606,,GO:0006357,12192602,p73,N-myc,"Our data suggest that the N-myc gene modulates expression of p73, allowing neuroblastoma cells to escape the growth suppressing properties of p73",1.14,PMID.dPMID12192602.s0.p0,3,2,N-myc|p73|p73,N-myc|p73,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,1.2.6.5.2,4613,9606,,GO:0006357,12192602,p73,N-myc,"Our data suggest that the N-myc gene modulates expression of p73, allowing neuroblastoma cells to escape the growth suppressing properties of p73",0.26,PMID.dPMID12192602.s0.p1,3,2,N-myc|p73|p73,N-myc|p73,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,16430884,p73,NFkappaB,Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells.,0.31,PMID.dPMID16430884.s9.p0,3,3,NFkappaB|p73|p53,NFkappaB|p53|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,20160496,p73,NFkappaB,"We found in agreement with a recent report showing that NFkappaB is required for the efficient activation of the BH3-only protein Noxa by the p53 family member p73, that p53's ability to induce Noxa is also impeded by inhibition of NFkappaB.",0.12,PMID.dPMID20160496.s4.p3,7,4,NFkappaB|Noxa|p53|p73|p53|Noxa|NFkappaB,NFkappaB|Noxa|p53|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20528922,p73,Sp1,"Therefore, Sp1 directly regulates TAp73 transcription and affects DeltaNup73 levels in lung cancer.",2.09,PMID.dPMID20528922.s1.p0,3,2,Sp1|p73|p73,p73|Sp1,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20528922,p73,Sp1,"Therefore, Sp1 directly regulates TAp73 transcription and affects DeltaNup73 levels in lung cancer.",0.81,PMID.dPMID20528922.s1.p1,3,2,Sp1|p73|p73,p73|Sp1,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,20528922,p73,Sp1,Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer.,0.52,PMID.dPMID20528922.s8.p1,3,2,Sp1|p73|p73,p73|Sp1,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16234237,p73,Sp1 transcription factor,"Mutations in the Sp1 transcription factor-binding sites of the proximal core promoter region significantly abolished p73-induced repression, suggesting that the effect is mediated by Sp1.",0.07,PMID.dPMID16234237.s2.p0,3,2,Sp1 transcription factor|p73|Sp1,p73|Sp1|Sp1 transcription factor,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.5.4.0.4,6910,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,12789260,p73,Hos,"Namely, in Hos p73 transcription is activated by E2F1-Rb2/p130-p300 complexes, while in HosDXR150 it is kept repressed by E2F4-Rb2/p130-HDAC1 complexes.",0.78,PMID.dPMID12789260.s0.p0,7,5,Hos|p73|E2F1|p130|Hos|E2F4|p130,E2F1|E2F4|Hos|p130|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,3.1.6.3.1,6935,9606,GO:0016564,GO:0006357|GO:0016481,16087177,p73,ZEB,We also demonstrate that DNA methylation contributes to increased levels of p73 in FA-A cells by hampering the binding of the transcriptional repressor ZEB to an intronic regulatory region of the p73 gene.,0.28,PMID.dPMID16087177.s1.p2,3,2,p73|ZEB|p73,p73|ZEB,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10884390,p73,p53,"Furthermore, p53His175 and p53Gly281 mutants markedly reduce the transcriptional activity of the various isoforms of p73.",1.62,PMID.dPMID10884390.s2.p2,3,2,p53|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12917626,p73,p53,"In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta.",1.41,PMID.dPMID12917626.s6.p2,4,2,p53|p53|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12880968,p73,p53,Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.,1.16,PMID.dPMID12880968.s8.p2,3,2,p73|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10884390,p73,p53,"Furthermore, p53His175 and p53Gly281 mutants markedly reduce the transcriptional activity of the various isoforms of p73.",1.15,PMID.dPMID10884390.s2.p1,3,2,p53|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12101410,p73,p53,"p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop.",1.03,PMID.dPMID12101410.s10.p0,2,2,p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10773878,p73,p53,"In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer",0.94,PMID.dPMID10773878.s0.p1,3,3,p53|p63|p73,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12917626,p73,p53,"In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta.",0.85,PMID.dPMID12917626.s6.p4,4,2,p53|p53|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10469295,p73,p53,"The p53-like genes, p73 and the several KET splicing variants, are recently described genes of uncertain biologic and pathologic significance.",0.83,PMID.dPMID10469295.s1.p0,3,3,p53|p73|KET,KET|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12917626,p73,p53,We determined the ability of a panel of 61 p53 mutants to inhibit p73beta activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter.,0.70,PMID.dPMID12917626.s5.p0,4,3,p53|p73|ADE2|p53,ADE2|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11028915,p53-related protein p73,p53,"One involves the tumour-suppressor protein p53, the other is mediated by the p53-related protein p73.",0.68,PMID.dPMID11028915.s3.p0,2,2,p53|p53-related protein p73,p53|p53-related protein p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16835297,p73,p53,"Some of the compounds activate a p53 response by increasing p73 expression, and knockdown of transactivating isoforms of p73 by small interfering RNA reduces their induction of p53-responsive transcriptional activity.",0.63,PMID.dPMID16835297.s3.p0,4,2,p53|p73|p73|p53,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15849742,p73,p53,"p53-Related genes, p73 and p63, encode 2 classes of proteins, TA-p73/p63 and DeltaN-p73/p63.",0.62,PMID.dPMID15849742.s9.p3,7,3,p53|p73|p63|p73|p63|p73|p63,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10637430,p73,p53,"The p53-related genes, p51/p63 and p73, have been isolated respectively from cDNA libraries of skeletal muscle and the brain, and their structural features and biological functions have been compared.",0.50,PMID.dPMID10637430.s7.p3,4,3,p53|p51|p63|p73,p51|p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15849742,p73,p53,"p53-Related genes, p73 and p63, encode 2 classes of proteins, TA-p73/p63 and DeltaN-p73/p63.",0.49,PMID.dPMID15849742.s9.p0,7,3,p53|p73|p63|p73|p63|p73|p63,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15849742,p73,p53,"p53-Related genes, p73 and p63, encode 2 classes of proteins, TA-p73/p63 and DeltaN-p73/p63.",0.48,PMID.dPMID15849742.s9.p10,7,3,p53|p73|p63|p73|p63|p73|p63,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11909952,p73,p53,"Here we report that p73, but not p53, directly activates the transcription of endogenous Delta Np73 by binding to the p73-specific target element located at positions -76 to -57 within the Delta Np73 promoter region.",0.46,PMID.dPMID11909952.s4.p4,5,2,p73|p53|p73|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12716888,TP73,TP53,"Although the TP53 gene is frequently mutated in human cancers, the TP73 gene is rarely inactivated.",0.44,PMID.dPMID12716888.s6.p0,2,2,TP53|TP73,TP53|TP73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9891077,p73,p53,"By cotransfecting p73alpha along with either p53 mutant and a p53-responsive reporter, we found that both R175H and R248W reduces the transcriptional activity of p73alpha.",0.43,PMID.dPMID9891077.s2.p4,4,2,p73|p53|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11389695,p73,p53,The main structural difference between p73 and p53 is the additional C-terminal region of p73.,0.41,PMID.dPMID11389695.s9.p2,3,2,p73|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18547443,p73,p53,"RESULTS: Here we have studied, mostly in human HCT116 colon adenocarcinoma cells with an intact p53 pathway, the effects of dominant-inhibitory p53 mutants and of Deltaex2/3p73, a tumor-associated DeltaTA-competitor of wild-type p53, on the nuclear transactivation-dependent and extra-nuclear transactivation-independent functions of wild-type p53.",0.39,PMID.dPMID18547443.s3.p2,5,2,p53|p53|p73|p53|p53,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11844800,p73,p53,"Because inhibition of p53 is a common theme in human cancer, our data strongly support a role of DeltaTA-p73 expression for tumor formation",0.37,PMID.dPMID11844800.s0.p0,2,2,p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10761704,p73,p53,"Two p53-related genes, p73 and p51, were recently identified as structural homologues of the p53 tumor suppressor gene, suggesting that the roles of these two genes may be similar to those of p53, including growth suppression and induction of apoptosis.",0.35,PMID.dPMID10761704.s11.p0,5,3,p53|p73|p51|p53 tumor suppressor|p53,p51|p53|p53 tumor suppressor|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16430884,p73,p53,"Over-expression of p53 suppressed the TAD-truncated p73alpha-mediated luciferase expression, suggesting that p53 interferes with the TAD-truncated p73alpha-mediated activation of NFkappaB.",0.27,PMID.dPMID16430884.s3.p0,5,3,p53|p73|p53|p73|NFkappaB,NFkappaB|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11327702,p73,p53,"Here, we describe the relation between Wnt/beta-catenin signaling and the p53-related gene p73.",0.26,PMID.dPMID11327702.s3.p0,2,2,p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20026309,p73,p53,Altogether our results showed that TQ mediates its growth inhibitory effects on ALL p53-mutated cells via the activation of a p73-dependent mitochondrial and cell cycle checkpoint signaling pathway which subsequently targets UHRF1,0.25,PMID.dPMID20026309.s0.p0,3,3,p53|p73|UHRF1,p53|p73|UHRF1,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18348649,TP73,TP53,"Unlike in TP53 gene, mutations in TP63 and TP73 genes are rare, however, germline mutations in TP63 are linked to the human developmental diseases.",0.24,PMID.dPMID18348649.s1.p1,4,3,TP53|TP63|TP73|TP63,TP53|TP63|TP73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19861456,p73,p53,"p73 is a major determinant of chemosensitivity in humans, and mutant p53 proteins carrying specific polymorphisms can induce drug resistance by inhibiting TAp73.",0.22,PMID.dPMID19861456.s3.p2,3,2,p73|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11314010,p73,p53,"We also found that p53 and p73, but not mutant p53(R249S) and p73beta292, directly induce the expression of the p73 gene.",0.22,PMID.dPMID11314010.s3.p8,5,2,p53|p73|p53|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10435630,p73,p53,"The p53-related gene product, p73, occurs as two distinct protein isoforms, referred to as alpha and beta, which differ in the length of the C-terminal region and arise through alternative splicing of the p73 RNA.",0.21,PMID.dPMID10435630.s6.p0,3,2,p53|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11909952,p73,p53,"Here we report that p73, but not p53, directly activates the transcription of endogenous Delta Np73 by binding to the p73-specific target element located at positions -76 to -57 within the Delta Np73 promoter region.",0.16,PMID.dPMID11909952.s4.p2,5,2,p73|p53|p73|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11314010,p73,p53,"We also found that p53 and p73, but not mutant p53(R249S) and p73beta292, directly induce the expression of the p73 gene.",0.15,PMID.dPMID11314010.s3.p6,5,2,p53|p73|p53|p73|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11238924,p73,p53,"The p53 protein is related by sequence homology and function to the products of two other genes, p63 and p73, that each encode several isoforms.",0.13,PMID.dPMID11238924.s8.p1,3,3,p53|p63|p73,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12761493,p73,p53,"The newly identified p53-related gene, p73, encodes a nuclear transcription factor.",0.12,PMID.dPMID12761493.s9.p0,2,2,p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10371354,p73,p53,"Recently, a p53-related gene, termed p73, has been cloned and its gene product possesses a function similar to p53.",0.12,PMID.dPMID10371354.s7.p0,3,2,p53|p73|p53,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19952113,p73,p53,"We have previously characterized how p53 family proteins control the transcriptional regulation of the platelet-derived growth factor beta-receptor (PDGFRB) and found that DeltaNp73alpha, acting dominant-negatively to p53 and p73, can upregulate PDGFRB promoter activity.",0.10,PMID.dPMID19952113.s6.p0,4,2,p53|p73|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15237589,p73,p53,"BACKGROUND: The recent discovery of two p53-related genes, p63 and p73, has revealed an additional level of complexity to the study of p53 function.",0.09,PMID.dPMID15237589.s6.p1,4,3,p53|p63|p73|p53,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10207112,p73,p53,"We could not detect significant inhibition of p53 functions by E4orf6, but a clear repression of the transcription activation by p73 by this Ad early protein was observed.",0.08,PMID.dPMID10207112.s3.p0,2,2,p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15919663,p73,p53,"This degradation-inducing property of TAp73 was inhibited only by p73 mutants that also inhibit the transactivation activity TAp73 but not by mutant p53, highlighting the specificity in the regulation of p73 stability.",0.08,PMID.dPMID15919663.s3.p9,5,2,p73|p73|p73|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12934105,p73,p53,p73alpha expression induces both accumulation and activation of wt-p53 independent of the p73alpha transcriptional activity.,0.07,PMID.dPMID12934105.s7.p2,3,2,p73|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20231765,p73,TP53,"Unlike the TP53 gene, the gene encoding p73 protein is rarely mutated in tumors although the protein is found to be inactive.",0.06,PMID.dPMID20231765.s2.p0,2,2,TP53|p73,p73|TP53,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16131611,p73,p53,"The recently discovered p53-related genes, p73 and p63, express multiple splice variants and N-terminally truncated forms initiated from an alternative promoter in intron 3.",0.05,PMID.dPMID16131611.s8.p0,3,3,p53|p73|p63,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9891077,p73,p53,"By cotransfecting p73alpha along with either p53 mutant and a p53-responsive reporter, we found that both R175H and R248W reduces the transcriptional activity of p73alpha.",0.03,PMID.dPMID9891077.s2.p5,4,2,p73|p53|p53|p73,p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19067706,p73,p53,Bexarotene-mediated ataxia telangiectasia mutated protein (ATM) activation in all studied lines suggests that ATM is likely to be the p53/p73 upstream activator.,0.02,PMID.dPMID19067706.s2.p5,4,3,ATM|ATM|p53|p73,ATM|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19754415,p73,p53,"While p53 is the most frequently mutated gene in human tumors, p73 and p63 are rarely mutated or lost in cancers.",0.01,PMID.dPMID19754415.s7.p0,3,3,p53|p73|p63,p53|p63|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11550287,TP73,TP53,"Molecular analysis of the TP73 gene on 1p36 and the TP53 gene revealed a deletion of one-allele in TP73 with partial demethylation of another allele in the initial clone of YSK, and a point mutation consisting of an A-->T substitution in codon 288 of the TP53 gene in the developed clone of YSK-21.",0.01,PMID.dPMID11550287.s1.p2,4,2,TP73|TP53|TP73|TP53,TP53|TP73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11844794,p73,p53,"Overexpression of MM1 in p53-deficient osteosarcoma SAOS-2 cells enhanced the p73 alpha-dependent transcription from the p53/p73-responsive Bax and PG13 promoters, whereas p73 beta- and p53-mediated transcriptional activation was unaffected in the presence of MM1.",0.00,PMID.dPMID11844794.s4.p5,7,3,p53|p73|p53|p73|Bax|p73|p53,Bax|p53|p73,<--
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,1.2.3.2.1,7291,9606,,,16738062,p73,twist,p19ras brings a new twist to the regulation of p73 by Mdm2.,1.17,PMID.dPMID16738062.s5.p0,3,3,twist|p73|Mdm2,Mdm2|p73|twist,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,17716971,p73,VDR,"In conclusion, our results indicate that VDR is regulated by p63 and p73 and that the induction of VDR expression upon DNA damage is p73-dependent",1.51,PMID.dPMID17716971.s0.p1,5,3,VDR|p63|p73|VDR|p73,p63|p73|VDR,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,17716971,p73,VDR,"In conclusion, our results indicate that VDR is regulated by p63 and p73 and that the induction of VDR expression upon DNA damage is p73-dependent",0.91,PMID.dPMID17716971.s0.p9,5,3,VDR|p63|p73|VDR|p73,p63|p73|VDR,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,17716971,p73,VDR,"In conclusion, our results indicate that VDR is regulated by p63 and p73 and that the induction of VDR expression upon DNA damage is p73-dependent",0.24,PMID.dPMID17716971.s0.p6,5,3,VDR|p63|p73|VDR|p73,p63|p73|VDR,e
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,10744705,p73,WT1,"Similarly, WT1 inhibits p73-induced transcription activation in reporter assays and counteracts p73-induced expression of endogenous Mdm2.",0.02,PMID.dPMID10744705.s1.p1,4,3,WT1|p73|p73|Mdm2,Mdm2|p73|WT1,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,16413463,p73,p63,"These data define a pathway in which deltaNp63alpha promotes survival in squamous epithelial malignancy by repressing a p73-dependent proapoptotic transcriptional program, suggesting that p63 levels and p73 status may be key determinants of tumor response in patients with HNSCC",0.98,PMID.dPMID16413463.s0.p0,4,2,p63|p73|p63|p73,p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17446929,p73,p63,"Here we demonstrated that the p53 family member p63 controls a pathway for p73-dependent cisplatin sensitivity specific to these ""triple-negative"" tumors.",0.57,PMID.dPMID17446929.s6.p2,3,3,p53|p63|p73,p53|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17334395,p73,p63,"The net effect of p63/p73 expression in a given context depends on the ratio of TA/DeltaN isoforms expressed, on physical interaction between p63 and p73 isoforms, and on functional interactions with p53 at the promoters of specific downstream target genes.",0.57,PMID.dPMID17334395.s2.p0,5,3,p63|p73|p63|p73|p53,p53|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20298673,p73,p63,"p73 and p63 regulate the expression of fibroblast growth factor receptor 3.    p53, p63 and p73 make a family of transcription factors that play a vital role in development and cancer.",0.55,PMID.dPMID20298673.s7.p7,5,3,p73|p63|p53|p63|p73,p53|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,19194497,p73,p63,"Employing histological, tissue culture, and molecular biological read-outs, we show that this novel pro-survival response, initiated through the rapid induction of p63, is mediated ultimately by the transcriptional repression of a pro-apoptotic isoform of p73 by ZEB1.",0.35,PMID.dPMID19194497.s4.p0,3,3,p63|p73|ZEB1,p63|p73|ZEB1,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,10773878,p73,p63,"In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer",0.20,PMID.dPMID10773878.s0.p2,3,3,p53|p63|p73,p53|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12969350,p73,p63,"Differential expressions of p63, p73 and p53 proteins in the carcinoma samples were: p63+/p73+/p53 + (n = 28; 70%); p63+/p73+/p53- (n = 4; 10%); p63+/p73-/p53- (n = 8; 20%), respectively; and p63+/p73+/p53- for normal mucosa (n = 10; 100%).",0.20,PMID.dPMID12969350.s3.p54,15,3,p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53,p53|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,12969350,p73,p63,"Differential expressions of p63, p73 and p53 proteins in the carcinoma samples were: p63+/p73+/p53 + (n = 28; 70%); p63+/p73+/p53- (n = 4; 10%); p63+/p73-/p53- (n = 8; 20%), respectively; and p63+/p73+/p53- for normal mucosa (n = 10; 100%).",0.17,PMID.dPMID12969350.s3.p27,15,3,p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53|p63|p73|p53,p53|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,17477357,p73,p63,p63 is a member of a gene family also including the p53 tumor suppressor and p73.,0.14,PMID.dPMID17477357.s7.p1,3,3,p63|p53 tumor suppressor|p73,p53 tumor suppressor|p63|p73,
6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,6.1.2.2.1,10848,9606,,,18593889,p73,iASPP,"Along these lines, a recent study reports that a p53-derived peptide that targets iASPP-a common negative regulator of p53 family members--can effectively trigger tumor cell death by a p73-dependent mechanism.",0.02,PMID.dPMID18593889.s1.p4,4,3,p53|iASPP|p53|p73,iASPP|p53|p73,
1.2.3.2.1,7291,9606,,,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,15829502,Twist,Runx2,"Significantly, forced expression of Fgfr2 restored Runx2 and osteoblast marker genes, whereas a dominant-negative Fgfr2 further decreased Runx2 and downstream genes in Twist mutant osteoblasts, indicating that alteration of Fgfr2 results in downregulation of osteoblast genes in Twist mutant osteoblasts.",0.48,PMID.dPMID15829502.s2.p16,7,3,Fgfr2|Runx2|Fgfr2|Runx2|Twist|Fgfr2|Twist,Fgfr2|Runx2|Twist,
1.2.3.2.1,7291,9606,,,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,15829502,Twist,Runx2,"Significantly, forced expression of Fgfr2 restored Runx2 and osteoblast marker genes, whereas a dominant-negative Fgfr2 further decreased Runx2 and downstream genes in Twist mutant osteoblasts, indicating that alteration of Fgfr2 results in downregulation of osteoblast genes in Twist mutant osteoblasts.",0.31,PMID.dPMID15829502.s2.p7,7,3,Fgfr2|Runx2|Fgfr2|Runx2|Twist|Fgfr2|Twist,Fgfr2|Runx2|Twist,
1.2.3.2.1,7291,9606,,,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,11948912,TWIST,GLI1,Cooperative E-box regulation of human GLI1 by TWIST and USF.,0.36,PMID.dPMID11948912.s9.p0,3,3,GLI1|TWIST|USF,GLI1|TWIST|USF,-->
1.2.3.2.1,7291,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,20564230,Twist,basic helix loop helix transcription factor,"The basic helix loop helix transcription factor, Twist, plays a master regulatory role in all of these processes and, therefore, a thorough understanding of the mechanistic insights in the role of Twist in lineage specification/differentiation and tumorigenesis is vital to the success of future clinical applications for the therapeutic use of MSCs.",0.76,PMID.dPMID20564230.s2.p1,3,2,basic helix loop helix transcription factor|Twist|Twist,basic helix loop helix transcription factor|Twist,
1.2.3.2.1,7291,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,17437280,TWIST1,basic helix-loop-helix transcription factor,"The Saethre-Chotzen syndrome is an autosomal, dominantly inherited craniosynostosis caused by mutations in the basic helix-loop-helix transcription factor gene TWIST1.",0.14,PMID.dPMID17437280.s10.p0,2,2,basic helix-loop-helix transcription factor|TWIST1,basic helix-loop-helix transcription factor|TWIST1,
1.2.3.2.1,7291,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,16585154,Twist1,basic helix-loop-helix transcription factor,"Here, we show that N-cadherin mRNA expression in PC-3 prostate carcinoma cells is dependent on beta(1) integrin-mediated cell adhesion to fibronectin and the basic helix-loop-helix transcription factor Twist1.",0.01,PMID.dPMID16585154.s5.p5,4,4,N-cadherin|PC-3|basic helix-loop-helix transcription factor|Twist1,basic helix-loop-helix transcription factor|N-cadherin|PC-3|Twist1,
1.2.3.2.1,7291,9606,,,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,18172301,Twist,YB-1,"Significantly, reexpression of YB-1 led to increase colony formation when Twist expression was down-regulated by small interfering RNA.",0.27,PMID.dPMID18172301.s4.p0,2,2,YB-1|Twist,Twist|YB-1,
1.2.3.2.1,7291,9606,,,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,20491776,Twist1,YB-1,Luciferase reporter assays revealed that PCAF manipulation modulated YB-1 transcription in a Twist1-dependent manner.,0.20,PMID.dPMID20491776.s4.p2,3,3,PCAF|YB-1|Twist1,PCAF|Twist1|YB-1,
1.2.3.2.1,7291,9606,,,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,18172301,Twist,YB-1,"Here, we show that the E-box-binding transcription factor Twist is overexpressed in cisplatin-resistant cells and that YB-1 is a target gene of Twist.",0.18,PMID.dPMID18172301.s6.p2,3,2,Twist|YB-1|Twist,Twist|YB-1,
1.2.3.2.1,7291,9606,,,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,18172301,Twist,YB-1,"Collectively, these data suggest that YB-1 is a major downstream target of Twist.",0.05,PMID.dPMID18172301.s2.p0,2,2,YB-1|Twist,Twist|YB-1,
1.2.3.2.1,7291,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18353781,Twist,STAT3,Activation of STAT3 by interleukin-6 or expression of activated Src induced Twist expression at protein and mRNA levels.,2.15,PMID.dPMID18353781.s8.p0,2,2,STAT3|Twist,STAT3|Twist,
1.2.3.2.1,7291,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18353781,Twist,STAT3,"Inhibiting STAT3 by a small molecule inhibitor, JSI-124, STAT3 small hairpin RNAs, or dominant negative STAT3 resulted in significant reduction of Twist protein and mRNA expression.",0.37,PMID.dPMID18353781.s7.p5,4,2,STAT3|STAT3|STAT3|Twist,STAT3|Twist,
1.2.3.2.1,7291,9606,,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,18353781,Twist,STAT3,Ten normal and 46 tumor specimens of breast tissues were examined for activation of STAT3 and expression of Twist.,0.14,PMID.dPMID18353781.s3.p0,2,2,STAT3|Twist,STAT3|Twist,
1.2.3.2.1,7291,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18504427,Twist,p53,"Importantly, we found that p53-dependent growth suppression was canceled by the expression of either Twist or YB-1.",1.13,PMID.dPMID18504427.s1.p0,3,3,p53|Twist|YB-1,p53|Twist|YB-1,
1.2.3.2.1,7291,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18504427,Twist,p53,Transcriptional activation of the p21 promoter by p53 was significantly repressed by the expression of Twist.,0.90,PMID.dPMID18504427.s3.p0,2,2,p53|Twist,p53|Twist,
1.2.3.2.1,7291,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11237596,twist,p53,"These results support the idea, proposed by us earlier, that torsional stress may play a role in the regulation of p53 binding through modulation of twist at the binding site",0.14,PMID.dPMID11237596.s0.p0,2,2,p53|twist,p53|twist,
6.7.3.0.1,7342,9606,GO:0016566,GO:0006357|GO:0016481,6.7.2.0.1,7024,9606,,GO:0006357,19751393,LBP-1b,LBP-1c,It revealed that dimers composed of LBP-1a and LBP-1c were re-formed probably by a partner-exchange of LBP-1b-containing heterodimers,0.02,PMID.dPMID19751393.s0.p2,3,2,LBP-1a|LBP-1c|LBP-1b,LBP-1a|LBP-1b|LBP-1c,
6.7.3.0.1,7342,9606,GO:0016566,GO:0006357|GO:0016481,6.7.2.0.2,29842,9606,,GO:0006357,15471945,LBP-1b,LBP-9,"In transient transfection assays, LBP-1b activated the -155/-131 element whereas LBP-9 suppressed its LBP-1b-stimulated expression.",0.91,PMID.dPMID15471945.s8.p2,3,2,LBP-1b|LBP-9|LBP-1b,LBP-1b|LBP-9,
6.7.3.0.1,7342,9606,GO:0016566,GO:0006357|GO:0016481,6.7.2.0.2,29842,9606,,GO:0006357,10644752,LBP-1b,LBP-9,"When the -155/-131 fragment was linked to a minimal promoter, co-expression of LBP-1b increased transcription 21-fold in a dose-dependent fashion, but addition of LBP-9 suppressed the stimulatory effect of LBP-1b.",0.44,PMID.dPMID10644752.s2.p2,3,2,LBP-1b|LBP-9|LBP-1b,LBP-1b|LBP-9,
4.1.6.0.1,7343,9606,GO:0003701,GO:0006356|GO:0045943,8.1.1.0.1,6908,9606,GO:0003702|GO:0016251,,7982918,UBF,TBP,Microsequence analysis reveals that the 95-kDa TBP-binding protein is hUBF.,0.61,PMID.dPMID7982918.s3.p0,2,2,TBP|UBF,TBP|UBF,
1.2.6.2.1,7391,9606,,GO:0000430|GO:0000432|GO:0010551|GO:0010552|GO:0045990,3.5.2.3.1,1997,9606,GO:0016563,GO:0045944,10557089,USF,Elf-1,The USF factors were shown to bind predominantly as a heterodimeric complex of USF-1 and 2 while Elf-1 bound the promoter when it was not occupied by USF.,0.17,PMID.dPMID10557089.s2.p5,4,2,USF|USF-1|Elf-1|USF,Elf-1|USF|USF-1,
1.2.6.2.1,7391,9606,,GO:0000430|GO:0000432|GO:0010551|GO:0010552|GO:0045990,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,11948912,USF,GLI1,Cooperative E-box regulation of human GLI1 by TWIST and USF.,0.28,PMID.dPMID11948912.s9.p1,3,3,GLI1|TWIST|USF,GLI1|TWIST|USF,-->
1.2.6.2.1,7391,9606,,GO:0000430|GO:0000432|GO:0010551|GO:0010552|GO:0045990,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,12923186,upstream stimulatory factor,basic helix-loop-helix transcription factor,"Cha, a basic helix-loop-helix transcription factor involved in the regulation of upstream stimulatory factor activity.",1.08,PMID.dPMID12923186.s12.p2,3,3,Cha|basic helix-loop-helix transcription factor|upstream stimulatory factor,basic helix-loop-helix transcription factor|Cha|upstream stimulatory factor,
1.2.6.2.2,7392,9606,,GO:0000430|GO:0000432|GO:0010552,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,12576297,USF2,Transcription factor,Transcription factor USF2 is developmentally regulated in fetal lung and acts together with USF1 to induce SP-A gene expression.,0.46,PMID.dPMID12576297.s12.p0,4,4,Transcription factor|USF2|USF1|SP-A,SP-A|Transcription factor|USF1|USF2,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,3.1.7.2.1,1523,9606,GO:0003702,GO:0006357,19888899,VDR,CDP,These findings suggest that CDP is a novel differentiation stage-specific coactivator of the VDR in osteoblasts.,0.45,PMID.dPMID19888899.s0.p0,2,2,CDP|VDR,CDP|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,10330159,VDR,Fos,"This DNA element is a composite site that is recognized by both Fos-Jun and NFAT1; it is directly bound by VDR in the absence of a retinoid X receptor as an apparent monomer, and it is bound in a unique tertiary conformation.",0.20,PMID.dPMID10330159.s11.p3,4,4,Fos|Jun|NFAT1|VDR,Fos|Jun|NFAT1|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10330159,VDR,Jun,"This DNA element is a composite site that is recognized by both Fos-Jun and NFAT1; it is directly bound by VDR in the absence of a retinoid X receptor as an apparent monomer, and it is bound in a unique tertiary conformation.",0.20,PMID.dPMID10330159.s11.p4,4,4,Fos|Jun|NFAT1|VDR,Fos|Jun|NFAT1|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11983707,VDR,AP-1,"Both the p38 and JNK MAPK pathways and the downstream transcription factor c-Jun/AP-1 are required for the VDR stimulation, as revealed by application of their dominant negatives, the specific p38 inhibitor SB203580, and site-directed mutagenesis of the AP-1 element in the VDR promoter.",0.01,PMID.dPMID11983707.s2.p9,8,4,p38|JNK|c-Jun|AP-1|VDR|p38|AP-1|VDR,AP-1|c-Jun|JNK|p38|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,11983707,VDR,c-Jun,"Both the p38 and JNK MAPK pathways and the downstream transcription factor c-Jun/AP-1 are required for the VDR stimulation, as revealed by application of their dominant negatives, the specific p38 inhibitor SB203580, and site-directed mutagenesis of the AP-1 element in the VDR promoter.",0.01,PMID.dPMID11983707.s2.p8,8,4,p38|JNK|c-Jun|AP-1|VDR|p38|AP-1|VDR,AP-1|c-Jun|JNK|p38|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,19667161,VDR,PPAR,"In contrast, treatment with the PPAR ligands had no pronounced effect on the 1,25(OH)2D3-induced increase in VDR expression.",0.50,PMID.dPMID19667161.s4.p0,2,2,PPAR|VDR,PPAR|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,4.1.3.0.3,6934,9606,GO:0003702|GO:0016566,GO:0006357|GO:0010552|GO:0010553|GO:0043433,19924301,VDR,TCF-4,"Furthermore, we show 1,25(OH)2D3 increases TCF-4 at the RNA and protein levels in several human colorectal cancer cell lines, the effect of which is completely dependent on the VDR.",0.60,PMID.dPMID19924301.s5.p0,2,2,TCF-4|VDR,TCF-4|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17716971,VDR,p53,"Our results demonstrate that p53 itself does not induce VDR expression, nor does it affect p63-mediated VDR induction in the cell lines tested in this study.",0.54,PMID.dPMID17716971.s5.p0,4,3,p53|VDR|p63|VDR,p53|p63|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20227041,VDR,p53,"Mutp53 is recruited to VDR-regulated genes and modulates their expression, augmenting the transactivation of some genes and relieving the repression of others.",0.39,PMID.dPMID20227041.s3.p0,2,2,p53|VDR,p53|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17716971,VDR,p73,We have demonstrated that ectopic expression of various p73 isoforms can induce VDR expression.,0.83,PMID.dPMID17716971.s3.p0,2,2,p73|VDR,p73|VDR,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,11773605,VDR,WT1,Nuclear run on experiments demonstrated that the effect of WT1 on VDR expression is at the transcriptional level.,1.94,PMID.dPMID11773605.s4.p0,2,2,WT1|VDR,VDR|WT1,p
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,11050081,vdr,WT1,"In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1.",0.35,PMID.dPMID11050081.s6.p5,5,2,vdr|WT1|WT1|vdr|WT1,vdr|WT1,
2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,19184984,VDR,Lef-1,"Molecular crosstalk was observed between the antagonistic VDR-dependent signals, in that beta-catenin/Lef-1/Tcf molecules modulated VDR activation of OPN.",0.17,PMID.dPMID19184984.s5.p4,4,3,VDR|Lef-1|Tcf|VDR,Lef-1|Tcf|VDR,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,10422290,WT1,AML1,"However, AML1/MTG8 transcripts were detected at all stages of the disease even when the expression level of WT1 gene was low.",0.28,PMID.dPMID10422290.s1.p1,3,3,AML1|MTG8|WT1,AML1|MTG8|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.3.2.1.2,1958,9606,,GO:0045941,8876223,Wilms tumor,EGR-1,"The EGR-1-stimulated transactivation was inhibited by expression of the Wilms tumor suppressor, a known specific DNA-binding competitor.",0.75,PMID.dPMID8876223.s1.p0,2,2,EGR-1|Wilms tumor,EGR-1|Wilms tumor,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.3.2.1.2,1958,9606,,GO:0045941,8058069,WT1,Egr-1,"We have also shown in a cotransfection assay that Egr-1, an immediate early growth response gene, activates transcription of the TGF-beta 1 gene through the same response element and that WT1 represses both the basal and Egr-1-induced TGF-beta 1 promoter activity in monkey kidney CV-1 cells.",0.04,PMID.dPMID8058069.s2.p3,6,3,Egr-1|early growth response|TGF-beta 1|WT1|Egr-1|TGF-beta 1,early growth response|Egr-1|TGF-beta 1|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,18708366,WT1,ERalpha,"The expressions of ERalpha and its downstream target genes were significantly repressed following overexpression of WT1, whereas the down-regulation of WT1 by WT1 shRNA could enhance ERalpha expression and the sensitivity to tamoxifen treatment in ERalpha-negative MDA468 and HCC1954 cells that express high levels of WT1.",0.20,PMID.dPMID18708366.s2.p0,7,2,ERalpha|WT1|WT1|WT1|ERalpha|ERalpha|WT1,ERalpha|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,18212735,WT1,ETS-1,The ETS-1 promoter was stimulated approximately 10-fold by transient co-transfection of a WT1 expression construct and WT1 bound to the ETS-1 promoter in chromatin immunoprecipitation and electrophoretic mobility shift assays.,0.07,PMID.dPMID18212735.s2.p0,4,2,ETS-1|WT1|WT1|ETS-1,ETS-1|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.5.2.2.5,2118,9606,GO:0016563,GO:0006355,14988020,WT1,Pea3,Our results position Pea3 upstream of WT1 and define a gene hierarchy important for mesenchymal-epithelial transitions.,0.11,PMID.dPMID14988020.s0.p0,2,2,Pea3|WT1,Pea3|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,8683991,WT1,GATA-1,Previous studies of WT1 gene regulation showed that GATA-1 may regulate WT1 expression.,2.07,PMID.dPMID8683991.s5.p2,3,2,WT1|GATA-1|WT1,GATA-1|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,14531904,WT1,GATA-1,"PAX2, PAX8 and GATA-1 are known physiological regulators of WT1.",1.32,PMID.dPMID14531904.s7.p5,4,4,PAX2|PAX8|GATA-1|WT1,GATA-1|PAX2|PAX8|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,14531904,WT1,GATA-1,"In conclusion, PAX2, and possibly PAX8, appears to be a candidate for the upregulation of WT1 in a proportion of AML, whereas GATA-1 expression cannot be explained as an inducer of WT1.",0.12,PMID.dPMID14531904.s1.p9,5,4,PAX2|PAX8|WT1|GATA-1|WT1,GATA-1|PAX2|PAX8|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.2.1.0.1,2623,9606,,GO:0006357,10360378,WT1,GATA-1,"Using a sensitive, isotopic duplex RT-PCR procedure amplifying WT1 or GATA-1 together with beta-actin as the internal control in a single reaction mix, we quantitated the expression of WT1 and GATA-1 mRNA of 16 patients with myelodysplastic syndrome (MDS), 56 with acute myeloid leukemia (AML) and 22 with acute lymphoblastic leukemia (ALL).",0.02,PMID.dPMID10360378.s5.p4,5,3,WT1|GATA-1|mix|WT1|GATA-1,GATA-1|mix|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.5.3.0.8,3394,9606,,GO:0000122,20237505,WT1,IRF8,"In this study, we show that overexpression of BCR/ABL1 in CD34+ progenitor cells leads to reduced expression of interferon regulatory factor 8 (IRF8), in addition to increased WT1 expression.",1.46,PMID.dPMID20237505.s7.p9,5,5,BCR|ABL1|CD34|IRF8|WT1,ABL1|BCR|CD34|IRF8|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.5.3.0.8,3394,9606,,GO:0000122,20237505,WT1,IRF8,"A reporter construct with the IRF8 promoter was repressed by WT1, dependent on a putative WT1-response element.",0.45,PMID.dPMID20237505.s2.p0,3,2,IRF8|WT1|WT1,IRF8|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.5.3.0.8,3394,9606,,GO:0000122,20237505,WT1,IRF8,"A reporter construct with the IRF8 promoter was repressed by WT1, dependent on a putative WT1-response element.",0.09,PMID.dPMID20237505.s2.p1,3,2,IRF8|WT1|WT1,IRF8|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,20038731,WT1,MLL,"NPM1, FLT3, CEBPA, and MLL were assessed for mutations and WT1 expression was quantified.",0.10,PMID.dPMID20038731.s7.p5,4,4,NPM1|FLT3|MLL|WT1,FLT3|MLL|NPM1|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.2.2.0.2,4297,9606,GO:0003702,GO:0045893,20442368,WT1,MLL,"A WT1 mutation-associated gene-expression signature, reported here for the first time, included CD96, a leukemia stem cell-specific marker, and genes involved in gene regulation (eg, MLL, PML, and SNRPN) and in proliferative and metabolic processes (eg, INSR, IRS2, and PRKAA1), supporting the role of mutated WT1 in deregulating multiple homeostatic processes.",0.01,PMID.dPMID20442368.s2.p7,5,4,WT1|MLL|PML|SNRPN|WT1,MLL|PML|SNRPN|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,15752709,WT1,c-Myb,"Furthermore, p300 and c-Myb synergistically activated the expression of WT1 gene.",1.42,PMID.dPMID15752709.s1.p2,3,3,p300|c-Myb|WT1,c-Myb|p300|WT1,-->
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15286719,WT1,c-myc,The WT1-binding site near the second major transcription start site of the c-myc promoter was confirmed to be involved in upregulation of human c-myc by WT1.,0.59,PMID.dPMID15286719.s2.p5,4,2,WT1|c-myc|c-myc|WT1,c-myc|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,12802290,WT1,c-MYC,"These data, in addition to the coexpression of c-MYC and WT1 in embryonic renal mesenchyme, strongly suggest that c-MYC is a biologically relevant target of WT1 in Wilmstumors.",0.42,PMID.dPMID12802290.s0.p5,4,2,c-MYC|WT1|c-MYC|WT1,c-MYC|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,7585606,WT1,c-myc,Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.,0.04,PMID.dPMID7585606.s4.p2,3,3,bcl-2|c-myc|WT1,bcl-2|c-myc|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,1.2.6.5.2,4613,9606,,GO:0006357,10470095,WT1,N-myc,Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.,0.17,PMID.dPMID10470095.s9.p0,2,2,N-myc|WT1,N-myc|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,9178767,WT1,PAX2,"These findings suggest that PAX2 is a tissue-specific modulator of WT1 expression, and is involved in cell growth control via WT1",1.61,PMID.dPMID9178767.s0.p0,3,2,PAX2|WT1|WT1,PAX2|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,9916932,WT1,PAX2,We suggest that persistent expression of PAX2 is likely to result from the loss of WT1 dependent transcriptional repression and may participate in the pathological mechanisms leading to glomerular dysfunction.,1.35,PMID.dPMID9916932.s2.p0,2,2,PAX2|WT1,PAX2|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,14531904,WT1,PAX2,"PAX2, PAX8 and GATA-1 are known physiological regulators of WT1.",0.90,PMID.dPMID14531904.s7.p3,4,4,PAX2|PAX8|GATA-1|WT1,GATA-1|PAX2|PAX8|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,19401348,WT1,PAX2,Additional analyses indicated that PAX2 repressor WT1 and cancer-linked hypomethylation are not important for transcriptional regulation of PAX2 in ccRCC.,0.89,PMID.dPMID19401348.s1.p0,3,2,PAX2|WT1|PAX2,PAX2|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,9178767,WT1,PAX2,The overlap of PAX2 and WT1 expression in fetal kidney prompted us to determine whether PAX2 regulates the WT1 gene.,0.37,PMID.dPMID9178767.s6.p5,4,2,PAX2|WT1|PAX2|WT1,PAX2|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,4.1.1.1.1,6736,9606,GO:0016563,,11278460,WT1,SRY,In this study we investigated the regulation of the sex determination gene SRY by WT1.,0.98,PMID.dPMID11278460.s5.p0,2,2,SRY|WT1,SRY|WT1,-->
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,4.1.1.1.1,6736,9606,GO:0016563,,12970737,WT1,SRY,"Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1.",0.89,PMID.dPMID12970737.s8.p0,2,2,SRY|WT1,SRY|WT1,-->
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,4.1.1.1.1,6736,9606,GO:0016563,,11278460,WT1,SRY,The human sex-determining gene SRY is a direct target of WT1.,0.31,PMID.dPMID11278460.s8.p0,2,2,SRY|WT1,SRY|WT1,-->
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,9531608,WT1,Stat3,"As for signal transduction mediated by G-CSF receptor (G-CSFR), Stat3alpha was constitutively activated in wild-type WT1-infected 32D cl3 in response to G-CSF, whereas, in WT1-uninfected 32D cl3, activation of Stat3alpha was only transient.",0.18,PMID.dPMID9531608.s6.p2,5,3,G-CSFR|Stat3|WT1|WT1|Stat3,G-CSFR|Stat3|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15155752,WT1,p53,Our results show that PODXL is a bona fide target of p53-mediated transcriptional repression while being positively regulated by WT1.,1.68,PMID.dPMID15155752.s1.p2,3,3,PODXL|p53|WT1,p53|PODXL|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9719458,WT1,p53,These results may provide a plausible diagnostic marker for determination of drug sensitivity in cancer patients and suggest that p53 may mediate directly or indirectly the expression of mdr-1 via WT1 in VCR-resistant hematologic cell lines,0.76,PMID.dPMID9719458.s0.p1,3,3,p53|mdr-1|WT1,mdr-1|p53|WT1,
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,11050081,WT1,vdr,"In transient cotransfection experiments, we observed an activation of a vdr promoter reporter by WT1 through a WT1 recognition element, indicating transcriptional regulation of the vdr gene expression by WT1.",1.32,PMID.dPMID11050081.s6.p9,5,2,vdr|WT1|WT1|vdr|WT1,vdr|WT1,p
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,14531904,WT1,PAX8,"PAX2, PAX8 and GATA-1 are known physiological regulators of WT1.",1.04,PMID.dPMID14531904.s7.p4,4,4,PAX2|PAX8|GATA-1|WT1,GATA-1|PAX2|PAX8|WT1,<--
2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,2.3.5.0.13,10664,9606,GO:0016563,GO:0045892|GO:0045893,17210670,WT1,CTCF,A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.,0.47,PMID.dPMID17210670.s11.p0,3,2,CTCF|WT1|WT1,CTCF|WT1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,8266081,YY1,c-Myc,"In cotransfections, c-Myc inhibits both the repressor and the activator functions of YY1, which suggests that one way c-Myc acts is by modulating the activity of YY1",0.97,PMID.dPMID8266081.s0.p5,4,2,c-Myc|YY1|c-Myc|YY1,c-Myc|YY1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15805285,YY1,c-Myc,"Whereas CHK had no significant effects on the expression of YY1, c-Myc, Max, and other YY1-binding proteins, CHK was found to modulate the YY1/c-Myc association.",0.13,PMID.dPMID15805285.s2.p7,6,3,YY1|c-Myc|Max|YY1|YY1|c-Myc,c-Myc|Max|YY1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,10.1.1.2.1,4904,9606,GO:0016564,GO:0006355,8972186,YY1,YB-1,A yeast interaction trap screen using LexA-YY1 as a bait and a HeLa cell cDNA-acid patch fusion library identified YB-1 as a YY1-interacting protein.,0.05,PMID.dPMID8972186.s2.p2,3,2,YY1|YB-1|YY1,YB-1|YY1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,19360355,YY1,Transcription factor,Transcription factor YY1 expression in human gastrointestinal cancer cells.,0.19,PMID.dPMID19360355.s10.p0,2,2,Transcription factor|YY1,Transcription factor|YY1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18332869,YY1,p53,"MDM2 is a key ubiquitin E3 ligase for p53 and its activity is critically regulated by a set of modulators, including ARF, p300, YY1 and recently by gankyrin, an oncoprotein frequently overexpressed in human heptocellular carcinomas.",0.76,PMID.dPMID18332869.s5.p7,6,6,MDM2|p53|ARF|p300|YY1|gankyrin,ARF|gankyrin|MDM2|p300|p53|YY1,-->
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18391986,YY1,p53,Intact p53 binding sites on the EGFR promoter are not required for activation by YY1.,0.20,PMID.dPMID18391986.s3.p1,3,3,p53|EGFR|YY1,EGFR|p53|YY1,-->
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17980704,YY1,p73,"The results presented here suggested the cooperative transcriptional regulation of p73 by YY1 and E2F1, and might provide a new regulation mechanism by the YY1 network on tumorigenesis, differentiation and development",0.46,PMID.dPMID17980704.s0.p3,4,3,p73|YY1|E2F1|YY1,E2F1|p73|YY1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17980704,YY1,p73,"The results presented here suggested the cooperative transcriptional regulation of p73 by YY1 and E2F1, and might provide a new regulation mechanism by the YY1 network on tumorigenesis, differentiation and development",0.42,PMID.dPMID17980704.s0.p0,4,3,p73|YY1|E2F1|YY1,E2F1|p73|YY1,
2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,7789179,YY1,WT1,"The zinc-finger domains of the predicted protein also showed homology with those of human genes such as WT1, transcriptional repressor YY1, and MYC-associated zinc-finger protein (MAZ).",0.11,PMID.dPMID7789179.s2.p0,3,3,WT1|YY1|MAZ,MAZ|WT1|YY1,
2.3.5.0.16,7702,9606,GO:0003704|GO:0003709,GO:0006357|GO:0006359,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,17707600,ZNF143,Transcription factor,Transcription factor hStaf/ZNF143 is required for expression of the human TFAM gene.,0.66,PMID.dPMID17707600.s6.p0,3,3,Transcription factor|ZNF143|TFAM,TFAM|Transcription factor|ZNF143,
2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,6.2.1.0.3,6774,9606,GO:0016563,GO:0000122|GO:0006357|GO:0045449,14712222,ZBP-89,Stat3,"In the light of these results, we propose that the interaction of Stat3 and ZBP-89 may be crucial for overcoming the effects of the repressor ZBP-89, which suggests a novel mode for Stat3 gene activation",0.13,PMID.dPMID14712222.s0.p1,4,2,Stat3|ZBP-89|ZBP-89|Stat3,Stat3|ZBP-89,
2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12840224,ZBP-89,p53,"Moreover, mutant p53 shifts the subnuclear location of ZBP-89 to the nuclear periphery, which is a domain rich in heterochromatin.",0.07,PMID.dPMID12840224.s3.p0,2,2,p53|ZBP-89,p53|ZBP-89,
2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,2.3.5.0.45,23528,9606,GO:0003704|GO:0016563|GO:0016564,GO:0000122|GO:0016481,10448078,ZBP-89,ZBP-99,"Collectively, the data suggest that ZBP-99 binds GC-rich promoters and may complement the activities mediated by ZBP-89",0.12,PMID.dPMID10448078.s0.p0,2,2,ZBP-99|ZBP-89,ZBP-89|ZBP-99,
2.3.5.0.26,7716,9606,GO:0003704,GO:0006357,2.3.2.1.2,1958,9606,,GO:0045941,8035792,DB1,EGR1,"These results suggest that EGR1 has a role in inducible transcription of the IL-3 gene, while DB1 sustains basal transcriptional activity and also cooperates with Tax to activate the IL-3 promoter",0.85,PMID.dPMID8035792.s0.p1,4,3,EGR1|IL-3|DB1|IL-3,DB1|EGR1|IL-3,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.1.2.8.1,3087,9606,GO:0016564,GO:0010552|GO:0010553|GO:0010621|GO:0010944,15062550,Pax8,Hex,"In fact, cotransfection of both Hex and Pax8 expression vectors doubled the transcriptional activity of Hex promoter with respect to the condition in which the Pax8 expression vector only was transfected.",0.22,PMID.dPMID15062550.s2.p3,4,2,Hex|Pax8|Hex|Pax8,Hex|Pax8,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,16277182,PAX8,PAX2,CONCLUSIONS: Expression of PAX2 gene was found in 97% and expression of PAX8 gene was found in 89% of analyzed tumor samples.,0.75,PMID.dPMID16277182.s5.p0,2,2,PAX2|PAX8,PAX2|PAX8,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.2.2.2.1,5076,9606,GO:0016563,GO:0045941,19525927,PAX8,PAX2,"In contrast to PAX2, little is known about the expression of PAX8 in adult kidney and renal tumors.",0.23,PMID.dPMID19525927.s8.p0,2,2,PAX2|PAX8,PAX2|PAX8,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15362967,PAX8,PPARgamma,"We investigated in a series of thyroid samples, including 14 normal, 13 hyperfunctioning tissues, 26 follicular adenomas, 21 follicular and 41 papillary carcinomas, both the frequency of the PAX8-PPARgamma1 rearrangement and the expression of the PAX8 and PPARgamma transcripts.",0.37,PMID.dPMID15362967.s8.p2,4,2,PAX8|PPARgamma|PAX8|PPARgamma,PAX8|PPARgamma,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,16609007,PAX8,PPARG,"A subset of follicular thyroid carcinomas contains a balanced translocation, t(2;3)(q13;p25), that results in fusion of the paired box gene 8 (PAX8) and peroxisome proliferator-activated receptor gamma (PPARG) genes with concomitant expression of a PAX8-PPARgamma fusion protein, PPFP.",0.32,PMID.dPMID16609007.s6.p2,4,2,PAX8|PPARG|PAX8|PPARgamma,PAX8|PPARG|PPARgamma,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15483076,PAX8,PPARgamma,"We studied a cohort of well-characterized follicular adenomas (FA), FTC, and Hurthle cell carcinomas (HCC) from patients with complete clinical follow-up, to determine whether PPARgamma immunohistochemistry (as a surrogate of PAX8/PPARgamma expression) helps to distinguish FA from FTC and to assess its diagnostic accuracy as an adjunct to frozen section.",0.19,PMID.dPMID15483076.s5.p0,3,2,PPARgamma|PAX8|PPARgamma,PAX8|PPARgamma,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,15483076,PAX8,PPARgamma,PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.,0.01,PMID.dPMID15483076.s8.p0,3,2,PPARgamma|PAX8|PPARgamma,PAX8|PPARgamma,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.1.10.28.1,5626,9606,GO:0003702,,11508826,Pax8,Prop1,"The following topics are addressed: molecular mutations causing central hypothyroidism (isolated autosomal recessive TRH deficiency; autosomal recessive TRH-receptor inactivating mutations; TSH beta-subunit bio-inactivating mutations; Pit-1 mutations; Prop1 mutations; high molecular weight bio-inactive TSH); defects in response to TSH (mutations in the TSH receptor: TSH receptor gain-of-function mutations; TSH receptor loss-of-function mutations); defects in thyroid gland formation: transcription factor mutations (TTF-2 and Pax8); defects in peripheral thyroid hormone metabolism (defective intrapituitary conversion of T4 to T3; hemangioma consumption of thyroid hormone); and defects in tissue response to thyroid hormone (generalized thyroid hormone resistance, selective pituitary thyroid hormone resistance).",0.08,PMID.dPMID11508826.s1.p1,3,3,Prop1|TTF-2|Pax8,Pax8|Prop1|TTF-2,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.6.1.0.1,7003,9606,,,14630715,PAX8,Ref-1,These data demonstrate a role for APE/Ref-1 protein in the transcriptional regulation of NIS gene expression by itself and in cooperation with PAX8.,0.04,PMID.dPMID14630715.s1.p1,3,3,Ref-1|NIS|PAX8,NIS|PAX8|Ref-1,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,12441357,Pax8,TTF-1,"Despite the presence of Pax8 and TTF-1 also in a few other tissues, the simultaneous expression of the two transcription factors occurs only in the thyroid, supporting the idea that Pax8 and TTF-1 might cooperate to influence thyroid-specific gene expression.",0.52,PMID.dPMID12441357.s6.p2,4,2,Pax8|TTF-1|Pax8|TTF-1,Pax8|TTF-1,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,3.1.2.14.1,7080,9606,GO:0016563,GO:0010552|GO:0045893|GO:0045944,9001192,Pax-8,TTF-1,"Results were related to clinical parameters, transcript levels of thyroglobulin (TG), and thyroid peroxidase (TPO), as well as transcript levels of thyroid transcription factor 1 (TTF-1) which regulates the expression of all three genes and paired box-gene 8 (Pax-8) which regulates TG and TPO gene expression.",0.05,PMID.dPMID9001192.s14.p9,6,4,thyroglobulin|TPO|thyroid transcription factor 1|TTF-1|Pax-8|TPO,Pax-8|thyroglobulin|thyroid transcription factor 1|TPO|TTF-1,
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,14531904,PAX8,WT1,Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias.,0.11,PMID.dPMID14531904.s10.p1,4,4,WT1|PAX2|PAX8|GATA-1,GATA-1|PAX2|PAX8|WT1,-->
3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,20463571,PAX8,p63,The p63 was positive in 3 of 21 (14%) CDC cases (PAX8+/p63+).,0.33,PMID.dPMID20463571.s9.p0,3,2,p63|PAX8|p63,p63|PAX8,
2.1.4.0.3,8013,9606,,GO:0034339,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18855877,NR4A3,PPARG,Western blot or immunohistochemical analyses confirm that PPARG and NDRG2 are expressed in tumours positive for EWSR1/NR4A3.,0.06,PMID.dPMID18855877.s4.p1,3,3,PPARG|EWSR1|NR4A3,EWSR1|NR4A3|PPARG,
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,19758438,Fra-1,c-Fos,"Comparison of AP-1 family proteins demonstrated high expression of JunD and c-Fos in HPV positive tumors, but interestingly, Fra-1 expression was extremely low or nil in these tumor tissues.",0.49,PMID.dPMID19758438.s1.p5,4,4,AP-1|JunD|c-Fos|Fra-1,AP-1|c-Fos|Fra-1|JunD,<--
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,10639331,fra-1,c-fos,"Moreover, induction of c-fos resulted in the concomitant increase in the expression of fra-1 and c-jun, further highlighting the importance of AP-1 transcription factors in chondrocyte differentiation.",0.38,PMID.dPMID10639331.s1.p0,2,2,c-fos|fra-1,c-fos|fra-1,<--
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,15514944,fra-1,c-fos,"Results indicate that though AP-1 showed high binding activity and the majority of its members were highly expressed in tumor tissues, there is a distinct pattern of gradual increase of c-fos and a concomitant decrease of fra-1 expression that perfectly match the progression of cervical lesions.",0.25,PMID.dPMID15514944.s10.p2,3,3,AP-1|c-fos|fra-1,AP-1|c-fos|fra-1,<--
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.2.1,2353,9606,GO:0003704,GO:0006357|GO:0045941|GO:0051090,15514944,fra-1,c-fos,"While c-fos is highly expressed in invasive cervical tumor, the expression of fra-1 becomes almost nil or absent, but the reverse is true in both controls and early precancerous lesions.",0.09,PMID.dPMID15514944.s9.p0,2,2,c-fos|fra-1,c-fos|fra-1,<--
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,10557095,fra-1,Jun,"Overexpression of Jun causes significant alterations in the composition of AP-1, decreased junB and increased fra-1 expression and results in an increased biologic aggressiveness.",1.00,PMID.dPMID10557095.s4.p0,2,2,Jun|fra-1,fra-1|Jun,
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19795388,Fra-1,AP-1,"Significant and quantitative changes were seen in the expression of six AP-1 transcription factor genes, FosB, c-Fos, Fra-1, c-Jun, JunB, and ATF3 from 1-8 h following OS.",0.32,PMID.dPMID19795388.s6.p3,4,4,AP-1|FosB|c-Fos|Fra-1,AP-1|c-Fos|FosB|Fra-1,
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,14625389,FRA-1,c-JUN,We show that c-JUN and FRA-1 expression is dependent on ERK activity and that different thresholds of ERK activity control the expression of FRA-1.,0.29,PMID.dPMID14625389.s3.p6,5,3,c-JUN|FRA-1|ERK|ERK|FRA-1,c-JUN|ERK|FRA-1,
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19758438,Fra-1,AP-1,"Comparison of AP-1 family proteins demonstrated high expression of JunD and c-Fos in HPV positive tumors, but interestingly, Fra-1 expression was extremely low or nil in these tumor tissues.",0.19,PMID.dPMID19758438.s1.p3,4,4,AP-1|JunD|c-Fos|Fra-1,AP-1|c-Fos|Fra-1|JunD,
1.1.1.2.3,8061,9606,,GO:0006357,1.1.1.1.3,3727,9606,GO:0003702,GO:0006357,19758438,Fra-1,JunD,"Comparison of AP-1 family proteins demonstrated high expression of JunD and c-Fos in HPV positive tumors, but interestingly, Fra-1 expression was extremely low or nil in these tumor tissues.",0.27,PMID.dPMID19758438.s1.p4,4,4,AP-1|JunD|c-Fos|Fra-1,AP-1|c-Fos|Fra-1|JunD,<--
1.1.1.2.3,8061,9606,,GO:0006357,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16288017,FRA1,Sp1,Syk interacts with transcription factor Sp1 at the Sp1 DNA-binding site in the FRA1 promoter to repress Sp1-activated FRA1 transcription.,0.46,PMID.dPMID16288017.s1.p14,6,3,Syk|Sp1|Sp1|FRA1|Sp1|FRA1,FRA1|Sp1|Syk,<--
1.1.1.2.3,8061,9606,,GO:0006357,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,17496887,Fra-1,p73,"Chromatin immunoprecipitation and electrophoretic mobility shift analysis indicated that p73 enhanced the binding of phosphorylated c-Jun and Fra-1, another AP-1 family member, to AP-1 consensus DNA sequences, by regulating c-Jun phosphorylation and Fra-1 expression.",0.41,PMID.dPMID17496887.s1.p6,5,3,p73|Fra-1|AP-1|AP-1|Fra-1,AP-1|Fra-1|p73,
8.2.1.0.2,8091,9606,,,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,15291748,HMGA2,PPARalpha,"We then evaluated the expression of the PPARalpha, PPARgamma2, HMGA2, leptin and TSHr genes before and after 24 h of fenofibrate treatment, using semiquantitative and real-time PCR.",0.00,PMID.dPMID15291748.s7.p1,5,5,PPARalpha|PPARgamma|HMGA2|leptin|TSHr,HMGA2|leptin|PPARalpha|PPARgamma|TSHr,
8.2.1.0.2,8091,9606,,,2.3.5.0.39,59348,9606,GO:0016564,GO:0006355|GO:0016481,20007691,HMGA2,ZBRK1,"Here, we show that ZBRK1, BRCA1, and CtIP form a repression complex that coordinately regulates HMGA2 expression via a ZBRK1 recognition site in the HMGA2 promoter.",0.48,PMID.dPMID20007691.s4.p3,6,5,ZBRK1|BRCA1|CtIP|HMGA2|ZBRK1|HMGA2,BRCA1|CtIP|HMGA2|ZBRK1,
3.1.10.1.1,8092,9606,GO:0016563,GO:0000122,1.2.3.2.1,7291,9606,,,18495103,Alx1,Twist,"Evidence is presented that Twist expression is required for the maintenance of the PMC specification state, and a reciprocal regulation between Alx1 and Twist offers stability for the subsequent processes, such as PMC differentiation and skeletogenesis.",0.68,PMID.dPMID18495103.s1.p0,3,2,Twist|Alx1|Twist,Alx1|Twist,
1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18059336,SRC-3,myc,Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3.,1.31,PMID.dPMID18059336.s6.p7,5,5,Ets-2|myc|p160|SRC-1|SRC-3,Ets-2|myc|p160|SRC-1|SRC-3,e
1.2.5.3.3,8202,9606,,GO:0045893|GO:0045944,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,16916939,SRC-3,Sp1,"Sp1, E2F1, and SRC-3 are specifically recruited to this Sp1 site and the interaction between E2F1 and Sp1 is essential to modulate SRC-3 expression.",0.97,PMID.dPMID16916939.s2.p20,7,3,Sp1|E2F1|SRC-3|Sp1|E2F1|Sp1|SRC-3,E2F1|Sp1|SRC-3,
2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,2.2.1.0.1,2623,9606,,GO:0006357,16177182,Gfi-1B,GATA-1,Our laboratory has previously defined the human Gfi-1B promoter region and shown that GATA-1 mediates erythroid-specific Gfi-1B transcription.,0.96,PMID.dPMID16177182.s3.p2,3,2,Gfi-1B|GATA-1|Gfi-1B,GATA-1|Gfi-1B,
2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,2.2.1.0.1,2623,9606,,GO:0006357,15280509,Gfi-1B,GATA-1,"Using gel-shift and chromatin immunoprecipitation (ChIP) assays, we have demonstrated that NF-Y and GATA-1 directly participate in transcriptional activation of the Gfi-1B gene in K562 cells.",0.86,PMID.dPMID15280509.s3.p0,2,2,GATA-1|Gfi-1B,GATA-1|Gfi-1B,
2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,2.2.1.0.1,2623,9606,,GO:0006357,16177182,Gfi-1B,GATA-1,GATA-1 mediates auto-regulation of Gfi-1B transcription in K562 cells.,0.63,PMID.dPMID16177182.s5.p0,2,2,GATA-1|Gfi-1B,GATA-1|Gfi-1B,
2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,2.2.1.0.1,2623,9606,,GO:0006357,16177182,Gfi-1B,GATA-1,"These results not only demonstrate that interaction of GATA-1 and Gfi-1B participates in a feedback regulatory pathway in controlling the expression of the Gfi-1B gene, but also provide the first evidence that Gfi-1B can exert its repression function by acting on GATA-1-mediated transcription without direct binding to the Gfi-1 site of the target genes.",0.21,PMID.dPMID16177182.s1.p1,6,3,GATA-1|Gfi-1B|Gfi-1B|Gfi-1B|GATA-1|Gfi-1,GATA-1|Gfi-1|Gfi-1B,
2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,2.2.1.0.3,2625,9606,,,17272506,Gfi1b,Gata3,"We also show that ectopic expression of Gata3 in lymphomas promotes expression of Gfi1b, indicating that these proteins may function in an autoregulatory loop that maintains appropriate levels of Gata3.",0.35,PMID.dPMID17272506.s1.p0,3,2,Gata3|Gfi1b|Gata3,Gata3|Gfi1b,
2.3.5.0.33,8328,9606,GO:0003704,GO:0000114|GO:0000122,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,18625887,GFI1B,SCL,"They include FOG1, the NURD complex, the pentameric complex containing SCL/TAL-1, the zinc-finger regulators GFI1B and ZFP143, and the corepressor ETO2.",0.36,PMID.dPMID18625887.s4.p2,4,4,FOG1|SCL|GFI1B|ETO2,ETO2|FOG1|GFI1B|SCL,
4.1.1.2.4,8403,9606,GO:0016564,GO:0000122,3.3.1.1.2,3170,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010551|GO:0010552|GO:0010553|GO:0045941|GO:0051090,20074681,SOX14,FOXA2,In the present study we identified the positive control element and provided the first evidence that FOXA2 is involved in up-regulation of SOX14 expression in HepG2 and U87MG cell lines.,0.77,PMID.dPMID20074681.s5.p0,2,2,FOXA2|SOX14,FOXA2|SOX14,
2.1.6.0.2,8431,9606,,GO:0034339,3.1.7.1.1,3175,9606,GO:0016563,GO:0006355,18459945,SHP,HNF-6,Our results suggest that HNF-6 is a novel target of SHP in the regulation of gluconeogenesis,0.65,PMID.dPMID18459945.s0.p0,2,2,HNF-6|SHP,HNF-6|SHP,
2.1.6.0.2,8431,9606,,GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15292277,SHP,c-Jun,"Taken together, these works suggest that c-Jun works to activate the expression of SHP genes associated with the cascade regulation of monocytic differentiation",1.17,PMID.dPMID15292277.s0.p0,2,2,c-Jun|SHP,c-Jun|SHP,e
2.1.6.0.2,8431,9606,,GO:0034339,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15292277,SHP,c-Jun,"Electrophoretic mobility shift assays using oligonucleotides derived from the SHP promoter reveal that c-Jun exhibit TPA-induced DNA binding, providing a mechanism for the transcriptional activation of SHP gene expression.",0.71,PMID.dPMID15292277.s2.p2,3,2,SHP|c-Jun|SHP,c-Jun|SHP,
2.1.6.0.2,8431,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19749791,SHP-1,p53,These results indicate that p53 repression of SHP-1 expression leads to trkA-Y674/Y675 phosphorylation and trkA-dependent suppression of breast-cancer cell proliferation.,1.39,PMID.dPMID19749791.s1.p0,4,3,p53|SHP-1|trkA|trkA,p53|SHP-1|trkA,
2.1.6.0.2,8431,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19749791,SHP-1,p53,"This study investigates the functional relationship between trkA, p53 and SHP-1 in breast-cancer, and reveals that in wild-type (wt) trkA expressing breast-cancer cells both endogenous wtp53, activated by therapeutic agents, and transfected wtp53 repress expression of SHP-1 through the proximal CCAAT sequence of the SHP-1-P1-promoter and the transcription factor NF-Y.",0.63,PMID.dPMID19749791.s10.p20,8,3,trkA|p53|SHP-1|trkA|p53|p53|SHP-1|SHP-1,p53|SHP-1|trkA,
2.1.6.0.2,8431,9606,,GO:0034339,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19749791,SHP-1,p53,"This study investigates the functional relationship between trkA, p53 and SHP-1 in breast-cancer, and reveals that in wild-type (wt) trkA expressing breast-cancer cells both endogenous wtp53, activated by therapeutic agents, and transfected wtp53 repress expression of SHP-1 through the proximal CCAAT sequence of the SHP-1-P1-promoter and the transcription factor NF-Y.",0.60,PMID.dPMID19749791.s10.p26,8,3,trkA|p53|SHP-1|trkA|p53|p53|SHP-1|SHP-1,p53|SHP-1|trkA,
2.1.6.0.2,8431,9606,,GO:0034339,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,16455805,SHP,PXR,PXR concomitantly inhibits SHP gene transcription and maximizes the PXR induction of the CYP3A4 gene in human livers.,0.42,PMID.dPMID16455805.s1.p0,4,3,PXR|SHP|PXR|CYP3A4,CYP3A4|PXR|SHP,<--
2.3.2.2.23,8462,9606,,GO:0000122,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,15531587,KLF11,Sp1,"Mechanistically, cholesterol depletion results in displacement of KLF11 from an Sp1 site flanking an SRE, indicating that activation by SREBP/Sp1 requires antagonism of KLF11 repression.",0.34,PMID.dPMID15531587.s2.p5,4,2,KLF11|Sp1|Sp1|KLF11,KLF11|Sp1,
1.2.4.1.12,8553,9606,,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18556654,DEC1,p53,"Taken together, our study suggests that p53 trans-repressional activity can be mediated by its own target DEC1 and ID1 is an effector of the p53-dependent DNA damage response pathway",0.09,PMID.dPMID18556654.s0.p0,4,3,p53|DEC1|ID1|p53,DEC1|ID1|p53,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,1.1.4.1.4,1052,9606,,,17903252,p63,C/EBPdelta,"RESULTS: C/EBPdelta, member of a family with known roles in differentiation pathways, emerged as a gene repressed by p63.",0.35,PMID.dPMID17903252.s8.p0,2,2,C/EBPdelta|p63,C/EBPdelta|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,1.1.4.1.4,1052,9606,,,17903252,p63,C/EBPdelta,"Finally, C/EBPdelta is found on the p63 targets in vivo by ChIP analysis, indicating that coregulation is direct.",0.14,PMID.dPMID17903252.s1.p0,2,2,C/EBPdelta|p63,C/EBPdelta|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,3.1.2.5.3,1747,9606,,,17164413,p63,Dlx3,Homeobox gene Dlx3 is regulated by p63 during ectoderm development: relevance in the pathogenesis of ectodermal dysplasias.,1.78,PMID.dPMID17164413.s6.p0,2,2,Dlx3|p63,Dlx3|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,3.1.2.5.3,1747,9606,,,17164413,p63,Dlx3,"Here, we demonstrate that Dlx3 is a downstream target of p63.",0.21,PMID.dPMID17164413.s2.p0,2,2,Dlx3|p63,Dlx3|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,9266972,p51,ETS1,"Data presented in this paper indicate that the naturally occurring spliced variant protein, p42-ETS1, lacking the region encoded by ETS1 exon VII, represses the tumorigenicity, while p51-ETS1 reduces the tumorigenicity.",0.15,PMID.dPMID9266972.s2.p1,4,2,ETS1|ETS1|p51|ETS1,ETS1|p51,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.1.5.0.2,2494,9606,,GO:0034339|GO:0043193|GO:0045449|GO:0045941,15700448,cusp,CPF,"Transesophageal echocardiography showed a stalked CPF on the aortic side of the left coronary cusp, and a smaller CPF on the right coronary cusp.",0.59,PMID.dPMID15700448.s4.p5,4,2,CPF|cusp|CPF|cusp,CPF|cusp,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.1.5.0.2,2494,9606,,GO:0034339|GO:0043193|GO:0045449|GO:0045941,15700448,cusp,CPF,"Transesophageal echocardiography showed a stalked CPF on the aortic side of the left coronary cusp, and a smaller CPF on the right coronary cusp.",0.34,PMID.dPMID15700448.s4.p3,4,2,CPF|cusp|CPF|cusp,CPF|cusp,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.1.5.0.2,2494,9606,,GO:0034339|GO:0043193|GO:0045449|GO:0045941,15700448,cusp,CPF,"Transesophageal echocardiography showed a stalked CPF on the aortic side of the left coronary cusp, and a smaller CPF on the right coronary cusp.",0.13,PMID.dPMID15700448.s4.p0,4,2,CPF|cusp|CPF|cusp,CPF|cusp,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.2.1.0.3,2625,9606,,,19092634,p63,GATA3,"One of 2 proliferating Brenner tumors was positive for S100P, whereas both cases were positive for GATA3 and p63; the malignant Brenner tumor was positive for S100P and p63, but negative for GATA3.",0.03,PMID.dPMID19092634.s5.p7,6,3,S100P|GATA3|p63|S100P|p63|GATA3,GATA3|p63|S100P,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.3.2.3.1,2735,9606,GO:0016563,GO:0043193|GO:0045944,15024701,LMS,GLI,"We evaluated amplification and overrepresentation of CDK4, MDM2, GLI and SAS genes of the 12q13-15 region, in a group of soft tissue sarcomas including leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS) and embryonal (anaplastic and classic variants) rhabdomyosarcomas (ERMS), to ascertain genomic alterations and possible differences within histologic subtypes of rhabdomyosarcoma (RMS).",0.02,PMID.dPMID15024701.s7.p5,4,4,CDK4|MDM2|GLI|LMS,CDK4|GLI|LMS|MDM2,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,20607803,p63,c-jun,Point mutation of the sp1 binding site within the TAp63 promoter region attenuated the effect of c-jun on TAp63 expression.,1.54,PMID.dPMID20607803.s1.p2,3,2,p63|c-jun|p63,c-jun|p63,e
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,3.3.1.15.3,4303,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,19476522,p63,AFX,"All 10 SCSCC showed strong expression of p63, whereas all 20 AFX were p63 negative.",0.16,PMID.dPMID19476522.s3.p2,3,2,p63|AFX|p63,AFX|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,3.3.1.15.3,4303,9606,GO:0003704|GO:0016563|GO:0016566,GO:0006355|GO:0010553|GO:0045944|GO:0051090,18787630,p63,AFX,"Overall, the most effective combination to distinguish AFX from SCSCC was p63 and cytokeratin AE-1/3.",0.14,PMID.dPMID18787630.s2.p0,3,3,AFX|p63|AE-1,AE-1|AFX|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,19458633,p63,PPARalpha,"Distinct PPARalpha transcripts are differentially regulated by p63, indicating a bimodal action in promoter and/or transcription start specification.",0.89,PMID.dPMID19458633.s4.p0,2,2,PPARalpha|p63,p63|PPARalpha,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,19458633,p63,PPARalpha,"Furthermore, we show that PPARalpha is a negative regulator of DeltaNp63alpha levels and that it also binds to a functional region of the DeltaNp63 promoter that lacks PPRE motifs.",0.75,PMID.dPMID19458633.s2.p0,3,2,PPARalpha|p63|p63,p63|PPARalpha,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.1.1.2.1,5970,9606,GO:0016563|GO:0016564,GO:0032582|GO:0045944|GO:0051092,20052674,p63,RelA,Ectopic expression of RelA stimulates TAp63 promoter-driven reporter activity and increases endogenous TAp63 mRNA levels.,0.28,PMID.dPMID20052674.s5.p0,3,2,RelA|p63|p63,p63|RelA,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,19661786,p63,Sox2,All of the ACA diffusely positive for Sox2 were p63 negative.,0.29,PMID.dPMID19661786.s3.p0,2,2,Sox2|p63,p63|Sox2,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,19661786,p63,Sox2,Ninety-four percent of SCC coexpressed Sox2 and p63; 1 case was only focally positive for p63 but diffusely positive for Sox2.,0.27,PMID.dPMID19661786.s5.p1,4,2,Sox2|p63|p63|Sox2,p63|Sox2,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,19661786,p63,Sox2,"Among non-small cell lung carcinoma overall, there was a significant association between Sox2+/p63- expression and high-grade histology (P = 0.02).",0.26,PMID.dPMID19661786.s2.p0,2,2,Sox2|p63,p63|Sox2,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,4.1.1.2.2,6657,9606,,GO:0006355|GO:0045941|GO:0045944,19661786,p63,Sox2,Twenty-nine percent of ACA were at least focally p63+; 12% were Sox2+/p63+.,0.01,PMID.dPMID19661786.s4.p2,3,2,p63|Sox2|p63,p63|Sox2,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,11546792,p63,Sp1,"Transient transfection assays show that the EGFR promoter region between -348 and -293, containing two Sp1 sites, is crucial for the repression of the EGFR expression by TAp63gamma.",0.66,PMID.dPMID11546792.s3.p4,4,3,EGFR|Sp1|EGFR|p63,EGFR|p63|Sp1,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15944736,p63,p53,"Unlike p53, the expression of p63 is regulated by two different promoters resulting in proteins with opposite functions: the full-length transcriptionally active TAp63 and the dominant-negative DeltaNp63.",1.08,PMID.dPMID15944736.s7.p1,4,2,p53|p63|p63|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20457941,p63,p53,"RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability.",0.87,PMID.dPMID20457941.s7.p2,3,3,RNPC1|p53|p63,p53|p63|RNPC1,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17029809,p63,p53,"These data strongly suggest that in anaplastic carcinomas, impairment of p53-mediated repression results in increased GLUT1 and p63 expression, and that this probably reflects the differential regulation of hypoxia-responsive pathways and basal/stem cell regulatory pathways",0.76,PMID.dPMID17029809.s0.p1,3,3,p53|GLUT1|p63,GLUT1|p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11181451,p63,p53,"p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization.",0.74,PMID.dPMID11181451.s9.p1,4,2,p53|p51|p63|p53,p51|p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11181451,p51,p53,"p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization.",0.74,PMID.dPMID11181451.s9.p0,4,2,p53|p51|p63|p53,p51|p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20663147,p63,p53,RESULTS: We now report that phosphorylation of the p53 tumour suppressor is positively regulated by DeltaNp63alpha in immortalised human keratinocytes.,0.74,PMID.dPMID20663147.s6.p0,2,2,p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15944736,p63,p53,"Unlike p53, the expression of p63 is regulated by two different promoters resulting in proteins with opposite functions: the full-length transcriptionally active TAp63 and the dominant-negative DeltaNp63.",0.72,PMID.dPMID15944736.s7.p3,4,2,p53|p63|p63|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19664188,p63,p53,Transforming growth factor-beta and mutant p53 conspire to induce metastasis by antagonizing p63: a (ternary) complex affair.,0.68,PMID.dPMID19664188.s6.p0,2,2,p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10469295,KET,p53,"The p53-like genes, p73 and the several KET splicing variants, are recently described genes of uncertain biologic and pathologic significance.",0.66,PMID.dPMID10469295.s1.p1,3,3,p53|p73|KET,KET|p53|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15970683,p63,p53,"Recent work from our laboratory has determined that the p53 target gene Perp is required for the integrity of the stratified epithelia specified by p63, and that expression of Perp in these structures depends on the presence of p63.",0.65,PMID.dPMID15970683.s2.p6,5,3,p53|Perp|p63|Perp|p63,p53|p63|Perp,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15849742,p63,p53,"p53-Related genes, p73 and p63, encode 2 classes of proteins, TA-p73/p63 and DeltaN-p73/p63.",0.62,PMID.dPMID15849742.s9.p6,7,3,p53|p73|p63|p73|p63|p73|p63,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10773878,p63,p53,"In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer",0.57,PMID.dPMID10773878.s0.p0,3,3,p53|p63|p73,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15849742,p63,p53,"p53-Related genes, p73 and p63, encode 2 classes of proteins, TA-p73/p63 and DeltaN-p73/p63.",0.48,PMID.dPMID15849742.s9.p15,7,3,p53|p73|p63|p73|p63|p73|p63,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10637430,p51,p53,"The p53-related genes, p51/p63 and p73, have been isolated respectively from cDNA libraries of skeletal muscle and the brain, and their structural features and biological functions have been compared.",0.43,PMID.dPMID10637430.s7.p0,4,3,p53|p51|p63|p73,p51|p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10637430,p63,p53,"The p53-related genes, p51/p63 and p73, have been isolated respectively from cDNA libraries of skeletal muscle and the brain, and their structural features and biological functions have been compared.",0.43,PMID.dPMID10637430.s7.p1,4,3,p53|p51|p63|p73,p51|p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15849742,p63,p53,"p53-Related genes, p73 and p63, encode 2 classes of proteins, TA-p73/p63 and DeltaN-p73/p63.",0.39,PMID.dPMID15849742.s9.p1,7,3,p53|p73|p63|p73|p63|p73|p63,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15970683,p63,p53,"Recent work from our laboratory has determined that the p53 target gene Perp is required for the integrity of the stratified epithelia specified by p63, and that expression of Perp in these structures depends on the presence of p63.",0.36,PMID.dPMID15970683.s2.p1,5,3,p53|Perp|p63|Perp|p63,p53|p63|Perp,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15944736,p63,p53,"Unlike p53, the expression of p63 is regulated by two different promoters resulting in proteins with opposite functions: the full-length transcriptionally active TAp63 and the dominant-negative DeltaNp63.",0.34,PMID.dPMID15944736.s7.p0,4,2,p53|p63|p63|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11593387,p63,p53,"In addition to transcription activation of p53-responsive genes, we found that p63 and p73 repress transcription of the cdk1 and cyclin B genes, both of which are irreversibly repressed in senescent human fibroblast.",0.31,PMID.dPMID11593387.s3.p0,4,4,p53|p63|p73|cdk1,cdk1|p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18937546,p63,p53,"In this study we investigated the function of p63, a p53 family member, in the regulation of the expression of various types of chemokine ligands by focusing on the property of p63 as an epitheliotropic transcription factor.",0.30,PMID.dPMID18937546.s4.p2,3,2,p63|p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15754365,p63,p53,The p53 homologous squamous stem-cell regulatory protein p63 is expressed in squamous carcinomas but is not characteristically detected in small-cell carcinomas (SCCs).,0.28,PMID.dPMID15754365.s12.p0,2,2,p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17334395,p63,p53,"The p53-related genes p63 and p73 exhibit significant structural homology to p53; however, they do not function as classical tumor suppressors and are rarely mutated in human cancers.",0.27,PMID.dPMID17334395.s6.p0,4,3,p53|p63|p73|p53,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,10761704,p51,p53,"Two p53-related genes, p73 and p51, were recently identified as structural homologues of the p53 tumor suppressor gene, suggesting that the roles of these two genes may be similar to those of p53, including growth suppression and induction of apoptosis.",0.22,PMID.dPMID10761704.s11.p1,5,3,p53|p73|p51|p53 tumor suppressor|p53,p51|p53|p53 tumor suppressor|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,12049655,p40,p53,"In the present study, we demonstrate by Western-blot analysis that, in addition to the p53 protein, these molecules were able to induce the expression of a shorter protein with an apparent molecular mass of 40 kDa (p40), recognized by antibodies raised against the N-terminus of p53.",0.20,PMID.dPMID12049655.s8.p0,3,2,p53|p40|p53,p40|p53,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18348649,TP63,TP53,"Unlike in TP53 gene, mutations in TP63 and TP73 genes are rare, however, germline mutations in TP63 are linked to the human developmental diseases.",0.18,PMID.dPMID18348649.s1.p0,4,3,TP53|TP63|TP73|TP63,TP53|TP63|TP73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15578720,p63,p53,We tested 7 p53-related proteins of the p63 and p73 families for their ability to induce maspin expression.,0.17,PMID.dPMID15578720.s10.p0,4,4,p53|p63|p73|maspin,maspin|p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17287142,p63,p53,"The discovery of the p53-related genes p63 and p73 raised the possibility that they may be cancer-associated genes and as a consequence that p53 is not the only component in predicting prognosis and response to chemotherapy, but instead the status of a network that contains p53, p73 and p63.",0.17,PMID.dPMID17287142.s7.p0,7,3,p53|p63|p73|p53|p53|p73|p63,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11893750,p63,p53,Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.,0.16,PMID.dPMID11893750.s8.p0,2,2,p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11957139,p63,p53,"Although no statistical correlation was found between p53 and p63 or p73, p53-negative tumors overexpressed either p63 or p73.",0.15,PMID.dPMID11957139.s2.p9,6,3,p53|p63|p73|p53|p63|p73,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11893750,p63,p53,"Unlike wild-type p53, the binding to specific p53 mutants markedly counteracts p63-induced growth inhibition.",0.14,PMID.dPMID11893750.s2.p2,3,2,p53|p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15634666,p63,p53,"Most interestingly, when the p53DBD is replaced by the p63DBD, p53 is converted from a repressor working through the HT site to an activator working through the APE.",0.12,PMID.dPMID15634666.s1.p0,4,3,p53|p63|p53|APE,APE|p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,9703973,p73L,p53,"We have cloned a second human p53-related gene, termed p73L, which shows strong amino-acid similarity to p73.",0.10,PMID.dPMID9703973.s3.p0,3,3,p53|p73L|p73,p53|p73|p73L,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11181451,p51,p53,"Thus, p53CP appears to be p51/p63, the third member of the p53 gene family",0.09,PMID.dPMID11181451.s0.p0,4,2,p53|p51|p63|p53,p51|p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,11181451,p63,p53,"Thus, p53CP appears to be p51/p63, the third member of the p53 gene family",0.09,PMID.dPMID11181451.s0.p1,4,2,p53|p51|p63|p53,p51|p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,16131611,p63,p53,"The recently discovered p53-related genes, p73 and p63, express multiple splice variants and N-terminally truncated forms initiated from an alternative promoter in intron 3.",0.09,PMID.dPMID16131611.s8.p1,3,3,p53|p73|p63,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,18315848,p63,p53,Barriers to the rotation of sidechains containing aromatic rings at the core of the proteins were reduced several-fold when p53 was mutated; in contrast they increased when p73 was mutated and decreased by a small amount in p63.,0.09,PMID.dPMID18315848.s6.p1,3,3,p53|p73|p63,p53|p63|p73,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15988026,p63,p53,The p53-related p63 gene encodes six isoforms with differing N and C termini.,0.06,PMID.dPMID15988026.s8.p0,2,2,p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17426453,p63,p53,Can we exploit the biochemical know how gained from the mass of p53 research to further elucidate deltaNp63alpha gene function?,0.00,PMID.dPMID17426453.s1.p0,2,2,p53|p63,p53|p63,<--
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10373484,p63,p73,In vivo co-transfection assays of the ability of p53 and its homologues to activate reporter genes showed that a DNA-binding mutant of p53 was not able to act in a dominant negative manner over wild-type p73 or p63 but that a p73 mutant could inhibit the activity of wild-type p63.,0.66,PMID.dPMID10373484.s2.p14,6,3,p53|p53|p73|p63|p73|p63,p53|p63|p73,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,20298673,p63,p73,"p73 and p63 regulate the expression of fibroblast growth factor receptor 3.    p53, p63 and p73 make a family of transcription factors that play a vital role in development and cancer.",0.65,PMID.dPMID20298673.s7.p3,5,3,p73|p63|p53|p63|p73,p53|p63|p73,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,18315848,p63,p73,Barriers to the rotation of sidechains containing aromatic rings at the core of the proteins were reduced several-fold when p53 was mutated; in contrast they increased when p73 was mutated and decreased by a small amount in p63.,0.50,PMID.dPMID18315848.s6.p2,3,3,p53|p73|p63,p53|p63|p73,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,12944917,p63,p73,"In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels.",0.12,PMID.dPMID12944917.s5.p0,3,3,p73|p63|p53,p53|p63|p73,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,11727253,p63,p53-related protein,Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.,0.05,PMID.dPMID11727253.s16.p0,2,2,p53-related protein|p63,p53-related protein|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,6.3.1.0.3,7161,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045893,10918601,p63,p53-related protein,"However, immunohistochemistry consistently revealed that all the tumour cells express substantial amounts of the p53-related protein p63.",0.01,PMID.dPMID10918601.s4.p0,2,2,p53-related protein|p63,p53-related protein|p63,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.1.2.4.1,7421,9606,,GO:0010553|GO:0016481|GO:0034339,17716971,p63,VDR,"In conclusion, our results indicate that VDR is regulated by p63 and p73 and that the induction of VDR expression upon DNA damage is p73-dependent",1.87,PMID.dPMID17716971.s0.p0,5,3,VDR|p63|p73|VDR|p73,p63|p73|VDR,e
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,2.3.2.3.8,7490,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0016481|GO:0032582|GO:0043193|GO:0045941,19708185,p63,WT-1,"Both SCC of the fallopian tube and cervical SCC in situ were positive for p63, while the non-involved tubal epithelium was positive for WT-1, but negative for p63.",0.08,PMID.dPMID19708185.s2.p9,5,3,SCC|SCC|p63|WT-1|p63,p63|SCC|WT-1,
6.3.1.0.2,8626,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0043193|GO:0045892|GO:0045893,3.2.2.2.3,7849,9606,GO:0016563,GO:0045893,20463571,p63,PAX8,The inverse PAX8/p63 expression seen in CDC and UUC supports a renal tubular rather than an urothelial differentiation in CDC given the nephric lineage restriction of PAX8,0.53,PMID.dPMID20463571.s0.p0,3,2,PAX8|p63|PAX8,p63|PAX8,
1.2.5.3.1,8648,9606,,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,18059336,SRC-1,myc,Ets-2 regulation of myc was found to be reliant on the p160 proteins SRC-1 and SRC-3.,1.05,PMID.dPMID18059336.s6.p4,5,5,Ets-2|myc|p160|SRC-1|SRC-3,Ets-2|myc|p160|SRC-1|SRC-3,
1.2.5.3.1,8648,9606,,,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,16455805,SRC-1,PXR,"Results suggest that PXR strongly induces CYP3A4 gene transcription by interacting with HNF4alpha, SRC-1, and PGC-1alpha.",0.20,PMID.dPMID16455805.s2.p3,5,5,PXR|CYP3A4|HNF4alpha|SRC-1|PGC-1alpha,CYP3A4|HNF4alpha|PGC-1alpha|PXR|SRC-1,
3.1.10.10.1,8820,9606,,,5.1.2.0.1,6722,9606,GO:0003704,GO:0010735|GO:0045944|GO:0060261,17468179,ANF,SRF,"This finding was similar to that observed in embryos with cardiac-specific ablation of serum response factor (SRF), a direct transcriptional regulator of ANF expression.",1.16,PMID.dPMID17468179.s4.p0,2,2,SRF|ANF,ANF|SRF,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,18305375,PXR,NR2A1,"In this study, we examined the involvement of hepatocyte nuclear factor 4alpha (HNF4alpha; NR2A1) in the transcriptional regulation of the human PXR gene in the human liver.",0.83,PMID.dPMID18305375.s6.p2,3,2,HNF4alpha|NR2A1|PXR,HNF4alpha|NR2A1|PXR,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,18305375,PXR,HNF4alpha,These results suggested that HNF4alpha transactivated the human PXR gene by binding to the DR1 element located at -88/-76 of the promoter and was involved in the expression of PXR in the human liver,0.32,PMID.dPMID18305375.s0.p1,3,2,HNF4alpha|PXR|PXR,HNF4alpha|PXR,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,16455805,PXR,HNF4alpha,Mutation of the putative HNF4alpha binding site in the distal xenobiotic responsive element module did not affect CYP3A4 basal promoter activity and synergistic stimulation by PXR and HNF4alpha.,0.09,PMID.dPMID16455805.s7.p1,4,3,HNF4alpha|CYP3A4|PXR|HNF4alpha,CYP3A4|HNF4alpha|PXR,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,17687072,PXR,HNF4alpha,These results suggest that HNF4alpha plays a central role in the control of SULT2A1 transcription and that rifampicin-liganded PXR suppresses SULT2A1 expression by interfering with HNF4alpha activity.,0.06,PMID.dPMID17687072.s1.p1,5,3,HNF4alpha|SULT2A1|PXR|SULT2A1|HNF4alpha,HNF4alpha|PXR|SULT2A1,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,16243957,PXR,PPARalpha,"Further analysis of this regulatory region has shown that transcriptional activation of PXR by peroxisome proliferator-activated receptor alpha (PPARalpha) is via a binding site located approximately 1.3 kb upstream of the putative transcription start site, with ablation of this site preventing PPARalpha-mediated activation of PXR gene expression.",0.05,PMID.dPMID16243957.s1.p4,4,2,PXR|PPARalpha|PPARalpha|PXR,PPARalpha|PXR,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.6.0.2,8431,9606,,GO:0034339,16455805,PXR,SHP,"On the other hand, SHP reduced PXR recruitment of HNF4alpha and SRC-1 to the CYP3A4 chromatin.",0.14,PMID.dPMID16455805.s5.p0,5,5,SHP|PXR|HNF4alpha|SRC-1|CYP3A4,CYP3A4|HNF4alpha|PXR|SHP|SRC-1,-->
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.2.4.3,9970,9606,,GO:0034339,16724925,PXR,CAR,"Current evidence suggests that the CAR gene arose from a duplication of an ancestral PXR gene, and that PXR and VDR arose from duplication of an ancestral gene, represented now by a single gene in the invertebrate Ciona intestinalis.",0.59,PMID.dPMID16724925.s4.p0,4,3,CAR|PXR|PXR|VDR,CAR|PXR|VDR,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.2.4.3,9970,9606,,GO:0034339,16608920,PXR,CAR,We have previously shown that PXR and CAR expression is controlled by the glucocorticoid receptor (GR) and proposed the existence of a signal transmission cascade GR-(PXR/CAR)-drug metabolizing and transporter systems.,0.18,PMID.dPMID16608920.s7.p2,4,2,PXR|CAR|PXR|CAR,CAR|PXR,
2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,2.1.2.4.3,9970,9606,,GO:0034339,10924340,PXR,CAR,"As the transcriptional activity of PXR and CAR is not affected by IL-6 in cell-based reporter assays, our data suggest that the loss of CYP2 and CYP3 inducibility results from the negative regulation of PXR and CAR gene expression by this cytokine",0.15,PMID.dPMID10924340.s0.p7,6,4,PXR|CAR|IL-6|CYP2|PXR|CAR,CAR|CYP2|IL-6|PXR,
3.3.1.8.1,8928,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045941|GO:0045944|GO:0051090,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,10822381,hFAST-1,Smad2,All mutant Smad2 and Smad4 were in fact found to be defective in transmitting growth inhibitory signals originating from TGF-beta and incapable of activating Smad/hFAST-1-mediated transcription.,0.57,PMID.dPMID10822381.s4.p3,4,4,Smad2|Smad4|TGF-beta|hFAST-1,hFAST-1|Smad2|Smad4|TGF-beta,
3.3.1.8.1,8928,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045941|GO:0045944|GO:0051090,7.1.1.2.1,4089,9606,,GO:0045892|GO:0045893|GO:0045941,10822381,hFAST-1,Smad4,All mutant Smad2 and Smad4 were in fact found to be defective in transmitting growth inhibitory signals originating from TGF-beta and incapable of activating Smad/hFAST-1-mediated transcription.,0.55,PMID.dPMID10822381.s4.p4,4,4,Smad2|Smad4|TGF-beta|hFAST-1,hFAST-1|Smad2|Smad4|TGF-beta,
1.2.3.3.4,9242,9606,,,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,20519630,ABF-1,KLF4,"In addition, we found that KLF4 negatively regulates CXCL10, CD86, and MSC/ABF-1 genes.",0.97,PMID.dPMID20519630.s2.p3,4,4,KLF4|CXCL10|CD86|ABF-1,ABF-1|CD86|CXCL10|KLF4,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.3.2.2.20,688,9606,GO:0003702,,12087155,Klf4,Klf5,The complementary tissue localization of expression of Klf4 and Klf5 and the opposing effect of the two Klfs on the Klf4 promoter activity may provide a basis for the coordinated regulation of expression of the Klf4 gene in the intestinal epithelium,0.17,PMID.dPMID12087155.s0.p4,4,2,Klf4|Klf5|Klf4|Klf4,Klf4|Klf5,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.3.2.2.20,688,9606,GO:0003702,,12087155,Klf4,Klf5,"Moreover, Klf5 abrogates the activating effect of Klf4 on the Klf4 promoter and Klf4 abrogates the inhibitory effect of Klf5 on the same promoter.",0.01,PMID.dPMID12087155.s2.p0,5,2,Klf5|Klf4|Klf4|Klf4|Klf5,Klf4|Klf5,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,19503094,KLF4,ERalpha,We also showed that activation of p53 decreased the transcriptional activity of ERalpha by elevating KLF4 expression.,1.75,PMID.dPMID19503094.s2.p2,3,3,p53|ERalpha|KLF4,ERalpha|KLF4|p53,e
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,19551868,KLF4,PPARgamma,"This indicates that PPARgamma activation induces KLF4 expression, which in turn increases GPA33 expression.",0.97,PMID.dPMID19551868.s1.p0,3,3,PPARgamma|KLF4|GPA33,GPA33|KLF4|PPARgamma,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,17513608,KLF-4,PPARgamma,This shows for the first time that PPARgamma agonists derived from glycyrrhetinic acid induced cell-dependent caveolin-1 and KLF-4 expression through receptor-dependent pathways,0.18,PMID.dPMID17513608.s0.p1,3,3,PPARgamma|caveolin-1|KLF-4,caveolin-1|KLF-4|PPARgamma,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17085651,KLF4,Sp1,"Sp1 positively regulated its own promoter, whereas KLF4 did the opposite.",0.85,PMID.dPMID17085651.s1.p0,2,2,Sp1|KLF4,KLF4|Sp1,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17085651,KLF4,Sp1,"Specifically, strong Sp1 expression but loss of KLF4 expression was found in cancer tissue, whereas the adjacent noncancerous tissue showed negative Sp1 expression but strong KLF4 expression.",0.44,PMID.dPMID17085651.s4.p0,4,2,Sp1|KLF4|Sp1|KLF4,KLF4|Sp1,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,19503094,KLF4,p53,We also showed that activation of p53 decreased the transcriptional activity of ERalpha by elevating KLF4 expression.,1.48,PMID.dPMID19503094.s2.p1,3,3,p53|ERalpha|KLF4,ERalpha|KLF4|p53,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,15806166,KLF4,p53,"However, centrosome amplification could be suppressed in irradiated HCT116 p53-/- cells by conditional induction of exogenous KLF4.",0.04,PMID.dPMID15806166.s4.p0,2,2,p53|KLF4,KLF4|p53,
2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,2.3.2.2.16,10661,9606,,,17762869,KLF4,Kruppel-like factor,The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation.,1.02,PMID.dPMID17762869.s9.p0,2,2,Kruppel-like factor|KLF4,KLF4|Kruppel-like factor,
1.2.3.2.4,9464,9606,GO:0016563,GO:0006355|GO:0045944,3.1.1.7.16,3239,9606,,,18407260,Hand2,Hoxd13,"We found that Hoxd13 binds invivo, in developing limbs, the loci of Hand2, a gene crucial to limb AP axis patterning, of Meis1 and Meis2, involved in PD patterning, of the Sfrp1, Barx1, and Fbn1 genes, involved in skeletogenesis, and of the Dach1, Bmp2, Bmp4, andEmx2 genes.",0.08,PMID.dPMID18407260.s2.p0,6,6,Hoxd13|Hand2|Meis1|Meis2|Fbn1|Bmp4,Bmp4|Fbn1|Hand2|Hoxd13|Meis1|Meis2,
3.1.6.3.2,9839,9606,,GO:0016481,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,15061132,Smad-interacting protein 1,Runx2,"To date, osteogenesis governed by Smad5-mediated signals is delicately orchestrated by its comprehensive interactions with global osteogenesis regulator Runx2, transcriptional repressor Rob and Smad-interacting protein 1.",0.51,PMID.dPMID15061132.s1.p2,3,3,Smad5|Runx2|Smad-interacting protein 1,Runx2|Smad5|Smad-interacting protein 1,
2.1.2.4.3,9970,9606,,GO:0034339,6.1.1.1.1,4790,9606,GO:0016563,GO:0010553|GO:0045941|GO:0051092,15382119,CAR,NF-kappaB,"In conclusion, GR/NF-kappaB interaction affects CAR gene transcription through chromatin remodeling and provide a mechanistic explanation for the long-standing observation that inflammation and sepsis inhibit drug metabolism while inducing intrahepatic cholestasis or hyperbilirubinemia",0.30,PMID.dPMID15382119.s0.p0,2,2,NF-kappaB|CAR,CAR|NF-kappaB,
2.1.2.4.3,9970,9606,,GO:0034339,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,11502872,CAR,PXR,"PXR was shown to be capable of activating the phenobarbital-responsive enhancer module (PBREM) region of the CYP2B6 gene, a 51-base-pair enhancer element that mediates induction of CYP2B6 expression by CAR.",0.25,PMID.dPMID11502872.s2.p3,4,3,PXR|CYP2B6|CYP2B6|CAR,CAR|CYP2B6|PXR,
2.1.2.4.3,9970,9606,,GO:0034339,2.1.2.4.2,8856,9606,GO:0016564,GO:0016481|GO:0034339|GO:0045941,16608920,CAR,PXR,We have previously shown that PXR and CAR expression is controlled by the glucocorticoid receptor (GR) and proposed the existence of a signal transmission cascade GR-(PXR/CAR)-drug metabolizing and transporter systems.,0.13,PMID.dPMID16608920.s7.p3,4,2,PXR|CAR|PXR|CAR,CAR|PXR,
2.1.2.7.3,9971,9606,,GO:0034339,2.1.2.5.1,5465,9606,GO:0003706|GO:0016563,GO:0010552|GO:0010553|GO:0034339|GO:0072363|GO:0072366|GO:0072369,12554753,FXR,PPARalpha,"In concert, these results demonstrate that bile acids stimulate PPARalpha expression in a species-specific manner via a FXRE located within the human PPARalpha promoter.",0.01,PMID.dPMID12554753.s1.p2,4,3,bile acid|PPARalpha|FXR|PPARalpha,bile acid|FXR|PPARalpha,-->
1.2.3.4.14,10215,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,17627137,Olig2,basic helix-loop-helix transcription factor,"Conversely, the basic helix-loop-helix transcription factor Olig2 is widely expressed in subsets of glia cells and progenitors, and it is strongly induced at different sites by both acute and chronic injury, albeit with different mechanisms.",0.83,PMID.dPMID17627137.s3.p0,2,2,basic helix-loop-helix transcription factor|Olig2,basic helix-loop-helix transcription factor|Olig2,
1.2.3.4.14,10215,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,16554441,OLIG2,basic helix-loop-helix transcription factor,The basic helix-loop-helix transcription factor OLIG2 is specifically expressed in cells of the oligodendrocyte lineage.,0.75,PMID.dPMID16554441.s9.p0,2,2,basic helix-loop-helix transcription factor|OLIG2,basic helix-loop-helix transcription factor|OLIG2,
1.2.3.4.14,10215,9606,,,1.2.3.4.1,4760,9606,GO:0003702,GO:0045944,18676824,Olig2,basic helix-loop-helix transcription factor,We identified a novel mechanism for L1CAM regulation of cell survival as L1CAM knockdown decreased expression of the basic helix-loop-helix transcription factor Olig2 and up-regulated the p21(WAF1/CIP1) tumor suppressor in CD133(+) glioma cells.,0.71,PMID.dPMID18676824.s3.p5,7,6,L1CAM|L1CAM|basic helix-loop-helix transcription factor|Olig2|WAF1|CIP1|CD133,basic helix-loop-helix transcription factor|CD133|CIP1|L1CAM|Olig2|WAF1,
2.3.2.2.1,10320,9606,,,4.1.3.0.9,6872,9606,GO:0016986,GO:0000117|GO:0010552|GO:0045944|GO:0060261,17952504,Ikaros,TAF1,Promoter assays performed in NT2/D1 and in U87 cells demonstrate that TAF1-independent transcription of exons d2-d4 is driven by a TATA box-less promoter that is regulated by transcription factor Ikaros.,0.94,PMID.dPMID17952504.s3.p0,2,2,TAF1|Ikaros,Ikaros|TAF1,
3.5.3.0.9,10379,9606,,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,11004486,ISGF3 gamma,Transcription factor,Transcription factor C/EBP-beta is required for inducing ISGF3 gamma gene expression through GATE.,0.34,PMID.dPMID11004486.s2.p1,3,3,Transcription factor|C/EBP-beta|ISGF3 gamma,C/EBP-beta|ISGF3 gamma|Transcription factor,
1.2.5.3.2,10499,9606,,GO:0006355,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12554755,GRIP1,AP-1,"Moreover, the negative effect of RIP140 on AP-1-mediated transcription is relieved by GRIP1 overexpression and, conversely, RIP140 inhibits the stimulatory effect of GRIP1.",1.76,PMID.dPMID12554755.s2.p2,5,3,RIP140|AP-1|GRIP1|RIP140|GRIP1,AP-1|GRIP1|RIP140,
1.2.5.3.2,10499,9606,,GO:0006355,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,12554755,GRIP1,AP-1,"Moreover, the negative effect of RIP140 on AP-1-mediated transcription is relieved by GRIP1 overexpression and, conversely, RIP140 inhibits the stimulatory effect of GRIP1.",0.17,PMID.dPMID12554755.s2.p7,5,3,RIP140|AP-1|GRIP1|RIP140|GRIP1,AP-1|GRIP1|RIP140,
1.2.5.3.2,10499,9606,,GO:0006355,3.2.1.1.1,5077,9606,GO:0016563,GO:0010552,19953635,NCOA2,PAX3,"The PAX3-NCOA1 and PAX3-NCOA2 transcripts encode chimeric proteins composed of the paired-box and homeodomain DNA-binding domains of PAX3, and the CID domain, the Q-rich region, and the activation domain 2 (AD2) domain of NCOA1 or NCOA2.",0.11,PMID.dPMID19953635.s6.p5,7,3,PAX3|NCOA1|PAX3|NCOA2|PAX3|NCOA1|NCOA2,NCOA1|NCOA2|PAX3,
2.3.2.2.24,11278,9606,,GO:0000122|GO:0006357,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,19745787,AP-2rep,AP-1,"Two transcription factors, activating protein-1 (AP-1) and activating protein-2 repressor (AP-2rep), were predicted to bind to the promoter in the region of g.-66T>C.",0.21,PMID.dPMID19745787.s5.p0,2,2,AP-1|AP-2rep,AP-1|AP-2rep,
1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,1.1.2.0.10,1388,9606,,,14973138,ATF6alpha,ATF6beta,"These results indicate that compared with ATF6alpha, ATF6beta is a very poor activator of ERSRG induction and it represses ATF6alpha-mediated ERSRG induction.",0.91,PMID.dPMID14973138.s1.p2,3,2,ATF6alpha|ATF6beta|ATF6alpha,ATF6alpha|ATF6beta,
1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,1.1.1.1.4,7494,9606,,,19122331,ATF6,XBP1,We conclude that pXBP1(U) functions as a negative regulator of the UPR-specific transcription factors ATF6 and pXBP1(S).,0.18,PMID.dPMID19122331.s0.p0,3,2,XBP1|ATF6|XBP1,ATF6|XBP1,-->
1.1.2.0.9,22926,9606,GO:0003702,GO:0006357|GO:0006990,1.1.1.1.4,7494,9606,,,19122331,ATF6,XBP1,"pXBP1(U), a negative regulator of the unfolded protein response activator pXBP1(S), targets ATF6 but not ATF4 in proteasome-mediated degradation.",0.10,PMID.dPMID19122331.s12.p1,4,3,XBP1|XBP1|ATF6|ATF4,ATF4|ATF6|XBP1,-->
4.1.1.9.1,23152,9606,,,1.2.6.3.1,6720,9606,GO:0003702,GO:0006357|GO:0045944,17350599,CIC,SREBP-1,These results show that SRE/SREBP-1 play a role in the transcriptional regulation of CIC by insulin and PUFA,0.66,PMID.dPMID17350599.s0.p0,2,2,SREBP-1|CIC,CIC|SREBP-1,
1.2.4.1.8,23462,9606,,GO:0010553,1.1.1.1.1,3725,9606,GO:0016563|GO:0016564,GO:0043922|GO:0043923|GO:0045941|GO:0045944|GO:0051090,15314183,HERP2,Jun,Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2.,0.01,PMID.dPMID15314183.s8.p1,3,3,Jun|GATA-1|HERP2,GATA-1|HERP2|Jun,
1.2.4.1.9,23493,9606,GO:0016564,GO:0000122|GO:0010553,1.2.4.1.10,26508,9606,,,18078851,HRT2,HRT3,"CONCLUSIONS: At 95% fixed specificity, most HRT3 parameters exhibited at least the same sensitivity for glaucoma diagnosis as the analogous parameters for the HRT2.",0.36,PMID.dPMID18078851.s2.p0,2,2,HRT3|HRT2,HRT2|HRT3,
1.2.4.1.9,23493,9606,GO:0016564,GO:0000122|GO:0010553,1.2.4.1.10,26508,9606,,,17719642,HRT2,HRT3,CONCLUSIONS: The HRT3 generally provided smaller stereometric disc measurements than HRT2.,0.02,PMID.dPMID17719642.s1.p0,2,2,HRT3|HRT2,HRT2|HRT3,
3.5.2.4.1,26298,9606,,GO:0045893,3.1.2.16.1,4824,9606,GO:0016564,GO:0006355|GO:0032582,20479932,ESE3,Nkx3.1,We further demonstrated that the prostate-specific tumor suppressor gene Nkx3.1 was controlled by ERG and ESE3 both directly and through induction of EZH2.,0.35,PMID.dPMID20479932.s2.p0,3,3,Nkx3.1|ESE3|EZH2,ESE3|EZH2|Nkx3.1,
1.2.4.1.10,26508,9606,,,1.2.4.1.9,23493,9606,GO:0016564,GO:0000122|GO:0010553,18078851,HRT3,HRT2,Burk (RB) discriminant function of the HRT2 and 83.3% for the FSM discriminant function of the HRT3.,0.38,PMID.dPMID18078851.s4.p0,2,2,HRT2|HRT3,HRT2|HRT3,
3.3.1.4.3,27022,9606,GO:0003704|GO:0016563|GO:0016566,GO:0000122|GO:0010553|GO:0045944|GO:0051090,3.3.1.13.1,2305,9606,GO:0003702|GO:0003704|GO:0016563|GO:0016566,GO:0010552|GO:0010553|GO:0051090,10460485,HFH2,HNF-3,"A novel repressor of the Winged Helix (formerly HNF-3/Forkhead) transcriptional regulatory family, termed Genesis (also called HFH2), was previously found to be exclusively expressed in primitive embryonic cell lines.",0.22,PMID.dPMID10460485.s8.p0,2,2,HNF-3|HFH2,HFH2|HNF-3,
3.3.1.4.3,27022,9606,GO:0003704|GO:0016563|GO:0016566,GO:0000122|GO:0010553|GO:0045944|GO:0051090,2.3.1.0.6,7528,9606,,GO:0006357|GO:0010553,19034670,FoxD3,YY1,"On the other hand, infection of primary cultured human microglia significantly reduced YY1 expression and induced FoxD3 as determined by immunoblotting and reverse transcription real-time PCR.",0.34,PMID.dPMID19034670.s2.p0,2,2,YY1|FoxD3,FoxD3|YY1,
3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,3.1.10.19.3,5309,9606,GO:0016563,GO:0045449,20175877,FoxP1,Pitx3,"This transcriptional regulation of Pitx3 by FoxP1 depends on the presence of two high affinity binding sites in the distal Pitx3 promoter, through which FoxP1 directly binds as demonstrated by chromatin immunoprecipitation and electrophoretic mobility shift assay.",1.39,PMID.dPMID20175877.s1.p0,4,2,Pitx3|FoxP1|Pitx3|FoxP1,FoxP1|Pitx3,
3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,3.3.1.16.2,93986,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032582|GO:0051090,18461604,FOXP1,FOXP2,"Expression of FOXP2 in the developing monkey forebrain: comparison with the expression of the genes FOXP1, PBX3, and MEIS2.",0.10,PMID.dPMID18461604.s9.p0,4,4,FOXP2|FOXP1|PBX3|MEIS2,FOXP1|FOXP2|MEIS2|PBX3,
3.3.1.16.1,27086,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0051090,3.3.1.16.2,93986,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0032582|GO:0051090,12687690,Foxp1,Foxp2,"Since Foxp2 appears to be important in language, we wanted to explore the expression of this gene and a homologous gene, Foxp1, in the developing brain.",0.00,PMID.dPMID12687690.s8.p0,2,2,Foxp2|Foxp1,Foxp1|Foxp2,
6.5.2.0.3,30009,9606,,GO:0006355,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17705132,T-BET,Sp1,"Collectively, our results suggest that Sp1 is a positive transcriptional regulator of T-BET.",2.00,PMID.dPMID17705132.s1.p0,2,2,Sp1|T-BET,Sp1|T-BET,e
6.5.2.0.3,30009,9606,,GO:0006355,2.3.1.0.2,6667,9606,GO:0003702|GO:0016563,GO:0006355|GO:0043923|GO:0045817|GO:0045893|GO:0045944,17705132,T-BET,Sp1,Ectopic overexpression of Sp1 also enhanced T-BET expression and cytokine-induced IFN-gamma secretion in NK cells and T cells.,0.82,PMID.dPMID17705132.s3.p0,3,3,Sp1|T-BET|IFN-gamma,IFN-gamma|Sp1|T-BET,
3.1.2.21.3,30012,9606,,,3.1.2.17.2,1482,9606,GO:0016563|GO:0016564,GO:0000122|GO:0010552|GO:0010553|GO:0010735|GO:0043193|GO:0045893|GO:0045944|GO:0060261,14500364,TLX3,NKX2-5,"In this t(5;14) variant, NKX2-5 is expressed instead of TLX3 at both RNA and protein levels.",0.77,PMID.dPMID14500364.s3.p0,2,2,NKX2-5|TLX3,NKX2-5|TLX3,
3.1.2.21.3,30012,9606,,,1.2.3.1.3,4066,9606,GO:0016563,GO:0045449,12130513,HOX11L2,LYL1,"High expression of LYL1, LMO2, or TAL1 was observed mainly in samples negative for HOX11L2 expression.",0.13,PMID.dPMID12130513.s3.p3,4,4,LYL1|LMO2|TAL1|HOX11L2,HOX11L2|LMO2|LYL1|TAL1,
3.1.2.21.3,30012,9606,,,1.2.3.1.1,6886,9606,GO:0016563,GO:0010551,12130513,HOX11L2,TAL1,"High expression of LYL1, LMO2, or TAL1 was observed mainly in samples negative for HOX11L2 expression.",0.85,PMID.dPMID12130513.s3.p5,4,4,LYL1|LMO2|TAL1|HOX11L2,HOX11L2|LMO2|LYL1|TAL1,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19800266,FoxP3,RUNX1,"In addition, knockdown of RUNX1 showed that RUNX1 is required for the optimal regulation of FoxP3 expression in human T cells.",1.11,PMID.dPMID19800266.s1.p2,3,2,RUNX1|RUNX1|FoxP3,FoxP3|RUNX1,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.4.1.0.2,861,9606,GO:0016563,GO:0045941|GO:0045944,19800266,FoxP3,RUNX1,"In addition, knockdown of RUNX1 showed that RUNX1 is required for the optimal regulation of FoxP3 expression in human T cells.",0.27,PMID.dPMID19800266.s1.p1,3,2,RUNX1|RUNX1|FoxP3,FoxP3|RUNX1,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,20130130,Foxp3,Eralpha,"HPV-16 VLPs significantly increased the levels of lymphoproliferation, proinflammatory cytokine (gamma interferon [IFN-gamma], interleukin-1beta [IL-1beta], IL-2, IL-6, IL-8, IL-12p70, IL-17, tumor necrosis factor alpha [TNF-alpha]) production, anti-inflammatory cytokine (IL-1ra, IL-10) production, and the expression of Eralpha and Erbeta but decreased the levels of Foxp3 expression and production of transforming growth factor beta (TGF-beta).",0.36,PMID.dPMID20130130.s2.p53,12,12,IFN-gamma|IL-2|IL-6|IL-8|IL-17|TNF-alpha|IL-1ra|IL-10|Eralpha|Erbeta|Foxp3|TGF-beta,Eralpha|Erbeta|Foxp3|IFN-gamma|IL-10|IL-17|IL-1ra|IL-2|IL-6|IL-8|TGF-beta|TNF-alpha,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,2.1.1.2.2,2100,9606,,GO:0006355|GO:0034339,20130130,Foxp3,Erbeta,"HPV-16 VLPs significantly increased the levels of lymphoproliferation, proinflammatory cytokine (gamma interferon [IFN-gamma], interleukin-1beta [IL-1beta], IL-2, IL-6, IL-8, IL-12p70, IL-17, tumor necrosis factor alpha [TNF-alpha]) production, anti-inflammatory cytokine (IL-1ra, IL-10) production, and the expression of Eralpha and Erbeta but decreased the levels of Foxp3 expression and production of transforming growth factor beta (TGF-beta).",0.46,PMID.dPMID20130130.s2.p54,12,12,IFN-gamma|IL-2|IL-6|IL-8|IL-17|TNF-alpha|IL-1ra|IL-10|Eralpha|Erbeta|Foxp3|TGF-beta,Eralpha|Erbeta|Foxp3|IFN-gamma|IL-10|IL-17|IL-1ra|IL-2|IL-6|IL-8|TGF-beta|TNF-alpha,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,20574810,Foxp3,Ets-1,"We therefore propose that Ets-1 is part of a larger protein complex, which binds to the TSDR only in its demethylated state, thereby restricting stable Foxp3 expression to the Treg lineage",0.28,PMID.dPMID20574810.s0.p0,2,2,Ets-1|Foxp3,Ets-1|Foxp3,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,3.3.1.15.1,2308,9606,GO:0003704|GO:0016563|GO:0016566,GO:0010553|GO:0045944|GO:0051090,20603315,Foxp3,Foxo1,"New studies show that the Foxo proteins Foxo1 and Foxo3a, which are inactivated by Akt, drive Foxp3 expression.",0.45,PMID.dPMID20603315.s1.p1,3,3,Foxo1|Akt|Foxp3,Akt|Foxo1|Foxp3,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,1.2.5.1.5,3091,9606,,GO:0006355|GO:0043193|GO:0043619|GO:0045449|GO:0045941|GO:0045944,19549358,Foxp3,HIF-1alpha,"The Jurkat cells were incubated with hypoxia (1% O(>2)) and its simulant CoCl(2) for different times (0, 6, 12, 24 hours), the viability was measured by trypan blue staining, the expression of HIF-1alpha was detected by Western blot, the expression of Foxp3 was detected by real-time PCR, the expressions of HIF-1alpha and Foxp3 were assayed after HIF-1alpha in Jurkat cells was inhibited by using RNA interference technique.",0.33,PMID.dPMID19549358.s2.p0,5,2,HIF-1alpha|Foxp3|HIF-1alpha|Foxp3|HIF-1alpha,Foxp3|HIF-1alpha,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,7.1.1.1.3,4088,9606,,GO:0000122|GO:0045941|GO:0045944,20870174,Foxp3,Smad3,"Thus, control of accessibility and binding of pSmad3 provides a common framework for positive and negative regulation of TGF--induced Foxp3 transcription",0.79,PMID.dPMID20870174.s0.p0,2,2,Smad3|Foxp3,Foxp3|Smad3,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,3.5.1.0.1,4602,9606,GO:0016563|GO:0016566,GO:0006355|GO:0010552|GO:0010553,20414968,Foxp3,c-Myb,"We analysed and demonstrated potent new E47/c-Myb -dependent regulation elements in rs3761548, oppositely controlling Foxp3 gene transcription at G1 and G2/M phases of Treg cells in psoriatic patients.",0.93,PMID.dPMID20414968.s2.p0,2,2,c-Myb|Foxp3,c-Myb|Foxp3,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.1.3.0.1,4772,9606,GO:0016563,GO:0006355,19564342,FOXP3,NFAT2,"We demonstrate that transcription from the NFAT2 promoter is significantly suppressed by FOXP3, and NFAT2 protein expression is markedly diminished in activated CD4(+)CD25(+)FOXP3(+) T(REG) compared with CD4(+)CD25(-)FOXP3(-) T cells.",0.07,PMID.dPMID19564342.s3.p0,7,3,NFAT2|FOXP3|NFAT2|CD4|FOXP3|CD4|FOXP3,CD4|FOXP3|NFAT2,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,17463169,FOXP3,NFAT1,Transfection of FOXP3-deficient CD4(+)CD25(+) T cells from patients with a plasmid encoding wild-type NFAT1 resulted in increased FOXP3 expression in these cells.,1.87,PMID.dPMID17463169.s3.p5,4,3,FOXP3|CD4|NFAT1|FOXP3,CD4|FOXP3|NFAT1,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.1.3.0.2,4773,9606,GO:0016563,GO:0006355|GO:0045941,17463169,FOXP3,NFAT1,Our findings indicate that decreased NFAT1 could explain low FOXP3 expression and diminished Treg frequency in aplastic anemia.,0.55,PMID.dPMID17463169.s1.p0,2,2,NFAT1|FOXP3,FOXP3|NFAT1,
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.1.1.2.3,5966,9606,,,20162555,Foxp3,c-Rel,"Moreover, c-Rel is shown to regulate Foxp3 transcription directly by binding to cis-regulatory elements at the Foxp3 locus upon TCR/CD28 stimulation, including the promoter and the newly identified conserved non-coding DNA sequence harboring a ""permissive"" chromatin status in Treg precursors.",1.62,PMID.dPMID20162555.s1.p0,4,3,c-Rel|Foxp3|Foxp3|CD28,CD28|c-Rel|Foxp3,p
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.1.1.2.3,5966,9606,,,20162555,Foxp3,c-Rel,"Moreover, c-Rel is shown to regulate Foxp3 transcription directly by binding to cis-regulatory elements at the Foxp3 locus upon TCR/CD28 stimulation, including the promoter and the newly identified conserved non-coding DNA sequence harboring a ""permissive"" chromatin status in Treg precursors.",0.69,PMID.dPMID20162555.s1.p1,4,3,c-Rel|Foxp3|Foxp3|CD28,CD28|c-Rel|Foxp3,p
3.3.1.16.3,50943,9606,GO:0003704|GO:0016563|GO:0016564|GO:0016566,GO:0006355|GO:0010552|GO:0010553|GO:0032088|GO:0032792|GO:0043433|GO:0045892|GO:0045941,6.5.2.0.3,30009,9606,,GO:0006355,17445472,FOXP3,T-bet,"CONCLUSIONS: There are a predominant expression of GATA-3 and T-bet, but a decreased expression of FOXP3 in Df-stimulated PBMCs from patients with asthma.",0.03,PMID.dPMID17445472.s0.p2,3,3,GATA-3|T-bet|FOXP3,FOXP3|GATA-3|T-bet,
1.2.6.6.3,51085,9606,GO:0016563|GO:0016564,GO:0006355|GO:0010552|GO:0045892|GO:0045893,2.1.1.2.1,2099,9606,,GO:0006355|GO:0034339,10951405,MIO,ERalpha,Deficient osteoblast and osteocyte ERalpha protein expression could explain the bone loss in these MIO patients.,0.05,PMID.dPMID10951405.s0.p0,2,2,ERalpha|MIO,ERalpha|MIO,
1.2.6.6.3,51085,9606,GO:0016563|GO:0016564,GO:0006355|GO:0010552|GO:0045892|GO:0045893,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,19359385,ChREBP,Oct-1,"Furthermore, overexpression of Oct-1 repressed endogenous ChREBP mRNA and protein expression, whereas knockdown of Oct-1 expression, using a lentivirus-based small hairpin RNA approach, led to increased ChREBP mRNA and protein expression.",0.64,PMID.dPMID19359385.s4.p5,4,2,Oct-1|ChREBP|Oct-1|ChREBP,ChREBP|Oct-1,
1.2.6.6.3,51085,9606,GO:0016563|GO:0016564,GO:0006355|GO:0010552|GO:0045892|GO:0045893,3.1.4.2.1,5451,9606,GO:0016564|GO:0030528,GO:0016481|GO:0045892,19359385,ChREBP,Oct-1,"Furthermore, overexpression of Oct-1 repressed endogenous ChREBP mRNA and protein expression, whereas knockdown of Oct-1 expression, using a lentivirus-based small hairpin RNA approach, led to increased ChREBP mRNA and protein expression.",0.09,PMID.dPMID19359385.s4.p3,4,2,Oct-1|ChREBP|Oct-1|ChREBP,ChREBP|Oct-1,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,6.4.1.0.1,860,9606,GO:0003702|GO:0016563,GO:0016481,20128911,Lef-1,RUNX2,"We found that SLUG is positively correlated with RUNX2 expression and deposition of mineralized matrix, and is regulated by Lef-1 and beta-catenin.",0.02,PMID.dPMID20128911.s3.p2,3,3,SLUG|RUNX2|Lef-1,Lef-1|RUNX2|SLUG,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,1.1.4.1.1,1050,9606,,GO:0045945,17063141,LEF-1,C/EBPalpha,"C/EBPalpha, a key transcription factor in granulopoiesis, was directly regulated by LEF-1.",0.69,PMID.dPMID17063141.s1.p0,2,2,C/EBPalpha|LEF-1,C/EBPalpha|LEF-1,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,3.5.2.1.1,2113,9606,GO:0003702,GO:0010552|GO:0045893|GO:0045941,7774816,LEF-1,Ets-1,Stable occupancy of the Ets-1- and PEBP2 alpha-binding sites in a DNase I protection assay was found to depend on both a specific helical phasing relationship with a nonadjacent ATF/CREB-binding site at the other end of the enhancer and on LEF-1.,0.73,PMID.dPMID7774816.s3.p0,2,2,Ets-1|LEF-1,Ets-1|LEF-1,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,20735988,LEF1,TCF,"Our results show that activation of Wnt/-catenin signaling increases TCF-mediated transcription and the expression of the Wnt target genes Axin2, LEF1 and CyclinD1 in ReNcell VM cells.",0.56,PMID.dPMID20735988.s2.p0,2,2,TCF|LEF1,LEF1|TCF,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,2.1.3.2.1,3172,9606,,GO:0010551|GO:0010552|GO:0034339|GO:0043193|GO:0045944,11326276,LEF1,TCF,"beta-catenin/TCF complexes can activate the promoter for full-length LEF1, indicating that in cancer high levels of these complexes misregulate transcription to favor a positive feedback loop for Wnt signaling by inducing selective expression of full-length, beta-catenin-sensitive forms of LEF/TCFs",0.13,PMID.dPMID11326276.s0.p2,5,3,beta-catenin|TCF|LEF1|beta-catenin|TCF,beta-catenin|LEF1|TCF,[51176-->51176]
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,7.1.1.3.2,4092,9606,,GO:0010553|GO:0010944|GO:0043433,15684397,LEF1,Smad7,Smad7 was found to be required for TGF-beta1-induced accumulation of beta-catenin and LEF1 in human prostate cancer (PC-3U) cells as well as in human keratinocytes (HaCaT cells).,0.31,PMID.dPMID15684397.s2.p1,3,3,Smad7|TGF-beta|LEF1,LEF1|Smad7|TGF-beta,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,1.2.6.1.4,4286,9606,GO:0016563,GO:0006355,12032083,LEF-1,MITF,"This study therefore suggests that the MITF/TFE3 family is a new class of nuclear modulators for LEF-1, which may ensure efficient propagation of Wnt signals in many types of cells",0.26,PMID.dPMID12032083.s0.p1,3,3,MITF|TFE3|LEF-1,LEF-1|MITF|TFE3,-->
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,17466981,Lef-1,c-Myc,"In epidermal keratinocytes, c-Myc was reported to be repressed by Lef-1 and PG.",0.72,PMID.dPMID17466981.s4.p0,2,2,c-Myc|Lef-1,c-Myc|Lef-1,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,3.1.10.19.2,5308,9606,,GO:0006355,15728254,LEF-1,PITX2,beta-catenin directly interacts with PITX2 to synergistically regulate LEF-1 expression.,1.37,PMID.dPMID15728254.s2.p2,3,3,beta-catenin|PITX2|LEF-1,beta-catenin|LEF-1|PITX2,e
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,2.3.5.0.2,6591,9606,,GO:0000122,20128911,Lef-1,SLUG,"We found that SLUG is positively correlated with RUNX2 expression and deposition of mineralized matrix, and is regulated by Lef-1 and beta-catenin.",0.23,PMID.dPMID20128911.s3.p1,3,3,SLUG|RUNX2|Lef-1,Lef-1|RUNX2|SLUG,
4.1.3.0.4,51176,9606,GO:0016563|GO:0016564,GO:0010552|GO:0016481|GO:0032582|GO:0043923|GO:0045892|GO:0045893|GO:0045941,1.2.6.1.1,7030,9606,,GO:0010552,12032083,LEF-1,TFE3,"This study therefore suggests that the MITF/TFE3 family is a new class of nuclear modulators for LEF-1, which may ensure efficient propagation of Wnt signals in many types of cells",0.26,PMID.dPMID12032083.s0.p2,3,3,MITF|TFE3|LEF-1,LEF-1|MITF|TFE3,
3.5.2.6.2,51513,9606,GO:0003704,,1.2.6.5.1,4609,9606,GO:0016563,GO:0006357|GO:0045941,15743832,TEL2,Myc,"Nonetheless, inactivation of the p53 pathway was a hallmark of all TEL2/Emu-Myc lymphomas, indicating that TEL2 expression alone is insufficient to bypass this apoptotic checkpoint.",0.12,PMID.dPMID15743832.s2.p2,3,2,TEL2|Myc|TEL2,Myc|TEL2,
4.1.1.6.3,54345,9606,GO:0003702,GO:0010552|GO:0045892|GO:0045893,2.3.2.1.2,1958,9606,,GO:0045941,20054233,SOX18,EGR1,By in vitro binding assays and functional analyses we have shown that these three putative binding sites are functionally relevant and sufficient for EGR1-induced SOX18 transcription.,0.94,PMID.dPMID20054233.s2.p0,2,2,EGR1|SOX18,EGR1|SOX18,
4.1.1.6.3,54345,9606,GO:0003702,GO:0010552|GO:0045892|GO:0045893,2.3.5.0.44,7707,9606,GO:0003704|GO:0016564,,18496767,SOX18,ZBP-89,"In this paper, for the first time, we have demonstrated that Sp3, ZBP-89 and NF-Y are involved in transcriptional regulation of the human SOX18 gene expression.",0.02,PMID.dPMID18496767.s1.p2,3,3,Sp3|ZBP-89|SOX18,SOX18|Sp3|ZBP-89,
6.7.1.1.3,57822,9606,,,4.1.1.5.3,6663,9606,GO:0003702,GO:0006357,16735048,SOM,DOM,"On the other hand, the sorbed DOM on soil solids after the addition of heavy metals in soils was found to be much more reactive and have far stronger capacity of phenanthrene uptake than the inherent SOM.",0.28,PMID.dPMID16735048.s1.p0,2,2,DOM|SOM,DOM|SOM,
2.3.5.0.39,59348,9606,GO:0016564,GO:0006355|GO:0016481,8.2.1.0.2,8091,9606,,,20007691,ZBRK1,HMGA2,"Using microarray analysis, we found that HMGA2, along with a dozen of other genes, was co-repressed by ZBRK1, BRCA1, and CtIP.",0.52,PMID.dPMID20007691.s6.p0,4,4,HMGA2|ZBRK1|BRCA1|CtIP,BRCA1|CtIP|HMGA2|ZBRK1,
2.3.5.0.39,59348,9606,GO:0016564,GO:0006355|GO:0016481,8.2.1.0.2,8091,9606,,,20007691,ZBRK1,HMGA2,"Here, we show that ZBRK1, BRCA1, and CtIP form a repression complex that coordinately regulates HMGA2 expression via a ZBRK1 recognition site in the HMGA2 promoter.",0.06,PMID.dPMID20007691.s4.p9,6,5,ZBRK1|BRCA1|CtIP|HMGA2|ZBRK1|HMGA2,BRCA1|CtIP|HMGA2|ZBRK1,
2.3.5.0.39,59348,9606,GO:0016564,GO:0006355|GO:0016481,8.2.1.0.2,8091,9606,,,20007691,ZBRK1,HMGA2,These results suggest that activation of HMGA2 gene expression through derepression of the ZBRK1/BRCA1/CtIP complex is a significant step in accelerating breast tumorigenesis,0.04,PMID.dPMID20007691.s0.p0,4,4,HMGA2|ZBRK1|BRCA1|CtIP,BRCA1|CtIP|HMGA2|ZBRK1,
1.1.2.0.6,64764,9606,,GO:0045941,2.1.2.5.3,5468,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0010552|GO:0010553|GO:0034339|GO:0045944|GO:0051091,18757431,CREB3L2,PPARgamma,The CREB3L2-PPARgamma fusion encodes a CREB3L2-PPARgamma fusion protein that is composed of the transactivation domain of CREB3L2 and all functional domains of PPARgamma1.,0.37,PMID.dPMID18757431.s7.p2,6,2,CREB3L2|PPARgamma|CREB3L2|PPARgamma|CREB3L2|PPARgamma,CREB3L2|PPARgamma,
3.1.2.12.1,79923,9606,,GO:0006355,2.2.1.0.6,2627,9606,GO:0016564,GO:0010552|GO:0010553,18941526,Nanog,Gata-6,The model is based upon differential equations and makes two plausible assumptions; activation of Gata-6 by Oct4 and repression of Nanog by an Oct4-Gata-6 heterodimer.,0.63,PMID.dPMID18941526.s5.p1,5,3,Gata-6|Oct4|Nanog|Oct4|Gata-6,Gata-6|Nanog|Oct4,
3.1.2.12.1,79923,9606,,GO:0006355,7.1.1.1.2,4087,9606,GO:0016563,GO:0043193|GO:0045892|GO:0045893|GO:0045941|GO:0045944,18393632,NANOG,SMAD 2,"Our data reveal that SMAD 2/3 signaling directly supports NANOG expression, while SMAD 1/5/8 activation moderately represses SOX2.",0.04,PMID.dPMID18393632.s3.p0,3,3,SMAD 2|NANOG|SMAD 1,NANOG|SMAD 1|SMAD 2,
3.1.2.12.1,79923,9606,,GO:0006355,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,20631301,NANOG,p53,The longevity-promoting NAD+-dependent class III histone deacetylase Sirtuin 1 (SIRT1) is involved in stem cell function by controlling cell fate decision and/or by regulating the p53-dependent expression of NANOG.,1.39,PMID.dPMID20631301.s3.p5,4,3,Sirtuin 1|SIRT1|p53|NANOG,NANOG|p53|SIRT1|Sirtuin 1,
3.1.2.12.1,79923,9606,,GO:0006355,2.3.2.2.19,9314,9606,GO:0016563|GO:0016564,GO:0010552|GO:0045892|GO:0045941,19522013,NANOG,KLF4,KLF4 and PBX1 directly regulate NANOG expression in human embryonic stem cells.,1.55,PMID.dPMID19522013.s10.p1,3,3,KLF4|PBX1|NANOG,KLF4|NANOG|PBX1,e
1.2.3.2.2,117581,9606,GO:0016564,GO:0045892,3.2.1.1.2,5081,9606,,,18344491,Dermo-1,Pax7,"In this study we report the identification of a trout orthologue of the dermal marker Dermo-1, and show that trout somitic external cells, which are all potentially myogenic as indicated by the transcription of Pax7 gene, express Dermo-1.",0.47,PMID.dPMID18344491.s3.p2,3,2,Dermo-1|Pax7|Dermo-1,Dermo-1|Pax7,
1.2.2.2.4,121549,9606,GO:0003702,GO:0006357,1.2.2.2.3,56676,9606,GO:0030528,GO:0006357,15475265,Hash4,Hash3,"Expression of Hash3 was detected in all samples tested, while the expression of Hash4 was restricted to skin.",0.31,PMID.dPMID15475265.s2.p0,2,2,Hash3|Hash4,Hash3|Hash4,
3.1.10.9.1,145258,9606,,,6.3.1.0.1,7157,9606,GO:0016563|GO:0016564|GO:0016566,GO:0000122|GO:0006355|GO:0010552|GO:0010553|GO:0045941|GO:0045944,17523278,GSC,p53,"RESULTS: Fourteen p53 mutations were found, 5 in GSC (29%) and 9 in IPGC (36%).",0.04,PMID.dPMID17523278.s8.p0,2,2,p53|GSC,GSC|p53,
3.1.8.3.2,147912,9606,,,3.1.4.7.1,6927,9606,GO:0003702,GO:0010551|GO:0045893,17357085,SIX5,Transcription factor,Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome.,0.09,PMID.dPMID17357085.s9.p0,2,2,Transcription factor|SIX5,SIX5|Transcription factor,
